Sequences	O
and	O
PCR	O
conditions	O
of	O
these	O
primers	O
are	O
provided	O
in	O
Table	O
2	O
.	O

"	O
Missing	O
alleles	O
"	O
in	O
seemingly	O
accidental	O
carriers	O
of	O
recessive	O
RD	O
gene	O
mutations	O
were	O
partly	O
large	O
CNVs	O
and	O
mutations	O
affecting	O
non	O
-	O
coding	O
5	O
'	O
exons	O
,	O
demonstrating	O
that	O
both	O
UTR	O
inclusion	O
and	O
quantitative	O
analysis	O
should	O
be	O
part	O
of	O
a	O
comprehensive	O
NGS	O
approach	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
the	O
currently	O
available	O
Next	O
Generation	O
Sequencing	O
(	O
NGS	O
)	O
technologies	O
are	O
already	O
suitable	O
for	O
molecular	O
diagnostics	O
of	O
USH	B-DISEASE
.	O

In	O
silico	O
data	O
and	O
co	O
-	O
segregation	O
are	O
summarised	O
in	O
Table	O
3	O
.	O

None	O
of	O
these	O
mutations	O
were	O
observed	O
in	O
100	O
analysed	O
population	O
-	O
matched	O
control	O
individuals	O
.	O

However	O
,	O
because	O
IV	O
:	O
1	O
is	O
25	O
years	O
of	O
age	O
,	O
it	O
is	O
possible	O
that	O
he	O
will	O
suffer	O
from	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
his	O
late	O
years	O
.	O

Table	O
2	O
.	O

Compared	O
to	O
Sanger	O
sequencing	O
this	O
simplifies	O
the	O
workflow	O
,	O
speeds	O
up	O
the	O
diagnostic	O
procedure	O
,	O
and	O
might	O
also	O
help	O
to	O
save	O
costs	O
.	O

All	O
primer	O
sequences	O
and	O
PCR	O
conditions	O
are	O
available	O
upon	O
request	O
.	O

The	O
qualified	O
3	O
mu	O
g	O
genomic	O
DNA	O
for	O
each	O
sample	O
was	O
randomly	O
sheared	O
into	O
150	O
~	O
250	O
bp	O
fragments	O
(	O
Covaris	O
,	O
Woburn	O
,	O
MA	O
,	O
USA	O
)	O
and	O
purified	O
using	O
MinElute	O
PCR	O
purification	O
kit	O
(	O
Qiagen	O
)	O
.	O

Patient	O
25	O
was	O
compound	O
-	O
heterozygous	O
for	O
two	O
truncating	O
RP1	B-GENE
alleles	O
,	O
c	B-VARIANT
.	I-VARIANT
597C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Tyr199	I-VARIANT
*	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
3157delT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Tyr1053Thrfs	I-VARIANT
*	I-VARIANT
4	I-VARIANT
)	O
,	O
and	O
additionally	O
carried	O
a	O
nonsense	O
mutation	O
in	O
CDH23	B-GENE
which	O
has	O
previously	O
been	O
described	O
in	O
recessive	O
deafblindness	B-DISEASE
(	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1D	I-DISEASE
,	O
USH1D	B-DISEASE
)	O
[	O
29	O
]	O
.	O

However	O
,	O
if	O
new	O
genes	O
are	O
identified	O
in	O
context	O
of	O
a	O
heterogeneous	O
disorder	O
such	O
as	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
a	O
revised	O
version	O
of	O
enrichment	O
baits	O
has	O
to	O
be	O
designed	O
and	O
ordered	O
.	O

Click	O
here	O
for	O
file	O
We	O
thank	O
the	O
patients	O
and	O
their	O
family	O
for	O
their	O
invaluable	O
support	O
and	O
cooperation	O
,	O
and	O
Jeroen	O
Roelofsen	O
for	O
assistance	O
with	O
investigating	O
PRS	O
-	O
I	O
enzyme	O
activity	O
.	O

The	O
resulting	O
SNP	O
-	O
based	O
genotyping	O
data	O
(	O
as	O
in	O
Linkage	O
Analysis	O
)	O
was	O
analyzed	O
to	O
detect	O
regions	O
of	O
homozygosity	O
using	O
CNAG	O
3	O
.	O
0	O
and	O
GTConsole	O
Version	O
3	O
.	O
0	O
.	O
1	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
software	O
packages	O
.	O

WES	O
was	O
performed	O
on	O
one	O
affected	O
member	O
from	O
each	O
of	O
11	O
unrelated	O
families	O
.	O

Among	O
48	O
patients	O
with	O
NSEVA	B-DISEASE
and	O
non	O
-	O
EVA	B-DISEASE
inner	B-DISEASE
ear	I-DISEASE
malformations	I-DISEASE
,	O
we	O
identified	O
one	O
case	O
(	O
1	O
/	O
48	O
,	O
2	O
.	O
1	O
%	O
)	O
with	O
the	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
812G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
KCNJ10	B-GENE
.	O

It	O
is	O
clear	O
from	O
the	O
structure	O
that	O
E129	O
,	O
which	O
sits	O
on	O
a	O
beta	O
strand	O
,	O
interacts	O
with	O
tryptophan	O
179	O
(	O
W179	O
)	O
,	O
glutamine	O
277	O
(	O
Q277	O
)	O
and	O
lysine	O
285	O
(	O
K285	O
)	O
by	O
forming	O
hydrogen	O
bonds	O
(	O
Figure	O
4	O
C	O
)	O
.	O

The	O
variant	O
causes	O
a	O
transition	O
of	O
adenine	O
to	O
guanine	O
at	O
nucleotide	O
position	O
3562	O
(	O
c	B-VARIANT
.	I-VARIANT
3562A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
,	O
which	O
results	O
in	O
the	O
substitution	O
of	O
the	O
polar	O
amino	O
acid	O
threonine	O
by	O
the	O
apolar	O
amino	O
acid	O
alanine	O
at	O
amino	O
acid	O
position	O
1188	O
(	O
p	B-VARIANT
.	I-VARIANT
T1188A	I-VARIANT
)	O
.	O

The	O
first	O
variant	O
,	O
corresponding	O
to	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
8183G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R2728H	I-VARIANT
)	O
,	O
was	O
supported	O
by	O
50	O
%	O
(	O
43	O
/	O
86	O
)	O
of	O
reads	O
and	O
is	O
predicted	O
to	O
be	O
damaging	O
by	O
PolyPhen2	O
and	O
SIFT	O
.	O

This	O
suggests	O
that	O
relatively	O
unbiased	O
approaches	O
to	O
genetic	O
testing	O
,	O
such	O
as	O
WES	O
,	O
would	O
be	O
an	O
efficient	O
and	O
successful	O
approach	O
to	O
reach	O
a	O
molecular	O
diagnosis	O
in	O
at	O
least	O
a	O
subset	O
of	O
patients	O
.	O

49	O
,	O
50	O
In	O
summary	O
,	O
CIB2	B-GENE
mutations	O
underlie	O
Usher	B-DISEASE
syndrome	I-DISEASE
1J	I-DISEASE
and	O
nonsyndromic	O
deafness	B-DISEASE
DFNB48	B-DISEASE
.	O

MG	O
,	O
SM	O
,	O
DW	O
,	O
AEA	O
,	O
LJ	O
,	O
JL	O
,	O
JAS	O
participated	O
in	O
manuscript	O
writing	O
.	O

1	O
)	O
.	O

The	O
ophthalmoscopic	O
examination	O
demonstrated	O
obvious	O
waxy	O
pallor	O
of	O
the	O
optic	O
discs	O
,	O
attenuation	O
of	O
the	O
retinal	O
vessels	O
,	O
and	O
bone	O
spicule	O
-	O
type	O
pigment	O
deposits	O
(	O
Figure	O
3	O
)	O
.	O

W26	O
)	O
.	O

Acadians	O
to	O
a	O
great	O
extent	O
came	O
from	O
different	O
parts	O
of	O
France	O
than	O
do	O
Quebecois	O
.	O

The	O
molecular	O
genetic	O
basis	O
of	O
this	O
subset	O
of	O
AC	B-DISEASE
remains	O
partly	O
unknown	O
.	O

36	O
Large	O
genomic	O
deletions	O
and	O
duplications	O
have	O
also	O
been	O
reported	O
in	O
MYO7A	B-GENE
,	O
CDH23	B-GENE
,	O
GPR98	B-GENE
,	O
and	O
USH2A	B-GENE
.	O

The	O
activity	O
of	O
the	O
USH	B-DISEASE
gene	O
carrying	O
biallelic	O
mutations	O
may	O
indeed	O
turn	O
out	O
to	O
be	O
only	O
partly	O
restored	O
by	O
gene	O
therapy	O
,	O
and	O
the	O
presence	O
of	O
a	O
third	O
mutation	O
in	O
another	O
USH	B-DISEASE
gene	O
may	O
then	O
critically	O
impact	O
on	O
the	O
benefits	O
of	O
the	O
gene	O
therapy	O
.	O

Importantly	O
,	O
10	O
/	O
87	O
heterozygous	O
patients	O
(	O
6M	O
/	O
4F	O
)	O
(	O
11	O
,	O
5	O
%	O
)	O
reached	O
ESKD	B-DISEASE
at	O
ages	O
ranging	O
from	O
37	O
-	O
69	O
-	O
yo	O
(	O
mean	O
50	O
,	O
1	O
-	O
yo	O
)	O
.	O

In	O
addition	O
,	O
members	O
of	O
the	O
eya	O
gene	O
family	O
were	O
suggested	O
to	O
induce	O
apoptosis	O
by	O
triggering	O
the	O
caspase	O
-	O
dependent	O
and	O
-	O
independent	O
pathways	O
(	O
17	O
)	O
.	O

Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

In	O
this	O
study	O
,	O
patient	O
VI	O
-	O
1	O
,	O
aged	O
8	O
years	O
old	O
,	O
had	O
normal	O
thyroid	O
size	O
and	O
function	O
and	O
a	O
moderate	O
HL	B-DISEASE
.	O

ADOA	B-DISEASE
has	O
considerable	O
intra	O
-	O
and	O
interfamilial	O
clinical	O
variability	O
with	O
incomplete	O
penetrance	O
estimated	O
to	O
be	O
about	O
90	O
%	O
in	O
the	O
familial	O
forms	O
of	O
the	O
disease	O
[	O
9	O
]	O
.	O

Analysis	O
of	O
the	O
other	O
affected	O
case	O
from	O
whom	O
DNA	O
was	O
available	O
(	O
2907	O
)	O
confirmed	O
the	O
CRB1	B-GENE
mutation	O
as	O
the	O
pathogenic	O
cause	O
of	O
disease	O
.	O

The	O
sequence	O
results	O
were	O
analyzed	O
using	O
an	O
ABI	O
3100	O
DNA	O
sequencing	O
machine	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
ABI	O
3100	O
Analysis	O
Software	O
v	O
.	O
3	O
.	O
7	O
NT	O
,	O
according	O
to	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Family	O
Z421	O
is	O
of	O
Jewish	O
Ashkenazi	O
origin	O
.	O

Recruited	O
patients	O
and	O
contributed	O
clinical	O
material	O
:	O
IS	O
CS	O
MZ	O
YA	O
KI	O
C	O
.	O

Intraindividual	O
subanalysis	O
of	O
the	O
mean	O
thickness	O
values	O
for	O
subfields	O
5	O
to	O
8	O
revealed	O
significant	O
difference	O
between	O
the	O
nasal	O
,	O
temporal	O
,	O
inferior	O
,	O
and	O
superior	O
subfields	O
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
shows	O
that	O
exome	O
sequencing	O
is	O
a	O
promising	O
method	O
with	O
which	O
to	O
identify	O
genetic	O
variants	O
that	O
cause	O
structural	O
fetal	B-DISEASE
abnormalities	I-DISEASE
and	O
thereby	O
improve	O
the	O
clinical	O
management	O
of	O
pregnancies	O
and	O
better	O
inform	O
the	O
reproductive	O
decisions	O
of	O
affected	O
families	O
.	O

For	O
the	O
vast	O
majority	O
of	O
patients	O
referred	O
to	O
ESDN	O
with	O
a	O
provisional	O
diagnosis	O
of	O
PSACH	B-DISEASE
,	O
the	O
panel	O
agreed	O
with	O
the	O
diagnosis	O
and	O
a	O
COMP	B-GENE
mutation	O
was	O
subsequently	O
found	O
(	O
Table	O
1	O
)	O
.	O

We	O
found	O
causative	O
mutations	O
in	O
16	O
families	O
,	O
representing	O
28	O
,	O
1	O
%	O
.	O

The	O
significant	O
tissue	O
specificity	O
and	O
phenotypic	O
heterogeneity	O
of	O
mutated	O
mt	O
-	O
aaRSs	O
was	O
unexpected	O
,	O
considering	O
that	O
a	O
deficiency	O
in	O
these	O
ubiquitously	O
expressed	O
enzymes	O
should	O
affect	O
all	O
tissue	O
types	O
[	O
9	O
]	O
.	O

(	O
B	O
)	O
Number	O
of	O
patients	O
according	O
to	O
circumstances	O
of	O
MT	O
discovery	O
:	O
B	O
,	O
bleeding	B-DISEASE
;	O
FS	O
,	O
familial	O
study	O
;	O
SS	O
,	O
systematic	O
study	O
.	O
Dr	O
Xiong	O
and	O
Dr	O
Cao	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Following	O
12	O
-	O
20	O
days	O
of	O
selection	O
,	O
cells	O
were	O
harvested	O
for	O
dipstick	O
assays	O
.	O

Type	O
1	O
consists	O
of	O
brachycephaly	B-DISEASE
,	O
a	O
hypoplastic	O
mid	O
-	O
face	O
,	O
and	O
finger	O
and	O
toe	O
abnormalities	O
with	O
normal	O
to	O
near	O
-	O
normal	O
intelligence	O
(	O
classic	O
type	O
)	O
.	O

Exons	O
are	O
represented	O
with	O
boxes	O
.	O

In	O
patients	O
with	O
multiple	O
hypothalamic	B-DISEASE
-	I-DISEASE
pituitary	I-DISEASE
deficiencies	I-DISEASE
due	O
to	O
pituitary	O
stalk	O
interruption	O
syndrome	O
,	O
we	O
found	O
that	O
all	O
the	O
boys	O
with	O
gonadotropin	O
deficiency	O
had	O
micropenis	B-DISEASE
and	O
/	O
or	O
cryptorchidism	B-DISEASE
[	O
2	O
]	O
.	O

Sequence	O
analysis	O
was	O
performed	O
on	O
an	O
automated	O
sequencer	O
(	O
ABI	O
3730	O
,	O
Applied	O
Biosystems	O
)	O
for	O
both	O
affected	O
and	O
normal	O
individuals	O
of	O
the	O
family	O
.	O

Finally	O
,	O
five	O
cases	O
had	O
germline	O
truncation	O
variants	O
in	O
other	O
genes	O
on	O
the	O
cancer	O
gene	O
list	O
,	O
including	O
:	O
ERCC2	B-GENE
(	O
n	O
=	O
1	O
)	O
,	O
TET2	B-GENE
(	O
n	O
=	O
1	O
)	O
,	O
FANCD2	B-GENE
(	O
n	O
=	O
2	O
)	O
,	O
and	O
NF1	B-GENE
(	O
n	O
=	O
1	O
)	O
while	O
one	O
case	O
had	O
a	O
germline	O
mutation	O
in	O
RAD51B	B-GENE
which	O
has	O
recently	O
been	O
linked	O
to	O
breast	B-DISEASE
cancer	I-DISEASE
susceptibility	O
16	O
and	O
whose	O
family	O
members	O
(	O
RAD50	B-GENE
,	O
RAD51C	B-GENE
,	O
RAD51D	B-GENE
)	O
have	O
previously	O
been	O
implicated	O
in	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
.	O

In	O
addition	O
,	O
we	O
looked	O
for	O
this	O
change	O
at	O
the	O
NCBI	O
dbSNP	O
.	O

A	O
mutation	O
in	O
DMD	B-DISEASE
was	O
identified	O
by	O
multiplex	O
PCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
method	O
using	O
exon	O
-	O
specific	O
probes	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
two	O
novel	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E1248K	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
6051	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
donor	O
splice	O
site	O
mutation	O
in	O
intron	O
44	O
)	O
,	O
of	O
MYO7A	B-GENE
in	O
a	O
Chinese	O
non	O
-	O
consanguineous	O
family	O
with	O
USH1	B-DISEASE
.	O

In	O
addition	O
,	O
this	O
variant	O
has	O
never	O
been	O
identified	O
in	O
our	O
laboratory	O
(	O
so	O
far	O
we	O
analyzed	O
the	O
WFS1	B-GENE
sequence	O
in	O
200	O
European	O
patient	O
chromosomes	O
)	O
.	O

Sequencing	O
of	O
the	O
~	O
430	O
bp	O
product	O
confirmed	O
that	O
the	O
cryptic	O
splice	O
donor	O
within	O
exon	O
IIIc	O
was	O
preferred	O
in	O
the	O
mutant	O
allele	O
(	O
Figure	O
2	O
D	O
)	O
,	O
while	O
the	O
~	O
330	O
bp	O
product	O
demonstrated	O
complete	O
skipping	O
of	O
exon	O
IIIc	O
(	O
Figure	O
2	O
E	O
)	O
.	O

However	O
,	O
the	O
majority	O
of	O
patients	O
remain	O
euthyroid	O
[	O
13	O
]	O
.	O

For	O
the	O
five	O
missense	O
mutations	O
detected	O
,	O
estimated	O
conservation	O
and	O
pathogenicity	O
scores	O
(	O
Table	O
1	O
)	O
suggested	O
that	O
single	O
amino	O
acid	O
changes	O
were	O
likely	O
to	O
be	O
highly	O
damaging	O
to	O
protein	O
function	O
.	O

CACNA1D	B-GENE
encodes	O
the	O
pore	O
-	O
forming	O
alpha	O
1	O
subunit	O
of	O
a	O
voltage	O
-	O
gated	O
calcium	O
channel	O
.	O

Zhang	O
et	O
al	O
.	O
,	O
[	O
12	O
]	O
identified	O
a	O
homozygous	O
mutation	O
T322M	B-VARIANT
in	O
two	O
Chinese	O
siblings	O
;	O
Ohno	O
S	O
et	O
al	O
.	O
,	O
[	O
11	O
]	O
described	O
another	O
homozygous	O
mutation	O
W248F	B-VARIANT
in	O
a	O
Japanese	O
family	O
in	O
2008	O
.	O

To	O
address	O
this	O
challenge	O
,	O
we	O
developed	O
a	O
new	O
pipeline	O
to	O
detect	O
low	O
-	O
level	O
somatic	O
mosaicism	O
with	O
statistical	O
confidence	O
using	O
base	O
position	O
-	O
and	O
strand	O
-	O
specific	O
error	O
rate	O
maps	O
for	O
the	O
NLRP3	B-GENE
amplicons	O
to	O
be	O
studied	O
.	O

For	O
live	O
imaging	O
of	O
CD164	B-GENE
fusion	O
proteins	O
,	O
HEK	O
cells	O
were	O
co	O
-	O
transfected	O
in	O
glass	O
bottom	O
35mm	O
dishes	O
(	O
MatTek	O
)	O
with	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
CTR	O
-	O
mCherry	O
and	O
pcDNA3	O
.	O
1	O
-	O
CD164R192	B-VARIANT
*	I-VARIANT
-	O
CTR	O
-	O
eGFP	O
.	O

It	O
was	O
not	O
found	O
in	O
200	O
control	O
alleles	O
and	O
the	O
segregation	O
analysis	O
confirmed	O
that	O
this	O
mutation	O
co	O
-	O
segregates	O
with	O
the	O
disease	O
.	O

In	O
this	O
study	O
,	O
102	O
index	O
patients	O
(	O
51	O
%	O
)	O
referred	O
for	O
LQTS	B-DISEASE
testing	O
were	O
negative	O
after	O
sequencing	O
of	O
the	O
KCNQ1	B-GENE
,	O
KCNH2	B-GENE
,	O
KCNE1	B-GENE
,	O
KCNE2	B-GENE
and	O
SCN5A	B-GENE
genes	O
.	O

B	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
cumulative	O
distribution	O
of	O
COMP	B-GENE
missense	O
mutations	O
from	O
this	O
study	O
and	O
that	O
published	O
by	O
Kennedy	O
et	O
al	O
.	O

CC	O
,	O
MRD	O
decided	O
the	O
study	O
;	O
CC	O
,	O
FR	O
collected	O
blood	O
samples	O
and	O
performed	O
the	O
experiments	O
;	O
SG	O
,	O
FS	O
wrote	O
the	O
paper	O
,	O
GN	O
coordinated	O
this	O
study	O
.	O

ADOA	B-DISEASE
occurs	O
with	O
an	O
estimated	O
prevalence	O
of	O
1	O
:	O
50	O
,	O
000	O
in	O
most	O
populations	O
[	O
3	O
]	O
,	O
and	O
1	O
:	O
10	O
,	O
000	O
in	O
Denmark	O
[	O
4	O
]	O
.	O

Wolframin	O
in	O
vivo	O
is	O
organized	O
as	O
a	O
tetramer	O
which	O
originates	O
a	O
membrane	O
Ca	O
2	O
+	O
channel	O
of	O
the	O
Endoplasmic	O
Reticulum	O
(	O
ER	O
)	O
and	O
lack	O
of	O
function	O
of	O
WFS1	B-GENE
determines	O
apoptotic	O
input	O
signaling	O
[	O
40	O
]	O
.	O

Most	O
variants	O
were	O
clearly	O
polymorphic	O
,	O
but	O
at	O
least	O
two	O
out	O
of	O
the	O
15	O
nonsynonymous	O
variants	O
(	O
p	B-VARIANT
.	I-VARIANT
R350W	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R882S	I-VARIANT
)	O
are	O
predicted	O
to	O
impair	O
whirlin	O
structure	O
and	O
function	O
,	O
suggesting	O
eventual	O
pathogenicity	O
.	O

Ophthalmological	O
evaluations	O
comprised	O
funduscopy	O
,	O
a	O
acuity	O
test	O
,	O
a	O
visual	O
field	O
test	O
,	O
and	O
electroretinography	O
.	O

Isoform	O
a	O
encompasses	O
21	O
exons	O
and	O
generates	O
a	O
secreted	O
and	O
extracellular	O
protein	O
of	O
1546	O
residues	O
,	O
while	O
isoform	O
b	O
contains	O
51	O
additional	O
exons	O
at	O
the	O
C	O
terminal	O
,	O
and	O
encodes	O
a	O
protein	O
with	O
5202	O
amino	O
acids	O
(	O
Figure	O
1A	O
)	O
.	O

Support	O
for	O
the	O
exome	O
sequencing	O
was	O
provided	O
by	O
the	O
NIMH	O
Grand	O
Opportunity	O
grant	O
RCMH089905	O
,	O
the	O
Sylvan	O
C	O
.	O

29	O
Since	O
familial	O
cancer	O
predisposition	O
genes	O
are	O
also	O
often	O
somatically	O
mutated	O
in	O
non	O
-	O
familial	O
cases	O
30	O
,	O
we	O
examined	O
previously	O
characterized	O
somatic	O
SMGs	O
(	O
and	O
BRCA2	B-GENE
)	O
that	O
met	O
our	O
expression	O
criteria	O
for	O
putative	O
germline	O
functional	O
variants	O
(	O
truncation	O
and	O
predicted	O
deleterious	O
missense	O
)	O
in	O
the	O
germline	O
data	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
.	O

The	O
mean	O
hemoglobin	O
A1c	O
was	O
7	O
.	O
7	O
%	O
,	O
indicating	O
fairly	O
good	O
glycemic	O
control	O
.	O

In	O
total	O
,	O
13	O
POLR1C	B-GENE
mutations	O
were	O
detected	O
in	O
eight	O
cases	O
(	O
Supplementary	O
Table	O
2a	O
,	O
Fig	O
.	O

Polymerase	O
chain	O
reaction	O
duplicates	O
were	O
removed	O
using	O
picard	O
-	O
tools	O
-	O
1	O
.	O
59	O
(	O
http	O
:	O
/	O
/	O
picard	O
.	O
sourceforge	O
.	O
net	O
)	O
.	O

In	O
electrocochleography	O
recordings	O
,	O
cochlear	O
microphonic	O
had	O
enhanced	O
amplitudes	O
while	O
summating	O
potential	O
showed	O
normal	O
latency	O
and	O
peak	O
amplitude	O
consistent	O
with	O
preservation	O
of	O
both	O
outer	O
and	O
inner	O
hair	O
cell	O
activities	O
.	O

For	O
control	O
purposes	O
,	O
the	O
study	O
included	O
180	O
age	O
-	O
matched	O
individuals	O
with	O
normal	O
hearing	O
.	O

However	O
,	O
we	O
did	O
not	O
detect	O
any	O
disease	O
-	O
causing	O
gene	O
mutations	O
but	O
identified	O
6	O
SNPs	O
(	O
Table	O
S2	O
)	O
,	O
which	O
includes	O
two	O
novel	O
DNA	O
variants	O
.	O

Data	O
are	O
given	O
as	O
mean	O
+	O
-	O
s	O
.	O
d	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
subjects	O
or	O
guardians	O
prior	O
to	O
blood	O
sampling	O
and	O
genetic	O
testing	O
.	O

Three	O
genetic	O
loci	O
have	O
been	O
reported	O
so	O
far	O
in	O
USH2	B-DISEASE
(	O
USH2A	B-GENE
,	O
USH2C	B-GENE
and	O
USH2D	B-GENE
)	O
and	O
the	O
corresponding	O
genes	O
have	O
been	O
identified	O
.	O

A	O
dose	O
-	O
response	O
curve	O
with	O
a	O
variable	O
slope	O
could	O
be	O
obtained	O
for	O
the	O
longitudinal	O
data	O
of	O
individual	O
E10	O
for	O
each	O
frequency	O
(	O
bold	O
line	O
)	O
.	O

Linkage	O
analysis	O
studies	O
revealed	O
common	O
alleles	O
among	O
all	O
of	O
the	O
affected	O
individuals	O
for	O
DFN3	B-GENE
-	O
linked	O
STR	O
markers	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
resulting	O
mean	O
coverage	O
was	O
221x	O
(	O
patient	O
1	O
)	O
,	O
168x	O
(	O
patient	O
2	O
)	O
and	O
194x	O
(	O
patient	O
3	O
)	O
.	O

The	O
situation	O
of	O
USH	B-DISEASE
patients	O
diagnosed	O
with	O
a	O
given	O
clinical	O
subtype	O
,	O
who	O
carry	O
mutations	O
in	O
a	O
gene	O
involved	O
in	O
a	O
different	O
subtype	O
,	O
is	O
not	O
unprecedented	O
,	O
and	O
was	O
previously	O
reported	O
[	O
25	O
]	O
.	O

The	O
subjects	O
,	O
or	O
their	O
legal	O
guardians	O
in	O
the	O
case	O
of	O
subjects	O
under	O
18	O
years	O
,	O
volunteered	O
to	O
give	O
informed	O
consent	O
.	O

(	O
B	O
)	O
Segregation	O
of	O
the	O
nonsense	O
EPS8	B-GENE
mutation	O
in	O
the	O
family	O
.	O

All	O
individuals	O
were	O
evaluated	O
for	O
the	O
following	O
clinical	O
ophthalmic	O
parameters	O
:	O
best	O
-	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
,	O
color	O
vision	O
,	O
orthoptic	O
assessment	O
,	O
eyelid	O
ptosis	B-DISEASE
(	O
positive	O
if	O
the	O
margin	O
of	O
the	O
upper	O
eyelid	O
was	O
more	O
than	O
2	O
mm	O
below	O
the	O
superior	O
limbus	O
)	O
,	O
presence	O
of	O
relative	B-DISEASE
afferent	I-DISEASE
pupillary	I-DISEASE
defects	I-DISEASE
(	O
RAPD	B-DISEASE
)	O
,	O
slit	O
-	O
lamp	O
biomicroscopy	O
of	O
the	O
anterior	O
segment	O
,	O
and	O
fundus	O
examination	O
with	O
particular	O
attention	O
to	O
the	O
optic	O
nerve	O
head	O
characteristics	O
(	O
when	O
possible	O
,	O
fundus	O
photographs	O
were	O
obtained	O
)	O
.	O

Furthermore	O
,	O
p	B-VARIANT
.	I-VARIANT
Ala138Glu	I-VARIANT
has	O
a	O
milder	O
effect	O
than	O
p	B-VARIANT
.	I-VARIANT
Val199Met	I-VARIANT
(	O
family	O
C	O
versus	O
families	O
D	O
/	O
F	O
)	O
and	O
also	O
a	O
milder	O
effect	O
than	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
(	O
family	O
B	O
versus	O
families	O
D	O
/	O
F	O
)	O
.	O

De	O
novo	O
variants	O
in	O
genes	O
known	O
to	O
be	O
involved	O
in	O
developmental	O
disease	O
were	O
not	O
necessarily	O
classified	O
as	O
possibly	O
causal	O
,	O
where	O
the	O
phenotype	O
of	O
the	O
fetus	O
did	O
not	O
overlap	O
sufficiently	O
with	O
previously	O
reported	O
phenotypes	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
S190L	I-VARIANT
variant	O
was	O
found	O
in	O
the	O
same	O
patient	O
(	O
RP	O
-	O
1232	O
)	O
that	O
possessed	O
mutation	O
p	B-VARIANT
.	I-VARIANT
C224X	I-VARIANT
in	O
a	O
homozygous	O
state	O
,	O
although	O
in	O
this	O
patient	O
,	O
mutation	O
p	B-VARIANT
.	I-VARIANT
C224X	I-VARIANT
alone	O
was	O
sufficient	O
to	O
cause	O
the	O
disease	O
.	O

Although	O
the	O
number	O
of	O
targeted	O
genes	O
was	O
low	O
compared	O
to	O
previous	O
studies	O
,	O
the	O
mutation	O
detection	O
rate	O
was	O
highest	O
(	O
70	O
%	O
)	O
which	O
likely	O
results	O
from	O
completeness	O
and	O
depth	O
of	O
coverage	O
,	O
and	O
quantitative	O
data	O
analysis	O
.	O

The	O
remaining	O
two	O
genetic	O
variants	O
in	O
ZNF366	B-GENE
and	O
in	O
BDP1	B-GENE
genes	O
were	O
respectively	O
a	O
non	O
-	O
synonymous	O
and	O
a	O
stop	O
-	O
loss	O
nucleotide	O
substitution	O
.	O

HEK293T	O
cells	O
and	O
COS7	O
cells	O
(	O
ATCC	O
,	O
Manassas	O
,	O
VA	O
,	O
USA	O
)	O
were	O
grown	O
in	O
Dulbecco	O
'	O
s	O
Modified	O
Eagle	O
'	O
s	O
Medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
FBS	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Accordingly	O
,	O
polymorphisms	O
were	O
excluded	O
before	O
the	O
analysis	O
.	O

Retained	O
as	O
well	O
as	O
improperly	O
processed	O
mutant	O
CLRN1	B-GENE
polypeptides	O
are	O
likely	O
to	O
cause	O
ER	O
stress	O
,	O
which	O
in	O
turn	O
may	O
trigger	O
apoptosis	O
in	O
retinal	O
and	O
cochlear	O
sensory	O
epithelia	O
.	O

The	O
proband	O
of	O
Family	O
DE2624	O
was	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Figure	O
2E	O
)	O
and	O
normal	O
temporal	O
bone	O
imaging	O
results	O
.	O

Pure	O
-	O
tone	O
audiometry	O
(	O
PTA	O
)	O
was	O
performed	O
to	O
define	O
hearing	O
threshold	O
levels	O
(	O
dB	O
HL	B-DISEASE
)	O
for	O
both	O
air	O
and	O
bone	O
conduction	O
at	O
frequencies	O
of	O
250	O
,	O
500	O
,	O
1000	O
,	O
2000	O
,	O
4000	O
,	O
6000	O
and	O
8000	O
Hz	O
.	O

TD	O
-	O
PC	O
[	O
58	O
and	O
9	O
-	O
136	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
)	O
:	O
61	O
.	O
07	O
+	O
-	O
28	O
.	O
52	O
)	O
;	O
for	O
52	O
out	O
of	O
69	O
TD	O
patients	O
,	O
G	O
-	O
[	O
14	O
.	O
5	O
and	O
1	O
-	O
56	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
17	O
.	O
71	O
+	O
-	O
13	O
.	O
54	O
)	O
;	O
M	O
[	O
46	O
and	O
13	O
-	O
72	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
45	O
.	O
04	O
+	O
-	O
13	O
.	O
39	O
)	O
;	O
N	O
[	O
33	O
.	O
5	O
and	O
4	O
-	O
84	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
37	O
.	O
44	O
+	O
-	O
19	O
.	O
69	O
)	O
.	O

The	O
EMG	O
was	O
performed	O
in	O
the	O
abductor	O
pollicis	O
brevis	O
,	O
tibialis	O
anterior	O
and	O
vastus	O
lateralis	O
muscles	O
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
2607A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Ala869Ala	I-VARIANT
mutation	O
.	O

To	O
determine	O
the	O
in	O
vivo	O
effect	O
of	O
c	B-VARIANT
.	I-VARIANT
794T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
,	O
if	O
any	O
,	O
on	O
the	O
splicing	O
of	O
ELMOD3	B-GENE
transcripts	O
,	O
total	O
RNA	O
was	O
isolated	O
from	O
fresh	O
blood	O
samples	O
of	O
two	O
affected	O
individuals	O
(	O
V	O
:	O
2	O
and	O
V	O
:	O
11	O
)	O
and	O
one	O
normal	O
hearing	O
individual	O
(	O
V	O
:	O
3	O
)	O
by	O
use	O
of	O
TRIzol	O
reagent	O
(	O
Life	O
Technologies	O
)	O
.	O

(	O
b	O
)	O
Shown	O
are	O
scanning	O
electron	O
microscopy	O
images	O
of	O
OHC	O
(	O
arrow	O
)	O
and	O
IHC	O
(	O
arrowhead	O
)	O
stereocilia	O
bundles	O
at	O
P14	O
.	O

Similarly	O
,	O
NM_000307	O
.	O
4	O
:	O
c	B-VARIANT
.	I-VARIANT
346delG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Ala116ProfsX26	I-VARIANT
)	I-VARIANT
)	O
,	O
which	O
has	O
been	O
previously	O
reported	O
in	O
a	O
Korean	O
family	O
with	O
severe	O
deafness	B-DISEASE
[	O
21	O
]	O
,	O
leads	O
to	O
a	O
truncation	O
that	O
eliminates	O
both	O
POU	O
domains	O
.	O

Thus	O
,	O
some	O
of	O
the	O
12	O
out	O
of	O
272	O
probands	O
in	O
which	O
one	O
pathologic	O
variant	O
was	O
found	O
may	O
have	O
been	O
chance	O
findings	O
that	O
were	O
not	O
related	O
to	O
retinal	B-DISEASE
dystrophy	I-DISEASE
.	O

Briefly	O
,	O
the	O
ratio	O
of	O
CI	O
activity	O
to	O
citrate	O
synthase	O
or	O
relative	O
to	O
Complex	O
II	O
,	O
was	O
required	O
to	O
be	O
<	O
=	O
25	O
%	O
of	O
normal	O
,	O
and	O
the	O
normalized	O
activity	O
of	O
complexes	O
II	O
,	O
III	O
,	O
and	O
IV	O
were	O
required	O
to	O
be	O
at	O
least	O
twofold	O
higher	O
than	O
CI	O
activity	O
(	O
Supplementary	O
Fig	O
.	O

The	O
novel	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R668H	I-VARIANT
was	O
found	O
to	O
be	O
heterozygous	O
in	O
all	O
affected	O
family	O
members	O
,	O
but	O
it	O
was	O
absent	O
in	O
unaffected	O
family	O
members	O
.	O

It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
vascular	O
H	O
+	O
-	O
ATPase	O
proton	O
pumps	O
in	O
the	O
inner	O
ear	O
,	O
epididymis	O
and	O
kidney	O
[	O
30	O
]	O
.	O

We	O
also	O
thank	O
Tina	O
M	O
.	O

1	O
)	O
.	O

The	O
case	O
group	O
was	O
comprised	O
of	O
32	O
females	O
and	O
41	O
males	O
,	O
with	O
onset	O
age	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
varying	O
from	O
infancy	O
to	O
adolescence	O
(	O
=	O
14	O
.	O
6	O
+	O
-	O
3	O
.	O
3	O
)	O
(	O
Figure	O
S	O
1	O
)	O
.	O

Of	O
note	O
,	O
none	O
of	O
the	O
three	O
men	O
with	O
KAL1	B-GENE
mutation	O
[	O
24	O
]	O
had	O
features	O
suggesting	O
reversal	O
of	O
HH	B-DISEASE
,	O
whereas	O
at	O
least	O
1	O
out	O
of	O
6	O
(	O
17	O
%	O
)	O
of	O
KS	B-DISEASE
male	O
patients	O
with	O
an	O
FGFR1	B-GENE
mutation	O
reversed	O
[	O
24	O
]	O
.	O

The	O
delineation	O
of	O
the	O
underlying	O
cellular	O
mechanisms	O
is	O
subject	O
to	O
intensive	O
investigation	O
for	O
cytoplasmic	O
as	O
well	O
as	O
mitochondrial	O
aaRS	O
[	O
10	O
,	O
11	O
]	O
.	O

WS	B-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
WS1	B-DISEASE
,	O
OMIM	O
193500	O
)	O
and	O
type	O
2	O
(	O
WS2	B-DISEASE
)	O
are	O
more	O
common	O
than	O
type	O
3	O
(	O
WS3	B-DISEASE
)	O
and	O
type	O
4	O
(	O
WS4	B-DISEASE
)	O
.	O

(	O
A	O
)	O
Staining	O
with	O
F	O
-	O
actin	O
shows	O
three	O
rows	O
of	O
OHCs	O
and	O
one	O
row	O
of	O
IHCs	O
in	O
the	O
cochlea	O
.	O

Early	O
onset	O
AS	B-DISEASE
is	O
often	O
associated	O
with	O
large	O
exon	O
deletions	O
,	O
nonsense	O
mutations	O
or	O
splice	O
site	O
changes	O
.	O

A	O
novel	O
variant	O
may	O
represent	O
a	O
previously	O
undiscovered	O
common	O
population	O
-	O
specific	O
polymorphism	O
or	O
a	O
truly	O
private	O
mutation	O
.	O

Selected	O
variant	O
candidates	O
were	O
filtered	O
with	O
the	O
average	O
base	O
QV	O
(	O
minimum	O
average	O
base	O
quality	O
25	O
)	O
,	O
variant	O
frequency	O
(	O
40	O
-	O
60	O
%	O
for	O
heterozygous	O
mutations	O
and	O
80	O
-	O
100	O
%	O
for	O
homozygous	O
mutations	O
)	O
and	O
coverage	O
of	O
depth	O
(	O
minimum	O
coverage	O
of	O
depth	O
10	O
)	O
.	O

Although	O
the	O
molecular	O
structure	O
of	O
the	O
normal	O
BDP1	B-GENE
protein	O
has	O
not	O
yet	O
been	O
solved	O
we	O
can	O
hypothesize	O
that	O
this	O
extension	O
might	O
influence	O
the	O
structure	O
of	O
the	O
protein	O
possibly	O
leading	O
to	O
a	O
failure	O
to	O
fold	O
correctly	O
as	O
has	O
been	O
described	O
for	O
other	O
abnormal	O
proteins	O
[	O
22	O
]	O
.	O

Thirty	O
-	O
two	O
male	O
patients	O
,	O
previously	O
diagnosed	O
with	O
KS	B-DISEASE
or	O
normosmic	B-DISEASE
HH	I-DISEASE
,	O
who	O
participated	O
in	O
the	O
current	O
study	O
,	O
were	O
enrolled	O
from	O
the	O
5	O
different	O
university	O
hospitals	O
in	O
Finland	O
.	O

The	O
authors	O
would	O
like	O
to	O
acknowledge	O
the	O
efforts	O
of	O
Dr	O
Reid	O
Sutton	O
,	O
Dr	O
Carlos	O
Bacino	O
,	O
Dr	O
Fernando	O
Scaglia	O
,	O
Dr	O
Ross	O
Tonini	O
,	O
Claudia	O
Emery	O
and	O
Janet	O
Maxian	O
.	O

AIFM1	B-GENE
encodes	O
apoptosis	B-GENE
-	I-GENE
inducing	I-GENE
factor	I-GENE
1	I-GENE
,	O
a	O
flavoprotein	O
located	O
in	O
the	O
mitochondrial	O
intermembrane	O
space	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
UKK	O
.	O

Mallmann	O
(	O
Essen	O
)	O
,	O
J	O
.	O

In	O
this	O
study	O
,	O
we	O
included	O
four	O
unrelated	O
Greek	O
families	O
with	O
clinically	O
diagnosed	O
optic	B-DISEASE
atrophy	I-DISEASE
and	O
screened	O
the	O
entire	O
coding	O
and	O
flanking	O
sequences	O
of	O
the	O
OPA1	B-GENE
gene	O
in	O
the	O
four	O
probands	O
.	O

Clinical	O
and	O
genetic	O
findings	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

PCR	O
amplification	O
was	O
carried	O
out	O
using	O
standard	O
protocols	O
for	O
all	O
samples	O
with	O
the	O
exception	O
of	O
exon	O
1c	O
,	O
which	O
was	O
amplified	O
with	O
the	O
GC	O
RICH	O
PCR	O
system	O
(	O
Roche	O
,	O
Rotkreuz	O
,	O
Zug	O
,	O
Switzerland	O
)	O
due	O
to	O
its	O
high	O
GC	O
content	O
.	O

However	O
,	O
almost	O
79	O
%	O
of	O
patients	O
with	O
nonsyndromic	O
hereditary	O
deafness	B-DISEASE
in	O
China	O
do	O
not	O
have	O
mutations	O
in	O
GJB2	B-GENE
[	O
11	O
]	O
.	O

This	O
allowed	O
us	O
to	O
i	O
)	O
verify	O
the	O
familial	O
relationships	O
;	O
ii	O
)	O
assess	O
the	O
presence	O
of	O
CNVs	O
;	O
iii	O
)	O
obtain	O
accurate	O
haplotypes	O
.	O

B	O
.	O

In	O
PCDH15	B-GENE
patients	O
for	O
whom	O
detailed	O
clinical	O
information	O
was	O
obtained	O
,	O
a	O
typical	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
phenotype	O
was	O
observed	O
.	O

The	O
average	O
hearing	O
level	O
of	O
the	O
subjects	O
with	O
an	O
allele	O
featuring	O
truncating	O
mutations	O
associated	O
with	O
missense	O
mutations	O
was	O
90	O
.	O
3	O
+	O
-	O
17	O
.	O
2	O
dB	O
,	O
whereas	O
that	O
of	O
patients	O
with	O
biallelic	O
missense	O
mutations	O
was	O
90	O
.	O
0	O
+	O
-	O
10	O
.	O
2	O
dB	O
.	O

They	O
include	O
tetralogy	B-DISEASE
of	I-DISEASE
Fallot	I-DISEASE
(	O
TOF	B-DISEASE
)	O
,	O
double	B-DISEASE
outlet	I-DISEASE
of	I-DISEASE
right	I-DISEASE
ventricle	I-DISEASE
(	O
DORV	B-DISEASE
)	O
,	O
pulmonary	B-DISEASE
atresia	I-DISEASE
with	I-DISEASE
ventricular	I-DISEASE
septal	I-DISEASE
defect	I-DISEASE
(	O
PA	B-DISEASE
/	I-DISEASE
VSD	I-DISEASE
)	O
,	O
transposition	B-DISEASE
of	I-DISEASE
the	I-DISEASE
great	I-DISEASE
arteries	I-DISEASE
(	O
TGA	B-DISEASE
)	O
,	O
interrupted	B-DISEASE
aortic	I-DISEASE
arch	I-DISEASE
(	O
IAA	B-DISEASE
)	O
,	O
and	O
persistent	B-DISEASE
truncus	I-DISEASE
arteriosus	I-DISEASE
(	O
PTA	B-DISEASE
)	O
,	O
leading	O
to	O
cardiac	B-DISEASE
enlargement	I-DISEASE
,	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
,	O
poor	O
quality	O
of	O
life	O
,	O
and	O
even	O
sudden	B-DISEASE
death	I-DISEASE
in	O
the	O
absence	O
of	O
surgical	O
treatment	O
.	O

Furthermore	O
,	O
it	O
is	O
vital	O
to	O
ensure	O
EM	O
and	O
ideally	O
IF	O
for	O
collagen	O
proteins	O
are	O
available	O
and	O
reviewed	O
in	O
patients	O
with	O
unexplained	O
haematuria	B-DISEASE
even	O
in	O
the	O
absence	O
of	O
a	O
family	O
history	O
.	O

One	O
affected	O
subject	O
was	O
investigated	O
for	O
the	O
presence	O
of	O
a	O
mutation	O
in	O
MYO7A	B-GENE
.	O

Scale	O
bar	O
represents	O
10	O
mu	O
m	O
.	O

M	O
.	O

More	O
than	O
90	O
%	O
of	O
the	O
target	O
genomic	O
sequences	O
were	O
successfully	O
designed	O
to	O
be	O
captured	O
by	O
the	O
SureSelect	O
Target	O
Enrichment	O
System	O
(	O
Agilent	O
Technologies	O
,	O
CA	O
,	O
USA	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

7	O
Observed	O
DNA	O
sequence	O
variations	O
were	O
assessed	O
for	O
pathogenicity	O
by	O
review	O
of	O
the	O
scientific	O
literature	O
,	O
and	O
mutation	O
and	O
polymorphism	O
databases	O
,	O
8	O
-	O
11	O
through	O
the	O
use	O
of	O
in	O
silico	O
tools	O
including	O
sorting	O
intolerant	O
from	O
tolerant	O
(	O
SIFT	O
)	O
and	O
polymorphism	O
phenotyping	O
(	O
PolyPhen	O
)	O
,	O
12	O
13	O
and	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
and	O
Genomics	O
for	O
the	O
interpretation	O
of	O
DNA	O
sequence	O
variations	O
.	O

Detailed	O
clinical	O
,	O
imaging	O
,	O
and	O
laboratory	O
data	O
needed	O
to	O
be	O
described	O
for	O
case	O
reports	O
.	O

B	O
:	O
Chromatograms	O
of	O
normal	O
USH2A	B-GENE
DNA	O
sequence	O
and	O
subjects	O
with	O
autosomal	O
recessive	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
arRP	B-DISEASE
)	O
show	O
mutations	O
at	O
the	O
c	O
.	O
4325	O
and	O
c	O
.	O
15188	O
nucleotide	O
positions	O
in	O
USH2A	B-GENE
exons	O
20	O
and	O
70	O
,	O
respectively	O
.	O

Genetic	O
testing	O
is	O
usually	O
restricted	O
to	O
a	O
small	O
subset	O
of	O
genes	O
according	O
to	O
the	O
patient	O
'	O
s	O
phenotype	O
[	O
4	O
]	O
.	O

Nevertheless	O
,	O
the	O
comparison	O
of	O
the	O
exon	O
coverage	O
between	O
the	O
Long	O
-	O
PCR	O
and	O
in	O
-	O
solution	O
method	O
shows	O
that	O
the	O
Long	O
-	O
PCR	O
approach	O
guarantees	O
always	O
a	O
higher	O
number	O
of	O
exons	O
sequenced	O
for	O
any	O
selected	O
coverage	O
(	O
Figure	O
3	O
)	O
.	O

(	O
K	O
-	O
L	O
)	O
Fundus	O
photographies	O
evidence	O
pale	B-DISEASE
and	I-DISEASE
atrophic	I-DISEASE
papilla	I-DISEASE
,	O
substantially	O
narrowed	O
vessels	O
,	O
sparse	O
pigmentation	B-DISEASE
,	O
patches	O
of	O
chorioretinal	B-DISEASE
atrophy	I-DISEASE
in	O
the	O
mid	O
-	O
periphery	O
of	O
BE	O
,	O
and	O
a	O
well	O
-	O
defined	O
atrophic	O
macular	O
lesion	O
in	O
RE	O
and	O
RPE	O
alteration	O
in	O
LE	O
.	O

7	O
.	O
9	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Most	O
of	O
the	O
variants	O
caused	O
retention	O
of	O
pendrin	O
in	O
the	O
intracellular	O
region	O
.	O

Cellular	O
localization	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
L54P	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
and	O
WT	O
CLRN1	O
-	O
HA	O
polypeptides	O
.	O

Briefly	O
,	O
HEK293T	O
cells	O
(	O
10	O
x	O
10	O
cm	O
plates	O
)	O
were	O
transfected	O
at	O
90	O
%	O
confluency	O
with	O
1	O
u	O
g	O
/	O
mL	O
DNA	O
after	O
mixing	O
with	O
polyethyleneimine	O
(	O
PEI	O
-	O
MAX	O
;	O
Polysciences	O
,	O
Inc	O
.	O
;	O
Warrington	O
,	O
PA	O
)	O
at	O
a	O
1	O
:	O
3	O
ratio	O
of	O
DNA	O
:	O
PEI	O
in	O
Opti	O
-	O
MEM	O
medium	O
(	O
Life	O
Technologies	O
)	O
.	O

ACG2	B-DISEASE
:	I-DISEASE
Achondrogenesis	B-DISEASE
type	I-DISEASE
2	I-DISEASE
;	I-DISEASE
AVN	B-DISEASE
:	I-DISEASE
Avascular	B-DISEASE
necrosis	I-DISEASE
;	I-DISEASE
COL2A1	B-GENE
:	O
Collagen	O
,	O
type	O
II	O
,	O
alpha	O
1	O
;	O
HIV	O
:	O
Human	O
lummunodeficiency	O
virus	O
;	O
LCP	B-DISEASE
:	I-DISEASE
Legg	B-DISEASE
-	I-DISEASE
Calv	I-DISEASE
e	I-DISEASE
-	I-DISEASE
Perthes	I-DISEASE
disease	I-DISEASE
;	I-DISEASE
OA	B-DISEASE
:	I-DISEASE
Osteoarthritis	B-DISEASE
;	I-DISEASE
SEDC	B-DISEASE
:	I-DISEASE
Spondyloepiphyseal	B-DISEASE
dysplasia	I-DISEASE
congenita	I-DISEASE
;	I-DISEASE
SEMD	B-DISEASE
:	I-DISEASE
Spondyloepimetaphyseal	B-DISEASE
dysplasia	I-DISEASE
;	I-DISEASE
SLE	B-DISEASE
:	I-DISEASE
Systemic	B-DISEASE
lupus	I-DISEASE
erythematosus	I-DISEASE
;	I-DISEASE
SNP	O
:	O
Single	O
nucleic	O
acid	O
polymorphism	O
.	O

Saliva	O
samples	O
were	O
collected	O
in	O
Oragene	O
RNA	O
Self	O
-	O
Collection	O
Vials	O
(	O
DNA	O
Genotek	O
)	O
according	O
to	O
the	O
instructions	O
of	O
the	O
manufacturer	O
and	O
stored	O
at	O
-	O
20	O
deg	O
C	O
.	O

Congenital	B-DISEASE
hyperinsulinism	I-DISEASE
of	I-DISEASE
infancy	I-DISEASE
(	O
CHI	B-DISEASE
)	O
is	O
a	O
rare	O
disorder	O
characterized	O
by	O
severe	O
hypoglycemia	B-DISEASE
due	O
to	O
inappropriate	B-DISEASE
insulin	I-DISEASE
secretion	I-DISEASE
.	O

The	O
Homer2	B-GENE
-	O
/	O
-	O
colony	O
was	O
maintained	O
on	O
a	O
C57BL	O
/	O
6J	O
background	O
.	O

[	O
41	O
]	O
no	O
female	O
predominance	O
among	O
mutation	O
carriers	O
and	O
no	O
non	O
-	O
random	O
inheritance	O
,	O
with	O
a	O
significant	O
greater	O
number	O
of	O
affected	O
than	O
expected	O
,	O
could	O
be	O
observed	O
in	O
this	O
cohort	O
.	O

This	O
systematic	O
review	O
of	O
genetic	O
skeletal	O
diseases	O
also	O
revealed	O
that	O
reporting	O
of	O
rare	O
diseases	O
varies	O
significantly	O
in	O
different	O
regions	O
and	O
medical	O
resources	O
available	O
in	O
China	O
.	O

The	O
patients	O
were	O
collected	O
from	O
the	O
11	O
institutes	O
listed	O
below	O
:	O
National	O
Tokyo	O
Medical	O
Center	O
,	O
Chiba	O
Children	O
'	O
s	O
Hospital	O
,	O
National	O
Mie	O
Hospital	O
,	O
National	O
Center	O
for	O
Child	O
Health	O
and	O
Development	O
,	O
Hyogo	O
Prefectural	O
Kobe	O
Children	O
'	O
s	O
Hospital	O
,	O
Keio	O
University	O
School	O
of	O
Medicine	O
,	O
National	O
Hospital	O
Organization	O
Kanazawa	O
Medical	O
Center	O
,	O
Kanagawa	O
Children	O
'	O
s	O
Medical	O
Center	O
,	O
National	O
Hospital	O
Organization	O
Sendai	O
Medical	O
Center	O
,	O
Kanto	O
Rosai	O
Hospital	O
,	O
and	O
Hiroshima	O
Prefectural	O
Hospital	O
.	O

Note	O
different	O
alleles	O
for	O
D11S1349	O
on	O
the	O
chromosome	O
carrying	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
in	O
patients	O
465	O
and	O
505	O
,	O
respectively	O
.	O

This	O
study	O
implies	O
that	O
the	O
frequency	O
of	O
DOA	B-DISEASE
is	O
much	O
lower	O
than	O
that	O
of	O
Leber	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
in	O
Chinese	O
compared	O
with	O
other	O
ethnic	O
groups	O
.	O

This	O
was	O
performed	O
by	O
screening	O
DFNB1	B-GENE
and	O
to	O
initiate	O
prioritized	O
linkage	O
analysis	O
or	O
homozygosity	O
mapping	O
for	O
a	O
pilot	O
number	O
of	O
families	O
in	O
which	O
DFNB1	B-GENE
has	O
been	O
excluded	O
.	O

This	O
approach	O
ensures	O
highly	O
specific	O
discrimination	O
without	O
allele	O
-	O
specific	O
hybridization	O
,	O
because	O
the	O
primer	O
to	O
be	O
extended	O
anneals	O
just	O
adjacent	O
to	O
the	O
DNA	O
base	O
that	O
needs	O
to	O
be	O
identified	O
.	O

We	O
aligned	O
the	O
raw	O
sequencing	O
data	O
to	O
the	O
latest	O
reference	O
human	O
genome	O
(	O
Feb	O
.	O

CAKUT	B-DISEASE
cover	O
a	O
wide	O
range	O
of	O
structural	O
malformations	O
that	O
result	O
from	O
a	O
defect	O
in	O
the	O
morphogenesis	O
of	O
the	O
kidney	O
and	O
/	O
or	O
the	O
urinary	O
tract	O
3	O
-	O
5	O
.	O

In	O
our	O
study	O
,	O
this	O
mutation	O
was	O
found	O
in	O
homozygous	O
form	O
in	O
twelve	O
additional	O
Roma	O
families	O
originating	O
from	O
two	O
Central	O
European	O
countries	O
(	O
Slovakia	O
and	O
Hungary	O
)	O
.	O

All	O
affected	O
individuals	O
had	O
an	O
enlarged	B-DISEASE
blind	I-DISEASE
spot	I-DISEASE
at	I-DISEASE
Goldmann	I-DISEASE
perimetry	I-DISEASE
,	O
loss	B-DISEASE
of	I-DISEASE
neuroretinal	I-DISEASE
rim	I-DISEASE
on	I-DISEASE
HRT	I-DISEASE
,	O
and	B-DISEASE
a	I-DISEASE
deviating	I-DISEASE
VEP	I-DISEASE
.	O

The	O
wild	O
-	O
type	O
sequence	O
resulted	O
in	O
predicted	O
scores	O
of	O
0	O
.	O
92	O
and	O
0	O
.	O
90	O
,	O
while	O
the	O
calculated	O
values	O
of	O
the	O
numerical	O
score	O
for	O
the	O
altered	O
sequence	O
were	O
0	O
.	O
62	O
and	O
0	O
.	O
60	O
,	O
respectively	O
.	O

Complex	O
III	O
activity	O
was	O
determined	O
by	O
measuring	O
the	O
reduction	O
of	O
cytochrome	O
c	O
by	O
an	O
increase	O
of	O
absorbance	O
at	O
550	O
nm	O
.	O

All	O
the	O
affected	O
individuals	O
(	O
III	O
:	O
1	O
,	O
III	O
:	O
3	O
,	O
III	O
:	O
5	O
,	O
IV	O
:	O
1	O
,	O
IV	O
:	O
2	O
)	O
and	O
the	O
carriers	O
(	O
III	O
:	O
2	O
,	O
IV	O
:	O
3	O
)	O
have	O
three	O
bands	O
(	O
228	O
bp	O
,	O
164	O
bp	O
,	O
and	O
64	O
bp	O
)	O
,	O
while	O
the	O
unaffected	O
individuals	O
only	O
have	O
two	O
bands	O
(	O
164	O
bp	O
and	O
64	O
bp	O
)	O
.	O
The	O
patient	O
IV1	O
who	O
is	O
homozygous	O
for	O
the	O
p	B-VARIANT
.	I-VARIANT
G1734R	I-VARIANT
(	O
c	B-VARIANT
.	I-VARIANT
5200G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
mutation	O
displayed	O
only	O
one	O
228	O
bp	O
band	O
.	O

Normal	O
samples	O
appear	O
above	O
the	O
corresponding	O
tumor	O
samples	O
.	O

In	O
retrospect	O
,	O
all	O
adult	O
patients	O
fulfilled	O
the	O
following	O
criteria	O
:	O
1	O
)	O
absent	B-DISEASE
or	I-DISEASE
incomplete	I-DISEASE
pubertal	I-DISEASE
development	I-DISEASE
by	O
the	O
age	O
of	O
18	O
yrs	O
,	O
2	O
)	O
low	B-DISEASE
circulating	I-DISEASE
basal	I-DISEASE
sex	I-DISEASE
steroid	I-DISEASE
levels	I-DISEASE
in	O
association	O
with	O
inappropriately	B-DISEASE
low	I-DISEASE
or	I-DISEASE
normal	I-DISEASE
gonadotropin	I-DISEASE
levels	I-DISEASE
,	O
and	O
subnormal	B-DISEASE
or	I-DISEASE
normal	I-DISEASE
response	I-DISEASE
to	I-DISEASE
GnRH	I-DISEASE
stimulation	I-DISEASE
test	I-DISEASE
,	O
3	O
)	O
otherwise	O
normal	O
anterior	O
pituitary	O
function	O
,	O
4	O
)	O
anosmia	B-DISEASE
or	O
hyposmia	B-DISEASE
based	O
on	O
either	O
anamnestic	O
information	O
,	O
formal	O
testing	O
(	O
e	O
.	O
g	O
.	O

The	O
human	O
myosin	B-GENE
VIIA	I-GENE
is	O
composed	O
of	O
a	O
N	O
-	O
terminal	O
motor	O
domain	O
(	O
1	O
-	O
729	O
)	O
,	O
a	O
neck	O
region	O
containing	O
five	O
IQ	O
motifs	O
(	O
745	O
-	O
857	O
)	O
,	O
a	O
short	O
predicted	O
coiled	O
coil	O
domain	O
(	O
858	O
-	O
935	O
)	O
,	O
a	O
MyTH4	O
domain	O
(	O
1017	O
-	O
1253	O
)	O
,	O
a	O
4	O
.	O
1	O
-	O
Ezrin	O
-	O
radixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
(	O
1258	O
-	O
1602	O
)	O
,	O
an	O
SH3	O
domain	O
(	O
1603	O
-	O
1672	O
)	O
,	O
and	O
a	O
second	O
C	O
-	O
terminal	O
MyTH4	O
-	O
FERM	O
tandem	O
domain	O
(	O
1747	O
-	O
2205	O
)	O
.	O

(	O
3	O
)	O
A	O
paid	O
commercial	O
bioinformatic	O
analysis	O
platform	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
dnanexus	O
.	O
com	O
)	O
.	O

Functional	O
studies	O
in	O
cultured	O
podocytes	O
transfected	O
with	O
wild	O
type	O
or	O
mutant	O
COL4A3	B-GENE
chains	O
showed	O
retention	O
of	O
mutant	O
collagens	O
and	O
differential	O
activation	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
cascade	O
.	O

To	O
confirm	O
mutations	O
indicated	O
by	O
exome	O
sequencing	O
,	O
Sanger	O
sequencing	O
was	O
performed	O
for	O
PCR	O
products	O
obtained	O
with	O
primers	O
flanking	O
the	O
detected	O
mutations	O
,	O
using	O
a	O
3500xL	O
genetic	O
analyzer	O
(	O
Life	O
Technologies	O
)	O
.	O

NNSPLICE	O
version	O
0	O
.	O
9	O
was	O
used	O
to	O
predict	O
splice	O
sites	O
.	O

Exons	O
were	O
amplified	O
and	O
cycle	O
sequencing	O
was	O
performed	O
as	O
described	O
above	O
.	O

A	O
consanguineous	O
family	O
consisting	O
of	O
8	O
family	O
members	O
(	O
4	O
patients	O
,	O
2	O
healthy	O
siblings	O
and	O
their	O
healthy	O
parents	O
)	O
was	O
selected	O
for	O
the	O
analysis	O
and	O
included	O
in	O
the	O
study	O
(	O
Figure	O
1A	O
)	O
.	O

One	O
patient	O
,	O
a	O
27	O
-	O
year	O
-	O
old	O
woman	O
,	O
had	O
c	B-VARIANT
.	I-VARIANT
2728A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
22	O
(	O
p	B-VARIANT
.	I-VARIANT
K910Q	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4270G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
in	O
exon	O
31	O
(	O
p	B-VARIANT
.	I-VARIANT
D1424N	I-VARIANT
)	O
,	O
probably	O
present	O
in	O
different	O
chromosomes	O
(	O
Capria	O
et	O
al	O
.	O

that	O
showed	O
the	O
degree	O
of	O
proteinuria	B-DISEASE
in	O
mice	O
with	O
a	O
COL4A4	B-GENE
mutation	O
is	O
dependent	O
on	O
their	O
genetic	O
background	O
26	O
.	O

Among	O
the	O
various	O
patterns	O
of	O
RP	B-DISEASE
inheritance	O
,	O
arRP	B-DISEASE
is	O
the	O
most	O
frequent	O
inheritance	O
pattern	O
and	O
accounts	O
for	O
approximately	O
50	O
%	O
to	O
60	O
%	O
of	O
all	O
RP	B-DISEASE
patients	O
[	O
1	O
]	O
.	O

BE	O
-	O
1	O
:	O
(	O
Meire	O
et	O
al	O
.	O

Nonsense	O
,	O
frameshift	O
,	O
and	O
canonical	O
splice	O
site	O
variants	O
were	O
considered	O
to	O
be	O
pathogenic	O
.	O

Variants	O
were	O
called	O
by	O
real	O
-	O
time	O
SpectroCaller	O
algorithm	O
,	O
analyzed	O
by	O
SpectroTyper	O
v	O
.	O
4	O
.	O
0	O
software	O
and	O
manually	O
reviewed	O
for	O
rare	O
variants	O
.	O

Overall	O
,	O
92	O
.	O
6	O
%	O
(	O
684	O
/	O
739	O
)	O
of	O
the	O
pathogenic	O
mutations	O
are	O
frame	O
-	O
shift	O
truncation	O
or	O
nonsense	O
mutations	O
.	O

Audiometry	O
results	O
for	O
III	O
:	O
5	O
and	O
IV	O
:	O
1	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
collected	O
in	O
EDTA	O
tubes	O
using	O
an	O
automated	O
DNA	O
extractor	O
(	O
MagNA	O
Pure	O
compact	O
Instrument	O
,	O
Roche	O
Applied	O
Science	O
,	O
GmbH	O
)	O
.	O

Most	O
of	O
the	O
mutations	O
were	O
detected	O
by	O
only	O
the	O
massively	O
parallel	O
DNA	O
sequencing	O
.	O

One	O
Italian	O
Perrault	B-DISEASE
syndrome	I-DISEASE
family	O
,	O
with	O
two	O
affected	O
(	O
one	O
male	O
,	O
II1	O
;	O
and	O
one	O
female	O
,	O
II3	O
)	O
and	O
two	O
healthy	O
siblings	O
,	O
was	O
recruited	O
.	O

A	O
methodological	O
drawback	O
of	O
the	O
targeted	O
hybridisation	O
approach	O
is	O
that	O
regions	O
containing	O
repeat	O
sequences	O
cannot	O
be	O
adequately	O
covered	O
due	O
to	O
binding	O
of	O
the	O
target	O
DNA	O
to	O
multiple	O
sites	O
of	O
repetitive	O
sequence	O
.	O

WS	B-DISEASE
is	O
caused	O
by	O
homozygous	O
mutations	O
in	O
WFS1	B-GENE
,	O
a	O
gene	O
located	O
at	O
4p16	O
.	O
1	O
and	O
composed	O
of	O
seven	O
coding	O
exons	O
[	O
6	O
,	O
7	O
]	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
G45E	I-VARIANT
mutation	O
was	O
not	O
detected	O
in	O
our	O
patients	O
.	O

Moreover	O
,	O
nephropathy	B-DISEASE
occurred	O
earlier	O
in	O
MDP	O
(	O
median	O
=	O
18	O
.	O
5	O
years	O
)	O
than	O
in	O
TDP	O
(	O
median	O
=	O
40	O
years	O
)	O
,	O
P	O
=	O
0	O
.	O
062	O
.	O

Furthermore	O
,	O
heterozygosity	O
for	O
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
co	O
-	O
segregated	O
with	O
the	O
phenotype	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
pedigree	O
(	O
Figure	O
3B	O
)	O
,	O
and	O
the	O
amino	O
acid	O
residue	O
p	O
.	O
S680	O
was	O
evolutionarily	O
conserved	O
(	O
Figure	O
3C	O
)	O
.	O

The	O
header	O
of	O
each	O
picture	O
indicates	O
the	O
nucleotide	O
mutation	O
.	O

2	O
)	O
.	O

c	O
Conservation	O
of	O
the	O
amino	O
acid	O
sequence	O
in	O
the	O
p	B-VARIANT
.	I-VARIANT
T487I	I-VARIANT
mutation	O
region	O
.	O

We	O
show	O
that	O
CIB2	B-GENE
is	O
a	O
new	O
member	O
of	O
the	O
vertebrate	O
Usher	B-DISEASE
interactome	O
.	O

The	O
hearing	O
level	O
of	O
the	O
prelingual	O
or	O
early	O
-	O
onset	O
deaf	B-DISEASE
probands	O
should	O
exceed	O
70	O
dB	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
version	O
of	O
the	O
manuscript	O
.	O

Roux	O
et	O
al	O
.	O

Apple	O
-	O
Mathews	O
for	O
help	O
in	O
preparing	O
the	O
manuscript	O
,	O
and	O
Dr	O
.	O

Seventy	O
patients	O
had	O
at	O
least	O
one	O
assessable	O
de	O
novo	O
mutation	O
,	O
and	O
29	O
(	O
41	O
.	O
4	O
%	O
)	O
of	O
these	O
resided	O
in	O
the	O
hot	O
zone	O
(	O
Supplementary	O
Table	O
S7	O
online	O
)	O
.	O

Furthermore	O
,	O
it	O
was	O
also	O
identified	O
in	O
two	O
individuals	O
among	O
the	O
100	O
normal	O
controls	O
.	O

This	O
is	O
also	O
the	O
case	O
for	O
the	O
collagen	O
variants	O
described	O
in	O
our	O
cohort	O
.	O

Analyzed	O
the	O
data	O
:	O
KV	O
LP	O
PD	O
GP	O
CD	O
M	O
.	O

In	O
two	O
presumed	O
isolated	O
cases	O
,	O
mutations	O
were	O
found	O
in	O
autosomal	O
dominant	O
RP	B-DISEASE
genes	O
,	O
but	O
re	O
-	O
evaluation	O
of	O
both	O
families	O
revealed	O
that	O
one	O
of	O
the	O
parents	O
also	O
had	O
RP	B-DISEASE
.	O

A	O
targeted	O
panel	O
of	O
known	O
IRDs	B-DISEASE
causative	O
genes	O
would	O
help	O
to	O
obtain	O
a	O
potential	O
molecular	O
diagnosis	O
for	O
50	O
-	O
70	O
%	O
of	O
IRDs	B-DISEASE
cases	O
[	O
4	O
]	O
.	O

In	O
bold	O
:	O
HSCR	B-DISEASE
affected	O
individuals	O
;	O
In	O
italics	O
:	O
individual	O
affected	O
with	O
WS4	B-DISEASE
.	O

This	O
work	O
was	O
funded	O
by	O
the	O
Wellcome	O
Trust	O
(	O
093329	O
and	O
102731	O
)	O
and	O
Oxford	O
NIHR	O
Biomedical	O
Research	O
Centre	O
(	O
A	O
.	O
O	O
.	O
M	O
.	O
W	O
)	O
.	O
Congenital	B-DISEASE
long	I-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
cLQTS	B-DISEASE
)	O
is	O
a	O
genetic	O
disorder	O
predisposing	O
to	O
ventricular	B-DISEASE
arrhythmia	I-DISEASE
,	O
syncope	B-DISEASE
and	O
sudden	O
death	B-DISEASE
.	O

COL4A3	B-GENE
mutation	O
identified	O
in	O
Family	O
2	O
.	O

This	O
finding	O
adds	O
support	O
to	O
the	O
fact	O
that	O
even	O
a	O
single	O
mutation	O
in	O
autosomal	O
dominant	O
MH	B-DISEASE
,	O
can	O
offer	O
the	O
ground	O
for	O
a	O
more	O
severe	O
progression	O
which	O
often	O
times	O
results	O
in	O
FSGS	B-DISEASE
and	O
/	O
or	O
autosomal	B-DISEASE
dominant	I-DISEASE
Alport	I-DISEASE
-	I-DISEASE
like	I-DISEASE
nephritis	I-DISEASE
with	O
or	O
without	O
the	O
pathognomonic	O
ultrastructural	O
features	O
or	O
extrarenal	O
findings	O
.	O

We	O
applied	O
TDT	O
and	O
haplotype	O
analyses	O
to	O
highlight	O
possible	O
susceptibility	O
/	O
modifier	O
CHI	B-DISEASE
genes	O
.	O

James	O
Hurley	O
(	O
NIDDK	O
)	O
)	O
and	O
a	O
modification	O
of	O
the	O
method	O
that	O
was	O
described	O
in	O
Aricescu	O
et	O
al	O
[	O
37	O
]	O
.	O

Interestingly	O
,	O
Gipc3	B-GENE
343A	O
/	O
A	O
homozygotes	O
with	O
the	O
transgene	O
(	O
tg	O
+	O
A	O
/	O
A	O
)	O
showed	O
hearing	O
thresholds	O
to	O
the	O
click	O
,	O
8	O
and	O
16	O
kHz	O
stimulus	O
that	O
were	O
significantly	O
lower	O
than	O
those	O
of	O
the	O
tg	O
-	O
A	O
/	O
A	O
mice	O
.	O

In	O
both	O
families	O
,	O
compound	O
heterozygous	O
sequence	O
variants	O
were	O
detected	O
(	O
Table	O
1	O
)	O
.	O

The	O
relationship	O
between	O
mutations	O
in	O
SLC26A4	B-GENE
and	O
Mondini	B-DISEASE
deformity	I-DISEASE
without	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
has	O
not	O
been	O
studied	O
in	O
any	O
Chinese	O
deaf	O
population	O
.	O

Since	O
6	O
,	O
033	O
non	O
-	O
synonymous	O
and	O
6	O
,	O
667	O
synonymous	O
variants	O
were	O
found	O
to	O
be	O
present	O
in	O
groups	O
1	O
+	O
2	O
but	O
not	O
specific	O
to	O
groups	O
1	O
+	O
2	O
,	O
and	O
83	O
non	O
-	O
synonymous	O
and	O
86	O
synonymous	O
variants	O
were	O
revealed	O
to	O
be	O
present	O
in	O
groups	O
1	O
+	O
2	O
and	O
absent	O
from	O
group	O
3	O
,	O
a	O
certain	O
fraction	O
of	O
functional	O
variants	O
may	O
constitute	O
protective	O
factor	O
(	O
s	O
)	O
for	O
cardiovascular	O
lesion	O
and	O
susceptibility	O
factor	O
(	O
s	O
)	O
for	O
developmental	O
delay	O
.	O

Nucleotide	O
alterations	O
were	O
identified	O
by	O
sequence	O
alignment	O
with	O
the	O
NCBI	O
Reference	O
Sequence	O
(	O
RefSeq	O
)	O
using	O
DNAStar	O
software	O
V	O
.	O
5	O
.	O
0	O
(	O
DNASTAR	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
USA	O
)	O
.	O

It	O
is	O
possible	O
that	O
individuals	O
with	O
these	O
variants	O
are	O
hearing	B-DISEASE
impaired	I-DISEASE
due	O
to	O
another	O
unknown	O
mutation	O
at	O
these	O
genes	O
or	O
another	O
gene	O
.	O

Secondary	O
to	O
this	O
audiometric	O
hallmark	O
,	O
MYO1A	B-GENE
is	O
a	O
gene	O
with	O
variable	O
penetrance	O
.	O

EA	O
coordinated	O
and	O
supervised	O
the	O
study	O
and	O
drafted	O
the	O
manuscript	O
.	O

This	O
unusual	O
case	O
raised	O
a	O
question	O
whether	O
the	O
patient	O
F1	O
-	O
II	O
-	O
4	O
carried	O
a	O
de	O
novo	O
dominant	O
mutation	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R825X	I-VARIANT
mutation	O
was	O
detected	O
in	O
patient	O
II	O
-	O
5	O
of	O
the	O
SR	O
-	O
149	O
family	O
(	O
figure	O
1	O
a	O
)	O
.	O

Sequence	O
capture	O
was	O
performed	O
following	O
the	O
"	O
Titanium	O
Optimized	O
Sequence	O
Capture	O
Array	O
Delivery	O
"	O
protocol	O
(	O
version	O
1	O
.	O
0	O
)	O
,	O
as	O
supplied	O
by	O
Roche	O
and	O
optimized	O
for	O
sequence	O
capture	O
by	O
NimbleGen	O
arrays	O
.	O

Thomas	O
Friedman	O
from	O
NIH	O
)	O
.	O

Sequencing	O
of	O
all	O
genes	O
by	O
traditional	O
DNA	O
sequencing	O
technology	O
is	O
labor	O
intensive	O
and	O
not	O
cost	O
effective	O
[	O
5	O
]	O
.	O

WFS	O
prevalence	O
or	O
carrier	O
frequencies	O
in	O
Mexico	O
are	O
currently	O
unknown	O
.	O

(	O
m	O
)	O
,	O
Bright	O
field	O
image	O
of	O
a	O
neuromast	O
in	O
a	O
zebrafish	O
injected	O
with	O
control	O
morpholino	O
and	O
with	O
cib2	B-GENE
morpholino	O
.	O

The	O
study	O
is	O
designed	O
as	O
a	O
retrospective	O
observational	O
case	O
series	O
.	O

The	O
missense	O
variants	O
accounted	O
for	O
60	O
.	O
76	O
%	O
(	O
48	O
/	O
79	O
,	O
excluding	O
the	O
UTR	O
variant	O
and	O
intron	O
variants	O
)	O
of	O
all	O
the	O
SLC26A4	B-GENE
variants	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
MdCM	O
EP	O
GM	O
RGD	O
.	O

MYH9	B-GENE
-	O
RD	O
is	O
characterized	O
by	O
congenital	B-DISEASE
macrothrombocytopenia	I-DISEASE
and	O
typical	O
inclusion	O
bodies	O
in	O
neutrophils	O
associated	O
with	O
a	O
variable	O
risk	O
of	O
developing	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
presenile	B-DISEASE
cataract	I-DISEASE
,	O
and	O
/	O
or	O
progressive	B-DISEASE
nephropathy	I-DISEASE
.	O

a	O
Monozygotic	O
twins	O
.	O

No	O
dimerization	O
was	O
detected	O
with	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
NARS2	B-GENE
construct	O
.	O

DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
and	O
quality	O
and	O
quantity	O
assessed	O
using	O
standard	O
techniques	O
.	O

The	O
financial	O
support	O
of	O
the	O
research	O
grants	O
of	O
Telethon	O
projects	O
GTB07001ER	O
,	O
Eurobiobank	O
project	O
QLTR	O
-	O
2001	O
-	O
02769	O
and	O
GUP09004C	O
is	O
gratefully	O
acknowledged	O
.	O

Chromosome	O
10	O
open	O
reading	O
frame	O
2	O
(	O
C10orf2	B-GENE
)	O
,	O
also	O
known	O
as	O
Twinkle	B-GENE
or	O
PEO1	B-GENE
,	O
encodes	O
the	O
mitochondrial	B-GENE
helicase	I-GENE
Twinkle	I-GENE
.	O

It	O
was	O
proposed	O
that	O
digenic	O
inheritance	O
of	O
mutations	O
in	O
both	O
FOXI1	B-GENE
and	O
SLC26A4	B-GENE
were	O
involved	O
in	O
the	O
genetic	O
basis	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
,	O
as	O
mutations	O
in	O
FOX1	B-GENE
were	O
shown	O
to	O
reduce	O
the	O
transcription	O
of	O
SLC26A4	B-GENE
[	O
19	O
]	O
.	O

The	O
disorder	O
is	O
divided	O
into	O
three	O
clinical	O
types	O
:	O
type	O
I	O
(	O
USH1	B-DISEASE
)	O
characterised	O
by	O
profound	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
absent	B-DISEASE
vestibular	I-DISEASE
function	I-DISEASE
and	O
onset	O
of	O
RP	B-DISEASE
usually	O
within	O
the	O
first	O
decade	O
of	O
life	O
;	O
type	O
II	O
(	O
USH2	B-DISEASE
)	O
,	O
characterised	O
by	O
congenital	O
,	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
with	O
normal	O
vestibular	O
function	O
and	O
onset	O
of	O
RP	B-DISEASE
around	O
or	O
after	O
puberty	O
;	O
and	O
type	O
III	O
(	O
USH3	B-DISEASE
)	O
,	O
defined	O
by	O
postlingual	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
variable	O
vestibular	O
response	O
together	O
with	O
RP	B-DISEASE
.	O

Other	O
affected	O
deafness	B-DISEASE
genes	O
and	O
the	O
frequency	O
of	O
occurrence	O
for	O
each	O
gene	O
are	O
given	O
in	O
the	O
Table	O
3	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
members	O
of	O
these	O
families	O
ranged	O
from	O
moderate	O
to	O
profound	O
with	O
greater	O
severity	O
at	O
higher	O
frequencies	O
(	O
Figure	O
4	O
)	O
,	O
which	O
is	O
in	O
agreement	O
with	O
degeneration	O
of	O
sensory	O
hair	O
cells	O
from	O
base	O
to	O
apex	O
seen	O
in	O
the	O
Cldn14	B-GENE
knockout	O
mice	O
.	O

E	O
.	O
S	O
.	O

Neurological	O
examination	O
at	O
21	O
years	O
of	O
age	O
revealed	O
severe	O
distal	O
muscle	B-DISEASE
atrophy	I-DISEASE
,	O
pes	B-DISEASE
cavus	I-DISEASE
,	O
and	O
scoliosis	B-DISEASE
.	O

Filled	O
symbols	O
represent	O
affected	O
individuals	O
,	O
whereas	O
clear	O
symbols	O
represent	O
unaffected	O
individuals	O
.	O

b	O
Histogram	O
showing	O
a	O
unimodal	O
distribution	O
pattern	O
of	O
MFs	O
with	O
diameter	O
<	O
6	O
mu	O
m	O
,	O
representing	O
97	O
.	O
0	O
%	O
of	O
total	O
MFs	O
.	O

We	O
designed	O
oligonucleotides	O
to	O
capture	O
the	O
exons	O
and	O
regulatory	O
regions	O
of	O
246	O
genes	O
involved	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
in	O
human	O
or	O
in	O
mouse	O
.	O

Two	O
novel	O
missense	O
homozygous	O
variants	O
,	O
c	B-VARIANT
.	I-VARIANT
508C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
H170N	I-VARIANT
)	O
in	O
GIPC3	B-GENE
and	O
c	B-VARIANT
.	I-VARIANT
1328C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T443M	I-VARIANT
)	O
in	O
ZNF57	B-GENE
,	O
were	O
identified	O
in	O
the	O
same	O
~	O
6	O
Mb	O
autozygous	O
region	O
on	O
chromosome	O
19	O
in	O
affected	O
members	O
of	O
the	O
family	O
.	O

Myosin	B-GENE
VI	I-GENE
is	O
expressed	O
in	O
the	O
early	O
stage	O
of	O
hair	O
cell	O
differentiation	O
[	O
26	O
]	O
.	O

The	O
chi	O
-	O
squared	O
test	O
was	O
used	O
for	O
variants	O
for	O
which	O
all	O
expected	O
values	O
were	O
>	O
1	O
,	O
and	O
the	O
Fisher	O
'	O
s	O
exact	O
test	O
with	O
simulated	O
p	O
-	O
values	O
was	O
used	O
for	O
all	O
other	O
variants	O
[	O
23	O
]	O
.	O

The	O
mutation	O
creates	O
a	O
unique	O
Eco	O
88I	O
site	O
.	O

In	O
the	O
MYO7A	B-GENE
gene	O
,	O
ten	O
missense	O
variants	O
were	O
found	O
;	O
three	O
patients	O
were	O
compound	O
heterozygous	O
,	O
and	O
two	O
were	O
homozygous	O
.	O

PCR	O
primers	O
were	O
designed	O
with	O
online	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
idtdna	O
.	O
com	O
/	O
primerquest	O
/	O
Home	O
/	O
Index	O
)	O
.	O

Satisfactory	O
auditory	O
performance	O
in	O
the	O
patients	O
with	O
various	O
deafness	B-DISEASE
gene	O
mutations	O
indicates	O
that	O
genetic	O
background	O
would	O
be	O
helpful	O
in	O
predicting	O
performance	O
after	O
CI	O
[	O
2	O
]	O
.	O

We	O
performed	O
further	O
testing	O
for	O
KCNJ10	B-GENE
in	O
one	O
of	O
the	O
pedigrees	O
containing	O
11	O
subjects	O
with	O
the	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
812G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
.	O

Genetic	O
analysis	O
revealed	O
that	O
more	O
than	O
three	O
generations	O
carried	O
the	O
COL2A1	B-GENE
mutation	O
causing	O
this	O
disorder	O
.	O

Particularly	O
,	O
identification	O
of	O
shared	O
(	O
which	O
indicate	O
a	O
common	O
founder	O
effect	O
)	O
or	O
extended	O
haplotypes	O
over	O
closely	O
mapping	O
genes	O
(	O
which	O
strengthen	O
cosegregation	O
)	O
are	O
invaluable	O
clues	O
to	O
directly	O
pinpoint	O
the	O
causative	O
mutation	O
,	O
unveil	O
unexpected	O
candidates	O
,	O
and	O
/	O
or	O
prompt	O
re	O
-	O
evaluation	O
of	O
clinical	O
features	O
.	O

Among	O
different	O
Chinese	O
sub	O
-	O
ethnic	O
groups	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
allele	O
frequency	O
was	O
the	O
lowest	O
(	O
0	O
.	O
8	O
%	O
)	O
in	O
the	O
Tibetan	O
and	O
the	O
highest	O
(	O
31	O
.	O
0	O
%	O
)	O
in	O
Maan	O
.	O

Many	O
mutations	O
in	O
MYO7A	B-GENE
,	O
USH1C	B-GENE
,	O
CDH23	B-GENE
,	O
PCDH15	B-GENE
and	O
USH1G	B-GENE
have	O
been	O
identified	O
by	O
several	O
screenings	O
performed	O
in	O
USH1	B-DISEASE
patients	O
(	O
http	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
/	O
)	O
.	O

The	O
clinical	O
findings	O
of	O
a	O
representative	O
case	O
are	O
shown	O
in	O
Figure	O
3	O
(	O
Patient	O
1	O
-	O
II	O
-	O
1	O
)	O
.	O

Alternatively	O
,	O
the	O
methods	O
adopted	O
for	O
treacle	O
quantification	O
in	O
the	O
previous	O
report	O
were	O
not	O
able	O
to	O
detect	O
a	O
slight	O
reduction	O
in	O
protein	O
levels	O
[	O
5	O
]	O
.	O

If	O
the	O
participant	O
was	O
underage	O
,	O
the	O
participants	O
'	O
parents	O
or	O
guardians	O
signed	O
the	O
consent	O
.	O

Elmod1	B-GENE
has	O
been	O
shown	O
to	O
be	O
part	O
of	O
a	O
large	O
cluster	O
of	O
genes	O
expressed	O
in	O
the	O
developing	O
inner	O
ear	O
,	O
while	O
Elmod3	B-GENE
level	O
was	O
below	O
the	O
detectable	O
range	O
[	O
31	O
]	O
.	O

In	O
the	O
present	O
eight	O
families	O
,	O
four	O
different	O
missense	O
mutations	O
and	O
two	O
frameshift	O
mutations	O
were	O
detected	O
.	O

The	O
fraction	O
of	O
well	O
-	O
captured	O
exons	O
was	O
much	O
more	O
than	O
expectation	O
by	O
the	O
model	O
of	O
independent	O
uncaptured	O
exons	O
(	O
Figs	O
.	O

More	O
than	O
60	O
genes	O
have	O
been	O
implicated	O
in	O
nonsyndromic	B-DISEASE
RP	I-DISEASE
(	O
RetNet	O
)	O
.	O

Four	O
novel	O
truncating	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
R34fs	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S2828fs	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
W3150X	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
,	O
either	O
directly	O
or	O
indirectly	O
result	O
in	O
premature	O
termination	O
of	O
USH2A	B-GENE
translation	O
or	O
lead	O
to	O
deletion	O
of	O
more	O
than	O
one	O
amino	O
acid	O
residue	O
.	O

While	O
exome	O
sequencing	O
has	O
become	O
more	O
common	O
,	O
including	O
for	O
diagnostic	O
purposes	O
[	O
11	O
-	O
14	O
]	O
,	O
analysis	O
of	O
mutations	O
in	O
heterogeneous	O
disease	O
groups	O
in	O
which	O
the	O
associated	O
genes	O
are	O
largely	O
known	O
has	O
been	O
successfully	O
carried	O
out	O
with	O
a	O
limited	O
number	O
of	O
genes	O
using	O
the	O
targeted	O
panel	O
sequencing	O
approach	O
[	O
2	O
,	O
15	O
-	O
19	O
]	O
.	O

Following	O
ultracentrifugation	O
,	O
alpha	O
-	O
actinin	O
was	O
recovered	O
in	O
the	O
supernatant	O
fraction	O
(	O
lane	O
3	O
)	O
.	O

Variants	O
putative	O
to	O
affect	O
the	O
splicing	O
process	O
are	O
usually	O
considered	O
pathogenic	O
on	O
the	O
basis	O
of	O
their	O
conservation	O
in	O
the	O
canonical	O
splice	O
site	O
,	O
their	O
absence	O
in	O
control	O
samples	O
,	O
cosegregation	O
with	O
the	O
disease	O
in	O
families	O
and	O
results	O
from	O
bioinformatic	O
predictions	O
[	O
26	O
]	O
.	O

The	O
report	O
cited	O
above	O
of	O
de	O
novo	O
c	B-VARIANT
.	I-VARIANT
937C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
mutations	O
in	O
two	O
individuals	O
with	O
WS	B-DISEASE
seems	O
to	O
indicate	O
that	O
WS	B-DISEASE
can	O
rarely	O
be	O
caused	O
by	O
heterozygous	O
mutations	O
.	O

OA	B-DISEASE
(	O
visual	O
acuity	O
5	O
/	O
10	O
)	O
was	O
diagnosed	O
by	O
fundoscopy	O
at	O
age	O
of	O
9	O
.	O
5	O
years	O
.	O

Individuals	O
B3	O
,	O
C4	O
,	O
and	O
H3	O
were	O
implanted	O
with	O
a	O
Nucleus	O
Freedom	O
(	O
Cochlear	O
)	O
,	O
individuals	O
E8	O
and	O
G3	O
with	O
a	O
Nucleus	O
Contour	O
CI24R	O
(	O
Cochlear	O
)	O
,	O
and	O
individuals	O
E9	O
,	O
E10	O
and	O
E13	O
with	O
a	O
Clarion	O
AB	O
-	O
5100H	O
(	O
Advanced	O
Bionics	O
)	O
.	O

and	O
S	O
.	O
G	O
.	O
,	O
H	O
.	O
G	O
.	O
B	O
.	O

Coverage	O
for	O
all	O
exons	O
was	O
99	O
.	O
09	O
%	O
,	O
with	O
9	O
bp	O
being	O
left	O
out	O
from	O
COL4A4	B-GENE
,	O
107	O
bp	O
from	O
COL4A3	B-GENE
and	O
53	O
bp	O
from	O
COL4A5	B-GENE
.	O

In	O
addition	O
,	O
Gln277	O
interacts	O
with	O
Gly251	O
,	O
which	O
is	O
close	O
proximity	O
to	O
the	O
R5P	O
binding	O
site	O
(	O
Figure	O
1	O
E	O
)	O
.	O

In	O
one	O
affected	O
patient	O
,	O
Yang	O
and	O
colleagues	O
identified	O
the	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R348C	I-VARIANT
)	O
mutation	O
as	O
being	O
in	O
double	O
heterozygosity	O
with	O
a	O
SLC26A4	B-GENE
mutation	O
,	O
whereas	O
this	O
was	O
not	O
observed	O
in	O
controls	O
of	O
European	O
or	O
Chinese	O
descent	O
with	O
normal	O
hearing	O
[	O
14	O
]	O
.	O

The	O
second	O
step	O
examines	O
exome	O
sequences	O
to	O
identify	O
genetic	O
variation	O
at	O
base	O
-	O
pair	O
resolution	O
and	O
survey	O
the	O
protein	O
coding	O
portion	O
of	O
the	O
human	O
genome	O
[	O
7	O
]	O
.	O

PTA	O
was	O
calculated	O
as	O
the	O
average	O
threshold	O
measured	O
at	O
500	O
,	O
1000	O
,	O
2000	O
,	O
and	O
4000	O
Hz	O
,	O
and	O
air	O
-	O
conduction	O
threshold	O
measurements	O
were	O
performed	O
at	O
125	O
-	O
8000	O
Hz	O
[	O
18	O
,	O
19	O
]	O
.	O

c	B-VARIANT
.	I-VARIANT
6049G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G2017S	I-VARIANT
,	O
CDH23	B-GENE
)	O
.	O

B	O
:	O
Electropherogram	O
corresponding	O
to	O
the	O
patient	O
,	O
carrying	O
the	O
mutation	O
in	O
homozygous	O
state	O
(	O
c	B-VARIANT
.	I-VARIANT
369delA	I-VARIANT
)	O
.	O

Therefore	O
,	O
we	O
hypothesized	O
that	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
may	O
function	O
by	O
forming	O
direct	O
interactions	O
with	O
tTJ	O
proteins	O
.	O

Normosmic	B-DISEASE
HH	I-DISEASE
patients	O
with	O
a	O
R262Q	B-VARIANT
mutation	O
in	O
GHRHR	B-GENE
accompanied	O
by	O
other	O
GNRHR	B-GENE
mutation	O
may	O
be	O
prone	O
to	O
reversal	O
of	O
HH	B-DISEASE
.	O

If	O
markers	O
were	O
uninformative	O
,	O
other	O
markers	O
were	O
substituted	O
in	O
that	O
family	O
[	O
3	O
]	O
.	O

The	O
accession	O
numbers	O
of	O
our	O
data	O
set	O
at	O
the	O
Gem	O
.	O
app	O
database	O
are	O
87004	O
and	O
87005	O
.	O

Provenance	O
and	O
peer	O
review	O
:	O
Not	O
commissioned	O
;	O
externally	O
peer	O
reviewed	O
.	O

For	O
Agilent	O
exome	O
enrichment	O
3	O
u	O
g	O
genomic	O
DNA	O
was	O
used	O
.	O

The	O
most	O
common	O
form	O
of	O
syndromic	O
RP	B-DISEASE
is	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
which	O
usually	O
includes	O
both	O
recessive	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
2	O
]	O
.	O

To	O
induce	O
pubertal	O
development	O
and	O
to	O
maintain	O
adult	O
sex	O
steroid	O
levels	O
,	O
the	O
majority	O
of	O
HH	B-DISEASE
male	O
patients	O
need	O
life	O
-	O
long	O
testosterone	O
replacement	O
therapy	O
(	O
TRT	O
)	O
[	O
5	O
]	O
.	O

The	O
results	O
identified	O
two	O
compound	O
heterozygous	O
disease	O
-	O
segregating	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
589G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G197R	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
1171C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Q391X	I-VARIANT
)	O
,	O
in	O
the	O
TMC1	B-GENE
gene	O
.	O

(	O
Milan	O
)	O
,	O
Franco	O
Meschi	O
M	O
.	O
D	O
.	O
,	O
Elena	O
Grechi	O
M	O
.	O
D	O
.	O

A	O
,	O
B	O
)	O
Three	O
dimensional	O
CT	O
shows	O
closure	O
of	O
bilateral	O
coronal	O
sutures	O
(	O
arrows	O
)	O
and	O
left	O
lambdoidal	O
suture	O
(	O
arrows	O
)	O
with	O
sclerotic	O
changes	O
,	O
and	O
hypoplastic	O
facial	O
bone	O
and	O
shallow	O
orbit	O
.	O

DYW	O
and	O
YCW	O
interpreted	O
the	O
results	O
and	O
prepared	O
the	O
paper	O
.	O

Authors	O
are	O
grateful	O
to	O
the	O
patients	O
participating	O
in	O
the	O
study	O
and	O
to	O
their	O
family	O
members	O
,	O
and	O
also	O
to	O
the	O
FARPE	O
,	O
FIAPAS	O
,	O
ONCE	O
(	O
Valencia	O
)	O
and	O
La	O
Caixa	O
-	O
Camp	O
de	O
Morvedre	O
for	O
their	O
help	O
and	O
co	O
-	O
operation	O
.	O

Raye	O
L	O
.	O

B	O
:	O
Positions	O
of	O
mutations	O
indicated	O
in	O
schematic	O
of	O
protein	O
topology	O
.	O

USH3	B-DISEASE
is	O
characterized	O
by	O
progressive	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
variable	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Interestingly	O
,	O
we	O
found	O
that	O
novel	O
heterozygous	O
mutation	O
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
evoked	O
a	O
RWS	B-DISEASE
phenotype	O
within	O
a	O
JLNS	B-DISEASE
lineage	O
when	O
joined	O
with	O
c	B-VARIANT
.	I-VARIANT
1032G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
.	O

e	O
-	O
f	O
ATPase	O
staining	O
at	O
pH	O
9	O
.	O
4	O
revealed	O
grouping	O
of	O
type	O
1	O
and	O
type	O
2	O
myofibers	O
.	O

Three	O
of	O
the	O
five	O
mutations	O
identified	O
by	O
direct	O
sequencing	O
of	O
known	O
deafness	B-DISEASE
genes	O
in	O
the	O
candidate	O
regions	O
identified	O
by	O
linkage	O
analysis	O
/	O
homozygosity	O
mapping	O
in	O
5	O
families	O
in	O
which	O
DFNB1	B-GENE
had	O
been	O
excluded	O
have	O
been	O
reported	O
previously	O
(	O
Table	O
1	O
)	O
.	O

Overall	O
,	O
these	O
new	O
findings	O
,	O
added	O
to	O
our	O
previously	O
published	O
data	O
raise	O
the	O
total	O
number	O
of	O
archived	O
Cypriot	O
families	O
with	O
familial	B-DISEASE
MH	I-DISEASE
to	O
68	O
,	O
with	O
27	O
of	O
them	O
showing	O
heterozygous	O
COL4A3	B-GENE
/	I-GENE
A4	I-GENE
mutations	O
,	O
representing	O
39	O
,	O
7	O
%	O
.	O

PCR	O
with	O
H	O
taq	O
polymerase	O
(	O
Solgent	O
,	O
Daejeon	O
,	O
South	O
Korea	O
)	O
proceeded	O
as	O
following	O
cycles	O
:	O
15	O
minutes	O
at	O
95	O
deg	O
C	O
,	O
repeated	O
of	O
30	O
-	O
40	O
cycles	O
of	O
denaturation	O
at	O
94	O
deg	O
C	O
for	O
20	O
seconds	O
;	O
annealing	O
at	O
*	O
deg	O
C	O
for	O
40	O
seconds	O
;	O
extension	O
at	O
72	O
deg	O
C	O
for	O
30	O
seconds	O
(	O
*	O
is	O
depended	O
by	O
melting	O
temperature	O
of	O
primers	O
)	O
.	O

PCR	O
amplicons	O
were	O
sequenced	O
to	O
identify	O
the	O
variants	O
responsible	O
for	O
alterations	O
in	O
the	O
electrophoretic	O
mobility	O
detected	O
by	O
multi	O
-	O
CE	O
-	O
SSCP	O
analysis	O
.	O

1	O
B	O
)	O
,	O
which	O
was	O
used	O
as	O
a	O
tag	O
for	O
each	O
sample	O
.	O

The	O
amounts	O
of	O
total	O
plasmid	O
DNA	O
used	O
for	O
transfection	O
experiments	O
were	O
kept	O
constant	O
by	O
adding	O
pEF	O
-	O
BOS	O
vector	O
DNA	O
.	O

Controls	O
are	O
age	O
-	O
matched	O
muscle	O
biopsies	O
.	O

She	O
had	O
problems	B-DISEASE
in	I-DISEASE
visual	I-DISEASE
fixation	I-DISEASE
,	O
such	O
as	O
in	O
reading	O
during	O
walking	O
and	O
feeling	O
insecure	O
when	O
walking	O
in	O
unfamiliar	O
areas	O
like	O
walking	O
on	O
a	O
sandy	O
beach	O
.	O

Additional	O
file	O
1	O
:	O
Comparison	O
of	O
Osbpl2	B-GENE
mRNA	O
levels	O
between	O
wildtype	O
and	O
homozygous	O
Mir96	O
mutant	O
diminuendo	O
(	O
Mir96	O
Dmdo	O
)	O
mice	O
.	O

While	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
is	O
becoming	O
cheaper	O
and	O
for	O
many	O
indications	O
more	O
practical	O
,	O
a	O
focused	O
deafness	B-DISEASE
-	O
specific	O
panel	O
continues	O
to	O
offer	O
the	O
advantages	O
of	O
better	O
coverage	O
of	O
targeted	O
regions	O
,	O
greater	O
facility	O
to	O
detect	O
multiple	O
variant	O
types	O
(	O
including	O
CNVs	O
and	O
complicated	O
genomic	O
rearrangements	O
)	O
,	O
substantially	O
lower	O
costs	O
,	O
higher	O
throughput	O
,	O
simpler	O
bioinformatics	O
analysis	O
,	O
and	O
focused	O
testing	O
,	O
obviating	O
the	O
need	O
to	O
deal	O
with	O
secondary	O
/	O
incidental	O
findings	O
that	O
otherwise	O
inevitably	O
arise	O
with	O
WES	O
.	O

AN	O
,	O
SJ	O
,	O
AR	O
:	O
conception	O
and	O
design	O
,	O
analysis	O
and	O
revision	O
of	O
manuscript	O
.	O

Functional	O
analysis	O
of	O
G25V	B-VARIANT
and	O
G60D	B-VARIANT
showed	O
a	O
gain	O
-	O
of	O
-	O
function	O
of	O
the	O
I	B-GENE
Ks	I-GENE
current	O
.	O

Cases	O
with	O
nephropathy	B-DISEASE
,	O
deafness	B-DISEASE
and	O
cataracts	B-DISEASE
were	O
also	O
studied	O
in	O
relation	O
to	O
the	O
location	O
of	O
the	O
mutation	O
.	O

For	O
HGMD	O
variants	O
,	O
there	O
is	O
also	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
groups	O
(	O
p	O
<	O
9e	O
-	O
4	O
by	O
ANOVA	O
)	O
,	O
with	O
East	O
Asians	O
having	O
the	O
fewest	O
variants	O
on	O
average	O
recorded	O
in	O
that	O
database	O
(	O
Table	O
2	O
)	O
.	O

We	O
have	O
developed	O
an	O
assay	O
to	O
improve	O
the	O
molecular	O
diagnosis	O
of	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
by	O
simultaneous	O
sequencing	O
of	O
the	O
exons	O
,	O
UTRs	O
and	O
alternative	O
transcripts	O
of	O
15	O
deafness	B-DISEASE
genes	O
.	O

Though	O
our	O
family	O
is	O
not	O
large	O
,	O
a	O
moderate	O
type	O
of	O
XLAS	B-DISEASE
is	O
considered	O
due	O
to	O
the	O
mutation	O
located	O
in	O
COL4A5	B-GENE
exon	O
9	O
and	O
the	O
late	B-DISEASE
-	I-DISEASE
onset	I-DISEASE
ESRD	I-DISEASE
(	O
ESRD	B-DISEASE
at	O
36	O
years	O
,	O
II	O
:	O
1	O
;	O
Table	O
1	O
)	O
.	O

Only	O
one	O
other	O
case	O
of	O
compound	O
heterozygosity	O
has	O
previously	O
been	O
described	O
in	O
a	O
female	O
patient	O
from	O
a	O
German	O
family	O
,	O
and	O
she	O
carried	O
two	O
presumed	O
pathogenic	O
substitutions	O
in	O
exon	O
8	O
:	O
c	B-VARIANT
.	I-VARIANT
808G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E270K	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
868C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R290W	I-VARIANT
)	O
(	O
Pesch	O
et	O
al	O
.	O

PCR	O
primers	O
for	O
OTOF	B-GENE
gene	O
screening	O
and	O
non	O
-	O
pathogenic	O
sequence	O
variants	O
identified	O
in	O
this	O
study	O
.	O

Magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
was	O
accomplished	O
in	O
individual	O
B3	O
.	O

The	O
resulting	O
cDNA	O
products	O
were	O
numbered	O
according	O
to	O
NCBI	O
Reference	O
Sequence	O
:	O
NM_000141	O
.	O
4	O
.	O

Prevalent	O
deafness	O
-	O
associated	O
gene	O
mutations	O
in	O
the	O
nine	O
loci	O
studied	O
were	O
less	O
frequently	O
detected	O
in	O
Uyghur	O
NSD	B-DISEASE
patients	O
than	O
in	O
Han	O
Chinese	O
patients	O
.	O

Data	O
for	O
continuous	O
variables	O
are	O
presented	O
as	O
mean	O
,	O
standard	O
deviations	O
(	O
SD	O
)	O
and	O
/	O
or	O
range	O
.	O

Leber	B-DISEASE
hereditary	I-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
(	O
LHON	B-DISEASE
)	O
mitochondrial	O
mutations	O
and	O
mutations	O
in	O
the	O
Optic	B-GENE
atrophy	I-GENE
-	I-GENE
1	I-GENE
gene	O
(	O
OPA1	B-GENE
)	O
were	O
excluded	O
.	O

Pedigree	O
of	O
our	O
patient	O
'	O
s	O
family	O
.	O

Because	O
we	O
acquired	O
a	O
thorough	O
roadmap	O
from	O
whole	O
-	O
exome	O
sequencing	O
of	O
five	O
family	O
members	O
and	O
undertook	O
a	O
subsequent	O
segregation	O
study	O
using	O
Sanger	O
sequencing	O
from	O
an	O
additional	O
four	O
members	O
,	O
we	O
propose	O
a	O
novel	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

The	O
deletion	O
of	O
exon	O
14	O
in	O
USH2A	B-GENE
has	O
also	O
been	O
detected	O
by	O
our	O
group	O
,	O
in	O
one	O
Spanish	O
USH	B-DISEASE
patient	O
in	O
a	O
homozygous	O
state	O
(	O
unpublished	O
results	O
)	O
.	O

Hereditary	B-DISEASE
cardiomyopathies	I-DISEASE
and	O
arrhythmic	O
syndromes	O
are	O
conventionally	O
considered	O
distinct	O
groups	O
of	O
genetic	O
disorders	O
,	O
commonly	O
caused	O
by	O
mutations	O
in	O
genes	O
encoding	O
the	O
structural	O
/	O
contractile	O
proteins	O
and	O
ion	O
channels	O
,	O
respectively	O
.	O

As	O
for	O
the	O
non	O
-	O
genic	O
CNVs	O
present	O
in	O
II	O
-	O
5	O
,	O
we	O
identified	O
3	O
inherited	O
and	O
10	O
de	O
novo	O
CNVs	O
(	O
Table	O
S3	O
)	O
.	O

2	O
D	O
)	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
is	O
accelerating	O
the	O
qualitative	O
improvement	O
of	O
mutational	O
studies	O
for	O
numerous	O
heterogeneous	O
disorders	O
due	O
to	O
its	O
ability	O
to	O
perform	O
simultaneous	O
and	O
massively	O
parallel	O
sequencing	O
.	O

Myosin	B-GENE
VIIA	I-GENE
physiologic	O
function	O
is	O
best	O
studied	O
in	O
the	O
sensory	O
hair	O
cells	O
of	O
the	O
inner	O
ear	O
and	O
the	O
retina	O
.	O

We	O
also	O
identified	O
a	O
broad	O
range	O
of	O
in	O
-	O
frame	O
deletion	O
,	O
duplication	O
,	O
and	O
deletion	O
/	O
insertion	O
mutations	O
including	O
the	O
previously	O
reported	O
p	B-VARIANT
.	I-VARIANT
Asp473dup	I-VARIANT
[	O
Delot	O
et	O
al	O
.	O
,	O
1999	O
]	O
.	O

COS	O
-	O
1	O
cells	O
were	O
transiently	O
transfected	O
with	O
myc	O
-	O
tagged	O
WT	O
or	O
mutated	O
FGFR1	B-GENE
cDNA	O
.	O

Organ	O
of	O
Corti	O
dissection	O
,	O
RNA	O
extraction	O
and	O
cDNA	O
creation	O
were	O
carried	O
out	O
as	O
described	O
previously	O
[	O
32	O
]	O
.	O

These	O
mutations	O
co	O
-	O
segregate	O
with	O
auditory	B-DISEASE
and	I-DISEASE
peripheral	I-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
while	O
carriers	O
have	O
normal	O
hearing	O
and	O
sensory	O
ability	O
.	O

The	O
genomic	O
results	O
in	O
conjunction	O
with	O
subsequent	O
abnormal	O
electron	O
microscopy	O
,	O
Collagen	O
IV	O
minor	O
chain	O
immunohistochemistry	O
and	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
confirmed	O
AS	B-DISEASE
.	O

During	O
the	O
past	O
five	O
years	O
,	O
new	O
high	O
-	O
throughput	O
DNA	O
sequencing	O
technologies	O
collectively	O
referred	O
to	O
as	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
have	O
emerged	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
.	O

Deletion	O
of	O
a	O
single	O
nucleotide	O
is	O
predicted	O
to	O
cause	O
a	O
translation	O
reading	O
frameshift	O
and	O
premature	O
truncation	O
of	O
the	O
encoded	O
protein	O
,	O
p	B-VARIANT
.	I-VARIANT
V17fsX1	I-VARIANT
.	O

The	O
variant	O
calling	O
process	O
was	O
run	O
using	O
SAMtools	O
(	O
http	O
:	O
/	O
/	O
samtools	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
.	O

Contributors	O
:	O
The	O
first	O
three	O
authors	O
(	O
LZ	O
,	O
JG	O
,	O
ME	O
)	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

PCR	O
amplification	O
was	O
performed	O
by	O
published	O
protocol	O
for	O
SCN5A	B-GENE
.	O
23	O
Primer	O
sequences	O
and	O
PCR	O
conditions	O
for	O
KCNQ1	B-GENE
,	O
KCNH2	B-GENE
,	O
KCNE1	B-GENE
and	O
KCNE2	B-GENE
are	O
available	O
upon	O
request	O
(	O
phy	O
@	O
ssi	O
.	O
dk	O
)	O
.	O

Furthermore	O
,	O
in	O
zebrafish	O
and	O
Drosophila	O
,	O
CIB2	B-GENE
is	O
essential	O
for	O
the	O
function	O
and	O
proper	O
development	O
of	O
hair	O
cells	O
and	O
retinal	O
photoreceptor	O
cells	O
.	O

The	O
yellow	O
structure	O
represents	O
a	O
substrate	O
for	O
the	O
serine	O
protease	O
domain	O
(	O
figure	O
made	O
using	O
the	O
model	O
for	O
TMPRSS	O
and	O
YASARA	O
)	O
.	O

Successive	O
AO	O
images	O
were	O
taken	O
at	O
adjacent	O
retinal	O
locations	O
with	O
an	O
angular	O
spacing	O
of	O
2	O
degrees	O
in	O
the	O
horizontal	O
and	O
vertical	O
directions	O
.	O

These	O
results	O
provide	O
fundamental	O
information	O
to	O
predict	O
the	O
primary	O
cause	O
of	O
NSHL	B-DISEASE
in	O
Korean	O
patients	O
and	O
will	O
be	O
useful	O
for	O
EYA4	B-GENE
or	O
GRHL2	B-GENE
-	O
related	O
hearing	B-DISEASE
loss	I-DISEASE
diagnosis	O
in	O
Koreans	O
.	O

The	O
identification	O
of	O
a	O
large	O
founder	O
family	O
with	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
in	O
KCNH2	B-GENE
may	O
become	O
of	O
importance	O
for	O
local	O
patient	O
management	O
as	O
well	O
as	O
studies	O
into	O
the	O
prevention	O
of	O
sudden	O
cardiac	O
death	O
in	O
LQT2	O
.	O

The	O
libraries	O
were	O
cleaned	O
and	O
size	O
-	O
selected	O
using	O
the	O
AMPure	O
DNA	O
Purification	O
kit	O
(	O
Beckman	O
Agencourt	O
,	O
Danvers	O
,	O
MA	O
)	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
allele	O
of	O
slightly	O
longer	O
GJB2	B-GENE
transcripts	O
,	O
with	O
38	O
bp	O
of	O
intronic	O
sequence	O
inserted	O
in	O
the	O
5	O
'	O
UTR	O
,	O
but	O
otherwise	O
encoding	O
wild	O
-	O
type	O
Cx26	B-GENE
.	O

First	O
,	O
the	O
target	O
region	O
of	O
MPS	O
cannot	O
cover	O
all	O
coding	O
exons	O
of	O
USH	B-DISEASE
genes	O
.	O

16	O
17	O
A	O
recent	O
systematic	O
review	O
of	O
published	O
information	O
on	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Stickler	B-DISEASE
syndrome	I-DISEASE
18	O
concluded	O
that	O
more	O
than	O
half	O
of	O
all	O
patients	O
have	O
some	O
form	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
but	O
that	O
this	O
may	O
vary	O
between	O
the	O
different	O
types	O
.	O

Subpopulations	O
were	O
defined	O
by	O
clustering	O
the	O
subjects	O
on	O
the	O
calculated	O
admixture	O
proportions	O
.	O

Indeed	O
,	O
heterozygous	O
TBX1	B-GENE
mutations	O
have	O
been	O
identified	O
in	O
several	O
deletion	O
-	O
negative	O
patients	O
with	O
22q11	O
.	O
2DS	O
phenotype	O
[	O
2	O
]	O
-	O
[	O
8	O
]	O
,	O
and	O
mouse	O
studies	O
argue	O
for	O
the	O
critical	O
role	O
of	O
Tbx1	B-GENE
in	O
the	O
development	O
of	O
22q11	O
.	O
2DS	O
phenotypes	O
[	O
3	O
]	O
.	O

This	O
region	O
may	O
directly	O
bind	O
to	O
CEN2	B-GENE
at	O
the	O
negatively	O
charged	O
residues	O
,	O
and	O
substitution	O
with	O
uncharged	O
residues	O
leads	O
to	O
an	O
approximately	O
10	O
-	O
fold	O
decrease	O
in	O
the	O
binding	O
affinity	O
between	O
MFS	O
and	O
CEN	O
[	O
27	O
]	O
.	O

B	O
:	O
COR	O
audiogram	O
finding	O
(	O
1y	O
6	O
m	O
)	O
.	O

We	O
showed	O
before	O
that	O
the	O
AB8	O
/	O
13	O
cells	O
used	O
here	O
,	O
do	O
express	O
endogenously	O
the	O
collagen	O
IV	O
alpha	O
3	O
-	O
alpha	O
5	O
chains	O
[	O
19	O
]	O
.	O

The	O
G48S	B-VARIANT
mutation	O
is	O
located	O
in	O
the	O
first	O
immunoglobulin	O
-	O
like	O
domain	O
(	O
D1	O
)	O
,	O
involved	O
in	O
the	O
receptor	O
autoinhibition	O
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
is	O
a	O
common	O
birth	O
defect	O
.	O

The	O
major	O
complaint	O
of	O
ANSD	B-DISEASE
patients	O
is	O
their	O
difficulty	B-DISEASE
in	I-DISEASE
understanding	I-DISEASE
words	I-DISEASE
,	O
especially	O
of	O
loud	O
voices	O
or	O
in	O
noisy	O
environments	O
[	O
5	O
]	O
.	O

A	O
mitochondrial	O
MTTS1	B-GENE
mutation	O
was	O
identified	O
in	O
one	O
maternally	O
inherited	O
deaf	B-DISEASE
family	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Dotted	O
horizontal	O
line	O
:	O
likely	O
consanguinity	O
.	O

More	O
than	O
70	O
mutations	O
in	O
the	O
GJB2	B-GENE
gene	O
have	O
been	O
reported	O
[	O
5	O
]	O
,	O
and	O
although	O
the	O
majority	O
are	O
rare	O
or	O
private	O
,	O
the	O
prevalence	O
of	O
four	O
mutations	O
define	O
specific	O
ethnic	O
origins	O
.	O

In	O
addition	O
to	O
the	O
mutations	O
listed	O
in	O
this	O
table	O
,	O
several	O
missense	O
variants	O
and	O
in	O
-	O
frame	O
indels	O
with	O
unknown	O
functions	O
have	O
been	O
found	O
in	O
patients	O
with	O
isolated	O
cardiovascular	B-DISEASE
anomalies	I-DISEASE
and	O
in	O
those	O
with	O
DGS	O
/	O
VCFS	O
-	O
like	O
phenotype	O
[	O
4	O
]	O
.	O

CIBERER	O
is	O
an	O
initiative	O
of	O
the	O
Institute	O
of	O
Health	O
Carlos	O
III	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Science	O
and	O
Innovation	O
.	O

One	O
mutant	O
allele	O
in	O
each	O
family	O
is	O
capable	O
of	O
synthesising	O
a	O
normal	O
alpha	O
1	O
(	O
XI	O
)	O
procollagen	O
molecule	O
,	O
via	O
variable	O
pre	O
-	O
mRNA	O
processing	O
.	O

Updating	O
the	O
panel	O
accordingly	O
will	O
identify	O
the	O
causative	O
mutations	O
in	O
additional	O
patients	O
.	O

2	O
,	O
25	O
-	O
27	O
The	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
,	O
which	O
is	O
a	O
rare	O
functional	O
variant	O
with	O
a	O
relatively	O
large	O
functional	O
effect	O
size	O
,	O
in	O
conjunction	O
with	O
yet	O
-	O
to	O
-	O
be	O
identified	O
functional	O
variant	O
(	O
s	O
)	O
,	O
might	O
be	O
responsible	O
for	O
the	O
clinical	O
phenotype	O
of	O
AC	B-DISEASE
in	O
the	O
index	O
case	O
.	O

The	O
other	O
two	O
mutations	O
were	O
known	O
mutations	O
.	O

The	O
assay	O
measures	O
the	O
rate	O
of	O
the	O
NADH	O
absorbance	O
decrease	O
at	O
340	O
nm	O
,	O
which	O
is	O
proportional	O
to	O
the	O
rate	O
of	O
steady	O
-	O
state	O
ATP	O
hydrolysis	O
[	O
21	O
]	O
.	O

The	O
mutation	O
analysis	O
of	O
the	O
DMD	B-DISEASE
gene	O
was	O
performed	O
using	O
multiplex	O
PCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
technique	O
and	O
a	O
kit	O
from	O
MRC	O
-	O
Holland	O
,	O
Amsterdam	O
,	O
the	O
Netherlands	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
.	O

For	O
individual	O
II	O
.	O
3	O
at	O
the	O
age	O
of	O
3	O
months	O
,	O
brainstem	O
-	O
evoked	O
response	O
audiometry	O
demonstrated	O
a	O
threshold	O
of	O
~	O
80	O
dB	O
HL	O
.	O

In	O
contrast	O
,	O
cochlear	O
receptor	O
outer	O
hair	O
cell	O
activities	O
are	O
preserved	O
(	O
otoacoustic	O
emissions	O
,	O
cochlear	O
microphonic	O
)	O
(	O
Santarelli	O
et	O
al	O
.	O

Red	O
:	O
European	O
,	O
Blue	O
:	O
Central	O
Asian	O
,	O
Cyan	O
:	O
East	O
Asian	O
,	O
Yellow	O
:	O
African	O
,	O
Green	O
:	O
Native	O
American	O
,	O
Magenta	O
:	O
Oceania	O
.	O

In	O
summary	O
,	O
we	O
described	O
a	O
novel	O
heterozygote	O
frameshift	O
mutation	O
in	O
the	O
USH2A	B-GENE
in	O
a	O
Korean	O
woman	O
with	O
USH2	B-DISEASE
.	O

Milder	O
cerebral	O
midline	O
defects	O
including	O
isolated	O
corpus	B-DISEASE
callosum	I-DISEASE
agenesis	I-DISEASE
or	O
arhinencephaly	O
(	O
the	O
absence	O
of	O
olfactory	O
bulbs	O
and	O
tracts	O
)	O
have	O
also	O
been	O
classified	O
as	O
falling	O
within	O
the	O
HPE	B-DISEASE
spectrum	O
,	O
at	O
least	O
in	O
some	O
instances	O
.	O

1	O
)	O
.	O

However	O
,	O
there	O
is	O
evidence	O
to	O
show	O
that	O
a	O
cohort	O
of	O
patients	O
affected	O
by	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
EVA	B-DISEASE
,	O
have	O
only	O
one	O
mutant	O
allele	O
of	O
SCL26A4	B-GENE
;	O
Yang	O
et	O
al	O
.	O

Bizarre	B-DISEASE
T	I-DISEASE
waves	I-DISEASE
were	O
seen	O
in	O
3	O
/	O
4	O
JLNS	B-DISEASE
patients	O
.	O

This	O
study	O
reports	O
a	O
novel	O
missense	O
mutation	O
in	O
EDN3	B-GENE
and	O
a	O
deletion	O
mutation	O
in	O
DMD	B-DISEASE
in	O
the	O
same	O
Indian	O
family	O
.	O

The	O
exome	O
data	O
analysis	O
was	O
limited	O
to	O
the	O
genomic	O
region	O
with	O
a	O
linkage	O
LOD	O
score	O
greater	O
than	O
3	O
.	O
0	O
.	O

At	O
age	O
33	O
when	O
presented	O
to	O
our	O
hospital	O
,	O
slit	O
lamp	O
examination	O
of	O
the	O
anterior	O
segment	O
showed	O
bilateral	B-DISEASE
anterior	I-DISEASE
and	I-DISEASE
posterior	I-DISEASE
lenticonus	I-DISEASE
;	O
fundus	O
photography	O
and	O
optical	O
coherence	O
tomography	O
showed	O
bilateral	O
giant	B-DISEASE
macular	I-DISEASE
holes	I-DISEASE
which	O
were	O
larger	O
than	O
photographed	O
at	O
age	O
28	O
.	O

To	O
identify	O
the	O
mutation	O
c	B-VARIANT
.	I-VARIANT
3742G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
a	O
454	O
-	O
bp	O
fragment	O
was	O
amplified	O
and	O
digested	O
by	O
BstXI	O
.	O

20	O
However	O
,	O
in	O
our	O
two	O
families	O
we	O
did	O
not	O
observe	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
heterozygous	O
mothers	O
(	O
Figures	O
1	O
and	O
3	O
)	O
.	O

Progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
did	O
not	O
seem	O
to	O
be	O
significant	O
,	O
because	O
the	O
average	O
aggravation	O
rate	O
(	O
0	O
.	O
64	O
dB	O
/	O
yr	O
)	O
did	O
not	O
exceed	O
1	O
dB	O
/	O
yr	O
for	O
1	O
kHz	O
,	O
which	O
showed	O
the	O
most	O
prominent	O
aggravation	O
among	O
those	O
at	O
other	O
frequencies	O
in	O
the	O
affected	O
subjects	O
.	O

Sequence	O
analysis	O
of	O
CLDN14	B-GENE
revealed	O
four	O
likely	O
pathogenic	O
variants	O
.	O

As	O
the	O
patient	O
was	O
suspected	O
of	O
having	O
giant	O
-	O
cell	O
arteritis	B-DISEASE
and	O
arteritic	O
anterior	O
ischemic	O
optic	B-DISEASE
neuropathy	I-DISEASE
,	O
she	O
was	O
treated	O
with	O
500	O
mg	O
I	O
.	O
V	O
.	O

In	O
category	O
B	O
,	O
two	O
affected	O
siblings	O
and	O
an	O
unaffected	O
parent	O
underwent	O
WES	O
in	O
most	O
instances	O
.	O

In	O
this	O
assay	O
CIB2	B-GENE
does	O
not	O
interact	O
with	O
harmonin	O
,	O
cadherin	O
23	O
,	O
protocadherin15	O
-	O
CD1	O
,	O
-	O
CD2	O
and	O
-	O
CD3	O
,	O
Sans	O
,	O
usherin	O
,	O
vlgr1	O
or	O
clarin	O
-	O
1	O
.	O

DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
standard	O
protocols	O
.	O

As	O
WES	O
typically	O
identifies	O
many	O
thousands	O
of	O
exomic	O
variants	O
,	O
a	O
selection	O
strategy	O
is	O
important	O
to	O
facilitate	O
the	O
identification	O
of	O
the	O
mutation	O
that	O
causes	O
the	O
disease	O
[	O
13	O
,	O
14	O
]	O
.	O

The	O
causative	O
mutations	O
were	O
either	O
not	O
found	O
or	O
were	O
of	O
uncertain	O
pathogenicity	O
(	O
UV2	O
)	O
.	O

We	O
undertook	O
this	O
analysis	O
with	O
our	O
patient	O
cohort	O
and	O
plotted	O
the	O
time	O
of	O
survival	O
as	O
a	O
measure	O
of	O
phenotypic	O
severity	O
on	O
the	O
y	O
-	O
axis	O
(	O
Figure	O
2	O
)	O
.	O

(	O
1	O
)	O
In	O
the	O
formula	O
,	O
n	O
denotes	O
total	O
depth	O
(	O
wild	O
type	O
+	O
mutation	O
allele	O
)	O
of	O
each	O
mapped	O
position	O
,	O
j	O
denotes	O
the	O
observed	O
number	O
of	O
mutational	O
alleles	O
at	O
each	O
mapped	O
position	O
,	O
and	O
p	O
denotes	O
the	O
relative	O
frequency	O
of	O
the	O
mutation	O
allele	O
in	O
the	O
pool	O
.	O

Rostron	O
for	O
DNA	O
sequencing	O
,	O
and	O
W	O
.	O

Deafness	B-DISEASE
is	O
then	O
followed	O
by	O
progressive	O
visual	B-DISEASE
impairment	I-DISEASE
caused	O
by	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
which	O
usually	O
becomes	O
apparent	O
in	O
childhood	O
.	O

AIFM1	B-GENE
has	O
at	O
least	O
two	O
functions	O
.	O

Along	O
with	O
progression	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
began	O
to	O
involve	O
other	O
frequencies	O
.	O

A	O
:	O
Single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
for	O
the	O
heterozygous	O
mutation	O
c	B-VARIANT
.	I-VARIANT

The	O
family	O
in	O
this	O
study	O
comprised	O
six	O
affected	O
individuals	O
from	O
a	O
three	O
generation	O
pedigree	O
(	O
Fig	O
.	O

The	O
nasal	O
ciliary	O
beat	O
frequency	O
was	O
significantly	O
different	O
between	O
CDH23	B-GENE
group	O
and	O
Control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

They	O
result	O
from	O
mutations	O
in	O
many	O
genes	O
which	O
has	O
long	O
hampered	O
comprehensive	O
genetic	O
analysis	O
.	O

All	O
novel	O
pathogenic	O
missense	O
variants	O
and	O
the	O
previously	O
described	O
variant	O
p	B-VARIANT
.	I-VARIANT
Arg4192His	I-VARIANT
in	O
USH2A	B-GENE
were	O
tested	O
in	O
a	O
healthy	O
Spanish	O
control	O
population	O
.	O

A	O
total	O
of	O
254	O
non	O
-	O
synonymous	O
or	O
splicing	O
site	O
variants	O
were	O
identified	O
in	O
117	O
simplex	O
or	O
recessive	O
multiplex	O
probands	O
with	O
allele	O
frequencies	O
of	O
0	O
.	O
0025	O
or	O
lower	O
(	O
Additional	O
file	O
3	O
:	O
Table	O
S3	O
)	O
.	O

*	O
*	O
*	O
5	O
'	O
UTR	O
refers	O
to	O
200	O
bp	O
upstream	O
of	O
initiation	O
codon	O
,	O
3	O
'	O
UTR	O
is	O
defined	O
as	O
200	O
bp	O
downstream	O
of	O
termination	O
codon	O
.	O

It	O
has	O
been	O
shown	O
that	O
mutations	O
in	O
the	O
USH2A	B-GENE
gene	O
are	O
responsible	O
for	O
USH2	B-DISEASE
.	O

GJB2	B-GENE
sequencing	O
was	O
performed	O
as	O
a	O
screening	O
test	O
for	O
51	O
probands	O
without	O
any	O
noticeable	O
phenotypic	O
marker	O
.	O

Thus	O
,	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
of	O
alpha	B-GENE
-	I-GENE
tectorin	I-GENE
and	O
p	B-VARIANT
.	I-VARIANT
Cys282Gly	I-VARIANT
of	O
SLC26A4	B-GENE
were	O
considered	O
as	O
candidate	O
causative	O
mutations	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
studied	O
Mongolian	O
family	O
.	O

Filled	O
symbols	O
indicate	O
deaf	O
individuals	O
.	O

Mutations	O
in	O
this	O
gene	O
are	O
also	O
described	O
in	O
Turkey	O
[	O
22	O
]	O
and	O
Pakistan	O
[	O
23	O
]	O
with	O
prelingual	O
severe	O
to	O
profound	B-DISEASE
deafness	I-DISEASE
.	O

List	O
of	O
sequence	O
variants	O
with	O
a	O
presumably	O
pathogenic	O
effect	O
.	O

Utilisation	O
of	O
the	O
cryptic	O
donor	O
would	O
lead	O
to	O
an	O
in	O
-	O
frame	O
deletion	O
of	O
the	O
last	O
17	O
amino	O
acids	O
of	O
exon	O
IIIc	O
(	O
p	B-VARIANT
.	I-VARIANT
Gly345_Pro361del	I-VARIANT
)	O
,	O
including	O
four	O
residues	O
that	O
form	O
specific	O
contacts	O
with	O
the	O
ligand	O
FGF2	O
[	O
25	O
]	O
.	O

The	O
MYO7A	B-GENE
gene	O
has	O
49	O
exons	O
,	O
spans	O
approximately	O
87	O
kb	O
of	O
genomic	O
sequence	O
on	O
chromosome	O
11q13	O
.	O
5	O
,	O
and	O
encodes	O
the	O
actin	O
-	O
based	O
motor	O
protein	O
myosin	B-GENE
VIIa	I-GENE
.	O

The	O
latter	O
can	O
be	O
achieved	O
by	O
using	O
one	O
of	O
several	O
enrichment	O
methods	O
including	O
long	O
-	O
range	O
PCR	O
(	O
LR	O
-	O
PCR	O
)	O
,	O
fragment	O
-	O
capture	O
using	O
solid	O
surface	O
arrays	O
and	O
in	O
-	O
solution	O
oligonucleotide	O
capture	O
[	O
44	O
]	O
,	O
[	O
45	O
]	O
,	O
[	O
46	O
]	O
,	O
[	O
47	O
]	O
.	O

We	O
also	O
obtained	O
tissue	O
samples	O
from	O
TCS16	B-DISEASE
,	O
from	O
three	O
other	O
patients	O
(	O
TCS21	B-DISEASE
to	O
23	O
)	O
,	O
and	O
from	O
six	O
controls	O
submitted	O
to	O
reconstructive	O
plastic	O
surgery	O
at	O
University	O
of	O
S	O
a	O
o	O
Paulo	O
Medical	O
School	O
.	O

From	O
this	O
cohort	O
,	O
for	O
15	O
Caucasian	O
patients	O
we	O
have	O
identified	O
mutations	O
in	O
PAX3	B-GENE
or	O
MITF	B-GENE
that	O
have	O
not	O
been	O
described	O
previously	O
.	O

The	O
percentage	O
of	O
regions	O
of	O
interest	O
with	O
coverage	O
greater	O
than	O
10X	O
was	O
above	O
90	O
%	O
(	O
93	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
05	O
%	O
)	O
and	O
with	O
coverage	O
greater	O
than	O
20X	O
was	O
just	O
under	O
90	O
%	O
(	O
89	O
.	O
3	O
+	O
/	O
-	O
0	O
.	O
08	O
%	O
)	O
.	O

Because	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
oftentimes	O
monogenic	O
,	O
genetic	O
testing	O
can	O
accurately	O
predict	O
the	O
deafness	B-DISEASE
phenotype	O
.	O

For	O
these	O
putative	O
splicing	O
variants	O
,	O
the	O
exon	O
and	O
intronic	O
flanking	O
sequences	O
were	O
amplified	O
from	O
the	O
patient	O
'	O
s	O
DNA	O
,	O
using	O
the	O
High	O
Fidelity	O
Phusion	O
polymerase	O
(	O
Finnzymes	O
,	O
Espoo	O
,	O
Finland	O
)	O
with	O
primers	O
detailed	O
in	O
Table	O
1	O
.	O

Reference	O
values	O
:	O
calcium	O
,	O
9	O
.	O
0	O
-	O
11	O
.	O
0	O
mg	O
/	O
dL	O
in	O
infants	O
and	O
8	O
.	O
8	O
-	O
10	O
.	O
2	O
mg	O
/	O
dL	O
in	O
adults	O
;	O
inorganic	O
phosphate	O
,	O
4	O
.	O
8	O
-	O
7	O
.	O
5	O
mg	O
/	O
dL	O
in	O
infants	O
and	O
2	O
.	O
5	O
-	O
4	O
.	O
5	O
mg	O
/	O
dL	O
in	O
adults	O
,	O
and	O
intact	O
PTH	O
,	O
10	O
-	O
65	O
pg	O
/	O
dL	O
in	O
infants	O
and	O
14	O
-	O
55	O
pg	O
/	O
dL	O
in	O
adults	O
.	O

Negative	O
controls	O
were	O
selected	O
among	O
healthy	O
individuals	O
.	O

While	O
the	O
Mito10K	O
project	O
successfully	O
identified	O
or	O
confirmed	O
pathogenic	O
mutations	O
in	O
half	O
of	O
the	O
103	O
patients	O
with	O
CI	B-DISEASE
deficiency	I-DISEASE
(	O
Figure	O
5	O
)	O
,	O
it	O
is	O
notable	O
that	O
we	O
were	O
unable	O
to	O
identify	O
"	O
smoking	O
gun	O
"	O
mutations	O
for	O
the	O
remaining	O
half	O
.	O

Taken	O
together	O
,	O
these	O
results	O
strongly	O
indicated	O
disease	O
-	O
causing	O
mutations	O
in	O
the	O
USH2A	B-GENE
gene	O
.	O

Clinical	O
and	O
genetic	O
data	O
in	O
the	O
patients	O
with	O
biallelic	O
CDH23	B-GENE
mutations	O
*	O
1	O
Cases	O
were	O
shown	O
in	O
the	O
order	O
of	O
their	O
ages	O
at	O
the	O
latest	O
examination	O
.	O

There	O
were	O
3	O
men	O
and	O
2	O
women	O
whose	O
age	O
ranged	O
from	O
37	O
to	O
57	O
years	O
(	O
mean	O
,	O
46	O
.	O
8	O
+	O
-	O
6	O
.	O
5	O
years	O
)	O
in	O
the	O
glaucoma	O
group	O
.	O

S3	O
)	O
.	O

Apically	O
located	O
pendrin	O
seems	O
to	O
be	O
responsible	O
for	O
the	O
efflux	O
of	O
iodide	O
into	O
the	O
follicular	O
lumen	O
[	O
3	O
]	O
.	O

That	O
diagnostic	O
approach	O
was	O
reinforced	O
by	O
the	O
fact	O
that	O
no	O
phenotypic	O
difference	O
,	O
apart	O
from	O
the	O
presence	O
or	O
absence	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
was	O
observed	O
between	O
patients	O
with	O
ATP6V1B1	B-GENE
vs	O
.	O

ACTG1	B-GENE
was	O
identified	O
in	O
a	O
patient	O
with	O
post	O
-	O
lingual	O
deafness	B-DISEASE
with	O
EAS	O
(	O
Case	O
#	O
4	O
)	O
.	O

Evolutionary	O
conservation	O
across	O
species	O
was	O
assessed	O
through	O
the	O
alignment	O
of	O
orthologous	O
USH2A	B-GENE
protein	O
sequences	O
(	O
chimpanzee	O
,	O
dog	O
,	O
bovine	O
,	O
mouse	O
,	O
rat	O
,	O
chicken	O
,	O
and	O
zebrafish	O
)	O
with	O
the	O
human	O
USH2A	B-GENE
protein	O
sequence	O
,	O
using	O
HomoloGene	O
and	O
Clustal	O
Omega	O
(	O
ClustalO	O
)	O
Tool	O
.	O

PCR	O
products	O
were	O
tested	O
on	O
1	O
.	O
5	O
%	O
agarose	O
gel	O
and	O
purified	O
by	O
ExoSAP	O
.	O

Patients	O
were	O
followed	O
over	O
time	O
allowing	O
ongoing	O
assessment	O
of	O
phenotypes	O
and	O
hearing	O
status	O
,	O
and	O
continuous	O
refinement	O
of	O
suspected	O
aetiologies	O
.	O

All	O
transfections	O
were	O
performed	O
with	O
300	O
ng	O
of	O
DNA	O
(	O
50	O
ng	O
of	O
myc	O
-	O
tagged	O
WT	O
or	O
mutated	O
FGFR1	B-GENE
cDNA	O
and	O
250	O
ng	O
of	O
empty	O
vector	O
(	O
EV	O
)	O
)	O
in	O
24	O
-	O
well	O
plates	O
,	O
using	O
FuGene	O
HD	O
transfection	O
reagent	O
(	O
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
framshift	O
mutation	O
indicated	O
a	O
deletion	O
of	O
two	O
coding	O
nucleotides	O
at	O
c	O
.	O
581	O
and	O
c	O
.	O
582	O
.	O

Prior	O
studies	O
have	O
reported	O
that	O
the	O
TBX1	B-GENE
G310S	B-VARIANT
variant	O
prevents	O
TBX1	O
-	O
SMAD1	O
interaction	O
that	O
could	O
not	O
affect	O
by	O
the	O
mutations	O
that	O
abolish	O
transactivation	O
[	O
33	O
]	O
.	O

Identification	O
of	O
the	O
USH	B-DISEASE
causative	O
mutations	O
is	O
important	O
for	O
early	O
diagnosis	O
,	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O
.	O

Thus	O
,	O
the	O
carrier	O
frequency	O
of	O
GJB2	B-GENE
mutation	O
in	O
the	O
Chinese	O
population	O
is	O
not	O
negligible	O
.	O

histolytica	O
residue	O
corresponding	O
to	O
human	O
NARS2	B-GENE
p	O
.	O
Asn381	O
is	O
p	O
.	O
Val355	O
and	O
shown	O
by	O
an	O
orange	O
sphere	O
.	O

,	O
2008	O
)	O
.	O

However	O
,	O
as	O
shown	O
in	O
her	O
family	O
pedigree	O
,	O
and	O
her	O
family	O
clinical	O
findings	O
,	O
more	O
than	O
three	O
generations	O
of	O
her	O
family	O
have	O
hip	O
joint	O
lesions	O
:	O
the	O
proband	O
(	O
IV	O
-	O
1	O
)	O
,	O
her	O
father	O
(	O
III	O
-	O
20	O
)	O
and	O
her	O
grandmother	O
(	O
II	O
-	O
9	O
)	O
,	O
II	O
-	O
1	O
,	O
3	O
,	O
5	O
,	O
III	O
-	O
3	O
,	O
6	O
,	O
11	O
,	O
15	O
(	O
Figure	O
1	O
,	O
Table	O
1	O
)	O
.	O

By	O
studying	O
45	O
DOA	O
+	O
families	O
from	O
different	O
geographical	O
backgrounds	O
,	O
we	O
have	O
shown	O
that	O
additional	O
neuromuscular	O
features	O
frequently	O
develop	O
as	O
the	O
disease	O
progresses	O
,	O
with	O
an	O
adverse	O
impact	O
on	O
the	O
pre	O
-	O
existing	O
visual	O
morbidity	O
.	O

are	O
funded	O
by	O
the	O
Wellcome	O
Trust	O
,	O
and	O
the	O
UK	O
National	O
Commissioning	O
Group	O
for	O
Rare	O
Mitochondrial	B-DISEASE
Disorders	I-DISEASE
of	O
Adults	O
and	O
Children	O
.	O

Seven	O
loci	O
for	O
USH1	B-DISEASE
have	O
been	O
mapped	O
so	O
far	O
,	O
and	O
five	O
of	O
these	O
genes	O
have	O
been	O
identified	O
:	O
myosin	B-GENE
VIIA	I-GENE
(	O
MYO7A	B-GENE
,	O
USH1B	B-GENE
)	O
,	O
Usher	B-GENE
syndrome	I-GENE
1C	I-GENE
(	O
USH1C	B-GENE
,	O
USH1C	B-GENE
)	O
,	O
cadherin	B-GENE
-	I-GENE
23	I-GENE
(	O
CDH23	B-GENE
,	O
USH1D	B-GENE
)	O
,	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
(	O
PCDH15	B-GENE
,	O
USH1F	B-GENE
)	O
,	O
and	O
Usher	B-GENE
syndrome	I-GENE
1G	I-GENE
(	O
USH1G	B-GENE
,	O
USH1G	B-GENE
)	O
[	O
6	O
,	O
7	O
]	O
.	O

Mutations	O
in	O
this	O
gene	O
cause	O
DFNB3	B-GENE
hearing	B-DISEASE
loss	I-DISEASE
in	O
individuals	O
from	O
different	O
populations	O
worldwide	O
[	O
17	O
]	O
.	O

Variant	O
calling	O
and	O
annotations	O
were	O
obtained	O
using	O
the	O
Samtools	O
mpileup	O
utility	O
[	O
11	O
]	O
and	O
Annovar	O
tools	O
[	O
12	O
]	O
respectively	O
.	O

References	O
for	O
published	O
DNA	O
variations	O
as	O
well	O
as	O
dbSNP	O
identifiers	O
are	O
all	O
included	O
in	O
USHbases	O
.	O

Profound	B-DISEASE
congenital	I-DISEASE
deafness	I-DISEASE
affects	O
about	O
1	O
out	O
of	O
1000	O
newborns	O
[	O
1	O
]	O
,	O
and	O
is	O
mainly	O
of	O
genetic	O
origin	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MHS	O
JHJ	O
W	O
-	O
SL	O
JYC	O
.	O

We	O
found	O
expression	O
of	O
Bdp1	B-GENE
in	O
specific	O
cell	O
types	O
in	O
the	O
cochlea	O
including	O
endothelial	O
cells	O
of	O
the	O
blood	O
vessels	O
of	O
the	O
stria	O
vascularis	O
,	O
further	O
supporting	O
a	O
role	O
for	O
this	O
gene	O
in	O
auditory	O
function	O
.	O

Anterior	B-DISEASE
lenticonus	I-DISEASE
results	O
from	O
bulging	B-DISEASE
of	I-DISEASE
the	I-DISEASE
lens	I-DISEASE
through	O
a	O
thinned	B-DISEASE
anterior	I-DISEASE
capsule	I-DISEASE
.	O

(	O
2009	O
)	O
identified	O
KCNH2	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
R328C	I-VARIANT
in	O
a	O
control	O
individual	O
.	O

Over	O
98	O
%	O
coverage	O
of	O
the	O
targeted	O
regions	O
was	O
achieved	O
for	O
each	O
proband	O
.	O

Sequencing	O
analysis	O
failed	O
to	O
identify	O
mutations	O
in	O
the	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
genes	O
in	O
the	O
DNA	O
isolated	O
from	O
this	O
family	O
.	O

As	O
to	O
family	O
history	O
,	O
all	O
families	O
were	O
recessive	O
inheritance	O
or	O
sporadic	O
cases	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
using	O
the	O
phenol	O
-	O
chloroform	O
method	O
[	O
9	O
]	O
.	O

Our	O
initial	O
cohort	O
was	O
assembled	O
as	O
part	O
of	O
an	O
ongoing	O
epidemiological	O
study	O
of	O
inherited	O
optic	O
neuropathies	O
in	O
the	O
North	O
of	O
England	O
.	O

(	O
c	O
)	O
Histogram	O
of	O
amino	O
acid	O
conservation	O
score	O
(	O
#	O
species	O
with	O
identical	O
amino	O
acid	O
,	O
out	O
of	O
44	O
aligned	O
vertebrate	O
exons	O
)	O
shown	O
for	O
training	O
data	O
:	O
missense	O
variants	O
annotated	O
as	O
disease	O
-	O
associated	O
in	O
HGMD	O
(	O
red	O
curve	O
)	O
or	O
present	O
in	O
dbSNP128	O
(	O
blue	O
curve	O
)	O
.	O

Children	O
were	O
referred	O
to	O
one	O
of	O
us	O
(	O
M	O
.	O
K	O
.	O
)	O
by	O
their	O
teachers	O
.	O

In	O
a	O
subset	O
of	O
patients	O
with	O
dilated	B-DISEASE
cardiomyopathy	I-DISEASE
,	O
VT	B-DISEASE
is	O
the	O
initial	O
and	O
the	O
cardinal	O
manifestation	O
of	O
the	O
disease	O
.	O

dCib2	O
RNAi	O
response	O
amplitudes	O
to	O
individual	O
flicker	O
stimuli	O
also	O
approached	O
noise	O
levels	O
at	O
lower	O
frequencies	O
than	O
those	O
of	O
controls	O
(	O
Fig	O
6d	O
)	O
.	O

Our	O
study	O
intended	O
to	O
determine	O
the	O
frequency	O
of	O
mutations	O
and	O
deletions	O
in	O
these	O
genes	O
,	O
to	O
assess	O
the	O
clinical	O
phenotype	O
in	O
detail	O
and	O
to	O
identify	O
rational	O
priorities	O
for	O
molecular	O
genetic	O
diagnostics	O
procedures	O
.	O

Clinical	O
findings	O
in	O
parents	O
of	O
two	O
families	O
with	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
.	O

Together	O
,	O
the	O
mutation	O
data	O
and	O
complementation	O
experiments	O
support	O
NUBPL	B-GENE
and	O
FOXRED1	B-GENE
as	O
bona	O
fide	O
CI	O
disease	O
-	O
related	O
genes	O
in	O
individuals	O
DT35	O
and	O
DT22	O
,	O
respectively	O
.	O

However	O
,	O
at	O
least	O
two	O
cases	O
were	O
not	O
genetically	O
solved	O
.	O

(	O
A	O
-	O
B	O
)	O
Fundus	O
photographs	O
of	O
the	O
24	O
-	O
year	O
-	O
old	O
proband	O
of	O
family	O
USH01	O
reveal	O
attenuation	O
of	O
retinal	O
vessels	O
,	O
pallor	O
of	O
optic	O
disc	O
,	O
and	O
pigmentary	O
migration	O
,	O
indicating	O
an	O
atypical	O
RP	B-DISEASE
fundus	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
variant	O
resides	O
at	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
KCNQ1	B-GENE
protein	O
(	O
Figure	O
1	O
B	O
)	O
and	O
affects	O
a	O
conserved	O
amino	O
acid	O
across	O
species	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
Tools	O
/	O
msa	O
/	O
clustalo	O
/	O
)	O
(	O
Figure	O
1	O
C	O
)	O
.	O

The	O
third	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
nasal	O
ciliary	O
beat	O
frequency	O
in	O
eight	O
USH1	B-DISEASE
patients	O
and	O
compare	O
it	O
with	O
thirty	O
control	O
subjects	O
.	O

Adaptive	O
optics	O
(	O
AO	O
)	O
technology	O
has	O
enabled	O
clinicians	O
to	O
view	O
the	O
retina	O
with	O
high	O
microscopic	O
lateral	O
resolution	O
[	O
26	O
,	O
27	O
]	O
.	O

Ser86Cys	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT

To	O
evaluate	O
cochlear	O
function	O
of	O
Homer2	B-GENE
-	O
/	O
-	O
mice	O
,	O
we	O
measured	O
auditory	O
brainstem	O
responses	O
(	O
ABR	O
)	O
,	O
an	O
electrophysiological	O
hearing	O
test	O
that	O
reflects	O
the	O
activity	O
of	O
afferent	O
auditory	O
neurons	O
downstream	O
of	O
IHCs	O
.	O

We	O
thank	O
the	O
families	O
and	O
the	O
staff	O
of	O
the	O
Palestinian	O
schools	O
for	O
children	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
their	O
enthusiastic	O
participation	O
.	O

Although	O
this	O
study	O
contained	O
a	O
small	O
number	O
of	O
patients	O
,	O
the	O
identified	O
mutations	O
were	O
clearly	O
validated	O
by	O
Sanger	O
sequencing	O
as	O
well	O
as	O
co	O
-	O
segregation	O
in	O
the	O
kindred	O
(	O
Fig	O
.	O

The	O
mutation	O
carriers	O
in	O
both	O
families	O
exhibit	O
features	O
of	O
mild	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
a	O
minority	O
required	O
craniofacial	O
surgery	O
.	O

Although	O
we	O
found	O
an	O
improvement	O
over	O
the	O
low	O
GC	O
targets	O
(	O
Figure	O
2d	O
)	O
,	O
the	O
overall	O
target	O
uniformity	O
after	O
excluding	O
mtDNA	O
did	O
not	O
improve	O
over	O
the	O
commercial	O
products	O
.	O

Further	O
,	O
common	O
findings	O
were	O
hypokalemia	B-DISEASE
(	O
15	O
cases	O
had	O
K	O
<	O
3	O
.	O
5	O
mEq	O
/	O
L	O
)	O
,	O
diffuse	O
nephrocalcinosis	B-DISEASE
which	O
was	O
demonstrated	O
in	O
all	O
but	O
three	O
children	O
(	O
nephrocalcinosis	B-DISEASE
was	O
not	O
observed	O
in	O
subjects	O
7	O
.	O
1	O
and	O
19	O
.	O
1	O
and	O
ultrasound	O
data	O
was	O
not	O
available	O
in	O
case	O
11	O
.	O
1	O
)	O
,	O
rickets	B-DISEASE
(	O
5	O
cases	O
)	O
,	O
and	O
total	O
hearing	B-DISEASE
loss	I-DISEASE
/	O
cophosis	B-DISEASE
(	O
16	O
cases	O
)	O
.	O

However	O
,	O
the	O
copy	O
number	O
of	O
each	O
exon	O
in	O
the	O
tested	O
patients	O
did	O
not	O
differ	O
from	O
those	O
in	O
the	O
healthy	O
control	O
subject	O
(	O
Figure	O
S1	O
in	O
File	O
S1	O
)	O
.	O

We	O
referred	O
to	O
cases	O
assigned	O
a	O
diagnosis	O
in	O
this	O
way	O
as	O
"	O
resolved	O
.	O

CNVs	O
are	O
important	O
factors	O
for	O
human	O
genetic	O
and	O
phenotypic	O
diversity	O
[	O
6	O
]	O
.	O

This	O
patient	O
highlights	O
the	O
limitations	O
of	O
2	O
nd	O
generation	O
sequencing	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
,	O
MIM	O
276900	O
,	O
MIM	O
276905	O
,	O
MIM	O
605472	O
)	O
combines	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
with	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
[	O
1	O
]	O
.	O

Schematic	O
representation	O
of	O
PRPS1	B-GENE
with	O
the	O
location	O
of	O
the	O
novel	O
heterozygous	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
in	O
exon	O
1	O
(	O
in	O
red	O
)	O
and	O
previously	O
known	O
mutations	O
in	O
Arts	B-DISEASE
syndrome	I-DISEASE
(	O
in	O
orange	O
)	O
,	O
PRS	B-DISEASE
-	I-DISEASE
I	I-DISEASE
Superactivity	I-DISEASE
(	O
in	O
green	O
)	O
,	O
Charcot	B-DISEASE
-	I-DISEASE
Marie	I-DISEASE
-	I-DISEASE
Tooth	I-DISEASE
disease	I-DISEASE
-	I-DISEASE
5	I-DISEASE
(	O
in	O
blue	O
)	O
,	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
nonsyndromic	I-DISEASE
sensorineural	I-DISEASE
deafness	I-DISEASE
(	O
in	O
purple	O
)	O
,	O
and	O
also	O
the	O
recently	O
reported	O
mutation	O
associated	O
with	O
retinal	B-DISEASE
dystrophy	I-DISEASE
(	O
in	O
brown	O
)	O
.	O

In	O
our	O
study	O
,	O
almost	O
half	O
of	O
the	O
mutations	O
have	O
not	O
been	O
previously	O
described	O
in	O
the	O
literature	O
,	O
confirming	O
a	O
high	O
rate	O
of	O
novel	O
variants	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
novel	O
mutations	O
detected	O
in	O
this	O
study	O
are	O
marked	O
in	O
bold	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
individuals	O
recruited	O
in	O
accordance	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
(	O
Seoul	O
,	O
2008	O
)	O
.	O

Mutation	O
analysis	O
-	O
sequence	O
data	O
Sequence	O
chromatogram	O
of	O
a	O
normal	O
control	O
(	O
NC	O
)	O
,	O
an	O
individual	O
heterozygous	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
728C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
)	O
mutation	O
(	O
CARRIER	O
)	O
and	O
a	O
homozygous	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
(	O
indicated	O
by	O
an	O
arrow	O
)	O
mutation	O
in	O
an	O
affected	O
patient	O
(	O
PATIENT	O
)	O
.	O

This	O
would	O
facilitate	O
targeted	O
NGS	O
analysis	O
for	O
genetic	O
diagnosis	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Audiological	O
screening	O
included	O
a	O
comprehensive	O
questionnaire	O
(	O
collecting	O
information	O
regarding	O
any	O
history	O
of	O
exposure	O
to	O
noise	O
,	O
ototoxic	O
agents	O
,	O
and	O
genetic	O
factors	O
related	O
to	O
hearing	B-DISEASE
impairment	I-DISEASE
)	O
,	O
as	O
well	O
as	O
physical	O
and	O
audiometric	O
examinations	O
.	O

They	O
received	O
cochlear	O
implants	O
at	O
the	O
ages	O
of	O
3	O
years	O
and	O
9	O
months	O
,	O
respectively	O
.	O

Western	O
blot	O
analysis	O
of	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
CLRN1	O
-	O
HA	O
polypeptides	O
.	O

We	O
used	O
anti	O
-	O
neurofilament	O
200	O
monoclonal	O
primary	O
antibody	O
(	O
N0142	O
,	O
Sigma	O
-	O
Aldrich	O
,	O
Saint	O
Louis	O
,	O
MO	O
)	O
and	O
Alexa	O
-	O
Fluor	O
488	O
Goat	O
anti	O
-	O
mouse	O
as	O
a	O
secondary	O
antibody	O
to	O
visualize	O
spiral	O
ganglions	O
neurons	O
.	O

ELMOD3	B-GENE
belongs	O
to	O
the	O
engulfment	O
and	O
cell	O
motility	O
(	O
ELMO	O
)	O
family	O
,	O
which	O
consists	O
of	O
six	O
paralogs	O
in	O
mammals	O
.	O

This	O
observation	O
is	O
in	O
agreement	O
with	O
the	O
reports	O
from	O
the	O
studies	O
of	O
other	O
Asian	O
NSHI	B-DISEASE
patients	O
[	O
10	O
,	O
11	O
,	O
24	O
,	O
30	O
,	O
34	O
]	O
.	O

Multiple	O
sequence	O
alignments	O
were	O
performed	O
and	O
we	O
found	O
that	O
codons	O
995	O
-	O
997	O
,	O
where	O
the	O
mutation	O
occurred	O
,	O
were	O
located	O
within	O
an	O
extremely	O
conserved	O
region	O
in	O
various	O
species	O
(	O
Fig	O
.	O

For	O
example	O
,	O
the	O
EGF	O
-	O
like	O
repeats	O
of	O
COMP	B-GENE
and	O
MATN3	B-GENE
and	O
the	O
EGF	O
-	O
like	O
and	O
A	O
-	O
domains	O
of	O
matrilin	O
-	O
1	O
and	O
-	O
4	O
are	O
important	O
for	O
protein	O
integrity	O
and	O
interactions	O
in	O
cartilage	O
[	O
Wagener	O
et	O
al	O
.	O
,	O
2005	O
]	O
.	O

We	O
are	O
the	O
first	O
to	O
study	O
the	O
effect	O
of	O
an	O
YHTL	O
-	O
disrupting	O
CD164	B-GENE
mutation	O
identified	O
in	O
humans	O
.	O

Using	O
direct	O
DNA	O
sequence	O
analysis	O
of	O
exons	O
2	O
-	O
72	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
USH2A	B-GENE
,	O
we	O
found	O
two	O
novel	O
compound	O
heterozygous	O
mutations	O
:	O
one	O
missense	O
mutation	O
and	O
one	O
splicing	O
site	O
mutation	O
.	O

Sequences	O
were	O
analyzed	O
with	O
Sequencing	O
Analysis	O
software	O
v	O
.	O
5	O
.	O
2	O
(	O
Applied	O
Biosystems	O
)	O
and	O
compared	O
with	O
the	O
references	O
sequences	O
of	O
each	O
gene	O
(	O
Ensembl	O
identifiers	O
:	O
ATP6V1B1	B-GENE
:	O
ENSG00000116039	O
,	O
ATP6V0A4	B-GENE
:	O
ENSG00000105929	O
and	O
SLC4A1	B-GENE
:	O
ENSG00000004939	O
)	O
,	O
using	O
SeqScape	O
software	O
v	O
.	O
2	O
.	O
5	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Electropherogram	O
results	O
of	O
two	O
novel	O
SLC26A4	B-GENE
variants	O
in	O
family	O
Iranian	O
3	O
and	O
normal	O
alleles	O
.	O

In	O
addition	O
95	O
pan	O
-	O
ethnic	O
controls	O
were	O
sequenced	O
for	O
FOXI1	B-GENE
.	O

This	O
covered	O
1	O
,	O
253	O
exons	O
with	O
a	O
total	O
coding	O
region	O
of	O
193	O
,	O
634	O
bp	O
.	O

PE	O
physical	O
exam	O
,	O
CGT	O
comprehensive	O
genetic	O
testing	O
,	O
NSHL	B-DISEASE
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
TFT	O
thyroid	O
function	O
test	O
.	O

We	O
supposed	O
the	O
possibility	O
of	O
other	O
genes	O
participating	O
in	O
the	O
ANSD	B-DISEASE
pathogenesis	O
cooperation	O
with	O
OTOF	B-GENE
and	O
PJVK	B-GENE
or	O
that	O
the	O
disorder	O
resulted	O
from	O
a	O
combination	O
of	O
genetic	O
and	O
environmental	O
conditions	O
.	O

(	O
A	O
)	O
Pedigree	O
of	O
family	O
I	O
comprised	O
of	O
two	O
generations	O
.	O

The	O
diagnostic	O
yield	O
of	O
exome	O
sequencing	O
for	O
patients	O
with	O
Mendelian	O
diseases	O
is	O
25	O
%	O
(	O
5	O
)	O
,	O
suggesting	O
that	O
it	O
might	O
complement	O
conventional	O
prenatal	O
diagnostic	O
techniques	O
.	O

7162	O
)	O
with	O
autosomal	B-DISEASE
recessive	I-DISEASE
USH1	I-DISEASE
.	O

Mutations	O
in	O
the	O
CREBBP	B-GENE
gene	O
are	O
one	O
of	O
the	O
most	O
commonly	O
reported	O
genetic	O
etiologies	O
of	O
RSTS	B-DISEASE
(	O
Table	O
S2	O
)	O
.	O

An	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
with	O
complete	O
penetrance	O
and	O
a	O
disease	O
allele	O
frequency	O
of	O
0	O
.	O
001	O
were	O
used	O
in	O
the	O
analysis	O
.	O

The	O
diabetic	B-DISEASE
mother	O
and	O
son	O
(	O
III	O
-	O
2	O
and	O
IV	O
-	O
2	O
)	O
of	O
this	O
family	O
had	O
blunted	O
insulin	O
and	O
C	O
-	O
peptide	O
responses	O
when	O
challenged	O
with	O
a	O
glucose	O
load	O
of	O
75	O
g	O
.	O

Informed	O
written	O
consent	O
was	O
obtained	O
from	O
all	O
study	O
participants	O
.	O

Interestingly	O
,	O
even	O
though	O
a	O
substantial	O
number	O
of	O
genes	O
are	O
known	O
to	O
cause	O
ARNSHL	B-DISEASE
,	O
mutations	O
at	O
the	O
first	O
identified	O
DFNB1	B-GENE
locus	O
,	O
account	O
for	O
up	O
to	O
50	O
%	O
of	O
all	O
cases	O
with	O
this	O
diagnosis	O
in	O
various	O
populations	O
.	O

The	O
epidemiologic	O
study	O
presented	O
here	O
is	O
based	O
on	O
the	O
largest	O
number	O
of	O
random	O
samples	O
describing	O
an	O
unbiased	O
general	O
population	O
screen	O
and	O
once	O
more	O
supports	O
the	O
heterogeneous	O
composition	O
of	O
the	O
Languedoc	O
Roussillon	O
population	O
.	O

Also	O
,	O
as	O
no	O
316	O
-	O
bp	O
product	O
was	O
detected	O
,	O
the	O
alternative	O
site	O
1	O
from	O
the	O
35delG	B-VARIANT
allele	O
seems	O
to	O
be	O
minimally	O
used	O
or	O
not	O
used	O
at	O
all	O
.	O

Residue	O
p	O
.	O
Glu638	O
is	O
salt	O
bridging	O
p	O
.	O
Lys644	O
at	O
the	O
edge	O
of	O
the	O
KMSKS	O
loop	O
,	O
stabilizing	O
its	O
closed	O
state	O
.	O

A	O
COL4A5	B-GENE
c	B-VARIANT
.	I-VARIANT
499delC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro167Gln	I-VARIANT
fs	I-VARIANT
*	I-VARIANT
36	I-VARIANT
)	O
mutation	O
in	O
exon	O
9	O
,	O
cosegregating	O
with	O
the	O
disease	O
,	O
was	O
identified	O
.	O

RM	O
and	O
AAC	O
provided	O
analytic	O
and	O
data	O
assistance	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pedigrees	O
of	O
the	O
seven	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

According	O
to	O
their	O
research	O
,	O
mutant	O
gamma	O
-	O
actin	O
expressing	O
leukemia	O
cells	O
display	O
resistance	B-DISEASE
to	I-DISEASE
anti	I-DISEASE
-	I-DISEASE
microtubule	I-DISEASE
drugs	I-DISEASE
.	O

Neither	O
this	O
manuscript	O
nor	O
one	O
with	O
substantially	O
similar	O
content	O
under	O
our	O
authorship	O
has	O
been	O
published	O
or	O
is	O
being	O
considered	O
for	O
publication	O
elsewhere	O
.	O
Stickler	B-DISEASE
syndromes	I-DISEASE
types	O
1	O
,	O
2	O
and	O
3	O
are	O
usually	O
dominant	O
disorders	O
caused	O
by	O
mutations	O
in	O
the	O
genes	O
COL2A1	B-GENE
,	O
COL11A1	B-GENE
and	O
COL11A2	B-GENE
that	O
encode	O
the	O
fibrillar	O
collagens	O
types	O
II	O
and	O
XI	O
present	O
in	O
cartilage	O
and	O
vitreous	O
.	O

Myosin	B-GENE
VIIA	I-GENE
has	O
been	O
implicated	O
in	O
recessively	O
inherited	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
1B	I-GENE
(	O
USH1B	B-DISEASE
)	O
[	O
8	O
]	O
,	O
atypical	B-DISEASE
Usher	I-DISEASE
syndrome	I-DISEASE
(	O
USH3	B-DISEASE
)	O
[	O
9	O
]	O
,	O
nonsyndromic	O
recessive	O
(	O
Deafness	B-DISEASE
,	O
Neurosensory	O
,	O
Autosomal	O
Recessive	O
2	O
[	O
DFNB2	B-GENE
]	O
)	O
[	O
10	O
]	O
,	O
and	O
dominant	O
(	O
DFNA11	B-GENE
)	O
[	O
11	O
]	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
HL	B-DISEASE
)	O
.	O

This	O
distinction	O
is	O
not	O
clear	O
-	O
cut	O
in	O
all	O
renal	O
diseases	O
associated	O
with	O
collagen	O
(	O
IV	O
)	O
abnormalities	O
given	O
their	O
variable	O
natural	O
history	O
and	O
phenotypes	O
.	O

The	O
ability	O
of	O
WES	O
to	O
transition	O
from	O
clinical	O
testing	O
to	O
research	O
studies	O
in	O
such	O
a	O
fashion	O
will	O
increase	O
the	O
diagnostic	O
success	O
rate	O
in	O
the	O
long	O
-	O
term	O
and	O
is	O
a	O
significant	O
advantage	O
of	O
WES	O
over	O
current	O
clinical	O
methodologies	O
[	O
Ku	O
et	O
al	O
.	O
,	O
2012	O
]	O
.	O

We	O
first	O
applied	O
the	O
LOH	O
analysis	O
to	O
germline	O
truncation	O
variants	O
in	O
BRCA1	B-GENE
and	O
BRCA2	B-GENE
and	O
a	O
small	O
set	O
of	O
other	O
tumor	O
suppressor	O
genes	O
,	O
demonstrating	O
a	O
strong	O
tendency	O
to	O
induce	O
LOH	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
the	O
tumor	O
.	O

Mutations	O
were	O
detected	O
on	O
both	O
alleles	O
in	O
21	O
USH1	B-DISEASE
patients	O
(	O
including	O
the	O
six	O
consanguineous	O
families	O
)	O
,	O
and	O
on	O
one	O
allele	O
in	O
the	O
remaining	O
three	O
USH1	B-DISEASE
patients	O
.	O

However	O
,	O
RP	B-DISEASE
in	O
the	O
Iranian	O
DFNB2	B-GENE
family	O
was	O
ruled	O
out	O
by	O
funduscopy	O
excluding	O
severe	O
but	O
not	O
mild	O
RP	B-DISEASE
.	O

In	O
two	O
German	O
siblings	O
(	O
DE	O
-	O
1	O
)	O
,	O
both	O
the	O
c	B-VARIANT
.	I-VARIANT
635_636del	I-VARIANT
(	O
amino	O
acid	O
)	O
deletion	O
(	O
p	B-VARIANT
.	I-VARIANT
K212fsX4	I-VARIANT
)	O
in	O
exon	O
6	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
1642G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V548I	I-VARIANT
)	O
missense	O
mutation	O
in	O
exon	O
17	O
were	O
present	O
.	O

Abbreviations	O
:	O
N	O
/	O
A	O
,	O
data	O
not	O
available	O
;	O
the	O
asterisk	O
indicates	O
that	O
the	O
allele	O
frequency	O
referred	O
to	O
patients	O
sample	O
.	O

Considerable	O
advances	O
have	O
been	O
made	O
in	O
our	O
understanding	O
of	O
the	O
genetics	O
of	O
monogenic	O
diabetes	B-DISEASE
,	O
which	O
accounts	O
for	O
1	O
-	O
3	O
%	O
of	O
diabetes	B-DISEASE
cases	O
(	O
1	O
-	O
3	O
)	O
.	O

Family	O
W19	O
was	O
not	O
reported	O
to	O
be	O
related	O
to	O
family	O
W4	O
.	O

The	O
24_49ins26bp	B-VARIANT
variant	O
is	O
a	O
novel	O
frameshift	O
,	O
which	O
results	O
in	O
a	O
premature	O
stop	O
codon	O
and	O
a	O
truncated	O
Cx31	O
protein	O
.	O

.	O

The	O
novel	O
mutation	O
p	B-VARIANT
.	I-VARIANT
P678S	I-VARIANT
is	O
located	O
in	O
the	O
poly	O
-	O
L	O
-	O
proline	O
stretch	O
of	O
the	O
FH1	O
domain	O
.	O

In	O
this	O
study	O
,	O
both	O
families	O
with	O
ARNSHL	B-DISEASE
caused	O
by	O
CDH23	B-GENE
mutations	O
carried	O
the	O
p	B-VARIANT
.	I-VARIANT
Pro240Leu	I-VARIANT
mutation	O
and	O
,	O
additionally	O
,	O
two	O
of	O
93	O
hearing	B-DISEASE
-	I-DISEASE
loss	I-DISEASE
patients	O
were	O
heterozygous	O
for	O
the	O
mutation	O
.	O

Our	O
results	O
indicate	O
that	O
none	O
of	O
patients	O
have	O
PS	B-DISEASE
.	O

II	O
-	O
3	O
and	O
III	O
-	O
2	O
declined	O
renal	O
biopsy	O
.	O

Ambrogio	O
for	O
Illumina	O
sequence	O
project	O
management	O
,	O
T	O
.	O

Variants	O
found	O
at	O
a	O
frequency	O
greater	O
than	O
3	O
%	O
in	O
the	O
exome	O
samples	O
were	O
classified	O
as	O
"	O
benign	O
,	O
"	O
and	O
variants	O
with	O
an	O
exome	O
frequency	O
between	O
1	O
%	O
and	O
3	O
%	O
or	O
variants	O
with	O
a	O
frequency	O
of	O
3	O
%	O
or	O
more	O
in	O
the	O
100	O
blindness	O
samples	O
were	O
classified	O
"	O
unknown	O
.	O

Expectation	O
number	O
was	O
calculated	O
by	O
the	O
model	O
assuming	O
that	O
uncapturing	O
of	O
exons	O
occur	O
independently	O
between	O
samples	O
.	O

Data	O
of	O
the	O
Family	O
295	O
.	O

Mean	O
duration	O
of	O
remission	O
in	O
WSD	B-DISEASE
was	O
2	O
.	O
3	O
+	O
-	O
2	O
.	O
4	O
vs	O
.	O

The	O
hyporeflective	O
region	O
in	O
the	O
IR	O
image	O
coincided	O
well	O
with	O
the	O
area	O
containing	O
the	O
microcystic	O
structures	O
in	O
the	O
AO	O
images	O
(	O
Figures	O
7	O
(	O
a	O
)	O
-	O
7	O
(	O
d	O
)	O
)	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
novel	O
missense	O
mutation	O
of	O
TECTA	B-GENE
in	O
a	O
Chinese	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
family	O
characterized	O
by	O
prelingual	O
-	O
onset	O
,	O
progressive	O
all	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Both	O
genes	O
are	O
located	O
in	O
the	O
same	O
chromosome	O
(	O
PCDH15	B-GENE
in	O
10q21	O
.	O
1	O
and	O
CDH23	B-GENE
in	O
10q22	O
.	O
3	O
)	O
.	O

Both	O
mutations	O
were	O
incorporated	O
in	O
the	O
Usher	O
genotyping	O
microchip	O
from	O
Asper	O
Ophthamics	O
(	O
Tartu	O
,	O
Estonia	O
)	O
.	O

Audiogram	O
of	O
probands	O
who	O
were	O
genetically	O
diagnosed	O
by	O
TRS	O
-	O
204	O
.	O

The	O
difference	O
may	O
due	O
to	O
the	O
relatively	O
small	O
sample	O
size	O
.	O

The	O
novel	O
CEP250	B-GENE
[	O
10	O
]	O
had	O
not	O
been	O
associated	O
with	O
USH	B-DISEASE
at	O
the	O
beginning	O
of	O
this	O
study	O
,	O
so	O
it	O
was	O
not	O
included	O
in	O
our	O
work	O
.	O

Ca	O
V	O
1	O
.	O
3	O
I770M	B-VARIANT
showed	O
inactivation	O
shifted	O
to	O
more	O
hyperpolarized	O
potentials	O
(	O
Fig	O
.	O

Usher	B-DISEASE
Syndrome	I-DISEASE
Missense	O
Analysis	O
is	O
a	O
web	O
-	O
based	O
tool	O
dedicated	O
to	O
analysis	O
of	O
missense	O
variants	O
in	O
Usher	B-DISEASE
genes	O
available	O
through	O
USHbases	O
.	O

We	O
determined	O
the	O
cause	O
of	O
disease	O
in	O
67	O
%	O
of	O
our	O
patients	O
.	O

The	O
evaluation	O
included	O
MRI	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
region	O
and	O
olfactive	O
bulbs	O
(	O
n	O
=	O
27	O
)	O
,	O
olfactometry	O
(	O
n	O
=	O
16	O
)	O
,	O
and	O
ultrasound	O
evaluation	O
of	O
the	O
kidneys	O
in	O
KS	B-DISEASE
(	O
n	O
=	O
3	O
)	O
and	O
in	O
CHARGE	B-DISEASE
(	O
coloboma	B-DISEASE
,	O
heart	O
defects	O
,	O
atresia	O
choanae	O
,	O
retardation	O
of	O
growth	O
and	O
/	O
or	O
development	O
,	O
genitourinary	O
problems	O
,	O
ear	O
abnormalities	O
combined	O
with	O
deafness	B-DISEASE
,	O
n	O
=	O
1	O
)	O
.	O

It	O
is	O
worth	O
noting	O
that	O
whole	O
genome	O
sequencing	O
data	O
for	O
2	O
cases	O
were	O
generated	O
using	O
the	O
SOLiD	O
platform	O
,	O
furnishing	O
orthogonal	O
validation	O
of	O
the	O
variants	O
discovered	O
using	O
Illumina	O
sequencing	O
data	O
.	O

(	O
Figs	O
5d	O
and	O
6e	O
,	O
f	O
)	O
performed	O
experiments	O
.	O

Primers	O
used	O
for	O
generating	O
PCR	O
products	O
for	O
sequencing	O
were	O
tagged	O
with	O
M13	O
sequence	O
.	O

b	O
ARTA	O
derived	O
from	O
a	O
longitudinal	O
regression	O
analysis	O
of	O
mean	O
AC	O
threshold	O
levels	O
of	O
individual	O
E10	O
.	O

HI	B-DISEASE
was	O
evaluated	O
by	O
pure	O
-	O
tone	O
audiometry	O
,	O
testing	O
for	O
air	O
conduction	O
(	O
frequencies	O
125	O
-	O
8	O
,	O
000	O
Hz	O
)	O
and	O
for	O
bone	O
conduction	O
(	O
frequencies	O
250	O
-	O
4	O
,	O
000	O
Hz	O
)	O
.	O

The	O
discovery	O
broadens	O
the	O
genotypic	O
spectrum	O
of	O
COL4A5	B-GENE
mutations	O
associated	O
with	O
AS	B-DISEASE
and	O
has	O
implications	O
for	O
genetic	O
diagnosis	O
,	O
therapy	O
,	O
and	O
genetic	O
counseling	O
of	O
this	O
family	O
.	O

6a	O
-	O
d	O
)	O
performed	O
and	O
analysed	O
experiments	O
.	O

However	O
,	O
the	O
molecular	O
etiology	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
Yunnan	O
Province	O
population	O
where	O
more	O
than	O
52	O
minorities	O
live	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

Polymorphisms	O
in	O
SLC26A4	B-GENE
appear	O
to	O
be	O
rare	O
in	O
the	O
general	O
population	O
in	O
comparison	O
to	O
those	O
in	O
GJB2	B-GENE
[	O
22	O
]	O
.	O

These	O
two	O
mutations	O
have	O
been	O
inherited	O
from	O
apparently	O
normal	O
mothers	O
.	O

GATK	O
v1	O
.	O
6	O
[	O
9	O
]	O
was	O
used	O
to	O
mark	O
duplicated	O
reads	O
,	O
perform	O
local	O
realignment	O
around	O
short	O
insertions	O
and	O
deletions	O
,	O
recalibrate	O
the	O
base	O
quality	O
scores	O
,	O
and	O
call	O
SNPs	O
and	O
short	O
indels	O
.	O

It	O
has	O
been	O
reported	O
that	O
most	O
sequencing	O
platforms	O
,	O
including	O
Illumina	O
sequencers	O
,	O
show	O
a	O
GC	O
content	O
-	O
dependent	O
bias	O
coverage	O
,	O
and	O
protocols	O
should	O
be	O
modified	O
to	O
minimize	O
these	O
events	O
[	O
61	O
]	O
.	O

Multiple	O
protein	O
sequence	O
alignment	O
to	O
assess	O
evolutionary	O
conservation	O
of	O
residues	O
was	O
performed	O
using	O
UCSC	O
Genome	O
Browser	O
(	O
http	O
:	O
/	O
/	O
genome	O
.	O
ucsc	O
.	O
edu	O
)	O
.	O

After	O
controlling	O
for	O
data	O
quality	O
(	O
coverage	O
>	O
=	O
20	O
and	O
Phred	O
-	O
like	O
quality	O
score	O
>	O
=	O
30	O
)	O
,	O
we	O
obtained	O
the	O
VCF	O
reports	O
for	O
the	O
coding	O
regions	O
and	O
the	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
targeted	O
deafness	B-DISEASE
genes	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

The	O
COX	O
/	O
citrate	O
synthase	O
ratio	O
in	O
patient	O
'	O
s	O
fibroblasts	O
was	O
0	O
.	O
29	O
versus	O
0	O
.	O
66	O
+	O
-	O
0	O
.	O
12	O
(	O
n	O
=	O
6	O
)	O
in	O
controls	O
(	O
Table	O
1	O
)	O
.	O

The	O
variant	O
list	O
from	O
analysing	O
3340	O
highlighted	O
only	O
the	O
previously	O
reported	O
LCA	B-DISEASE
causing	O
RDH12	B-GENE
variant	O
(	O
c	B-VARIANT
.	I-VARIANT
506G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R169Q	I-VARIANT
)	O
[	O
29	O
]	O
as	O
the	O
likely	O
cause	O
of	O
disease	O
.	O

The	O
phenotypic	O
characteristics	O
of	O
the	O
WSD	B-DISEASE
cohort	O
compared	O
with	O
the	O
data	O
of	O
24	O
,	O
164	O
patients	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
from	O
the	O
DPV	O
database	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

The	O
threshold	O
for	O
the	O
maximum	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
was	O
set	O
to	O
1	O
%	O
10	O
.	O

Mutations	O
in	O
the	O
FGFR2	B-GENE
at	O
chromosome	O
10q25	O
-	O
q26	O
were	O
reported	O
in	O
all	O
three	O
subtypes	O
13	O
)	O
,	O
including	O
1036T	B-VARIANT
-	I-VARIANT
>	I-VARIANT
C	I-VARIANT
3	O
)	O
and	O
1037G	B-VARIANT
-	I-VARIANT
>	I-VARIANT
A	I-VARIANT
which	O
were	O
also	O
detected	O
in	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
14	O
)	O
.	O

STRC	B-GENE
-	O
specific	O
sequences	O
were	O
verified	O
using	O
BLAT	O
.	O

Bieg	O
CN	O
GN	O
PN	O
CB	O
.	O

#	O
636643	O
,	O
lot	O
No	O
.	O

Thus	O
,	O
29	O
.	O
23	O
%	O
(	O
83	O
/	O
284	O
)	O
of	O
the	O
unrelated	O
families	O
of	O
deaf	O
patients	O
in	O
typical	O
areas	O
in	O
China	O
had	O
molecular	O
defects	O
in	O
GJB2	B-GENE
,	O
and	O
18	O
.	O
31	O
%	O
(	O
52	O
/	O
284	O
)	O
had	O
confirmed	O
molecular	O
etiology	O
of	O
nonsyndromic	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
51	O
autosomal	O
recessive	O
and	O
1	O
autosomal	O
dominant	O
)	O
in	O
the	O
GJB2	B-GENE
gene	O
.	O

Informed	O
consent	O
was	O
obtained	O
from	O
all	O
parents	O
prior	O
to	O
blood	O
sampling	O
.	O

Although	O
truncating	O
mutations	O
are	O
often	O
deleterious	O
,	O
this	O
variant	O
is	O
not	O
likely	O
to	O
be	O
strongly	O
pathogenic	O
since	O
the	O
mutation	O
is	O
near	O
the	O
C	O
-	O
terminal	O
end	O
of	O
the	O
protein	O
,	O
consistent	O
with	O
the	O
301	O
reports	O
in	O
BIC	O
listing	O
this	O
variant	O
as	O
not	O
clinically	O
important	O
.	O

Although	O
the	O
results	O
of	O
segregation	O
in	O
RP	O
#	O
002	O
,	O
RP	O
#	O
004	O
,	O
RP	O
#	O
016	O
and	O
RP	O
#	O
019	O
matched	O
the	O
inheritance	O
pattern	O
,	O
two	O
USH2A	B-GENE
variants	O
in	O
RP	O
#	O
011	O
(	O
Table	O
S1	O
in	O
File	O
S1	O
)	O
did	O
not	O
match	O
the	O
inheritance	O
pattern	O
because	O
the	O
father	O
of	O
RP	O
#	O
011	O
carried	O
two	O
identical	O
USH2A	B-GENE
variants	O
.	O

Note	O
the	O
threshold	O
shifts	O
of	O
80	O
-	O
120	O
dB	O
HL	O
above	O
normal	O
hearing	O
levels	O
.	O

These	O
findings	O
expand	O
the	O
spectrum	O
of	O
mutations	O
in	O
longer	O
isoform	O
of	O
USH2A	B-GENE
and	O
provide	O
useful	O
information	O
for	O
genetic	O
counseling	O
for	O
patients	O
and	O
families	O
with	O
USH2	B-DISEASE
.	O

Primer	O
information	O
for	O
confirmation	O
of	O
USH2A	B-GENE
mutations	O
.	O

The	O
minor	O
allele	O
frequencies	O
estimated	O
from	O
read	O
counts	O
correlated	O
strongly	O
with	O
expected	O
frequencies	O
in	O
HapMap	O
pools	O
(	O
R	O
2	O
=	O
0	O
.	O
96	O
)	O
,	O
indicating	O
high	O
fidelity	O
of	O
the	O
pooled	O
sequencing	O
protocol	O
(	O
Supplementary	O
Fig	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
find	O
frequent	O
arRP	B-DISEASE
genes	O
in	O
the	O
Japanese	O
population	O
.	O

Among	O
the	O
80	O
deafness	B-DISEASE
genes	O
(	O
total	O
of	O
1253	O
exons	O
)	O
analyzed	O
from	O
the	O
79	O
patient	O
samples	O
,	O
we	O
identified	O
a	O
total	O
of	O
97	O
CNVs	O
.	O

All	O
three	O
affected	O
individuals	O
had	O
bilateral	O
profound	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
before	O
cochlear	O
implantation	O
.	O

In	O
the	O
family	O
of	O
patient	O
110	O
afflicted	O
with	O
LCA	B-DISEASE
,	O
we	O
performed	O
genome	O
-	O
wide	O
homozygosity	O
mapping	O
using	O
the	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
10K	O
Array	O
,	O
version	O
2	O
.	O
0	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

The	O
resulting	O
data	O
were	O
processed	O
and	O
annotated	O
with	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA	O
)	O
,	O
Genome	O
Analysis	O
Toolkit	O
(	O
GATK	O
)	O
,	O
and	O
SeattleSeq	O
.	O

The	O
Taiwanese	O
family	O
with	O
LFSNHL	B-DISEASE
was	O
phenotypically	O
characterized	O
using	O
audiologic	O
examination	O
and	O
pedigree	O
analysis	O
.	O

The	O
standard	O
clinical	O
classification	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
has	O
three	O
clinical	O
categories	O
,	O
types	O
I	O
,	O
II	O
,	O
and	O
III	O
[	O
4	O
,	O
5	O
]	O
.	O

The	O
beads	O
were	O
then	O
washed	O
with	O
WB1	O
buffer	O
at	O
room	O
temperature	O
for	O
15	O
minutes	O
once	O
and	O
WB3	O
buffer	O
at	O
65	O
deg	O
C	O
for	O
15	O
minutes	O
three	O
times	O
.	O

A	O
set	O
of	O
50	O
healthy	O
unrelated	O
Spanish	O
samples	O
were	O
used	O
as	O
controls	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
disorder	O
characterized	O
by	O
visual	O
and	O
hearing	O
impairments	O
.	O

5S	O
-	O
rRNA	O
probe	O
was	O
used	O
as	O
a	O
loading	O
control	O
on	O
the	O
same	O
membrane	O
.	O

We	O
thank	O
the	O
participants	O
of	O
the	O
Deafness	B-DISEASE
Gene	O
Study	O
Consortium	O
:	O
Drs	O
.	O

The	O
influence	O
of	O
local	O
GC	O
percent	O
on	O
the	O
read	O
depth	O
is	O
more	O
evident	O
with	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
:	O
the	O
exon	O
1	O
of	O
GJB2	B-GENE
co	O
-	O
localizes	O
with	O
a	O
CpG	O
island	O
on	O
which	O
no	O
reads	O
were	O
mapped	O
;	O
across	O
the	O
exon2	O
,	O
the	O
read	O
depth	O
tended	O
to	O
decrease	O
with	O
increasing	O
GC	O
percent	O
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
total	O
of	O
97	O
CNVs	O
(	O
72	O
CNV	O
gains	O
and	O
25	O
CNV	O
losses	O
)	O
in	O
27	O
deafness	B-DISEASE
genes	O
.	O

The	O
patient	O
carrying	O
GJB3	B-GENE
24_49ins26bp	B-VARIANT
in	O
our	O
cohort	O
had	O
congenital	O
symmetric	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
no	O
relevant	O
family	O
history	O
.	O

The	O
sequence	O
of	O
pendrin	B-GENE
in	O
affected	O
members	O
of	O
Family	O
BF	O
revealed	O
1001G	B-VARIANT
>	I-VARIANT
T	I-VARIANT
.	O

They	O
received	O
a	O
standard	O
ophthalmologic	O
examination	O
,	O
visual	O
field	O
testing	O
,	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
scan	O
,	O
and	O
electrophysiological	O
tests	O
.	O

Pure	O
tone	O
air	O
and	O
bone	O
conduction	O
audiometry	O
revealed	O
inter	O
-	O
and	O
intra	O
-	O
familial	O
variability	O
in	O
the	O
severity	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Figures	O
3d	O
-	O
e	O
and	O
4	O
)	O
in	O
these	O
families	O
.	O

This	O
is	O
the	O
first	O
study	O
characterizing	O
WSD	B-DISEASE
in	O
a	O
large	O
European	O
cohort	O
of	O
patients	O
in	O
comparison	O
with	O
a	O
nationwide	O
cohort	O
of	O
patients	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
.	O

We	O
performed	O
exome	O
sequencing	O
of	O
14	O
APAs	B-DISEASE
and	O
matched	O
germline	O
DNA	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Germline	O
-	O
somatic	O
interaction	O
analysis	O
combined	O
with	O
extensive	O
bioinformatics	O
annotation	O
identifies	O
237	O
candidate	O
functional	O
germline	O
truncation	O
and	O
missense	O
variants	O
,	O
including	O
2	O
pathogenic	O
BRCA1	B-GENE
and	O
1	O
TP53	B-GENE
deleterious	O
variants	O
.	O

Mouse	O
inner	O
ear	O
tissues	O
were	O
harvested	O
from	O
three	O
to	O
five	O
mice	O
at	O
P0	O
,	O
P30	O
,	O
and	O
P90	O
.	O

The	O
60	O
patients	O
plus	O
43	O
patient	O
controls	O
had	O
a	O
definite	O
diagnosis	O
of	O
isolated	O
CI	B-DISEASE
deficiency	I-DISEASE
,	O
based	O
on	O
spectrophotometric	O
enzyme	O
assays	O
interpreted	O
by	O
previously	O
described	O
criteria	O
5	O
,	O
42	O
.	O

In	O
one	O
study	O
,	O
the	O
compound	O
mutation	O
carriers	O
had	O
longer	O
QTc	O
intervals	O
and	O
a	O
younger	O
age	O
-	O
at	O
-	O
onset	O
compared	O
to	O
patients	O
with	O
only	O
one	O
mutation	O
[	O
19	O
]	O
.	O

The	O
studydemonstrates	O
no	O
correlation	O
between	O
the	O
included	O
clinical	O
parameters	O
.	O

(	O
C	O
)	O
Pedigree	O
of	O
the	O
Family	O
3	O
demonstrating	O
that	O
PS	B-DISEASE
was	O
transmitted	O
by	O
autosomal	O
dominant	O
trait	O
and	O
(	O
D	O
)	O
DNA	O
-	O
sequence	O
showing	O
portion	O
of	O
FGFR2	B-GENE
exon	O
8	O
of	O
an	O
affected	O
member	O
.	O

The	O
KCNJ10	B-GENE
K	O
+	O
channel	O
buffers	O
the	O
K	O
+	O
levels	O
in	O
brain	O
glial	O
cells	O
,	O
and	O
mutations	O
in	O
this	O
gene	O
may	O
lead	O
to	O
the	O
so	O
-	O
called	O
'	O
EAST	B-DISEASE
/	I-DISEASE
SeSAME	I-DISEASE
syndrome	I-DISEASE
,	O
'	O
which	O
is	O
manifested	O
by	O
seizures	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
ataxia	B-DISEASE
,	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
and	O
electrolyte	B-DISEASE
imbalance	I-DISEASE
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

(	O
b	O
)	O
IGV	O
view	O
of	O
a	O
tRNA	O
-	O
Met	O
gene	O
transcribed	O
by	O
POLR3	O
.	O

If	O
GIPC3	B-GENE
was	O
not	O
known	O
as	O
a	O
cause	O
of	O
deafness	B-DISEASE
we	O
could	O
have	O
concluded	O
that	O
the	O
variant	O
in	O
ZNF57	B-GENE
was	O
causative	O
.	O

The	O
cleaved	O
caspase	O
-	O
3	O
was	O
obviously	O
increased	O
in	O
the	O
variant	O
MCM2	B-GENE
expressed	O
cells	O
comparing	O
with	O
the	O
wild	O
-	O
type	O
MCM2	B-GENE
(	O
P	O
<	O
0	O
.	O
01	O
,	O
Fig	O
3C	O
and	O
3D	O
)	O
.	O

However	O
,	O
the	O
ERG	O
of	O
another	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
USH1G	B-GENE
showed	O
severe	O
retinal	B-DISEASE
degeneration	I-DISEASE
[	O
2	O
]	O
.	O

Neurological	O
examination	O
showed	O
a	O
mild	O
bilateral	O
ptosis	B-DISEASE
and	O
ophthalmoparesis	B-DISEASE
;	O
he	O
also	O
presented	O
pes	B-DISEASE
cavus	I-DISEASE
on	O
the	O
left	O
side	O
with	O
a	O
decreased	B-DISEASE
/	I-DISEASE
absent	I-DISEASE
achilles	I-DISEASE
tendon	I-DISEASE
reflex	I-DISEASE
bilaterally	O
.	O

In	O
addition	O
,	O
108	O
negative	O
samples	O
and	O
56	O
ARNSHL	B-DISEASE
families	O
were	O
also	O
screened	O
for	O
the	O
mutations	O
by	O
direct	O
sequencing	O
.	O

In	O
both	O
cases	O
,	O
the	O
result	O
is	O
likely	O
to	O
be	O
a	O
reduced	O
amount	O
of	O
Kv11	O
.	O
1	O
protein	O
and	O
therefore	O
reduced	O
repolarisation	O
capacity	O
.	O

646	O
specific	O
primer	O
pairs	O
for	O
all	O
exons	O
and	O
most	O
of	O
the	O
UTR	O
of	O
the	O
15	O
selected	O
genes	O
were	O
designed	O
using	O
primerXL	O
.	O

This	O
study	O
was	O
granted	O
approval	O
by	O
the	O
Beijing	O
Tongren	O
Hospital	O
Joint	O
Committee	O
on	O
Clinical	O
Investigation	O
and	O
conformed	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

In	O
conclusion	O
,	O
the	O
simultaneous	O
examination	O
of	O
the	O
multiple	O
deafness	B-DISEASE
mutations	O
by	O
Invader	O
assay	O
followed	O
by	O
direct	O
sequencing	O
if	O
necessary	O
,	O
will	O
enable	O
us	O
to	O
detect	O
deafness	B-DISEASE
mutations	O
in	O
an	O
efficient	O
and	O
practical	O
manner	O
for	O
clinical	O
use	O
.	O

By	O
analyzing	O
the	O
CNVs	O
only	O
for	O
samples	O
that	O
were	O
hybridized	O
together	O
,	O
we	O
could	O
control	O
the	O
level	O
of	O
variation	O
introduced	O
by	O
the	O
experimental	O
conditions	O
.	O

,	O
2008	O
,	O
2011	O
)	O
.	O

The	O
predicted	O
amino	O
acid	O
changes	O
and	O
surrounding	O
ones	O
are	O
indicated	O
above	O
the	O
sequences	O
.	O

Specifically	O
,	O
five	O
USH1	B-DISEASE
patients	O
carried	O
biallelic	O
mutations	O
in	O
an	O
USH1	B-DISEASE
gene	O
plus	O
one	O
or	O
two	O
additional	O
mutations	O
in	O
another	O
USH1	B-DISEASE
(	O
three	O
patients	O
)	O
or	O
USH2	B-DISEASE
(	O
two	O
patients	O
)	O
gene	O
,	O
and	O
two	O
USH2	B-DISEASE
patients	O
carried	O
biallelic	O
mutations	O
in	O
USH2	B-DISEASE
genes	O
plus	O
one	O
additional	O
,	O
presumably	O
pathogenic	O
mutation	O
in	O
an	O
USH1	B-DISEASE
or	O
an	O
USH2	B-DISEASE
gene	O
(	O
Table	O
1	O
)	O
.	O

B	O
.	O
C	O
.	O

Both	O
69th	O
residues	O
and	O
97th	O
residues	O
are	O
gathered	O
near	O
interface	O
region	O
,	O
which	O
explains	O
why	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R97Q	I-VARIANT
mutations	O
weakening	O
the	O
localization	O
.	O

Precordial	O
leads	O
V2	O
,	O
V3	O
,	O
V4	O
,	O
and	O
V5	O
are	O
shown	O
in	O
half	O
voltage	O
.	O

Either	O
way	O
this	O
emphasizes	O
the	O
importance	O
of	O
sequencing	O
all	O
known	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
when	O
performing	O
molecular	O
diagnosis	O
of	O
STGD	B-DISEASE
.	O

For	O
in	O
silico	O
analysis	O
of	O
the	O
missense	O
mutations	O
,	O
PolyPhen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
index	O
.	O
shtml	O
)	O
,	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
Mutation	O
Taster	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
mutationtaster	O
.	O
org	O
/	O
)	O
were	O
used	O
for	O
the	O
prediction	O
of	O
the	O
effect	O
of	O
amino	O
acid	O
substitutions	O
on	O
protein	O
function	O
.	O

We	O
sequenced	O
TMPRSS3	B-GENE
in	O
an	O
affected	O
child	O
from	O
Family	O
W	O
and	O
identified	O
988delA	B-VARIANT
,	O
a	O
frameshift	O
mutation	O
in	O
exon	O
10	O
leading	O
to	O
a	O
stop	O
at	O
codon	O
357	O
.	O

F	O
)	O
.	O

The	O
arginine	O
at	O
amino	O
acid	O
position	O
205	O
of	O
myosin	B-GENE
VI	I-GENE
is	O
highly	O
conserved	O
among	O
several	O
species	O
.	O

Recently	O
,	O
a	O
de	O
novo	O
deletion	O
encompassing	O
SOX10	B-GENE
regulatory	O
elements	O
have	O
been	O
identified	O
in	O
a	O
WS4	B-DISEASE
patient	O
with	O
no	O
CDS	O
mutations	O
,	O
underscoring	O
the	O
relevance	O
of	O
regulatory	O
sequences	O
in	O
rare	O
disorders	O
[	O
11	O
]	O
.	O

Exonic	O
regions	O
are	O
well	O
covered	O
by	O
our	O
method	O
,	O
and	O
despite	O
examining	O
a	O
number	O
of	O
patients	O
with	O
high	O
density	O
aCGH	O
,	O
no	O
copy	O
number	O
variations	O
were	O
observed	O
.	O

As	O
typical	O
for	O
POLR3	B-DISEASE
-	I-DISEASE
related	I-DISEASE
leukodystrophy	I-DISEASE
,	O
the	O
ventrolateral	O
thalamus	O
(	O
white	O
arrow	O
,	O
a	O
,	O
d	O
)	O
,	O
the	O
optic	O
radiation	O
(	O
thick	O
arrowhead	O
blue	O
,	O
d	O
)	O
and	O
the	O
dentate	O
nucleus	O
(	O
open	O
red	O
arrowhead	O
,	O
b	O
)	O
show	O
a	O
relative	O
hypointense	O
signal	O
on	O
the	O
T2	O
-	O
weighted	O
images	O
resulting	O
in	O
an	O
easily	O
visible	O
dentate	O
nucleus	O
(	O
b	O
)	O
as	O
compared	O
with	O
the	O
control	O
(	O
h	O
)	O
as	O
well	O
as	O
a	O
small	O
dot	O
in	O
the	O
posterior	O
limb	O
of	O
the	O
internal	O
capsule	O
(	O
red	O
arrowhead	O
,	O
d	O
)	O
.	O

Testing	O
resulted	O
in	O
identification	O
of	O
the	O
underlying	O
genetic	O
cause	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
440	O
patients	O
(	O
39	O
%	O
)	O
.	O

We	O
used	O
PolyPhen	O
-	O
2	O
software	O
(	O
DeLano	O
Scientific	O
LLC	O
)	O
to	O
study	O
3D	O
structure	O
of	O
the	O
protein	O
,	O
and	O
found	O
that	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
V1773M	I-VARIANT
)	O
changes	O
the	O
shape	O
of	O
the	O
protein	O
in	O
this	O
region	O
,	O
which	O
may	O
alter	O
its	O
ability	O
to	O
bind	O
to	O
other	O
molecules	O
.	O

In	O
conclusion	O
,	O
we	O
here	O
report	O
biallelic	O
novel	O
heterozygous	O
mutations	O
in	O
MYO7A	B-GENE
gene	O
leading	O
to	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
in	O
a	O
Chinese	O
family	O
.	O

For	O
audiologic	O
evaluation	O
,	O
pure	O
tone	O
audiogram	O
(	O
PTA	O
)	O
,	O
impedance	O
audiogram	O
,	O
and	O
auditory	O
brainstem	O
evoked	O
response	O
were	O
performed	O
.	O

(	O
Figure	O
3	O
)	O
.	O

The	O
direct	O
sequencing	O
of	O
the	O
MYH9	B-GENE
gene	O
in	O
the	O
patient	O
showed	O
that	O
he	O
was	O
heterozygous	O
for	O
a	O
missense	O
mutation	O
in	O
exon	O
1	O
of	O
MYH9	B-GENE
.	O

All	O
patients	O
were	O
Caucasian	O
.	O

Genetic	O
testing	O
is	O
the	O
gold	O
standard	O
in	O
diagnosing	O
collagen	B-DISEASE
IV	I-DISEASE
-	I-DISEASE
related	I-DISEASE
nephropathies	I-DISEASE
.	O

No	O
small	O
indels	O
or	O
exon	O
deletions	O
were	O
present	O
in	O
the	O
Collagen	B-GENE
4A3	I-GENE
,	O
A4	B-GENE
or	O
A5	B-GENE
genes	O
.	O

Still	O
,	O
for	O
the	O
clinical	O
diagnosis	O
of	O
the	O
most	O
common	O
skeletal	B-DISEASE
disorders	I-DISEASE
,	O
or	O
for	O
molecular	O
screening	O
studies	O
of	O
more	O
complex	O
diseases	O
,	O
the	O
panel	O
becomes	O
feasible	O
,	O
since	O
it	O
contains	O
the	O
majority	O
of	O
the	O
causative	O
genes	O
of	O
known	O
skeletal	B-DISEASE
disorders	I-DISEASE
.	O

4b	O
)	O
.	O

Gly259Val	I-VARIANT
)	O
confirm	O
its	O
putative	O
pathogenicity	O
.	O

There	O
was	O
a	O
consensus	O
that	O
before	O
the	O
clinical	O
application	O
of	O
a	O
custom	O
TGE	O
kit	O
,	O
its	O
performance	O
should	O
be	O
extensively	O
evaluated	O
and	O
validated	O
.	O

All	O
experimental	O
procedures	O
were	O
approved	O
by	O
the	O
Institutional	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
the	O
University	O
at	O
Buffalo	O
that	O
conform	O
to	O
the	O
guidelines	O
issued	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

5	O
mu	O
M	O
sections	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
normal	O
human	O
adrenal	O
cortex	O
(	O
2	O
patients	O
)	O
were	O
obtained	O
from	O
the	O
Yale	O
Pathology	O
Tissue	O
Service	O
.	O

S91	O
,	O
with	O
Spanish	O
and	O
Algerian	O
origins	O
,	O
carried	O
a	O
homozygous	O
mutation	O
p	O
.	O
(	O
Arg389	O
*	O
)	O
in	O
TMC1	B-GENE
.	O

The	O
research	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
(	O
IRB	O
)	O
at	O
the	O
Hadassah	O
medical	O
center	O
.	O

These	O
represent	O
either	O
funnel	B-DISEASE
retinal	I-DISEASE
detachment	I-DISEASE
and	O
/	O
or	O
pseudogliomas	B-DISEASE
(	O
dysplastic	B-DISEASE
retina	I-DISEASE
/	O
optic	B-DISEASE
nerve	I-DISEASE
mass	I-DISEASE
)	O
.	O

Red	O
arrows	O
indicate	O
products	O
of	O
amplification	O
corresponding	O
to	O
deleted	O
mitochondrial	O
genomes	O
.	O

Fresh	O
media	O
was	O
applied	O
to	O
the	O
cells	O
16	O
hours	O
post	O
-	O
transfection	O
and	O
,	O
following	O
24	O
hours	O
incubation	O
,	O
supernatants	O
containing	O
packaged	O
virus	O
were	O
harvested	O
and	O
filtered	O
through	O
a	O
0	O
.	O
45	O
mu	O
M	O
membrane	O
filter	O
.	O

Both	O
parents	O
were	O
healthy	O
and	O
had	O
no	O
familial	O
history	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
or	O
psychiatric	B-DISEASE
disorders	I-DISEASE
.	O

Recently	O
,	O
targeted	O
sequencing	O
approaches	O
aiming	O
at	O
enriching	O
for	O
a	O
subset	O
of	O
Usher	B-DISEASE
genes	O
or	O
related	O
conditions	O
have	O
been	O
used	O
as	O
an	O
alternative	O
to	O
classical	O
methods	O
for	O
molecular	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
mutations	O
and	O
yielded	O
high	O
rates	O
of	O
mutation	O
detection	O
(	O
70	O
-	O
80	O
%	O
)	O
[	O
17	O
]	O
,	O
[	O
50	O
]	O
,	O
[	O
51	O
]	O
.	O

Sudden	O
and	O
complete	O
loss	O
of	O
visual	O
acuity	O
was	O
observed	O
in	O
one	O
patient	O
after	O
prolonged	O
severe	O
hypoglycemia	B-DISEASE
.	O

These	O
variants	O
were	O
selected	O
according	O
to	O
bioinformatic	O
analysis	O
.	O

Scripts	O
developed	O
in	O
-	O
house	O
at	O
the	O
CCG	O
were	O
applied	O
to	O
variants	O
predicted	O
to	O
result	O
in	O
protein	O
changes	O
,	O
variants	O
affecting	O
donor	O
and	O
acceptor	O
splice	O
sites	O
,	O
and	O
those	O
overlapping	O
with	O
known	O
variants	O
.	O

These	O
genes	O
were	O
ACTG1	B-GENE
,	O
DFNA5	B-DISEASE
,	O
POU4F3	B-GENE
,	O
SLC26A5	B-GENE
,	O
SIX1	B-GENE
,	O
MYO7A	B-GENE
,	O
CDH23	B-GENE
,	O
PCDH15	B-GENE
,	O
and	O
USH2A	B-GENE
,	O
suggesting	O
that	O
a	O
variety	O
of	O
genes	O
underlie	O
early	O
-	O
childhood	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Japanese	O
patients	O
.	O

The	O
other	O
patients	O
with	O
exon	O
2	O
and	O
17	O
mutations	O
who	O
have	O
not	O
yet	O
developed	O
extrahematological	O
symptoms	O
are	O
generally	O
young	O
and	O
need	O
a	O
close	O
follow	O
-	O
up	O
.	O

Myosin	B-GENE
VIIA	I-GENE
,	O
an	O
unconventional	O
myosin	O
,	O
is	O
a	O
member	O
of	O
a	O
large	O
superfamily	O
of	O
actin	O
-	O
associated	O
molecular	O
motors	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
of	O
our	O
patient	O
'	O
s	O
family	O
and	O
a	O
normal	O
control	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
four	O
-	O
generation	O
Chinese	O
family	O
with	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Clinical	O
and	O
molecular	O
characteristics	O
of	O
patients	O
with	O
DOA	O
+	O
phenotypes	O
AU	O
=	O
Austria	O
;	O
BE	O
=	O
Belgium	O
;	O
BR	O
=	O
Brazil	O
;	O
CN	O
=	O
China	O
;	O
DE	O
=	O
Germany	O
;	O
ES	O
=	O
Spain	O
;	O
FI	O
=	O
Finland	O
;	O
FR	O
=	O
France	O
;	O
IT	O
=	O
Italy	O
;	O
NO	O
=	O
Norway	O
;	O
UK	O
=	O
United	O
Kingdom	O
;	O
US	O
=	O
USA	O
;	O
AA	O
=	O
amino	O
acid	O
;	O
FHx	O
=	O
family	O
history	O
;	O
HSP	B-DISEASE
=	O
hereditary	B-DISEASE
spastic	I-DISEASE
paraplegia	I-DISEASE
;	I-DISEASE
MS	B-DISEASE
=	O
multiple	B-DISEASE
sclerosis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
;	I-DISEASE
CAPOS	B-DISEASE
=	O
cerebellar	B-DISEASE
ataxia	I-DISEASE
,	O
areflexia	B-DISEASE
,	O
pes	B-DISEASE
cavus	I-DISEASE
,	O
optic	B-DISEASE
atrophy	I-DISEASE
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
;	I-DISEASE
CC	O
=	O
coiled	O
-	O
coil	O
domain	O
;	O
GE	O
=	O
GTPase	O
effector	O
domain	O
;	O
PEO	B-DISEASE
=	O
progressive	B-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
.	O

The	O
English	O
in	O
this	O
document	O
has	O
been	O
checked	O
by	O
at	O
least	O
two	O
professional	O
editors	O
,	O
both	O
native	O
speakers	O
of	O
English	O
.	O

It	O
is	O
a	O
region	O
populated	O
by	O
a	O
variety	O
of	O
ethnicities	O
but	O
mainly	O
by	O
Uyghur	O
ethnicity	O
.	O

Haplotype	O
analysis	O
in	O
the	O
family	O
FRP	O
-	O
360	O
was	O
compatible	O
with	O
disease	O
association	O
with	O
the	O
USH3A	B-GENE
locus	O
.	O

CRKL	B-GENE
(	O
CRK	B-GENE
-	I-GENE
Like	I-GENE
)	O
,	O
another	O
gene	O
located	O
within	O
the	O
22q11	O
.	O
2	O
and	O
expressed	O
in	O
the	O
developing	O
heart	O
,	O
was	O
found	O
to	O
be	O
deleted	O
in	O
a	O
few	O
CTDs	B-DISEASE
patients	O
with	O
atypical	O
distal	O
22q11	O
.	O
2	O
deletions	O
not	O
including	O
TBX1	B-GENE
[	O
7	O
,	O
8	O
]	O
.	O

The	O
DNA	O
was	O
used	O
as	O
a	O
template	O
to	O
amplify	O
the	O
OPA1	B-GENE
gene	O
.	O

The	O
study	O
on	O
this	O
Chinese	O
family	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Family	O
#	O
51	O
)	O
was	O
approved	O
by	O
the	O
Medical	O
Ethics	O
Committee	O
of	O
Peking	O
University	O
First	O
Hospital	O
.	O

The	O
model	O
for	O
myosin	B-GENE
VI	I-GENE
was	O
constructed	O
from	O
myosin	B-GENE
VI	I-GENE
of	O
wild	O
boar	O
,	O
which	O
is	O
98	O
%	O
identical	O
to	O
the	O
human	O
sequence	O
over	O
784	O
residues	O
[	O
40	O
]	O
.	O

Follow	O
up	O
testing	O
at	O
1	O
month	O
of	O
age	O
showed	O
absent	O
Auditory	O
Brainstem	O
Response	O
(	O
ABR	O
)	O
with	O
preserved	O
cochlear	O
microphonics	O
,	O
diagnostic	O
of	O
bilateral	O
auditory	B-DISEASE
neuropathy	I-DISEASE
.	O

Functional	O
consequences	O
of	O
the	O
protein	O
variant	O
predicted	O
to	O
be	O
damaging	O
,	O
were	O
evaluated	O
with	O
SIFT	O
and	O
PolyPhen2	O
(	O
with	O
a	O
score	O
of	O
0	O
.	O
953	O
)	O
.	O

Seventeen	O
families	O
were	O
from	O
Turkey	O
and	O
three	O
were	O
from	O
Iran	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
we	O
screened	O
13	O
unrelated	O
subjects	O
from	O
our	O
laboratory	O
collection	O
who	O
had	O
late	O
-	O
onset	O
HI	B-DISEASE
(	O
presbycusis	O
)	O
.	O

Brachydactyly	B-DISEASE
E	O
associated	O
with	O
metaphyseal	O
changes	O
is	O
the	O
most	O
peculiar	O
clinical	O
feature	O
of	O
C	O
propeptide	O
mutations	O
of	O
collagen	O
type	O
2	O
,	O
which	O
differentiate	O
them	O
from	O
other	O
types	O
of	O
collagenopathies	B-DISEASE
.	O

This	O
Usher	O
protein	O
network	O
is	O
hypothesized	O
to	O
be	O
essential	O
for	O
the	O
regulation	O
of	O
cargo	O
transfer	O
from	O
the	O
photoreceptor	O
inner	O
segment	O
to	O
the	O
outer	O
segment	O
by	O
the	O
ciliary	O
transport	O
system	O
[	O
18	O
]	O
.	O

Three	O
cases	O
of	O
digenic	O
inheritance	O
of	O
USH1	B-DISEASE
have	O
been	O
reported	O
so	O
far	O
[	O
42	O
]	O
,	O
all	O
caused	O
by	O
mutations	O
in	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
,	O
in	O
agreement	O
with	O
the	O
contribution	O
of	O
cadherin	B-GENE
-	I-GENE
23	I-GENE
and	O
protocadherin	B-GENE
-	I-GENE
15	I-GENE
to	O
the	O
hair	O
bundle	O
transient	O
lateral	O
links	O
and	O
tip	O
-	O
links	O
[	O
31	O
,	O
32	O
,	O
36	O
,	O
67	O
-	O
69	O
]	O
.	O

Total	O
mitochondrial	O
RNA	O
preparations	O
were	O
obtained	O
from	O
mitochondria	O
isolated	O
from	O
fibroblast	O
cell	O
lines	O
(	O
4	O
.	O
0	O
x	O
10	O
7	O
cells	O
)	O
.	O

We	O
are	O
thankful	O
to	O
Lucia	O
Valent	O
i	O
nov	O
a	O
for	O
preparing	O
some	O
of	O
the	O
figures	O
.	O
To	O
analyze	O
the	O
spectrum	O
of	O
sequence	O
variants	O
in	O
the	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
genes	O
in	O
a	O
group	O
of	O
Italian	O
patients	O
affected	O
by	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
.	O

The	O
model	O
was	O
built	O
using	O
the	O
expasy	O
Swiss	O
-	O
Model	O
repository	O
used	O
in	O
automated	O
mode	O
(	O
http	O
:	O
/	O
/	O
swissmodel	O
.	O
expasy	O
.	O
org	O
/	O
repository	O
/	O
)	O
.	O

Before	O
P07	O
,	O
ELMOD3	B-GENE
staining	O
was	O
very	O
weak	O
in	O
the	O
inner	O
hair	O
cells	O
stereocilia	O
.	O

The	O
variants	O
p	B-VARIANT
.	I-VARIANT
R303H	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Y1992C	I-VARIANT
were	O
described	O
previously	O
[	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
,	O
[	O
35	O
]	O
]	O
.	O

A	O
consanguineous	O
patient	O
,	O
DT16	O
,	O
harbored	O
a	O
homozygous	O
c	B-VARIANT
.	I-VARIANT
221G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
W74X	I-VARIANT
)	O
within	O
a	O
6	O
.	O
3Mb	O
region	O
of	O
homozygosity	O
(	O
determined	O
by	O
Affymetrix	O
250K	O
Nsp	O
SNP	O
chip	O
)	O
.	O

Retinal	O
thickness	O
values	O
from	O
ILM	O
to	O
RPE	O
are	O
compared	O
to	O
the	O
normative	O
data	O
.	O

no	O
known	O
renal	O
disease	O
in	O
a	O
patient	O
with	O
an	O
HNF1B	B-GENE
mutation	O
as	O
previously	O
described	O
by	O
Edghill	O
et	O
al	O
[	O
9	O
]	O
)	O
,	O
had	O
not	O
yet	O
presented	O
(	O
e	O
.	O
g	O
.	O

In	O
these	O
families	O
,	O
the	O
segregation	O
of	O
TMPRSS3	B-GENE
and	O
MSRB3	B-GENE
mutations	O
was	O
analyzed	O
with	O
restriction	O
digestion	O
with	O
the	O
enzymes	O
AciI	O
and	O
TseI	O
,	O
respectively	O
(	O
New	O
England	O
Biolabs	O
Inc	O
.	O

All	O
646	O
amplification	O
reactions	O
of	O
the	O
15	O
genes	O
were	O
carried	O
out	O
as	O
singleplex	O
PCR	O
in	O
two	O
384	O
-	O
well	O
plates	O
per	O
patient	O
.	O

In	O
this	O
cohort	O
we	O
had	O
biopsies	O
from	O
patients	O
in	O
21	O
families	O
(	O
36	O
.	O
8	O
%	O
)	O
and	O
only	O
in	O
seven	O
among	O
those	O
we	O
found	O
mutations	O
,	O
as	O
this	O
invasive	O
procedure	O
was	O
not	O
justified	O
in	O
the	O
majority	O
of	O
cases	O
.	O

Mean	O
amplitude	O
and	O
latency	O
of	O
the	O
prolonged	O
potentials	O
(	O
OPA1	B-GENE
-	O
Prolonged	O
)	O
are	O
also	O
reported	O
.	O

In	O
the	O
pedigree	O
the	O
individual	O
number	O
,	O
the	O
age	O
of	O
the	O
individual	O
,	O
and	O
the	O
WFS1	B-GENE
genotypes	O
are	O
depicted	O
.	O

B	O
:	O
c	B-VARIANT
.	I-VARIANT
8483delC	I-VARIANT
created	O
an	O
MslI	O
restriction	O
site	O
that	O
cosegregated	O
with	O
the	O
affected	O
individuals	O
and	O
the	O
carriers	O
(	O
150	O
bp	O
,	O
340	O
bp	O
,	O
and	O
490	O
bp	O
)	O
,	O
but	O
not	O
with	O
unaffected	O
individuals	O
and	O
normal	O
control	O
(	O
490	O
bp	O
)	O
.	O

These	O
investigations	O
were	O
supported	O
by	O
Key	O
Project	O
of	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
81030017	O
)	O
,	O
National	O
Science	O
Fund	O
for	O
Distinguished	O
Young	O
Scholars	O
(	O
81125008	O
)	O
to	O
HJ	O
Yuan	O
,	O
the	O
National	O
Basic	O
Research	O
Programs	O
(	O
No	O
.	O

Six	O
single	O
nucleotide	O
variants	O
and	O
two	O
indels	O
were	O
found	O
co	O
-	O
segregated	O
with	O
the	O
phenotypes	O
.	O

To	O
investigate	O
the	O
potential	O
pathogenic	O
effect	O
of	O
the	O
three	O
novel	O
splice	O
site	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
1140	I-VARIANT
+	I-VARIANT
1	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	I-VARIANT
c	B-VARIANT
.	I-VARIANT
1598	I-VARIANT
-	I-VARIANT
2	I-VARIANT
A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
699	I-VARIANT
+	I-VARIANT
5	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
on	O
normal	O
splicing	O
,	O
each	O
exon	O
and	O
the	O
flanking	O
intronic	O
sequences	O
sufficient	O
to	O
allow	O
splicing	O
were	O
inserted	O
into	O
a	O
pSPL3	O
or	O
pSPL3b	O
vector	O
.	O

Sequence	O
analysis	O
was	O
performed	O
with	O
the	O
Big	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
and	O
the	O
ABI	O
PRISM	O
3730	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
mapped	O
a	O
novel	O
locus	O
(	O
DFNA66	B-GENE
)	O
for	O
NSHI	B-DISEASE
to	O
chromosome	O
6q15	O
-	O
21	O
.	O

Even	O
within	O
the	O
protein	O
coding	O
portion	O
of	O
the	O
genome	O
,	O
each	O
person	O
carries	O
an	O
estimated	O
400	O
-	O
500	O
protein	O
-	O
modifying	O
rare	O
variants	O
35	O
,	O
36	O
.	O

Closure	O
of	O
air	O
-	O
bone	O
gap	O
also	O
failed	O
in	O
this	O
patient	O
who	O
is	O
currently	O
using	O
hearing	O
aids	O
on	O
both	O
sides	O
for	O
auditory	O
rehabilitation	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
USH1C	B-GENE
splicing	O
variants	O
.	O

Initial	O
data	O
filtering	O
with	O
allele	O
frequencies	O
(	O
<	O
5	O
%	O
in	O
the	O
1000	O
Genomes	O
Project	O
and	O
5400	O
NHLBI	O
exomes	O
)	O
and	O
PolyPhen2	O
/	O
SIFT	O
scores	O
(	O
>	O
0	O
.	O
95	O
)	O
prioritized	O
5	O
indels	O
(	O
insertions	O
/	O
deletions	O
)	O
and	O
36	O
missense	O
variants	O
in	O
the	O
12	O
multiplex	O
families	O
.	O

The	O
targeted	O
regions	O
were	O
not	O
captured	O
with	O
uniformity	O
(	O
Figure	O
S1	O
)	O
and	O
we	O
present	O
this	O
as	O
an	O
issue	O
which	O
needs	O
to	O
be	O
evaluated	O
with	O
care	O
when	O
using	O
exome	O
sequencing	O
as	O
a	O
tool	O
for	O
Mendelian	B-DISEASE
disease	I-DISEASE
gene	O
discovery	O
.	O

A	O
missense	O
variant	O
was	O
also	O
classified	O
as	O
UV2	O
if	O
it	O
was	O
the	O
only	O
possibly	O
pathogenic	O
variant	O
in	O
the	O
gene	O
.	O

14	O
,	O
144	O
genetic	O
variants	O
were	O
automatically	O
detected	O
,	O
including	O
21	O
of	O
the	O
24	O
known	O
mutations	O
.	O

The	O
R668H	B-VARIANT
residue	O
was	O
predicted	O
by	O
modeling	O
to	O
seriously	O
disturb	O
the	O
function	O
of	O
the	O
motor	O
domain	O
of	O
the	O
protein	O
.	O

Furthermore	O
,	O
it	O
has	O
been	O
reported	O
to	O
be	O
a	O
non	O
-	O
pathogenic	O
polymorphism	O
in	O
several	O
studies	O
that	O
provided	O
strong	O
evidence	O
that	O
this	O
variant	O
was	O
not	O
the	O
genetic	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
KNUF34	O
family	O
[	O
19	O
,	O
20	O
]	O
.	O

This	O
is	O
in	O
line	O
with	O
our	O
knowledge	O
of	O
the	O
timing	O
of	O
developmental	O
maturation	O
processes	O
in	O
the	O
cochlea	O
and	O
auditory	O
nerve	O
.	O

The	O
proband	O
was	O
emmetropic	O
with	O
Snellen	O
visual	O
acuity	O
recorded	O
as	O
0	O
.	O
6	O
in	O
both	O
eyes	O
.	O

The	O
GRHL2	B-GENE
gene	O
is	O
responsible	O
for	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
,	O
affecting	O
the	O
DFNA28	B-GENE
locus	O
.	O

In	O
particular	O
,	O
two	O
patients	O
were	O
diagnosed	O
by	O
multiple	O
retinal	O
and	O
pediatric	O
ophthalmology	O
specialists	O
with	O
STGD	B-DISEASE
but	O
had	O
disease	O
causing	O
mutations	O
outside	O
ABCA4	B-GENE
.	O

B	O
.	O

Higher	O
scores	O
correspond	O
to	O
higher	O
differences	O
in	O
chemical	O
properties	O
,	O
thus	O
increase	O
the	O
probability	O
of	O
a	O
substitution	O
being	O
damaging	O
to	O
protein	O
function	O
[	O
27	O
]	O
.	O

Actin	O
cytoskeleton	O
was	O
labelled	O
with	O
rhodamine	O
phalloidin	O
(	O
gray	O
)	O
.	O

We	O
analyzed	O
somatic	O
mutations	O
in	O
429	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
.	O

Frequencies	O
of	O
the	O
sequence	O
variations	O
identified	O
in	O
the	O
general	O
population	O
from	O
Languedoc	O
-	O
Roussillon	O
.	O

In	O
this	O
study	O
,	O
micropenis	B-DISEASE
and	O
/	O
or	O
cryptorchidism	B-DISEASE
were	O
present	O
in	O
all	O
of	O
the	O
boys	O
in	O
whom	O
the	O
information	O
was	O
available	O
except	O
one	O
.	O

All	O
these	O
sequence	O
variations	O
were	O
shown	O
to	O
globally	O
weaken	O
the	O
natural	O
5	O
'	O
splice	O
site	O
and	O
to	O
induce	O
aberrant	O
splicing	O
.	O

A	O
)	O
Nucleotide	O
sequence	O
of	O
exon	O
20	O
(	O
capital	O
letters	O
)	O
and	O
its	O
flanking	O
intronic	O
regions	O
where	O
the	O
c	B-VARIANT
.	I-VARIANT
2539_2559dup	I-VARIANT
mutation	O
is	O
indicated	O
.	O

Multiple	O
sequence	O
alignment	O
in	O
other	O
organisms	O
(	O
including	O
human	O
,	O
macaque	O
,	O
chimpanzee	O
,	O
elephant	O
,	O
pig	O
,	O
platypus	O
and	O
zebrafish	O
)	O
revealed	O
the	O
mutation	O
was	O
present	O
in	O
a	O
highly	O
conserved	O
position	O
(	O
Figure	O
S3	O
)	O
.	O

The	O
most	O
common	O
mutation	O
was	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
accounting	O
for	O
nearly	O
67	O
%	O
(	O
29	O
/	O
43	O
)	O
of	O
all	O
GJB2	B-GENE
mutated	O
patients	O
.	O

Click	O
here	O
for	O
file	O
Results	O
of	O
mutation	O
screening	O
in	O
patient	O
1881	O
in	O
the	O
CDH23	B-GENE
gene	O
(	O
USH1D	B-GENE
)	O
(	O
no	O
mutations	O
found	O
)	O
.	O

34	O
50	O
Because	O
52	O
.	O
5	O
%	O
of	O
pathogenic	O
and	O
likely	O
pathogenic	O
variants	O
were	O
novel	O
,	O
the	O
use	O
of	O
microarray	O
chips	O
for	O
molecular	O
diagnosis	O
in	O
a	O
disorder	O
with	O
a	O
large	O
number	O
of	O
private	O
mutations	O
such	O
as	O
USH	B-DISEASE
is	O
limited	O
.	O

One	O
subject	O
,	O
II	O
:	O
7	O
,	O
is	O
married	O
to	O
one	O
of	O
the	O
sibling	O
,	O
II	O
:	O
4	O
,	O
and	O
was	O
identified	O
to	O
carry	O
a	O
homogeneous	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
A1555G	B-VARIANT
mutation	O
(	O
Figure	O
1	O
)	O
.	O

This	O
consistency	O
in	O
the	O
data	O
indicates	O
a	O
failure	O
at	O
the	O
capture	O
step	O
of	O
these	O
sequences	O
,	O
probably	O
caused	O
by	O
sequence	O
complexity	O
and	O
GC	O
content	O
.	O

For	O
the	O
microsatellite	O
marker	O
loci	O
,	O
equal	O
allele	O
frequencies	O
were	O
used	O
.	O

Using	O
the	O
Pb867	O
antibody	O
on	O
cochlear	O
sections	O
,	O
we	O
detected	O
Gipc3	O
-	O
specific	O
immunoreactivity	O
in	O
IHCs	O
and	O
OHCs	O
,	O
as	O
well	O
as	O
in	O
cochlear	O
spiral	O
ganglion	O
neurons	O
in	O
C3HeB	O
/	O
FeJ	O
mice	O
.	O

They	O
are	O
caused	O
by	O
mutations	O
in	O
the	O
MYH9	B-GENE
gene	O
encoding	O
the	O
nonmuscle	B-GENE
myosin	I-GENE
heavy	I-GENE
chain	I-GENE
II	I-GENE
-	I-GENE
A	I-GENE
(	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
)	O
.	O

common	B-DISEASE
cavity	I-DISEASE
(	O
a	B-DISEASE
cystic	I-DISEASE
cavity	I-DISEASE
representing	I-DISEASE
the	I-DISEASE
cochlea	I-DISEASE
and	I-DISEASE
vestibule	I-DISEASE
without	I-DISEASE
showing	I-DISEASE
any	I-DISEASE
differentiation	I-DISEASE
into	I-DISEASE
cochlea	I-DISEASE
and	I-DISEASE
vestibule	I-DISEASE
)	O
;	O
e	O
.	O

3	O
B	O
and	O
C	O
)	O
.	O

Open	O
symbols	O
represent	O
unaffected	O
individuals	O
and	O
filled	O
symbols	O
affected	O
individuals	O
.	O

Genetics	O
of	O
the	O
German	O
DFNA67	B-DISEASE
family	O
.	O

The	O
families	O
with	O
postlingual	O
hearing	B-DISEASE
impairment	I-DISEASE
initially	O
presented	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
of	O
the	O
high	O
frequencies	O
which	O
was	O
followed	O
by	O
an	O
increase	O
of	O
the	O
low	O
-	O
and	O
mid	O
-	O
frequency	O
threshold	O
values	O
with	O
advancing	O
age	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
adult	O
subjects	O
and	O
parents	O
of	O
minor	O
subjects	O
.	O

Direct	O
sequencing	O
revealed	O
a	O
heterozygous	O
variation	O
involving	O
multiple	O
nucleotides	O
in	O
exon	O
4	O
region	O
.	O

We	O
observe	O
that	O
FGFR1	B-GENE
mutations	O
responsible	O
for	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
occur	O
in	O
several	O
clusters	O
in	O
important	O
functional	O
domains	O
(	O
figure	O
4	O
)	O
:	O
homozygous	O
mutations	O
in	O
the	O
ligand	O
binding	O
domain	O
D2	O
;	O
heterozygous	O
substitutions	O
in	O
the	O
TKD	O
core	O
.	O

The	O
age	O
at	O
onset	O
of	O
DM	B-DISEASE
was	O
chosen	O
as	O
an	O
indicator	O
of	O
disease	O
severity	O
.	O

2	O
A	O
-	O
D	O
)	O
.	O

Loss	B-DISEASE
of	I-DISEASE
sensory	I-DISEASE
and	I-DISEASE
tendon	I-DISEASE
reflexes	I-DISEASE
was	O
similar	O
to	O
those	O
of	O
her	O
younger	O
brother	O
.	O

Two	O
intronic	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
1566	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
453	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
in	O
TMC1	B-GENE
are	O
proposed	O
to	O
affect	O
splicing	O
,	O
leading	O
to	O
a	O
frameshift	O
and	O
formation	O
of	O
a	O
non	O
-	O
functional	O
protein	O
.	O

The	O
following	O
sets	O
of	O
primers	O
and	O
Power	O
SYBR	O
Green	O
PCR	O
Master	O
Mix	O
(	O
Applied	O
Biosystems	O
)	O
were	O
used	O
for	O
real	O
-	O
time	O
PCR	O
:	O
human	O
actin	O
,	O
ACCATGGATGATGATATCGCC	O
and	O
GCCTTGCACATGCCGG	O
;	O
human	O
WFS1	B-GENE
,	O
GAGCCCTGAGGACCTGCC	O
(	O
exon	O
7	O
)	O
and	O
TCTCCATGATGGCGTGCA	O
(	O
exon	O
8	O
)	O
.	O

For	O
centuries	O
,	O
marriages	O
have	O
been	O
arranged	O
within	O
extended	O
families	O
in	O
these	O
villages	O
,	O
leading	O
to	O
high	O
levels	O
of	O
consanguinity	O
and	O
consequently	O
high	O
frequencies	O
of	O
recessive	O
traits	O
[	O
1	O
,	O
2	O
]	O
.	O

Human	O
NARS2	B-GENE
p	O
.	O
Val213	O
residue	O
corresponds	O
to	O
the	O
p	O
.	O
Lys181	O
residue	O
in	O
Pyrococcus	O
horikoshii	O
(	O
Fig	O
.	O

Two	O
of	O
the	O
men	O
were	O
of	O
other	O
than	O
Finnish	O
origin	O
.	O

These	O
are	O
automatic	O
tools	O
for	O
predicting	O
the	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
.	O

As	O
POLR3	O
binding	O
is	O
well	O
correlated	O
to	O
tRNA	O
expression	O
22	O
23	O
24	O
,	O
this	O
decreased	O
POLR3	O
occupancy	O
is	O
likely	O
to	O
cause	O
reduced	O
transcription	O
of	O
tRNAs	O
and	O
other	O
essential	O
small	O
non	O
-	O
coding	O
RNAs	O
.	O

In	O
addition	O
the	O
amino	O
acid	O
substitution	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
protein	O
that	O
is	O
conserved	O
across	O
different	O
species	O
(	O
Figure	O
S1D	O
)	O
and	O
therefore	O
probably	O
affects	O
the	O
core	O
structure	O
of	O
the	O
peptidase	O
domain	O
(	O
Figure	O
4	O
)	O
.	O

In	O
some	O
cases	O
the	O
delay	O
led	O
to	O
prolonged	O
periods	O
of	O
polyuria	B-DISEASE
,	O
vision	O
problems	O
,	O
or	O
hearing	O
problems	O
before	O
those	O
features	O
were	O
diagnosed	O
and	O
treated	O
.	O

The	O
KCNQ4	B-GENE
gene	O
,	O
which	O
encodes	O
the	O
voltage	O
-	O
gated	O
potassium	O
channel	O
KCNQ4	B-GENE
in	O
outer	O
hair	O
cells	O
,	O
has	O
been	O
identified	O
at	O
the	O
ADNSHL	B-DISEASE
DFNA2	B-DISEASE
locus	O
on	O
the	O
human	O
chromosome	O
1p34	O
[	O
37	O
]	O
.	O

Our	O
initial	O
strategy	O
was	O
to	O
screen	O
one	O
family	O
member	O
(	O
III	O
.	O
10	O
)	O
for	O
pathogenic	O
variants	O
in	O
known	O
deafness	B-DISEASE
-	O
causing	O
genes	O
using	O
a	O
deafness	B-DISEASE
-	O
specific	O
TGE	O
+	O
MPS	O
panel	O
(	O
OtoSCOPE	O
)	O
[	O
21	O
]	O
.	O

They	O
found	O
that	O
prevalence	O
of	O
KAL1	B-GENE
mutations	O
in	O
Brazilian	O
male	O
patients	O
with	O
KS	B-DISEASE
is	O
approximatively	O
22	O
%	O
(	O
27	O
%	O
familial	O
and	O
16	O
%	O
sporadic	O
cases	O
)	O
.	O

The	O
dotted	O
curve	O
represents	O
presbyacusis	B-DISEASE
and	O
was	O
previously	O
established	O
for	O
patients	O
with	O
presbyacusis	B-DISEASE
.	O

However	O
,	O
the	O
ophthalmological	O
examinations	O
of	O
her	O
son	O
were	O
unremarkable	O
.	O

An	O
in	O
vitro	O
splicing	O
assay	O
was	O
performed	O
to	O
test	O
for	O
a	O
splicing	O
alteration	O
.	O

Each	O
genomic	O
DNA	O
pool	O
was	O
fragmented	O
using	O
the	O
Covaris	O
(	O
tm	O
)	O
S2	O
System	O
(	O
Covaris	O
,	O
Woburn	O
,	O
MA	O
)	O
to	O
about	O
200	O
bp	O
fragment	O
length	O
.	O

In	O
brief	O
,	O
1	O
mu	O
g	O
DNA	O
library	O
was	O
mixed	O
with	O
Buffer	O
BL	O
and	O
GenCap	O
probe	O
(	O
MyGenostics	O
,	O
Beijing	O
)	O
,	O
heated	O
at	O
95	O
deg	O
C	O
for	O
7	O
min	O
and	O
65	O
deg	O
C	O
for	O
2	O
min	O
on	O
a	O
PCR	O
machine	O
;	O
23	O
mu	O
l	O
of	O
the	O
65	O
deg	O
C	O
prewarmed	O
Buffer	O
HY	O
(	O
MyGenostics	O
,	O
Beijing	O
)	O
was	O
then	O
added	O
to	O
the	O
mix	O
,	O
and	O
the	O
mixture	O
was	O
hold	O
at	O
65	O
deg	O
C	O
with	O
PCR	O
lid	O
heat	O
on	O
for	O
22	O
hours	O
for	O
hybridization	O
.	O

Bioinformatics	O
analysis	O
of	O
sequencing	O
data	O
was	O
based	O
on	O
the	O
Illumina	O
pipeline	O
(	O
CASAVA	O
1	O
.	O
8	O
)	O
.	O

Filled	O
symbols	O
represent	O
affected	O
individuals	O
,	O
whereas	O
clear	O
symbols	O
represent	O
unaffected	O
individuals	O
.	O

2C	O
)	O
.	O

Non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
NSHI	B-DISEASE
)	O
accounts	O
for	O
60	O
-	O
70	O
%	O
of	O
inherited	O
hearing	B-DISEASE
impairments	I-DISEASE
.	O

The	O
encoded	O
protein	O
,	O
myosin	O
-	O
VIIa	O
,	O
is	O
an	O
actin	O
-	O
based	O
motor	O
protein	O
that	O
plays	O
an	O
important	O
role	O
in	O
intracellular	O
transport	O
,	O
endocytosis	O
,	O
and	O
intercellular	O
adhesion	O
[	O
37	O
]	O
.	O

laevis	O
oocytes	O
,	O
KCNE1	B-GENE
-	O
G25V	B-VARIANT
and	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
showed	O
a	O
gain	O
-	O
of	O
-	O
function	O
for	O
I	B-GENE
Ks	I-GENE
both	O
with	O
respect	O
to	O
steady	O
-	O
state	O
current	O
levels	O
,	O
kinetics	O
,	O
and	O
heart	O
rate	O
-	O
dependent	O
modulation	O
of	O
I	B-GENE
Ks	I-GENE
(	O
for	O
G60D	B-VARIANT
)	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Knowledge	O
of	O
these	O
ER	O
stress	O
-	O
enhancing	O
factors	O
may	O
be	O
important	O
in	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
.	O

Detailed	O
phenotypic	O
description	O
of	O
the	O
seven	O
tested	O
patients	O
Positions	O
of	O
the	O
mutations	O
refer	O
to	O
coding	O
DNA	O
reference	O
sequence	O
CCDS6107	O
.	O
2	O
and	O
Uniprot	O
protein	O
sequence	O
P11362	O
-	O
1	O
.	O

We	O
thank	O
Shiro	O
Ikegawa	O
for	O
his	O
helpful	O
discussion	O
regarding	O
the	O
subject	O
of	O
epiphyseal	B-DISEASE
dysplasia	I-DISEASE
and	O
assistance	O
in	O
sequencing	O
all	O
the	O
coding	O
regions	O
of	O
COL2A1	B-GENE
.	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
2	I-DISEASE
(	O
USH2	B-DISEASE
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
moderate	O
to	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
589G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
G197R	B-VARIANT
)	O
lies	O
in	O
TM2	O
and	O
c	B-VARIANT
.	I-VARIANT
1171G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
Q391X	B-VARIANT
)	O
lies	O
between	O
TM3	O
and	O
TM4	O
extracellularly	O
,	O
and	O
the	O
mutations	O
may	O
affect	O
an	O
ion	O
channel	O
function	O
in	O
hair	O
cells	O
.	O

Structural	O
analysis	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Glu236Ala	I-VARIANT
mutation	O
showed	O
that	O
the	O
wild	O
-	O
type	O
glutamate	O
residue	O
has	O
a	O
possible	O
stabilizing	O
relationship	O
with	O
the	O
lysine	O
residue	O
(	O
Lys202	O
)	O
residing	O
within	O
the	O
alpha	O
helix	O
across	O
the	O
glutamate	O
.	O

Arrows	O
indicate	O
probands	O
in	O
each	O
family	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
common	O
sensory	O
defect	O
that	O
can	O
significantly	O
impact	O
quality	O
of	O
life	O
.	O

Full	O
-	O
field	O
ERGs	O
were	O
performed	O
(	O
RetiPort	O
ERG	O
system	O
,	O
Roland	O
Consult	O
,	O
Wiesbaden	O
,	O
Germany	O
)	O
in	O
selected	O
patients	O
.	O

Profound	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
onset	O
before	O
age	O
2	O
was	O
present	O
in	O
one	O
and	O
one	O
other	O
probably	O
also	O
had	O
very	O
early	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
as	O
noted	O
above	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
QW	O
YZ	O
.	O

To	O
identify	O
the	O
disease	O
locus	O
,	O
two	O
-	O
point	O
genome	O
-	O
wide	O
linkage	O
analysis	O
was	O
performed	O
on	O
the	O
family	O
members	O
that	O
were	O
indicated	O
by	O
asterisks	O
(	O
Figure	O
1	O
-	O
a	O
)	O
.	O

Direct	O
sequencing	O
analysis	O
of	O
the	O
coding	O
region	O
of	O
the	O
USH2A	B-GENE
gene	O
.	O

The	O
highest	O
threshold	O
was	O
most	O
often	O
found	O
at	O
1000	O
Hz	O
and	O
followed	O
by	O
2000	O
Hz	O
.	O

,	O
2006	O
)	O
.	O

Based	O
on	O
our	O
previous	O
experience	O
with	O
studies	O
on	O
collagen	B-DISEASE
IV	I-DISEASE
nephropathies	I-DISEASE
and	O
also	O
based	O
on	O
recent	O
technology	O
trends	O
,	O
we	O
herewith	O
used	O
molecular	O
testing	O
as	O
the	O
first	O
line	O
of	O
investigation	O
in	O
most	O
of	O
our	O
patients	O
.	O

A	O
-	O
1	O
to	O
F	O
-	O
1	O
show	O
the	O
normal	O
sequence	O
data	O
for	O
the	O
CNGA1	B-GENE
gene	O
.	O

Jonard	O
et	O
al	O
.	O

The	O
nucleotides	O
that	O
have	O
been	O
modified	O
are	O
indicated	O
in	O
bold	O
.	O

The	O
mutation	O
could	O
thereby	O
create	O
a	O
profibrillatory	O
substrate	O
within	O
the	O
atrium	O
[	O
10	O
,	O
11	O
]	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
A	O
3	O
/	O
4	O
-	O
shaded	O
icon	O
denotes	O
individual	O
with	O
impaired	O
renal	O
function	O
;	O
a	O
half	O
-	O
shaded	O
icon	O
denotes	O
individuals	O
with	O
microscopic	B-DISEASE
hematuria	I-DISEASE
and	O
proteinuria	B-DISEASE
but	O
with	O
normal	O
renal	O
function	O
;	O
1	O
/	O
4	O
-	O
shaded	O
icon	O
denotes	O
isolated	O
hematuria	O
.	O

The	O
USH2	B-DISEASE
protein	O
network	O
,	O
localized	O
at	O
the	O
periciliary	O
ridge	O
complex	O
region	O
,	O
contributes	O
to	O
the	O
trafficking	O
of	O
cargos	O
moving	O
from	O
the	O
inner	O
segment	O
to	O
the	O
outer	O
segment	O
of	O
the	O
photoreceptor	O
cells	O
through	O
the	O
connecting	O
cilium	O
.	O

b	O
Patient	O
II	O
-	O
1	O
was	O
wheelchair	O
-	O
bound	O
by	O
7	O
years	O
of	O
age	O
.	O

Our	O
approach	O
successfully	O
discovered	O
novel	O
pathogenic	O
roles	O
for	O
NUBPL	B-GENE
and	O
FOXRED1	B-GENE
.	O

Despite	O
the	O
presence	O
of	O
several	O
highly	O
evolutionarily	O
conserved	O
variants	O
in	O
protein	O
-	O
coding	O
genes	O
and	O
the	O
16S	O
rRNA	O
gene	O
[	O
57	O
]	O
,	O
the	O
extremely	O
low	O
penetrance	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
the	O
1095T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
implies	O
that	O
the	O
mitochondrial	O
variants	O
may	O
not	O
have	O
a	O
modifying	O
role	O
in	O
phenotypic	O
expression	O
of	O
the	O
1095T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
these	O
Chinese	O
families	O
.	O

Shafique	O
S	O
.	O

The	O
arrow	O
shows	O
the	O
location	O
of	O
the	O
substitution	O
and	O
,	O
as	O
a	O
consequence	O
,	O
the	O
exposure	O
of	O
a	O
cryptic	O
GT	O
site	O
at	O
position	O
c	O
.	O
5765	O
+	O
51	O
.	O

Missplicing	O
percentages	O
were	O
measured	O
using	O
the	O
Alpha	O
Imager	O
2200	O
(	O
version	O
3	O
.	O
1	O
.	O
2	O
)	O
software	O
(	O
AlphaInnotech	O
Corporation	O
,	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Figure	O
2	O
Clinical	O
findings	O
in	O
parents	O
of	O
two	O
families	O
with	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
.	O

We	O
made	O
use	O
of	O
the	O
data	O
provided	O
by	O
the	O
CNV	O
analysis	O
to	O
search	O
for	O
any	O
specific	O
feature	O
that	O
could	O
account	O
for	O
the	O
heterochromia	B-DISEASE
iridum	I-DISEASE
in	O
that	O
individual	O
,	O
bearing	O
in	O
mind	O
that	O
the	O
search	O
for	O
another	O
genetic	O
lesion	O
would	O
require	O
the	O
scrutiny	O
of	O
the	O
whole	O
genome	O
and	O
that	O
therefore	O
,	O
our	O
CNV	O
analysis	O
is	O
limited	O
.	O

We	O
also	O
analyzed	O
all	O
the	O
data	O
with	O
VIPR	O
,	O
a	O
program	O
established	O
and	O
validated	O
for	O
use	O
with	O
pooled	O
samples	O
[	O
24	O
]	O
.	O

Following	O
incubation	O
with	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
HA	O
antibodies	O
on	O
ice	O
,	O
the	O
cells	O
were	O
either	O
fixed	O
(	O
T0	O
,	O
0	O
min	O
)	O
or	O
incubated	O
in	O
complete	O
medium	O
without	O
antibody	O
for	O
10	O
(	O
T10	O
)	O
and	O
30	O
(	O
T30	O
)	O
minutes	O
,	O
respectively	O
,	O
and	O
then	O
fixed	O
.	O

It	O
is	O
possible	O
that	O
this	O
lower	O
yield	O
is	O
due	O
to	O
the	O
more	O
than	O
10	O
years	O
of	O
publications	O
of	O
several	O
large	O
LQTS	B-DISEASE
studies	O
,	O
which	O
suggests	O
that	O
the	O
increase	O
in	O
new	O
LQTS	B-DISEASE
mutations	O
is	O
beginning	O
to	O
be	O
saturated	O
.	O

Missense	O
changes	O
in	O
USH2A	B-GENE
+	O
:	O
Denotes	O
pathogenic	O
mutations	O
;	O
UV3	O
:	O
Probably	O
pathogenic	O
mutations	O
;	O
UV2	O
:	O
probably	O
non	O
-	O
pathogenic	O
mutations	O
;	O
-	O
:	O
neutral	O
varirants	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
direct	O
sequencing	O
were	O
used	O
to	O
screen	O
for	O
DNA	O
variations	O
in	O
the	O
coding	O
and	O
the	O
5	O
'	O
and	O
3	O
'	O
flanking	O
regions	O
of	O
the	O
known	O
WS4	B-DISEASE
candidate	O
genes	O
EDN3	B-GENE
,	O
EDNRB	B-GENE
,	O
SOX10	B-GENE
,	O
as	O
well	O
as	O
those	O
of	O
RET	B-GENE
(	O
the	O
main	O
HSCR	B-DISEASE
gene	O
)	O
.	O

MLPA	O
was	O
performed	O
in	O
seven	O
patients	O
without	O
recessive	O
WFS1	B-GENE
mutations	O
.	O

The	O
latter	O
are	O
suggested	O
to	O
represent	O
a	O
mild	O
end	O
of	O
CHARGE	B-DISEASE
phenotypic	O
spectrum	O
due	O
to	O
overlapping	O
features	O
of	O
these	O
syndromes	O
such	O
as	O
hypogonadism	B-DISEASE
,	O
anosmia	B-DISEASE
,	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
,	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
and	O
semicircular	B-DISEASE
canal	I-DISEASE
hypoplasia	I-DISEASE
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

A	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
scan	O
of	O
patient	O
II	O
-	O
2	O
showed	O
decreased	O
metabolic	O
changes	O
throughout	O
the	O
brain	O
.	O

Now	O
called	O
MYH9	B-DISEASE
-	I-DISEASE
Related	I-DISEASE
Disorders	I-DISEASE
(	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
:	O
MIM	O
160775	O
)	O
,	O
they	O
are	O
thus	O
characterized	O
by	O
significant	O
phenotypic	O
and	O
genotypic	O
heterogeneity	O
(	O
Heath	O
et	O
al	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Applying	O
genotyping	O
microarray	O
and	O
next	O
-	O
generation	O
sequencing	O
will	O
allow	O
for	O
large	O
-	O
scale	O
screening	O
in	O
patients	O
with	O
USH	B-DISEASE
.	O

Both	O
variants	O
were	O
also	O
found	O
in	O
an	O
affected	O
sibling	O
and	O
p	B-VARIANT
.	I-VARIANT
Pro240Leu	I-VARIANT
was	O
confirmed	O
in	O
the	O
father	O
by	O
Sanger	O
sequencing	O
(	O
Figure	O
1	O
B	O
)	O
.	O

The	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
reference	O
genome	O
(	O
hg19	O
)	O
using	O
BWA	O
(	O
v	O
.	O

Of	O
the	O
31	O
JLNS	B-DISEASE
-	O
causing	O
mutations	O
previously	O
reported	O
[	O
Table	O
2	O
and	O
Figure	O
7	O
]	O
,	O
three	O
were	O
splicing	O
,	O
three	O
nonsense	O
,	O
14	O
missense	O
,	O
and	O
11	O
were	O
frameshift	O
(	O
insertion	O
/	O
deletion	O
)	O
mutations	O
.	O

In	O
total	O
,	O
128	O
,	O
557	O
variants	O
(	O
including	O
six	O
large	O
deletions	O
)	O
were	O
identified	O
(	O
Fig	O
.	O

Here	O
we	O
demonstrate	O
association	O
of	O
variants	O
in	O
the	O
mitochondrial	B-GENE
asparaginyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
NARS2	B-GENE
with	O
human	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
Leigh	B-DISEASE
syndrome	I-DISEASE
.	O

Cells	O
expressing	O
WT	O
receptor	O
showed	O
clear	O
phosphorylation	O
of	O
MAPK	O
after	O
10	O
and	O
30	O
min	O
of	O
FGF2	O
treatment	O
(	O
Figure	O
2C	O
)	O
.	O

SALL1	B-GENE
,	O
HNF1B	B-GENE
and	O
PAX2	B-GENE
were	O
the	O
most	O
prevalent	O
disease	O
causing	O
genes	O
in	O
our	O
cohort	O
.	O

NMD	B-DISEASE
can	O
be	O
of	O
benefit	O
and	O
perhaps	O
reduce	O
disease	O
severity	O
,	O
for	O
example	O
,	O
in	O
removing	O
aberrant	O
transcripts	O
that	O
encode	O
proteins	O
with	O
dominant	O
-	O
negative	O
effects	O
.	O

Our	O
results	O
,	O
however	O
,	O
show	O
that	O
carriers	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
allele	O
haplotype	O
belonged	O
to	O
the	O
early	O
founders	O
of	O
both	O
the	O
Acadian	O
and	O
the	O
Quebec	O
population	O
.	O

To	O
assess	O
the	O
functional	O
status	O
of	O
neuromast	O
hair	O
cells	O
in	O
the	O
lateral	O
lines	O
,	O
we	O
briefly	O
exposed	O
larvae	O
to	O
FM1	O
-	O
43	O
,	O
a	O
styryl	O
pyridinium	O
dye	O
,	O
which	O
enters	O
the	O
hair	O
cells	O
via	O
partially	O
open	O
MET	O
channels	O
at	O
rest	O
18	O
-	O
21	O
,	O
or	O
its	O
fixable	O
analog	O
AM1	O
-	O
43	O
.	O

The	O
other	O
two	O
variants	O
(	O
c	B-VARIANT
.	I-VARIANT
6049G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
8722	I-VARIANT
+	I-VARIANT
1delG	I-VARIANT
in	O
the	O
CDH23	B-GENE
gene	O
)	O
showed	O
a	O
score	O
of	O
3	O
.	O

WS	B-DISEASE
is	O
a	O
rare	O
progressive	O
neurodegenerative	O
disorder	O
usually	O
characterized	O
by	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
early	O
-	O
onset	O
diabetes	B-DISEASE
,	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
and	O
deafness	B-DISEASE
(	O
hence	O
the	O
acronym	O
DIDMOAD	O
)	O
,	O
with	O
diabetes	B-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
being	O
the	O
most	O
consistent	O
features	O
(	O
17	O
,	O
24	O
)	O
.	O

The	O
genotype	O
-	O
positive	O
cases	O
stemmed	O
from	O
64	O
distinct	O
mutations	O
,	O
of	O
which	O
28	O
%	O
were	O
novel	O
to	O
this	O
cohort	O
.	O

ELMOD3	B-GENE
exhibited	O
GAP	O
activity	O
against	O
Arl2	O
,	O
a	O
small	O
GTPase	O
,	O
providing	O
a	O
potential	O
functional	O
link	O
between	O
Arf	O
family	O
signaling	O
and	O
stereocilia	O
actin	O
-	O
based	O
cytoskeletal	O
architecture	O
.	O

B	O
:	O
Southern	O
blot	O
analysis	O
of	O
muscle	O
-	O
derived	O
mtDNA	O
of	O
Patient	O
2	O
,	O
two	O
positive	O
controls	O
(	O
POLG1	B-GENE
-	O
mutated	O
patients	O
)	O
and	O
a	O
negative	O
control	O
(	O
adult	O
healthy	O
subject	O
)	O
.	O

The	O
vertebral	O
bodies	O
are	O
mildly	O
foreshortened	O
with	O
posterior	B-DISEASE
scalloping	I-DISEASE
.	O

DNA	O
from	O
50	O
individuals	O
without	O
a	O
family	O
history	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
or	O
visual	O
alterations	O
were	O
screened	O
as	O
healthy	O
controls	O
to	O
evaluate	O
the	O
frequency	O
of	O
the	O
mutations	O
found	O
in	O
the	O
patient	O
sample	O
.	O

1	O
)	O
,	O
although	O
the	O
biological	O
significance	O
of	O
this	O
observation	O
remains	O
unknown	O
.	O

Examination	O
of	O
her	O
peripheral	O
blood	O
smears	O
showed	O
giant	B-DISEASE
platelets	I-DISEASE
and	O
D	O
o	O
hle	O
-	O
like	O
inclusions	O
.	O

We	O
investigated	O
how	O
CNVs	O
in	O
80	O
known	O
deafness	B-DISEASE
genes	O
may	O
result	O
in	O
deafness	B-DISEASE
.	O

We	O
identified	O
four	O
novel	O
heterozygous	O
mutations	O
in	O
MYO6	B-GENE
.	O

However	O
,	O
a	O
recent	O
study	O
demonstrated	O
a	O
rapid	O
turnover	O
of	O
the	O
actin	O
filaments	O
only	O
at	O
the	O
tip	O
of	O
the	O
stereocilia	O
,	O
without	O
a	O
treadmilling	O
process	O
[	O
10	O
]	O
,	O
emphasizing	O
the	O
specific	O
role	O
of	O
proteins	O
at	O
the	O
stereocilia	O
tip	O
in	O
the	O
regulation	O
of	O
actin	O
filaments	O
.	O

(	O
H	O
)	O
Normal	O
autofluorescence	O
.	O

Wfs1	B-GENE
deficient	O
mice	O
have	O
glucose	O
intolerance	O
associated	O
with	O
loss	O
of	O
pancreatic	O
beta	O
cells	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

The	O
age	O
at	O
which	O
macrothrombocytopenia	B-DISEASE
was	O
first	O
reported	O
was	O
available	O
for	O
74	O
patients	O
(	O
Table	O
S1	O
,	O
panel	O
A	O
)	O
and	O
included	O
52	O
children	O
and	O
22	O
adults	O
,	O
indicating	O
that	O
in	O
our	O
cohort	O
,	O
macrothrombocytopenia	B-DISEASE
was	O
discovered	O
during	O
childhood	O
for	O
a	O
majority	O
of	O
patients	O
(	O
70	O
.	O
3	O
%	O
)	O
half	O
of	O
whom	O
were	O
under	O
5	O
years	O
of	O
age	O
(	O
52	O
.	O
7	O
%	O
)	O
.	O

(	O
C	O
)	O
Autofluorescence	O
reveals	O
hypofluorescence	O
areas	O
corresponding	O
with	O
pigmented	O
spicules	O
and	O
atrophic	O
lesions	O
.	O

By	O
combining	O
the	O
results	O
obtained	O
from	O
these	O
methods	O
,	O
we	O
efficiently	O
identified	O
a	O
causative	O
mutation	O
from	O
the	O
family	O
data	O
.	O

The	O
Allegro	O
module	O
of	O
the	O
Easy	O
Linkage	O
software	O
package	O
was	O
used	O
to	O
calculate	O
multipoint	O
logarithm	O
of	O
the	O
odds	O
(	O
LOD	O
)	O
scores	O
,	O
with	O
the	O
parameters	O
that	O
assume	O
a	O
disease	O
model	O
with	O
an	O
autosomal	O
-	O
recessive	O
mode	O
of	O
inheritance	O
with	O
100	O
%	O
penetrance	O
and	O
a	O
disease	O
allele	O
frequency	O
of	O
0	O
.	O
0001	O
.	O

However	O
,	O
apart	O
from	O
the	O
c	B-VARIANT
.	I-VARIANT
2991	I-VARIANT
+	I-VARIANT
1655A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
CEP290	B-GENE
previously	O
reported	O
to	O
be	O
present	O
in	O
20	O
%	O
of	O
patients	O
with	O
Leber	B-DISEASE
congenital	I-DISEASE
amaurosis	I-DISEASE
(	O
LCA	B-DISEASE
)	O
and	O
RPGR	B-GENE
in	O
male	O
RP	B-DISEASE
patients	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
there	O
is	O
no	O
major	O
mutation	O
or	O
disease	O
gene	O
for	O
RP	B-DISEASE
and	O
LCA	B-DISEASE
,	O
and	O
clear	O
-	O
cut	O
genotype	O
-	O
phenotype	O
correlations	O
are	O
largely	O
lacking	O
,	O
which	O
prevents	O
efficient	O
targeted	O
Sanger	O
sequencing	O
.	O

G490	O
,	O
D623	O
,	O
and	O
N628	O
are	O
in	O
close	O
proximity	O
to	O
the	O
ATP	O
'	O
s	O
phosphates	O
or	O
coordinating	O
magnesium	O
.	O

We	O
therefore	O
propose	O
that	O
loss	O
and	O
aberrant	O
splicing	O
of	O
EYS	B-GENE
exon	O
1	O
should	O
impair	O
transcription	O
of	O
the	O
mutant	O
gene	O
copy	O
and	O
result	O
in	O
a	O
null	O
allele	O
.	O

N	O
.	O
C	O
.	O
,	O
J	O
.	O
R	O
.	O
H	O
.	O

2011	O
;	O
Shearer	O
et	O
al	O
.	O

The	O
in	O
vitro	O
splicing	O
analysis	O
was	O
replicated	O
by	O
transfecting	O
the	O
plasmids	O
into	O
COS	O
-	O
1	O
cells	O
.	O

Indeed	O
,	O
in	O
the	O
last	O
few	O
years	O
,	O
causative	O
mutations	O
were	O
identified	O
in	O
five	O
genes	O
:	O
HSD17B4	B-GENE
(	O
17	B-GENE
-	I-GENE
beta	I-GENE
hydroxysteroid	I-GENE
dehydrogenase	I-GENE
4	I-GENE
;	O
MIM	O
*	O
601860	O
)	O
,	O
HARS2	B-GENE
(	O
mitochondrial	B-GENE
histidyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
;	O
MIM	O
*	O
600783	O
)	O
,	O
LARS2	B-GENE
(	O
mitochondrial	B-GENE
leucyl	I-GENE
-	I-GENE
tRNA	I-GENE
synthetase	I-GENE
;	O
MIM	O
*	O
604544	O
)	O
,	O
CLPP	B-GENE
(	O
mitochondrial	B-GENE
ATP	I-GENE
-	I-GENE
dependent	I-GENE
chambered	I-GENE
protease	I-GENE
;	O
MIM	O
*	O
601119	O
)	O
,	O
and	O
C10ORF2	B-GENE
(	O
mitochondrial	B-GENE
DNA	I-GENE
helicase	I-GENE
Twinkle	I-GENE
;	O
MIM	O
*	O
606075	O
)	O
3	O
-	O
7	O
.	O

PCR	O
primers	O
surrounding	O
the	O
suspected	O
variants	O
of	O
7	O
genes	O
.	O

To	O
our	O
knowledge	O
this	O
is	O
the	O
first	O
case	O
of	O
a	O
retinal	B-DISEASE
dystrophy	I-DISEASE
caused	O
by	O
CRB1	B-GENE
mutation	O
with	O
a	O
normal	O
ERG	O
,	O
as	O
usually	O
CRB1	B-GENE
mutations	O
lead	O
to	O
severe	O
RP	B-DISEASE
or	O
LCA	B-DISEASE
with	O
extinguished	O
or	O
severely	O
diminished	O
ERGs	O
.	O

Click	O
here	O
for	O
file	O
Flow	O
cytometry	O
analysis	O
of	O
mesenchymal	O
cells	O
from	O
patients	O
TCS16	B-DISEASE
,	O
21	O
,	O
22	O
,	O
and	O
23	O
.	O

The	O
effect	O
of	O
the	O
identified	O
novel	O
missense	O
mutation	O
was	O
assessed	O
using	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
,	O
PolyPhen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
index	O
.	O
shtml	O
)	O
and	O
MUpro	O
(	O
http	O
:	O
/	O
/	O
mupro	O
.	O
proteomics	O
.	O
ics	O
.	O
uci	O
.	O
edu	O
/	O
)	O
,	O
automatic	O
tools	O
for	O
prediction	O
of	O
the	O
possible	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
.	O

MB9	O
had	O
a	O
mild	O
peripheral	O
RP	B-DISEASE
,	O
while	O
MB60	O
had	O
only	O
some	O
pigments	O
.	O

Parents	O
were	O
interviewed	O
with	O
regard	O
to	O
age	O
of	O
onset	O
,	O
family	O
history	O
,	O
health	O
of	O
the	O
mother	O
during	O
pregnancy	O
and	O
the	O
clinical	O
history	O
of	O
the	O
patient	O
,	O
including	O
infection	O
,	O
possible	O
head	O
or	O
brain	O
injury	O
,	O
and	O
the	O
use	O
of	O
aminoglycoside	O
antibiotics	O
.	O

2009	O
;	O
Du	O
et	O
al	O
.	O

TMC1	B-GENE
has	O
been	O
predicted	O
to	O
be	O
an	O
ion	O
channel	O
or	O
transporter	O
that	O
mediates	O
K	O
+	O
homeostasis	O
in	O
the	O
inner	O
ear	O
[	O
27	O
]	O
.	O

A	O
-	O
O	O
Chromatograms	O
of	O
characterized	O
pathogenic	O
mutations	O
in	O
TCS	B-DISEASE
patients	O
.	O

dbSNP135	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
projects	O
/	O
SNP	O
/	O
5	O
.	O

Approximately	O
99	O
%	O
and	O
98	O
.	O
98	O
%	O
(	O
2739	O
Mb	O
and	O
2942	O
Mb	O
in	O
length	O
,	O
respectively	O
)	O
of	O
the	O
targeted	O
bases	O
were	O
covered	O
sufficiently	O
to	O
pass	O
our	O
thresholds	O
for	O
calling	O
SNPs	O
and	O
short	O
insertions	O
or	O
deletions	O
(	O
indels	O
)	O
.	O

For	O
a	O
focused	O
evaluation	O
of	O
the	O
whole	O
-	O
exome	O
data	O
,	O
a	O
list	O
of	O
272	O
genes	O
arising	O
from	O
three	O
functional	O
criteria	O
of	O
inclusion	O
was	O
used	O
:	O
ten	O
genes	O
known	O
to	O
be	O
causative	O
for	O
CHI	B-DISEASE
(	O
ABCC8	B-GENE
,	O
KCNJ11	B-GENE
,	O
GLUD1	B-GENE
,	O
GCK	B-GENE
,	O
HADH	B-GENE
,	O
HFN4A	B-GENE
,	O
SLC16A1	B-GENE
,	O
UCP2	B-GENE
,	O
INSR	B-GENE
and	O
HNF1A	B-GENE
)	O
;	O
51	O
genes	O
suggested	O
by	O
TDT	O
association	O
analysis	O
(	O
Table	O
S1	O
)	O
;	O
145	O
genes	O
associated	O
to	O
regulation	O
of	O
insulin	O
secretion	O
reported	O
in	O
the	O
Rat	O
Genome	O
Database	O
[	O
58	O
]	O
and	O
66	O
genes	O
indicated	O
by	O
reviewing	O
the	O
literature	O
concerning	O
the	O
beta	O
-	O
cell	O
function	O
and	O
its	O
metabolic	O
regulation	O
(	O
Table	O
S3	O
)	O
.	O

In	O
the	O
family	O
,	O
five	O
autozygous	O
segments	O
longer	O
than	O
2	O
Mb	O
were	O
present	O
on	O
chromosomes	O
8	O
,	O
15	O
,	O
16	O
,	O
19	O
and	O
21	O
(	O
Table	O
1	O
)	O
.	O

KpnI	O
-	O
R	O
contains	O
protective	O
base	O
and	O
KpnI	O
restriction	O
sites	O
,	O
its	O
3	O
'	O
end	O
partial	O
sequence	O
for	O
PCR	O
amplify	O
target	O
gene	O
.	O

The	O
phenotypes	O
of	O
the	O
different	O
families	O
were	O
compared	O
when	O
at	O
least	O
one	O
identical	O
mutation	O
in	O
TMPRSS3	B-GENE
was	O
present	O
.	O

AUTHOR	O
CONTRIBUTIONS	O
This	O
study	O
was	O
conceived	O
and	O
designed	O
by	O
SEC	O
,	O
DRT	O
,	O
and	O
VKM	O
with	O
input	O
from	O
MJD	O
and	O
SBG	O
.	O

Thirty	O
-	O
three	O
patients	O
were	O
screened	O
for	O
mutations	O
in	O
the	O
USH1C	B-GENE
gene	O
by	O
direct	O
sequencing	O
.	O

Each	O
found	O
mutation	O
was	O
confirmed	O
with	O
bidirectional	O
sequencing	O
.	O

Protein	O
structural	O
models	O
for	O
ZNF57	B-GENE
(	O
the	O
wild	O
type	O
and	O
p	B-VARIANT
.	I-VARIANT
T443M	I-VARIANT
)	O
were	O
built	O
(	O
Figure	O
3	O
)	O
.	O

Affected	O
individuals	O
did	O
not	O
have	O
delays	O
in	O
gross	O
motor	O
development	O
;	O
neither	O
did	O
they	O
have	O
balance	O
problems	O
,	O
vertigo	O
,	O
dizziness	O
,	O
nor	O
spontaneous	O
and	O
positional	O
nystagmus	O
.	O

Finally	O
,	O
in	O
only	O
one	O
patient	O
,	O
U1067	O
clinically	O
diagnosed	O
as	O
USH3	B-DISEASE
,	O
no	O
candidate	O
pathogenic	O
alteration	O
could	O
be	O
identified	O
.	O

Mutations	O
in	O
CDH23	B-GENE
are	O
responsible	O
for	O
both	O
Usher	B-DISEASE
syndrome	I-DISEASE
1D	I-DISEASE
(	O
USH1D	B-DISEASE
:	O
OMIM	O
#	O
601067	O
)	O
[	O
6	O
-	O
9	O
]	O
and	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
DFNB12	B-DISEASE
:	O
OMIM	O
#	O
601386	O
)	O
[	O
10	O
-	O
12	O
]	O
.	O

In	O
the	O
majority	O
of	O
our	O
patients	O
behavioral	B-DISEASE
problems	I-DISEASE
or	O
depression	B-DISEASE
were	O
evident	O
at	O
much	O
younger	O
ages	O
.	O

This	O
study	O
used	O
the	O
automatic	O
modeling	O
approach	O
to	O
model	O
the	O
complete	O
human	O
myosin	B-GENE
VIIa	I-GENE
protein	O
,	O
including	O
its	O
2215	O
amino	O
acids	O
(	O
NP_000251	O
.	O
3	O
)	O
with	O
or	O
without	O
the	O
mutations	O
.	O

Oxidative	O
stress	O
is	O
also	O
inducible	O
by	O
cytokine	O
storm	O
(	O
3	O
)	O
.	O

Paired	O
-	O
end	O
libraries	O
were	O
prepared	O
by	O
shearing	O
3	O
mu	O
g	O
of	O
germline	O
DNA	O
to	O
a	O
peak	O
size	O
of	O
200	O
bp	O
using	O
a	O
Covaris	O
S2	O
.	O

An	O
important	O
fact	O
is	O
that	O
the	O
samples	O
we	O
used	O
were	O
collected	O
randomly	O
from	O
33	O
different	O
hospitals	O
distributed	O
throughout	O
Japan	O
,	O
therefore	O
we	O
believe	O
them	O
to	O
be	O
a	O
representative	O
cohort	O
of	O
Japanese	O
patients	O
and	O
suitable	O
for	O
epidemiological	O
evaluation	O
.	O

Identification	O
of	O
these	O
genotype	O
-	O
phenotype	O
correlations	O
is	O
important	O
to	O
improve	O
the	O
accuracy	O
of	O
genetic	O
counselling	O
.	O

Linkage	O
analysis	O
with	O
microsatellite	O
markers	O
surrounding	O
the	O
USH1B	B-GENE
locus	O
on	O
11q13	O
.	O
5	O
and	O
USH2A	B-GENE
on	O
1q41	O
were	O
previously	O
reported	O
on	O
six	O
families	O
[	O
28	O
]	O
,	O
[	O
29	O
]	O
.	O

Finally	O
,	O
visual	B-DISEASE
loss	I-DISEASE
ranges	O
from	O
a	O
very	O
mild	O
affection	O
to	O
severe	O
impairment	O
[	O
5	O
,	O
6	O
]	O
.	O

Pedigree	O
,	O
sequence	O
results	O
and	O
typical	O
audiogram	O
of	O
each	O
family	O
are	O
shown	O
.	O

1	O
)	O
.	O

Clinical	O
findings	O
of	O
patient	O
and	O
family	O
with	O
lesions	O
of	O
the	O
femoral	O
head	O
Table	O
1	O
shows	O
the	O
clinical	O
findings	O
of	O
more	O
than	O
three	O
generations	O
of	O
the	O
patient	O
'	O
s	O
family	O
who	O
have	O
hip	O
joint	O
lesions	O
:	O
the	O
proband	O
(	O
IV	O
-	O
1	O
)	O
,	O
her	O
father	O
(	O
III	O
-	O
20	O
)	O
and	O
her	O
grandmother	O
(	O
II	O
-	O
9	O
)	O
,	O
II	O
-	O
1	O
,	O
3	O
,	O
5	O
,	O
III	O
-	O
3	O
,	O
6	O
,	O
11	O
,	O
15	O
.	O

However	O
,	O
these	O
mutations	O
are	O
located	O
throughout	O
the	O
gene	O
without	O
any	O
identified	O
mutational	O
hot	O
spot	O
.	O

In	O
the	O
other	O
56	O
patients	O
in	O
whom	O
we	O
identified	O
a	O
COMP	B-GENE
,	O
MATN3	B-GENE
or	O
type	B-GENE
IX	I-GENE
collagen	I-GENE
gene	O
mutation	O
,	O
the	O
majority	O
had	O
been	O
referred	O
to	O
ESDN	O
with	O
a	O
diagnosis	O
of	O
MED	B-DISEASE
(	O
Table	O
3	O
)	O
,	O
which	O
would	O
indicate	O
that	O
the	O
"	O
classical	O
"	O
forms	O
of	O
MED	B-DISEASE
(	O
i	O
.	O
e	O
.	O
,	O
those	O
patients	O
in	O
whom	O
we	O
identified	O
a	O
mutation	O
)	O
are	O
also	O
relatively	O
easy	O
to	O
diagnose	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
following	O
research	O
grants	O
:	O
FIS	O
PI09	O
/	O
90047	O
,	O
FIS	O
PI09	O
/	O
00459	O
and	O
Merck	O
Serono	O
30171	O
/	O
006	O
.	O
LZ	O
,	O
JG	O
,	O
ME	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

This	O
protein	O
belongs	O
to	O
the	O
POU	O
-	O
domain	O
class	O
IV	O
transcription	O
factor	O
family	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
maturation	O
,	O
differentiation	O
and	O
survival	O
of	O
hair	O
cells	O
[	O
25	O
]	O
.	O

Cochleae	O
from	O
two	O
Albino	O
guinea	O
pigs	O
were	O
ground	O
in	O
lysis	O
buffer	O
(	O
50mM	O
Tris	O
HCL	O
,	O
pH	O
7	O
.	O
4	O
,	O
with	O
150mM	O
NaCl	O
,	O
1mM	O
EDTA	O
,	O
and	O
1	O
%	O
TRITON	O
X	O
-	O
100	O
)	O
supplemented	O
with	O
protease	O
inhibitor	O
cocktail	O
(	O
M221	O
,	O
AMRESCO	O
)	O
to	O
produce	O
cochlear	O
total	O
protein	O
.	O

Analysis	O
of	O
germline	O
truncations	O
in	O
somatically	O
mutated	O
chromatin	O
modifier	O
genes	O
also	O
identified	O
truncations	O
in	O
SETD4	B-GENE
(	O
Y129fs	B-VARIANT
)	O
,	O
SETD6	B-GENE
(	O
M264fs	B-VARIANT
)	O
,	O
MLL3	B-GENE
(	O
e14	O
-	O
2	O
)	O
,	O
SMC5	B-GENE
(	O
Q810fs	B-VARIANT
)	O
,	O
and	O
SMC6	B-GENE
(	O
Y954	B-VARIANT
*	I-VARIANT
)	O
.	O

In	O
spite	O
of	O
the	O
intense	O
mapping	O
efforts	O
over	O
the	O
past	O
two	O
decades	O
,	O
mutations	O
detectable	O
in	O
known	O
RP	B-DISEASE
genes	O
have	O
been	O
able	O
to	O
explain	O
only	O
a	O
relatively	O
small	O
percentage	O
of	O
cases	O
.	O

However	O
,	O
the	O
secreted	O
(	O
Medium	O
)	O
amount	O
of	O
mutant	O
CEACAM16	B-GENE
is	O
much	O
lower	O
than	O
the	O
WT	O
CEACAM16	B-GENE
.	O

Unfortunately	O
,	O
the	O
difficulty	O
to	O
obtain	O
the	O
eye	O
tissues	O
has	O
impeded	O
further	O
study	O
of	O
the	O
X	O
-	O
inactivation	O
pattern	O
of	O
II	O
-	O
2	O
.	O

However	O
,	O
we	O
calculated	O
that	O
there	O
was	O
only	O
a	O
0	O
.	O
0046	O
probability	O
that	O
this	O
case	O
is	O
a	O
happenstance	O
carrier	O
[	O
27	O
]	O
.	O

Shearer	O
et	O
al	O
.	O

Detailed	O
clinical	O
examination	O
of	O
the	O
diabetic	B-DISEASE
family	O
members	O
did	O
not	O
reveal	O
any	O
of	O
the	O
other	O
clinical	O
features	O
of	O
the	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
(	O
WS	B-DISEASE
)	O
(	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
audiograms	O
,	O
optic	B-DISEASE
atrophy	I-DISEASE
or	I-DISEASE
vision	I-DISEASE
impairment	I-DISEASE
in	O
annual	O
ophthalmoscopy	O
examinations	O
,	O
or	O
diabetes	B-DISEASE
insipidus	I-DISEASE
)	O
.	O

PCR	O
products	O
were	O
purified	O
by	O
ExoSAP	O
-	O
IT	O
(	O
Amersham	O
)	O
and	O
directly	O
sequenced	O
using	O
the	O
PRISMTM	O
Ready	O
Reaction	O
Sequencing	O
Kit	O
(	O
PE	O
Applied	O
Biosystems	O
)	O
on	O
an	O
automatic	O
sequencer	O
(	O
ABI	O
3130	O
,	O
PE	O
Applied	O
Biosystems	O
)	O
.	O

PCR	O
was	O
performed	O
with	O
PE9700	O
thermocyclers	O
(	O
Applied	O
Biosystems	O
)	O
.	O

MD	B-DISEASE
was	O
also	O
detected	O
in	O
three	O
of	O
the	O
patients	O
inspected	O
(	O
Table	O
2	O
,	O
Fig	O
.	O

Protein	O
A	O
-	O
Sepharose	O
CL	O
-	O
4B	O
beads	O
were	O
incubated	O
4	O
hours	O
with	O
5ug	O
of	O
anti	O
-	O
GFP	O
antibody	O
and	O
washed	O
three	O
times	O
with	O
PBS	O
containing	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
.	O

Given	O
the	O
availability	O
of	O
genomics	O
tools	O
,	O
it	O
is	O
now	O
possible	O
to	O
develop	O
gene	O
discovery	O
strategies	O
best	O
suited	O
to	O
the	O
demography	O
of	O
each	O
community	O
.	O

The	O
SNV	O
was	O
not	O
present	O
in	O
Exome	O
Variant	O
Server	O
nor	O
1000	O
Genomes	O
,	O
altered	O
a	O
residue	O
conserved	O
to	O
bacteria	O
within	O
a	O
predicted	O
NAD	O
-	O
binding	O
domain	O
,	O
and	O
is	O
predicted	O
to	O
be	O
"	O
probably	O
damaging	O
"	O
by	O
PolyPhen2	O
.	O

Unfortunately	O
,	O
the	O
combination	O
of	O
compound	O
heterozygous	O
defects	O
found	O
in	O
our	O
series	O
has	O
never	O
been	O
reported	O
in	O
literature	O
.	O

Alternatively	O
,	O
these	O
ABCA4	B-GENE
mutations	O
may	O
act	O
in	O
a	O
di	O
-	O
genic	O
or	O
multi	O
-	O
genic	O
fashion	O
to	O
cause	O
disease	O
.	O

Comprehending	O
and	O
producing	O
Wh	O
-	O
questions	O
are	O
crucial	O
abilities	O
in	O
communication	O
,	O
for	O
example	O
,	O
Wh	O
-	O
questions	O
that	O
begin	O
with	O
which	O
and	O
who	O
and	O
the	O
ability	O
of	O
orally	O
trained	O
deaf	O
children	O
to	O
understand	O
and	O
produce	O
other	O
structures	O
that	O
involve	O
the	O
same	O
syntactic	O
construction	O
,	O
Wh	O
-	O
movement	O
[	O
9	O
]	O
.	O

Among	O
the	O
76	O
patients	O
44	O
could	O
be	O
otoscopically	O
examined	O
,	O
and	O
pure	O
tone	O
audiometry	O
was	O
performed	O
in	O
the	O
special	O
medical	O
service	O
(	O
of	O
the	O
town	O
Gorno	O
-	O
Altaisk	O
)	O
.	O

The	O
DNA	O
is	O
pelleted	O
after	O
the	O
precipitation	O
step	O
,	O
washed	O
with	O
70	O
%	O
ethanol	O
,	O
and	O
resuspended	O
in	O
Tris	O
-	O
EDTA	O
buffer	O
.	O

Arrowhead	O
:	O
variant	O
site	O
.	O

The	O
first	O
two	O
groups	O
were	O
used	O
as	O
controls	O
and	O
we	O
mainly	O
focused	O
on	O
the	O
differences	O
between	O
wild	O
type	O
and	O
variant	O
type	O
MCM2	B-GENE
expressed	O
cells	O
.	O

A	O
total	O
of	O
35	O
.	O
74	O
%	O
deaf	B-DISEASE
patients	O
showed	O
evidence	O
of	O
genetic	O
involvement	O
based	O
on	O
either	O
genetic	O
screening	O
or	O
family	O
history	O
,	O
and	O
17	O
.	O
45	O
%	O
,	O
9	O
.	O
79	O
%	O
,	O
and	O
8	O
.	O
51	O
%	O
of	O
the	O
patients	O
were	O
determined	O
to	O
have	O
inherited	O
hearing	B-DISEASE
impairment	I-DISEASE
caused	O
by	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
,	O
and	O
mtDNA	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutations	O
.	O

Indigenous	O
inhabitants	O
of	O
the	O
Altai	O
Republic	O
are	O
the	O
Altaians	O
originated	O
from	O
several	O
ancient	O
Turkic	O
-	O
speaking	O
tribes	O
[	O
19	O
]	O
.	O

We	O
additionally	O
identified	O
the	O
heterozygous	O
CNGA1	B-GENE
missense	O
variants	O
c	B-VARIANT
.	I-VARIANT
G860A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R287K	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
G1271A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R424Q	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
G2042C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G681A	I-VARIANT
)	O
(	O
Table	O
2	O
)	O
.	O

28	O
Another	O
kinase	O
domain	O
germline	O
variant	O
,	O
D837N	B-VARIANT
,	O
in	O
EGFR	B-GENE
was	O
absent	O
in	O
WHISP	O
controls	O
but	O
found	O
in	O
5	O
/	O
387	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
with	O
a	O
position	O
matching	O
a	O
reported	O
somatic	O
mutation	O
(	O
D837G	B-VARIANT
)	O
in	O
COSMIC	O
.	O

A	O
25	O
-	O
year	O
-	O
old	O
man	O
presented	O
in	O
1984	O
with	O
intermittent	O
macroscopic	O
haematuria	B-DISEASE
,	O
hypertension	B-DISEASE
,	O
normal	O
renal	O
function	O
(	O
creatinine	O
clearance	O
154	O
mL	O
/	O
min	O
)	O
and	O
proteinuria	B-DISEASE
(	O
0	O
.	O
2	O
g	O
/	O
24	O
h	O
)	O
.	O

BCVA	O
=	O
decimal	O
corrective	O
visual	O
acuity	O
;	O
ERG	O
=	O
electroretinography	O
;	O
M	O
=	O
male	O
;	O
F	O
=	O
female	O
.	O

In	O
fact	O
,	O
in	O
frame	O
-	O
deletions	O
have	O
been	O
reported	O
not	O
only	O
in	O
ADOA	B-DISEASE
or	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
phenotypes	O
but	O
even	O
also	O
in	O
a	O
multisystemic	B-DISEASE
disorder	I-DISEASE
in	O
the	O
absence	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
[	O
15	O
]	O
.	O

A	O
two	O
-	O
step	O
approach	O
of	O
linkage	O
analysis	O
using	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
microarrays	O
to	O
detect	O
high	O
logarithm	O
of	O
odds	O
(	O
LOD	O
)	O
score	O
regions	O
and	O
subsequent	O
targeted	O
re	O
-	O
sequencing	O
of	O
regions	O
of	O
interest	O
has	O
been	O
utilized	O
in	O
many	O
genomic	O
studies	O
to	O
intensify	O
the	O
power	O
of	O
detection	O
[	O
7	O
]	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ankara	O
University	O
Medical	O
School	O
Ethics	O
Committee	O
(	O
Turkey	O
)	O
,	O
and	O
by	O
the	O
University	O
of	O
Miami	O
Institutional	O
Review	O
Board	O
(	O
USA	O
)	O
.	O

Finally	O
,	O
six	O
missense	O
mutations	O
were	O
considered	O
as	O
pathogenic	O
.	O

Collection	O
of	O
DNA	O
samples	O
and	O
clinical	O
data	O
:	O
The	O
Deafness	B-DISEASE
Gene	O
Study	O
Consortium	O
.	O

The	O
OPA1	B-GENE
gene	O
encodes	O
a	O
dynamin	O
-	O
related	O
guanosine	O
triphosphatase	O
(	O
GTPase	O
)	O
and	O
is	O
composed	O
of	O
31	O
exons	O
[	O
9	O
]	O
.	O

No	O
change	O
in	O
protein	O
levels	O
of	O
beta	O
-	O
and	O
gamma	O
-	O
actin	O
were	O
seen	O
between	O
these	O
two	O
cell	O
lines	O
(	O
Fig	O
.	O

Sequence	O
analysis	O
of	O
the	O
SLC26A4	B-GENE
gene	O
in	O
these	O
235	O
patients	O
identified	O
nine	O
patients	O
with	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
and	O
five	O
patients	O
carried	O
one	O
confirmed	O
pathogenic	O
mutation	O
.	O

Thereby	O
,	O
our	O
mutation	O
detection	O
rate	O
rises	O
considerably	O
to	O
76	O
.	O
1	O
%	O
(	O
102	O
/	O
134	O
)	O
,	O
making	O
our	O
percentage	O
similar	O
to	O
those	O
obtained	O
by	O
Baux	O
et	O
al	O
.	O

Affected	O
and	O
unaffected	O
individuals	O
were	O
submitted	O
to	O
clinical	O
evaluation	O
,	O
which	O
included	O
general	O
and	O
craniofacial	O
examination	O
.	O

Control	O
immunoblots	O
demonstrated	O
appropriate	O
co	O
-	O
expression	O
of	O
the	O
two	O
constructs	O
(	O
Fig	O
5B	O
middle	O
and	O
lower	O
panel	O
)	O
.	O

The	O
a	O
-	O
CGH	O
technique	O
to	O
confirm	O
the	O
presence	O
of	O
the	O
heterozygous	O
duplication	O
of	O
CDH23	B-GENE
(	O
exon	O
29	O
)	O
in	O
patient	O
RP	O
-	O
1781	O
was	O
not	O
succesful	O
due	O
to	O
technical	O
problems	O
.	O

We	O
found	O
11	O
cases	O
with	O
a	O
heterozygous	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
812G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
(	O
1	O
.	O
95	O
%	O
,	O
11	O
/	O
563	O
)	O
and	O
three	O
cases	O
with	O
a	O
heterozygous	O
KCNJ10	B-GENE
c	B-VARIANT
.	I-VARIANT
1042C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
(	O
0	O
.	O
53	O
%	O
,	O
3	O
/	O
563	O
)	O
(	O
Fig	O
.	O

Asterisks	O
indicate	O
individuals	O
whose	O
DNA	O
was	O
used	O
for	O
exome	O
sequencing	O
.	O

The	O
missing	O
regions	O
were	O
caused	O
by	O
systematic	O
drop	O
-	O
out	O
of	O
some	O
amplicons	O
during	O
PCR	O
.	O

Similarly	O
,	O
in	O
the	O
inner	O
ear	O
,	O
pendrin	O
is	O
thought	O
to	O
mediate	O
Cl	O
-	O
/	O
HCO	O
3	O
-	O
exchange	O
,	O
and	O
is	O
therefore	O
involved	O
in	O
the	O
conditioning	O
of	O
endolymphatic	O
fluid	O
,	O
presumably	O
due	O
to	O
HCO	O
3	O
-	O
secretion	O
[	O
5	O
]	O
.	O

2013	O
)	O
.	O

Both	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
mutant	O
proteins	O
distributed	O
in	O
a	O
diffuse	O
manner	O
in	O
the	O
cytoplasm	O
with	O
no	O
obvious	O
differences	O
in	O
localization	O
patterns	O
(	O
S2	O
Fig	O
)	O
.	O

The	O
observation	O
that	O
some	O
carriers	O
of	O
GJB3	B-GENE
mutations	O
showed	O
a	O
normal	O
phenotype	O
challenges	O
the	O
involvement	O
of	O
these	O
mutations	O
in	O
dominant	O
deafness	B-DISEASE
.	O

This	O
was	O
followed	O
by	O
a	O
sonication	O
step	O
(	O
6	O
x	O
5	O
s	O
with	O
an	O
MSE	O
sonicator	O
)	O
.	O

lupus	O
)	O
,	O
NP_083229	O
.	O
1	O
(	O
M	O
.	O

Ca	O
V	O
1	O
.	O
3	O
WT	O
exhibited	O
a	O
half	O
-	O
maximal	O
activation	O
voltage	O
(	O
V	O
1	O
/	O
2	O
)	O
at	O
-	O
9	O
.	O
2	O
+	O
-	O
1	O
.	O
0	O
mV	O
(	O
s	O
.	O
e	O
.	O
m	O
.	O
,	O
n	O
=	O
7	O
)	O
,	O
while	O
V	O
1	O
/	O
2	O
for	O
Ca	O
V	O
1	O
.	O
3	O
G403R	B-VARIANT
and	O
Ca	O
V	O
1	O
.	O
3	O
I770M	B-VARIANT
was	O
-	O
25	O
.	O
6	O
+	O
-	O
2	O
.	O
5	O
mV	O
(	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
001	O
versus	O
WT	O
)	O
and	O
-	O
31	O
.	O
7	O
+	O
-	O
1	O
.	O
1	O
mV	O
(	O
n	O
=	O
6	O
,	O
P	O
<	O
0	O
.	O
001	O
versus	O
WT	O
)	O
respectively	O
,	O
indicating	O
that	O
these	O
mutations	O
facilitated	O
channel	O
opening	O
(	O
Fig	O
.	O

Leigh	B-DISEASE
syndrome	I-DISEASE
patient	O
fibroblasts	O
exhibit	O
a	O
decreased	O
steady	O
-	O
state	O
level	O
of	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
.	O

Interactions	O
between	O
Sox10	B-GENE
,	O
Edn3	B-GENE
and	O
Ednrb	B-GENE
during	O
enteric	O
nervous	O
system	O
and	O
melanocyte	O
development	O
have	O
also	O
been	O
described	O
[	O
21	O
]	O
in	O
mice	O
.	O

Two	O
genes	O
,	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
,	O
have	O
been	O
investigated	O
for	O
their	O
role	O
in	O
the	O
PDS	B-DISEASE
disease	O
spectrum	O
and	O
it	O
has	O
been	O
proposed	O
that	O
digenic	O
mutations	O
in	O
both	O
SLC26A4	B-GENE
and	O
either	O
FOXI1	B-GENE
or	O
KCNJ10	B-GENE
may	O
cause	O
Pendred	B-DISEASE
syndrome	I-DISEASE
[	O
19	O
,	O
21	O
]	O
.	O

Properly	O
mapped	O
reads	O
were	O
filtered	O
with	O
the	O
SAMtools	O
package	O
,	O
which	O
was	O
also	O
used	O
to	O
sort	O
and	O
index	O
SAM	O
files	O
.	O

Audiograms	O
of	O
individuals	O
with	O
the	O
p	B-VARIANT
.	I-VARIANT
Lys836Asn	I-VARIANT
mutation	O
in	O
the	O
WFS1	B-GENE
gene	O
.	O

2010	O
)	O
.	O

Notably	O
,	O
two	O
affected	O
siblings	O
of	O
W7	O
were	O
diagnosed	O
with	O
attention	O
deficit	O
hyperactivity	O
disorder	O
as	O
early	O
as	O
the	O
onset	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
.	O

Alternatively	O
,	O
a	O
pathogenic	O
mutation	O
exists	O
in	O
another	O
known	O
gene	O
uncovered	O
by	O
WES	O
or	O
the	O
causative	O
mutation	O
is	O
in	O
an	O
as	O
-	O
yet	O
-	O
unidentified	O
hearing	B-DISEASE
loss	I-DISEASE
gene	O
.	O

The	O
age	O
-	O
related	O
typical	O
audiogram	O
(	O
ARTA	O
)	O
derived	O
from	O
these	O
data	O
confirmed	O
the	O
down	O
-	O
sloping	O
audiometric	O
configuration	O
and	O
demonstrated	O
fairly	O
similar	O
progression	O
across	O
all	O
frequencies	O
.	O

SWISS	O
-	O
MODEL	O
online	O
server	O
was	O
used	O
to	O
predict	O
the	O
crystal	O
structures	O
of	O
the	O
wide	O
type	O
and	O
mutant	O
proteins	O
[	O
32	O
]	O
,	O
[	O
33	O
]	O
.	O

While	O
this	O
approach	O
has	O
broad	O
utility	O
,	O
it	O
may	O
not	O
be	O
readily	O
applicable	O
to	O
individual	O
,	O
sporadic	O
cases	O
of	O
disease	O
.	O

This	O
approach	O
allowed	O
us	O
to	O
identify	O
the	O
pathogenic	O
mutation	O
in	O
17	O
families	O
out	O
of	O
36	O
(	O
47	O
,	O
2	O
%	O
)	O
,	O
depicted	O
in	O
Figure	O
2	O
:	O
2	O
/	O
2	O
in	O
X	O
-	O
linked	O
families	O
,	O
6	O
/	O
18	O
of	O
recessive	O
non	O
-	O
consanguineous	O
families	O
(	O
33	O
,	O
3	O
%	O
)	O
,	O
8	O
/	O
10	O
recessive	O
consanguineous	O
families	O
(	O
80	O
%	O
)	O
and	O
1	O
/	O
6	O
of	O
dominant	O
families	O
(	O
16	O
,	O
6	O
%	O
)	O
.	O

An	O
alternative	O
explanation	O
may	O
be	O
that	O
defective	B-DISEASE
peroxisomal	I-DISEASE
fatty	I-DISEASE
acid	I-DISEASE
catabolism	I-DISEASE
can	O
lead	O
to	O
secondary	B-DISEASE
mitochondrial	I-DISEASE
dysfunction	I-DISEASE
[	O
25	O
]	O
,	O
indicating	O
biochemical	O
crosstalk	O
across	O
the	O
two	O
organelles	O
.	O

Non	O
-	O
syndromic	O
hearing	O
loss	O
(	O
NSHL	O
)	O
accounts	O
for	O
approximately	O
80	O
%	O
of	O
cases	O
of	O
hereditary	O
deafness	B-DISEASE
and	O
variety	O
of	O
genes	O
are	O
involved	O
in	O
NSHL	O
[	O
1	O
]	O
.	O

Perilymphatic	O
gusher	O
occurred	O
after	O
cochleostomy	O
but	O
was	O
easily	O
controlled	O
by	O
conventional	O
methods	O
.	O

Scale	O
bar	O
:	O
10	O
u	O
m	O
.	O

The	O
most	O
frequent	O
sensory	O
disorder	O
worldwide	O
is	O
hearing	O
impairment	O
.	O

We	O
used	O
the	O
Autism	B-DISEASE
diagnostic	O
observation	O
schedule	O
(	O
ADOS	O
)	O
and	O
Autism	B-DISEASE
diagnostic	O
interview	O
revised	O
(	O
ADI	O
-	O
R	O
)	O
to	O
confirm	O
her	O
diagnosis	O
of	O
Autism	B-DISEASE
.	O

In	O
two	O
other	O
probands	O
heterozygous	O
for	O
TMC1	B-GENE
p	B-VARIANT
.	I-VARIANT
S647P	I-VARIANT
,	O
the	O
novel	O
variant	O
TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
1210T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
W404R	I-VARIANT
,	O
with	O
PolyPhen2	O
score	O
0	O
.	O
567	O
,	O
was	O
revealed	O
as	O
a	O
possible	O
second	O
pathogenic	O
allele	O
(	O
Figure	O
1	O
)	O
.	O

Our	O
perception	O
is	O
supported	O
by	O
two	O
recent	O
study	O
that	O
reported	O
in	O
Pakistani	O
[	O
16	O
]	O
and	O
Brazilian	O
[	O
10	O
]	O
populations	O
,	O
in	O
which	O
was	O
found	O
a	O
quite	O
different	O
mutation	O
spectrum	O
from	O
those	O
previously	O
reported	O
as	O
well	O
.	O

Fibroblast	O
growth	O
factor	O
(	O
FGFs	O
)	O
binding	O
to	O
FGFR2	B-GENE
causes	O
effects	O
in	O
cell	O
growth	O
and	O
differentiation	O
during	O
embryo	O
genesis	O
and	O
angiogenesis	O
(	O
12	O
,	O
24	O
,	O
25	O
)	O
.	O

We	O
analyzed	O
119	O
trios	O
to	O
identify	O
both	O
diagnostic	O
genotypes	O
in	O
known	O
genes	O
and	O
candidate	O
genotypes	O
in	O
novel	O
genes	O
.	O

ADOA	B-DISEASE
is	O
characterized	O
by	O
a	O
decrease	B-DISEASE
in	I-DISEASE
the	I-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
that	O
develops	O
in	O
childhood	O
,	O
temporal	B-DISEASE
palor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
discs	I-DISEASE
,	O
centrocecal	B-DISEASE
scotoma	I-DISEASE
,	O
and	O
color	B-DISEASE
vision	I-DISEASE
defects	I-DISEASE
[	O
5	O
,	O
6	O
]	O
.	O

Usher	B-DISEASE
type	I-DISEASE
I	I-DISEASE
(	O
USH1	B-DISEASE
)	O
is	O
the	O
most	O
severe	O
form	O
and	O
is	O
characterized	O
by	O
severe	O
to	O
profound	O
congenital	O
deafness	B-DISEASE
,	O
vestibular	B-DISEASE
areflexia	I-DISEASE
,	O
and	O
prepubertal	O
onset	O
of	O
progressive	O
RP	B-DISEASE
.	O

The	O
most	O
common	O
mutation	O
,	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
accounted	O
for	O
58	O
.	O
14	O
%	O
(	O
25	O
/	O
43	O
)	O
of	O
all	O
SLC26A4	B-GENE
mutant	O
alleles	O
.	O

They	O
also	O
recognized	O
that	O
the	O
severity	O
of	O
the	O
INL	O
atrophy	O
appeared	O
to	O
be	O
related	O
to	O
the	O
severity	O
of	O
RGC	O
atrophy	O
.	O

Several	O
loci	O
or	O
genes	O
responsible	O
for	O
RP	B-DISEASE
have	O
been	O
reported	O
.	O

Both	O
are	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
5527	I-VARIANT
G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
from	O
Asp	O
to	O
Tyr	O
at	O
position	O
p	O
.	O
1843	O
in	O
exon	O
43	O
.	O

The	O
different	O
enrichment	O
kits	O
are	O
reported	O
in	O
Information	O
S1	O
.	O

Despite	O
a	O
shortage	O
of	O
functional	O
information	O
and	O
a	O
long	O
collection	O
period	O
nearly	O
all	O
mutations	O
identified	O
were	O
reasonably	O
classified	O
as	O
causative	O
.	O

47	O
Grunnet	O
et	O
al	O
.	O

After	O
quality	O
control	O
and	O
SNP	O
pruning	O
,	O
11	O
,	O
034	O
markers	O
in	O
approximate	O
linkage	O
equilibrium	O
were	O
included	O
in	O
a	O
parametric	O
linkage	O
analysis	O
using	O
an	O
autosomal	O
dominant	O
model	O
with	O
full	O
penetrance	O
and	O
allele	O
frequencies	O
obtained	O
from	O
the	O
CEU	O
population	O
.	O

We	O
describe	O
64	O
different	O
mutations	O
in	O
70	O
unrelated	O
Danish	O
families	O
using	O
a	O
routine	O
five	O
-	O
gene	O
screen	O
,	O
comprising	O
KCNQ1	B-GENE
,	O
KCNH2	B-GENE
and	O
SCN5A	B-GENE
as	O
well	O
as	O
KCNE1	B-GENE
and	O
KCNE2	B-GENE
.	O

The	O
mutant	O
(	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
)	O
trimer	O
model	O
was	O
then	O
constructed	O
from	O
the	O
wild	O
-	O
type	O
trimer	O
model	O
using	O
Fold	O
X	O
(	O
http	O
:	O
/	O
/	O
foldx	O
.	O
crg	O
.	O
es	O
/	O
)	O
(	O
Fig	O
.	O

The	O
clinical	O
features	O
associated	O
with	O
this	O
novel	O
mutation	O
in	O
the	O
JSNY	O
-	O
027	O
family	O
lends	O
support	O
to	O
the	O
pathogenic	O
nature	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
G38D	I-VARIANT
variant	O
.	O

conceived	O
experiments	O
;	O
R	O
.	O
J	O
.	O
C	O
.	O
A	O
.	O

Differently	O
from	O
all	O
other	O
OPA1	B-GENE
-	O
M	O
patients	O
,	O
Subject	O
7	O
showed	O
only	O
the	O
cochlear	O
microphonic	O
potential	O
without	O
a	O
superimposed	O
negative	O
activity	O
at	O
each	O
stimulation	O
intensity	O
.	O

J	O
.	O
R	O
.	O
L	O
.	O

PCRs	O
were	O
performed	O
on	O
10	O
-	O
20	O
ng	O
of	O
genomic	O
DNA	O
,	O
following	O
standard	O
procedures	O
.	O

Dr	O
.	O

3d	O
)	O
.	O

Three	O
clinical	O
types	O
of	O
USH	B-DISEASE
(	O
types	O
I	O
,	O
II	O
and	O
III	O
;	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
and	O
USH3	B-DISEASE
)	O
are	O
recognized	O
,	O
mainly	O
on	O
the	O
basis	O
of	O
the	O
severity	O
and	O
progression	O
of	O
hearing	O
loss	O
,	O
the	O
age	O
of	O
onset	O
of	O
RP	B-DISEASE
and	O
the	O
presence	O
of	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
5	O
]	O
.	O

Fig	O
.	O

Northern	O
blot	O
and	O
reverse	O
-	O
transcription	O
PCR	O
analyses	O
indicate	O
expression	O
of	O
different	O
splice	O
variants	O
of	O
CLRN1	B-GENE
mRNA	O
in	O
several	O
tissues	O
including	O
retina	O
,	O
cochlea	O
,	O
brain	O
,	O
and	O
thymus	O
[	O
22	O
,	O
23	O
,	O
29	O
]	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
The	O
State	O
of	O
Minas	O
Gerais	O
Research	O
Foundation	O
-	O
FAPEMIG	O
,	O
Minas	O
Gerais	O
,	O
Brazil	O
and	O
the	O
National	O
Council	O
for	O
Scientific	O
and	O
Technological	O
Development	O
-	O
CNPq	O
,	O
Bras	O
i	O
lia	O
,	O
Brazil	O
.	O
HMJ	O
,	O
MJBA	O
and	O
RDC	O
designed	O
the	O
study	O
and	O
drafted	O
the	O
paper	O
.	O

Also	O
,	O
chamber	O
-	O
specific	O
interaction	O
partners	O
yet	O
to	O
be	O
identified	O
may	O
modulate	O
the	O
effects	O
of	O
mutations	O
in	O
atria	O
and	O
ventricles	O
.	O

ABRs	O
were	O
normal	O
in	O
the	O
OPA1	B-GENE
-	O
H	O
subject	O
,	O
whereas	O
OPA1	B-GENE
-	O
M	O
patients	O
had	O
no	O
brainstem	O
responses	O
(	O
#	O
4	O
-	O
L	O
)	O
or	O
showed	O
a	O
delayed	O
wave	O
V	O
(	O
#	O
1	O
-	O
L	O
)	O
.	O

This	O
four	O
-	O
fold	O
incidence	O
in	O
men	O
as	O
compared	O
to	O
women	O
was	O
consistent	O
with	O
the	O
estimates	O
for	O
single	O
tertiary	O
referral	O
centers	O
[	O
6	O
,	O
8	O
]	O
.	O

We	O
gratefully	O
thank	O
all	O
the	O
subjects	O
in	O
this	O
study	O
for	O
their	O
collaboration	O
.	O

Otoscopy	O
was	O
performed	O
on	O
all	O
family	O
members	O
to	O
rule	O
out	O
middle	O
ear	O
pathology	O
.	O

a	O
High	O
-	O
intensity	O
lesions	O
of	O
the	O
bilateral	O
middle	O
cerebellar	O
peduncle	O
(	O
arrows	O
)	O
in	O
T2	O
-	O
weighted	O
imaging	O
(	O
patient	O
II	O
-	O
1	O
;	O
20	O
years	O
of	O
age	O
)	O
.	O

Representative	O
current	O
traces	O
for	O
KCNE1	B-GENE
-	O
WT	O
(	O
A	O
)	O
and	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
(	O
B	O
)	O
channel	O
subunits	O
co	O
-	O
expressed	O
with	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
in	O
X	O
.	O
laevis	O
oocytes	O
in	O
a	O
1	O
:	O
1	O
molar	O
ratio	O
.	O

A	O
dominant	O
negative	O
effect	O
is	O
likely	O
to	O
be	O
the	O
case	O
in	O
this	O
family	O
because	O
both	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
allele	O
appear	O
to	O
have	O
similar	O
levels	O
of	O
steady	O
-	O
state	O
transcription	O
,	O
the	O
patient	O
and	O
control	O
fibroblasts	O
have	O
the	O
same	O
level	O
of	O
OPA1	B-GENE
protein	O
expression	O
.	O

1	O
)	O
,	O
which	O
were	O
distributed	O
between	O
seven	O
exons	O
(	O
exons	O
9	O
,	O
10	O
,	O
11	O
,	O
13	O
,	O
14	O
,	O
16	O
,	O
and	O
18	O
)	O
and	O
comprised	O
missense	O
mutations	O
(	O
67	O
%	O
)	O
or	O
small	O
deletions	O
(	O
30	O
%	O
)	O
and	O
deletions	O
/	O
insertions	O
(	O
3	O
%	O
)	O
.	O

No	O
patient	O
was	O
excluded	O
based	O
on	O
phenotype	O
,	O
inheritance	O
or	O
previous	O
testing	O
.	O

Recombination	O
events	O
are	O
indicated	O
by	O
grey	O
background	O
.	O

List	O
of	O
the	O
genes	O
captured	O
in	O
the	O
present	O
study	O
.	O

In	O
addition	O
to	O
the	O
WFS1	B-GENE
mutations	O
associated	O
with	O
this	O
syndrome	O
,	O
polymorphisms	O
were	O
found	O
as	O
listed	O
in	O
Table	O
S3	O
in	O
File	O
S1	O
.	O

(	O
A	O
)	O
Schematic	O
of	O
the	O
constructs	O
(	O
B	O
)	O
Wild	O
-	O
type	O
fusion	O
protein	O
(	O
mCherry	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
CTR	O
)	O
(	O
red	O
)	O
was	O
intracellularly	O
located	O
while	O
the	O
truncated	O
fusion	O
protein	O
(	O
eGFP	O
-	O
CD164	B-GENE
-	O
R192	B-VARIANT
*	I-VARIANT
-	O
CTR	O
)	O
was	O
primarily	O
present	O
at	O
the	O
plasma	O
membrane	O
.	O

Moreover	O
,	O
all	O
single	O
amino	O
acid	O
changes	O
were	O
located	O
within	O
conserved	O
domains	O
of	O
the	O
protein	O
(	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
we	O
could	O
not	O
confirm	O
its	O
pathogenicity	O
by	O
segregation	O
analysis	O
.	O

All	O
119	O
patients	O
underwent	O
a	O
clinical	O
genetics	O
evaluation	O
,	O
with	O
traditional	O
genetic	O
diagnostics	O
performed	O
whenever	O
clinically	O
indicated	O
.	O

If	O
pre	O
-	O
determined	O
quality	O
control	O
values	O
were	O
not	O
met	O
,	O
the	O
sample	O
was	O
rerun	O
,	O
as	O
previously	O
described	O
(	O
Shearer	O
et	O
al	O
.	O

Initial	O
sequencing	O
of	O
seven	O
known	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
(	O
WFS1	B-GENE
[	O
OMIM	O
606201	O
]	O
,	O
GRHL2	B-GENE
[	O
OMIM	O
608576	O
]	O
,	O
EYA4	B-GENE
[	O
OMIM	O
603550	O
]	O
,	O
ACTG1	B-GENE
[	O
OMIM	O
102560	O
]	O
,	O
GJB2	B-GENE
[	O
OMIM	O
121011	O
]	O
,	O
MYO6	B-GENE
(	O
exon	O
25	O
)	O
[	O
OMIM	O
600970	O
]	O
,	O
and	O
SLC26A4	B-GENE
[	O
OMIM	O
605646	O
]	O
)	O
failed	O
to	O
identify	O
any	O
mutations	O
,	O
prompting	O
us	O
to	O
perform	O
a	O
genome	O
-	O
wide	O
linkage	O
analysis	O
to	O
identify	O
the	O
responsible	O
locus	O
for	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
family	O
.	O

The	O
authors	O
also	O
thank	O
Dr	O
.	O

Overlapping	O
audiograms	O
of	O
the	O
better	O
-	O
hearing	O
ear	O
of	O
20	O
subjects	O
with	O
homozygous	O
or	O
compound	O
heterozygous	O
CDH23	B-GENE
mutations	O
.	O

Multifocal	O
ERG	O
and	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
findings	O
suggested	O
a	O
sectorial	O
affectation	O
of	O
perifoveal	O
photoreceptors	O
.	O

We	O
would	O
like	O
to	O
thank	O
the	O
technical	O
and	O
scientific	O
staff	O
in	O
the	O
Regional	O
Molecular	O
Genetics	O
Laboratory	O
,	O
Cambridge	O
UK	O
,	O
for	O
their	O
assistance	O
with	O
the	O
genetic	O
analysis	O
.	O

Comparison	O
between	O
results	O
obtained	O
from	O
the	O
sample	O
included	O
in	O
the	O
present	O
report	O
with	O
the	O
global	O
results	O
for	O
our	O
total	O
series	O
.	O

Another	O
plausible	O
non	O
mutually	O
exclusive	O
function	O
of	O
CIB2	B-GENE
is	O
the	O
maintenance	O
of	O
Ca	O
2	O
+	O
homeostasis	O
in	O
the	O
hair	O
cell	O
body	O
,	O
which	O
in	O
turn	O
may	O
modulate	O
the	O
OHC	O
electromotility	O
.	O

Click	O
here	O
for	O
file	O
Definition	O
of	O
nine	O
categories	O
of	O
mutations	O
/	O
variants	O
in	O
targeted	O
deafness	B-DISEASE
genes	O
detected	O
by	O
the	O
NGS	O
method	O
.	O

B	O
:	O
De	O
novo	O
mutation	O
in	O
RHO	B-GENE
.	O

Their	O
ages	O
ranged	O
from	O
3	O
to	O
80	O
years	O
old	O
(	O
mean	O
30	O
.	O
2	O
)	O
.	O

All	O
amplicons	O
were	O
ampli	O
fi	O
ed	O
by	O
emPCR	O
and	O
sequenced	O
together	O
in	O
a	O
multiplex	O
fashion	O
.	O

The	O
screening	O
of	O
five	O
known	O
mitochondrial	O
mutations	O
(	O
m	B-VARIANT
.	I-VARIANT
A1555G	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7445A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7472insC	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7510T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
m	B-VARIANT
.	I-VARIANT
7511T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
was	O
performed	O
in	O
the	O
GJB2	B-GENE
negative	O
patients	O
that	O
were	O
compatible	O
with	O
a	O
maternal	O
inheritance	O
of	O
HI	B-DISEASE
.	O

Van	O
Buren	O
observed	O
atrophy	O
of	O
the	O
RGC	O
following	O
a	O
right	O
occipital	O
lobectomy	O
in	O
monkeys	O
[	O
50	O
]	O
.	O

The	O
mutation	O
found	O
in	O
10	O
propositi	O
,	O
(	O
c	B-VARIANT
.	I-VARIANT
287C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
S96L	I-VARIANT
]	O
:	O
3	O
,	O
c	B-VARIANT
.	I-VARIANT
2104C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
R702C	I-VARIANT
]	O
:	O
1	O
,	O
c	B-VARIANT
.	I-VARIANT
2105G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
R702H	I-VARIANT
]	O
:	O
1	O
,	O
c	B-VARIANT
.	I-VARIANT
2114G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
R705H	I-VARIANT
]	O
:	O
1	O
,	O
c	B-VARIANT
.	I-VARIANT
4336T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
F1446L	I-VARIANT
]	O
:	O
1	O
,	O
c	B-VARIANT
.	I-VARIANT
5521G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
E1841K	I-VARIANT
]	O
:	O
2	O
,	O
c	B-VARIANT
.	I-VARIANT
5794del	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
R1932Afs	I-VARIANT
*	I-VARIANT
16	I-VARIANT
]	O
:	O
1	O
was	O
not	O
identified	O
in	O
the	O
parents	O
suggesting	O
the	O
de	O
novo	O
nature	O
of	O
the	O
mutation	O
.	O

Forty	O
-	O
seven	O
Usher	B-DISEASE
patients	O
(	O
test	O
sample	O
)	O
,	O
either	O
negative	O
for	O
USH	B-DISEASE
gene	O
mutations	O
or	O
carrying	O
a	O
single	O
mutation	O
after	O
Sanger	O
sequencing	O
and	O
array	O
-	O
CGH	O
analyses	O
,	O
were	O
used	O
as	O
a	O
test	O
cohort	O
to	O
establish	O
criteria	O
and	O
thresholds	O
for	O
accurate	O
generation	O
and	O
filtering	O
of	O
the	O
data	O
,	O
as	O
well	O
as	O
prioritization	O
and	O
annotation	O
of	O
the	O
variants	O
,	O
and	O
calculation	O
of	O
analytical	O
sensitivity	O
.	O

Pedigree	O
with	O
phenotype	O
and	O
experimental	O
information	O
.	O

Polyphen2	O
,	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
ARNSHL	B-DISEASE
:	O
Autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
;	O
NGS	O
:	O
Next	O
-	O
generation	O
sequencing	O
;	O
WES	O
:	O
Next	O
-	O
generation	O
sequencing	O
;	O
CT	O
:	O
Computed	O
tomography	O
;	O
PCR	O
:	O
Polymerase	O
chain	O
reaction	O
.	O

Here	O
we	O
describe	O
two	O
families	O
heterozygous	O
for	O
the	O
same	O
,	O
previously	O
unreported	O
apparently	O
synonymous	O
variant	O
in	O
FGFR2	B-GENE
[	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Pro361Pro	I-VARIANT
)	O
]	O
,	O
although	O
caused	O
by	O
differing	O
nucleotide	O
substitutions	O
.	O

St	O
.	O

A	O
homozygous	O
missense	O
mutation	O
(	O
[	O
c	B-VARIANT
.	I-VARIANT
637G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
]	O
)	O
is	O
the	O
underlying	O
cause	O
of	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
DFNB94	B-DISEASE
)	O
and	O
compound	O
heterozygous	O
mutations	O
(	O
[	O
c	B-VARIANT
.	I-VARIANT
969T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Tyr323	I-VARIANT
*	I-VARIANT
]	O
+	O
[	O
c	B-VARIANT
.	I-VARIANT
1142A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
;	O
p	B-VARIANT
.	I-VARIANT
Asn381Ser	I-VARIANT
]	O
)	O
result	O
in	O
mitochondrial	B-DISEASE
respiratory	I-DISEASE
chain	I-DISEASE
deficiency	I-DISEASE
and	O
Leigh	B-DISEASE
syndrome	I-DISEASE
,	O
which	O
is	O
a	O
neurodegenerative	B-DISEASE
disease	I-DISEASE
characterized	O
by	O
symmetric	O
,	O
bilateral	O
lesions	O
in	O
the	O
basal	O
ganglia	O
,	O
thalamus	O
,	O
and	O
brain	O
stem	O
.	O

A	O
561	O
nm	O
wavelength	O
laser	O
was	O
applied	O
for	O
bleaching	O
and	O
excitation	O
of	O
Alexa	O
Fluor	O
568	O
while	O
a	O
647	O
nm	O
wavelength	O
laser	O
was	O
applied	O
for	O
Alexa	O
Fluor	O
647	O
.	O

Taking	O
into	O
consideration	O
a	O
solved	O
rate	O
of	O
83	O
%	O
,	O
we	O
calculated	O
a	O
potential	O
diagnostic	O
yield	O
of	O
nearly	O
50	O
%	O
in	O
RP	B-DISEASE
for	O
this	O
NGS	O
-	O
based	O
diagnostic	O
approach	O
(	O
see	O
Results	O
for	O
details	O
)	O
,	O
thereby	O
outperforming	O
previously	O
used	O
approaches	O
such	O
as	O
traditional	O
Sanger	O
sequencing	O
and	O
APEX	O
analysis	O
[	O
Hartong	O
et	O
al	O
.	O
,	O
2006	O
;	O
A	O
vila	O
-	O
Fern	O
a	O
ndez	O
et	O
al	O
.	O
,	O
2010	O
]	O
.	O

Presumably	O
these	O
families	O
and	O
patients	O
have	O
inherited	O
mutations	O
in	O
other	O
,	O
yet	O
unknown	O
,	O
less	O
deleterious	O
genes	O
.	O

D3165fs	I-VARIANT
(	O
M6	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
G2375fs	I-VARIANT
(	O
M7	O
)	O
;	O
p	B-VARIANT
.	I-VARIANT
Y4801X	I-VARIANT
(	O
M8	O
)	O
.	O

The	O
mutation	O
may	O
cause	O
lethality	O
in	O
infancy	O
and	O
is	O
associated	O
with	O
low	O
levels	O
of	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Glu	I-GENE
.	O

Interestingly	O
,	O
studies	O
using	O
Slc26a4	B-GENE
-	O
/	O
-	O
mice	O
have	O
revealed	O
an	O
association	O
between	O
SLC26A4	B-GENE
and	O
KCNJ10	B-GENE
.	O

Thus	O
,	O
DT35	O
contains	O
one	O
NUBPL	B-GENE
allele	O
harboring	O
a	O
deletion	O
spanning	O
exons	O
1	O
-	O
4	O
and	O
a	O
second	O
allele	O
that	O
harbors	O
both	O
a	O
p	B-VARIANT
.	I-VARIANT
G56R	I-VARIANT
missense	O
mutation	O
and	O
a	O
c	B-VARIANT
.	I-VARIANT
815	I-VARIANT
-	I-VARIANT
27T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
that	O
likely	O
causes	O
exon	O
10	O
skipping	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
patients	O
recruited	O
for	O
this	O
study	O
presented	O
the	O
following	O
complications	O
:	O
diabetes	B-DISEASE
insipidus	I-DISEASE
in	O
37	O
patients	O
(	O
55	O
%	O
)	O
,	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
50	O
(	O
75	O
%	O
)	O
,	O
renal	B-DISEASE
tract	I-DISEASE
abnormalities	I-DISEASE
in	O
31	O
(	O
46	O
%	O
)	O
,	O
and	O
neuro	B-DISEASE
-	I-DISEASE
psychiatric	I-DISEASE
symptoms	I-DISEASE
in	O
46	O
(	O
69	O
%	O
)	O
.	O

Modeling	O
the	O
variants	O
in	O
the	O
context	O
of	O
protein	O
structure	O
and	O
function	O
can	O
also	O
contribute	O
to	O
risk	O
prediction	O
since	O
the	O
variants	O
in	O
our	O
generally	O
healthy	O
cohort	O
tend	O
to	O
occur	O
at	O
positions	O
tolerant	O
of	O
substitution	O
.	O

b	O
.	O

RT	O
-	O
PCR	O
was	O
used	O
to	O
amplify	O
the	O
cDNAs	O
of	O
OPA1	B-GENE
.	O

De	O
novo	O
variation	O
,	O
being	O
less	O
frequent	O
and	O
potentially	O
more	O
deleterious	O
,	O
could	O
offer	O
insights	O
into	O
risk	O
-	O
determining	O
genes	O
.	O

We	O
previously	O
showed	O
that	O
compound	O
heterozygous	O
mutations	O
are	O
detected	O
in	O
less	O
than	O
5	O
%	O
of	O
consanguineous	O
families	O
with	O
deafness	B-DISEASE
[	O
3	O
]	O
.	O

However	O
,	O
causes	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
highly	O
heterogeneous	O
;	O
more	O
than	O
60	O
genes	O
have	O
been	O
identified	O
as	O
responsible	O
for	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
3	O
]	O
,	O
and	O
several	O
hundreds	O
of	O
syndromic	O
diseases	O
,	O
such	O
as	O
Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
are	O
accompanied	O
by	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

a	O
Gray	O
scale	O
image	O
of	O
toluidine	O
blue	O
-	O
stained	O
semi	O
-	O
thin	O
transverse	O
sections	O
revealing	O
an	O
absence	O
of	O
large	O
MFs	O
,	O
along	O
with	O
abundant	O
medium	O
and	O
small	O
-	O
sized	O
MFs	O
(	O
5	O
,	O
101	O
/	O
mm	O
2	O
)	O
.	O

(	O
A	O
)	O
Confocal	O
images	O
of	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
-	O
transfected	O
HEK293	O
cells	O
immuno	O
-	O
stained	O
with	O
Alexa	O
-	O
Fluor	O
-	O
568	O
(	O
red	O
)	O
;	O
F	O
-	O
actin	O
immuno	O
-	O
stained	O
with	O
conjugated	O
Alexa	O
-	O
Fluor	O
-	O
647	O
-	O
phalloidin	O
(	O
blue	O
)	O
.	O

One	O
of	O
these	O
biallelic	O
variants	O
was	O
a	O
conservative	O
missense	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1110A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E730D	I-VARIANT
)	O
,	O
in	O
BNC2	B-GENE
(	O
gene	O
ID	O
:	O
54796	O
,	O
NM_01763	B-VARIANT
)	O
,	O
predicted	O
to	O
be	O
nonpathogenic	O
by	O
PolyPhen	O
-	O
2	O
,	O
SIFT	O
,	O
and	O
Mutation	O
Taster	O
software	O
.	O

Here	O
we	O
describe	O
clinical	O
,	O
histological	O
and	O
molecular	O
features	O
of	O
two	O
patients	O
presenting	O
with	O
mitochondrial	B-DISEASE
myopathy	I-DISEASE
associated	O
with	O
PEO	B-DISEASE
.	O

The	O
vestibular	O
reflection	O
of	O
the	O
two	O
patients	O
was	O
normal	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
PD	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
(	O
p	O
=	O
0	O
.	O
083	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
.	O

These	O
include	O
possible	O
SNPs	O
that	O
have	O
not	O
been	O
previously	O
described	O
,	O
heterozygosity	O
for	O
recessive	O
mutations	O
and	O
potential	O
hypomorphic	O
alleles	O
.	O

There	O
is	O
no	O
consanguinity	O
in	O
this	O
family	O
.	O

Wrote	O
the	O
paper	O
:	O
SU	O
.	O

Three	O
patients	O
(	O
18	O
to	O
20	O
)	O
with	O
EVA	B-DISEASE
or	O
other	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
harbored	O
only	O
one	O
mutant	O
allele	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

After	O
obtaining	O
written	O
informed	O
consent	O
,	O
left	O
biceps	O
skeletal	O
muscle	O
biopsies	O
were	O
performed	O
according	O
to	O
a	O
protocol	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
"	O
IRCCS	O
Foundation	O
Ca	O
'	O
Granda	O
Ospedale	O
Maggiore	O
Policlinico	O
"	O
.	O

All	O
mutations	O
were	O
confirmed	O
by	O
reamplification	O
of	O
the	O
fragment	O
and	O
resequencing	O
of	O
the	O
proband	O
and	O
his	O
or	O
her	O
available	O
relatives	O
.	O

Figure	O
2	O
Overlapping	O
audiograms	O
of	O
subjects	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
caused	O
by	O
CDH23	B-GENE
mutations	O
.	O

USH1	B-DISEASE
is	O
the	O
most	O
severe	O
form	O
with	O
congenital	O
profound	O
HL	B-DISEASE
and	O
vestibular	B-DISEASE
areflexia	I-DISEASE
.	O

This	O
study	O
supports	O
the	O
hypothesis	O
that	O
gain	O
-	O
of	O
-	O
function	O
in	O
potassium	O
current	O
enhances	O
AF	B-DISEASE
susceptibility	O
.	O

The	O
motor	O
domain	O
mutations	O
were	O
associated	O
with	O
more	O
severe	O
clinical	O
phenotypes	O
than	O
those	O
in	O
the	O
tail	O
domain	O
.	O

PTA	O
was	O
calculated	O
as	O
an	O
average	O
of	O
the	O
threshold	O
measured	O
at	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
and	O
4	O
.	O
0	O
KHz	O
[	O
6	O
]	O
,	O
and	O
air	O
-	O
conduction	O
threshold	O
measurements	O
were	O
performed	O
at	O
125	O
-	O
8000	O
Hz	O
.	O

NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
is	O
a	O
protein	O
of	O
230	O
kDa	O
.	O

We	O
obtained	O
a	O
genetic	O
diagnosis	O
for	O
29	O
(	O
24	O
%	O
)	O
of	O
our	O
patients	O
.	O

To	O
increase	O
the	O
proportion	O
of	O
sequences	O
on	O
target	O
,	O
other	O
capture	O
and	O
enrichment	O
methods	O
commercially	O
available	O
kits	O
may	O
be	O
considered	O
[	O
83	O
]	O
.	O

Anticodon	O
binding	O
domain	O
is	O
represented	O
in	O
green	O
,	O
hinge	O
region	O
in	O
pink	O
,	O
catalytic	O
core	O
in	O
blue	O
and	O
second	O
monomer	O
is	O
shown	O
in	O
grey	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1289A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
inherited	O
from	O
the	O
patient	O
'	O
s	O
mother	O
,	O
and	O
is	O
predicted	O
to	O
cause	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
asparagine	O
residue	O
with	O
a	O
serine	O
(	O
p	B-VARIANT
.	I-VARIANT
N430S	I-VARIANT
)	O
(	O
Supplementary	O
Fig	O
.	O

A	O
second	O
form	O
of	O
WS	B-DISEASE
,	O
WFS2	B-GENE
,	O
maps	O
to	O
4q22	O
-	O
q25	O
[	O
16	O
]	O
and	O
has	O
been	O
recently	O
demonstrated	O
to	O
be	O
caused	O
by	O
homozygous	O
mutations	O
in	O
a	O
highly	O
conserved	O
zinc	O
-	O
finger	O
gene	O
,	O
ZCD2	B-GENE
[	O
17	O
]	O
.	O

Subject	O
II	O
-	O
4	O
was	O
reluctant	O
to	O
wear	O
a	O
hearing	O
aid	O
;	O
however	O
,	O
subject	O
III	O
-	O
2	O
(	O
F	O
/	O
6yr	O
)	O
had	O
begun	O
wearing	O
a	O
hearing	O
aid	O
.	O

Also	O
,	O
these	O
patients	O
were	O
screened	O
for	O
WFS1	B-GENE
mutations	O
.	O

Thus	O
,	O
they	O
exhibit	O
promising	O
potential	O
as	O
targets	O
for	O
diagnostic	O
and	O
/	O
or	O
therapeutic	O
intervention	O
[	O
12	O
]	O
,	O
[	O
13	O
]	O
.	O

The	O
audiogram	O
of	O
HI	B-DISEASE
individual	O
IV	O
-	O
4	O
displays	O
bilateral	O
,	O
severe	O
-	O
to	O
-	O
profound	O
HI	B-DISEASE
affecting	O
all	O
frequencies	O
(	O
Figure	O
2	O
)	O
.	O

More	O
than	O
78	O
%	O
of	O
the	O
target	O
regions	O
were	O
covered	O
by	O
10	O
or	O
more	O
reads	O
,	O
demonstrating	O
the	O
high	O
quality	O
of	O
the	O
sequencing	O
(	O
Table	O
2	O
)	O
.	O

Visual	B-DISEASE
field	I-DISEASE
defects	I-DISEASE
mainly	O
involve	O
the	O
central	O
portion	O
of	O
the	O
field	O
and	O
include	O
cecocentral	B-DISEASE
scotomas	I-DISEASE
,	O
paracentral	B-DISEASE
defects	I-DISEASE
,	O
and	B-DISEASE
pseudobitemporal	I-DISEASE
defects	I-DISEASE
.	O

These	O
two	O
-	O
and	O
three	O
-	O
way	O
admixtures	O
reflect	O
the	O
demographic	O
history	O
of	O
Latin	O
America	O
[	O
36	O
]	O
.	O

HapMap	O
samples	O
were	O
not	O
whole	O
-	O
genome	O
amplified	O
.	O

Threonine	O
at	O
this	O
position	O
is	O
highly	O
conserved	O
and	O
attains	O
a	O
ConSeq	O
conservation	O
score	O
of	O
8	O
in	O
a	O
scale	O
of	O
1	O
to	O
9	O
(	O
where	O
9	O
is	O
most	O
conserved	O
)	O
[	O
24	O
]	O
.	O

The	O
onset	O
of	O
the	O
visual	O
phenotype	O
occurred	O
when	O
she	O
was	O
14	O
years	O
old	O
but	O
progressed	O
rapidly	O
to	O
severe	O
RP	B-DISEASE
.	O

The	O
two	O
patients	O
having	O
a	O
germline	O
V2148D	B-VARIANT
variant	O
in	O
NF1	B-GENE
,	O
developed	O
ovarian	B-DISEASE
cancer	I-DISEASE
at	O
age	O
36	O
and	O
45	O
years	O
.	O

Segregation	O
analyses	O
for	O
identified	O
mutations	O
in	O
the	O
corresponding	O
families	O
were	O
performed	O
by	O
Sanger	O
sequencing	O
except	O
for	O
family	O
DFR24	O
and	O
DFR18	O
.	O

,	O
2008	O
;	O
Santarelli	O
et	O
al	O
.	O

In	O
this	O
regard	O
,	O
we	O
analyzed	O
WES	O
data	O
from	O
a	O
family	O
with	O
a	O
history	O
of	O
NSHL	B-DISEASE
by	O
focusing	O
on	O
three	O
categories	O
of	O
genetic	O
information	O
:	O
CNVs	O
,	O
linkage	O
analysis	O
,	O
and	O
SNVs	O
.	O

Cadherin	O
-	O
23	O
contains	O
conserved	O
extracellular	O
cadherin	O
(	O
EC	O
)	O
repeat	O
domains	O
.	O

The	O
substitution	O
of	O
this	O
valine	O
residue	O
with	O
phenylalanine	O
in	O
humans	O
is	O
predicted	O
to	O
create	O
a	O
sticky	O
patch	O
on	O
the	O
surface	O
that	O
could	O
affect	O
the	O
protein	O
-	O
protein	O
interactions	O
of	O
NARS2	B-GENE
.	O

The	O
genomic	O
regions	O
of	O
interest	O
were	O
amplified	O
by	O
PCR	O
and	O
subsequently	O
analyzed	O
by	O
double	O
strand	O
sequencing	O
to	O
detect	O
the	O
mutations	O
.	O

Pure	O
-	O
tone	O
audiometry	O
and	O
auditory	O
brainstem	O
response	O
were	O
used	O
to	O
assess	O
degree	O
and	O
progression	O
of	O
HL	B-DISEASE
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

In	O
this	O
study	O
,	O
TMPRSS3	B-GENE
was	O
identified	O
in	O
a	O
patient	O
with	O
post	O
-	O
lingual	O
deafness	B-DISEASE
with	O
EAS	O
(	O
Case	O
#	O
3	O
)	O
.	O

This	O
work	O
was	O
supported	O
by	O
Fondation	O
R	O
&	O
G	O
Strittmatter	O
(	O
under	O
the	O
aegis	O
of	O
Fondation	O
de	O
France	O
)	O
,	O
FAUN	O
Stiftung	O
(	O
Suchert	O
Foundation	O
)	O
,	O
EC	O
-	O
FP7	O
TREATRUSH	O
(	O
HEALTH	O
-	O
F2	O
-	O
2010	O
-	O
242013	O
)	O
,	O
Foundation	O
Fighting	O
Blindness	B-DISEASE
,	O
LHW	O
-	O
Stiftung	O
,	O
Fondation	O
Orange	O
,	O
The	O
Conny	O
-	O
Maeva	O
Charitable	O
Foundation	O
,	O
Genoscope	O
-	O
CNRG	O
project	O
AP2005	O
,	O
and	O
S	O
'	O
entendre	O
Foundation	O
.	O
Usher	B-DISEASE
syndrome	I-DISEASE
is	O
an	O
autosomal	O
recessive	O
disease	O
that	O
associates	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
and	O
,	O
in	O
some	O
cases	O
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

To	O
insert	O
the	O
Leu265Ser	B-VARIANT
mutation	O
,	O
we	O
performed	O
site	O
-	O
directed	O
mutagenesis	O
on	O
the	O
construct	O
using	O
the	O
QuikChange	O
Lightening	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
LFSNHL	B-DISEASE
in	O
an	O
affected	O
Taiwanese	O
family	O
.	O

A	O
total	O
of	O
29	O
patients	O
(	O
41	O
.	O
4	O
%	O
from	O
70	O
with	O
available	O
data	O
)	O
were	O
initially	O
misdiagnosed	O
as	O
having	O
Immune	B-DISEASE
Thrombocytopenic	I-DISEASE
purpura	I-DISEASE
(	O
ITP	B-DISEASE
)	O
.	O

3	O
)	O
.	O

Generation	O
numbers	O
are	O
depicted	O
on	O
the	O
left	O
and	O
individual	O
numbers	O
below	O
each	O
symbol	O
.	O

E	O
)	O
Non	O
-	O
conserved	O
residue	O
of	O
p	O
.	O
Leu7	O
across	O
10	O
species	O
.	O

WES	O
was	O
performed	O
on	O
one	O
person	O
from	O
the	O
AUNX1	B-GENE
family	O
(	O
III	O
:	O
12	O
)	O
and	O
three	O
persons	O
from	O
the	O
0223	O
family	O
(	O
II	O
:	O
1	O
,	O
III	O
:	O
1	O
and	O
III	O
:	O
3	O
)	O
.	O

Her	O
condition	O
was	O
characterized	O
by	O
groin	O
pain	O
,	O
a	O
short	O
femoral	O
neck	O
and	O
flattened	O
epiphyses	O
.	O

The	O
splice	O
site	O
mutation	O
was	O
transmitted	O
from	O
proband	O
to	O
her	O
unaffected	O
son	O
(	O
F3	O
-	O
IV	O
-	O
2	O
)	O
.	O

Sequence	O
alignment	O
of	O
the	O
non	O
-	O
muscle	O
class	O
II	O
myosin	O
showing	O
conservation	O
of	O
MYH14	B-GENE
A181	O
(	O
left	O
panel	O
;	O
red	O
underlined	O
)	O
(	O
B	O
)	O
.	O

Most	O
cases	O
of	O
STGD	B-DISEASE
are	O
caused	O
by	O
recessive	O
ABCA4	B-GENE
mutations	O
.	O

In	O
these	O
,	O
we	O
were	O
able	O
to	O
identify	O
two	O
new	O
mutations	O
in	O
CDH23	B-GENE
and	O
OTOF	B-GENE
.	O

Disease	O
association	O
,	O
in	O
31	O
.	O
2	O
%	O
of	O
cases	O
,	O
was	O
based	O
on	O
the	O
type	O
of	O
mutation	O
identified	O
(	O
nonsense	O
,	O
insertion	O
/	O
deletion	O
,	O
frameshift	O
or	O
splice	O
-	O
site	O
)	O
.	O

Reverse	O
transcriptase	O
-	O
PCR	O
experiments	O
performed	O
on	O
total	O
RNA	O
extracted	O
from	O
saliva	O
samples	O
from	O
one	O
of	O
these	O
siblings	O
confirmed	O
that	O
c	B-VARIANT
.	I-VARIANT

The	O
analysis	O
revealed	O
that	O
22	O
probands	O
were	O
negative	O
for	O
these	O
mutations	O
,	O
and	O
one	O
carried	O
the	O
monoallelic	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutation	O
.	O

E	O
:	O
Activation	O
rise	O
time	O
,	O
determined	O
as	O
the	O
time	O
to	O
1	O
/	O
2	O
max	O
following	O
a	O
depolarization	O
to	O
0	O
mV	O
or	O
+	O
20	O
mV	O
.	O

Although	O
the	O
exact	O
percentage	O
of	O
nonsyndromic	O
ANSD	B-DISEASE
is	O
unclear	O
,	O
responsible	O
genes	O
have	O
been	O
gradually	O
revealed	O
.	O

Analysis	O
of	O
DNA	O
from	O
other	O
family	O
members	O
highlighted	O
that	O
this	O
variant	O
segregated	O
with	O
the	O
disease	O
phenotype	O
as	O
expected	O
.	O

Later	O
,	O
Plantiga	O
et	O
al	O
.	O

Its	O
three	O
components	O
(	O
TBP	B-GENE
,	O
BRF1	B-GENE
and	O
BDP1	B-GENE
)	O
participate	O
in	O
crucial	O
molecular	O
events	O
that	O
include	O
RNA	O
polymerase	O
recruitment	O
,	O
formation	O
of	O
the	O
open	O
initiation	O
complex	O
[	O
20	O
]	O
and	O
recycling	O
of	O
transcription	O
.	O

The	O
most	O
frequent	O
genetic	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
identified	O
so	O
far	O
in	O
the	O
Slovak	O
Roma	O
population	O
is	O
the	O
c	B-VARIANT
.	I-VARIANT
71G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Trp24	I-VARIANT
*	I-VARIANT
)	O
mutation	O
in	O
GJB2	B-GENE
gene	O
[	O
26	O
]	O
.	O

Lane	O
a	O
:	O
1	O
-	O
kb	O
DNA	O
ladder	O
with	O
the	O
adjacent	O
numbers	O
indicating	O
the	O
size	O
of	O
the	O
band	O
;	O
lane	O
b	O
:	O
patient	O
;	O
lane	O
c	O
:	O
wild	O
-	O
type	O
control	O
.	O

The	O
sensory	O
system	O
appears	O
particularly	O
affected	O
,	O
with	O
defects	O
found	O
in	O
vision	O
,	O
hearing	O
,	O
the	O
vestibular	O
system	O
,	O
and	O
olfaction	O
soon	O
after	O
diagnosis	O
with	O
diabetes	B-DISEASE
.	O

Figure	O
2	O
(	O
A	O
)	O
Cumulative	O
distribution	O
curve	O
of	O
age	O
on	O
onset	O
of	O
visual	B-DISEASE
failure	I-DISEASE
in	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
,	O
and	O
(	O
B	O
)	O
comparison	O
of	O
mean	O
LogMAR	O
visual	O
acuity	O
between	O
patients	O
with	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
features	O
(	O
P	O
=	O
0	O
.	O
0170	O
)	O
.	O

Our	O
study	O
is	O
the	O
largest	O
study	O
to	O
screen	O
both	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
in	O
patients	O
who	O
were	O
heterozygous	O
for	O
a	O
single	O
SLC26A4	B-GENE
mutation	O
in	O
whom	O
the	O
promoter	O
variant	O
/	O
FOXI1	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
101T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
binding	O
site	O
had	O
already	O
been	O
excluded	O
.	O

The	O
arrow	O
points	O
to	O
the	O
intraretinal	O
cysts	O
.	O

GJB2	B-GENE
sequencing	O
indicated	O
that	O
neither	O
of	O
her	O
parents	O
carried	O
the	O
R75W	B-VARIANT
mutation	O
.	O

In	O
addition	O
,	O
they	O
also	O
include	O
exons	O
of	O
small	O
non	O
-	O
coding	O
RNAs	O
from	O
miRBase	O
and	O
Rfam	O
.	O

The	O
stimulus	O
paradigm	O
consisted	O
of	O
an	O
initial	O
click	O
,	O
followed	O
15	O
ms	O
later	O
by	O
10	O
clicks	O
with	O
an	O
interstimulus	O
interval	O
of	O
2	O
.	O
9	O
ms	O
,	O
and	O
the	O
sequence	O
was	O
repeated	O
every	O
191	O
ms	O
(	O
Santarelli	O
et	O
al	O
.	O

These	O
results	O
do	O
not	O
support	O
a	O
possible	O
digenic	O
inheritance	O
between	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
in	O
this	O
family	O
.	O

A	O
.	O

They	O
both	O
had	O
a	O
70	O
~	O
90	O
decibels	O
hearing	O
level	O
(	O
dB	O
HL	O
)	O
at	O
a	O
frequency	O
spectrum	O
from	O
0	O
.	O
5	O
to	O
2	O
.	O
0	O
kHz	O
.	O

In	O
Japanese	O
,	O
H723R	B-VARIANT
accounted	O
for	O
53	O
%	O
of	O
the	O
mutant	O
alleles	O
,	O
and	O
in	O
Korean	O
,	O
the	O
H723R	B-VARIANT
and	O
the	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
the	O
most	O
prevalent	O
mutation	O
accounting	O
for	O
45	O
.	O
5	O
%	O
of	O
patients	O
with	O
PS	B-DISEASE
or	O
EVA	B-DISEASE
[	O
19	O
,	O
29	O
]	O
.	O

Our	O
case	O
raises	O
the	O
hypothesis	O
that	O
azoospermia	B-DISEASE
can	O
be	O
a	O
feature	O
of	O
HSD17B4	B-GENE
deficiency	O
in	O
males	O
,	O
consistent	O
with	O
the	O
finding	O
that	O
HSD17B4	B-GENE
knockout	O
mice	O
exhibit	O
male	O
-	O
specific	O
sterility	O
with	O
testicular	O
lipid	O
accumulation	O
[	O
19	O
]	O
.	O

(	O
B	O
)	O
Steady	O
state	O
level	O
for	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
was	O
assessed	O
by	O
Northern	O
blot	O
and	O
the	O
results	O
were	O
validated	O
by	O
two	O
independent	O
laboratories	O
.	O

The	O
PCR	O
reaction	O
was	O
performed	O
with	O
50	O
ng	O
DNA	O
,	O
3	O
pmol	O
primers	O
F	O
and	O
R	O
,	O
2	O
mM	O
MgCl	O
2	O
,	O
0	O
.	O
2	O
mu	O
L	O
Taq	O
and	O
H	O
2	O
O	O
to	O
20	O
mu	O
L	O
.	O

Blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O

Previous	O
genetic	O
studies	O
have	O
yielded	O
inconsistent	O
results	O
due	O
to	O
the	O
variety	O
of	O
methods	O
used	O
for	O
genetic	O
analysis	O
.	O

Sequence	O
of	O
TMPRSS3	B-GENE
in	O
affected	O
members	O
of	O
the	O
family	O
revealed	O
frameshift	B-VARIANT
988	I-VARIANT
delta	I-VARIANT
A	I-VARIANT
(	O
357stop	B-VARIANT
)	O
,	O
which	O
abrogates	O
serine	O
protease	O
activity	O
.	O

NIH	O
NIDDK	O
5R01DK094987	O
to	O
MPW	O
.	O

Five	O
groups	O
(	O
group	O
8	O
,	O
12	O
,	O
14	O
,	O
18	O
,	O
21	O
)	O
defined	O
by	O
"	O
Nosology	O
and	O
Classification	O
of	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
"	O
have	O
not	O
been	O
reported	O
in	O
the	O
Chinese	O
biomedical	O
literature	O
.	O

Our	O
vertical	O
SD	O
-	O
OCT	O
image	O
between	O
the	O
optic	O
disc	O
and	O
macular	O
region	O
showed	O
that	O
the	O
temporal	O
RNFL	O
was	O
almost	O
completely	O
absent	O
in	O
all	O
of	O
the	O
patients	O
.	O

Variants	O
with	O
high	O
population	O
allele	O
frequencies	O
(	O
>	O
0	O
.	O
02	O
)	O
,	O
as	O
reported	O
by	O
data	O
collected	O
from	O
the	O
1000	O
genome	O
project	O
,	O
were	O
filtered	O
out	O
.	O

Screening	O
patients	O
for	O
C10orf2	B-GENE
mutations	O
may	O
be	O
beneficial	O
for	O
patients	O
with	O
sensorimotor	B-DISEASE
polyneuropathy	I-DISEASE
,	O
particularly	O
HMSN	B-DISEASE
patients	O
who	O
present	O
with	O
symptoms	O
of	O
spinocerebellar	B-DISEASE
ataxia	I-DISEASE
.	O

Dotted	O
lines	O
and	O
upward	O
triangular	O
symbols	O
indicate	O
first	O
available	O
and	O
straight	O
lines	O
,	O
and	O
downward	O
triangular	O
symbols	O
indicate	O
last	O
-	O
visit	O
mean	O
audiogram	O
.	O

Seven	O
men	O
in	O
the	O
same	O
family	O
carried	O
mutation	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
G1077D	I-VARIANT
)	I-VARIANT
,	O
three	O
of	O
whom	O
developed	O
added	O
proteinuria	B-DISEASE
and	O
one	O
progressed	O
to	O
CRF	B-DISEASE
.	O

In	O
the	O
wild	O
type	O
the	O
side	O
chain	O
solvent	O
accessibility	O
for	O
residue	O
H170	O
is	O
greater	O
than	O
10	O
%	O
.	O

A	O
renal	O
biopsy	O
was	O
avoided	O
unless	O
it	O
was	O
deemed	O
necessary	O
on	O
clinical	O
grounds	O
.	O

Among	O
samples	O
enriched	O
by	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
within	O
the	O
same	O
batch	O
,	O
the	O
proportion	O
of	O
bases	O
mapped	O
onto	O
mtDNA	O
varies	O
from	O
30	O
to	O
80	O
%	O
,	O
which	O
is	O
highly	O
correlated	O
with	O
the	O
proportion	O
of	O
total	O
on	O
-	O
target	O
bases	O
and	O
the	O
uniformity	O
over	O
all	O
target	O
regions	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
would	O
suggest	O
that	O
USH1C	B-GENE
is	O
a	O
rare	O
form	O
of	O
USH	B-DISEASE
in	O
this	O
population	O
.	O

Stable	O
transfected	O
cells	O
HEK	O
cells	O
were	O
generated	O
in	O
T75	O
flasks	O
using	O
a	O
total	O
of	O
11	O
.	O
25	O
mu	O
g	O
DNA	O
(	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
Zeo	O
,	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
WT	O
-	O
Hyg	O
or	O
pcDNA3	O
.	O
1	O
-	O
CD164	B-GENE
-	O
R192	B-VARIANT
*	I-VARIANT
-	O
Neo	O
)	O
and	O
33	O
.	O
75	O
mu	O
l	O
X	O
-	O
tremeGENE	O
9	O
transfection	O
reagent	O
and	O
selection	O
of	O
transfected	O
cells	O
were	O
done	O
using	O
medium	O
containing	O
antibiotics	O
(	O
Zeocine	O
100	O
mu	O
g	O
/	O
ml	O
(	O
Invitrogen	O
)	O
,	O
Hygromycin	O
100	O
mu	O
g	O
/	O
ml	O
(	O
Invitrogen	O
)	O
,	O
or	O
Neomycine	O
(	O
G418	O
)	O
1	O
.	O
5	O
mg	O
/	O
ml	O
(	O
VWR	O
,	O
Herlev	O
,	O
Denmark	O
)	O
)	O
.	O

A	O
total	O
of	O
529	O
CNV	O
regions	O
and	O
two	O
chromosomal	O
aberrations	O
(	O
CNV	O
>	O
1	O
Mb	O
)	O
were	O
identified	O
in	O
this	O
family	O
.	O

DNAs	O
were	O
extracted	O
by	O
the	O
standard	O
phenol	O
/	O
chloroform	O
method	O
.	O

It	O
is	O
likely	O
that	O
the	O
family	O
described	O
here	O
carries	O
the	O
mutation	O
on	O
the	O
founder	O
haplotype	O
.	O

This	O
underscores	O
the	O
importance	O
of	O
good	O
diabetes	B-DISEASE
control	O
in	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
to	O
retard	O
the	O
neurologic	O
and	O
endocrine	O
degenerative	O
course	O
of	O
the	O
disease	O
.	O

Macular	O
thickness	O
:	O
RE	O
274	O
mu	O
m	O
,	O
LE	O
260	O
mu	O
m	O
.	O

This	O
yielded	O
a	O
total	O
of	O
64	O
,	O
863	O
single	O
-	O
nucleotide	O
variants	O
,	O
of	O
which	O
1	O
,	O
928	O
were	O
not	O
found	O
in	O
the	O
dbSNP133	O
database	O
(	O
Table	O
S1	O
)	O
.	O

As	O
an	O
example	O
,	O
Usher	B-DISEASE
syndromes	I-DISEASE
,	O
which	O
are	O
characterized	O
by	O
both	O
HL	B-DISEASE
and	O
gradual	O
visual	B-DISEASE
impairment	I-DISEASE
,	O
share	O
the	O
same	O
disease	O
genes	O
as	O
several	O
types	O
of	O
autosomal	B-DISEASE
recessive	I-DISEASE
NSHL	I-DISEASE
but	O
are	O
not	O
readily	O
distinguished	O
from	O
autosomal	B-DISEASE
recessive	I-DISEASE
NSHL	I-DISEASE
in	O
infants	O
and	O
early	O
childhood	O
.	O

The	O
finding	O
of	O
the	O
homozygous	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
Ala179Thr	I-VARIANT
)	O
in	O
our	O
patients	O
added	O
one	O
more	O
case	O
of	O
BSNHL	B-DISEASE
caused	O
by	O
a	O
mutation	O
in	O
the	O
SRCR	O
domain	O
of	O
TMPRSS3	B-GENE
.	O

For	O
a	O
complete	O
list	O
of	O
syndromes	O
included	O
on	O
the	O
current	O
CGT	O
panel	O
see	O
Table	O
S8	O
.	O

Genotypes	O
of	O
participating	O
family	O
members	O
are	O
shown	O
below	O
each	O
symbol	O
in	O
single	O
letter	O
amino	O
acid	O
nomenclature	O
:	O
P	O
for	O
Proline	O
and	O
R	O
for	O
Arginine	O
.	O

The	O
systematic	O
search	O
for	O
OPA1	B-GENE
mutations	O
should	O
therefore	O
prove	O
useful	O
in	O
unexplained	O
and	O
atypical	O
cases	O
of	O
optic	B-DISEASE
atrophy	I-DISEASE
.	O

This	O
does	O
not	O
alter	O
the	O
authors	O
'	O
adherence	O
to	O
PLOS	O
ONE	O
policies	O
on	O
sharing	O
data	O
and	O
materials	O
.	O

The	O
coding	O
region	O
(	O
exons	O
2	O
-	O
72	O
)	O
and	O
the	O
exon	O
-	O
intron	O
boundaries	O
of	O
USH2A	B-GENE
were	O
amplified	O
by	O
PCR	O
in	O
the	O
probands	O
of	O
the	O
four	O
families	O
.	O

Consistently	O
,	O
this	O
mutational	O
spot	O
was	O
highly	O
conserved	O
among	O
all	O
species	O
analyzed	O
by	O
multiple	O
protein	O
sequences	O
alignment	O
(	O
Figure	O
1I	O
)	O
.	O

Because	O
she	O
decided	O
to	O
not	O
to	O
terminate	O
it	O
was	O
necessary	O
to	O
assemble	O
a	O
multidisciplinary	O
team	O
including	O
obstetricians	O
,	O
orthopaedists	O
,	O
cardiologists	O
,	O
a	O
pneumologist	O
and	O
an	O
anaesthetist	O
to	O
monitor	O
cardio	O
-	O
respiratory	O
and	O
orthopaedic	O
complications	O
.	O

They	O
described	O
the	O
method	O
and	O
results	O
in	O
the	O
text	O
.	O

GJB2	B-GENE
mutations	O
were	O
detected	O
in	O
23	O
.	O
7	O
%	O
of	O
the	O
patients	O
(	O
18	O
out	O
of	O
76	O
)	O
(	O
Table	O
1	O
)	O
.	O

is	O
supported	O
by	O
a	O
Banting	O
Postdoctoral	O
Fellowship	O
from	O
the	O
Canadian	O
Institutes	O
of	O
Health	O
Research	O
.	O

Patients	O
were	O
identified	O
through	O
the	O
German	O
Diabetes	B-DISEASE
Prospective	O
Documentation	O
(	O
DPV	O
)	O
database	O
,	O
a	O
nationwide	O
prospective	O
registry	O
that	O
evaluates	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
,	O
and	O
inquiries	O
at	O
scientific	O
meetings	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Neither	O
these	O
clinical	O
features	O
,	O
however	O
,	O
nor	O
the	O
fact	O
that	O
HH	B-DISEASE
diagnosis	O
was	O
confirmed	O
by	O
molecular	O
genetic	O
analyses	O
in	O
two	O
thirds	O
of	O
reversal	O
patients	O
,	O
are	O
consistent	O
with	O
CDP	B-DISEASE
.	O

We	O
then	O
focused	O
on	O
the	O
functionally	O
interpretable	O
variants	O
that	O
included	O
:	O
SNVs	O
that	O
were	O
evolutionarily	O
conserved	O
(	O
GERP	O
>	O
2	O
.	O
0	O
)	O
and	O
caused	O
missense	O
or	O
nonsense	O
changes	O
;	O
or	O
SNVs	O
that	O
were	O
located	O
within	O
2	O
bp	O
of	O
intron	O
-	O
exon	O
boundaries	O
;	O
and	O
indels	O
that	O
caused	O
in	O
-	O
frame	O
or	O
frameshift	O
alternations	O
.	O

Table	O
4	O
Summary	O
of	O
putative	O
pathogenic	O
mutations	O
and	O
their	O
bioinformatics	O
predictions	O
SIFT	O
:	O
SIFT	O
Score	O
ranges	O
from	O
0	O
to	O
1	O
.	O

Sequencing	O
was	O
performed	O
using	O
the	O
ABI	O
3130	O
Avant	O
capillary	O
electrophoresis	O
system	O
.	O

Specific	O
enzymatic	O
activities	O
were	O
expressed	O
in	O
mIU	O
(	O
e	O
.	O
g	O
.	O
,	O
nanomoles	O
of	O
cytochrome	O
c	O
,	O
NADH	O
or	O
DTNB	O
/	O
min	O
/	O
mg	O
protein	O
,	O
respectively	O
)	O
.	O

ABRs	O
were	O
recorded	O
from	O
all	O
OPA1	B-GENE
-	O
H	O
subjects	O
with	O
normal	O
latencies	O
and	O
morphology	O
(	O
Fig	O
.	O

Variations	O
(	O
c	B-VARIANT
.	I-VARIANT
2802T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
8232G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
3788G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
14403C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
)	O
found	O
in	O
the	O
sequencing	O
were	O
confirmed	O
with	O
the	O
restriction	O
endonucleases	O
Hinc	O
II	O
(	O
TaKaRa	O
,	O
Dalian	O
,	O
China	O
)	O
,	O
HpyCH4V	O
,	O
BsaI	O
,	O
and	O
SpeI	O
(	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
,	O
MA	O
)	O
,	O
respectively	O
,	O
which	O
were	O
used	O
in	O
all	O
available	O
family	O
members	O
and	O
in	O
the100	O
normal	O
controls	O
.	O

The	O
mitochondria	O
of	O
the	O
skin	O
fibroblasts	O
were	O
labeled	O
by	O
mitotracker	O
and	O
then	O
their	O
morphology	O
was	O
observed	O
using	O
confocal	O
microscopy	O
.	O

The	O
filled	O
gray	O
square	O
indicates	O
the	O
individual	O
with	O
hematuria	B-DISEASE
.	O

Status	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
264	O
patients	O
was	O
:	O
mild	O
(	O
21	O
-	O
40	O
dB	O
)	O
in	O
39	O
patients	O
(	O
14	O
.	O
7	O
%	O
)	O
,	O
moderate	O
(	O
41	O
-	O
70	O
dB	O
)	O
in	O
84	O
(	O
31	O
.	O
8	O
%	O
)	O
,	O
severe	O
(	O
71	O
-	O
94	O
dB	O
)	O
in	O
39	O
(	O
14	O
.	O
8	O
%	O
)	O
and	O
profound	O
(	O
>	O
95	O
dB	O
)	O
in	O
56	O
patients	O
(	O
21	O
.	O
2	O
%	O
)	O
.	O

Both	O
have	O
now	O
transferred	O
from	O
insulin	O
to	O
sulfonylurea	O
therapy	O
.	O

As	O
a	O
control	O
,	O
we	O
conducted	O
KCNJ10	B-GENE
mutation	O
screening	O
in	O
563	O
patients	O
with	O
NSEVA	B-DISEASE
who	O
carried	O
two	O
mutations	O
in	O
SLC26A4	B-GENE
.	O

Mutations	O
that	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
first	O
identified	O
at	O
the	O
DFNB3	B-GENE
locus	O
,	O
in	O
residents	O
of	O
a	O
village	O
in	O
Indonesia	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

These	O
clinical	O
features	O
were	O
based	O
on	O
the	O
reported	O
phenotypes	O
of	O
DFNB12	B-DISEASE
and	O
USH1D	B-DISEASE
[	O
12	O
,	O
14	O
-	O
16	O
]	O
.	O

In	O
conclusion	O
,	O
DFNB1	B-GENE
is	O
a	O
very	O
minor	O
cause	O
of	O
ARNSHL	B-DISEASE
in	O
individuals	O
of	O
Saudi	O
Arabian	O
tribal	O
origin	O
.	O

Since	O
the	O
two	O
alleles	O
in	O
trans	O
of	O
the	O
M34T	B-VARIANT
corresponded	O
to	O
a	O
null	O
allele	O
,	O
Griffith	O
et	O
al	O
.	O

Missense	O
mutations	O
in	O
BRCA1	B-GENE
and	O
BRCA2	B-GENE
are	O
the	O
most	O
difficult	O
to	O
classify	O
clinically	O
[	O
49	O
]	O
.	O

The	O
phenotype	O
is	O
highly	O
variable	O
in	O
expressivity	O
and	O
incomplete	O
in	O
penetrance	O
[	O
3	O
]	O
.	O

There	O
is	O
currently	O
no	O
definitive	O
treatment	O
for	O
this	O
disorder	O
,	O
but	O
the	O
fact	O
that	O
these	O
complex	O
phenotypes	O
eventually	O
develop	O
in	O
up	O
to	O
20	O
%	O
of	O
all	O
mutational	O
carriers	O
has	O
important	O
implications	O
for	O
clinical	O
management	O
.	O

In	O
sum	O
,	O
our	O
exhaustive	O
genetic	O
analysis	O
shows	O
that	O
,	O
in	O
this	O
Brazilian	O
family	O
of	O
European	O
ancestry	O
,	O
the	O
manifestation	O
of	O
the	O
HSCR	B-DISEASE
phenotype	O
may	O
require	O
mutations	O
in	O
two	O
genes	O
of	O
the	O
same	O
pathway	O
.	O

While	O
all	O
other	O
mutations	O
identified	O
in	O
our	O
study	O
were	O
absent	O
in	O
100	O
French	O
Canadian	O
control	O
samples	O
from	O
Quebec	O
,	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
present	O
in	O
a	O
heterozygous	O
state	O
in	O
one	O
out	O
of	O
227	O
healthy	O
control	O
individuals	O
,	O
suggesting	O
a	O
carrier	O
rate	O
of	O
about	O
0	O
.	O
44	O
%	O
in	O
the	O
Quebec	O
population	O
.	O

Therefore	O
,	O
it	O
has	O
been	O
nearly	O
impossible	O
to	O
identify	O
the	O
precise	O
pathogenic	O
mutations	O
in	O
affected	O
individuals	O
from	O
small	O
families	O
who	O
cannot	O
be	O
examined	O
either	O
through	O
linkage	O
analysis	O
or	O
standard	O
capillary	O
sequencing	O
analysis	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
RP	O
RWP	O
DLP	O
.	O

We	O
identified	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
IVS25	I-VARIANT
+	I-VARIANT
3G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
8375	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V2792A	I-VARIANT
)	O
as	O
the	O
disease	O
-	O
causing	O
mutations	O
.	O

Genotypes	O
were	O
determined	O
using	O
the	O
GenScan	O
(	O
tm	O
)	O
and	O
GenoTyper	O
(	O
tm	O
)	O
software	O
(	O
Applied	O
Biosystems	O
)	O
.	O

All	O
enriched	O
libraries	O
were	O
sequenced	O
on	O
the	O
Illumina	O
HiSeq	O
2000	O
(	O
Illumina	O
,	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
using	O
100bp	O
paired	O
-	O
end	O
reads	O
.	O

Furthermore	O
,	O
in	O
both	O
previous	O
studies	O
,	O
only	O
point	O
mutations	O
were	O
detected	O
.	O

Moreover	O
,	O
it	O
was	O
subsequently	O
detected	O
in	O
five	O
additional	O
families	O
[	O
31	O
]	O
.	O

More	O
than	O
400	O
syndromes	O
can	O
include	O
hearing	B-DISEASE
loss	I-DISEASE
or	O
deficient	O
hearing	O
functions	O
as	O
a	O
component	O
.	O

The	O
technical	O
assistance	O
of	O
A	O
.	O

It	O
has	O
been	O
detected	O
in	O
Spanish	O
people	O
,	O
Grecians	O
,	O
Newfoundlanders	O
,	O
and	O
Pakistan	O
populations	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

This	O
patient	O
has	O
parents	O
with	O
normal	O
hearing	O
and	O
GJB2	B-GENE
mutations	O
have	O
been	O
excluded	O
.	O

For	O
sequencing	O
candidate	O
genes	O
,	O
primer	O
pairs	O
were	O
designed	O
to	O
amplify	O
and	O
sequence	O
the	O
entire	O
coding	O
regions	O
and	O
splice	O
sites	O
of	O
all	O
isoforms	O
of	O
GJB2	B-GENE
(	O
connexin	B-GENE
26	I-GENE
)	O
,	O
[	O
4	O
]	O
TMPRSS3	B-GENE
,	O
[	O
5	O
]	O
pendrin	B-GENE
[	O
6	O
]	O
and	O
otoancorin	B-GENE
[	O
7	O
]	O
.	O

Based	O
on	O
the	O
severity	O
and	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
age	O
at	O
onset	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
,	O
and	O
presence	O
or	O
absence	O
of	O
vestibular	B-DISEASE
impairment	I-DISEASE
,	O
the	O
majority	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
cases	O
can	O
be	O
classified	O
into	O
three	O
clinical	O
subtypes	O
.	O

The	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
variant	O
of	O
controversial	O
pathogenicity	O
was	O
identified	O
in	O
another	O
two	O
ADNSHL	B-DISEASE
families	O
.	O

noted	O
that	O
patients	O
with	O
LHON	B-DISEASE
and	O
DOA	O
do	O
not	O
have	O
any	O
fluorescein	O
leakage	O
as	O
expected	O
for	O
the	O
noninflammatory	O
status	O
of	O
their	O
disease	O
[	O
22	O
]	O
.	O

Pedigree	O
of	O
Family	O
1953	O
with	O
ARNSHL	B-DISEASE
Affected	O
subjects	O
are	O
denoted	O
in	O
black	O
.	O

Thus	O
,	O
despite	O
a	O
dearth	O
of	O
direct	O
mechanistic	O
data	O
on	O
the	O
role	O
of	O
KCNQ1	B-GENE
in	O
regulating	O
myocardial	O
structure	O
and	O
function	O
,	O
complex	O
biological	O
functions	O
of	O
the	O
KCNQ1	B-GENE
in	O
modulating	O
the	O
biology	O
of	O
myocytes	O
offer	O
plausible	O
explanations	O
for	O
the	O
putative	O
mechanism	O
(	O
s	O
)	O
.	O

Moreover	O
,	O
seven	O
novel	O
polymorphisms	O
were	O
also	O
described	O
.	O

The	O
eluates	O
were	O
digested	O
with	O
trypsin	O
and	O
the	O
resulting	O
tryptic	O
peptides	O
were	O
purified	O
and	O
identified	O
with	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
using	O
a	O
microcapillary	O
reversed	O
-	O
phase	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
-	O
coupled	O
LTQ	O
-	O
Orbitrap	O
(	O
ThermoElectron	O
)	O
quadrupole	O
ion	O
trap	O
mass	O
spectrometer	O
with	O
a	O
nanospray	O
interface	O
,	O
as	O
recently	O
described	O
40	O
.	O

Serum	O
enzymes	O
related	O
to	O
energy	O
metabolism	O
,	O
such	O
as	O
lactate	O
dehydrogenase	O
and	O
creatine	O
kinase	O
,	O
were	O
measured	O
.	O

As	O
the	O
PCR	O
fragments	O
used	O
in	O
SSCP	O
analysis	O
were	O
between	O
150	O
to	O
300	O
bp	O
,	O
two	O
pairs	O
of	O
specific	O
primers	O
were	O
designed	O
for	O
detecting	O
the	O
mutation	O
in	O
exons	O
43	O
and	O
61	O
(	O
Appendix	O
1	O
)	O
.	O

[	O
34	O
]	O
screened	O
SLC26A4	B-GENE
,	O
FOXI1	B-GENE
and	O
KCNJ10	B-GENE
(	O
as	O
well	O
as	O
GJB2	B-GENE
)	O
in	O
patients	O
with	O
bilateral	O
deafness	B-DISEASE
and	O
inner	O
ear	O
malformations	O
and	O
found	O
no	O
mutations	O
in	O
FOXI1	B-GENE
or	O
KCNJ10	B-GENE
in	O
the	O
15	O
who	O
had	O
one	O
or	O
zero	O
SLC26A4	B-GENE
mutations	O
;	O
Mercer	O
et	O
al	O
.	O

Results	O
of	O
a	O
former	O
study	O
suggest	O
that	O
SLC26A4	B-GENE
could	O
be	O
considered	O
as	O
the	O
second	O
cause	O
of	O
HI	B-DISEASE
,	O
after	O
GJB2	B-GENE
,	O
in	O
Iran	O
[	O
13	O
]	O
.	O

(	O
A	O
)	O
Reference	O
chromatogram	O
in	O
exon	O
7	O
.	O

This	O
combination	O
of	O
double	O
heterozygous	O
mutations	O
has	O
been	O
reported	O
[	O
46	O
]	O
.	O

This	O
C	O
-	O
terminal	O
has	O
a	O
tobacco	O
mosaic	O
virus	O
signature	O
and	O
could	O
serve	O
as	O
a	O
protein	O
binding	O
motif	O
[	O
9	O
]	O
.	O

Full	O
diagnosis	O
was	O
attained	O
in	O
17	O
/	O
36	O
Spanish	O
pedigrees	O
,	O
yielding	O
12	O
new	O
and	O
12	O
previously	O
reported	O
mutations	O
in	O
9	O
RD	B-DISEASE
genes	O
.	O

13	O
Here	O
,	O
we	O
applied	O
a	O
similar	O
design	O
philosophy	O
to	O
our	O
custom	O
kit	O
using	O
the	O
Agilent	O
'	O
s	O
SureSelect	O
technology	O
.	O

However	O
,	O
this	O
becomes	O
more	O
difficult	O
in	O
the	O
presence	O
of	O
any	O
locus	O
heterogeneity	O
.	O

5	O
)	O
.	O

1A	O
)	O
[	O
20	O
]	O
.	O

AN	B-DISEASE
was	O
mapped	O
to	O
chromosome	O
2p22	O
-	O
p23	O
and	O
the	O
OTOF	B-GENE
gene	O
(	O
MIM	O
#	O
603681	O
)	O
was	O
subsequently	O
found	O
be	O
responsible	O
for	O
that	O
disease	O
[	O
7	O
]	O
.	O

Typical	O
audiograms	O
of	O
affected	O
and	O
unaffected	O
subjects	O
(	O
B	O
)	O
.	O

We	O
did	O
not	O
perform	O
a	O
functional	O
analysis	O
of	O
the	O
mutated	O
protein	O
,	O
but	O
a	O
molecular	O
difference	O
between	O
these	O
two	O
residues	O
(	O
glutamic	O
acid	O
is	O
an	O
acidic	O
amino	O
acid	O
,	O
whereas	O
lysine	O
is	O
a	O
basic	O
one	O
)	O
supports	O
the	O
hypothesis	O
that	O
this	O
replacement	O
may	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
subunit	O
,	O
thus	O
the	O
function	O
,	O
folding	O
,	O
or	O
trafficking	O
of	O
that	O
protein	O
.	O

The	O
genomic	O
DNA	O
of	O
87	O
subjects	O
and	O
100	O
normal	O
controls	O
was	O
extracted	O
from	O
blood	O
or	O
buccal	O
cells	O
using	O
a	O
FlexiGene	O
DNA	O
Extraction	O
Kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

To	O
predict	O
the	O
effect	O
of	O
non	O
-	O
synonymous	O
mutations	O
on	O
the	O
encoded	O
proteins	O
of	O
the	O
selected	O
gene	O
list	O
,	O
we	O
used	O
two	O
different	O
web	O
tools	O
:	O
SIFT	O
[	O
59	O
]	O
and	O
PolyPhen	O
v2	O
.	O
0	O
[	O
60	O
]	O
.	O

Moreover	O
,	O
a	O
specific	O
marriage	O
structure	O
(	O
patrilineal	O
clan	O
exogamy	O
)	O
practiced	O
by	O
the	O
Altaians	O
for	O
a	O
long	O
time	O
to	O
avoid	O
close	O
inbreeding	O
,	O
could	O
influence	O
apparent	O
scarcity	O
of	O
affected	O
GJB2	B-GENE
homozygotes	O
by	O
restriction	O
of	O
random	O
marriages	O
of	O
Altaians	O
belonged	O
to	O
certain	O
clans	O
.	O

In	O
cell	O
culture	O
studies	O
CLRN1	B-GENE
forms	O
microdomains	O
in	O
the	O
plasma	O
membrane	O
,	O
affects	O
F	O
-	O
actin	O
organization	O
and	O
induces	O
lamellipodia	O
formation	O
,	O
implicating	O
CLRN1	B-GENE
involvement	O
in	O
actin	O
cytoskeleton	O
regulation	O
[	O
28	O
]	O
.	O

Sequence	O
analysis	O
was	O
performed	O
with	O
the	O
ABI	O
PRISM	O
Big	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
V3	O
.	O
1	O
Ready	O
Reaction	O
Kit	O
and	O
the	O
ABI	O
PRISM	O
3730	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
)	O
.	O

We	O
also	O
observed	O
other	O
mutations	O
occurring	O
multiple	O
times	O
;	O
segregating	O
in	O
four	O
families	O
were	O
previously	O
published	O
p	B-VARIANT
.	I-VARIANT
Glu2288X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Trp3521Arg	I-VARIANT
.	O

Thus	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
1343	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
allele	O
is	O
expected	O
to	O
lead	O
to	O
a	O
NMD	O
of	O
the	O
corresponding	O
mRNA	O
,	O
which	O
is	O
not	O
detectable	O
by	O
minigene	O
assay	O
,	O
or	O
,	O
less	O
likely	O
,	O
result	O
into	O
a	O
truncated	O
MYO7A	B-GENE
proteins	O
,	O
p	B-VARIANT
.	I-VARIANT
Ser448Argfs	I-VARIANT
*	I-VARIANT
18	I-VARIANT
.	O

In	O
mice	O
,	O
Osbpl2	B-GENE
was	O
prominently	O
expressed	O
in	O
stereocilia	O
of	O
cochlear	O
outer	O
and	O
inner	O
hair	O
cells	O
.	O

Two	O
cases	O
carried	O
EVA	B-DISEASE
but	O
without	O
any	O
mutations	O
found	O
in	O
Invader	O
assay	O
,	O
c	B-VARIANT
[	I-VARIANT
1931	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
]	I-VARIANT
;	O
[	B-VARIANT
1931	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
]	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
[	I-VARIANT
V659L	I-VARIANT
]	I-VARIANT
;	O
c	B-VARIANT
[	I-VARIANT
1219delCT	I-VARIANT
]	I-VARIANT
compound	O
heterozygous	O
mutations	O
were	O
found	O
by	O
direct	O
sequencing	O
.	O

[	O
a	O
]	O
This	O
study	O
,	O
b	O
Mutations	O
previously	O
identified	O
by	O
APEX	O
c	O
Unknown	O
pathogenicity	O
,	O
n	O
.	O
i	O
Not	O
identified	O
.	O

Extensive	O
clinical	O
testing	O
and	O
genetic	O
research	O
are	O
invaluable	O
to	O
elucidate	O
underlying	O
mechanisms	O
and	O
sites	O
of	O
pathology	O
.	O

In	O
these	O
eleven	O
families	O
,	O
we	O
could	O
successfully	O
find	O
mutations	O
by	O
PCR	O
sequencing	O
,	O
which	O
were	O
mostly	O
located	O
in	O
the	O
reported	O
sites	O
(	O
Table	O
1	O
)	O
.	O

The	O
fact	O
that	O
the	O
carriers	O
of	O
the	O
WFS1	B-GENE
mutations	O
associated	O
with	O
WS	B-DISEASE
do	O
not	O
exhibit	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
heterozygosity	O
for	O
other	O
WFS1	B-GENE
mutations	O
resulting	O
in	O
nonsyndromic	O
autosomal	O
dominant	O
LSFHNL	B-DISEASE
reveals	O
our	O
incomplete	O
knowledge	O
of	O
the	O
function	O
of	O
the	O
WFS1	B-GENE
protein	O
and	O
the	O
impact	O
of	O
the	O
different	O
types	O
of	O
WFS1	B-GENE
mutations	O
.	O

SpectroCHIPs	O
were	O
analyzed	O
in	O
automated	O
mode	O
by	O
a	O
MassArray	O
MALDI	O
-	O
TOF	O
Compact	O
system	O
with	O
a	O
solid	O
phase	O
laser	O
mass	O
spectrometer	O
(	O
Bruker	O
Daltonics	O
Inc	O
.	O
,	O
2005	O
)	O
.	O

Analysis	O
of	O
splice	O
sites	O
in	O
the	O
GJB2	B-GENE
intronic	O
sequence	O
was	O
performed	O
by	O
NNSplice	O
software	O
,	O
version	O
0	O
.	O
9	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
fruitfly	O
.	O
org	O
/	O
seq_tools	O
/	O
splice	O
.	O
html	O
)	O
[	O
24	O
]	O
.	O

Huawei	O
Li	O
received	O
grant	O
support	O
from	O
the	O
National	O
Science	O
Foundation	O
of	O
China	O
(	O
#	O
30728029	O
and	O
#	O
81230019	O
)	O
and	O
the	O
973	O
program	O
(	O
2011CB504506	O
)	O
.	O

Most	O
affected	O
individuals	O
carry	O
recessive	O
mutations	O
in	O
the	O
Wolfram	B-GENE
syndrome	I-GENE
1	I-GENE
gene	I-GENE
(	O
WFS1	B-GENE
)	O
.	O

It	O
is	O
the	O
leading	O
cause	O
of	O
deafblindness	B-DISEASE
,	O
with	O
a	O
general	O
prevalence	O
of	O
2	O
to	O
6	O
.	O
2	O
in	O
100	O
,	O
000	O
[	O
1	O
,	O
2	O
]	O
.	O

Analyses	O
of	O
exxon	O
5	O
of	O
the	O
FGFR1	B-GENE
and	O
exxons	O
5	O
,	O
8	O
,	O
10	O
,	O
11	O
,	O
15	O
,	O
and	O
16	O
of	O
the	O
FGFR2	B-GENE
gene	O
was	O
performed	O
by	O
using	O
specific	O
primers	O
flanking	O
these	O
coding	O
exxons	O
and	O
their	O
splice	O
junctions	O
.	O

Wrote	O
the	O
paper	O
:	O
ZR	O
.	O

The	O
y	O
-	O
axis	O
gives	O
the	O
R	O
CNV	O
ratio	O
calculated	O
for	O
CNVs	O
.	O

Reduced	O
amount	O
of	O
EDNRB	B-GENE
receptor	O
might	O
alter	O
the	O
signalling	O
pathway	O
and	O
hence	O
,	O
the	O
differentiation	O
and	O
development	O
of	O
neural	O
crest	O
cells	O
could	O
be	O
affected	O
.	O

Yellow	O
and	O
blue	O
amino	O
acids	O
indicate	O
negatively	O
and	O
positively	O
charged	O
residues	O
,	O
respectively	O
.	O

In	O
the	O
EVS	O
,	O
however	O
,	O
no	O
homozygous	O
occurrence	O
of	O
the	O
mutated	O
allele	O
has	O
been	O
reported	O
to	O
date	O
(	O
Table	O
S1	O
)	O
.	O

We	O
did	O
not	O
directly	O
assay	O
whether	O
this	O
specific	O
mutation	O
would	O
affect	O
splicing	O
,	O
but	O
the	O
patient	O
tested	O
mutation	O
negative	O
for	O
COMP	B-GENE
,	O
MATN3	B-GENE
,	O
COL9A1	B-GENE
,	O
and	O
COL9A3	B-GENE
,	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
186	I-VARIANT
+	I-VARIANT
4a	I-VARIANT
>	I-VARIANT
c	I-VARIANT
mutation	O
co	O
-	O
segregated	O
with	O
the	O
affected	O
mother	O
and	O
brother	O
of	O
the	O
proband	O
.	O

The	O
failure	O
to	O
identify	O
a	O
genetic	O
aetiology	O
in	O
many	O
patients	O
in	O
this	O
study	O
highlights	O
the	O
extreme	O
heterogeneity	O
of	O
genetic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
the	O
incompleteness	O
of	O
current	O
knowledge	O
of	O
aetiologies	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
the	O
limitations	O
of	O
conventional	O
DNA	O
sequencing	O
strategies	O
that	O
evaluate	O
only	O
coding	O
and	O
near	O
-	O
coding	O
segments	O
of	O
genes	O
.	O

Interestingly	O
,	O
this	O
study	O
and	O
a	O
subsequent	O
survey	O
of	O
the	O
cardiology	O
clinics	O
revealed	O
that	O
Andersen	B-DISEASE
syndrome	I-DISEASE
,	O
despite	O
being	O
originally	O
described	O
in	O
Denmark	O
[	O
68	O
]	O
,	O
as	O
well	O
as	O
Jervell	B-DISEASE
and	I-DISEASE
Lange	I-DISEASE
-	I-DISEASE
Nielsen	I-DISEASE
syndrome	I-DISEASE
and	O
Timothy	B-DISEASE
syndrome	I-DISEASE
patients	O
,	O
are	O
not	O
found	O
in	O
Danish	O
cardiology	O
clinics	O
(	O
Kanters	O
,	O
pers	O
.	O
com	O
.	O
)	O
.	O

Evaluated	O
by	O
examination	O
of	O
peripheral	O
blood	O
smears	O
.	O

As	O
in	O
the	O
eye	O
,	O
the	O
alpha	O
5	O
(	O
IV	O
)	O
chain	O
is	O
normally	O
present	O
in	O
the	O
lens	O
capsule	O
,	O
Descemet	O
,	O
Bruch	O
and	O
internal	O
limiting	O
membranes	O
[	O
25	O
]	O
,	O
it	O
is	O
reasonable	O
to	O
infer	O
that	O
dysfunction	B-DISEASE
of	I-DISEASE
the	I-DISEASE
lens	I-DISEASE
capsule	I-DISEASE
,	I-DISEASE
Bruch	I-DISEASE
and	I-DISEASE
internal	I-DISEASE
limiting	I-DISEASE
membranes	I-DISEASE
resulted	O
from	O
deposit	O
of	O
abnormal	B-DISEASE
type	I-DISEASE
IV	I-DISEASE
collagen	I-DISEASE
was	O
responsible	O
for	O
this	O
severe	O
ocular	O
phenotype	O
in	O
II	O
-	O
2	O
.	O

Both	O
biological	O
parents	O
were	O
healthy	O
with	O
no	O
clinically	O
significant	O
medical	B-DISEASE
,	I-DISEASE
developmental	I-DISEASE
,	I-DISEASE
or	I-DISEASE
neuropsychological	I-DISEASE
illnesses	I-DISEASE
.	O

The	O
goal	O
of	O
this	O
study	O
is	O
to	O
characterize	O
the	O
variation	O
in	O
cancer	O
-	O
susceptibility	O
genes	O
in	O
a	O
general	O
population	O
.	O

The	O
arrowhead	O
marks	O
the	O
lysine	O
residue	O
(	O
K	O
)	O
at	O
position	O
836	O
.	O

Alleles	O
forming	O
the	O
risk	O
haplotype	O
are	O
shown	O
in	O
grey	O
boxes	O
.	O

Plates	O
were	O
spun	O
at	O
2500rpm	O
for	O
90	O
minutes	O
and	O
incubated	O
for	O
24	O
hours	O
at	O
37	O
deg	O
C	O
before	O
replacing	O
media	O
.	O

Most	O
cases	O
of	O
STGD	B-DISEASE
are	O
caused	O
by	O
recessive	O
3	O
.	O

To	O
-	O
date	O
,	O
174	O
SLC26A4	B-GENE
mutations	O
have	O
been	O
reported	O
[	O
12	O
]	O
.	O

Chromosome	O
22q11	O
.	O
2	O
deletion	O
syndrome	O
(	O
22q11	O
.	O
2DS	O
)	O
is	O
a	O
developmental	O
disorder	O
associated	O
with	O
characteristic	O
craniofacial	O
features	O
with	O
velopharyngeal	B-DISEASE
incompetence	I-DISEASE
,	O
cardiovascular	B-DISEASE
anomalies	I-DISEASE
primarily	O
affecting	O
the	O
outflow	O
tracts	O
,	O
hypoparathyroidism	B-DISEASE
and	O
resultant	O
hypocalcemia	B-DISEASE
,	O
and	O
thymic	B-DISEASE
hypoplasia	I-DISEASE
leading	O
to	O
susceptibility	O
to	O
infection	O
[	O
1	O
]	O
.	O

We	O
acknowledge	O
partial	O
support	O
for	O
U54	O
HG003273	O
(	O
RG	O
)	O
.	O

Mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
were	O
excluded	O
previously	O
.	O

The	O
pedigree	O
structure	O
and	O
information	O
about	O
consanguinity	O
is	O
based	O
on	O
interviews	O
with	O
family	O
members	O
.	O

(	O
d	O
)	O
Conservation	O
analysis	O
showed	O
that	O
Arg44	O
in	O
human	O
MCM2	B-GENE
is	O
conserved	O
across	O
human	O
,	O
bovine	O
,	O
zebra	O
finch	O
,	O
green	O
anole	O
,	O
zebrafish	O
,	O
nile	O
tilapia	O
,	O
acorn	O
worm	O
,	O
sea	O
urchin	O
lineages	O
.	O

Y	O
.	O

M	O
.	O
G	O
.	O

However	O
,	O
we	O
did	O
not	O
detect	O
any	O
mutations	O
,	O
supporting	O
the	O
fact	O
that	O
mutations	O
in	O
WDR11	B-GENE
are	O
rarely	O
involved	O
in	O
congenital	O
HH	B-DISEASE
,	O
at	O
least	O
in	O
the	O
Finnish	O
population	O
.	O

Two	O
Col4a5	B-GENE
truncation	O
mutations	O
have	O
been	O
identified	O
in	O
dogs	O
(	O
Samoyed	O
and	O
Navasota	O
dogs	O
)	O
with	O
clinical	O
features	O
of	O
proteinuria	B-DISEASE
and	O
progressive	O
kidney	O
disease	O
leading	O
to	O
terminal	O
failure	O
[	O
27	O
]	O
.	O

Myosin	B-GENE
VI	I-GENE
is	O
a	O
motor	O
protein	O
that	O
uses	O
energy	O
derived	O
from	O
ATP	O
hydrolysis	O
by	O
actin	O
-	O
activated	O
ATPase	O
[	O
31	O
]	O
,	O
and	O
half	O
of	O
all	O
myosin	B-GENE
VI	I-GENE
mutations	O
have	O
been	O
found	O
in	O
the	O
motor	O
domain	O
[	O
10	O
,	O
12	O
,	O
21	O
,	O
23	O
]	O
.	O

The	O
mtDNA	O
target	O
regions	O
showed	O
substantially	O
higher	O
coverage	O
(	O
10	O
,	O
144X	O
median	O
coverage	O
)	O
.	O

RNA	O
was	O
then	O
isolated	O
from	O
the	O
transfected	O
cells	O
and	O
reverse	O
transcribed	O
into	O
cDNA	O
and	O
sequenced	O
.	O

In	O
humans	O
,	O
myosin	B-GENE
VIIa	I-GENE
is	O
expressed	O
in	O
a	O
variety	O
of	O
cells	O
,	O
including	O
the	O
inner	O
ear	O
hair	O
cells	O
,	O
retinal	O
pigment	O
epithelium	O
,	O
and	O
photoreceptor	O
cells	O
of	O
the	O
retina	O
[	O
20	O
]	O
.	O

Eighty	O
percent	O
of	O
these	O
sequences	O
overlapped	O
the	O
targeted	O
region	O
and	O
52	O
%	O
of	O
data	O
were	O
mapped	O
on	O
target	O
(	O
Fig	O
.	O

Both	O
simple	O
nonsyndromic	O
and	O
complex	O
syndromic	O
forms	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
can	O
be	O
resolved	O
efficiently	O
using	O
WES	O
,	O
especially	O
in	O
small	O
families	O
with	O
distinct	O
and	O
interesting	O
phenotypes	O
that	O
were	O
once	O
too	O
small	O
to	O
map	O
[	O
3	O
]	O
.	O

The	O
English	O
in	O
this	O
document	O
has	O
been	O
checked	O
by	O
at	O
least	O
two	O
professional	O
editors	O
,	O
both	O
native	O
speakers	O
of	O
English	O
.	O

Because	O
a	O
number	O
of	O
pathogenic	O
mutations	O
have	O
been	O
registered	O
as	O
dbSNPs	O
in	O
international	O
biological	O
databases	O
,	O
all	O
previously	O
reported	O
coding	O
SNPs	O
were	O
ruled	O
out	O
by	O
confirming	O
their	O
allele	O
frequency	O
in	O
several	O
populations	O
and	O
non	O
-	O
pathogenic	O
properties	O
in	O
the	O
NCBI	O
database	O
(	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
)	O
and	O
HAPMAP	O
project	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hapmap	O
.	O
org	O
)	O
.	O

The	O
parents	O
elected	O
to	O
continue	O
the	O
pregnancy	O
.	O

27	O
in	O
diagnosing	O
mitochondrial	O
disorders	O
)	O
,	O
it	O
also	O
incurred	O
a	O
great	O
loss	O
in	O
enrichment	O
efficiency	O
.	O

All	O
patients	O
with	O
the	O
5	O
mutations	O
presented	O
dystopia	B-DISEASE
canthorum	I-DISEASE
and	O
different	B-DISEASE
colors	I-DISEASE
of	I-DISEASE
the	I-DISEASE
irises	I-DISEASE
and	O
fundi	O
but	O
none	O
of	O
those	O
showed	O
visible	O
pigmentary	B-DISEASE
changes	I-DISEASE
on	I-DISEASE
their	I-DISEASE
hair	I-DISEASE
and	I-DISEASE
skin	I-DISEASE
,	O
indicating	O
an	O
ethnic	O
specific	O
phenotypes	O
.	O

Minimum	O
coverage	O
obtained	O
with	O
different	O
enrichments	O
methods	O
.	O

This	O
variant	O
with	O
a	O
minor	O
allele	O
frequency	O
of	O
2	O
.	O
98	O
%	O
in	O
public	O
and	O
internal	O
databases	O
was	O
predicted	O
to	O
be	O
benign	O
or	O
likely	O
benign	O
by	O
ClinVar	O
and	O
to	O
be	O
tolerated	O
(	O
score	O
was	O
0	O
.	O
27	O
)	O
by	O
SIFT	O
,	O
while	O
this	O
variant	O
was	O
predicted	O
to	O
be	O
possibly	O
damaging	O
(	O
score	O
was	O
0	O
.	O
880	O
)	O
by	O
PolyPhen	O
-	O
2	O
and	O
to	O
be	O
disease	O
-	O
causing	O
by	O
MutationTaster	O
.	O

JH	O
and	O
SDK	O
validated	O
the	O
primers	O
.	O

The	O
preparation	O
of	O
the	O
pooled	O
libraries	O
for	O
sequencing	O
on	O
the	O
MiSeq	O
platform	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Using	O
more	O
permissive	O
parameters	O
,	O
HotNet	O
identifies	O
two	O
additional	O
subnetworks	O
(	O
See	O
Methods	O
)	O
,	O
including	O
a	O
subnetwork	O
containing	O
MLL	B-GENE
,	O
MLL3	B-GENE
,	O
and	O
SETD1A	B-GENE
(	O
Fig	O
.	O

Untargeted	O
and	O
high	O
GC	O
content	O
sequences	O
are	O
indicated	O
.	O

H	O
u	O
bner	O
(	O
Frankfurt	O
)	O
,	O
A	O
.	O

Five	O
patients	O
were	O
found	O
to	O
carry	O
the	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
,	O
and	O
4	O
patients	O
carried	O
the	O
1095T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
the	O
mtDNA	O
12S	B-GENE
rRNA	I-GENE
gene	O
.	O

In	O
three	O
different	O
families	O
,	O
heterozygous	O
COL11A1	B-GENE
biallelic	O
null	O
,	O
null	O
/	O
missense	O
or	O
silent	O
/	O
missense	O
mutations	O
,	O
were	O
found	O
.	O

Genomic	O
extraction	O
of	O
DNA	O
was	O
performed	O
using	O
the	O
standard	O
salting	O
-	O
out	O
method	O
[	O
8	O
]	O
.	O

For	O
the	O
following	O
25	O
days	O
the	O
child	O
was	O
maintained	O
in	O
nasal	O
Continuous	O
Positive	O
Airway	O
Pressure	O
(	O
CPAP	O
)	O
.	O

Clonal	O
cells	O
were	O
obtained	O
by	O
transfection	O
with	O
Transit	O
-	O
LT	O
Transfection	O
Reagent	O
(	O
Mirus	O
Bio	O
,	O
Madison	O
,	O
WI	O
USA	O
)	O
using	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
and	O
FLAG	O
-	O
tagged	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
plasmid	O
constructs	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

For	O
this	O
reason	O
,	O
the	O
filtering	O
and	O
prioritizing	O
process	O
resulted	O
,	O
in	O
most	O
cases	O
,	O
in	O
several	O
alterations	O
that	O
are	O
predicted	O
by	O
the	O
algorithms	O
(	O
PolyPhen	O
,	O
Mutation	O
Taster	O
)	O
to	O
be	O
deleterious	O
.	O

Future	O
versions	O
of	O
the	O
panel	O
sequencing	O
technology	O
will	O
require	O
exon	O
-	O
specific	O
approaches	O
to	O
fill	O
in	O
the	O
missing	O
exons	O
.	O

K	O
.	O
,	O
Hamamatsu	O
City	O
,	O
Japan	O
)	O
controlled	O
by	O
Power	O
Macintosh	O
G5	O
and	O
IPLab	O
V3	O
.	O
9	O
.	O
5	O
software	O
(	O
BD	O
Biosciences	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
at	O
room	O
temperature	O
.	O

Wang	O
et	O
al	O
(	O
19	O
)	O
indicated	O
that	O
Eya4	B-GENE
regulates	O
Na	O
+	O
/	O
K	O
+	O
-	O
ATPase	O
,	O
which	O
is	O
crucial	O
for	O
the	O
development	O
of	O
mechanosensory	O
cells	O
of	O
the	O
inner	O
ear	O
and	O
the	O
maintenance	O
of	O
cardiac	O
function	O
in	O
zebrafish	O
,	O
which	O
potentially	O
provides	O
a	O
mechanism	O
by	O
which	O
human	O
EYA4	B-GENE
mutations	O
cause	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
heart	B-DISEASE
disease	I-DISEASE
.	O

The	O
pathogenicity	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
T1209A	I-VARIANT
mutation	O
in	O
CDH23	B-GENE
[	O
18	O
,	O
55	O
]	O
is	O
,	O
however	O
,	O
questionable	O
since	O
we	O
found	O
it	O
in	O
five	O
alleles	O
from	O
the	O
control	O
population	O
.	O

Strong	O
power	O
of	O
exome	O
sequencing	O
technology	O
in	O
identifying	O
causative	O
gene	O
has	O
been	O
exemplified	O
for	O
monogenic	O
disease	O
[	O
2	O
]	O
,	O
and	O
gradually	O
for	O
common	O
diseases	O
[	O
10	O
]	O
.	O

However	O
,	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
and	O
the	O
Acadian	O
population	O
of	O
the	O
Southern	O
United	O
States	O
,	O
founder	O
effects	O
for	O
USH1F	B-GENE
and	O
for	O
USH1C	B-GENE
,	O
respectively	O
,	O
lead	O
to	O
locally	O
high	O
incidences	O
of	O
these	O
genetic	O
subtypes	O
[	O
12	O
,	O
13	O
]	O
.	O

Mutations	O
in	O
this	O
gene	O
have	O
been	O
reported	O
to	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1B	I-DISEASE
(	O
USH1B	B-GENE
)	O
and	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
(	O
DFNB2	B-DISEASE
,	O
DFNA11	B-DISEASE
)	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
.	O

The	O
.	O
822G	B-VARIANT
<	I-VARIANT
C	I-VARIANT
allele	O
also	O
results	O
in	O
abnormal	O
splicing	O
of	O
intron	O
7	O
in	O
patient	O
lymphoblastoid	O
cell	O
lines	O
.	O

Although	O
thousands	O
of	O
variants	O
were	O
detected	O
in	O
each	O
proband	O
(	O
both	O
SNPs	O
and	O
indels	O
)	O
,	O
this	O
analysis	O
yielded	O
a	O
small	O
number	O
of	O
variants	O
that	O
may	O
affect	O
protein	O
function	O
.	O

Middle	O
and	O
bottom	O
left	O
:	O
cross	O
-	O
sectional	O
OCT	O
scans	O
.	O

In	O
the	O
Middle	O
East	O
,	O
these	O
include	O
specific	O
mutations	O
in	O
9	O
genes	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Israeli	O
Jewish	O
population	O
[	O
4	O
]	O
and	O
in	O
13	O
genes	O
in	O
the	O
Palestinian	O
Arab	O
population	O
[	O
5	O
-	O
7	O
]	O
.	O

No	O
African	O
American	O
patients	O
were	O
diagnosed	O
with	O
GJB2	B-GENE
-	O
related	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Fig	O
.	O

In	O
the	O
RPE	O
cells	O
,	O
myosin	B-GENE
VIIA	I-GENE
participates	O
in	O
the	O
light	O
cycle	O
-	O
dependent	O
movement	O
of	O
melanosome	O
transportation	O
[	O
19	O
]	O
and	O
the	O
normal	O
functioning	O
of	O
the	O
visual	O
retinoid	O
cycle	O
[	O
20	O
]	O
and	O
is	O
associated	O
with	O
lysosomes	O
[	O
21	O
]	O
.	O

Our	O
study	O
of	O
a	O
cohort	O
of	O
30	O
fetuses	O
with	O
diverse	O
abnormalities	O
has	O
allowed	O
us	O
to	O
estimate	O
the	O
current	O
diagnostic	O
yield	O
of	O
exome	O
sequencing	O
for	O
fetal	B-DISEASE
abnormalities	I-DISEASE
as	O
being	O
broadly	O
equivalent	O
to	O
aCGH	O
,	O
which	O
is	O
~	O
10	O
%	O
(	O
2	O
-	O
4	O
)	O
.	O

Adult	O
mice	O
(	O
C57	O
,	O
2	O
months	O
of	O
age	O
)	O
were	O
used	O
for	O
immunofluorescence	O
studies	O
.	O

In	O
patients	O
with	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
multiple	O
factors	O
have	O
to	O
be	O
considered	O
regarding	O
auditory	O
rehabilitation	O
,	O
including	O
combined	O
mental	O
retardation	O
and	O
developmental	O
delay	O
in	O
addition	O
to	O
various	O
inner	O
ear	O
malformations	O
.	O

Already	O
two	O
presumably	O
pathogenic	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
M1853L	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
T1868del	I-VARIANT
)	O
[	O
42	O
,	O
70	O
]	O
have	O
been	O
found	O
in	O
exon	O
34	O
that	O
is	O
specific	O
for	O
CD1	O
.	O

For	O
F33	O
,	O
a	O
combination	O
of	O
quantitative	O
fluorescent	O
PCR	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
revealed	O
no	O
aneuploidy	O
,	O
or	O
deletions	O
or	O
duplications	O
in	O
the	O
subtelomeric	O
regions	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
mutation	O
has	O
been	O
reported	O
previously	O
in	O
compound	O
heterozygosity	O
with	O
a	O
second	O
MYO7A	B-GENE
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
3750	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
an	O
USH1	B-DISEASE
patient	O
of	O
unknown	O
ethnicity	O
[	O
10	O
]	O
.	O

These	O
data	O
indicate	O
that	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
mutation	O
does	O
not	O
alter	O
subcellular	O
localization	O
of	O
HOMER2	B-GENE
.	O

Next	O
,	O
to	O
find	O
out	O
whether	O
a	O
link	O
could	O
be	O
established	O
between	O
the	O
presence	O
of	O
the	O
RET	B-GENE
risk	O
haplotype	O
and	O
the	O
EDNRB	B-GENE
mutation	O
with	O
regards	O
to	O
the	O
penetrance	O
of	O
the	O
latter	O
,	O
we	O
constructed	O
4	O
markers	O
RET	B-GENE
haplotypes	O
and	O
investigated	O
their	O
transmission	O
within	O
the	O
family	O
(	O
Figure	O
S2	O
)	O
.	O

VA	O
ranged	O
from	O
20	O
/	O
800	O
to	O
20	O
/	O
40	O
.	O

2010	O
;	O
Licastro	O
et	O
al	O
.	O

(	O
B	O
)	O
Audiogram	O
of	O
patient	O
SR	O
-	O
209	O
.	O

This	O
figure	O
is	O
very	O
similar	O
with	O
those	O
reported	O
in	O
previous	O
Korean	O
studies	O
,	O
again	O
supporting	O
a	O
significant	O
contribution	O
of	O
alteration	O
of	O
SLC26A4	B-GENE
to	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
population	O
[	O
44	O
,	O
45	O
]	O
.	O

Our	O
case	O
reports	O
document	O
the	O
range	O
of	O
phenotypic	O
consequences	O
associated	O
with	O
these	O
particular	O
mutations	O
.	O

These	O
mutations	O
have	O
unknown	O
functional	O
consequences	O
without	O
experimental	O
evidence	O
,	O
but	O
most	O
of	O
them	O
are	O
likely	O
to	O
result	O
in	O
milder	O
functional	O
deteriorations	O
than	O
the	O
mutations	O
in	O
group	O
1	O
.	O

A	O
single	O
line	O
between	O
the	O
aligned	O
amino	O
acids	O
indicates	O
that	O
there	O
is	O
no	O
base	O
in	O
the	O
aligned	O
species	O
,	O
and	O
a	O
double	O
line	O
indicates	O
that	O
the	O
aligned	O
species	O
has	O
one	O
or	O
more	O
bases	O
that	O
cannot	O
be	O
aligned	O
in	O
the	O
gap	O
region	O
.	O

A	O
pertinent	O
cautionary	O
aspect	O
in	O
this	O
line	O
of	O
management	O
is	O
the	O
possibility	O
of	O
a	O
"	O
stapes	B-DISEASE
gusher	I-DISEASE
"	O
that	O
is	O
well	O
described	O
in	O
some	O
patients	O
.	O

We	O
also	O
analyzed	O
normal	O
controls	O
and	O
patients	O
with	O
advanced	O
glaucoma	O
to	O
determine	O
whether	O
MME	B-DISEASE
was	O
present	O
.	O

Performed	O
the	O
experiments	O
:	O
EML	O
J	O
.	O

Computer	O
analysis	O
to	O
predict	O
the	O
effect	O
of	O
missense	O
variants	O
on	O
CDH23	B-GENE
protein	O
function	O
was	O
performed	O
with	O
Sorting	O
Intolerant	O
from	O
Tolerant	O
(	O
SIFT	O
;	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
Polymorphism	O
Phenotyping	O
(	O
PolyPhen2	O
;	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

(	O
E	O
)	O
Gln277	O
is	O
predicted	O
to	O
interact	O
with	O
Gly251	O
,	O
which	O
is	O
close	O
proximity	O
to	O
the	O
R5P	O
binding	O
site	O
The	O
p	B-VARIANT
.	I-VARIANT
Gln277Pro	I-VARIANT
change	O
will	O
result	O
in	O
a	O
loss	O
of	O
this	O
hydrogen	O
bonding	O
interaction	O
potentially	O
destabilizing	O
the	O
region	O
surrounding	O
the	O
R5P	O
binding	O
site	O
,	O
thus	O
affecting	O
the	O
PRPS1	B-GENE
catalytic	O
active	O
site	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

R	O
o	O
nnefarth	O
(	O
Jena	O
)	O
,	O
P	O
.	O

3B	O
)	O
.	O

In	O
2010	O
,	O
Israeli	O
residents	O
of	O
YJ	O
descent	O
comprised	O
about	O
2	O
.	O
5	O
%	O
(	O
140	O
,	O
000	O
)	O
of	O
the	O
Israeli	O
Jewish	O
population	O
.	O

ABR	O
and	O
OAE	O
testing	O
at	O
1	O
month	O
of	O
age	O
showed	O
comparable	O
bilateral	O
auditory	B-DISEASE
neuropathy	I-DISEASE
with	O
normal	O
middle	O
ear	O
function	O
.	O

2011	O
;	O
Baux	O
et	O
al	O
.	O

In	O
many	O
families	O
carrying	O
such	O
mutations	O
,	O
some	O
members	O
continue	O
to	O
exhibit	O
pure	O
and	O
isolated	O
MH	B-DISEASE
for	O
the	O
rest	O
of	O
their	O
lives	O
,	O
while	O
others	O
develop	O
proteinuria	B-DISEASE
later	O
on	O
in	O
life	O
,	O
usually	O
with	O
hypertension	B-DISEASE
and	O
a	O
variable	O
gradual	O
progression	O
to	O
CRF	B-DISEASE
,	O
up	O
to	O
ESKD	B-DISEASE
[	O
6	O
]	O
-	O
[	O
8	O
]	O
.	O

We	O
used	O
a	O
Genome	O
-	O
Wide	O
Human	O
SNP	O
Array	O
6	O
.	O
0	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
,	O
which	O
contains	O
328	O
,	O
125	O
SNP	O
markers	O
located	O
on	O
autosomal	O
chromosomes	O
.	O

Patients	O
were	O
grouped	O
according	O
to	O
their	O
genotypes	O
into	O
patients	O
with	O
missense	O
mutations	O
(	O
M	O
)	O
on	O
both	O
alleles	O
(	O
type	O
1	O
,	O
MM	O
)	O
,	O
with	O
premature	O
termination	O
codons	O
(	O
PTCs	O
,	O
P	O
)	O
on	O
both	O
alleles	O
(	O
type	O
3	O
,	O
PP	O
)	O
,	O
or	O
with	O
a	O
combination	O
of	O
a	O
PTC	O
with	O
a	O
missense	O
mutation	O
(	O
type	O
2	O
,	O
MP	O
)	O
.	O

Pure	O
tone	O
audiogram	O
for	O
the	O
left	O
and	O
right	O
ears	O
of	O
the	O
YS	O
-	O
151	O
patient	O
(	O
III	O
-	O
2	O
)	O
(	O
lower	O
panel	O
)	O
.	O

3	O
To	O
date	O
,	O
over	O
160	O
loci	O
have	O
been	O
identified	O
for	O
hereditary	O
HL	B-DISEASE
,	O
including	O
more	O
than	O
90	O
for	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
HL	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
and	O
more	O
than	O
60	O
for	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
.	O

Retinal	O
imaging	O
of	O
both	O
eyes	O
(	O
BE	O
)	O
of	O
the	O
proband	O
IV	O
:	O
3	O
at	O
age	O
35	O
.	O

Although	O
intriguing	O
from	O
a	O
mechanistic	O
perspective	O
,	O
the	O
broader	O
clinical	O
significance	O
of	O
our	O
observations	O
was	O
unclear	O
,	O
given	O
that	O
only	O
seven	O
families	O
had	O
been	O
identified	O
.	O

The	O
microsatellite	O
markers	O
were	O
amplified	O
by	O
the	O
PCR	O
on	O
a	O
Gene	O
AmpPCR	O
system	O
9700	O
(	O
Perkin	O
Elmer	O
,	O
USA	O
)	O
and	O
were	O
analyzed	O
on	O
ABI	O
3730	O
Genetic	O
Analyzer	O
(	O
AppliedBiosystems	O
,	O
USA	O
)	O
.	O

Most	O
were	O
oval	O
shaped	O
(	O
Figures	O
5	O
(	O
d	O
)	O
and	O
5	O
(	O
e	O
)	O
)	O
.	O

Sections	O
were	O
counterstained	O
with	O
haematoxylin	O
.	O

B	O
:	O
Mutant	O
sequence	O
in	O
proband	O
F4	O
III	O
:	O
1	O
.	O

Five	O
patients	O
had	O
maternally	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
the	O
mother	O
also	O
had	O
hearing	B-DISEASE
loss	I-DISEASE
)	O
,	O
but	O
one	O
subject	O
was	O
a	O
sporadic	O
case	O
(	O
the	O
mother	O
did	O
not	O
have	O
hearing	B-DISEASE
loss	I-DISEASE
from	O
the	O
anamnestic	O
evaluation	O
)	O
and	O
therefore	O
is	O
unlikely	O
to	O
be	O
a	O
mitochondrial	O
candidate	O
from	O
clinical	O
evaluation	O
.	O

Reads	O
were	O
aligned	O
to	O
the	O
reference	O
human	O
genome	O
(	O
GRCh37	O
)	O
and	O
pedigree	O
-	O
informed	O
variant	O
calling	O
was	O
performed	O
using	O
the	O
Real	O
Time	O
Genomics	O
(	O
RTG	O
)	O
integrated	O
analysis	O
tool	O
rtg	O
Family	O
v3	O
.	O
2	O
(	O
ref	O
.	O

Among	O
these	O
41	O
patients	O
,	O
deafness	B-DISEASE
(	O
n	O
=	O
35	O
;	O
34	O
.	O
70	O
%	O
)	O
was	O
the	O
most	O
frequent	O
,	O
followed	O
by	O
nephropathy	B-DISEASE
(	O
n	O
=	O
21	O
;	O
20	O
.	O
79	O
%	O
)	O
.	O

In	O
these	O
12	O
patients	O
,	O
a	O
total	O
of	O
14	O
,	O
144	O
genetic	O
variants	O
were	O
automatically	O
detected	O
,	O
including	O
21	O
of	O
the	O
24	O
known	O
mutations	O
(	O
Fig	O
.	O

Three	O
months	O
after	O
initiation	O
of	O
hemodialysis	O
,	O
she	O
noted	O
a	O
painless	O
mass	O
palpable	O
around	O
her	O
finger	O
joints	O
on	O
both	O
hands	O
,	O
without	O
antecedent	O
trauma	O
.	O

The	O
mutation	O
frequency	O
of	O
SLC26A4	B-GENE
is	O
14	O
.	O
57	O
%	O
(	O
22	O
/	O
151	O
)	O
in	O
Han	O
Chinese	O
NSD	B-DISEASE
patients	O
,	O
whilst	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutant	O
alleles	O
account	O
for	O
83	O
.	O
33	O
%	O
(	O
25	O
/	O
30	O
)	O
among	O
SLC26A4	B-GENE
mutation	O
.	O

Among	O
our	O
three	O
patients	O
with	O
p	B-VARIANT
.	I-VARIANT
L46F	I-VARIANT
,	O
this	O
variant	O
was	O
the	O
only	O
variant	O
in	O
one	O
patient	O
.	O

Nonsynonymous	O
variants	O
were	O
evaluated	O
by	O
three	O
algorithms	O
,	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
PolyPhen	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
and	O
PANTHER	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
pantherdb	O
.	O
org	O
/	O
tools	O
/	O
csnpScoreForm	O
.	O
jsp	O
)	O
,	O
to	O
determine	O
pathogenicity	O
.	O

The	O
condition	O
may	O
appear	O
as	O
an	O
isolated	O
feature	O
or	O
as	O
part	O
of	O
a	O
syndrome	O
in	O
association	O
with	O
extra	O
-	O
renal	O
manifestations	O
6	O
,	O
7	O
.	O

Follow	O
-	O
up	O
studies	O
revealed	O
progression	O
of	O
atrophic	B-DISEASE
changes	I-DISEASE
.	O

Thirty	O
of	O
the	O
individuals	O
were	O
of	O
Spanish	O
origin	O
;	O
21	O
of	O
them	O
were	O
clinically	O
USH1	B-DISEASE
,	O
but	O
we	O
could	O
not	O
obtain	O
sufficient	O
clinical	O
data	O
to	O
classify	O
the	O
remaining	O
nine	O
individuals	O
.	O

Brain	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
of	O
the	O
two	O
affected	O
siblings	O
.	O

Peripheral	O
blood	O
samples	O
which	O
were	O
collected	O
in	O
EDTA	O
tubes	O
and	O
stored	O
fresh	O
(	O
-	O
20	O
deg	O
C	O
)	O
were	O
obtained	O
from	O
participating	O
members	O
of	O
the	O
family	O
and	O
50	O
unrelated	O
healthy	O
volunteers	O
.	O

Recently	O
,	O
a	O
positron	O
emission	O
tomography	O
scan	O
using	O
Fluorine	O
-	O
18	O
L	O
-	O
3	O
,	O
4	O
-	O
dihydroxyphenylalanine	O
(	O
18	O
-	O
fluoro	O
DOPA	O
-	O
TC	O
-	O
PET	O
-	O
scan	O
)	O
has	O
been	O
used	O
to	O
distinguish	O
focal	O
from	O
diffuse	O
forms	O
.	O

B	O
.	O

We	O
found	O
that	O
the	O
patient	O
'	O
s	O
platelet	O
volume	O
was	O
low	O
,	O
but	O
she	O
did	O
not	O
have	O
thrombocytopenia	B-DISEASE
.	O

To	O
date	O
,	O
13	O
different	O
genes	O
have	O
been	O
associated	O
with	O
LQTS	B-DISEASE
,	O
all	O
encoding	O
subunits	O
of	O
cardiac	O
ion	O
-	O
channels	O
(	O
K	O
+	O
,	O
Na	O
+	O
or	O
Ca	O
2	O
+	O
)	O
or	O
ion	O
-	O
channel	O
regulatory	O
proteins	O
[	O
11	O
]	O
.	O

Direct	O
bidirectional	O
Sanger	O
sequencing	O
of	O
CACNA1D	B-GENE
from	O
genomic	O
DNA	O
in	O
tumor	O
-	O
blood	O
pairs	O
was	O
performed	O
following	O
PCR	O
amplification	O
using	O
specific	O
primers	O
.	O

While	O
other	O
USH1C	B-GENE
mutations	O
usually	O
cause	O
Usher	B-DISEASE
type	I-DISEASE
I	I-DISEASE
(	O
including	O
RP	B-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
and	O
congenital	O
deafness	B-DISEASE
)	O
,	O
audiometric	O
screening	O
of	O
10	O
patients	O
who	O
are	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
revealed	O
that	O
patients	O
under	O
40	O
years	O
of	O
age	O
had	O
normal	O
hearing	O
while	O
older	O
patients	O
showed	O
mild	O
to	O
severe	O
high	O
tone	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
is	O
the	O
most	O
severe	O
subtype	O
due	O
to	O
its	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
lack	B-DISEASE
of	I-DISEASE
vestibular	I-DISEASE
responses	I-DISEASE
,	O
and	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
that	O
appears	O
in	O
prepuberty	O
.	O

MJBA	O
and	O
LLL	O
performed	O
the	O
clinical	O
analysis	O
.	O

In	O
the	O
GRHL2	B-GENE
gene	O
,	O
a	O
total	O
of	O
4	O
substitutions	O
(	O
c	B-VARIANT
.	I-VARIANT
1152G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1243G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1572A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
1722C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
were	O
identified	O
(	O
Table	O
4	O
)	O
.	O

(	O
b	O
)	O
The	O
amplitude	O
reduction	O
is	O
significant	O
(	O
student	O
t	O
-	O
test	O
)	O
,	O
with	O
a	O
p	O
-	O
value	O
of	O
0	O
.	O
02	O
for	O
5	O
second	O
pulses	O
,	O
and	O
p	O
=	O
0	O
.	O
00005	O
for	O
300ms	O
pulses	O
.	O

The	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
sequence	O
,	O
hg19	O
,	O
using	O
Novoalign	O
(	O
v2	O
.	O
08	O
.	O
01	O
)	O
.	O

Recessive	O
mutations	O
in	O
TMC1	B-GENE
were	O
detected	O
in	O
more	O
than	O
a	O
third	O
(	O
38	O
%	O
)	O
of	O
hearing	O
impaired	O
Jews	O
of	O
Moroccan	O
origin	O
.	O

32	O
For	O
L688F	B-VARIANT
that	O
occurred	O
in	O
one	O
ovarian	B-DISEASE
cancer	I-DISEASE
case	O
and	O
was	O
not	O
observed	O
in	O
the	O
WHISP	O
dataset	O
no	O
other	O
truncation	O
mutations	O
were	O
observed	O
.	O

Due	O
to	O
financial	O
constraints	O
and	O
the	O
possibility	O
of	O
unwarranted	O
side	O
effects	O
,	O
their	O
parents	O
refused	O
installation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
(	O
ICD	O
)	O
.	O

In	O
30	O
NSHL	B-DISEASE
individuals	O
without	O
deletion	O
,	O
we	O
detected	O
one	O
with	O
compound	O
heterozygous	O
and	O
two	O
with	O
heterozygous	O
pathogenic	O
mutations	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

For	O
this	O
analysis	O
,	O
we	O
also	O
used	O
as	O
reference	O
a	O
pool	O
of	O
RNAs	O
.	O

SNPs	O
linked	O
to	O
CIB2	B-GENE
were	O
genotyped	O
in	O
unrelated	O
affected	O
individuals	O
homozygous	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
272T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
297C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutations	O
and	O
the	O
flanking	O
haplotypes	O
were	O
consistent	O
with	O
a	O
founder	O
effect	O
for	O
both	O
alleles	O
(	O
Supplementary	O
Tables	O
3	O
and	O
4	O
)	O
.	O

(	O
Occupational	O
Therapy	O
)	O
Alex	O
R	O
.	O

Few	O
ABCA4	B-GENE
mutations	O
were	O
observed	O
in	O
our	O
French	O
Canadian	O
patients	O
.	O

2	O
,	O
again	O
indicating	O
that	O
filtering	O
the	O
strand	O
-	O
specific	O
sequence	O
variations	O
is	O
unlikely	O
to	O
eliminate	O
real	O
genetic	O
variations	O
.	O

The	O
prevalence	O
increases	O
to	O
about	O
0	O
.	O
2	O
%	O
before	O
the	O
age	O
of	O
5	O
years	O
when	O
languages	O
have	O
been	O
acquired	O
.	O

The	O
stop	O
codon	O
in	O
exon	O
4	O
(	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
[	O
C154X	B-VARIANT
]	O
)	O
identified	O
in	O
this	O
study	O
is	O
close	O
to	O
the	O
reported	O
mutation	O
c	O
.	O
448C	O
>	O
T	O
(	O
R150X	O
)	O
[	O
9	O
]	O
.	O

Among	O
the	O
33	O
patients	O
clinically	O
classified	O
as	O
USH2	B-DISEASE
,	O
22	O
(	O
66	O
.	O
6	O
%	O
)	O
carried	O
two	O
USH2A	B-GENE
variants	O
,	O
two	O
(	O
6	O
.	O
1	O
%	O
)	O
carried	O
two	O
MYO7A	B-GENE
variants	O
,	O
one	O
(	O
3	O
%	O
)	O
carried	O
a	O
single	O
MYO7A	B-GENE
variant	O
,	O
two	O
(	O
6	O
.	O
1	O
%	O
)	O
carried	O
a	O
single	O
USH2A	B-GENE
variant	O
,	O
one	O
(	O
3	O
%	O
)	O
carried	O
a	O
MYO7A	B-GENE
variant	O
on	O
one	O
allele	O
and	O
an	O
USH2A	B-GENE
variant	O
on	O
the	O
other	O
allele	O
while	O
in	O
the	O
remaining	O
five	O
patients	O
no	O
MYO7A	B-GENE
or	O
USH2A	B-GENE
variant	O
was	O
detected	O
.	O

In	O
both	O
patients	O
wave	O
V	O
was	O
recorded	O
with	O
increasing	O
latency	O
from	O
apical	O
to	O
basal	O
electrodes	O
(	O
vertical	O
dashed	O
lines	O
,	O
middle	O
)	O
.	O

The	O
Cq	O
value	O
was	O
determined	O
and	O
the	O
size	O
of	O
the	O
amplified	O
products	O
was	O
verified	O
on	O
a	O
MultiNA	O
(	O
Shimadzu	O
Biotech	O
)	O
.	O

For	O
this	O
reason	O
,	O
this	O
change	O
has	O
been	O
classified	O
as	O
UV3	O
.	O

Excess	O
primers	O
and	O
dNTPs	O
were	O
removed	O
using	O
exonuclease	O
I	O
and	O
shrimp	O
alkaline	O
phosphatase	O
,	O
and	O
PCR	O
products	O
were	O
sequenced	O
with	O
the	O
BigDye	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Both	O
Iranian	O
families	O
were	O
seen	O
by	O
a	O
geneticist	O
and	O
filled	O
in	O
a	O
general	O
clinical	O
questionnaire	O
.	O

(	O
n	O
=	O
6	O
)	O
.	O

This	O
region	O
was	O
relatively	O
small	O
(	O
about	O
1	O
Mb	O
)	O
including	O
9	O
genes	O
,	O
one	O
of	O
which	O
is	O
USH1C	B-GENE
.	O

In	O
the	O
present	O
study	O
we	O
selected	O
Japanese	O
subjects	O
that	O
had	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
without	O
GJB2	B-GENE
mutations	O
,	O
mitochondrial	O
mutations	O
,	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
or	O
auditory	B-DISEASE
neuropathy	I-DISEASE
-	O
associated	O
OTOF	B-GENE
mutations	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
spectrum	O
of	O
rare	O
deafness	B-DISEASE
genes	O
in	O
these	O
patients	O
.	O

We	O
recorded	O
from	O
posterior	O
neuromasts	O
that	O
had	O
healthy	O
looking	O
hair	O
cells	O
.	O

It	O
is	O
also	O
possible	O
that	O
Ile386	O
appears	O
as	O
a	O
potential	O
"	O
mutation	O
hotspot	O
"	O
due	O
to	O
a	O
string	O
of	O
seven	O
cytosine	O
residues	O
at	O
the	O
surrounding	O
positions	O
,	O
suggesting	O
a	O
DNA	O
polymerase	O
slippage	O
during	O
replication	O
.	O

It	O
was	O
important	O
to	O
fully	O
sequence	O
such	O
genes	O
,	O
rather	O
than	O
only	O
screening	O
known	O
mutations	O
,	O
because	O
both	O
old	O
and	O
new	O
alleles	O
are	O
likely	O
to	O
appear	O
[	O
4	O
]	O
.	O

Key	O
to	O
success	O
of	O
our	O
approach	O
was	O
the	O
availability	O
of	O
cellular	O
models	O
of	O
disease	O
,	O
with	O
which	O
we	O
could	O
establish	O
pathogenicity	O
of	O
novel	O
mutations	O
in	O
single	O
patients	O
.	O

A	O
signed	O
informed	O
consent	O
form	O
was	O
obtained	O
from	O
each	O
participant	O
or	O
in	O
the	O
case	O
of	O
a	O
minor	O
,	O
from	O
parents	O
.	O

The	O
EYA4	B-GENE
gene	O
was	O
located	O
between	O
the	O
D6S262	O
and	O
D6S1038	O
microsatellite	O
markers	O
.	O

Nine	O
of	O
11	O
patients	O
carrying	O
OPA1	B-GENE
mutations	O
inducing	O
haploinsufficiency	B-DISEASE
had	O
normal	O
hearing	O
function	O
.	O

Similar	O
studies	O
of	O
GJB6	B-GENE
mutations	O
in	O
Taiwanese	O
prelingual	O
NSHI	B-DISEASE
patients	O
carrying	O
one	O
GJB2	B-GENE
mutant	O
allele	O
also	O
did	O
not	O
detect	O
any	O
deleterious	O
mutations	O
in	O
GJB6	B-GENE
,	O
consistent	O
with	O
our	O
results	O
[	O
30	O
]	O
.	O

We	O
sequenced	O
the	O
exomes	O
of	O
both	O
unaffected	O
parents	O
and	O
two	O
affected	O
siblings	O
.	O

Huaxia	O
school	O
is	O
the	O
only	O
secondary	O
special	O
education	O
school	O
for	O
the	O
disabled	O
in	O
Yunnan	O
,	O
whose	O
students	O
come	O
from	O
all	O
over	O
the	O
province	O
.	O

Inherited	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
Middle	O
Eastern	O
populations	O
is	O
highly	O
heterogeneous	O
,	O
both	O
in	O
the	O
number	O
of	O
genes	O
involved	O
and	O
in	O
the	O
number	O
of	O
alleles	O
at	O
each	O
gene	O
.	O

Analysis	O
of	O
WES	O
data	O
in	O
this	O
family	O
showed	O
that	O
the	O
truncating	O
compound	O
heterozygous	O
variant	O
in	O
COL4A3	B-GENE
is	O
the	O
only	O
variant	O
segregating	O
with	O
disease	O
in	O
this	O
family	O
.	O

Among	O
the	O
typical	O
RP	B-DISEASE
families	O
,	O
USH2A	B-GENE
was	O
the	O
most	O
frequently	O
mutated	O
gene	O
,	O
with	O
23	O
out	O
of	O
372	O
alleles	O
.	O

Direct	O
automated	O
sequencing	O
of	O
WFS1	B-GENE
was	O
performed	O
with	O
the	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
,	O
adding	O
about	O
15	O
ng	O
of	O
template	O
DNA	O
in	O
each	O
reaction	O
and	O
using	O
a	O
temperature	O
program	O
that	O
included	O
25	O
cycles	O
of	O
denaturation	O
at	O
97	O
deg	O
C	O
for	O
30	O
s	O
,	O
annealing	O
at	O
50	O
deg	O
C	O
for	O
15	O
s	O
,	O
and	O
extension	O
at	O
60	O
deg	O
C	O
for	O
4	O
min	O
.	O

(	O
b	O
)	O
Audiogenic	B-DISEASE
seizure	I-DISEASE
susceptibility	O
of	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
(	O
green	O
symbol	O
,	O
n	O
=	O
10	O
)	O
,	O
tg	O
+	O
A	O
/	O
A	O
(	O
blue	O
,	O
n	O
=	O
)	O
and	O
tg	O
-	O
A	O
/	O
A	O
(	O
red	O
,	O
n	O
=	O
16	O
)	O
was	O
assessed	O
at	O
3	O
weeks	O
of	O
age	O
using	O
white	O
noise	O
stimuli	O
(	O
90	O
,	O
100	O
and	O
110	O
dBSPL	O
;	O
dotted	O
lines	O
)	O
.	O

Results	O
of	O
renal	O
manifestations	O
were	O
evaluated	O
in	O
4	O
of	O
10	O
patients	O
.	O

CIB2	B-GENE
(	O
green	O
)	O
in	O
vestibular	O
hair	O
cell	O
stereocilia	O
cluster	O
in	O
patches	O
around	O
the	O
actin	O
core	O
(	O
red	O
)	O
.	O

It	O
is	O
also	O
possible	O
that	O
the	O
increased	O
amounts	O
of	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
protein	O
at	O
the	O
plasma	O
membrane	O
could	O
exert	O
a	O
"	O
toxic	O
"	O
effect	O
in	O
cells	O
in	O
the	O
inner	O
ear	O
.	O

The	O
quality	O
of	O
the	O
models	O
was	O
evaluated	O
using	O
the	O
Verify_3D	O
Structure	O
Evaluation	O
Server	O
[	O
25	O
,	O
26	O
]	O
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
conservation	O
analysis	O
shows	O
that	O
p	B-VARIANT
.	I-VARIANT
V1773M	I-VARIANT
(	O
red	O
arrow	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
T1796S	I-VARIANT
(	O
red	O
arrow	O
)	O
heterozygous	O
missense	O
mutation	O
in	O
TNC	B-GENE
is	O
at	O
a	O
highly	O
conserved	O
position	O
by	O
comparison	O
to	O
the	O
corresponding	O
sequence	O
of	O
human	O
,	O
macaque	O
,	O
chimpanzee	O
,	O
elephant	O
,	O
pig	O
,	O
platypus	O
and	O
zebrafish	O
.	O

The	O
15	O
-	O
year	O
-	O
old	O
Chinese	O
female	O
patient	O
with	O
R75W	B-VARIANT
mutation	O
developed	O
thickening	O
and	O
peeling	O
of	O
the	O
skin	O
at	O
medial	O
and	O
lateral	O
sides	O
of	O
both	O
hands	O
and	O
feet	O
at	O
1	O
year	O
of	O
age	O
.	O

He	O
first	O
presented	O
with	O
myoclonic	O
movements	O
of	O
the	O
right	O
arm	O
at	O
three	O
months	O
of	O
age	O
,	O
accompanied	O
by	O
lethargy	O
and	O
decreased	O
feedings	O
,	O
which	O
necessitated	O
the	O
placement	O
of	O
a	O
gastrostomy	O
tube	O
.	O

The	O
SIFT	O
program	O
predicted	O
that	O
the	O
missense	O
variant	O
p	B-VARIANT
.	I-VARIANT
Thr153Ala	I-VARIANT
in	O
RPE65	B-GENE
would	O
be	O
tolerated	O
(	O
SIFT	O
score	O
>	O
0	O
.	O
05	O
)	O
.	O

*	O
Different	O
from	O
mammals	O
having	O
multiple	O
ferlin	O
genes	O
,	O
drosophila	O
only	O
has	O
one	O
ferlin	O
gene	O
called	O
misfire	O
,	O
which	O
is	O
also	O
its	O
protein	O
name	O
[	O
28	O
]	O
OTOF	B-GENE
sequence	O
analysis	O
of	O
a	O
TS	B-DISEASE
-	I-DISEASE
NSRAN	I-DISEASE
family	O
at	O
mutation	O
sites	O
.	O

In	O
2	O
out	O
of	O
89	O
EVA	B-DISEASE
/	O
PDS	B-DISEASE
patients	O
who	O
were	O
heterozygous	O
for	O
a	O
single	O
pathogenic	O
SLC26A4	B-GENE
mutation	O
,	O
Yang	O
et	O
al	O
.	O

Figure	O
3	O
Molecular	O
investigations	O
and	O
MRI	O
neuroimaging	O
of	O
a	O
58	O
-	O
year	O
-	O
old	O
female	O
presenting	O
with	O
a	O
multiple	B-DISEASE
sclerosis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
and	O
harbouring	O
a	O
c	B-VARIANT
.	I-VARIANT
2613	I-VARIANT
+	I-VARIANT
1g	I-VARIANT
>	I-VARIANT
a	I-VARIANT
splice	O
-	O
site	O
mutation	O
within	O
intron	O
25	O
of	O
the	O
OPA1	B-GENE
gene	O
(	O
UK	O
-	O
6	O
)	O
.	O

In	O
total	O
,	O
126	O
patients	O
(	O
18	O
.	O
0	O
%	O
,	O
126	O
/	O
701	O
)	O
carried	O
a	O
homozygous	O
or	O
compound	O
heterozygous	O
GJB2	B-GENE
pathogenic	O
mutation	O
(	O
Table	O
1	O
)	O
.	O

Using	O
this	O
strategy	O
,	O
combination	O
the	O
mapped	O
interval	O
by	O
classical	O
linkage	O
analysis	O
with	O
results	O
of	O
exome	O
sequencing	O
,	O
only	O
one	O
causative	O
mutation	O
were	O
confirmed	O
.	O

These	O
findings	O
confirm	O
the	O
importance	O
of	O
including	O
at	O
least	O
GPR98	B-GENE
analysis	O
for	O
comprehensive	O
USH2	B-DISEASE
molecular	O
diagnosis	O
.	O

The	O
cells	O
expressing	O
variant	O
MCM2	B-GENE
displayed	O
an	O
increase	O
in	O
apoptosis	O
without	O
statistical	O
significant	O
changes	O
in	O
proliferation	O
or	O
cell	O
cycle	O
assay	O
.	O

-	O
Pfeiffer	B-DISEASE
Patients	O
The	O
patients	O
of	O
this	O
study	O
were	O
diagnosed	O
and	O
treated	O
for	O
craniosynostosis	B-DISEASE
in	O
the	O
Hospital	O
of	O
the	O
Clinics	O
at	O
the	O
State	O
University	O
of	O
Minas	O
Gerais	O
.	O

Wrote	O
the	O
paper	O
:	O
JG	O
QW	O
.	O

Pai	O
and	O
Rawles	O
suggested	O
a	O
link	O
between	O
AF	B-DISEASE
and	O
prolongation	O
of	O
the	O
mean	O
QT	O
interval	O
[	O
32	O
]	O
.	O

All	O
novel	O
variants	O
were	O
assessed	O
based	O
on	O
a	O
classification	O
system	O
for	O
variants	O
of	O
uncertain	O
clinical	O
significance	O
described	O
by	O
David	O
Baux	O
et	O
al	O
.	O

The	O
valine	O
is	O
in	O
the	O
interface	O
and	O
is	O
buried	O
from	O
the	O
solvent	O
(	O
exposed	O
surface	O
area	O
of	O
1	O
A	O
2	O
)	O
.	O

Marshall	B-DISEASE
syndrome	I-DISEASE
is	O
a	O
differential	O
diagnosis	O
to	O
type	B-DISEASE
2	I-DISEASE
Stickler	I-DISEASE
syndrome	I-DISEASE
,	O
it	O
results	O
mainly	O
from	O
exon	O
skipping	O
mutations	O
of	O
COL11A1	B-GENE
and	O
differs	O
in	O
the	O
severity	O
of	O
facial	O
features	O
that	O
may	O
be	O
present	O
.	O

The	O
coding	O
region	O
of	O
pendrin	O
cDNA	O
was	O
amplified	O
by	O
PCR	O
from	O
the	O
cDNA	O
library	O
of	O
human	O
thyroid	O
tissue	O
and	O
subcloned	O
into	O
the	O
pEGFP	O
-	O
N1	O
vector	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
using	O
the	O
Xho	O
I	O
and	O
Kpn	O
I	O
restriction	O
sites	O
.	O

[	O
14	O
]	O
In	O
the	O
remaining	O
55	O
index	O
patients	O
,	O
DNA	O
sequencing	O
revealed	O
a	O
total	O
of	O
24	O
sequence	O
variations	O
in	O
46	O
families	O
including	O
15	O
novel	O
mutations	O
.	O

2	O
)	O
,	O
and	O
protein	O
expression	O
levels	O
were	O
normalized	O
by	O
the	O
expression	O
level	O
of	O
the	O
bait	O
in	O
each	O
purification	O
(	O
Supplementary	O
Table	O
6	O
)	O
.	O

Two	O
homozygous	O
missense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
P2762A	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
G3320C	I-VARIANT
)	O
were	O
found	O
in	O
one	O
individual	O
family	O
suggesting	O
a	O
potential	O
double	O
hit	O
effect	O
.	O

This	O
information	O
can	O
be	O
important	O
in	O
developing	O
screening	O
strategies	O
.	O

The	O
frequencies	O
of	O
the	O
three	O
most	O
common	O
GJB2	B-GENE
mutations	O
in	O
the	O
23	O
regions	O
studied	O
are	O
listed	O
in	O
Table	O
2	O
.	O

Similar	O
presentation	O
with	O
early	O
onset	O
of	O
non	O
-	O
gap	O
metabolic	B-DISEASE
acidosis	I-DISEASE
,	O
hypokalemia	B-DISEASE
and	O
nephrocalcinosis	B-DISEASE
was	O
observed	O
in	O
almost	O
all	O
patients	O
despite	O
carrying	O
different	O
mutations	O
.	O

Mutational	O
screening	O
of	O
all	O
coding	O
and	O
flanking	O
intron	O
sequences	O
of	O
the	O
OPA1	B-GENE
gene	O
was	O
performed	O
by	O
DNA	O
sequencing	O
.	O

In	O
addition	O
two	O
patients	O
(	O
RP	O
-	O
1847	O
and	O
RP	O
-	O
1923	O
)	O
were	O
carriers	O
of	O
three	O
mutations	O
in	O
USH	B-DISEASE
genes	O
(	O
Table	O
3	O
)	O
.	O

This	O
SNP	O
is	O
in	O
exon	O
25	O
of	O
USH2A	B-GENE
(	O
NM_206933	O
)	O
.	O

Medical	O
histories	O
of	O
the	O
members	O
of	O
family	O
1953	O
were	O
obtained	O
using	O
a	O
questionnaire	O
regarding	O
the	O
following	O
aspects	O
of	O
this	O
condition	O
:	O
subjective	O
degree	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
age	O
at	O
onset	O
,	O
progression	O
,	O
symmetry	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
use	O
of	O
hearing	O
aids	O
,	O
presence	O
of	O
tinnitus	O
,	O
medication	O
,	O
noise	O
exposure	O
,	O
pathological	O
changes	O
in	O
the	O
ear	O
,	O
and	O
other	O
relevant	O
clinical	O
manifestations	O
.	O

,	O
2005	O
)	O
;	O
FI	O
-	O
1	O
:	O
(	O
Puomila	O
et	O
al	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
presented	O
a	O
Chinese	O
pedigree	O
with	O
a	O
novel	O
missense	O
EYA4	B-GENE
mutation	O
,	O
shedding	O
new	O
light	O
on	O
the	O
pathogenic	O
mechanism	O
of	O
EYA4	B-GENE
mutations	O
.	O

coli	O
(	O
lower	O
)	O
.	O

For	O
convenience	O
,	O
we	O
use	O
the	O
names	O
of	O
the	O
groups	O
(	O
European	O
,	O
African	O
,	O
etc	O
.	O
)	O
to	O
denote	O
ancestral	O
genetic	O
background	O
rather	O
than	O
geographic	O
region	O
of	O
birth	O
or	O
ethnicity	O
.	O

In	O
addition	O
,	O
subject	O
II	O
-	O
2	O
had	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
and	O
subject	O
III	O
-	O
5	O
had	O
Graves	B-DISEASE
'	I-DISEASE
disease	I-DISEASE
.	O

All	O
of	O
the	O
above	O
11	O
patients	O
had	O
a	O
clear	O
history	O
of	O
aminoglycoside	O
use	O
.	O

DNA	O
sequencing	O
revealed	O
a	O
insertion	O
of	O
the	O
GTGC	O
nucleotide	O
at	O
position	O
255_256	O
,	O
which	O
results	O
in	O
a	O
frameshift	O
beginning	O
at	O
codon	O
86	O
and	O
leading	O
to	O
a	O
premature	O
stop	O
signal	O
at	O
codon	O
304	O
(	O
p	B-VARIANT
.	I-VARIANT
Arg86ValfsX219	I-VARIANT
)	O
.	O

Both	O
the	O
c	B-VARIANT
.	I-VARIANT
215C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro72Arg	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
139C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro47Ser	I-VARIANT
)	O
SNPs	O
have	O
functional	O
effects	O
at	O
the	O
molecular	O
level	O
,	O
but	O
their	O
clinical	O
association	O
with	O
cancer	B-DISEASE
susceptibility	O
is	O
unclear	O
[	O
57	O
]	O
.	O

Somatic	O
truncation	O
mutations	O
were	O
also	O
observed	O
in	O
histone	O
modifier	O
genes	O
including	O
:	O
ARID1A	B-GENE
,	O
ARID1B	B-GENE
,	O
ARID2	B-GENE
,	O
SETD2	B-GENE
,	O
SETD4	B-GENE
,	O
SETD6	B-GENE
,	O
JARID1C	B-GENE
,	O
MLL	B-GENE
,	O
MLL2	B-GENE
,	O
and	O
MLL3	B-GENE
as	O
well	O
as	O
the	O
DNA	O
excision	O
repair	O
gene	O
ERCC6	B-GENE
(	O
Supplementary	O
Data	O
3	O
)	O
.	O

In	O
p	B-VARIANT
.	I-VARIANT
G243R	I-VARIANT
,	O
the	O
uncharged	O
glycine	O
is	O
substituted	O
by	O
a	O
large	O
polar	O
residue	O
,	O
arginine	O
,	O
which	O
may	O
affect	O
protein	O
-	O
folding	O
and	O
,	O
therefore	O
,	O
TMPRSS3	B-GENE
function	O
.	O

At	O
the	O
current	O
moment	O
it	O
is	O
not	O
clear	O
whether	O
the	O
monoallelic	O
variants	O
can	O
explain	O
the	O
milder	O
phenotypes	O
alone	O
or	O
whether	O
the	O
second	O
hits	O
were	O
simply	O
missed	O
due	O
to	O
technological	O
limitations	O
.	O

A	O
:	O
The	O
appearance	O
of	O
the	O
fundus	O
in	O
one	O
patient	O
(	O
II	O
:	O
4	O
)	O
with	O
RP	B-DISEASE
at	O
54	O
year	O
old	O
shows	O
typical	O
retinal	O
degeneration	O
with	O
obvious	O
waxy	O
pallor	O
of	O
the	O
optic	O
discs	O
,	O
attenuation	O
of	O
the	O
retinal	O
vessels	O
,	O
irregular	O
pigment	O
clumps	O
in	O
the	O
retina	O
.	O

[	O
11	O
]	O
showed	O
that	O
mutations	O
in	O
FGFR1	B-GENE
and	O
FGF8	B-GENE
synergized	O
to	O
cause	O
severe	O
congenital	O
HH	B-DISEASE
in	O
a	O
male	O
patient	O
.	O

A	O
study	O
of	O
the	O
patient	O
'	O
s	O
family	O
members	O
was	O
not	O
possible	O
,	O
except	O
for	O
her	O
mother	O
,	O
who	O
exhibited	O
no	O
specific	O
features	O
of	O
HDR	B-DISEASE
syndrome	I-DISEASE
.	O

The	O
fact	O
that	O
we	O
did	O
not	O
identify	O
mutations	O
in	O
SOX17	B-GENE
,	O
UMOD	B-GENE
,	O
BMP4	B-GENE
,	O
SIX1	B-GENE
,	O
and	O
UPK3A	B-GENE
suggests	O
that	O
mutations	O
in	O
those	O
genes	O
are	O
rarer	O
.	O

Another	O
proband	O
(	O
TCS	B-DISEASE
12	O
)	O
was	O
heterozygous	O
for	O
the	O
de	O
novo	O
c	B-VARIANT
.	I-VARIANT
3700_3704delACTCT	I-VARIANT
mutation	O
in	O
exon	O
22	O
(	O
Figure	O
1H	O
)	O
.	O

Davis	O
Windus	O
for	O
many	O
helpful	O
suggestions	O
.	O

alpha	O
-	O
Tectorin	O
is	O
a	O
large	O
modular	O
glycoprotein	O
that	O
contains	O
several	O
protein	O
-	O
protein	O
interaction	O
domains	O
:	O
the	O
entactin	O
domain	O
(	O
ENT	O
)	O
,	O
the	O
large	O
zonadhesin	O
region	O
(	O
ZA	O
)	O
containing	O
three	O
full	O
and	O
two	O
partial	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
type	O
D	O
repeats	O
,	O
an	O
N	O
-	O
terminal	O
entactin	O
G1	O
-	O
like	O
domain	O
,	O
a	O
C	O
-	O
terminal	O
zona	O
pellucida	O
(	O
ZP	O
)	O
domain	O
,	O
and	O
three	O
trypsin	O
inhibitor	O
-	O
like	O
cysteine	O
-	O
rich	O
domains	O
[	O
19	O
]	O
-	O
[	O
21	O
]	O
.	O

Fifteen	O
subjects	O
had	O
Pendred	B-DISEASE
syndrome	I-DISEASE
and	O
64	O
had	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Primer	O
sequences	O
are	O
listed	O
in	O
Supplementary	O
Table	O
6	O
.	O

Functional	O
comparison	O
of	O
mutations	O
identified	O
in	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
and	O
other	O
actinopathies	O
should	O
help	O
elucidate	O
both	O
the	O
distinct	O
and	O
overlapping	O
functions	O
of	O
cytoplasmic	O
beta	O
-	O
and	O
gamma	O
-	O
actin	O
isoforms	O
.	O

Arg4192His	I-VARIANT
in	O
USH2A	B-GENE
[	O
14	O
]	O
(	O
detected	O
by	O
sequence	O
analysis	O
in	O
RP	O
-	O
0561	O
,	O
RP	O
-	O
0260	O
,	O
and	O
RP	O
-	O
0653	O
,	O
respectively	O
)	O
.	O

It	O
was	O
shown	O
previously	O
that	O
transfected	O
alpha	O
chains	O
can	O
be	O
secreted	O
either	O
as	O
part	O
of	O
triple	O
helical	O
molecules	O
or	O
as	O
single	O
monomeric	O
chains	O
.	O

a	O
e	O
OPA1	B-GENE
online	O
database	O
(	O
http	O
:	O
/	O
/	O
lbbma	O
.	O
univ	O
-	O
angers	O
.	O
fr	O
/	O
lbbma	O
.	O
php	O
?	O
id	O
=	O
9	O
)	O
.	O

The	O
sensory	O
epithelia	O
were	O
dissected	O
in	O
PBS	O
.	O

Genomic	O
DNA	O
was	O
subjected	O
to	O
a	O
custom	O
-	O
designed	O
SureSelect	O
Target	O
Enrichment	O
System	O
to	O
capture	O
coding	O
exons	O
and	O
proximal	O
flanking	O
intronic	O
sequences	O
of	O
84	O
genes	O
responsible	O
for	O
nonsyndromic	O
or	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
DNA	O
was	O
sequenced	O
by	O
Illumina	O
GAIIx	O
(	O
paired	O
-	O
end	O
read	O
)	O
.	O

The	O
present	O
large	O
cohort	O
study	O
revealed	O
a	O
high	O
prevalence	O
(	O
82	O
%	O
82	O
/	O
100	O
)	O
of	O
SLC26A4	B-GENE
mutations	O
in	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
with	O
EVA	B-DISEASE
in	O
Japanese	O
.	O

Antiserum	O
Pb867	O
was	O
raised	O
against	O
EPPARARPRLVFRTQLAHGS	O
(	O
aa	O
13	O
-	O
32	O
)	O
;	O
Pb869	O
:	O
APSDVEAAAARRVDDL	O
(	O
aa	O
220	O
-	O
235	O
)	O
;	O
Pb877	O
VSSGRETLRLRSGGAATVEEA	O
(	O
aa	O
199	O
-	O
220	O
)	O
.	O

Jeremy	O
D	O
Schmahmann	O
and	O
Vamsi	O
K	O
Mootha	O
contributed	O
equally	O
to	O
this	O
work	O
as	O
co	O
-	O
senior	O
authors	O
.	O

In	O
patients	O
with	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
,	O
high	O
glucose	O
concentrations	O
impair	O
expression	O
and	O
secretion	O
of	O
insulin	O
in	O
beta	O
-	O
cells	O
and	O
accelerate	O
apoptosis	O
of	O
islet	O
cells	O
(	O
22	O
,	O
23	O
)	O
.	O

Their	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
anticipated	O
during	O
follow	O
-	O
up	O
,	O
which	O
may	O
support	O
the	O
finding	O
.	O

The	O
MAQ	O
alignments	O
formed	O
the	O
basis	O
of	O
the	O
depth	O
and	O
coverage	O
calculations	O
(	O
Figures	O
2	O
A	O
and	O
2B	O
)	O
.	O

For	O
first	O
strand	O
synthesis	O
we	O
used	O
the	O
SuperScriptIII	O
First	O
-	O
Strand	O
Synthesis	O
System	O
(	O
Invitrogen	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
with	O
1	O
mu	O
g	O
total	O
RNA	O
together	O
with	O
Oligo	O
(	O
dT	O
20	O
)	O
primers	O
according	O
to	O
the	O
specification	O
of	O
the	O
manufacturer	O
.	O

*	O
Percentage	O
of	O
patients	O
with	O
at	O
least	O
one	O
mutation	O
in	O
USH2A	B-GENE
:	O
patients	O
with	O
only	O
one	O
mutation	O
+	O
patients	O
with	O
2	O
mutations	O
(	O
1MUT	O
+	O
2MUT	O
)	O
.	O

Displayed	O
under	O
each	O
individual	O
are	O
the	O
SNP	O
markers	O
within	O
the	O
region	O
of	O
the	O
ESRRB	B-GENE
gene	O
and	O
the	O
p	B-VARIANT
.	I-VARIANT
Glu340del	I-VARIANT
mutation	O
.	O

Figure	O
5	O
.	O

In	O
2004	O
,	O
van	O
Wijk	O
et	O
al	O
.	O

In	O
contrast	O
to	O
Czech	B-DISEASE
dysplasia	I-DISEASE
,	O
spondyloperipheral	B-DISEASE
dysplasia	I-DISEASE
(	O
SPD	B-DISEASE
)	O
is	O
characterized	O
by	O
short	B-DISEASE
stature	I-DISEASE
,	O
clubfeet	B-DISEASE
,	O
platyspondyly	B-DISEASE
,	O
midface	B-DISEASE
hypoplasia	I-DISEASE
,	O
myopia	B-DISEASE
and	O
epiphyseal	B-DISEASE
dysplasia	I-DISEASE
.	O

8	O
9	O
Forty	O
per	O
cent	O
of	O
ANSD	B-DISEASE
is	O
estimated	O
to	O
have	O
a	O
genetic	O
basis	O
with	O
autosomal	O
-	O
dominant	O
,	O
autosomal	O
-	O
recessive	O
,	O
mitochondrial	O
and	O
X	O
-	O
linked	O
inheritance	O
all	O
reported	O
.	O

The	O
detailed	O
clinical	O
presentation	O
of	O
the	O
patient	O
was	O
previously	O
described	O
by	O
Boo	O
et	O
al	O
.	O

In	O
the	O
study	O
by	O
Jais	O
et	O
al	O
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
use	O
of	O
NGS	O
technology	O
holds	O
promises	O
as	O
a	O
tool	O
for	O
screening	O
congenital	O
deafness	B-DISEASE
genes	O
.	O

When	O
we	O
probed	O
western	O
blots	O
of	O
cochlea	O
and	O
testis	O
protein	O
extracts	O
from	O
BLSW	O
and	O
C3HeB	O
/	O
FeJ	O
we	O
detected	O
a	O
reduction	O
in	O
intensity	O
of	O
the	O
~	O
40	O
kDa	O
band	O
in	O
BLSW	O
cochlea	O
extracts	O
by	O
82	O
+	O
-	O
7	O
%	O
(	O
n	O
=	O
3	O
)	O
and	O
in	O
testis	O
extracts	O
by	O
42	O
+	O
-	O
9	O
%	O
(	O
n	O
=	O
3	O
)	O
compared	O
with	O
wild	O
-	O
type	O
C3HeB	O
/	O
FeJ	O
extracts	O
(	O
Fig	O
.	O

Gel	O
electrophoresis	O
shows	O
the	O
RT	O
-	O
PCR	O
products	O
obtained	O
for	O
USH1	B-DISEASE
patients	O
and	O
control	O
samples	O
.	O

Analysis	O
of	O
three	O
polymorphic	O
USH1C	B-GENE
SNPs	O
showed	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
496	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
is	O
associated	O
with	O
a	O
common	O
haplotype	O
-	O
-	O
that	O
is	O
,	O
'	O
A	O
-	O
C	O
-	O
G	O
'	O
(	O
'	O
rs2072227	B-VARIANT
-	O
rs2240488	B-VARIANT
-	O
rs2883581	B-VARIANT
'	O
)	O
.	O

8	O
)	O
.	O

Haplotype	O
analysis	O
was	O
performed	O
in	O
seventeen	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
homozygous	O
patients	O
:	O
5	O
Slovak	O
probands	O
,	O
7	O
Hungarian	O
probands	O
,	O
5	O
Czech	O
(	O
3	O
probands	O
,	O
2	O
relatives	O
)	O
and	O
4	O
Pakistani	O
patients	O
from	O
2	O
families	O
(	O
2	O
relatives	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
and	O
2	O
relatives	O
with	O
homozygous	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1183	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
.	O

The	O
research	O
adhered	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
(	O
Commissie	O
Mensgebonden	O
Onderzoek	O
)	O
,	O
Radboud	O
University	O
Nijmegen	O
Medical	O
Centre	O
,	O
Nijmegen	O
,	O
The	O
Netherlands	O
.	O

The	O
potential	O
effects	O
on	O
splicing	O
of	O
any	O
sequence	O
variation	O
were	O
analyzed	O
with	O
the	O
Human	O
Splicing	O
Finder	O
(	O
HSF	O
)	O
tool	O
.	O

In	O
this	O
patient	O
,	O
we	O
also	O
observed	O
the	O
polymorphism	O
rs755793	B-VARIANT
(	O
T	O
-	O
C	O
)	O
in	O
the	O
exxon	O
5	O
of	O
FGFR2	B-GENE
gene	O
.	O

The	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
modest	O
in	O
this	O
family	O
,	O
affecting	O
all	O
frequencies	O
with	O
increasing	O
age	O
and	O
resulting	O
in	O
a	O
flat	O
or	O
downward	O
sloping	O
audiogram	O
.	O

The	O
final	O
library	O
size	O
350	O
bp	O
-	O
450	O
bp	O
including	O
adapter	O
sequences	O
was	O
selected	O
.	O

Only	O
Whole	O
-	O
Exome	O
Sequencing	O
(	O
WES	O
)	O
or	O
Whole	O
-	O
Genome	O
Sequencing	O
(	O
WGS	O
)	O
are	O
likely	O
to	O
bring	O
answers	O
and	O
may	O
redefine	O
the	O
clinical	O
diagnosis	O
for	O
some	O
cases	O
.	O

Apple	O
-	O
Mathews	O
for	O
help	O
in	O
preparing	O
the	O
manuscript	O
.	O
Conflict	O
of	O
interest	O
The	O
authors	O
have	O
no	O
conflicts	O
of	O
interest	O
to	O
disclose	O
.	O

Considering	O
that	O
CNVs	O
could	O
be	O
also	O
detected	O
using	O
this	O
approach	O
,	O
the	O
multiphasic	O
analysis	O
of	O
WES	O
data	O
efficiently	O
narrowed	O
and	O
identified	O
candidate	O
variants	O
and	O
was	O
advantageous	O
compared	O
with	O
established	O
methods	O
such	O
as	O
initial	O
aCGH	O
,	O
variant	O
calling	O
according	O
to	O
WES	O
data	O
alone	O
,	O
or	O
linkage	O
analysis	O
based	O
on	O
SNP	O
microarray	O
data	O
.	O

Genetic	O
factors	O
account	O
for	O
more	O
than	O
50	O
%	O
of	O
cases	O
with	O
congenital	O
or	O
prelingual	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
with	O
autosomal	O
recessive	O
(	O
77	O
%	O
)	O
,	O
autosomal	O
dominant	O
(	O
22	O
%	O
)	O
,	O
and	O
X	O
-	O
linked	O
inheritance	O
(	O
1	O
%	O
)	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Progressive	O
nature	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
the	O
presence	O
of	O
residual	O
hearing	O
are	O
particular	O
phenotypic	O
features	O
of	O
the	O
patients	O
with	O
CDH23	B-GENE
mutations	O
.	O

Among	O
the	O
missense	O
variants	O
are	O
the	O
two	O
most	O
-	O
studied	O
polymorphisms	O
,	O
c	B-VARIANT
.	I-VARIANT
215C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro72Arg	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
139C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro47Ser	I-VARIANT
)	O
.	O

(	O
A	O
)	O
Cumulative	O
distribution	O
curve	O
of	O
age	O
on	O
onset	O
of	O
visual	B-DISEASE
failure	I-DISEASE
in	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
,	O
and	O
(	O
B	O
)	O
comparison	O
of	O
mean	O
LogMAR	O
visual	O
acuity	O
between	O
patients	O
with	O
pure	O
DOA	B-DISEASE
and	O
DOA	O
+	O
features	O
(	O
P	O
=	O
0	O
.	O
0170	O
)	O
.	O

This	O
demonstrated	O
a	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Pro361Pro	I-VARIANT
)	O
]	O
variant	O
within	O
exon	O
IIIc	O
,	O
which	O
was	O
also	O
present	O
in	O
II	O
-	O
1	O
and	O
I	O
-	O
1	O
.	O

As	O
we	O
observed	O
complete	O
absence	O
of	O
mutant	O
alleles	O
in	O
individuals	O
TCS21	B-DISEASE
and	O
22	O
,	O
but	O
partial	O
expression	O
in	O
TCS23	B-DISEASE
(	O
Figure	O
2	O
)	O
,	O
we	O
considered	O
that	O
NMD	B-DISEASE
was	O
present	O
,	O
but	O
with	O
variable	O
efficiency	O
.	O

The	O
work	O
was	O
also	O
supported	O
a	O
grant	O
from	O
the	O
German	O
Ministry	O
of	O
Research	O
and	O
Education	O
to	O
S	O
.	O

Sequencing	O
results	O
obtained	O
by	O
the	O
NGS	O
method	O
for	O
the	O
coding	O
region	O
of	O
the	O
GJB2	B-GENE
gene	O
were	O
compared	O
to	O
those	O
obtained	O
by	O
the	O
Sanger	O
method	O
(	O
N	O
=	O
8	O
)	O
for	O
validation	O
purposes	O
.	O

A	O
total	O
of	O
481	O
relatives	O
in	O
the	O
103	O
families	O
with	O
an	O
identified	O
mutation	O
have	O
participated	O
in	O
genetic	O
cascade	O
screening	O
,	O
of	O
which	O
41	O
%	O
were	O
found	O
to	O
be	O
mutation	O
carriers	O
,	O
and	O
59	O
%	O
were	O
not	O
carriers	O
.	O

The	O
two	O
individuals	O
whose	O
exomes	O
were	O
sequenced	O
are	O
shown	O
in	O
red	O
.	O

Other	O
changes	O
of	O
the	O
same	O
amino	O
acids	O
have	O
been	O
reported	O
.	O

Mutations	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
are	O
known	O
to	O
cause	O
Alport	B-DISEASE
syndrome	I-DISEASE
,	O
thin	B-DISEASE
basement	I-DISEASE
membrane	I-DISEASE
nephropathy	I-DISEASE
,	O
and	O
to	O
result	O
in	O
pathognomonic	O
glomerular	O
basement	O
membrane	O
findings	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Our	O
data	O
indicate	O
that	O
these	O
variants	O
are	O
not	O
common	O
polymorphisms	O
,	O
and	O
in	O
each	O
family	O
homozygosity	O
for	O
the	O
mutant	O
allele	O
of	O
CLDN14	B-GENE
co	O
-	O
segregated	O
with	O
deafness	B-DISEASE
while	O
carriers	O
had	O
normal	O
hearing	O
.	O

Large	O
rearrangements	O
in	O
USH2A	B-GENE
and	O
PCDH15	B-GENE
were	O
subsequently	O
confirmed	O
by	O
MLPA	O
,	O
whereas	O
patients	O
that	O
carried	O
duplications	O
affecting	O
CDH23	B-GENE
and	O
GPR98	B-GENE
were	O
analyzed	O
by	O
a	O
-	O
CGH	O
(	O
data	O
not	O
shown	O
)	O
.	O

A	O
:	O
Nonsense	O
or	O
frameshift	O
variants	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
variant	O
is	O
located	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
alpha	O
subunit	O
of	O
functional	O
KCNQ1	B-GENE
channel	O
complex	O
,	O
which	O
is	O
considered	O
an	O
interacting	O
domain	O
necessary	O
for	O
the	O
assembly	O
of	O
the	O
channels	O
at	O
the	O
membrane	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
main	O
variant	O
calling	O
process	O
,	O
for	O
both	O
indels	O
(	O
insertion	O
/	O
deletions	O
)	O
and	O
single	O
nucleotide	O
variants	O
,	O
was	O
operated	O
by	O
using	O
the	O
GATK	O
software	O
package	O
(	O
version	O
1	O
.	O
2	O
-	O
59	O
-	O
gd74367c1	O
)	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
heterozygous	O
mutation	O
and	O
the	O
homozygous	O
mutation	O
in	O
USH2A	B-GENE
may	O
cause	O
Usher	B-DISEASE
syndrome	I-DISEASE
Type	I-DISEASE
II	I-DISEASE
or	O
RP	B-DISEASE
,	O
respectively	O
.	O

Analysis	O
of	O
other	O
available	O
family	O
members	O
revealed	O
that	O
the	O
mutation	O
co	O
-	O
segregated	O
with	O
USH1	B-DISEASE
in	O
this	O
family	O
:	O
Both	O
affected	O
individuals	O
were	O
homozygotes	O
for	O
the	O
mutation	O
,	O
and	O
their	O
parents	O
are	O
heterozygotes	O
(	O
Figure	O
1D	O
)	O
.	O

In	O
particular	O
,	O
these	O
technologies	O
can	O
be	O
powerful	O
methods	O
for	O
familial	O
disorders	O
,	O
because	O
it	O
is	O
predicted	O
that	O
a	O
single	O
copy	O
-	O
number	O
change	O
or	O
mutation	O
is	O
shared	O
in	O
common	O
by	O
affected	O
subjects	O
and	O
is	O
absent	O
from	O
non	O
-	O
affected	O
subjects	O
within	O
a	O
family	O
.	O

DNA	O
sequencing	O
reveals	O
a	O
heterozygous	O
mutation	O
(	O
GC	O
to	O
KS	O
)	O
.	O

TRS	O
-	O
204	O
could	O
detect	O
a	O
causative	O
variant	O
from	O
additional	O
11	O
cases	O
(	O
11	O
.	O
8	O
%	O
)	O
.	O

OTOF	B-GENE
mutations	O
are	O
common	O
in	O
patients	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
,	O
which	O
is	O
characterized	O
by	O
normal	O
outer	O
hair	O
cell	O
function	O
and	O
abnormal	O
neural	O
conduction	O
[	O
5	O
]	O
.	O

These	O
mutations	O
lie	O
in	O
S6	O
segments	O
that	O
line	O
the	O
channel	O
pore	O
.	O

Computed	O
tomography	O
(	O
CT	O
)	O
of	O
the	O
temporal	O
bone	O
was	O
performed	O
in	O
ten	O
individuals	O
(	O
A5	O
,	O
C4	O
,	O
D4	O
,	O
E8	O
,	O
E9	O
,	O
E10	O
,	O
E13	O
,	O
F3	O
,	O
G3	O
,	O
and	O
H3	O
)	O
,	O
mainly	O
as	O
part	O
of	O
a	O
preoperative	O
CI	O
selection	O
procedure	O
.	O

Electrically	O
-	O
evoked	O
responses	O
in	O
auditory	O
nerve	O
fibres	O
(	O
electrically	O
-	O
evoked	O
compound	O
action	O
potentials	O
)	O
were	O
absent	O
in	O
all	O
but	O
one	O
(	O
Subject	O
7	O
)	O
implanted	O
OPA1	B-GENE
-	O
M	O
patient	O
.	O

None	O
of	O
the	O
patients	O
reported	O
by	O
Bonne	O
-	O
Tamir	O
et	O
al	O
.	O

SR	O
-	O
209	O
family	O
carried	O
two	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
Pro240Leu	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Asn342Ser	I-VARIANT
in	O
the	O
CDH23	B-GENE
.	O

2000	O
;	O
Verpy	O
et	O
al	O
.	O

Exome	O
analysis	O
resulted	O
in	O
the	O
identification	O
of	O
43	O
,	O
204	O
variants	O
in	O
the	O
index	O
patient	O
.	O

2010	O
)	O
.	O

Five	O
families	O
were	O
homozygous	O
for	O
p	B-VARIANT
.	I-VARIANT
Glu767SerfsX21	I-VARIANT
,	O
35	O
families	O
were	O
compound	O
heterozygotes	O
,	O
and	O
in	O
12	O
families	O
p	B-VARIANT
.	I-VARIANT
Glu767SerfsX21	I-VARIANT
was	O
the	O
only	O
pathogenic	O
variant	O
identified	O
.	O

The	O
other	O
types	O
of	O
IEM	B-DISEASE
included	O
six	O
cases	O
of	O
cystic	B-DISEASE
cochlea	I-DISEASE
,	O
dilated	B-DISEASE
vestibule	I-DISEASE
,	O
and	O
enlarged	B-DISEASE
internal	I-DISEASE
auditory	I-DISEASE
canal	I-DISEASE
,	O
two	O
cases	O
of	O
common	B-DISEASE
cavity	I-DISEASE
(	O
a	B-DISEASE
cystic	I-DISEASE
cavity	I-DISEASE
representing	I-DISEASE
the	I-DISEASE
cochlea	I-DISEASE
and	I-DISEASE
vestibule	I-DISEASE
without	I-DISEASE
showing	I-DISEASE
any	I-DISEASE
differentiation	I-DISEASE
into	I-DISEASE
cochlea	I-DISEASE
and	I-DISEASE
vestibule	I-DISEASE
)	O
,	O
semicircular	B-DISEASE
canal	I-DISEASE
aplasia	I-DISEASE
,	O
and	O
narrow	B-DISEASE
internal	I-DISEASE
auditory	I-DISEASE
canal	I-DISEASE
,	O
one	O
case	O
of	O
semicircular	B-DISEASE
canal	I-DISEASE
hypoplasia	I-DISEASE
,	O
one	O
case	O
of	O
inner	B-DISEASE
ear	I-DISEASE
ossification	I-DISEASE
,	O
one	O
case	O
of	O
vestibule	B-DISEASE
and	I-DISEASE
semicircular	I-DISEASE
ossification	I-DISEASE
,	O
three	O
cases	O
of	O
common	B-DISEASE
cavity	I-DISEASE
and	O
enlarged	B-DISEASE
internal	I-DISEASE
auditory	I-DISEASE
canal	I-DISEASE
,	O
one	O
case	O
of	O
common	B-DISEASE
cavity	I-DISEASE
,	O
and	O
one	O
case	O
of	O
common	B-DISEASE
cavity	I-DISEASE
with	O
narrow	B-DISEASE
internal	I-DISEASE
auditory	I-DISEASE
canal	I-DISEASE
(	O
Figure	O
1	O
)	O
.	O

23	O
24	O
Both	O
of	O
the	O
remaining	O
variants	O
were	O
confirmed	O
in	O
the	O
proband	O
by	O
Sanger	O
sequencing	O
,	O
but	O
only	O
AIFM1	B-GENE
p	B-VARIANT
.	I-VARIANT
R451Q	I-VARIANT
co	O
-	O
segregated	O
with	O
the	O
phenotype	O
in	O
the	O
extended	O
AUNX1	B-GENE
family	O
(	O
eight	O
informative	O
meioses	O
were	O
tested	O
;	O
figure	O
1	O
A	O
-	O
C	O
)	O
.	O

No	O
significant	O
differences	O
in	O
GJB2	B-GENE
detection	O
rate	O
were	O
found	O
among	O
these	O
four	O
ethnic	O
groups	O
(	O
chi	O
2	O
=	O
2	O
.	O
4893	O
,	O
P	O
=	O
0	O
.	O
4772	O
)	O
.	O

Out	O
of	O
the	O
fourteen	O
individuals	O
,	O
three	O
(	O
II	O
-	O
1	O
,	O
II	O
-	O
3	O
,	O
III	O
-	O
3	O
)	O
were	O
only	O
affected	O
with	O
the	O
most	O
severe	O
type	O
of	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
(	O
long	O
segment	O
aganglionosis	O
;	O
L	O
-	O
HSCR	B-DISEASE
)	O
and	O
one	O
(	O
II	O
-	O
5	O
)	O
was	O
affected	O
with	O
L	O
-	O
HSCR	B-DISEASE
and	O
complete	O
heterochromia	B-DISEASE
iridum	I-DISEASE
(	O
Figure	O
1	O
)	O
.	O

In	O
brief	O
,	O
1	O
u	O
g	O
of	O
DNA	O
library	O
was	O
mixed	O
with	O
Buffer	O
BL	O
and	O
biotinylated	O
probes	O
(	O
MyGenostics	O
Inc	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
and	O
then	O
heated	O
at	O
95	O
deg	O
C	O
for	O
7	O
min	O
and	O
65	O
deg	O
C	O
for	O
2	O
min	O
on	O
a	O
PCR	O
machine	O
.	O

Based	O
on	O
the	O
crystal	O
structure	O
of	O
murine	O
BRCA2	B-GENE
[	O
54	O
]	O
,	O
the	O
variants	O
occur	O
in	O
all	O
five	O
domains	O
that	O
comprise	O
the	O
DNA	O
-	O
binding	O
domain	O
,	O
and	O
six	O
variants	O
are	O
in	O
the	O
disordered	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
.	O

Ajmal	O
HK	O
RQ	O
.	O

Last	O
nucleotide	O
of	O
exon	O
;	O
causes	O
MYO7A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Val1953GlufsX12	I-VARIANT
.	O

Variant	O
filtering	O
was	O
performed	O
under	O
the	O
assumption	O
of	O
dominant	O
inheritance	O
.	O

Furthermore	O
,	O
the	O
high	O
coverage	O
obtained	O
in	O
our	O
study	O
allowed	O
us	O
to	O
detect	O
large	O
rearrangements	O
.	O

The	O
HW	O
helix	O
contains	O
the	O
actin	O
-	O
binding	O
motif	O
,	O
and	O
the	O
strand	O
is	O
part	O
of	O
the	O
central	O
beta	O
sheet	O
or	O
transducer	O
region	O
,	O
which	O
concerted	O
distortion	O
led	O
to	O
conformational	O
changes	O
of	O
the	O
motor	O
domain	O
.	O

In	O
the	O
mouse	O
ear	O
,	O
we	O
demonstrated	O
that	O
the	O
CD164	B-GENE
protein	O
is	O
expressed	O
in	O
hair	O
cells	O
and	O
other	O
sites	O
known	O
to	O
be	O
important	O
for	O
correct	O
hearing	O
.	O

Analyzed	O
the	O
data	O
:	O
MHS	O
T	O
-	O
JK	O
HRK	O
.	O

One	O
limitation	O
of	O
our	O
study	O
is	O
that	O
the	O
analysis	O
was	O
restricted	O
to	O
only	O
a	O
single	O
case	O
.	O

Sequencing	O
results	O
showed	O
high	O
depth	O
of	O
coverage	O
with	O
more	O
than	O
90	O
%	O
of	O
the	O
targeted	O
region	O
sequenced	O
at	O
a	O
depth	O
of	O
8	O
-	O
fold	O
or	O
greater	O
(	O
Figure	O
1b	O
)	O
.	O

P	O
-	O
values	O
<	O
0	O
.	O
05	O
were	O
assigned	O
as	O
significant	O
.	O

Segregation	O
of	O
the	O
mutations	O
in	O
MYO7A	B-GENE
,	O
USH1G	B-GENE
and	O
USH2A	B-GENE
in	O
family	O
U3	O
.	O

Frozen	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
Gomori	O
'	O
s	O
trichrome	O
stain	O
and	O
for	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NADH	O
)	O
-	O
tetrazolium	O
reductase	O
(	O
NADH	O
-	O
TR	O
)	O
,	O
succinate	O
dehydrogenase	O
(	O
SDH	O
)	O
,	O
and	O
cytochrome	O
oxidase	O
(	O
COX	O
)	O
.	O

Pure	O
tone	O
audiometry	O
(	O
PTA	O
)	O
with	O
air	O
and	O
bone	O
conduction	O
at	O
frequencies	O
ranging	O
from	O
250	O
to	O
8	O
,	O
000	O
Hz	O
was	O
obtained	O
from	O
the	O
recruited	O
subjects	O
according	O
to	O
standard	O
protocols	O
.	O

Quality	O
control	O
of	O
the	O
library	O
preparation	O
was	O
carried	O
out	O
on	O
a	O
RNA	O
6000	O
pico	O
labchip	O
(	O
Agilent	O
technologies	O
)	O
and	O
concentration	O
of	O
the	O
library	O
was	O
measured	O
with	O
the	O
Quant	O
-	O
it	O
Ribogreen	O
RNA	O
assay	O
(	O
Invitrogen	O
)	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
is	O
the	O
most	O
common	O
form	O
of	O
syndromic	O
deafness	B-DISEASE
that	O
accounts	O
for	O
about	O
10	O
%	O
of	O
hereditary	O
hearing	B-DISEASE
impairment	I-DISEASE
[	O
14	O
]	O
.	O

Our	O
work	O
further	O
demonstrates	O
that	O
two	O
KCNQ1	B-GENE
mutations	O
can	O
result	O
in	O
a	O
severe	O
variant	O
of	O
RWS	B-DISEASE
in	O
Chinese	O
.	O

During	O
the	O
course	O
of	O
this	O
study	O
,	O
the	O
TGE	O
+	O
MPS	O
platform	O
was	O
updated	O
from	O
v4	O
to	O
v5	O
as	O
part	O
of	O
our	O
standard	O
operating	O
procedure	O
,	O
increasing	O
the	O
number	O
of	O
genes	O
screened	O
from	O
66	O
to	O
89	O
.	O

Expectedly	O
,	O
no	O
CNVs	O
encompassing	O
any	O
of	O
the	O
WS4	B-DISEASE
candidate	O
genes	O
were	O
detected	O
.	O

The	O
animal	O
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
the	O
recommendations	O
in	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
of	O
Peking	O
University	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
EA	O
RR	O
MA	O
MDL	O
TJ	O
JMM	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Cys759Phe	I-VARIANT
variant	O
was	O
the	O
second	O
-	O
most	O
-	O
frequent	O
mutation	O
,	O
accounting	O
for	O
3	O
.	O
8	O
%	O
(	O
14	O
out	O
of	O
372	O
alleles	O
)	O
of	O
typical	O
RP	B-DISEASE
families	O
;	O
this	O
percentage	O
was	O
higher	O
than	O
reported	O
elsewhere	O
[	O
18	O
]	O
.	O

Our	O
study	O
of	O
Korean	O
patients	O
with	O
ADNSHL	B-DISEASE
identified	O
four	O
novel	O
mutations	O
in	O
the	O
MYO6	B-GENE
gene	O
that	O
appear	O
to	O
be	O
causally	O
related	O
to	O
deafness	B-DISEASE
.	O

Of	O
these	O
26	O
mutations	O
,	O
five	O
out	O
of	O
10	O
possible	O
pathologic	O
mutations	O
were	O
found	O
in	O
DRE	O
,	O
DXNDN	O
,	O
and	O
DXD	O
motifs	O
,	O
which	O
are	O
thought	O
to	O
be	O
important	O
for	O
calcium	O
binding	O
property	O
.	O

The	O
average	O
of	O
412	O
.	O
93	O
Mb	O
sequences	O
with	O
about	O
3	O
,	O
200	O
,	O
000	O
reads	O
was	O
obtained	O
by	O
one	O
Ion	O
318	O
chip	O
.	O

Indels	O
were	O
detected	O
through	O
the	O
alignment	O
result	O
with	O
Genome	O
Analysis	O
Toolkit	O
(	O
GATK	O
)	O
.	O

We	O
designed	O
43	O
pairs	O
of	O
primers	O
to	O
amplify	O
DNA	O
fragments	O
containing	O
all	O
exons	O
in	O
the	O
coding	O
regions	O
of	O
the	O
OTOF	B-GENE
gene	O
(	O
ENST00000403946	O
)	O
.	O

Audiological	O
characterization	O
of	O
all	O
patients	O
is	O
shown	O
in	O
Fig	O
.	O

Subsequently	O
harvested	O
amplicon	O
pools	O
were	O
submitted	O
to	O
another	O
PCR	O
-	O
step	O
to	O
tag	O
PCR	O
products	O
with	O
48	O
different	O
barcodes	O
and	O
Illumina	O
sequence	O
-	O
specific	O
adaptors	O
as	O
previously	O
described	O
35	O
,	O
39	O
.	O

Figure	O
3	O
Audiogram	O
of	O
probands	O
who	O
were	O
genetically	O
diagnosed	O
by	O
TRS	O
-	O
204	O
.	O

In	O
addition	O
,	O
all	O
controls	O
were	O
screened	O
for	O
SLC26A4	B-GENE
mutations	O
by	O
denaturing	O
high	O
-	O
pressure	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
followed	O
by	O
sequencing	O
.	O

In	O
summary	O
,	O
we	O
identified	O
mutations	O
in	O
27	O
patients	O
with	O
PSACH	B-DISEASE
and	O
56	O
patients	O
with	O
AD	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
.	O

In	O
this	O
case	O
,	O
the	O
PhNR	O
of	O
the	O
cone	O
ERG	O
was	O
decreased	O
,	O
and	O
the	O
peak	O
of	O
the	O
PhNR	O
was	O
a	O
positive	O
potential	O
relative	O
to	O
the	O
baseline	O
(	O
Figure	O
3	O
(	O
d	O
)	O
)	O
.	O

T	O
.	O

Overall	O
,	O
24	O
centers	O
from	O
Germany	O
and	O
Southeastern	O
European	O
countries	O
participated	O
in	O
this	O
study	O
(	O
Wolfram	B-DISEASE
Syndrome	I-DISEASE
Diabetes	B-DISEASE
Writing	O
Group	O
)	O
.	O

A	O
genotyping	O
microarray	O
commercially	O
available	O
(	O
Cremers	O
et	O
al	O
.	O

Similarly	O
,	O
in	O
our	O
previous	O
study	O
,	O
audiograms	O
from	O
multiple	O
affected	O
individuals	O
of	O
family	O
PKDF009	O
did	O
not	O
show	O
any	O
correlation	O
between	O
hearing	O
thresholds	O
and	O
age	O
of	O
the	O
affected	O
individuals	O
.	O

20	O
-	O
22	O
26	O
Mapping	O
of	O
mutations	O
G490R	B-VARIANT
,	O
D623Y	B-VARIANT
,	O
N628K	B-VARIANT
,	O
and	O
C725Y	B-VARIANT
on	O
FGFR1	B-GENE
tyrosine	O
kinase	O
domain	O
crystal	O
structure	O
.	O

RP	B-DISEASE
can	O
be	O
classified	O
as	O
syndromic	O
and	O
nonsyndromic	O
RP	B-DISEASE
,	O
based	O
on	O
whether	O
or	O
not	O
extra	B-DISEASE
-	I-DISEASE
ocular	I-DISEASE
diseases	I-DISEASE
exist	O
.	O

Mutations	O
and	O
Clinical	O
Features	O
in	O
MYH9	B-GENE
-	O
Related	O
Thrombocytopenia	B-DISEASE
5	O
-	O
7	O
,	O
16	O
,	O
19	O
-	O
24	O
NA	O
,	O
no	O
data	O
available	O
;	O
fs	O
,	O
frameshift	O
;	O
del	O
,	O
deletion	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

By	O
sequencing	O
the	O
exome	O
DNA	O
libraries	O
,	O
we	O
obtained	O
2	O
.	O
8	O
-	O
5	O
.	O
4	O
Gb	O
of	O
mapped	O
sequence	O
achieving	O
a	O
mean	O
depth	O
of	O
target	O
coverage	O
between	O
27	O
and	O
50	O
x	O
,	O
and	O
an	O
average	O
of	O
19	O
,	O
181	O
variations	O
per	O
patient	O
,	O
including	O
substitutions	O
and	O
indels	O
(	O
Table	O
2	O
)	O
.	O

Four	O
patients	O
with	O
early	O
-	O
onset	O
deafness	B-DISEASE
received	O
CI	O
,	O
and	O
4	O
late	O
-	O
onset	O
patients	O
had	O
residual	O
hearing	O
at	O
lower	O
frequencies	O
and	O
received	O
EAS	O
.	O

Analyses	O
did	O
not	O
detect	O
the	O
other	O
seven	O
mutations	O
in	O
the	O
100	O
normal	O
controls	O
,	O
with	O
the	O
exception	O
of	O
p	B-VARIANT
.	I-VARIANT
C934W	I-VARIANT
,	O
which	O
was	O
identified	O
in	O
its	O
heterozygous	O
state	O
in	O
two	O
individuals	O
among	O
the	O
100	O
normal	O
controls	O
(	O
Table	O
4	O
)	O
.	O

The	O
visual	O
fields	O
of	O
the	O
adult	O
patients	O
showed	O
characteristic	O
scotomata	O
.	O

These	O
patients	O
were	O
not	O
affected	O
by	O
diabetes	B-DISEASE
insipidus	I-DISEASE
,	O
but	O
showed	O
upper	B-DISEASE
gastrointestinal	I-DISEASE
ulceration	I-DISEASE
and	O
bleeding	B-DISEASE
.	O

We	O
measured	O
the	O
patients	O
sleep	O
quality	O
using	O
the	O
Pittsburgh	O
sleep	O
quality	O
index	O
(	O
PSQI	O
)	O
[	O
47	O
]	O
and	O
the	O
"	O
STOP	O
"	O
questionnaire	O
(	O
snoring	O
,	O
tiredness	O
during	O
daytime	O
,	O
observed	O
apnea	O
,	O
high	O
blood	O
pressure	O
)	O
[	O
48	O
]	O
.	O

Sequencing	O
genomic	O
DNA	O
from	O
Family	O
BF	O
revealed	O
a	O
different	O
mutation	O
in	O
pendrin	B-GENE
.	O

When	O
age	O
of	O
onset	O
is	O
considered	O
,	O
patients	O
with	O
congenital	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
had	O
a	O
diagnostic	O
rate	O
of	O
44	O
%	O
,	O
which	O
was	O
significantly	O
greater	O
than	O
the	O
diagnostic	O
rate	O
in	O
patients	O
with	O
childhood	O
(	O
29	O
%	O
)	O
-	O
or	O
adult	O
(	O
28	O
%	O
)	O
-	O
onset	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
p	O
<	O
0	O
.	O
005	O
in	O
both	O
cases	O
)	O
.	O

Patients	O
with	O
missense	O
mutations	O
on	O
both	O
PEX1	B-GENE
copies	O
(	O
type	O
1	O
)	O
show	O
the	O
longest	O
survival	O
,	O
106	O
months	O
on	O
average	O
(	O
eight	O
patients	O
)	O
.	O

Clinical	O
heterogeneity	O
is	O
accompanied	O
by	O
high	O
genetic	O
heterogeneity	O
.	O

MHA	B-DISEASE
and	O
SBS	B-DISEASE
were	O
previously	O
called	O
"	O
nonsyndromic	O
"	O
because	O
the	O
anomalies	O
are	O
restricted	O
to	O
blood	O
cells	O
,	O
platelets	O
,	O
and	O
leukocytes	O
.	O

Of	O
note	O
,	O
c	B-VARIANT
.	I-VARIANT
3157delT	I-VARIANT
RP1	B-GENE
has	O
been	O
reported	O
as	O
a	O
dominant	O
mutation	O
in	O
an	O
RP1	B-GENE
screening	O
study	O
[	O
30	O
]	O
.	O

At	O
age	O
52	O
the	O
patient	O
[	O
1184405	O
]	O
presented	O
with	O
proteinuria	B-DISEASE
(	O
3	O
+	O
)	O
and	O
hematuria	B-DISEASE
(	O
1	O
+	O
)	O
and	O
reported	O
hearing	O
loss	O
of	O
two	O
years	O
duration	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
these	O
additional	O
variants	O
have	O
a	O
modifying	O
phenotypic	O
effect	O
,	O
explaining	O
variability	O
in	O
age	O
of	O
onset	O
and	O
progression	O
.	O

Black	O
triangles	O
indicate	O
new	O
experimentally	O
established	O
genetic	O
diagnoses	O
.	O

2010	O
)	O
.	O

Our	O
novel	O
targeted	O
next	O
-	O
generation	O
sequencing	O
assay	O
provides	O
a	O
highly	O
sensitive	O
method	O
for	O
simultaneous	O
analysis	O
of	O
all	O
monogenic	O
diabetes	B-DISEASE
genes	O
.	O

1C	O
)	O
.	O

Most	O
patients	O
were	O
referred	O
to	O
Armand	O
-	O
Trousseau	O
Children	O
'	O
s	O
Hospital	O
in	O
Paris	O
,	O
and	O
other	O
patients	O
were	O
referred	O
to	O
genetic	O
consultations	O
throughout	O
France	O
.	O

Primer	O
sequences	O
and	O
PCR	O
conditions	O
are	O
available	O
on	O
request	O
.	O

To	O
identify	O
the	O
mutation	O
c	B-VARIANT
.	I-VARIANT
6051	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
a	O
99	O
-	O
bp	O
fragment	O
was	O
amplified	O
and	O
digested	O
by	O
ScrFI	O
.	O

These	O
alternative	O
extracellular	O
domains	O
interact	O
with	O
different	O
repertoires	O
of	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
to	O
regulate	O
downstream	O
processes	O
such	O
as	O
proliferation	O
,	O
differentiation	O
and	O
cell	O
migration	O
[	O
16	O
]	O
.	O

A	O
number	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
Wolfram	B-GENE
syndrome	I-GENE
1	I-GENE
gene	I-GENE
(	O
WFS1	B-GENE
)	O
have	O
been	O
described	O
in	O
patients	O
with	O
WFS	B-DISEASE
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
.	O

2	O
)	O
.	O

Although	O
some	O
correlations	O
have	O
been	O
determined	O
between	O
the	O
location	O
of	O
the	O
mutation	O
and	O
disease	O
phenotype	O
,	O
the	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
type	B-DISEASE
II	I-DISEASE
collagenopathies	I-DISEASE
are	O
still	O
far	O
from	O
clear	O
.	O

The	O
onset	O
was	O
mostly	O
perilingual	O
or	O
postlingual	O
although	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
demonstrated	O
in	O
two	O
of	O
the	O
patient	O
.	O

Homozygous	O
or	O
heterozygous	O
35de1G	B-VARIANT
mutation	O
is	O
also	O
found	O
in	O
Western	O
Asians	O
,	O
an	O
extended	O
family	O
of	O
Caucasian	O
[	O
22	O
,	O
23	O
]	O
.	O

At	O
the	O
same	O
time	O
though	O
,	O
notwithstanding	O
all	O
the	O
limitations	O
in	O
our	O
investigative	O
approach	O
,	O
it	O
is	O
more	O
than	O
certain	O
that	O
additional	O
unknown	O
genes	O
must	O
exist	O
,	O
mutations	O
in	O
which	O
may	O
also	O
cause	O
familial	B-DISEASE
MH	I-DISEASE
or	O
TBMN	B-DISEASE
.	O

However	O
,	O
the	O
ciliary	O
activity	O
was	O
sufficient	O
to	O
operate	O
normally	O
and	O
no	O
clinical	O
consequences	O
were	O
observed	O
in	O
these	O
patients	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Sequencing	O
of	O
both	O
genes	O
in	O
fifteen	O
additional	O
patients	O
revealed	O
disease	O
-	O
causing	O
mutations	O
in	O
all	O
probands	O
,	O
including	O
two	O
recurrent	O
de	O
novo	O
mutations	O
(	O
ACTB	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg196His	I-VARIANT
and	O
ACTG1	B-GENE
p	B-VARIANT
.	I-VARIANT
Ser155Phe	I-VARIANT
)	O
.	O

In	O
the	O
mutant	O
allele	O
(	O
g	O
)	O
,	O
a	O
heterozygous	O
one	O
base	O
-	O
pair	O
deletion	O
,	O
indicated	O
by	O
a	O
vertical	O
arrow	O
,	O
is	O
shown	O
(	O
c	B-VARIANT
.	I-VARIANT
1102delA	I-VARIANT
)	O
.	O

Type	O
IX	O
collagen	O
connects	O
heterotypic	O
type	O
II	O
/	O
XI	O
collagen	O
fibrils	O
to	O
other	O
components	O
of	O
the	O
extracellular	O
matrix	O
.	O

1	O
)	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
previously	O
described	O
pathogenic	O
gene	O
TMC1	B-GENE
were	O
predicted	O
to	O
be	O
damaging	O
:	O
TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
589G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
G197R	B-VARIANT
)	O
and	O
TMC1	B-GENE
c	B-VARIANT
.	I-VARIANT
1171G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
Q391X	B-VARIANT
)	O
(	O
according	O
to	O
GenBank	O
accession	O
number	O
NM_138691	O
.	O
2	O
)	O
.	O

All	O
but	O
one	O
of	O
the	O
OPA1	B-GENE
-	O
M	O
patients	O
had	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

2005	O
)	O
.	O

More	O
than	O
60	O
mutations	O
in	O
FGFR	O
,	O
a	O
majority	O
of	O
which	O
occur	O
in	O
FGFR2	B-GENE
,	O
are	O
associated	O
with	O
craniosynostosis	B-DISEASE
syndrome	O
such	O
as	O
Antley	B-DISEASE
-	I-DISEASE
Bixler	I-DISEASE
syndrome	I-DISEASE
,	O
Apert	B-DISEASE
syndrome	I-DISEASE
,	O
Bearse	B-DISEASE
-	I-DISEASE
Stevenson	I-DISEASE
syndrome	I-DISEASE
,	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
,	O
Muenke	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
Pfeiffer	B-DISEASE
syndrom	I-DISEASE
11	O
)	O
.	O

For	O
exclusion	O
of	O
the	O
common	O
c	B-VARIANT
.	I-VARIANT
2991	I-VARIANT
+	I-VARIANT
1655A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
the	O
CEP290	B-GENE
gene	O
mutation	O
in	O
all	O
LCA	B-DISEASE
patients	O
prior	O
to	O
NGS	O
analysis	O
,	O
the	O
region	O
of	O
interest	O
in	O
intron	O
26	O
was	O
amplified	O
by	O
PCR	O
.	O

A	O
total	O
of	O
83	O
genes	O
are	O
found	O
within	O
the	O
linkage	O
interval	O
,	O
including	O
the	O
known	O
ARNSHI	B-DISEASE
gene	O
,	O
ESRRB	B-GENE
.	O

49	O
Our	O
future	O
research	O
will	O
focus	O
on	O
detection	O
of	O
large	O
genomic	O
rearrangements	O
and	O
mutations	O
causing	O
splicing	O
aberrations	O
at	O
the	O
mRNA	O
level	O
and	O
will	O
aim	O
to	O
clarify	O
further	O
the	O
molecular	O
diagnosis	O
in	O
the	O
NCUS	O
cohort	O
.	O

All	O
mutations	O
were	O
checked	O
using	O
Mutalyzer	O
.	O

Although	O
several	O
red	O
and	O
green	O
signals	O
are	O
seen	O
,	O
there	O
is	O
no	O
portion	O
associated	O
with	O
>	O
=	O
3	O
consecutive	O
red	O
or	O
green	O
signals	O
.	O

Boys	O
in	O
the	O
pubertal	O
age	O
may	O
present	O
with	O
pubertal	O
delay	O
and	O
distinguishing	O
HH	B-DISEASE
from	O
constitutional	O
delay	O
of	O
growth	O
and	O
puberty	O
may	O
be	O
difficult	O
in	O
this	O
situation	O
.	O

In	O
the	O
disease	O
course	O
of	O
RP	B-DISEASE
,	O
rod	O
photoreceptors	O
will	O
initially	O
be	O
affected	O
thus	O
leading	O
to	O
night	B-DISEASE
blindness	I-DISEASE
and	O
visual	O
field	O
(	O
VF	O
)	O
constrictions	O
,	O
while	O
subsequent	O
cone	B-DISEASE
defects	I-DISEASE
will	O
cause	O
color	B-DISEASE
blindness	I-DISEASE
,	O
central	B-DISEASE
vision	I-DISEASE
impairments	I-DISEASE
,	O
and	O
finally	O
total	B-DISEASE
vision	I-DISEASE
loss	I-DISEASE
[	O
2	O
]	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Hirosaki	O
University	O
Graduate	O
School	O
of	O
Medicine	O
and	O
conducted	O
according	O
to	O
the	O
principles	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Plantar	O
responses	O
were	O
flexor	O
.	O

The	O
E	O
.	O

The	O
10	O
genes	O
with	O
>	O
=	O
10	O
diagnosis	O
for	O
the	O
entire	O
cohort	O
are	O
plotted	O
individually	O
;	O
all	O
other	O
genes	O
diagnosed	O
are	O
grouped	O
as	O
"	O
other	O
"	O
.	O

Although	O
most	O
of	O
the	O
patients	O
carrying	O
biallelic	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
suffer	O
from	O
profound	B-DISEASE
deafness	I-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
resulting	O
from	O
this	O
mutation	O
may	O
range	O
from	O
moderately	O
-	O
severe	O
to	O
profound	O
,	O
with	O
certain	O
inter	O
-	O
and	O
intrafamilial	O
variability	O
[	O
3	O
,	O
4	O
,	O
7	O
,	O
10	O
]	O
.	O

In	O
summary	O
,	O
the	O
identification	O
here	O
of	O
a	O
recessive	O
form	O
of	O
type	B-DISEASE
2	I-DISEASE
Stickler	I-DISEASE
syndrome	I-DISEASE
,	O
associated	O
with	O
unusually	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
highlights	O
the	O
necessity	O
for	O
a	O
detailed	O
examination	O
of	O
both	O
parents	O
and	O
a	O
detailed	O
gene	O
analysis	O
.	O

We	O
gratefully	O
acknowledge	O
patients	O
and	O
their	O
family	O
members	O
for	O
the	O
collaboration	O
,	O
and	O
Prof	O
.	O

Using	O
anti	O
-	O
cib2	B-GENE
specific	O
morpholinos	O
,	O
we	O
knocked	O
down	O
z	O
cib2	B-GENE
in	O
embryos	O
(	O
Supplementary	O
Figs	O
.	O

The	O
family	O
segregating	O
the	O
deafness	B-DISEASE
-	O
causing	O
mutation	O
in	O
HOMER2	B-GENE
(	O
MIM	O
604799	O
;	O
RefSeq	O
NM_004839	O
)	O
is	O
a	O
multi	O
-	O
generational	O
kindred	O
of	O
European	O
descent	O
(	O
Fig	O
1A	O
)	O
.	O

Collectively	O
,	O
these	O
data	O
indicate	O
that	O
dCib2	O
is	O
necessary	O
to	O
achieve	O
a	O
strong	O
,	O
sustained	O
photoresponse	O
and	O
to	O
track	O
fast	O
light	O
stimuli	O
,	O
phenotypes	O
consistent	O
with	O
transiently	O
elevated	O
intracellular	O
Ca	O
2	O
+	O
concentrations	O
.	O

2	O
)	O
.	O

lipolytica	O
,	O
human	O
NUBPL	B-GENE
is	O
essential	O
for	O
the	O
incorporation	O
of	O
Fe	O
/	O
S	O
clusters	O
into	O
CI	O
subunits	O
,	O
and	O
its	O
knockdown	O
causes	O
improper	O
assembly	O
of	O
the	O
peripheral	O
arm	O
of	O
CI	O
,	O
reduced	O
CI	O
activity	O
,	O
and	O
abnormal	O
mitochondrial	O
morphology	O
38	O
,	O
39	O
.	O

Furthermore	O
,	O
we	O
have	O
documented	O
clinical	O
outcomes	O
and	O
salient	O
ECG	O
irregularities	O
from	O
our	O
patients	O
that	O
with	O
further	O
research	O
may	O
potentially	O
prove	O
to	O
be	O
useful	O
in	O
evaluating	O
the	O
clinical	O
severity	O
of	O
JLNS	B-DISEASE
.	O

In	O
order	O
to	O
establish	O
the	O
correct	O
allelic	O
segregation	O
,	O
DNA	O
of	O
parents	O
were	O
sequenced	O
in	O
all	O
cases	O
except	O
in	O
parents	O
of	O
proband	O
7	O
,	O
whose	O
DNA	O
sample	O
was	O
not	O
available	O
when	O
molecular	O
investigation	O
was	O
performed	O
.	O

Novel	O
COMP	B-GENE
and	O
COL2A1	B-GENE
Mutations	O
Identified	O
in	O
Four	O
Patients	O
with	O
Clinically	O
and	O
Radiographically	O
Confirmed	O
PSACH	B-DISEASE
or	O
MED	B-DISEASE
COMP	B-GENE
EGF	O
-	O
like	O
mutations	O
were	O
identified	O
in	O
MED	B-DISEASE
patient	O
ESDN	O
-	O
00521	O
and	O
PSACH	B-DISEASE
patient	O
ESDN	O
-	O
01040	O
,	O
both	O
of	O
which	O
are	O
novel	O
variants	O
that	O
are	O
not	O
present	O
in	O
the	O
dbSNP	O
database	O
version	O
130	O
(	O
May	O
2009	O
)	O
.	O

The	O
most	O
severely	O
affected	O
of	O
three	O
affected	O
siblings	O
,	O
he	O
was	O
a	O
late	O
walker	O
and	O
has	O
a	O
clumsy	O
ataxic	O
gait	O
with	O
frequent	O
falls	O
,	O
especially	O
in	O
unfamiliar	O
areas	O
.	O

Pathogenic	O
DNA	O
variants	O
Novel	O
mutations	O
are	O
in	O
bold	O
.	O

,	O
2008	O
)	O
.	O

However	O
,	O
this	O
feature	O
may	O
not	O
be	O
applicable	O
for	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
because	O
major	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
such	O
as	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
predominantly	O
cause	O
autosomal	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Using	O
these	O
data	O
,	O
the	O
frequency	O
was	O
found	O
to	O
be	O
5	O
.	O
9	O
%	O
(	O
p	B-VARIANT
.	I-VARIANT
Trp24	I-VARIANT
*	I-VARIANT
)	O
and	O
4	O
.	O
3	O
%	O
(	O
p	B-VARIANT
.	I-VARIANT
Trp77	I-VARIANT
*	I-VARIANT
)	O
[	O
31	O
]	O
,	O
[	O
33	O
]	O
.	O

Most	O
of	O
the	O
mutations	O
identified	O
in	O
USH1C	B-GENE
so	O
far	O
(	O
except	O
for	O
p	B-VARIANT
.	I-VARIANT
Pro608Arg	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
2227	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
are	O
located	O
within	O
the	O
first	O
13	O
exons	O
,	O
which	O
are	O
present	O
in	O
all	O
USH1C	B-GENE
transcripts	O
reported	O
to	O
date	O
.	O

A	O
high	O
number	O
of	O
mutations	O
responsible	O
for	O
USH	B-DISEASE
have	O
been	O
identified	O
by	O
screenings	O
performed	O
in	O
USH	B-DISEASE
patients	O
.	O

To	O
date	O
,	O
about	O
20	O
monogenic	O
CAKUT	B-DISEASE
causing	O
genes	O
have	O
been	O
identified	O
to	O
result	O
in	O
isolated	O
CAKUT	B-DISEASE
or	O
syndromic	O
CAKUT	B-DISEASE
with	O
mild	O
extra	O
-	O
renal	O
manifestations	O
14	O
-	O
34	O
.	O

All	O
four	O
siblings	O
inherited	O
the	O
same	O
haplotype	O
from	O
their	O
father	O
(	O
blue	O
)	O
and	O
the	O
same	O
haplotype	O
(	O
red	O
)	O
from	O
their	O
mother	O
,	O
which	O
suggested	O
compound	O
heterozygosity	O
.	O

Both	O
patients	O
suffered	O
from	O
severe	O
bilateral	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
severe	O
speech	B-DISEASE
problems	I-DISEASE
since	O
childhood	O
.	O

2010	O
)	O
.	O

,	O
2005	O
)	O
.	O

No	O
differences	O
in	O
phenotype	O
were	O
noted	O
between	O
patients	O
with	O
PAX3	B-GENE
point	O
mutations	O
and	O
PAX3	B-GENE
deletions	O
.	O

Long	B-DISEASE
QT	I-DISEASE
syndrome	I-DISEASE
(	O
LQTS	B-DISEASE
)	O
is	O
an	O
autosomal	O
dominant	O
inherited	O
arrhythmogenic	B-DISEASE
disease	I-DISEASE
and	O
a	O
significant	O
cause	O
of	O
sudden	B-DISEASE
cardiac	I-DISEASE
death	I-DISEASE
(	O
SCD	B-DISEASE
)	O
,	O
usually	O
in	O
young	O
and	O
otherwise	O
healthy	O
individuals	O
.	O

Tables	O
S3A	O
and	O
S3B	O
)	O
.	O

Only	O
3	O
patients	O
had	O
previously	O
reported	O
pathogenic	O
mtDNA	O
mutations	O
and	O
only	O
8	O
patients	O
had	O
recessive	O
-	O
type	O
mutations	O
in	O
known	O
disease	O
genes	O
,	O
including	O
5	O
novel	O
and	O
2	O
previously	O
reported	O
mutations	O
(	O
Table	O
3	O
)	O
.	O

Corresponding	O
mutation	O
locations	O
are	O
indicated	O
by	O
arrows	O
Sequencing	O
chromatograms	O
of	O
pathogenic	O
variants	O
identified	O
in	O
this	O
work	O
.	O

For	O
BRCA1	B-GENE
,	O
none	O
of	O
the	O
variants	O
were	O
classified	O
as	O
pathogenic	O
.	O

If	O
haplotypes	O
are	O
compatible	O
with	O
USH3A	B-GENE
linkage	O
or	O
the	O
USH	B-DISEASE
microarray	O
detects	O
only	O
one	O
mutation	O
,	O
we	O
perform	O
direct	O
sequencing	O
of	O
CLRN1	B-GENE
.	O

We	O
also	O
found	O
49	O
non	O
-	O
pathogenic	O
CDH23	B-GENE
variants	O
,	O
including	O
12	O
new	O
variants	O
(	O
Additional	O
file	O
2	O
:	O
Table	O
S2	O
)	O
.	O

Cases	O
with	O
characteristic	O
radiologic	O
markers	O
such	O
as	O
bilateral	O
enlarged	O
vestibular	O
aqueduct	O
(	O
5	O
probands	O
)	O
or	O
incomplete	O
partition	O
type	O
III	O
(	O
5	O
probands	O
)	O
were	O
directly	O
subject	O
to	O
further	O
Sanger	O
sequencing	O
of	O
the	O
corresponding	O
candidate	O
genes	O
,	O
SLC26A4	B-GENE
and	O
POU3F4	B-GENE
,	O
respectively	O
.	O

The	O
two	O
other	O
patients	O
associated	O
p	B-VARIANT
.	I-VARIANT
L46F	I-VARIANT
and	O
another	O
mutation	O
.	O

To	O
date	O
,	O
36	O
genes	O
have	O
been	O
implicated	O
in	O
non	O
-	O
syndromic	O
arRP	B-DISEASE
and	O
three	O
additional	O
loci	O
have	O
been	O
mapped	O
(	O
RetNet	O
)	O
.	O

collected	O
the	O
samples	O
and	O
performed	O
the	O
experiments	O
.	O

The	O
ischiadic	O
bones	O
are	O
broad	O
.	O

Of	O
these	O
variants	O
,	O
approximately	O
65	O
%	O
of	O
the	O
novel	O
SNPs	O
were	O
predicted	O
,	O
using	O
SIFT	O
software	O
,	O
to	O
be	O
deleterious	O
mutations	O
[	O
36	O
]	O
.	O

and	O
Z	O
.	O
M	O
.	O
A	O
.	O
;	O
National	O
Institute	O
on	O
Deafness	B-DISEASE
and	O
Other	O
Communication	B-DISEASE
Disorders	I-DISEASE
(	O
NIDCD	O
/	O
NIH	O
)	O
research	O
grants	O
R01	O
DC03594	O
and	O
DC011651	O
to	O
S	O
.	O
M	O
.	O
L	O
.	O
;	O
R01	O
HL092544	O
to	O
L	O
.	O
V	O
.	O
P	O
.	O
;	O
R01	O
DC009645	O
to	O
M	O
.	O
T	O
.	O
;	O
R01	O
DC008861	O
to	O
G	O
.	O
I	O
.	O
F	O
.	O
;	O
R01	O
DC012564	O
and	O
R00	O
DC009287	O
to	O
Z	O
.	O
M	O
.	O
A	O
.	O
;	O
R01	O
DC011803	O
and	O
R01	O
DC011748	O
to	O
S	O
.	O
R	O
.	O

RNA	O
prepared	O
from	O
either	O
transfected	O
or	O
patients	O
'	O
cells	O
was	O
analysed	O
by	O
reverse	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
as	O
previously	O
described	O
.	O

All	O
four	O
parents	O
were	O
farmers	O
and	O
were	O
visually	O
asymptomatic	O
by	O
self	O
-	O
report	O
.	O

The	O
three	O
amino	O
acids	O
at	O
the	O
C	O
-	O
terminus	O
(	O
"	O
AKL	O
"	O
)	O
constitute	O
the	O
peroxisomal	O
targeting	O
signal	O
(	O
PTS	O
)	O
.	O

Two	O
families	O
(	O
F3	O
and	O
F5	O
)	O
carrying	O
compound	O
heterozygous	O
mutations	O
(	O
either	O
two	O
truncating	O
or	O
one	O
truncating	O
combined	O
with	O
one	O
missense	O
)	O
in	O
exons	O
22	O
-	O
72	O
,	O
presented	O
with	O
the	O
USH2	B-DISEASE
phenotype	O
.	O

We	O
identified	O
a	O
homozygous	O
13	O
bp	O
duplication	O
in	O
exon	O
11	O
(	O
c	B-VARIANT
.	I-VARIANT
1135	I-VARIANT
-	I-VARIANT
1147dup	I-VARIANT
;	O
Figure	O
2C	O
)	O
.	O

Here	O
we	O
describe	O
a	O
family	O
,	O
a	O
mother	O
and	O
her	O
son	O
,	O
with	O
SPD	B-DISEASE
and	O
a	O
novel	O
truncating	O
mutation	O
in	O
the	O
C	O
-	O
propeptide	O
domain	O
of	O
COL2A1	B-GENE
.	O

The	O
MYO7A	B-GENE
encodes	O
a	O
protein	O
classified	O
as	O
an	O
unconventional	O
myosin	O
.	O

His	O
mother	O
'	O
s	O
obstetric	O
history	O
was	O
unremarkable	O
.	O

Wolfram	B-DISEASE
syndrome	I-DISEASE
(	O
WS	O
;	O
OMIM	O
222300	O
)	O
is	O
an	O
uncommon	O
genetic	O
disease	O
defined	O
by	O
the	O
association	O
of	O
early	O
onset	O
optic	B-DISEASE
atrophy	I-DISEASE
and	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
both	O
appearing	O
during	O
the	O
first	O
two	O
decades	O
of	O
life	O
[	O
1	O
]	O
.	O

As	O
in	O
Fig	O
.	O

(	O
c	O
)	O
Western	O
blot	O
of	O
protein	O
extracts	O
of	O
HEK293T	O
cells	O
expressing	O
wild	O
type	O
(	O
WT	O
)	O
and	O
G169R	B-VARIANT
mutant	O
Flag	O
-	O
CEACAM16	B-GENE
and	O
of	O
culture	O
media	O
secreted	O
protein	O
precipitates	O
(	O
upper	O
panel	O
)	O
.	O

Note	O
that	O
the	O
orientation	O
of	O
the	O
graphic	O
is	O
opposite	O
to	O
Figure	O
1b	O
and	O
that	O
SNP	O
alleles	O
are	O
given	O
in	O
reverse	O
complement	O
.	O

The	O
study	O
comprised	O
749	O
individuals	O
from	O
650	O
families	O
with	O
CAKUT	B-DISEASE
from	O
25	O
different	O
pediatric	O
nephrology	O
units	O
worldwide	O
(	O
see	O
Supplementary	O
Table	O
1	O
)	O
.	O

No	O
mutation	O
was	O
identified	O
in	O
GJB2	B-GENE
and	O
in	O
subsequent	O
targeted	O
NGS	O
of	O
66	O
known	O
deafness	B-DISEASE
genes	O
.	O

Precipitates	O
were	O
immunoblotted	O
with	O
antibodies	O
to	O
the	O
GFP	O
and	O
HA	O
tags	O
.	O

Protein	O
structures	O
of	O
missense	O
mutations	O
in	O
myosin	B-GENE
VI	I-GENE
and	O
myosin	B-GENE
Ia	I-GENE
.	O

(	O
b	O
)	O
Ten	O
year	O
old	O
affected	O
individual	O
of	O
family	O
PKDF704	O
has	O
moderate	O
to	O
profound	O
,	O
bilateral	O
,	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
while	O
her	O
eleven	O
year	O
old	O
sibling	O
has	O
severe	O
to	O
profound	O
,	O
bilateral	O
sensorineural	O
hearing	O
impairment	O
.	O

Saul	O
Merin	O
who	O
passed	O
away	O
during	O
the	O
preparation	O
of	O
this	O
manuscript	O
.	O

Additional	O
STRs	O
on	O
2p	O
were	O
genotyped	O
,	O
and	O
haplotype	O
analysis	O
revealed	O
a	O
0	O
.	O
91	O
Mb	O
linkage	O
interval	O
that	O
was	O
delimited	O
by	O
the	O
markers	O
D2S1387	O
and	O
D2S2232	O
(	O
Figure	O
1A	O
)	O
.	O

Mutation	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
in	O
EYA4	B-GENE
(	O
NM_004100	O
.	O
4	O
)	O
was	O
the	O
only	O
nonsense	O
mutation	O
identified	O
in	O
this	O
study	O
.	O

Overview	O
of	O
data	O
production	O
.	O

Twenty	O
-	O
nine	O
were	O
considered	O
as	O
non	O
-	O
pathogenic	O
because	O
all	O
of	O
them	O
were	O
already	O
described	O
as	O
non	O
-	O
pathogenic	O
in	O
other	O
studies	O
[	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
,	O
[	O
35	O
]	O
]	O
.	O

We	O
sequenced	O
the	O
MYO6	B-GENE
and	O
MYO1A	B-GENE
genes	O
in	O
53	O
unrelated	O
Korean	O
ADNSHL	B-DISEASE
patients	O
.	O

Haplotype	O
analysis	O
,	O
using	O
six	O
polymorphic	O
microsatellite	O
markers	O
,	O
spanning	O
24	O
.	O
6	O
cM	O
,	O
flanking	O
the	O
KCNH2	B-GENE
gene	O
at	O
distances	O
ranging	O
from	O
10	O
.	O
1	O
Mb	O
3	O
'	O
to	O
2	O
.	O
9	O
Mb	O
5	O
'	O
as	O
shown	O
in	O
Figure	O
1	O
,	O
demonstrated	O
that	O
both	O
mutations	O
were	O
founder	O
mutations	O
(	O
Additional	O
file	O
1	O
:	O
Table	O
S1	O
)	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
from	O
patients	O
and	O
their	O
lineal	O
relatives	O
.	O

The	O
black	O
arrow	O
indicates	O
the	O
proband	O
in	O
each	O
family	O
.	O

A	O
majority	O
of	O
these	O
were	O
located	O
in	O
the	O
GTPase	O
regions	O
(	O
n	O
=	O
19	O
,	O
57	O
.	O
6	O
%	O
)	O
,	O
with	O
a	O
small	O
cluster	O
in	O
the	O
dynamin	O
domain	O
(	O
n	O
=	O
4	O
,	O
12	O
.	O
1	O
%	O
)	O
.	O

Additional	O
proteins	O
required	O
for	O
CI	O
activity	O
are	O
likely	O
to	O
reside	O
in	O
the	O
mitochondrion	O
and	O
aid	O
in	O
its	O
assembly	O
and	O
regulation	O
.	O

Comparison	O
of	O
genotypes	O
called	O
from	O
the	O
exome	O
data	O
with	O
those	O
also	O
called	O
on	O
the	O
HumanOmni2	O
.	O
5	O
-	O
8	O
BeadChip	O
for	O
each	O
individual	O
showed	O
a	O
mean	O
concordance	O
of	O
99	O
.	O
60	O
%	O
overall	O
(	O
n	O
=	O
123	O
,	O
376	O
-	O
126	O
,	O
328	O
)	O
,	O
99	O
.	O
83	O
%	O
in	O
coding	O
regions	O
(	O
n	O
=	O
63	O
,	O
929	O
-	O
64	O
,	O
093	O
)	O
and	O
99	O
.	O
48	O
%	O
at	O
heterozygous	O
sites	O
on	O
the	O
BeadChip	O
in	O
coding	O
regions	O
(	O
n	O
=	O
8	O
,	O
043	O
-	O
8	O
,	O
261	O
)	O
.	O

*	O
*	O
*	O
ASSR	O
,	O
auditory	O
steady	O
state	O
responses	O
.	O

13	O
Common	O
features	O
of	O
these	O
disorders	O
are	O
developmental	B-DISEASE
disabilities	I-DISEASE
such	O
as	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
motor	B-DISEASE
dysfunction	I-DISEASE
and	O
muscle	B-DISEASE
weakness	I-DISEASE
,	O
and	O
abnormal	O
MRI	O
findings	O
in	O
brain	O
.	O

So	O
far	O
,	O
CMTX5	B-DISEASE
,	O
Arts	B-DISEASE
syndrome	I-DISEASE
and	O
DFN2	B-DISEASE
were	O
only	O
reported	O
in	O
different	O
families	O
,	O
not	O
within	O
the	O
same	O
family	O
[	O
6	O
]	O
.	O

This	O
may	O
indicate	O
an	O
important	O
role	O
for	O
the	O
amino	O
acid	O
R134	O
in	O
the	O
protein	O
.	O

(	O
C	O
)	O
The	O
GATA3	B-GENE
gene	O
consists	O
of	O
exons	O
1	O
-	O
6	O
(	O
E1	O
-	O
E6	O
)	O
and	O
encodes	O
two	O
transactivating	O
domains	O
(	O
TA1	O
and	O
TA2	O
)	O
and	O
two	O
zinc	O
finger	O
domains	O
(	O
ZF1	O
and	O
ZF2	O
)	O
.	O

However	O
,	O
PolyPhen	O
classified	O
the	O
variant	O
as	O
possibly	O
damaging	O
.	O

The	O
organization	O
of	O
eukaryotic	O
cells	O
is	O
established	O
by	O
several	O
junctional	O
proteins	O
that	O
effectively	O
compartmentalize	O
internal	O
multicellular	O
environments	O
that	O
need	O
to	O
operate	O
as	O
specialized	O
functional	O
units	O
.	O

We	O
verified	O
that	O
the	O
TCOF1	B-GENE
transcript	O
levels	O
were	O
significantly	O
reduced	O
in	O
patients	O
as	O
compared	O
to	O
controls	O
in	O
all	O
the	O
cell	O
types	O
studied	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
a	O
large	O
cohort	O
of	O
patients	O
,	O
clinical	O
characteristics	O
(	O
onset	O
age	O
,	O
progression	O
,	O
audiograms	O
)	O
of	O
patients	O
with	O
CDH23	B-GENE
mutations	O
were	O
clarified	O
.	O

We	O
and	O
others	O
have	O
recently	O
reported	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
MYH9	B-GENE
-	O
RD	O
[	O
9	O
,	O
17	O
]	O
.	O

However	O
,	O
although	O
with	O
lower	O
efficiency	O
,	O
WES	O
could	O
in	O
principle	O
still	O
be	O
applied	O
.	O

1396	O
probands	O
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
patients	O
including	O
304	O
probands	O
used	O
in	O
the	O
first	O
screening	O
were	O
used	O
for	O
the	O
second	O
assay	O
.	O

These	O
values	O
never	O
exceeded	O
the	O
third	O
percentile	O
since	O
birth	O
.	O

A	O
small	O
number	O
of	O
patients	O
had	O
either	O
a	O
very	O
severe	O
thrombocytopenia	B-DISEASE
(	O
<	O
=	O
10	O
x	O
10	O
9	O
/	O
L	O
,	O
7	O
.	O
4	O
%	O
)	O
or	O
,	O
in	O
contrast	O
,	O
a	O
moderate	O
thrombocytopenia	B-DISEASE
(	O
>	O
101	O
x	O
10	O
9	O
/	O
L	O
,	O
10	O
.	O
3	O
%	O
)	O
.	O

After	O
the	O
products	O
were	O
purified	O
,	O
we	O
performed	O
standard	O
cycle	O
-	O
sequencing	O
reactions	O
with	O
ABI	O
Big	O
Dye	O
(	O
r	O
)	O
terminators	O
in	O
an	O
ABI	O
PRISM	O
3100	O
Genetic	O
Analyzer	O
autosequencer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

An	O
intronic	O
variant	O
,	O
c	B-VARIANT
.	I-VARIANT
1086	I-VARIANT
-	I-VARIANT
12G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
was	O
identified	O
in	O
a	O
homozygous	O
state	O
in	O
three	O
affected	O
patients	O
of	O
one	O
Turkish	O
family	O
(	O
FRP	O
-	O
284	O
;	O
patients	O
RP	O
-	O
1367	O
,	O
RP	O
-	O
1368	O
,	O
and	O
RP	O
-	O
1371	O
)	O
.	O

As	O
a	O
result	O
,	O
we	O
identified	O
a	O
homozygous	O
genotype	O
(	O
p	O
.	O
Leu440ArgfsTer19	O
)	O
that	O
has	O
not	O
been	O
previously	O
reported	O
in	O
SPG49	B-DISEASE
patients	O
.	O

Pigmentary	B-DISEASE
anomalies	I-DISEASE
suggest	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
and	O
mutations	O
in	O
PAX3	B-GENE
,	O
MITF	B-GENE
,	O
SOX10	B-GENE
or	O
other	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
-	O
associated	O
genes	O
.	O

Sequence	O
analysis	O
of	O
the	O
GJB2	B-GENE
gene	O
indicated	O
that	O
51	O
patients	O
carried	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
and	O
1	O
patient	O
had	O
an	O
R75W	B-VARIANT
mutation	O
,	O
which	O
has	O
been	O
reported	O
to	O
cause	O
autosomal	O
dominant	O
syndromic	O
deafness	B-DISEASE
with	O
palmoplantar	B-DISEASE
keratoderma	I-DISEASE
[	O
44	O
]	O
(	O
Table	O
1	O
)	O
.	O

Figure	O
3	O
illustrates	O
that	O
most	O
of	O
the	O
progression	O
at	O
the	O
higher	O
frequencies	O
,	O
in	O
the	O
absence	O
of	O
a	O
pronounced	O
congenital	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
already	O
occurred	O
before	O
the	O
age	O
of	O
10	O
years	O
.	O

Primers	O
were	O
designed	O
with	O
Primer3	O
software	O
[	O
62	O
]	O
to	O
amplify	O
exons	O
as	O
well	O
as	O
flanking	O
introns	O
and	O
untranslated	O
regions	O
(	O
S4	O
Table	O
)	O
.	O

Visual	O
evoked	O
potentials	O
and	O
brainstem	O
auditory	O
evoked	O
potentials	O
in	O
two	O
patients	O
(	O
II	O
-	O
1	O
and	O
II	O
-	O
2	O
)	O
were	O
done	O
.	O

If	O
we	O
could	O
diagnose	O
somatic	O
mosaicism	O
of	O
the	O
NLRP3	B-GENE
gene	O
within	O
a	O
reasonable	O
time	O
with	O
low	O
labour	O
and	O
costs	O
as	O
shown	O
in	O
this	O
study	O
,	O
the	O
success	O
rate	O
of	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
genetic	O
diagnosis	O
will	O
increase	O
from	O
60	O
to	O
80	O
%	O
or	O
higher	O
,	O
9	O
which	O
will	O
greatly	O
advance	O
the	O
health	O
and	O
care	O
of	O
these	O
patients	O
and	O
prevent	O
irreversible	O
bone	O
and	O
neurological	O
complications	O
of	O
disease	O
.	O

Image	O
analysis	O
and	O
base	O
calling	O
were	O
performed	O
using	O
the	O
Illumina	O
Real	O
-	O
Time	O
Analysis	O
Pipeline	O
version	O
1	O
.	O
14	O
with	O
default	O
parameters	O
[	O
9	O
]	O
.	O

50	O
mu	O
l	O
MyOne	O
beads	O
(	O
Life	O
Technology	O
)	O
was	O
washed	O
in	O
500	O
mu	O
L	O
1Xbinding	O
buffer	O
for	O
3	O
times	O
and	O
resuspended	O
in	O
80	O
mu	O
l	O
1Xbinding	O
buffer	O
.	O

Clinical	O
examination	O
failed	O
to	O
detect	O
additional	O
symptoms	O
indicating	O
a	O
syndromic	O
form	O
of	O
deafness	B-DISEASE
,	O
and	O
neither	O
proteinuria	O
nor	O
hematuria	O
was	O
observed	O
.	O

Some	O
KS	B-DISEASE
patients	O
without	O
CHD7	B-GENE
mutations	O
display	O
CHARGE	B-DISEASE
syndrome	O
-	O
associated	O
phenotypic	O
features	O
,	O
implying	O
that	O
,	O
in	O
addition	O
to	O
CHD7	B-GENE
,	O
there	O
may	O
be	O
other	O
genes	O
associated	O
with	O
both	O
syndromes	O
.	O

Speech	O
perception	O
measures	O
and	O
electrically	O
-	O
evoked	O
auditory	O
nerve	O
and	O
brainstem	O
responses	O
were	O
obtained	O
after	O
1	O
year	O
of	O
cochlear	O
implant	O
use	O
.	O

The	O
ratio	O
RPA	O
(	O
relative	O
peak	O
area	O
)	O
was	O
calculated	O
as	O
the	O
RPA	O
of	O
the	O
patient	O
versus	O
controls	O
.	O

3	O
)	O
.	O

Allele	O
frequencies	O
can	O
differ	O
between	O
populations	O
and	O
these	O
differences	O
can	O
have	O
important	O
medical	O
implications	O
[	O
35	O
]	O
.	O

The	O
first	O
was	O
a	O
novel	O
variant	O
,	O
and	O
all	O
three	O
patients	O
carrying	O
it	O
(	O
two	O
of	O
whom	O
were	O
sisters	O
)	O
came	O
from	O
the	O
area	O
of	O
Bari	O
in	O
southern	O
Italy	O
.	O

Genetic	O
analyses	O
were	O
performed	O
after	O
obtaining	O
the	O
subject	O
'	O
s	O
consent	O
.	O

Subsequently	O
molecular	O
analysis	O
revealed	O
mutations	O
in	O
POU3F4	B-GENE
(	O
POU	O
domain	O
,	O
class	O
III	O
,	O
transcription	O
factor	O
4	O
-	O
NM_000307	O
.	O
4	O
)	O
[	O
10	O
]	O
.	O

In	O
Western	O
deaf	O
population	O
,	O
L236P	B-VARIANT
,	O
T416P	B-VARIANT
,	O
E384G	B-VARIANT
,	O
and	O
IVS8	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
are	O
common	O
mutant	O
loci	O
of	O
SLC26A4	B-GENE
[	O
21	O
]	O
,	O
whereas	O
2168A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
is	O
the	O
primary	O
mutant	O
locus	O
in	O
Japanese	O
and	O
Korean	O
deaf	O
patients	O
[	O
27	O
,	O
28	O
]	O
.	O

Inter	O
-	O
exonic	O
primers	O
(	O
S5	O
Table	O
)	O
were	O
designed	O
with	O
Primer3	O
software	O
and	O
PCR	O
amplifications	O
were	O
performed	O
with	O
EconoTaq	O
(	O
Lucigen	O
)	O
.	O

20	O
h	O
later	O
,	O
the	O
cells	O
were	O
stimulated	O
with	O
FGF2	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
)	O
,	O
50	O
ng	O
/	O
ml	O
for	O
0	O
/	O
2	O
/	O
10	O
/	O
30	O
min	O
.	O

The	O
location	O
of	O
mutations	O
in	O
otoferlin	O
protein	O
and	O
the	O
evolutionary	O
conservation	O
of	O
the	O
amino	O
acids	O
.	O

(	O
B	O
)	O
A	O
close	O
view	O
of	O
the	O
residue	O
165	O
highlighting	O
the	O
wide	O
type	O
amino	O
acid	O
threonine	O
,	O
the	O
generated	O
hydrogen	O
bonds	O
(	O
in	O
red	O
)	O
,	O
and	O
their	O
interacted	O
amino	O
acids	O
,	O
including	O
Thr168	O
,	O
Lys169	O
,	O
Ser211	O
,	O
and	O
Asp437	O
.	O

However	O
,	O
the	O
genotype	O
R127H	B-VARIANT
/	O
M34T	B-VARIANT
was	O
identified	O
twice	O
in	O
our	O
patient	O
cohort	O
(	O
2	O
/	O
159	O
1	O
.	O
25	O
%	O
)	O
but	O
never	O
in	O
the	O
general	O
population	O
(	O
odds	O
to	O
be	O
associated	O
randomly	O
of	O
1	O
.	O
5	O
x	O
10	O
-	O
4	O
)	O
.	O

See	O
Table	O
3	O
for	O
primers	O
.	O

PCR	O
was	O
performed	O
using	O
AmpliTaq	O
Gold	O
360	O
Master	O
mix	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
with	O
50	O
ng	O
genomic	O
DNA	O
and	O
10	O
pmol	O
of	O
each	O
primer	O
in	O
a	O
total	O
volume	O
of	O
25	O
u	O
l	O
.	O

The	O
novel	O
are	O
in	O
boldface	O
.	O

We	O
also	O
characterize	O
patterns	O
of	O
loss	O
of	O
heterozygosity	O
in	O
tumor	O
suppressor	O
genes	O
,	O
including	O
BRCA1	B-GENE
,	O
BRCA2	B-GENE
,	O
BRIP1	B-GENE
,	O
ATM	B-GENE
,	O
CHEK2	B-GENE
,	O
and	O
PALB2	B-GENE
,	O
and	O
identify	O
significantly	O
mutated	O
pathways	O
,	O
including	O
Fanconi	O
anemia	O
,	O
MAPK	O
,	O
and	O
MLL	B-GENE
.	O

WS	B-DISEASE
is	O
an	O
autosomal	O
recessive	O
disorder	O
,	O
with	O
nearly	O
all	O
cases	O
harboring	O
mutations	O
in	O
both	O
alleles	O
of	O
WFS1	B-GENE
(	O
as	O
reviewed	O
in	O
17	O
,	O
25	O
)	O
(	O
Fig	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
variant	O
is	O
located	O
at	O
eyaHR	O
,	O
which	O
is	O
crucial	O
for	O
the	O
function	O
of	O
the	O
protein	O
.	O

This	O
suggested	O
that	O
the	O
age	O
at	O
onset	O
has	O
an	O
influence	O
on	O
the	O
different	O
phenotypes	O
shown	O
with	O
the	O
same	O
mutation	O
of	O
the	O
COL2A1	B-GENE
gene	O
.	O

WFS	B-DISEASE
causes	O
multiple	O
endocrine	O
and	O
neurologic	B-DISEASE
deficits	I-DISEASE
,	O
even	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
that	O
are	O
clinically	O
apparent	O
when	O
subjects	O
are	O
directly	O
examined	O
in	O
a	O
standardized	O
manner	O
.	O

The	O
concentrations	O
of	O
parathyroid	O
hormone	O
range	O
from	O
low	O
to	O
high	O
even	O
in	O
some	O
individuals	O
12	O
)	O
.	O

Summary	O
statistics	O
of	O
targeted	O
exome	O
sequencing	O
for	O
45	O
samples	O
[	O
57	O
-	O
60	O
]	O
.	O

34	O
The	O
patient	O
had	O
overlapping	O
manifestations	O
with	O
SPG49	B-DISEASE
,	O
including	O
severe	O
hypotonia	B-DISEASE
,	O
gastroesophageal	B-DISEASE
reflux	I-DISEASE
disease	I-DISEASE
,	O
areflexia	B-DISEASE
,	O
intellectual	B-DISEASE
disability	I-DISEASE
,	O
and	O
breathing	B-DISEASE
abnormalities	I-DISEASE
;	O
however	O
,	O
this	O
patient	O
did	O
not	O
have	O
any	O
qualifying	O
genotypes	O
.	O

Familial	O
genotyping	O
confirmed	O
the	O
deletion	O
was	O
inherited	O
from	O
the	O
father	O
,	O
and	O
compounded	O
with	O
a	O
missense	O
mutation	O
inherited	O
from	O
the	O
mother	O
(	O
Figure	O
2	O
)	O
.	O

In	O
-	O
house	O
generated	O
cDNA	O
capture	O
probes	O
with	O
lengths	O
ranging	O
from	O
100	O
to	O
~	O
5000	O
bps	O
were	O
used	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
CA	O
.	O

Two	O
of	O
this	O
patient	O
'	O
s	O
relatives	O
had	O
COL4A3	B-GENE
-	O
L1474P	B-VARIANT
mutation	O
.	O

A	O
47	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
haematuria	B-DISEASE
,	O
hypertension	B-DISEASE
,	O
abnormal	O
renal	O
function	O
(	O
serum	O
creatinine	O
114	O
u	O
mol	O
/	O
L	O
)	O
,	O
proteinuria	B-DISEASE
and	O
mild	O
high	O
-	O
tone	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

RNA	O
was	O
derived	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
the	O
three	O
patients	O
(	O
IV	O
:	O
2	O
,	O
IV	O
:	O
3	O
and	O
III	O
:	O
2	O
)	O
and	O
an	O
unaffected	O
control	O
(	O
IV	O
:	O
1	O
)	O
.	O

In	O
an	O
analysis	O
of	O
48	O
exons	O
of	O
MYO7A	B-GENE
in	O
the	O
families	O
heterozygous	O
for	O
USH1C	B-GENE
mutations	O
,	O
one	O
new	O
intronic	O
variant	O
c	B-VARIANT
.	I-VARIANT
736	I-VARIANT
-	I-VARIANT
73C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
was	O
observed	O
in	O
four	O
out	O
of	O
the	O
five	O
families	O
examined	O
.	O

C	O
Electropherogram	O
of	O
a	O
heterozygous	O
carrier	O
of	O
the	O
OSBPL2	B-GENE
mutation	O
in	O
exon	O
3	O
(	O
deleted	O
nucleotides	O
are	O
boxed	O
)	O
.	O

nos	O
.	O

Due	O
to	O
the	O
genetic	O
heterogeneity	O
in	O
sensorineural	O
genetic	O
disorders	O
,	O
the	O
high	O
-	O
throughput	O
method	O
can	O
be	O
adapted	O
for	O
the	O
efficient	O
diagnosis	O
.	O

Kidney	B-DISEASE
disease	I-DISEASE
associated	O
with	O
deafness	B-DISEASE
was	O
observed	O
in	O
the	O
majority	O
of	O
cases	O
with	O
exon	O
17	O
mutations	O
(	O
for	O
p	B-VARIANT
.	I-VARIANT
R702C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R702H	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R718W	I-VARIANT
)	O
,	O
and	O
in	O
half	O
of	O
the	O
cases	O
with	O
p	B-VARIANT
.	I-VARIANT
S96L	I-VARIANT
or	O
p	B-VARIANT
.	I-VARIANT
N93K	I-VARIANT
mutations	O
in	O
exon	O
2	O
.	O

Firefly	O
luciferase	O
activity	O
was	O
measured	O
using	O
the	O
Dual	O
-	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
and	O
normalized	O
to	O
Renilla	O
luciferase	O
values	O
of	O
the	O
cotransfected	O
pRL	O
-	O
TK	O
vector	O
(	O
Promega	O
)	O
to	O
control	O
for	O
differences	O
in	O
transfection	O
efficiency	O
.	O

Of	O
the	O
1119	O
patients	O
presenting	O
for	O
testing	O
in	O
our	O
clinical	O
diagnostic	O
laboratory	O
,	O
we	O
were	O
able	O
to	O
diagnose	O
a	O
genetic	O
cause	O
of	O
deafness	B-DISEASE
in	O
440	O
persons	O
(	O
39	O
%	O
)	O
.	O

Students	O
t	O
-	O
test	O
have	O
been	O
performed	O
for	O
statistical	O
analysis	O
.	O

The	O
Mann	O
-	O
Whitney	O
test	O
was	O
used	O
for	O
comparison	O
of	O
QTc	O
,	O
and	O
parametric	O
tests	O
were	O
used	O
for	O
comparison	O
of	O
normally	O
distributed	O
variables	O
.	O

After	O
further	O
validation	O
by	O
Sanger	O
sequencing	O
,	O
segregation	O
pattern	O
,	O
and	O
evolutionary	O
conservation	O
of	O
amino	O
acid	O
residues	O
,	O
we	O
identified	O
4	O
variants	O
in	O
4	O
different	O
genes	O
,	O
which	O
might	O
lead	O
to	O
SNHI	B-DISEASE
in	O
4	O
families	O
compatible	O
with	O
autosomal	O
dominant	O
inheritance	O
.	O

To	O
detect	O
smaller	O
mutations	O
,	O
we	O
developed	O
a	O
Sanger	O
sequencing	O
method	O
for	O
pseudogene	O
exclusion	O
.	O

Progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
affects	O
many	O
people	O
,	O
but	O
the	O
underlying	O
genetics	O
remain	O
largely	O
undefined	O
.	O

In	O
our	O
cases	O
,	O
the	O
father	O
did	O
not	O
have	O
kidney	B-DISEASE
disease	I-DISEASE
,	O
but	O
the	O
patient	O
had	O
the	O
classical	O
triad	O
HDR	B-DISEASE
syndrome	I-DISEASE
.	O

A	O
minimum	O
of	O
3	O
mu	O
g	O
DNA	O
was	O
used	O
for	O
the	O
indexed	O
Illumina	O
libraries	O
according	O
to	O
manufacturer	O
'	O
s	O
protocol	O
.	O

5F	O
,	O
5G	O
,	O
and	O
5H	O
)	O
.	O

The	O
circles	O
and	O
crosses	O
indicate	O
unmasked	O
air	O
conduction	O
thresholds	O
for	O
the	O
right	O
and	O
left	O
ears	O
,	O
respectively	O
.	O

Heterozygous	O
mutations	O
in	O
WFS1	B-GENE
have	O
been	O
demonstrated	O
to	O
be	O
a	O
cause	O
of	O
dominantly	O
inherited	O
nonsyndromic	O
low	O
-	O
frequency	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
18	O
]	O
.	O

Turner	B-DISEASE
'	I-DISEASE
s	I-DISEASE
syndrome	I-DISEASE
in	O
females	O
and	O
Noonan	B-DISEASE
'	I-DISEASE
s	I-DISEASE
syndrome	I-DISEASE
in	O
males	O
are	O
both	O
marked	O
by	O
hypoestrinism	B-DISEASE
and	O
include	O
the	O
HI	B-DISEASE
phenotype	O
.	O

The	O
error	O
bars	O
represent	O
the	O
standard	O
error	O
of	O
the	O
mean	O
.	O

12b	O
and	O
13	O
)	O
.	O

Total	O
RNA	O
was	O
reversely	O
transcribed	O
to	O
cDNA	O
with	O
ImProm	O
-	O
II	O
(	O
tm	O
)	O
Reverse	O
Transcription	O
System	O
(	O
Promega	O
)	O
using	O
random	O
primers	O
.	O

Therefore	O
,	O
our	O
results	O
show	O
that	O
mutations	O
in	O
DFNB1	B-GENE
account	O
for	O
only	O
3	O
%	O
of	O
ARNSHL	B-DISEASE
in	O
patients	O
of	O
Saudi	O
Arabian	O
tribal	O
ethnicity	O
.	O

(	O
A	O
)	O
Family	O
tree	O
of	O
the	O
affected	O
proband	O
(	O
II	O
-	O
3	O
)	O
.	O

We	O
detected	O
FOXRED1	B-GENE
mutations	O
in	O
a	O
male	O
infant	O
who	O
presented	O
at	O
birth	O
with	O
congenital	O
lactic	B-DISEASE
acidosis	I-DISEASE
and	O
was	O
diagnosed	O
with	O
Leigh	B-DISEASE
Syndrome	I-DISEASE
at	O
6	O
years	O
of	O
age	O
(	O
see	O
Supplementary	O
Note	O
for	O
complete	O
clinical	O
description	O
)	O
.	O

Raw	O
image	O
files	O
were	O
processed	O
by	O
Illumina	O
CASAVA	O
Software	O
version	O
1	O
.	O
7	O
for	O
base	O
-	O
calling	O
with	O
default	O
parameters	O
.	O

ERG	O
testing	O
performed	O
in	O
this	O
child	O
at	O
the	O
age	O
of	O
3	O
years	O
,	O
as	O
detailed	O
above	O
,	O
may	O
suggest	O
a	O
somewhat	O
more	O
severe	O
degenerative	O
process	O
at	O
least	O
as	O
compared	O
with	O
the	O
brother	O
manifesting	O
RP	B-DISEASE
due	O
to	O
the	O
homozygous	O
PDE6B	B-GENE
mutation	O
,	O
who	O
had	O
a	O
better	O
preserved	O
cone	O
function	O
at	O
the	O
older	O
age	O
of	O
7	O
years	O
.	O

We	O
therefore	O
developed	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
to	O
determine	O
if	O
the	O
mutation	O
was	O
present	O
in	O
50	O
normal	O
controls	O
.	O

3	O
)	O
subsequently	O
showed	O
that	O
HDR	B-DISEASE
syndrome	I-DISEASE
was	O
primarily	O
caused	O
by	O
haploinsufficiency	O
of	O
GATA3	B-GENE
on	O
chromosome	O
10p15	O
.	O

Immediately	O
,	O
tubes	O
were	O
inverted	O
about	O
5	O
times	O
and	O
labeled	O
with	O
the	O
subject	O
identification	O
code	O
.	O

Homozygous	O
Shaker	O
-	O
2	O
(	O
sh2	O
)	O
mice	O
are	O
deficient	O
in	O
myosin	B-GENE
XVA	I-GENE
due	O
to	O
a	O
premature	O
stop	O
codon	O
in	O
the	O
motor	O
domain	O
of	O
the	O
protein	O
[	O
24	O
]	O
.	O

From	O
this	O
list	O
of	O
rare	O
variants	O
,	O
we	O
identified	O
potential	O
de	O
novo	O
events	O
using	O
the	O
following	O
parameters	O
:	O
presence	O
of	O
>	O
=	O
2	O
variant	O
reads	O
in	O
the	O
proband	O
,	O
sequencing	O
depth	O
at	O
the	O
variant	O
position	O
>	O
=	O
4	O
in	O
both	O
parents	O
,	O
and	O
parental	O
allelic	O
balance	O
>	O
0	O
.	O
90	O
.	O

Click	O
here	O
for	O
file	O
PRPS1	B-GENE
sequencing	O
by	O
PCR	O
(	O
Sanger	O
sequencing	O
)	O
.	O

The	O
above	O
data	O
indicate	O
that	O
a	O
genetic	O
interaction	O
between	O
GJB3	B-GENE
and	O
GJB2	B-GENE
can	O
lead	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
61	O
]	O
.	O

,	O
2006	O
)	O
.	O

PCR	O
products	O
were	O
purified	O
with	O
Exo	O
-	O
SAP	O
(	O
USB	O
,	O
Cleveland	O
,	O
OH	O
)	O
and	O
then	O
sequenced	O
with	O
an	O
ABI2720	O
Automatic	O
DNA	O
sequencer	O
using	O
the	O
ABI	O
PRISM	O
BigDye	O
(	O
r	O
)	O
Terminator	O
v3	O
.	O
1	O
Cycle	O
Sequencing	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

All	O
parameters	O
were	O
defined	O
by	O
departmental	O
normative	O
data	O
.	O

The	O
most	O
likely	O
RET	O
haplotypes	O
of	O
the	O
pedigree	O
(	O
A	O
,	O
C	O
,	O
G	O
,	O
T	O
to	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
)	O
.	O

Among	O
the	O
query	O
results	O
,	O
in	O
any	O
case	O
of	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
,	O
the	O
medical	O
charts	O
were	O
manually	O
revised	O
,	O
and	O
all	O
patients	O
of	O
Finnish	O
origin	O
who	O
had	O
been	O
diagnosed	O
with	O
KS	B-DISEASE
on	O
the	O
basis	O
of	O
isolated	O
gonadotropin	B-DISEASE
deficiency	I-DISEASE
without	O
an	O
organic	O
cause	O
,	O
and	O
anosmia	B-DISEASE
or	O
hyposmia	B-DISEASE
,	O
were	O
identified	O
.	O

Out	O
of	O
the	O
9	O
novel	O
mutations	O
(	O
Table	O
2	O
)	O
identified	O
in	O
the	O
current	O
study	O
,	O
4	O
were	O
present	O
in	O
MYO15A	B-GENE
,	O
of	O
which	O
2	O
were	O
splice	O
site	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
9948G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
3866	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
,	O
one	O
was	O
a	O
nonsense	O
(	O
c	B-VARIANT
.	I-VARIANT
8767C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
)	O
and	O
one	O
a	O
missense	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
8222	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
.	O

Squares	O
represent	O
males	O
,	O
circles	O
represent	O
females	O
.	O

Do	O
,	O
and	O
S	O
.	O

Moreover	O
,	O
the	O
finding	O
of	O
a	O
wide	O
-	O
spread	O
founder	O
mutation	O
for	O
an	O
otherwise	O
rare	O
genetic	O
subtype	O
of	O
deafblindness	B-DISEASE
is	O
of	O
great	O
importance	O
to	O
the	O
medical	O
community	O
as	O
this	O
knowledge	O
should	O
strongly	O
influence	O
diagnostic	O
and	O
therapeutic	O
management	O
of	O
congenitally	O
deaf	O
children	O
in	O
Quebec	O
.	O

Basement	O
membrane	O
splitting	O
,	O
lamellation	O
and	O
basket	O
weaving	O
typical	O
of	O
AS	B-DISEASE
were	O
absent	O
in	O
all	O
of	O
the	O
EM	O
images	O
evaluated	O
.	O

The	O
threshold	O
of	O
individual	O
G3	O
at	O
these	O
frequencies	O
are	O
also	O
remarkably	O
high	O
in	O
comparison	O
to	O
the	O
thresholds	O
of	O
individuals	O
G4	O
and	O
G7	O
at	O
the	O
same	O
ages	O
.	O

Haruo	O
Takahashi	O
(	O
Nagasaki	O
University	O
)	O
,	O
Dr	O
.	O

In	O
two	O
of	O
the	O
studies	O
,	O
when	O
using	O
more	O
stringent	O
criteria	O
(	O
i	O
.	O
e	O
.	O

Statistics	O
of	O
whole	O
exome	O
sequencing	O
data	O
for	O
four	O
individuals	O
from	O
SNUBH18	O
.	O

Three	O
clinical	O
subtypes	O
(	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
,	O
and	O
USH3	B-DISEASE
)	O
are	O
described	O
,	O
of	O
which	O
USH1	B-DISEASE
is	O
the	O
most	O
severe	O
form	O
,	O
characterized	O
by	O
congenital	B-DISEASE
profound	I-DISEASE
deafness	I-DISEASE
,	O
constant	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
a	O
prepubertal	O
onset	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Due	O
to	O
the	O
high	O
amount	O
of	O
CD164	B-GENE
(	O
>	O
95	O
%	O
)	O
in	O
the	O
endo	O
-	O
lysosomal	O
system	O
under	O
normal	O
steady	O
-	O
state	O
conditions	O
,	O
and	O
in	O
order	O
to	O
observe	O
the	O
timing	O
of	O
the	O
endocytic	O
trafficking	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
proteins	O
,	O
all	O
CD164	B-GENE
present	O
at	O
the	O
cell	O
surface	O
on	O
living	O
transfectants	O
were	O
saturated	O
with	O
anti	O
-	O
CD164	B-GENE
antibodies	O
at	O
0	O
deg	O
C	O
,	O
as	O
cooling	O
arrests	O
internalisation	O
(	O
T0	O
)	O
.	O

The	O
USH1C	B-GENE
gene	O
mutations	O
represent	O
1	O
.	O
5	O
%	O
of	O
cases	O
.	O

We	O
clarified	O
the	O
mutation	O
spectrum	O
for	O
the	O
SLC26A4	B-GENE
mutations	O
and	O
also	O
summarized	O
hearing	O
levels	O
,	O
progression	O
,	O
fluctuation	B-DISEASE
and	O
existence	O
of	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

Figure	O
6	O
Comparison	O
of	O
mtDNA	O
copy	O
number	O
in	O
homogenate	O
skeletal	O
muscle	O
DNA	O
from	O
patients	O
with	O
OPA1	B-GENE
mutations	O
(	O
mean	O
=	O
5144	O
,	O
SD	O
=	O
2843	O
,	O
n	O
=	O
24	O
)	O
with	O
age	O
-	O
matched	O
healthy	O
controls	O
(	O
mean	O
=	O
4669	O
,	O
SD	O
=	O
2640	O
,	O
n	O
=	O
20	O
,	O
P	O
=	O
0	O
.	O
5719	O
)	O
,	O
and	O
patients	O
with	O
mtDNA	B-DISEASE
depletion	I-DISEASE
syndromes	I-DISEASE
(	O
mean	O
=	O
524	O
,	O
SD	O
=	O
345	O
,	O
n	O
=	O
6	O
,	O
P	O
=	O
0	O
.	O
0005	O
)	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
leukocytes	O
with	O
a	O
QIAmp	O
DNA	O
blood	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
in	O
accordance	O
to	O
the	O
manufacturer	O
'	O
s	O
protocols	O
,	O
and	O
stored	O
at	O
-	O
20	O
deg	O
C	O
before	O
used	O
.	O

Captured	O
libraries	O
were	O
sequenced	O
using	O
the	O
Solexa	O
GAIIx	O
Genome	O
Analyzer	O
with	O
78	O
-	O
bp	O
paired	O
-	O
end	O
reads	O
(	O
SR	O
-	O
106	O
)	O
and	O
the	O
Illumina	O
HiSeq	O
2000	O
system	O
with	O
101	O
-	O
bp	O
paired	O
-	O
end	O
reads	O
(	O
SR	O
-	O
209	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
protocols	O
.	O

A	O
total	O
of	O
58	O
,	O
262	O
and	O
61	O
,	O
340	O
variants	O
were	O
identified	O
in	O
each	O
of	O
the	O
two	O
individuals	O
,	O
respectively	O
.	O

Briefly	O
,	O
fibroblast	O
cells	O
from	O
patient	O
were	O
seeded	O
in	O
six	O
-	O
well	O
plates	O
and	O
transduced	O
22	O
hours	O
later	O
with	O
25	O
mu	O
l	O
of	O
concentrated	O
lentivirus	O
(	O
MOI	O
=	O
6	O
)	O
.	O

Between	O
age	O
5	O
and	O
6	O
,	O
no	O
progression	O
was	O
observed	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
8375	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V2792A	I-VARIANT
)	O
mutation	O
is	O
located	O
within	O
exon	O
47	O
and	O
predicted	O
to	O
lie	O
in	O
the	O
first	O
FERM	O
domain	O
of	O
myosin	B-GENE
XVa	I-GENE
.	O

,	O
2003	O
;	O
Chinnery	O
and	O
Griffiths	O
,	O
2006	O
)	O
.	O

Sequencing	O
of	O
the	O
coding	O
and	O
near	O
-	O
coding	O
regions	O
of	O
genes	O
relevant	O
to	O
each	O
patient	O
'	O
s	O
clinical	O
presentation	O
revealed	O
37	O
sequence	O
variations	O
of	O
known	O
or	O
uncertain	O
pathogenicity	O
in	O
25	O
patients	O
.	O

The	O
reported	O
incidence	O
varies	O
from	O
1	O
in	O
300	O
to	O
1	O
in	O
1000	O
children	O
[	O
1	O
-	O
4	O
]	O
.	O

LT	O
and	O
BA	O
are	O
the	O
two	O
gynecologists	O
who	O
followed	O
patient	O
1	O
from	O
the	O
17	O
th	O
to	O
the	O
32	O
nd	O
week	O
of	O
gestation	O
.	O

Notably	O
,	O
none	O
of	O
the	O
26	O
patients	O
had	O
a	O
second	O
mutation	O
,	O
while	O
the	O
NGS	O
analysis	O
verified	O
all	O
the	O
known	O
mutations	O
and	O
polymorphisms	O
we	O
had	O
found	O
in	O
these	O
patients	O
by	O
other	O
methods	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
why	O
some	O
autosomal	O
recessive	O
mutations	O
result	O
in	O
IOSCA	B-DISEASE
while	O
others	O
cause	O
hepatocerebral	B-DISEASE
syndrome	I-DISEASE
.	O

Linkage	O
analysis	O
reveals	O
a	O
LOD	O
score	O
of	O
2	O
.	O
5	O
on	O
chromosome	O
17q26	O
.	O
3	O
,	O
as	O
indicated	O
by	O
an	O
arrow	O
.	O

These	O
mutations	O
were	O
not	O
found	O
in	O
150	O
normal	O
DNA	O
samples	O
.	O

Candidate	O
variants	O
were	O
Sanger	O
validated	O
.	O

Bands	O
were	O
visualized	O
by	O
SuperSignal	O
(	O
r	O
)	O
West	O
Pico	O
Chemiluminescent	O
Substrate	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
and	O
captured	O
on	O
X	O
-	O
ray	O
film	O
(	O
Kodak	O
Biomax	O
MR	O
Film	O
,	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

No	O
percentages	O
are	O
calculated	O
if	O
there	O
are	O
less	O
than	O
10	O
cases	O
.	O

Based	O
on	O
the	O
X	O
-	O
ray	O
crystal	O
structures	O
(	O
PDB	O
entry	O
:	O
4A04	O
,	O
resolution	O
2	O
.	O
1	O
A	O
)	O
[	O
13	O
]	O
,	O
the	O
models	O
of	O
TBX1	B-GENE
and	O
its	O
mutant	O
for	O
the	O
MD	O
simulations	O
were	O
built	O
in	O
Sybyl	O
version	O
6	O
.	O
8	O
(	O
Tripos	O
Inc	O
.	O
,	O
St	O
.	O

[	O
12	O
]	O
studied	O
four	O
families	O
with	O
ANSD	B-DISEASE
by	O
linkage	O
and	O
mutation	O
analyses	O
and	O
found	O
that	O
the	O
OTOF	B-GENE
gene	O
is	O
responsible	O
for	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
three	O
of	O
the	O
families	O
.	O

Two	O
homology	O
models	O
of	O
NARS2	B-GENE
were	O
constructed	O
,	O
using	O
PYMOL	O
(	O
see	O
Web	O
Resources	O
)	O
.	O

Makishima	O
et	O
al	O
(	O
12	O
)	O
have	O
found	O
that	O
several	O
genetic	O
or	O
environmental	O
factors	O
may	O
modify	O
the	O
DFNA10	B-DISEASE
phenotype	O
.	O

We	O
identified	O
a	O
single	O
heterozygous	O
putative	O
pathogenic	O
variant	O
in	O
five	O
other	O
patients	O
,	O
while	O
we	O
could	O
not	O
recognize	O
any	O
pathogenic	O
sequence	O
variations	O
in	O
the	O
remaining	O
two	O
USH	B-DISEASE
patients	O
(	O
A26	O
and	O
USH135	O
,	O
Table	O
1	O
)	O
.	O

USH2A	B-GENE
accounts	O
for	O
80	O
%	O
of	O
Usher	B-DISEASE
type	I-DISEASE
2	I-DISEASE
cases	O
(	O
Besnard	O
et	O
al	O
.	O

One	O
patient	O
was	O
heterozygous	O
for	O
mutations	O
in	O
both	O
USH	B-DISEASE
genes	O
having	O
received	O
the	O
USH2A	B-GENE
variant	O
from	O
the	O
unaffected	O
father	O
and	O
the	O
MYO7A	B-GENE
variant	O
from	O
the	O
unaffected	O
mother	O
.	O

reported	O
T416P	B-VARIANT
and	O
IVS8	B-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
as	O
the	O
two	O
most	O
frequent	O
mutations	O
in	O
northern	O
European	O
population	O
[	O
22	O
]	O
,	O
while	O
Blons	O
et	O
al	O
.	O

carry	O
a	O
mutation	O
of	O
the	O
donor	O
splice	O
site	O
and	O
a	O
truncating	O
frameshift	O
mutation	O
.	O

Her	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
confirmed	O
at	O
10	O
months	O
of	O
age	O
via	O
auditory	O
brainstem	O
evoked	O
response	O
testing	O
.	O

Age	O
of	O
onset	O
varied	O
from	O
newborn	O
(	O
detected	O
through	O
neonatal	O
screening	O
)	O
,	O
age	O
3	O
-	O
6	O
or	O
early	O
twenties	O
.	O

Rivolta	O
et	O
al	O
.	O

Genotyping	O
was	O
performed	O
using	O
the	O
HumanCytoSNP	O
-	O
12	O
BeadChip	O
300K	O
SNPs	O
array	O
.	O

Furthermore	O
,	O
Detection	O
of	O
mutations	O
in	O
this	O
gene	O
may	O
have	O
implications	O
for	O
better	O
understanding	O
of	O
the	O
exact	O
structure	O
and	O
function	O
of	O
pendrin	O
as	O
well	O
as	O
designing	O
of	O
comfortable	O
and	O
more	O
cost	O
effective	O
strategies	O
in	O
genetic	O
diagnosis	O
of	O
HI	B-DISEASE
.	O

Murdock	O
and	O
The	O
MURDOCK	O
Study	O
Community	O
Registry	O
and	O
Biorepository	O
;	O
Dr	O
.	O

The	O
African	O
and	O
African	O
-	O
European	O
clusters	O
are	O
distinguished	O
by	O
the	O
degree	O
of	O
admixture	O
,	O
with	O
the	O
African	O
cluster	O
closer	O
to	O
the	O
African	O
ancestral	O
population	O
.	O

,	O
2008	O
;	O
Spinazzi	O
et	O
al	O
.	O

Patient	O
28	O
also	O
had	O
an	O
observed	O
novel	O
exonic	O
hit	O
and	O
is	O
thus	O
considered	O
solved	O
.	O

Recently	O
,	O
a	O
new	O
approach	O
has	O
been	O
developed	O
by	O
taking	O
advantage	O
of	O
the	O
depth	O
of	O
read	O
coverage	O
generated	O
in	O
the	O
NGS	O
data	O
analysis	O
of	O
each	O
base	O
pair	O
in	O
the	O
targeted	O
regions	O
[	O
9	O
,	O
18	O
]	O
,	O
which	O
is	O
similar	O
to	O
what	O
was	O
used	O
in	O
this	O
study	O
.	O

B	O
:	O
SSCP	O
analysis	O
for	O
c	B-VARIANT
.	I-VARIANT
7123delG	I-VARIANT
showed	O
that	O
the	O
mutant	O
pattern	O
(	O
three	O
bands	O
)	O
co	O
-	O
segregated	O
with	O
the	O
affected	O
individuals	O
and	O
carriers	O
,	O
but	O
not	O
with	O
the	O
unaffected	O
individuals	O
and	O
normal	O
controls	O
(	O
two	O
bands	O
)	O
.	O

All	O
DNA	O
samples	O
studied	O
were	O
anonymized	O
.	O

Merged	O
images	O
are	O
shown	O
in	O
(	O
C	O
,	O
F	O
,	O
I	O
)	O
.	O

Electron	O
micrograph	O
of	O
the	O
renal	O
biopsy	O
and	O
indirect	O
immunofluorescence	O
staining	O
of	O
the	O
skin	O
biopsy	O
.	O

Photoreceptor	O
morphology	O
was	O
monitored	O
in	O
live	O
flies	O
using	O
a	O
water	O
-	O
immersion	O
,	O
cornea	O
neutralization	O
,	O
epifluorescence	O
procedure	O
previously	O
described	O
.	O

The	O
mutation	O
was	O
found	O
in	O
241	O
reads	O
out	O
of	O
241	O
and	O
in	O
101	O
reads	O
out	O
of	O
101	O
for	O
patient	O
1	O
and	O
2	O
respectively	O
.	O

Non	O
-	O
coding	O
segments	O
,	O
sequences	O
encoding	O
ELMO	O
domain	O
and	O
other	O
coding	O
regions	O
of	O
exons	O
are	O
denoted	O
by	O
gray	O
,	O
blue	O
and	O
black	O
boxes	O
,	O
respectively	O
.	O

A	O
potential	O
limitation	O
of	O
our	O
methodology	O
was	O
the	O
inability	O
to	O
detect	O
easily	O
large	O
deletions	O
or	O
insertions	O
in	O
these	O
genes	O
,	O
which	O
may	O
account	O
for	O
a	O
subset	O
of	O
cases	O
.	O

Finally	O
,	O
Kapa	O
et	O
al	O
.	O

By	O
applying	O
the	O
Berendsen	O
algorithm	O
,	O
each	O
production	O
simulation	O
was	O
coupled	O
to	O
a	O
300	O
K	O
thermal	O
bath	O
at	O
1	O
.	O
0	O
atm	O
pressure	O
[	O
18	O
]	O
.	O

Full	O
field	O
electroretinogram	O
were	O
performed	O
according	O
to	O
International	O
Society	O
for	O
Clinical	O
Electrophysiology	O
of	O
Vision	O
(	O
ISCEV	O
)	O
protocols	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
chosen	O
112	O
genes	O
(	O
including	O
54	O
known	O
deafness	B-DISEASE
causing	O
genes	O
,	O
22	O
known	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
causing	O
genes	O
and	O
36	O
possible	O
candidate	O
genes	O
which	O
expressed	O
highly	O
in	O
the	O
inner	O
ear	O
)	O
and	O
conducted	O
genetic	O
analysis	O
to	O
1	O
)	O
confirm	O
the	O
potentiality	O
of	O
MPS	O
-	O
based	O
genetic	O
screening	O
strategies	O
for	O
such	O
a	O
genetically	O
heterogenous	O
disease	O
,	O
and	O
2	O
)	O
clarify	O
molecular	O
epidemiology	O
by	O
identifying	O
responsible	O
/	O
candidate	O
genes	O
in	O
a	O
large	O
number	O
of	O
patients	O
using	O
MPS	O
technology	O
.	O

The	O
asterisk	O
indicates	O
the	O
time	O
when	O
obvious	O
visual	O
deterioration	O
occurred	O
after	O
taking	O
antituberculosis	O
medicine	O
.	O

Cell	O
pellets	O
were	O
rinsed	O
once	O
with	O
PBS	O
and	O
lysed	O
in	O
M	O
-	O
PER	O
lysis	O
buffer	O
(	O
Pierce	O
)	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitor	O
cocktail	O
(	O
Sigma	O
)	O
.	O

Two	O
patients	O
reported	O
progressive	O
visual	B-DISEASE
loss	I-DISEASE
since	O
early	O
childhood	O
.	O

Patients	O
with	O
KS	B-DISEASE
usually	O
lack	O
puberty	O
,	O
but	O
the	O
reproductive	O
phenotype	O
may	O
vary	O
from	O
severe	O
hypogonadism	B-DISEASE
(	O
cryptorchidism	B-DISEASE
or	O
micropenis	B-DISEASE
in	O
male	O
infants	O
)	O
to	O
reversal	O
of	O
hypogonadotropism	B-DISEASE
later	O
in	O
life	O
[	O
4	O
,	O
5	O
]	O
.	O

To	O
date	O
,	O
no	O
mutation	O
has	O
been	O
reported	O
in	O
the	O
additional	O
exons	O
.	O

The	O
results	O
of	O
protein	O
modeling	O
revealed	O
the	O
slightly	O
bigger	O
side	O
chain	O
of	O
p	B-VARIANT
.	I-VARIANT
A112T	I-VARIANT
mutation	O
does	O
not	O
fit	O
in	O
the	O
core	O
of	O
the	O
ZO2	B-GENE
protein	O
,	O
and	O
it	O
supported	O
our	O
hypothesis	O
.	O

No	O
data	O
about	O
vestibular	O
function	O
were	O
available	O
.	O

All	O
P	O
-	O
values	O
are	O
hence	O
presented	O
as	O
not	O
corrected	O
.	O

Furthermore	O
,	O
substitution	O
of	O
this	O
particular	O
amino	O
acid	O
has	O
been	O
previously	O
proposed	O
to	O
be	O
pathogenic	O
(	O
19	O
)	O
.	O

Molecular	O
analysis	O
of	O
HLA	O
-	O
DR	O
and	O
HLA	O
-	O
DQ	O
regions	O
revealed	O
0	O
heterodimers	O
for	O
type	B-DISEASE
1	I-DISEASE
DM	I-DISEASE
susceptibility	O
.	O

1	O
-	O
2	O
:	O
haplotype	O
associated	O
with	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
in	O
our	O
patients	O
(	O
compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
748_759	I-VARIANT
+	I-VARIANT
5del	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
respectively	O
)	O
.	O

We	O
performed	O
pathway	O
analysis	O
using	O
PathScan	O
statistical	O
test	O
40	O
including	O
both	O
germline	O
truncation	O
variants	O
and	O
somatic	O
mutations	O
and	O
identified	O
the	O
KEGG	O
Fanconi	O
Anemia	O
DNA	O
repair	O
pathway	O
as	O
significant	O
(	O
P	O
=	O
4	O
.	O
2E	O
-	O
08	O
)	O
along	O
with	O
MAPK	O
,	O
Cell	O
cycle	O
,	O
and	O
TP53	B-GENE
signaling	O
pathways	O
(	O
Fig	O
.	O

Molecular	O
testing	O
allowed	O
the	O
correct	O
diagnosis	O
of	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
AS	I-DISEASE
to	O
be	O
made	O
.	O

The	O
ConSeq	O
server	O
revealed	O
that	O
all	O
of	O
the	O
causative	O
mutations	O
were	O
located	O
at	O
a	O
well	O
-	O
conserved	O
site	O
(	O
Figure	O
1	O
)	O
.	O

Sequence	O
analysis	O
of	O
NDP	B-GENE
in	O
DNA	O
samples	O
from	O
affected	O
individuals	O
of	O
Pakistani	O
family	O
PKDF740	O
revealed	O
a	O
novel	O
single	O
base	O
pair	O
deletion	O
,	O
c	B-VARIANT
.	I-VARIANT
49delG	I-VARIANT
,	O
in	O
exon	O
2	O
,	O
which	O
is	O
predicted	O
to	O
cause	O
premature	O
truncation	O
(	O
p	B-VARIANT
.	I-VARIANT
V17fsX1	I-VARIANT
)	O
of	O
Norrin	O
protein	O
,	O
and	O
thus	O
is	O
likely	O
to	O
be	O
a	O
functional	O
null	O
allele	O
.	O

4	O
,	O
5	O
,	O
6	O
Of	O
particular	O
interest	O
to	O
clinicians	O
is	O
target	O
capture	O
NGS	O
involving	O
a	O
subset	O
of	O
disease	O
-	O
relevant	O
genes	O
in	O
the	O
form	O
of	O
gene	O
panels	O
that	O
accommodate	O
sequencing	O
of	O
dozens	O
or	O
hundreds	O
of	O
genes	O
in	O
parallel	O
,	O
with	O
a	O
clear	O
advantage	O
over	O
conventional	O
polymerase	O
chain	O
reaction	O
-	O
based	O
Sanger	O
sequencing	O
approaches	O
by	O
achieving	O
faster	O
results	O
at	O
a	O
fraction	O
of	O
the	O
cost	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
was	O
caused	O
by	O
novel	O
compound	O
heterozygous	O
mutations	O
in	O
TMC1	B-GENE
.	O

The	O
audiograms	O
in	O
Figure	O
1B	O
refer	O
to	O
the	O
latest	O
audiological	O
examination	O
of	O
each	O
patient	O
performed	O
in	O
April	O
2012	O
.	O

This	O
contained	O
10	O
novel	O
mutations	O
leading	O
to	O
amino	O
acid	O
substitutions	O
already	O
known	O
to	O
cause	O
disease	O
and	O
mutations	O
known	O
to	O
cause	O
diseases	O
other	O
than	O
STGD	B-DISEASE
.	O

We	O
hypothesized	O
that	O
early	O
-	O
onset	O
lone	O
AF	B-DISEASE
is	O
associated	O
with	O
mutations	O
in	O
KCNE1	B-GENE
.	O

One	O
individual	O
from	O
the	O
undiagnosed	O
group	O
and	O
two	O
controls	O
did	O
not	O
display	O
any	O
variant	O
at	O
all	O
.	O

We	O
found	O
that	O
the	O
root	O
-	O
mean	O
-	O
square	O
deviation	O
(	O
RMSD	O
)	O
of	O
residue	O
69	O
converged	O
to	O
~	O
5	O
A	O
in	O
the	O
wild	O
-	O
type	O
trimer	O
model	O
,	O
but	O
the	O
RMSD	O
in	O
the	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
mutant	O
trimer	O
model	O
did	O
not	O
converge	O
,	O
varying	O
between	O
3	O
~	O
7	O
A	O
(	O
S2	O
Fig	O
.	O
)	O
.	O

Whilst	O
the	O
accepted	O
amino	O
acid	O
residue	O
substitution	O
profile	O
is	O
variable	O
at	O
position	O
170	O
across	O
the	O
PDZ	O
superfamily	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
,	O
histidine	O
for	O
the	O
GIPC	O
family	O
members	O
at	O
this	O
position	O
is	O
invariant	O
.	O

Clinical	O
characteristics	O
of	O
the	O
study	O
population	O
are	O
shown	O
in	O
Table	O
.	O

*	O
The	O
region	O
near	O
target	O
refers	O
to	O
flanking	O
region	O
within	O
200	O
bp	O
of	O
target	O
regions	O
.	O

In	O
most	O
of	O
the	O
cases	O
there	O
are	O
no	O
clinical	O
abnormalities	O
other	O
than	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
i	O
.	O
e	O
.	O

This	O
study	O
involved	O
33	O
unrelated	O
families	O
that	O
were	O
clinically	O
diagnosed	O
with	O
USH	B-DISEASE
,	O
23	O
of	O
which	O
were	O
diagnosed	O
with	O
USH1	B-DISEASE
(	O
21	O
Spanish	O
,	O
one	O
Italian	O
,	O
and	O
one	O
Turkish	O
family	O
)	O
and	O
ten	O
of	O
which	O
were	O
non	O
-	O
classified	O
(	O
nine	O
Spanish	O
and	O
one	O
Turkish	O
family	O
)	O
.	O

Five	O
were	O
located	O
in	O
the	O
C	O
-	O
terminus	O
,	O
only	O
five	O
mutations	O
were	O
located	O
in	O
the	O
pore	O
-	O
region	O
(	O
Table	O
2	O
)	O
.	O

dB	O
,	O
decibels	O
;	O
Hz	O
,	O
Hertz	O
.	O

PCR	O
products	O
were	O
directly	O
sequenced	O
using	O
standard	O
procedures	O
(	O
Table	O
2	O
)	O
.	O

In	O
such	O
a	O
case	O
,	O
family	O
studies	O
,	O
which	O
may	O
not	O
be	O
possible	O
in	O
small	O
families	O
,	O
and	O
electrophysiological	O
analysis	O
,	O
which	O
is	O
costly	O
and	O
time	O
consuming	O
,	O
may	O
be	O
necessary	O
to	O
ascribe	O
disease	O
causation	O
with	O
certainty	O
.	O

E	O
,	O
F	O
:	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
of	O
the	O
right	O
and	O
left	O
eyes	O
(	O
RE	O
and	O
LE	O
,	O
respectively	O
)	O
of	O
individual	O
II	O
:	O
1	O
demonstrates	O
normal	O
retinal	O
thickness	O
.	O

Contributed	O
in	O
the	O
critical	O
revision	O
of	O
the	O
manuscript	O
for	O
important	O
intellectual	O
content	O
:	O
JPH	O
CB	O
SA	O
CP	O
.	O

Figure	O
3	O
COL4A3	B-GENE
mutation	O
identified	O
in	O
Family	O
2	O
.	O

N	O
:	O
normal	O
sequence	O
.	O

However	O
,	O
until	O
now	O
,	O
there	O
has	O
been	O
no	O
multicenter	O
study	O
based	O
on	O
genetic	O
testing	O
.	O

All	O
patients	O
identified	O
with	O
disease	O
-	O
associated	O
mutations	O
had	O
no	O
other	O
genes	O
/	O
variants	O
that	O
fulfilled	O
our	O
filtering	O
criteria	O
,	O
except	O
for	O
individual	O
04	O
/	O
0834	O
.	O

A	O
novel	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
6016	I-VARIANT
G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
)	O
of	O
TECTA	B-GENE
gene	O
is	O
a	O
characteristic	O
TECTA	B-GENE
-	O
related	O
mutation	O
which	O
causes	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

A	O
common	O
haplotype	O
in	O
nine	O
of	O
ten	O
c	B-VARIANT
.	I-VARIANT
983A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
families	O
suggests	O
that	O
they	O
descend	O
from	O
a	O
single	O
founder	O
.	O

P	O
.	O
N	O
.	O

Initial	O
variant	O
transcript	O
annotation	O
was	O
based	O
on	O
a	O
combined	O
database	O
,	O
including	O
NCBI	O
Refseq	O
(	O
May	O
2009	O
)	O
and	O
Ensembl	O
(	O
version	O
54	O
)	O
.	O

A	O
mitochondrial	O
m	B-VARIANT
.	I-VARIANT
3243A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
found	O
in	O
two	O
patients	O
in	O
whom	O
HNF1A	B-GENE
testing	O
had	O
been	O
requested	O
and	O
confirmed	O
a	O
diagnosis	O
of	O
MIDD	B-DISEASE
.	O

Variants	O
in	O
the	O
regulatory	O
positions	O
,	O
such	O
as	O
phosphorylation	O
sites	O
and	O
protein	O
interaction	O
sites	O
in	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
[	O
56	O
]	O
,	O
are	O
lacking	O
and	O
only	O
a	O
single	O
variant	O
is	O
seen	O
in	O
dbSNP	O
.	O

Because	O
chip	O
-	O
based	O
analysis	O
for	O
previously	O
reported	O
mutations	O
detects	O
only	O
a	O
fraction	O
of	O
the	O
causative	O
alleles	O
[	O
8	O
]	O
,	O
and	O
gene	O
-	O
by	O
-	O
gene	O
analysis	O
by	O
Sanger	O
sequencing	O
is	O
too	O
laborious	O
and	O
expensive	O
,	O
genetic	O
testing	O
has	O
been	O
the	O
exception	O
until	O
recently	O
.	O

As	O
a	O
result	O
,	O
all	O
mutations	O
were	O
confirmed	O
to	O
co	O
-	O
segregate	O
well	O
with	O
the	O
disease	O
in	O
these	O
families	O
.	O

Their	O
genomic	O
DNAs	O
were	O
enriched	O
by	O
a	O
commercial	O
whole	O
-	O
exome	O
kit	O
and	O
a	O
custom	O
designed	O
HL	B-DISEASE
kit	O
(	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
)	O
targeting	O
252	O
known	O
and	O
candidate	O
HL	B-DISEASE
genes	O
,	O
respectively	O
.	O

TNC	B-GENE
gene	O
encodes	O
an	O
extracellular	O
matrix	O
protein	O
and	O
has	O
a	O
highly	O
conserved	O
sequence	O
in	O
different	O
species	O
,	O
for	O
example	O
,	O
the	O
sequence	O
originated	O
from	O
the	O
mouse	O
has	O
about	O
74	O
%	O
human	O
similarity	O
and	O
the	O
zebrafish	O
is	O
about	O
72	O
%	O
.	O

TY	O
and	O
HW	O
conceived	O
and	O
designed	O
the	O
experiments	O
.	O

The	O
captured	O
DNA	O
libraries	O
were	O
loaded	O
onto	O
the	O
Illumina	O
HiSeq	O
2000	O
for	O
sequencing	O
.	O

The	O
overexpression	O
of	O
NARS2	B-GENE
proteins	O
was	O
confirmed	O
by	O
SDS	O
PAGE	O
and	O
Western	O
blot	O
(	O
S9	O
Fig	O
)	O
.	O

51	O
Occasionally	O
,	O
the	O
presence	O
of	O
very	O
rare	O
variants	O
in	O
the	O
normal	O
population	O
(	O
e	O
.	O
g	O
.	O

Exon	O
3	O
has	O
287	O
nucleotides	O
and	O
encodes	O
96	O
amino	O
acids	O
(	O
66	O
-	O
162	O
)	O
.	O

For	O
all	O
three	O
cases	O
,	O
parental	O
testing	O
proved	O
paternity	O
(	O
Supp	O
.	O

Among	O
Long	O
-	O
PCR	O
products	O
,	O
we	O
registered	O
a	O
similar	O
coverage	O
performance	O
of	O
GS	O
-	O
FLX	O
up	O
to	O
24	O
-	O
25	O
x	O
,	O
but	O
above	O
that	O
value	O
the	O
curves	O
show	O
a	O
more	O
severe	O
drop	O
for	O
GS	O
-	O
FLX	O
compared	O
to	O
GAII	O
(	O
Figure	O
3	O
)	O
.	O

Black	O
filled	O
symbols	O
represented	O
individuals	O
affected	O
with	O
WS1	B-DISEASE
in	O
each	O
family	O
.	O

The	O
experimental	O
procedures	O
were	O
similar	O
for	O
the	O
two	O
kits	O
.	O

Gene	O
mutation	O
testing	O
was	O
performed	O
in	O
only	O
a	O
minor	O
portion	O
of	O
the	O
16	O
,	O
099	O
cases	O
of	O
GSDs	B-DISEASE
(	O
187	O
cases	O
,	O
1	O
.	O
16	O
%	O
)	O
.	O

The	O
ophthalmologic	O
exploration	O
included	O
visual	O
acuity	O
measurements	O
,	O
fundus	O
ophthalmoscopy	O
,	O
and	O
visual	O
field	O
examination	O
.	O

Molecular	O
analysis	O
revealed	O
two	O
novel	O
heterozygous	O
mutations	O
:	O
c	B-VARIANT
.	I-VARIANT
1133T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
exon	O
1	O
)	O
in	O
Patient	O
1	O
and	O
c	B-VARIANT
.	I-VARIANT
1609T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
exon	O
4	O
)	O
in	O
Patient	O
2	O
,	O
which	O
are	O
likely	O
to	O
result	O
in	O
p	B-VARIANT
.	I-VARIANT
Leu378Pro	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Tyr537His	I-VARIANT
changes	O
at	O
the	O
protein	O
level	O
,	O
respectively	O
(	O
Fig	O
.	O

and	O
M	O
.	O
S	O
.	O
v	O
.	O
d	O
.	O
K	O
.	O

Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1007	O
/	O
s10162	O
-	O
011	O
-	O
0282	O
-	O
3	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

The	O
mutation	O
site	O
is	O
highly	O
conserved	O
among	O
vertebrate	O
species	O
:	O
H	O
.	O

Furthermore	O
,	O
these	O
models	O
suggest	O
that	O
de	O
novo	O
SNVs	O
events	O
will	O
likely	O
explain	O
<	O
5	O
%	O
of	O
the	O
overall	O
variance	O
in	O
autism	B-DISEASE
risk	O
(	O
Supplementary	O
Table	O
4	O
)	O
.	O

Additional	O
direct	O
sequencing	O
,	O
as	O
well	O
as	O
a	O
new	O
version	O
of	O
the	O
screening	O
panel	O
which	O
includes	O
novel	O
identified	O
mutations	O
,	O
will	O
likely	O
improve	O
the	O
detection	O
rate	O
.	O

Mother	O
of	O
the	O
Family	O
3	O
was	O
submitted	O
to	O
surgical	O
correction	O
to	O
great	B-DISEASE
toes	I-DISEASE
(	O
IC	O
)	O
.	O

In	O
bold	O
:	O
variants	O
only	O
found	O
in	O
our	O
patients	O
(	O
n	O
=	O
21	O
)	O
;	O
In	O
italics	O
:	O
SNP	O
(	O
n	O
=	O
3	O
)	O
.	O

and	O
W	O
.	O
B	O
.	O

The	O
aminoacid	O
residues	O
that	O
are	O
identical	O
to	O
the	O
TBX1	B-GENE
sequences	O
are	O
shaded	O
.	O

However	O
,	O
the	O
classification	O
into	O
three	O
subtypes	O
that	O
was	O
thought	O
to	O
correspond	O
to	O
mutations	O
in	O
specific	O
genes	O
is	O
gradually	O
eroding	O
in	O
recent	O
years	O
.	O

Importantly	O
,	O
all	O
affected	O
individuals	O
carrying	O
the	O
EDNRB	B-GENE
mutation	O
(	O
II	O
-	O
1	O
,	O
II	O
-	O
3	O
,	O
II	O
-	O
5	O
and	O
III	O
-	O
3	O
;	O
Figure	O
1	O
)	O
also	O
had	O
this	O
EDN3	B-GENE
variant	O
.	O

is	O
an	O
Investigator	O
of	O
the	O
Howard	O
Hughes	O
Medical	O
Institute	O
,	O
a	O
Doris	O
Duke	O
Distinguished	O
Clinical	O
Scientist	O
,	O
and	O
the	O
Warren	O
E	O
.	O

Control	O
DNA	O
cohorts	O
consisted	O
of	O
381	O
unrelated	O
UK	O
blood	O
donors	O
(	O
European	O
Collection	O
of	O
Cell	O
Cultures	O
,	O
ECCAC	O
)	O
,	O
48	O
CEPH	O
control	O
DNAs	O
(	O
Caucasian	O
,	O
Utah	O
,	O
USA	O
)	O
,	O
and	O
57	O
individuals	O
of	O
Pakistani	O
origin	O
(	O
courtesy	O
of	O
Professor	O
Eamonn	O
R	O
Maher	O
,	O
Birmingham	O
,	O
UK	O
)	O
.	O

Data	O
provided	O
here	O
served	O
as	O
a	O
basis	O
to	O
explain	O
how	O
CNVs	O
disrupt	O
normal	O
functions	O
of	O
deafness	B-DISEASE
genes	O
.	O

The	O
present	O
study	O
revealed	O
that	O
its	O
sensitivity	O
for	O
CHD23	B-GENE
was	O
18	O
.	O
1	O
%	O
at	O
best	O
.	O

An	O
average	O
of	O
38	O
.	O
8	O
million	O
reads	O
were	O
obtained	O
for	O
each	O
individual	O
,	O
providing	O
coverage	O
>	O
=	O
14	O
-	O
fold	O
for	O
90	O
%	O
and	O
>	O
=	O
28	O
-	O
fold	O
for	O
80	O
%	O
of	O
the	O
protein	O
-	O
coding	O
base	O
pairs	O
in	O
GencodeV7	O
exons	O
.	O

Our	O
finding	O
that	O
most	O
currently	O
diagnostic	O
variants	O
from	O
exome	O
sequencing	O
arise	O
de	O
novo	O
is	O
in	O
agreement	O
with	O
recent	O
studies	O
of	O
patients	O
with	O
intellectual	B-DISEASE
disability	I-DISEASE
,	O
many	O
of	O
whom	O
also	O
have	O
congenital	O
structural	B-DISEASE
abnormalities	I-DISEASE
(	O
9	O
,	O
11	O
)	O
.	O

Primers	O
used	O
to	O
screen	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
The	O
complete	O
coding	O
regions	O
and	O
splice	O
sites	O
of	O
the	O
KCNJ10	B-GENE
and	O
FOXI1	B-GENE
exons	O
were	O
subjected	O
to	O
bidirectional	O
sequencing	O
using	O
ABI	O
PRISM	O
Big	O
Dye	O
Terminator	O
cycle	O
sequencing	O
ready	O
reaction	O
kit	O
(	O
Applied	O
Biosystems	O
)	O
and	O
analysed	O
on	O
an	O
ABI3730	O
Genetic	O
Analyser	O
(	O
Applied	O
Biosystems	O
)	O
using	O
standard	O
protocols	O
.	O

Both	O
types	O
2	O
and	O
3	O
are	O
more	O
severe	O
and	O
have	O
poor	O
neurodevelopmental	O
outcomes	O
.	O

The	O
wave	O
amplitudes	O
of	O
the	O
ERG	O
of	O
the	O
probands	O
were	O
indistinguishable	O
from	O
the	O
baseline	O
.	O

The	O
Agilent	O
Human	O
SureSelect	O
50	O
MB	O
kit	O
was	O
used	O
to	O
extract	O
the	O
target	O
regions	O
from	O
genomic	O
libraries	O
for	O
exome	O
sequencing	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
the	O
activity	O
of	O
complex	O
II	O
,	O
which	O
does	O
not	O
have	O
mtDNA	O
encoded	O
subunits	O
.	O

Each	O
patient	O
underwent	O
a	O
complete	O
medical	O
history	O
and	O
physical	O
examination	O
to	O
exclude	O
the	O
possibility	O
of	O
non	O
-	O
genetic	O
causes	O
or	O
any	O
syndromic	O
findings	O
.	O

Paternal	O
DNA	O
was	O
not	O
available	O
for	O
genotyping	O
.	O

In	O
most	O
cases	O
a	O
single	O
monogenic	O
mutation	O
is	O
sufficient	O
to	O
result	O
in	O
severe	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
2	O
,	O
3	O
]	O
.	O

Therefore	O
,	O
the	O
data	O
in	O
each	O
group	O
represented	O
a	O
sample	O
size	O
(	O
n	O
)	O
of	O
3	O
x	O
3	O
=	O
9	O
trials	O
for	O
each	O
plasmid	O
and	O
control	O
.	O

The	O
patient	O
was	O
the	O
fourth	O
child	O
of	O
healthy	O
parents	O
who	O
were	O
phenotypically	O
normal	O
and	O
did	O
not	O
have	O
any	O
history	O
of	O
consanguinity	O
.	O

f	O
i	O
=	O
P	O
affected	O
|	O
i	O
copies	O
of	O
the	O
disease	O
allele	O
The	O
recombination	O
fraction	O
between	O
the	O
disease	O
locus	O
and	O
markers	O
was	O
set	O
to	O
theta	O
=	O
0	O
by	O
default	O
.	O

We	O
identified	O
two	O
frequent	O
mutations	O
,	O
besides	O
the	O
already	O
known	O
frequent	O
founder	O
mutation	O
,	O
and	O
provide	O
evidence	O
for	O
a	O
founder	O
effect	O
in	O
one	O
and	O
a	O
probable	O
mutational	O
hotspot	O
in	O
the	O
other	O
.	O

For	O
families	O
RP	O
-	O
1147	O
,	O
RP	O
-	O
1311	O
,	O
RP	O
-	O
1106	O
,	O
RP	O
-	O
1023	O
,	O
RP	O
-	O
0467	O
,	O
RP	O
-	O
1016	O
,	O
RP	O
-	O
1053	O
,	O
and	O
RP	O
-	O
1071	O
,	O
which	O
presented	O
one	O
mutated	O
allele	O
found	O
by	O
the	O
genotyping	O
microarray	O
,	O
the	O
screening	O
of	O
the	O
respective	O
genes	O
did	O
not	O
show	O
any	O
other	O
pathogenic	O
variants	O
.	O

The	O
VEP	O
is	O
an	O
evoked	O
electrophysiological	O
potential	O
that	O
can	O
be	O
extracted	O
,	O
using	O
signal	O
averaging	O
,	O
from	O
the	O
electroencephalographic	O
activity	O
recorded	O
at	O
the	O
scalp	O
.	O

Mutation	O
confirmation	O
was	O
done	O
with	O
co	O
-	O
segregation	O
study	O
of	O
the	O
novel	O
variants	O
and	O
their	O
absence	O
in	O
100	O
ethnically	O
matched	O
normal	O
control	O
subjects	O
.	O

Secondly	O
,	O
if	O
CAM	O
binding	O
occurs	O
via	O
an	O
alternative	O
mechanism	O
for	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
localization	O
,	O
those	O
CAMs	O
must	O
also	O
be	O
localized	O
at	O
the	O
TCs	O
.	O

All	O
5	O
of	O
the	O
variations	O
marked	O
by	O
black	O
arrows	O
are	O
single	O
nucleotide	O
substitutions	O
leading	O
to	O
early	O
truncation	O
of	O
the	O
polypeptide	O
or	O
a	O
change	O
in	O
the	O
amino	O
acid	O
.	O

2	O
Considering	O
the	O
above	O
,	O
AC	B-DISEASE
might	O
be	O
used	O
to	O
define	O
a	O
broader	O
spectrum	O
of	O
hereditary	B-DISEASE
cardiomyopathies	I-DISEASE
,	O
including	O
the	O
classic	B-DISEASE
arrhythmogenic	I-DISEASE
right	I-DISEASE
ventricular	I-DISEASE
cardiomyopathy	I-DISEASE
,	O
whereby	O
a	O
key	O
characteristic	O
feature	O
is	O
a	O
propensity	O
to	O
ventricular	B-DISEASE
arrhythmia	I-DISEASE
out	O
of	O
proportion	O
to	O
the	O
extent	O
of	O
ventricular	B-DISEASE
dysfunction	I-DISEASE
.	O

Besides	O
these	O
genes	O
there	O
is	O
hardly	O
any	O
other	O
gene	O
that	O
is	O
routinely	O
analyzed	O
in	O
DNA	O
diagnostics	O
.	O

Black	O
stars	O
indicate	O
premature	O
termination	O
codons	O
(	O
PTC	O
)	O
.	O

This	O
mutation	O
was	O
located	O
in	O
the	O
N	O
-	O
terminal	O
region	O
,	O
upstream	O
from	O
the	O
ENT	O
-	O
like	O
domain	O
(	O
Fig	O
.	O

Squares	O
and	O
circles	O
represent	O
males	O
and	O
females	O
,	O
respectively	O
.	O

Citrate	O
synthase	O
was	O
assayed	O
by	O
standard	O
procedures	O
,	O
using	O
0	O
.	O
15	O
mM	O
5	O
-	O
5	O
-	O
dithiobis	O
(	O
2	O
-	O
nitrobenzoic	O
acid	O
)	O
(	O
DTNB	O
)	O
,	O
0	O
.	O
5	O
mM	O
oxaloacetate	O
,	O
0	O
.	O
3	O
mM	O
acetyl	O
-	O
CoA	O
,	O
and	O
0	O
.	O
1	O
%	O
(	O
V	O
/	O
V	O
)	O
Triton	O
X	O
-	O
100	O
.	O

Oculomotor	O
examination	O
showed	O
square	O
wave	O
jerks	O
at	O
rest	O
,	O
gaze	O
-	O
evoked	O
nystagmus	O
,	O
saccadic	O
intrusions	O
into	O
pursuit	O
,	O
hypermetric	O
saccades	O
,	O
and	O
failure	O
to	O
suppress	O
the	O
vestibular	O
ocular	O
reflex	O
.	O

For	O
cases	O
in	O
which	O
novel	O
variants	O
were	O
detected	O
,	O
segregation	O
analysis	O
was	O
performed	O
to	O
assess	O
the	O
family	O
.	O

The	O
predicted	O
effect	O
of	O
the	O
mutation	O
was	O
a	O
truncation	O
of	O
the	O
last	O
six	O
C	O
-	O
terminal	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
of	O
CD164	B-GENE
,	O
including	O
a	O
highly	O
conserved	O
canonical	O
sorting	O
motif	O
(	O
YXX	O
F	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
not	O
only	O
missense	O
mutation	O
but	O
also	O
in	O
frame	O
-	O
deletion	O
preserving	O
a	O
terminal	O
abnormal	O
transcript	O
,	O
could	O
lead	O
to	O
the	O
extraneurological	O
features	O
observed	O
in	O
OPA1	B-DISEASE
-	I-DISEASE
plus	I-DISEASE
patients	O
[	O
6	O
,	O
7	O
]	O
.	O

Fifty	O
homology	O
models	O
were	O
built	O
by	O
MODELER	O
.	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2350	O
/	O
15	O
/	O
31	O
/	O
prepub	O
Haplotyping	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
K101E	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
families	O
.	O

5	O
.	O
05	O
,	O
respectively	O
[	O
18	O
,	O
19	O
]	O
.	O

Mouse	O
anti	O
-	O
FLAG	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
rabbit	O
anti	O
-	O
claudin	O
-	O
3	O
polyclonal	O
antibody	O
(	O
pAb	O
)	O
and	O
Cy3	O
-	O
conjugated	O
donkey	O
anti	O
-	O
mouse	O
IgG	O
were	O
purchased	O
from	O
WAKO	O
Chemicals	O
(	O
Osaka	O
,	O
Japan	O
)	O
,	O
Zymed	O
(	O
San	O
Francisco	O
,	O
CA	O
,	O
USA	O
)	O
and	O
Jackson	O
ImmunoResearch	O
Laboratories	O
(	O
Bar	O
Harbor	O
,	O
ME	O
,	O
USA	O
)	O
,	O
respectively	O
.	O

These	O
data	O
demonstrate	O
the	O
challenge	O
of	O
interpretating	O
the	O
association	O
of	O
two	O
sequence	O
variations	O
.	O

OPA3	B-GENE
/	O
Type	B-DISEASE
III	I-DISEASE
methylglutaconic	I-DISEASE
aciduria	I-DISEASE
(	O
MIM	O
606580	O
)	O
,	O
OPA1	B-GENE
(	O
MIM	O
605290	O
)	O
or	O
Wolfram	B-DISEASE
Syndrome	I-DISEASE
(	O
MIM	O
606201	O
)	O
.	O

One	O
hundred	O
normal	O
controls	O
were	O
used	O
without	O
the	O
mutations	O
.	O

The	O
alpha	B-GENE
-	I-GENE
tectorin	I-GENE
is	O
composed	O
of	O
three	O
distinct	O
modules	O
:	O
the	O
entactin	O
G1	O
domain	O
,	O
the	O
zonadhesin	O
(	O
ZA	O
)	O
domain	O
and	O
the	O
zona	O
pellucida	O
(	O
ZP	O
)	O
domain	O
[	O
14	O
]	O
.	O

cDNA	O
synthesis	O
was	O
carried	O
out	O
with	O
M	O
-	O
MLV	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
,	O
cat	O
No	O
.	O

Chromatogram	O
showing	O
hemizygous	O
NM_000307	O
.	O
4	O
:	O
c	B-VARIANT
.	I-VARIANT
987T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Ile308Thr	I-VARIANT
)	I-VARIANT
)	O
mutation	O
in	O
the	O
affected	O
male	O
(	O
5A	O
)	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
was	O
found	O
to	O
be	O
more	O
frequent	O
in	O
the	O
study	O
cohort	O
than	O
anticipated	O
.	O

HH	B-DISEASE
reversal	O
was	O
assessed	O
either	O
prospectively	O
based	O
on	O
treatment	O
withdrawal	O
,	O
or	O
retrospectively	O
(	O
if	O
a	O
subject	O
had	O
been	O
off	O
treatment	O
)	O
based	O
on	O
medical	O
records	O
and	O
anamnestic	O
information	O
.	O

Eight	O
of	O
10	O
OPA1	B-GENE
-	O
M	O
patients	O
were	O
administered	O
this	O
procedure	O
as	O
part	O
of	O
our	O
standard	O
cochlear	O
implantation	O
assessment	O
protocol	O
,	O
which	O
includes	O
a	O
signed	O
patient	O
consent	O
form	O
.	O

Although	O
the	O
controls	O
in	O
our	O
study	O
including	O
those	O
with	O
advanced	O
glaucoma	O
did	O
not	O
show	O
MME	B-DISEASE
in	O
their	O
en	O
face	O
AO	O
images	O
,	O
we	O
need	O
to	O
determine	O
why	O
patients	O
with	O
advanced	O
glaucoma	O
did	O
not	O
show	O
en	O
face	O
MME	B-DISEASE
despite	O
the	O
RGC	B-DISEASE
loss	I-DISEASE
.	O

Authors	O
are	O
grateful	O
to	O
the	O
patients	O
participating	O
in	O
the	O
study	O
and	O
to	O
their	O
family	O
members	O
,	O
and	O
also	O
to	O
FARPE	O
for	O
their	O
help	O
and	O
co	O
-	O
operation	O
.	O

reported	O
a	O
lower	O
contribution	O
of	O
USH2A	B-GENE
(	O
57	O
%	O
)	O
with	O
four	O
patients	O
and	O
two	O
patients	O
for	O
GPR98	B-GENE
and	O
DFNB31	B-GENE
,	O
respectively	O
[	O
13	O
]	O
.	O

The	O
lower	O
right	O
part	O
shows	O
the	O
involvement	O
of	O
cysteine	O
725	O
in	O
the	O
positioning	O
of	O
the	O
alpha	O
G	O
-	O
containing	O
segment	O
,	O
along	O
with	O
T726	O
,	O
P722	O
,	O
and	O
K721	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
short	O
isoform	O
of	O
USH1C	B-GENE
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
RP	B-DISEASE
and	O
late	O
-	O
onset	O
deafness	B-DISEASE
(	O
Khateb	O
et	O
al	O
.	O

Furthermore	O
,	O
our	O
studies	O
in	O
transfected	O
HEK293T	O
cells	O
show	O
that	O
the	O
secretion	O
efficacy	O
of	O
the	O
mutant	O
CEACAM16	B-GENE
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
,	O
suggesting	O
a	O
deleterious	O
effect	O
of	O
the	O
sequence	O
variant	O
.	O

The	O
vulnerabilities	O
of	O
cochlea	O
caused	O
the	O
accumulation	O
of	O
detriment	O
and	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
progressed	O
.	O

The	O
platform	O
design	O
covers	O
1	O
.	O
22	O
%	O
of	O
human	O
genomic	O
regions	O
corresponding	O
to	O
the	O
NCBI	O
Consensus	O
CDS	O
Database	O
(	O
CCDS	O
)	O
,	O
including	O
more	O
than	O
700	O
human	O
miRNAs	O
from	O
the	O
Sanger	O
v13	O
database	O
and	O
more	O
than	O
300	O
additional	O
human	O
non	O
-	O
coding	O
RNAs	O
in	O
a	O
single	O
tube	O
.	O

The	O
number	O
of	O
VUS	O
will	O
decrease	O
as	O
more	O
is	O
learned	O
about	O
the	O
relationship	O
between	O
sequence	O
variation	O
and	O
phenotype	O
,	O
and	O
as	O
models	O
for	O
prediction	O
of	O
clinical	O
impact	O
improve	O
.	O

Ethnicity	O
impacted	O
diagnostic	O
rate	O
.	O

Common	O
mutations	O
,	O
such	O
as	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
or	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
in	O
GJB2	B-GENE
or	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
in	O
the	O
SLC26A4	B-GENE
gene	O
,	O
have	O
been	O
reported	O
in	O
many	O
recessive	O
deafness	B-DISEASE
genes	O
,	O
and	O
usually	O
they	O
are	O
population	O
-	O
specific	O
[	O
12	O
]	O
-	O
[	O
14	O
]	O
.	O

More	O
recently	O
,	O
we	O
have	O
identified	O
a	O
third	O
COMP	B-GENE
EGF	O
-	O
like	O
mutation	O
in	O
a	O
patient	O
with	O
PSACH	B-DISEASE
,	O
p	B-VARIANT
.	I-VARIANT
Gly258Arg	I-VARIANT
,	O
which	O
is	O
in	O
the	O
fourth	O
repeat	O
and	O
again	O
conserved	O
across	O
species	O
(	O
unpublished	O
data	O
)	O
,	O
but	O
the	O
precise	O
affect	O
of	O
these	O
COMP	B-GENE
mutations	O
remains	O
undetermined	O
and	O
will	O
require	O
extensive	O
studies	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
the	O
present	O
study	O
and	O
the	O
previously	O
published	O
MLPA	O
study	O
have	O
lead	O
us	O
to	O
perform	O
mutational	O
analysis	O
in	O
the	O
most	O
cost	O
-	O
effective	O
manner	O
:	O
initially	O
targeted	O
analysis	O
for	O
c	B-VARIANT
.	I-VARIANT
2826_2836delinsGGATGCTCCA	I-VARIANT
followed	O
by	O
MLPA	O
analysis	O
for	O
deletions	O
and	O
duplications	O
are	O
performed	O
.	O

Further	O
study	O
identified	O
four	O
new	O
mutations	O
,	O
providing	O
both	O
causative	O
changes	O
in	O
11	O
%	O
of	O
the	O
families	O
.	O

This	O
mutation	O
was	O
not	O
detected	O
in	O
the	O
control	O
group	O
.	O

Variants	O
were	O
not	O
included	O
in	O
dbSNP130	O
unless	O
they	O
were	O
reported	O
in	O
HGMD	O
or	O
were	O
previously	O
defined	O
as	O
a	O
pathogenic	O
blindness	O
mutation	O
.	O

These	O
studies	O
revealed	O
that	O
in	O
vitro	O
wild	O
type	O
NARS2	B-GENE
can	O
homodimerize	O
(	O
Fig	O
.	O

All	O
changes	O
have	O
been	O
characterized	O
in	O
our	O
cohort	O
of	O
patients	O
.	O

Articulation	O
curves	O
obtained	O
from	O
OPA1	B-GENE
-	O
H	O
and	O
OPA1	B-GENE
-	O
M	O
groups	O
have	O
been	O
superimposed	O
on	O
the	O
mean	O
articulation	O
functions	O
(	O
dashed	O
lines	O
)	O
with	O
95	O
%	O
confidence	O
limits	O
(	O
shadowed	O
areas	O
)	O
calculated	O
for	O
controls	O
at	O
corresponding	O
PTA	O
values	O
.	O

We	O
thank	O
Dr	O
Claudia	O
Kleinman	O
for	O
her	O
advice	O
regarding	O
ChIP	O
-	O
Seq	O
data	O
analysis	O
.	O

FIG	O
.	O

Usually	O
RP	B-DISEASE
develops	O
during	O
the	O
second	O
decade	O
.	O

Although	O
NGS	O
can	O
be	O
envisaged	O
to	O
have	O
multiple	O
applications	O
in	O
clinical	O
diagnostics	O
,	O
the	O
technology	O
is	O
currently	O
complex	O
and	O
requires	O
attention	O
to	O
technical	O
issues	O
,	O
including	O
sequencing	O
template	O
enrichment	O
and	O
management	O
of	O
massive	O
data	O
.	O

Mayumi	O
Sugamura	O
and	O
Takashi	O
Nakagawa	O
(	O
Fukuoka	O
University	O
)	O
,	O
Dr	O
.	O

Western	O
blotting	O
data	O
was	O
analyzed	O
using	O
Image	O
J	O
software	O
28	O
.	O

DNA	O
fragments	O
containing	O
the	O
entire	O
coding	O
region	O
were	O
sequenced	O
as	O
described	O
elsewhere	O
[	O
3	O
]	O
,	O
[	O
4	O
]	O
.	O

He	O
used	O
hearing	O
aids	O
,	O
but	O
due	O
to	O
insufficient	O
amplification	O
,	O
he	O
received	O
a	O
left	O
CI	O
at	O
the	O
age	O
of	O
2	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
causative	O
mutation	O
in	O
a	O
Korean	O
family	O
with	O
combined	O
phenotypes	O
of	O
IOSCA	B-DISEASE
,	O
sensorimotor	B-DISEASE
polyneuropathy	I-DISEASE
,	O
and	O
myopathy	B-DISEASE
.	O

Therefore	O
,	O
deletion	O
of	O
exon	O
16	O
would	O
most	O
likely	O
affect	O
the	O
conformation	O
of	O
MYO7A	B-GENE
and	O
would	O
result	O
in	O
a	O
functionally	O
altered	O
allele	O
.	O

The	O
contribution	O
of	O
the	O
GJB2	B-GENE
/	O
GJB6	B-GENE
genes	O
,	O
in	O
our	O
cohort	O
is	O
exclusively	O
found	O
in	O
non	O
syndromic	O
,	O
prelingual	O
,	O
bilateral	O
,	O
stable	O
deafness	B-DISEASE
and	O
is	O
about	O
33	O
%	O
(	O
28	O
/	O
84	O
)	O
.	O

In	O
particular	O
,	O
two	O
ESRRB	B-GENE
mutations	O
,	O
namely	O
,	O
p	B-VARIANT
.	I-VARIANT
Val342Leu	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Leu347Pro	I-VARIANT
[	O
2	O
]	O
,	O
also	O
occur	O
within	O
alpha	O
-	O
helix	O
8	O
.	O

SNVs	O
and	O
indels	O
were	O
called	O
using	O
GATKs	O
Unified	O
genotyper	O
[	O
34	O
]	O
and	O
subsequently	O
SNVs	O
were	O
filtered	O
in	O
order	O
to	O
exclude	O
SNVs	O
with	O
low	O
mapping	O
quality	O
,	O
low	O
coverage	O
and	O
/	O
or	O
low	O
quality	O
scores	O
.	O

5c	O
)	O
.	O

Variants	O
with	O
an	O
allele	O
frequency	O
greater	O
than	O
1	O
%	O
were	O
discarded	O
based	O
on	O
NHLBI	O
-	O
ESP	O
6500	O
,	O
1000	O
Genomes	O
Project	O
,	O
and	O
an	O
in	O
-	O
house	O
database	O
consisting	O
of	O
44	O
Korean	O
individuals	O
.	O

Summary	O
of	O
SNPs	O
in	O
Exome	O
Sequencing	O
for	O
each	O
Sample	O
.	O

Whole	O
-	O
exome	O
sequencing	O
was	O
completed	O
on	O
three	O
persons	O
in	O
family	O
0223	O
(	O
II	O
:	O
1	O
,	O
III	O
:	O
1	O
and	O
III	O
:	O
3	O
)	O
.	O

Three	O
clinical	O
subtypes	O
can	O
be	O
distinguished	O
.	O

The	O
Slc26a4	B-GENE
-	O
/	O
-	O
mouse	O
is	O
deaf	B-DISEASE
and	O
has	O
EVA	B-DISEASE
and	O
shows	O
loss	O
of	O
endocochlear	O
potential	O
and	O
no	O
expression	O
of	O
KCNJ10	B-GENE
protein	O
in	O
the	O
stria	O
vascularis	O
.	O

Mutations	O
in	O
DNA	B-GENE
polymerase	I-GENE
gamma	I-GENE
(	O
POLG	B-GENE
)	O
,	O
DNA	B-GENE
helicase	I-GENE
Twinkle	I-GENE
(	O
C10orf2	B-GENE
)	O
,	O
or	O
mitochondrial	B-GENE
transcription	I-GENE
factor	I-GENE
A	I-GENE
(	O
TFAM	B-GENE
)	O
have	O
been	O
linked	O
to	O
the	O
deterioration	O
of	O
mtDNA	O
[	O
3	O
]	O
.	O

The	O
domains	O
are	O
:	O
signal	O
peptide	O
domain	O
(	O
red	O
)	O
,	O
the	O
N	O
terminal	O
7S	O
domain	O
(	O
blue	O
)	O
,	O
the	O
central	O
triple	O
helix	O
collagenous	O
(	O
COL	O
)	O
domain	O
(	O
green	O
)	O
and	O
the	O
carboxy	O
-	O
terminal	O
non	O
-	O
collagenous	O
(	O
NC1	O
)	O
domain	O
(	O
yellow	O
)	O
.	O

(	O
b	O
)	O
Shown	O
are	O
ABR	O
wave	O
I	O
amplitudes	O
obtained	O
with	O
a	O
100	O
-	O
dBSPL	O
click	O
stimulus	O
of	O
BLSW	O
(	O
red	O
,	O
n	O
>	O
=	O
8	O
)	O
and	O
C3HeB	O
/	O
FeJ	O
(	O
blue	O
,	O
n	O
>	O
=	O
9	O
)	O
as	O
function	O
of	O
weeks	O
of	O
age	O
.	O

1	O
)	O
.	O

CD164	B-GENE
transcripts	O
are	O
also	O
expressed	O
in	O
the	O
human	O
fetal	O
cochlea	O
,	O
according	O
UniGene	O
Hs	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
using	O
the	O
Genomic	O
DNA	O
isolation	O
kit	O
(	O
HuaShun	O
,	O
Shanghai	O
)	O
.	O

(	O
A	O
-	O
D	O
)	O
WT	O
mice	O
(	O
n	O
=	O
2	O
)	O
.	O

MD	O
mutations	O
were	O
associated	O
with	O
a	O
significantly	O
higher	O
percentage	O
of	O
bleeders	O
(	O
65	O
%	O
)	O
as	O
compared	O
to	O
those	O
affecting	O
the	O
TD	O
(	O
33	O
.	O
9	O
%	O
)	O
,	O
P	O
=	O
0	O
.	O
045	O
(	O
Fig	O
.	O

The	O
co	O
-	O
purified	O
proteins	O
were	O
identified	O
using	O
LC	O
-	O
MS	O
/	O
MS	O
mass	O
spectrometry	O
.	O

The	O
goal	O
of	O
our	O
study	O
was	O
to	O
test	O
the	O
promising	O
NGS	O
technologies	O
that	O
could	O
be	O
applied	O
to	O
the	O
molecular	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

In	O
the	O
non	O
syndromic	O
forms	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
NSHL	O
)	O
,	O
familial	O
or	O
sporadic	O
cases	O
are	O
observed	O
and	O
the	O
transmission	O
is	O
predominantly	O
autosomal	O
recessive	O
.	O

*	O
Citations	O
[	O
#	O
]	O
for	O
patients	O
included	O
in	O
cohorts	O
exploring	O
independent	O
research	O
questions	O
.	O

Variants	O
not	O
affecting	O
protein	O
sequence	O
or	O
splicing	O
were	O
removed	O
.	O

As	O
expected	O
,	O
all	O
four	O
programs	O
similarly	O
predicted	O
that	O
the	O
DNA	O
variant	O
,	O
c	B-VARIANT
.	I-VARIANT
1343	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
would	O
abolish	O
the	O
original	O
splice	O
donor	O
site	O
,	O
resulting	O
in	O
the	O
insertion	O
of	O
the	O
beginning	O
of	O
intron	O
12	O
until	O
a	O
PTC	O
,	O
TAA	O
,	O
located	O
at	O
c	O
.	O
1343	O
+	O
50	O
to	O
c	O
.	O
1343	O
+	O
52	O
in	O
intron	O
12	O
.	O

Increased	O
Ca	O
2	O
+	O
influx	O
due	O
to	O
CACNA1D	B-GENE
mutations	O
phenocopies	O
the	O
consequence	O
of	O
KCNJ5	B-GENE
mutations	O
,	O
which	O
cause	O
increased	O
Ca	O
2	O
+	O
influx	O
by	O
depolarizing	O
glomerulosa	O
cells	O
.	O

To	O
rule	O
out	O
the	O
contribution	O
of	O
variants	O
in	O
potentially	O
important	O
regulatory	O
sites	O
not	O
captured	O
by	O
exome	O
sequencing	O
,	O
we	O
performed	O
Sanger	O
sequencing	O
on	O
all	O
13	O
members	O
of	O
the	O
family	O
,	O
targeting	O
an	O
~	O
2	O
.	O
20	O
-	O
kb	O
region	O
encompassing	O
0	O
.	O
973	O
kb	O
upstream	O
of	O
the	O
5	O
'	O
UTR	O
,	O
the	O
5	O
'	O
UTR	O
(	O
exon	O
1	O
,	O
0	O
.	O
165	O
kb	O
)	O
,	O
and	O
1	O
.	O
067	O
kb	O
into	O
intron	O
1	O
.	O

This	O
variant	O
has	O
not	O
been	O
annotated	O
in	O
any	O
of	O
the	O
above	O
databases	O
,	O
no	O
allele	O
frequency	O
is	O
available	O
,	O
and	O
it	O
co	O
-	O
segregated	O
perfectly	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
.	O

Molecular	O
analyses	O
in	O
mouse	O
models	O
have	O
shown	O
many	O
interactions	O
among	O
the	O
USH1	B-DISEASE
proteins	O
[	O
2	O
]	O
.	O

We	O
used	O
a	O
combined	O
approach	O
of	O
homozygosity	O
mapping	O
and	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
to	O
search	O
for	O
the	O
genetic	O
cause	O
of	O
autosomal	B-DISEASE
recessive	I-DISEASE
retinitis	I-DISEASE
pigmentosa	I-DISEASE
(	O
arRP	B-DISEASE
)	O
in	O
families	O
of	O
Yemenite	O
Jewish	O
origin	O
.	O

Due	O
to	O
the	O
multi	O
-	O
ethnic	O
coalition	O
of	O
over	O
one	O
thousand	O
years	O
,	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
(	O
NSD	B-DISEASE
)	O
patients	O
of	O
Uyghur	O
ethnicity	O
may	O
exhibit	O
a	O
unique	O
deafness	O
-	O
associated	O
gene	O
mutation	O
spectrum	O
as	O
compared	O
to	O
Han	O
Chinese	O
deaf	O
population	O
.	O

The	O
program	O
Conseq	O
was	O
used	O
to	O
calculate	O
conservation	O
scores	O
for	O
the	O
amino	O
acid	O
residue	O
affected	O
by	O
the	O
missense	O
variants	O
[	O
14	O
]	O
.	O

GJB2	B-GENE
gene	O
and	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
gene	O
are	O
two	O
of	O
the	O
most	O
prevalent	O
pathogenic	O
genes	O
responsible	O
for	O
NSHL	B-DISEASE
[	O
37	O
]	O
,	O
and	O
mutations	O
in	O
both	O
genes	O
had	O
been	O
identified	O
in	O
sporadic	O
AN	B-DISEASE
patients	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
.	O

Equality	O
of	O
variances	O
was	O
tested	O
by	O
Levene	O
'	O
s	O
test	O
.	O

Data	O
are	O
expressed	O
as	O
means	O
+	O
-	O
SD	O
.	O

We	O
attempted	O
to	O
validate	O
all	O
of	O
these	O
by	O
capillary	O
sequencing	O
of	O
whole	O
genome	O
amplified	O
genomic	O
DNA	O
,	O
irrespective	O
of	O
their	O
predicted	O
functional	O
consequence	O
.	O

Exome	O
sequencing	O
is	O
not	O
without	O
limitations	O
.	O

His	O
mother	O
found	O
that	O
his	O
hearing	O
in	O
the	O
morning	O
is	O
generally	O
better	O
than	O
in	O
the	O
afternoon	O
,	O
and	O
temperature	O
measurements	O
showed	O
that	O
his	O
body	O
temperature	O
in	O
the	O
afternoon	O
was	O
generally	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
pi	O
higher	O
than	O
that	O
in	O
the	O
morning	O
.	O

4	O
Genetic	O
screening	O
of	O
five	O
frequently	O
implicated	O
cLQTS	B-DISEASE
causative	O
genes	O
in	O
a	O
predominantly	O
white	O
South	O
African	O
cLQTS	B-DISEASE
cohort	O
led	O
to	O
the	O
identification	O
of	O
a	O
disease	O
-	O
causing	O
mutation	O
in	O
77	O
%	O
of	O
examined	O
cases	O
.	O

The	O
first	O
reported	O
pathogenic	O
microdeletion	O
was	O
a	O
c	B-VARIANT
.	I-VARIANT
519delT	I-VARIANT
in	O
exon	O
5	O
(	O
patient	O
TCS	B-DISEASE
2	O
)	O
(	O
Figure	O
1D	O
)	O
leading	O
to	O
formation	O
of	O
a	O
stop	O
codon	O
46	O
aminoacids	O
later	O
.	O

(	O
1B	O
-	O
5B	O
)	O
Showing	O
lateral	O
view	O
of	O
craniofacial	O
features	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
E1006K	I-VARIANT
mutation	O
was	O
reported	O
by	O
Schultz	O
et	O
al	O
.	O

All	O
known	O
inherited	O
retinal	B-DISEASE
disease	I-DISEASE
genes	O
(	O
n	O
=	O
111	O
)	O
were	O
captured	O
and	O
simultaneously	O
analyzed	O
using	O
NGS	O
in	O
100	O
RP	B-DISEASE
patients	O
without	O
a	O
molecular	O
diagnosis	O
.	O

With	O
this	O
approach	O
it	O
is	O
also	O
possible	O
to	O
sequence	O
samples	O
in	O
multiplex	O
,	O
further	O
decreasing	O
cost	O
due	O
to	O
increased	O
efficiency	O
[	O
2	O
,	O
19	O
,	O
20	O
]	O
.	O

Figure	O
S1	O
:	O
Sequence	O
alignment	O
of	O
amino	O
acid	O
residues	O
mutated	O
in	O
patients	O
carrying	O
missense	O
mutations	O
in	O
USH1	B-DISEASE
genes	O
.	O

(	O
b	O
)	O
In	O
cases	O
with	O
bulbous	O
dilatation	O
at	O
the	O
distal	O
end	O
of	O
the	O
IAC	O
and	O
basal	O
turn	O
of	O
the	O
cochlea	O
incompletely	O
separated	O
from	O
the	O
IAC	O
(	O
arrow	O
)	O
were	O
tested	O
for	O
POU3F4	B-GENE
.	O

Additionally	O
,	O
patients	O
with	O
unexplained	O
early	O
onset	O
aldosteronism	B-DISEASE
,	O
including	O
parents	O
in	O
selected	O
cases	O
,	O
were	O
also	O
studied	O
.	O

In	O
SR	O
-	O
285	O
,	O
we	O
identified	O
two	O
novel	O
nonsynomous	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
G1220R	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
S2161F	I-VARIANT
,	O
in	O
the	O
MYO15A	B-GENE
gene	O
.	O

>	O
before	O
number	O
of	O
months	O
indicates	O
patients	O
that	O
are	O
alive	O
and	O
reached	O
the	O
respective	O
age	O
at	O
the	O
last	O
follow	O
-	O
up	O
in	O
2010	O
.	O

About	O
5	O
%	O
of	O
patients	O
referred	O
to	O
hypertension	B-DISEASE
clinics	O
(	O
1	O
to	O
10	O
million	O
people	O
world	O
-	O
wide	O
)	O
have	O
aldosterone	B-DISEASE
-	I-DISEASE
producing	I-DISEASE
adenomas	I-DISEASE
(	O
APAs	B-DISEASE
)	O
3	O
,	O
4	O
.	O

Following	O
cycle	O
sequencing	O
,	O
the	O
samples	O
were	O
loaded	O
onto	O
an	O
ABI	O
PRISM	O
3730	O
DNA	O
Analyzer	O
.	O

Mapping	O
of	O
the	O
sequenced	O
reads	O
was	O
performed	O
by	O
BLAT	O
[	O
13	O
]	O
,	O
software	O
that	O
has	O
been	O
integrated	O
in	O
V	O
.	O
I	O
.	O
P	O
.	O

No	O
concentration	O
and	O
only	O
negligible	O
fluorescence	O
is	O
observed	O
in	O
the	O
stereocilia	O
(	O
arrowhead	O
)	O
,	O
and	O
mutated	O
ELMOD3	B-GENE
remains	O
in	O
the	O
cytosol	O
.	O

The	O
presence	O
of	O
309	O
kb	O
deletion	O
of	O
GJB6	B-GENE
was	O
analyzed	O
by	O
PCR	O
method	O
[	O
21	O
,	O
22	O
]	O
.	O

Understanding	O
the	O
typical	O
and	O
atypical	O
phenotypes	O
of	O
Chinese	O
WS1	B-DISEASE
patients	O
is	O
of	O
clinical	O
importance	O
as	O
such	O
patients	O
may	O
be	O
misdiagnosed	O
as	O
unilateral	B-DISEASE
ocular	I-DISEASE
albinism	I-DISEASE
,	O
especially	O
since	O
mild	O
dystopia	B-DISEASE
canthorum	I-DISEASE
is	O
not	O
uncommon	O
in	O
Southern	O
Chinese	O
population	O
.	O

Previously	O
described	O
variant	O
.	O

She	O
had	O
normal	O
blood	O
pressure	O
,	O
normal	O
renal	O
function	O
(	O
the	O
serum	O
level	O
of	O
creatinine	O
was	O
74	O
mu	O
mol	O
/	O
l	O
,	O
and	O
that	O
of	O
urea	O
nitrogen	O
was	O
4	O
.	O
10	O
mmol	O
/	O
l	O
)	O
,	O
microscopic	O
hematuria	B-DISEASE
with	O
mild	O
proteinuria	B-DISEASE
(	O
0	O
.	O
87	O
g	O
/	O
24	O
h	O
)	O
,	O
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
on	O
pure	O
-	O
tone	O
audiometry	O
;	O
electron	O
microscopy	O
showed	O
irregular	O
thinned	O
and	O
thickened	O
areas	O
of	O
the	O
GBM	O
with	O
splitting	O
of	O
the	O
lamina	O
densa	O
(	O
Figure	O
2A	O
)	O
.	O

Of	O
the	O
195	O
patients	O
,	O
116	O
patients	O
correspond	O
to	O
those	O
briefly	O
mentioned	O
in	O
previous	O
studies	O
[	O
13	O
,	O
16	O
]	O
.	O

There	O
were	O
abnormal	O
accessory	O
physes	O
on	O
the	O
side	O
of	O
the	O
distal	O
phalanx	O
,	O
as	O
well	O
as	O
other	O
abnormalities	O
in	O
the	O
physes	O
of	O
the	O
big	O
toes	O
of	O
both	O
feet	O
.	O

In	O
contrast	O
,	O
the	O
mutation	O
panorama	O
in	O
this	O
Swedish	O
cohort	O
is	O
characterised	O
by	O
two	O
founder	O
mutations	O
in	O
the	O
KCNQ1	B-GENE
gene	O
that	O
accounts	O
for	O
one	O
-	O
fourth	O
of	O
the	O
identified	O
mutations	O
.	O

-	I-VARIANT
23	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
is	O
the	O
most	O
frequent	O
DFNB1	B-GENE
pathogenic	O
allele	O
in	O
Mongolia	O
[	O
22	O
]	O
and	O
a	O
relatively	O
frequent	O
allele	O
in	O
the	O
Kurdish	O
,	O
Turkish	O
,	O
Czech	O
,	O
Polish	O
and	O
Chinese	O
populations	O
[	O
19	O
-	O
21	O
,	O
32	O
,	O
33	O
]	O
.	O

Dental	O
examination	O
showed	O
enamel	O
alterations	O
and	O
teeth	O
discoloration	O
.	O

It	O
also	O
suggests	O
that	O
it	O
might	O
serve	O
as	O
an	O
interesting	O
readout	O
and	O
surrogate	O
parameter	O
for	O
treatment	O
efficacy	O
.	O

Sensory	O
epithelium	O
of	O
the	O
retina	O
was	O
dissected	O
from	O
adult	O
CD1	O
mice	O
,	O
stained	O
with	O
the	O
CIB2	B-GENE
antibody	O
,	O
and	O
imaged	O
using	O
the	O
LSM700	O
system	O
.	O

M	O
:	O
DNA	O
marker	O
.	O

Both	O
ptosis	B-DISEASE
and	O
ophthalmoplegia	B-DISEASE
got	O
worse	O
in	O
the	O
following	O
two	O
years	O
,	O
thereafter	O
she	O
refused	O
any	O
medical	O
follow	O
-	O
up	O
and	O
she	O
did	O
not	O
change	O
her	O
mind	O
even	O
when	O
we	O
contacted	O
her	O
to	O
inform	O
her	O
about	O
the	O
genetic	O
results	O
.	O

B	O
:	O
Dystopia	B-DISEASE
canthorum	I-DISEASE
(	O
W	O
index	O
:	O
2	O
.	O
08	O
)	O
,	O
brilliant	O
blue	O
iris	O
,	O
and	O
synophyris	O
were	O
present	O
in	O
a	O
32	O
-	O
year	O
old	O
man	O
(	O
III	O
:	O
5	O
)	O
.	O

A	O
detailed	O
description	O
is	O
given	O
in	O
the	O
online	O
repository	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ingenuity	O
.	O
com	O
)	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
;	I-DISEASE
OMIM	O
276900	O
-	O
2	O
;	O
OMIM	O
276905	O
;	O
OMIM	O
605472	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
variable	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
visual	B-DISEASE
impairment	I-DISEASE
due	O
to	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
.	O

None	O
showed	O
worsening	O
of	O
the	O
hearing	O
threshold	O
with	O
respect	O
to	O
the	O
first	O
assessment	O
.	O

a	O
Meta	O
-	O
analysis	O
of	O
104	O
OPA1	B-GENE
mutation	O
carriers	O
from	O
45	O
DOA	O
+	O
families	O
,	O
which	O
includes	O
previously	O
published	O
data	O
on	O
44	O
individuals	O
from	O
18	O
DOA	O
+	O
families	O
.	O

WS	B-DISEASE
is	O
genetically	O
heterogeneous	O
.	O

We	O
thus	O
concluded	O
that	O
this	O
mutation	O
is	O
responsible	O
for	O
the	O
profound	O
congenital	B-DISEASE
deafness	I-DISEASE
in	O
the	O
patients	O
.	O

The	O
present	O
study	O
further	O
extends	O
the	O
mutational	O
spectrum	O
of	O
OPA1	B-GENE
with	O
the	O
report	O
of	O
a	O
novel	O
heterozygous	O
deletion	O
within	O
the	O
GTPase	O
effector	O
domain	O
(	O
GED	O
)	O
.	O

Sequencing	O
results	O
were	O
analyzed	O
and	O
aligned	O
against	O
the	O
TMPRSS3	B-GENE
NM_032404	O
sequence	O
shown	O
in	O
the	O
NCBI	O
database	O
using	O
the	O
GeneTool	O
1	O
.	O
0	O
software	O
(	O
BioTools	O
Inc	O
.	O
)	O
.	O

B	O
.	O

The	O
complexity	O
of	O
the	O
auditory	O
system	O
may	O
explain	O
why	O
so	O
many	O
genes	O
and	O
loci	O
are	O
linked	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Coronal	O
(	O
A	O
)	O
and	O
axial	O
(	O
B	O
and	O
C	O
)	O
CT	O
images	O
of	O
the	O
right	O
femoral	O
head	O
show	O
a	O
concave	O
articular	O
surface	O
and	O
a	O
free	O
body	O
in	O
the	O
hip	O
joint	O
of	O
the	O
left	O
femoral	O
head	O
.	O

Known	O
mutation	O
identified	O
in	O
proband	O
,	O
not	O
present	O
in	O
other	O
affected	O
siblings	O
,	O
but	O
contributing	O
to	O
a	O
more	O
severe	O
phenotype	O
in	O
the	O
proband	O
.	O

Meanwhile	O
,	O
the	O
patients	O
were	O
also	O
subjected	O
to	O
mutation	O
screening	O
for	O
genes	O
commonly	O
associated	O
with	O
NSHL	B-DISEASE
and	O
some	O
patients	O
of	O
ANSD	B-DISEASE
,	O
namely	O
,	O
the	O
GJB2	B-GENE
and	O
the	O
mitochondrial	B-GENE
12S	I-GENE
rRNA	I-GENE
genes	O
.	O

The	O
polymorphic	O
variation	O
present	O
in	O
Usher	B-DISEASE
genes	O
means	O
that	O
multiple	O
variants	O
are	O
likely	O
to	O
be	O
found	O
if	O
multiple	O
genes	O
are	O
sequenced	O
.	O

His	O
developmental	O
milestones	O
were	O
normal	O
except	O
for	O
speech	B-DISEASE
delay	I-DISEASE
.	O

The	O
distances	O
from	O
D11S902	O
and	O
D11S4138	O
to	O
the	O
USH1C	B-GENE
gene	O
are	O
26	O
,	O
790	O
bp	O
and	O
189	O
,	O
788	O
bp	O
,	O
respectively	O
.	O

Cross	O
-	O
sectional	O
analysis	O
was	O
performed	O
using	O
linear	O
regression	O
analysis	O
to	O
determine	O
the	O
local	O
average	O
slope	O
,	O
called	O
deterioration	O
rate	O
,	O
in	O
the	O
score	O
-	O
against	O
-	O
age	O
plot	O
and	O
deterioration	O
gradient	O
in	O
the	O
score	O
-	O
against	O
-	O
PTA	O
1	O
,	O
2	O
,	O
4	O
kHz	O
plot	O
.	O

Analysis	O
of	O
the	O
coding	O
regions	O
and	O
flanking	O
intronic	O
sequences	O
of	O
the	O
ATP6V1B1	B-GENE
gene	O
showed	O
the	O
presence	O
of	O
three	O
different	O
mutations	O
in	O
13	O
families	O
(	O
Table	O
2	O
)	O
.	O

Our	O
findings	O
demonstrate	O
that	O
CMTX5	B-DISEASE
,	O
Arts	B-DISEASE
syndrome	I-DISEASE
and	O
DFN2	B-DISEASE
are	O
phenotypic	O
clusters	O
on	O
an	O
intrafamilial	O
continuum	O
,	O
including	O
overlapping	O
phenotypes	O
even	O
within	O
individuals	O
.	O

No	O
RET	B-GENE
CDS	O
pathological	O
variants	O
or	O
mutations	O
were	O
detected	O
in	O
these	O
individuals	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participating	O
individuals	O
and	O
parents	O
of	O
minor	O
subjects	O
.	O

a	O
-	O
b	O
NADH	O
-	O
TR	O
staining	O
revealed	O
a	O
scattering	O
of	O
small	O
,	O
angulated	O
,	O
or	O
elongated	O
myofibers	O
with	O
condensed	O
positive	O
reactions	O
(	O
arrows	O
)	O
.	O

The	O
recessive	O
phenotype	O
exhibited	O
by	O
null	O
alleles	O
of	O
Homer2	B-GENE
makes	O
it	O
a	O
strong	O
candidate	O
for	O
autosomal	B-DISEASE
recessive	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
due	O
to	O
loss	O
of	O
function	O
in	O
humans	O
as	O
well	O
.	O

On	O
the	O
basis	O
of	O
this	O
genetic	O
diagnosis	O
strategy	O
in	O
patients	O
with	O
dRTA	B-DISEASE
,	O
which	O
is	O
based	O
on	O
the	O
presence	O
of	O
SNHL	B-DISEASE
,	O
the	O
initial	O
ATP6V1B1	B-GENE
gene	O
screening	O
resulted	O
in	O
a	O
mutation	O
detection	O
rate	O
of	O
81	O
.	O
25	O
%	O
(	O
26	O
/	O
32	O
alleles	O
)	O
.	O

Although	O
the	O
CLRN11	O
gene	O
was	O
initially	O
described	O
as	O
responsible	O
for	O
USH3	B-DISEASE
cases	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
mutations	O
in	O
CLRN1	B-GENE
are	O
also	O
seen	O
in	O
Usher	O
clinical	O
forms	O
similar	O
to	O
USH1	B-DISEASE
and	O
USH2	B-DISEASE
or	O
even	O
isolated	O
RP	B-DISEASE
[	O
14	O
-	O
16	O
]	O
.	O

3A	O
)	O
.	O

Numerous	O
,	O
presumably	O
neutral	O
,	O
isocoding	O
and	O
intronic	O
variants	O
were	O
also	O
observed	O
(	O
listed	O
in	O
Additional	O
file	O
2	O
Table	O
S1	O
)	O
.	O

The	O
scale	O
bar	O
is	O
5	O
mu	O
m	O
and	O
applies	O
to	O
all	O
panels	O
.	O

Deafness	B-DISEASE
is	O
such	O
a	O
condition	O
,	O
with	O
61	O
nuclear	O
genes	O
identified	O
thus	O
far	O
for	O
non	O
-	O
syndromic	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
[	O
1	O
]	O
and	O
many	O
more	O
for	O
syndromes	O
including	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Vestibular	B-DISEASE
dysfunction	I-DISEASE
evaluated	O
by	O
caloric	O
test	O
and	O
/	O
or	O
anamnestic	O
delayed	O
motor	O
milestones	O
(	O
walking	O
alone	O
>	O
20	O
months	O
)	O
.	O

This	O
is	O
the	O
first	O
human	O
missense	O
mutation	O
showing	O
that	O
TBX1	B-GENE
is	O
a	O
candidate	O
causing	O
isolated	O
CTDs	B-DISEASE
in	O
Chinese	O
patients	O
without	O
22q11	O
.	O
2	O
deletion	O
.	O

Toppari	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

According	O
to	O
literature	O
data	O
,	O
76	O
.	O
5	O
%	O
(	O
13	O
/	O
17	O
)	O
of	O
our	O
characterised	O
mutations	O
are	O
microdeletions	O
and	O
6	O
%	O
(	O
1	O
/	O
17	O
)	O
are	O
duplications	O
.	O

The	O
main	O
splice	O
variant	O
is	O
composed	O
of	O
three	O
exons	O
that	O
code	O
for	O
a	O
232	O
amino	O
acid	O
protein	O
,	O
clarin	O
1	O
.	O

Miyagawa	O
et	O
al	O
.	O

Understanding	O
the	O
concept	O
of	O
mutational	O
load	O
in	O
human	O
disorders	O
will	O
provide	O
insight	O
into	O
the	O
potential	O
role	O
of	O
rare	O
nonsynonymous	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
their	O
maintenance	O
throughout	O
human	O
evolution	O
,	O
and	O
their	O
predication	O
underlying	O
human	O
disease	O
.	O

Variants	O
with	O
allele	O
frequency	O
over	O
1	O
%	O
were	O
discarded	O
based	O
on	O
NHLBI	O
-	O
ESP	O
6500	O
,	O
1000	O
Genome	O
Project	O
,	O
and	O
our	O
in	O
-	O
house	O
database	O
consisting	O
of	O
exomes	O
of	O
81	O
Korean	O
individuals	O
.	O

KCNQ1	B-GENE
(	O
I	B-GENE
Ks	I-GENE
)	O
,	O
KCNH2	B-GENE
(	O
I	B-GENE
Kr	I-GENE
)	O
,	O
KCNJ2	B-GENE
(	O
I	B-GENE
K1	I-GENE
)	O
can	O
lead	O
to	O
increased	O
susceptibility	O
to	O
AF	B-DISEASE
[	O
6	O
]	O
.	O

1C	O
)	O
.	O

Interestingly	O
many	O
conservation	O
scores	O
(	O
Placental	O
Mammal	O
Basewise	O
Conservation	O
,	O
Vertebrate	O
Basewise	O
Conservation	O
,	O
Primate	O
Basewise	O
Conservation	O
)	O
drastically	O
decrease	O
exactly	O
after	O
the	O
above	O
nonsense	O
mutation	O
(	O
Figure	O
S7	O
)	O
.	O

(	O
d	O
)	O
Compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
the	O
novel	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R155X	I-VARIANT
(	O
patient	O
475	O
)	O
.	O

These	O
were	O
defined	O
by	O
minimum	O
and	O
maximum	O
(	O
10	O
-	O
14	O
dB	O
)	O
PTA	O
values	O
in	O
the	O
OPA1	B-GENE
-	O
H	O
group	O
,	O
whereas	O
the	O
OPA1	B-GENE
-	O
M	O
subjects	O
were	O
pooled	O
into	O
three	O
classes	O
characterized	O
by	O
increasing	O
PTA	O
values	O
(	O
15	O
-	O
28	O
dB	O
,	O
35	O
-	O
50	O
dB	O
,	O
58	O
-	O
73	O
dB	O
)	O
.	O

Nevertheless	O
,	O
we	O
set	O
out	O
to	O
explore	O
some	O
of	O
the	O
possibilities	O
mentioned	O
with	O
regards	O
to	O
the	O
EDNRB	B-GENE
mutation	O
.	O

Noteworthy	O
,	O
two	O
homozygous	O
missense	O
variations	O
were	O
revealed	O
as	O
RP	B-DISEASE
causative	O
for	O
patient	O
ARRP03	O
-	O
IV	O
:	O
3	O
,	O
implying	O
a	O
putative	O
double	O
hit	O
effect	O
.	O

(	O
d	O
)	O
Sequencing	O
chromatograms	O
demonstrating	O
the	O
343G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
transition	O
in	O
wild	O
-	O
type	O
(	O
left	O
)	O
and	O
mutant	O
(	O
right	O
)	O
are	O
shown	O
.	O

We	O
also	O
included	O
some	O
patients	O
with	O
presumed	O
diagnosis	O
of	O
hereditary	O
nephritis	B-DISEASE
or	O
family	O
history	O
of	O
kidney	O
disease	O
.	O

and	O
R	O
.	O
L	O
.	O
G	O
.	O

List	O
of	O
all	O
probes	O
used	O
to	O
enrich	O
for	O
the	O
target	O
genes	O
.	O

Twenty	O
-	O
two	O
of	O
30	O
individuals	O
(	O
16	O
of	O
23	O
index	O
probands	O
)	O
and	O
8	O
of	O
9	O
controls	O
were	O
sequenced	O
with	O
the	O
80	O
-	O
gene	O
panel	O
,	O
and	O
8	O
individuals	O
(	O
7	O
probands	O
and	O
1	O
control	O
)	O
were	O
sequenced	O
with	O
the	O
129	O
-	O
gene	O
panel	O
.	O

926	O
-	O
32210	O
)	O
.	O

The	O
percentage	O
(	O
median	O
)	O
of	O
the	O
three	O
groups	O
of	O
platelets	O
defined	O
in	O
Figure	O
2	O
A	O
was	O
17	O
,	O
44	O
,	O
and	O
33	O
%	O
representing	O
giant	O
,	O
intermediate	O
-	O
sized	O
,	O
and	O
normal	O
-	O
sized	O
platelets	O
,	O
respectively	O
.	O

As	O
result	O
,	O
12	O
novel	O
and	O
3	O
already	O
reported	O
mutations	O
were	O
characterised	O
together	O
with	O
7	O
novel	O
and	O
13	O
known	O
polymorphisms	O
.	O

Johansson	O
(	O
University	O
of	O
Bergen	O
,	O
Bergen	O
,	O
Norway	O
)	O
provided	O
DNA	O
samples	O
with	O
CEL	B-GENE
variants	O
/	O
mutations	O
.	O

Overall	O
,	O
the	O
results	O
of	O
this	O
study	O
underscore	O
the	O
extreme	O
genetic	O
heterogeneity	O
in	O
RP	B-DISEASE
by	O
identifying	O
putatively	O
causative	O
mutations	O
in	O
no	O
fewer	O
than	O
20	O
different	O
genes	O
(	O
Supp	O
.	O

Admixture	O
coefficients	O
were	O
estimated	O
for	O
each	O
subject	O
with	O
ADMIXTURE	O
[	O
21	O
]	O
using	O
the	O
procedure	O
described	O
by	O
Libiger	O
and	O
Schork	O
[	O
22	O
]	O
.	O

Note	O
broad	O
medially	O
deviated	O
/	O
great	B-DISEASE
toes	I-DISEASE
(	O
1D	O
-	O
5D	O
)	O
;	O
Note	O
syndactyly	B-DISEASE
in	O
Proband	O
5	O
(	O
5D	O
)	O
;	O
(	O
E	O
)	O
Patients	O
hands	O
.	O

(	O
VI	O
)	O
Tenascin	O
-	O
C	O
expresses	O
under	O
basilar	O
membrane	O
(	O
BM	O
)	O
in	O
cochlea	O
,	O
and	O
is	O
important	O
for	O
auditory	O
development	O
and	O
self	O
-	O
recovery	O
from	O
injuries	O
.	O

This	O
strategy	O
would	O
allow	O
us	O
to	O
identify	O
new	O
mutations	O
and	O
loci	O
.	O

Audiograms	O
of	O
family	O
members	O
were	O
obtained	O
using	O
pure	O
tone	O
audiometery	O
with	O
air	O
conduction	O
at	O
frequencies	O
from	O
250	O
to	O
8000	O
Hz	O
.	O

Supervised	O
experiments	O
:	O
TL	O
,	O
AOMW	O
.	O

Thus	O
,	O
we	O
could	O
analyse	O
~	O
100	O
patient	O
samples	O
with	O
a	O
single	O
run	O
(	O
~	O
10	O
h	O
)	O
using	O
this	O
MPS	O
platform	O
.	O

21	O
The	O
National	O
Collaborative	O
Usher	B-DISEASE
Study	O
(	O
NCUS	O
)	O
was	O
initiated	O
in	O
order	O
to	O
examine	O
the	O
molecular	O
epidemiology	O
of	O
USH	B-DISEASE
in	O
the	O
UK	O
in	O
anticipation	O
of	O
treatments	O
for	O
the	O
condition	O
,	O
and	O
to	O
look	O
specifically	O
for	O
the	O
contribution	O
of	O
digenic	O
inheritance	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

Gapdh	O
was	O
used	O
as	O
a	O
control	O
.	O

Captured	O
gDNA	O
fragments	O
were	O
enriched	O
using	O
streptavidin	O
dynabeads	O
(	O
Beckman	O
Coulter	O
,	O
Brea	O
,	O
CA	O
)	O
.	O

Two	O
mutations	O
in	O
LRTOMT	B-GENE
had	O
previously	O
been	O
reported	O
in	O
Tunisian	O
patients	O
,	O
c	B-VARIANT
.	I-VARIANT
242G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R81Q	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
313T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
W105R	I-VARIANT
)	O
.	O

Xl	O
,	O
X	O
-	O
linked	O
.	O

Although	O
we	O
specifically	O
selected	O
families	O
with	O
multiple	O
affected	O
members	O
to	O
allow	O
validation	O
of	O
the	O
findings	O
,	O
we	O
willingly	O
ignored	O
the	O
information	O
related	O
to	O
the	O
pedigree	O
,	O
to	O
simulate	O
the	O
use	O
of	O
this	O
technique	O
for	O
the	O
large	O
majority	O
of	O
people	O
with	O
RD	B-DISEASE
,	O
i	O
.	O
e	O
.	O

Fumie	O
Hiroyasu	O
and	O
Ms	O
.	O

Medical	O
histories	O
were	O
obtained	O
and	O
physical	O
,	O
audiological	O
,	O
and	O
radiological	O
examinations	O
were	O
carried	O
out	O
for	O
the	O
subjects	O
and	O
family	O
members	O
.	O

We	O
investigated	O
patients	O
from	O
57	O
families	O
with	O
>	O
=	O
3	O
patients	O
,	O
consecutively	O
referred	O
to	O
our	O
center	O
.	O

However	O
,	O
it	O
is	O
not	O
completely	O
unexpected	O
as	O
heterozygous	O
individuals	O
for	O
the	O
EDN3	B-GENE
mutations	O
have	O
been	O
reported	O
to	O
show	O
a	O
few	O
clinical	O
features	O
of	O
WS	B-DISEASE
[	O
25	O
,	O
29	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
even	O
among	O
family	O
members	O
carrying	O
the	O
same	O
GATA3	B-GENE
mutation	O
,	O
the	O
penetration	O
of	O
kidney	B-DISEASE
disease	I-DISEASE
and	O
parathyroid	B-DISEASE
gland	I-DISEASE
disease	I-DISEASE
can	O
vary	O
.	O

In	O
order	O
to	O
better	O
understand	O
the	O
molecular	O
genetics	O
of	O
MED	B-DISEASE
,	O
we	O
screened	O
for	O
COMP	B-GENE
,	O
COL9A1	B-GENE
,	O
COL9A2	B-GENE
,	O
COL9A3	B-GENE
,	O
MATN3	B-GENE
,	O
and	O
SLC26A2	B-GENE
mutations	O
in	O
over	O
100	O
patients	O
referred	O
to	O
the	O
European	O
Skeletal	O
Dysplasia	O
Network	O
(	O
ESDN	O
)	O
via	O
the	O
on	O
-	O
line	O
case	O
manager	O
(	O
www	O
.	O
ESDN	O
.	O
org	O
)	O
.	O

4	O
for	O
the	O
complete	O
data	O
)	O
.	O

She	O
was	O
first	O
examined	O
at	O
3	O
years	O
of	O
age	O
due	O
to	O
ataxia	B-DISEASE
and	O
athetoid	B-DISEASE
movements	I-DISEASE
;	I-DISEASE
however	O
,	O
symptoms	O
of	O
ophthalmoplegia	B-DISEASE
were	O
not	O
observed	O
.	O

Analyzed	O
the	O
data	O
:	O
IM	O
AS	O
PM	O
IJ	O
MH	O
MS	O
SA	O
AF	O
DG	O
LV	O
.	O

The	O
results	O
comprise	O
a	O
resource	O
capturing	O
cancer	O
-	O
gene	O
variation	O
in	O
6	O
ancestry	O
-	O
based	O
populations	O
,	O
and	O
define	O
quantitative	O
and	O
qualitative	O
expectations	O
for	O
the	O
results	O
of	O
personal	O
genome	O
sequencing	O
,	O
whether	O
whole	O
genome	O
,	O
exome	O
,	O
or	O
targeted	O
sequencing	O
.	O

Non	O
-	O
random	O
patterns	O
of	O
X	O
-	O
chromosome	O
inactivation	O
were	O
assessed	O
in	O
the	O
three	O
affecteds	O
(	O
III	O
:	O
2	O
,	O
IV	O
:	O
2	O
and	O
IV	O
:	O
3	O
)	O
and	O
one	O
unaffected	O
individual	O
(	O
IV	O
:	O
1	O
)	O
.	O

Each	O
25	O
mu	O
l	O
PCR	O
amplification	O
reaction	O
contained	O
1X	O
buffer	O
(	O
20	O
mu	O
M	O
Tris	O
-	O
Cl	O
,	O
100	O
mu	O
M	O
KCl	O
,	O
0	O
.	O
1	O
mu	O
M	O
EDTA	O
,	O
and	O
0	O
.	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
Tween	O
20	O
)	O
,	O
200	O
ng	O
of	O
genomic	O
DNA	O
,	O
0	O
.	O
2	O
mM	O
of	O
each	O
dNTP	O
,	O
2U	O
Taq	O
polymerase	O
,	O
1	O
mM	O
of	O
forward	O
and	O
reverse	O
primers	O
(	O
Table	O
1	O
)	O
,	O
and	O
1	O
.	O
5	O
mM	O
MgCl	O
2	O
.	O

Sequencing	O
of	O
all	O
known	O
USH	B-DISEASE
exons	O
and	O
not	O
only	O
the	O
screening	O
of	O
known	O
mutations	O
is	O
required	O
for	O
proper	O
molecular	O
diagnosis	O
and	O
an	O
accurate	O
genetic	O
counseling	O
.	O

(	O
K	O
)	O
Flash	O
visual	O
evoked	O
potential	O
(	O
F	O
-	O
VEP	O
)	O
.	O

To	O
confirm	O
candidate	O
variants	O
in	O
additional	O
Korean	O
controls	O
,	O
we	O
used	O
exome	O
data	O
from	O
an	O
additional	O
648	O
patient	O
samples	O
.	O

However	O
,	O
Pfarr	O
et	O
al	O
.	O

WES	O
allows	O
performing	O
post	O
in	O
silico	O
analysis	O
as	O
the	O
stored	O
data	O
comprises	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
genome	O
.	O

These	O
features	O
are	O
consistent	O
with	O
Ivemark	B-DISEASE
'	I-DISEASE
s	I-DISEASE
syndrome	I-DISEASE
(	O
MIM	O
208530	O
)	O
,	O
the	O
molecular	O
basis	O
of	O
which	O
is	O
unknown	O
.	O

One	O
of	O
the	O
key	O
structures	O
in	O
the	O
mechanotransduction	O
process	O
is	O
the	O
hair	O
cell	O
stereocilium	O
.	O

List	O
of	O
candidate	O
variants	O
detected	O
in	O
NSHL	B-DISEASE
group	O
Contributors	O
to	O
classification	O
:	O
a	O
,	O
protein	O
translation	O
predicts	O
a	O
PTC	O
;	O
b	O
,	O
allele	O
frequency	O
(	O
public	O
databases	O
or	O
control	O
samples	O
analyzed	O
by	O
our	O
laboratory	O
)	O
;	O
c	O
,	O
allele	O
frequency	O
(	O
patients	O
)	O
;	O
d	O
,	O
in	O
silico	O
predictions	O
(	O
missense	O
variants	O
)	O
;	O
e	O
,	O
in	O
silico	O
predictions	O
(	O
splicing	O
)	O
;	O
f	O
,	O
minigene	O
analysis	O
;	O
g	O
,	O
segregation	O
analysis	O
;	O
h	O
,	O
patient	O
genotype	O
.	O

Heterozygous	O
mutations	O
were	O
found	O
in	O
12	O
probands	O
.	O

Fourteen	O
mutations	O
occurred	O
in	O
the	O
PAX3	B-GENE
gene	O
:	O
one	O
small	O
insertion	O
,	O
two	O
missense	O
mutations	O
,	O
four	O
non	O
-	O
sense	O
mutations	O
,	O
two	O
small	O
deletions	O
,	O
one	O
splice	O
site	O
mutation	O
and	O
four	O
large	O
deletions	O
comprising	O
at	O
least	O
one	O
exon	O
.	O

Mutations	O
of	O
the	O
OPA1	B-GENE
gene	O
result	O
in	O
a	O
loss	O
of	O
function	O
in	O
most	O
ADOA	B-DISEASE
patients	O
indicating	O
that	O
haploinsufficiency	B-DISEASE
is	O
involved	O
in	O
the	O
pathomechanism	O
of	O
the	O
disease	O
[	O
21	O
]	O
.	O

In	O
rare	O
occasions	O
,	O
a	O
congenital	O
HH	B-DISEASE
patient	O
may	O
carry	O
mutation	O
(	O
s	O
)	O
in	O
more	O
than	O
one	O
HH	B-DISEASE
gene	O
;	O
Falardeau	O
et	O
al	O
.	O

Primer	O
information	O
of	O
EYA1	B-GENE
,	O
SIX1	B-GENE
and	O
SIX5	B-GENE
.	O

The	O
PAX3	B-GENE
protein	O
is	O
a	O
member	O
of	O
the	O
family	O
of	O
paired	O
domain	O
proteins	O
that	O
bind	O
DNA	O
and	O
regulate	O
gene	O
expression	O
[	O
7	O
]	O
.	O

Nucleotide	O
numbering	O
according	O
to	O
cDNA	O
sequence	O
with	O
GenBank	O
accession	O
number	O
NM_000095	O
.	O
2	O
.	O

Top	O
panel	O
shows	O
the	O
family	O
structure	O
and	O
segregation	O
of	O
the	O
variants	O
;	O
in	O
cases	O
where	O
the	O
variants	O
were	O
seen	O
in	O
more	O
than	O
one	O
family	O
,	O
a	O
single	O
representation	O
is	O
provided	O
;	O
middle	O
panel	O
shows	O
the	O
electropherogram	O
and	O
lower	O
panel	O
shows	O
the	O
conservation	O
of	O
the	O
mutated	O
residue	O
.	O

In	O
the	O
first	O
subject	O
group	O
,	O
we	O
analyzed	O
a	O
total	O
of	O
621	O
probands	O
,	O
and	O
492	O
underwent	O
clinical	O
selection	O
for	O
CDH23	B-GENE
gene	O
testing	O
after	O
excluding	O
individuals	O
with	O
GJB2	B-GENE
mutations	O
and	O
mitochondrial	O
deafness	B-DISEASE
.	O

For	O
ANSD	B-DISEASE
patients	O
,	O
the	O
result	O
of	O
cochlear	O
implant	O
may	O
depend	O
on	O
the	O
location	O
of	O
the	O
lesion	O
.	O

Stimulation	O
consisted	O
of	O
trains	O
of	O
biphasic	O
,	O
25	O
u	O
s	O
width	O
per	O
phase	O
pulses	O
presented	O
at	O
80	O
Hz	O
.	O

The	O
degree	O
of	O
HI	B-DISEASE
was	O
determined	O
by	O
calculating	O
the	O
binaural	O
mean	O
of	O
the	O
hearing	O
thresholds	O
for	O
air	O
conduction	O
at	O
frequencies	O
0	O
.	O
5	O
,	O
1	O
,	O
and	O
2	O
kHz	O
,	O
and	O
it	O
was	O
classified	O
as	O
mild	O
(	O
average	O
thresholds	O
in	O
the	O
range	O
of	O
21	O
-	O
40	O
dB	O
)	O
,	O
moderate	O
(	O
41	O
-	O
70	O
dB	O
)	O
,	O
severe	O
(	O
71	O
-	O
90	O
dB	O
)	O
,	O
or	O
profound	O
(	O
>	O
90	O
dB	O
)	O
.	O

1	O
)	O
.	O

The	O
entire	O
coding	O
region	O
of	O
COL4A5	B-GENE
mRNA	O
from	O
cultured	O
skin	O
fibroblast	O
of	O
III	O
-	O
1	O
was	O
analyzed	O
by	O
using	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
direct	O
sequencing	O
as	O
described	O
in	O
our	O
previous	O
report	O
[	O
17	O
]	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R826W	I-VARIANT
ABCC8	B-GENE
mutation	O
had	O
not	O
been	O
detected	O
previously	O
due	O
to	O
allelic	O
dropout	O
caused	O
by	O
a	O
polymorphism	O
(	O
rs139233603	B-VARIANT
)	O
within	O
a	O
primer	O
binding	O
site	O
that	O
was	O
not	O
listed	O
on	O
variant	O
databases	O
at	O
the	O
time	O
of	O
the	O
Sanger	O
sequencing	O
analysis	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
integrin	O
,	O
R33	O
and	O
E64	O
don	O
'	O
t	O
form	O
a	O
salt	O
bridge	O
due	O
to	O
a	O
conformational	O
change	O
(	O
Fig	O
.	O

The	O
gene	O
most	O
commonly	O
involved	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
worldwide	O
is	O
GJB2	B-GENE
[	O
2	O
]	O
,	O
while	O
SLC26A4	B-GENE
is	O
also	O
frequently	O
involved	O
in	O
congenital	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
.	O

2	O
)	O
,	O
a	O
finding	O
consistent	O
with	O
previous	O
results	O
[	O
19	O
]	O
,	O
[	O
32	O
]	O
.	O

Maximum	O
ABR	O
thresholds	O
were	O
capped	O
at	O
100	O
db	O
SPL	O
.	O

Arm	O
length	O
was	O
121	O
cm	O
,	O
lower	O
segment	O
length	O
was	O
60	O
cm	O
and	O
upper	O
segment	O
length	O
55	O
cm	O
.	O

Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
examination	O
was	O
selectively	O
conducted	O
on	O
patients	O
with	O
macular	O
involvements	O
.	O

We	O
report	O
a	O
strategy	O
of	O
focused	O
candidate	O
gene	O
prediction	O
,	O
high	O
-	O
throughput	O
sequencing	O
,	O
and	O
experimental	O
validation	O
to	O
uncover	O
the	O
molecular	O
basis	O
of	O
mitochondrial	B-DISEASE
complex	I-DISEASE
I	I-DISEASE
(	I-DISEASE
CI	I-DISEASE
)	I-DISEASE
disorders	I-DISEASE
.	O

However	O
,	O
these	O
genes	O
have	O
been	O
reported	O
in	O
few	O
studies	O
of	O
the	O
Korean	O
population	O
.	O

(	O
B	O
)	O
Number	O
of	O
patients	O
with	O
mutations	O
in	O
each	O
exon	O
.	O

Capture	O
Next	O
Generation	O
Sequencing	O
was	O
performed	O
as	O
previously	O
described	O
17	O
.	O

The	O
largest	O
integer	O
number	O
that	O
is	O
not	O
larger	O
than	O
the	O
value	O
giving	O
the	O
cumulative	O
distribution	O
function	O
of	O
0	O
.	O
025	O
of	O
the	O
binomial	O
distribution	O
was	O
used	O
as	O
the	O
threshold	O
value	O
,	O
and	O
the	O
position	O
was	O
selected	O
when	O
the	O
number	O
of	O
the	O
reads	O
of	O
the	O
variant	O
were	O
not	O
lower	O
than	O
the	O
threshold	O
value	O
indicated	O
in	O
formula	O
(	O
1	O
)	O
.	O

Using	O
the	O
Roche	O
GS	O
junior	O
454	O
sequencer	O
,	O
we	O
were	O
able	O
to	O
generate	O
an	O
average	O
of	O
40	O
Mb	O
of	O
pertinent	O
nucleotides	O
per	O
run	O
(	O
Fig	O
.	O

Applying	O
the	O
copy	O
-	O
number	O
and	O
homozygosity	O
mapping	O
analyses	O
on	O
17	O
probands	O
,	O
we	O
confirmed	O
the	O
absence	O
of	O
deletion	O
or	O
amplification	O
events	O
(	O
data	O
not	O
shown	O
)	O
;	O
conversely	O
,	O
in	O
two	O
probands	O
we	O
found	O
runs	O
of	O
homozygosity	O
(	O
ROH	O
)	O
longer	O
than	O
2	O
Mb	O
.	O

We	O
also	O
identified	O
a	O
homozygous	O
ABCC8	B-GENE
variant	O
(	O
p	B-VARIANT
.	I-VARIANT
A390E	I-VARIANT
)	O
in	O
exon	O
7	O
within	O
a	O
ROH	O
on	O
chromosome	O
11	O
(	O
proband	O
HI42	O
)	O
which	O
has	O
been	O
previously	O
reported	O
in	O
a	O
case	O
report	O
[	O
20	O
]	O
.	O

Two	O
cases	O
were	O
born	O
prematurely	O
,	O
case	O
16	O
at	O
26	O
weeks	O
and	O
case	O
20	O
at	O
33	O
weeks	O
of	O
gestation	O
.	O

Sequencing	O
analysis	O
of	O
novel	O
missense	O
mutation	O
in	O
exon	O
20	O
of	O
TECTA	B-GENE
.	O

Whole	O
-	O
exome	O
capture	O
and	O
sequencing	O
have	O
been	O
described	O
in	O
detail	O
previously	O
[	O
18	O
]	O
.	O

At	O
the	O
plasma	O
membrane	O
,	O
the	O
YHTL	O
motif	O
is	O
recognized	O
by	O
AP2	O
and	O
CD164	B-GENE
is	O
subsequently	O
rapidly	O
endocytosed	O
into	O
early	O
endosomes	O
,	O
a	O
process	O
known	O
as	O
the	O
indirect	O
route	O
[	O
10	O
]	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
the	O
10	O
patients	O
with	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
carried	O
one	O
missense	O
mutation	O
only	O
.	O

Patricia	O
Roa	O
-	O
Perez	O
for	O
performing	O
the	O
dental	O
examinations	O
,	O
and	O
Reyna	O
Martinez	O
,	O
from	O
Hospital	O
General	O
de	O
M	O
e	O
xico	O
for	O
performing	O
the	O
audiometric	O
tests	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

*	O
=	O
Significant	O
P	O
-	O
value	O
.	O

BAM	O
files	O
were	O
submitted	O
to	O
the	O
European	O
Nucleotide	O
Archive	O
(	O
ENA	O
)	O
under	O
the	O
accession	O
number	O
PRJEB7473	O
.	O

The	O
MYH9	B-GENE
gene	O
encodes	O
myosin	O
IIA	O
heavy	O
chain	O
,	O
which	O
is	O
involved	O
in	O
actomyosin	O
-	O
microtubule	O
crosstalk	O
,	O
cell	O
motility	O
,	O
and	O
maintenance	O
of	O
cell	O
shape	O
[	O
39	O
]	O
.	O

They	O
were	O
all	O
screened	O
the	O
coding	O
region	O
of	O
SLC26A4	B-GENE
firstly	O
.	O

Other	O
genetic	O
or	O
environmental	O
factors	O
are	O
possibly	O
play	O
a	O
role	O
in	O
the	O
etiology	O
of	O
Chinese	O
EVA	B-DISEASE
patients	O
with	O
zero	O
or	O
monoallelic	O
SLC26A4	B-GENE
mutation	O
.	O

S1	O
-	O
2	O
)	O
is	O
a	O
result	O
of	O
the	O
destruction	O
of	O
the	O
canonical	O
splice	O
acceptor	O
and	O
creating	O
a	O
new	O
splice	O
acceptor	O
insert	O
site	O
.	O

In	O
some	O
regions	O
of	O
China	O
,	O
testing	O
of	O
the	O
three	O
most	O
common	O
mutations	O
can	O
identify	O
at	O
least	O
one	O
GJB2	B-GENE
mutant	O
allele	O
in	O
all	O
patients	O
.	O

Of	O
the	O
171	O
variants	O
,	O
48	O
of	O
them	O
are	O
previously	O
reported	O
as	O
polymorphism	O
or	O
were	O
identified	O
in	O
several	O
patients	O
in	O
the	O
lab	O
.	O

8	O
.	O

To	O
address	O
the	O
pathogenicity	O
of	O
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
,	O
the	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
p	B-VARIANT
.	I-VARIANT
P69H	I-VARIANT
variant	O
protein	O
,	O
along	O
with	O
the	O
previously	O
reported	O
pathogenic	O
ILDR1	B-GENE
mutations	O
,	O
was	O
expressed	O
in	O
angulin	B-GENE
-	I-GENE
1	I-GENE
/	O
LSR	B-GENE
knockdown	O
epithelial	O
cells	O
.	O

A	O
total	O
of	O
123	O
variants	O
were	O
observed	O
in	O
this	O
study	O
,	O
of	O
which	O
10	O
are	O
known	O
deafness	O
mutations	O
,	O
23	O
are	O
previously	O
unreported	O
mutations	O
,	O
and	O
90	O
,	O
apparently	O
neutral	O
variants	O
.	O

Observe	O
the	O
broad	O
thumb	O
in	O
proband	O
2	O
(	O
2E	O
)	O
and	O
broad	O
medially	O
deviated	B-DISEASE
thumb	I-DISEASE
in	O
proband	O
5	O
(	O
5E	O
)	O
;	O
Note	O
partial	O
syndactyly	B-DISEASE
between	O
the	O
fi	O
ngers	O
in	O
proband	O
1	O
(	O
1E	O
)	O
.	O

The	O
epidemiological	O
study	O
identified	O
OPA1	B-GENE
mutations	O
in	O
14	O
genetically	O
distinct	O
OPA1	B-GENE
families	O
,	O
and	O
a	O
total	O
of	O
64	O
affected	O
family	O
members	O
were	O
living	O
in	O
the	O
North	O
of	O
England	O
.	O

Geographic	O
distribution	O
of	O
reported	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
with	O
gene	O
mutation	O
testing	O
in	O
Chinese	O
biomedical	O
literature	O
.	O

Calls	O
were	O
provided	O
by	O
the	O
Centre	O
for	O
Applied	O
Genomics	O
(	O
TCAG	O
;	O
www	O
.	O
tcag	O
.	O
ca	O
;	O
Toronto	O
,	O
Canada	O
)	O
.	O

In	O
contrast	O
,	O
all	O
but	O
one	O
subject	O
harbouring	O
OPA1	B-GENE
missense	O
mutations	O
displayed	O
impaired	B-DISEASE
speech	I-DISEASE
perception	I-DISEASE
,	O
abnormal	O
brainstem	O
responses	O
and	O
presence	O
of	O
otoacoustic	O
emissions	O
consistent	O
with	O
auditory	B-DISEASE
neuropathy	I-DISEASE
.	O

The	O
detection	O
rate	O
of	O
SLC26A4	B-GENE
mutation	O
in	O
the	O
isolated	O
MD	B-DISEASE
group	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
EVA	B-DISEASE
group	O
(	O
with	O
or	O
without	O
MD	B-DISEASE
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
detection	O
rate	O
of	O
SLC26A4	B-GENE
between	O
the	O
MD	B-DISEASE
group	O
and	O
IEM	B-DISEASE
group	O
(	O
P	O
>	O
0	O
.	O
5	O
)	O
.	O

Otoancorin	B-GENE
is	O
located	O
at	O
the	O
interface	O
between	O
the	O
apical	O
surface	O
of	O
the	O
sensory	O
epithelia	O
and	O
its	O
overlying	O
acellular	O
gels	O
,	O
and	O
is	O
expressed	O
only	O
in	O
the	O
inner	O
ear	O
[	O
7	O
]	O
.	O

The	O
GNAS	B-GENE
locus	O
has	O
a	O
highly	O
complex	O
imprinted	O
expression	O
pattern	O
and	O
encodes	O
four	O
main	O
transcripts	O
:	O
Gs	O
-	O
alpha	O
,	O
XL	O
alpha	O
s	O
,	O
NESP55	O
,	O
and	O
the	O
A	O
/	O
B	O
transcript	O
.	O

In	O
addition	O
,	O
Sanger	O
sequencing	O
analyses	O
of	O
the	O
direct	O
relatives	O
in	O
this	O
family	O
revealed	O
that	O
only	O
the	O
two	O
affected	O
brothers	O
have	O
the	O
homozygous	O
mutation	O
,	O
while	O
both	O
parents	O
are	O
carriers	O
of	O
the	O
heterozygous	O
mutation	O
and	O
the	O
unaffected	O
sister	O
does	O
not	O
carry	O
the	O
mutation	O
.	O

PCR	O
fragments	O
were	O
subcloned	O
into	O
pCR	O
-	O
TOPO	O
cloning	O
vector	O
(	O
Life	O
Technologies	O
)	O
,	O
and	O
the	O
sequences	O
were	O
verified	O
.	O

P	O
,	O
propositi	O
;	O
FM	O
,	O
number	O
of	O
affected	O
family	O
members	O
;	O
F	O
,	O
number	O
of	O
families	O
with	O
a	O
propositus	O
,	O
and	O
affected	O
family	O
members	O
.	O

The	O
majority	O
of	O
DFNB42	B-DISEASE
-	O
associated	O
mutations	O
within	O
the	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
protein	O
did	O
not	O
localize	O
at	O
TCs	O
in	O
the	O
angulin	B-GENE
-	I-GENE
1	I-GENE
/	O
LSR	B-GENE
knockdown	O
epithelial	O
cells	O
[	O
8	O
]	O
.	O

Variants	O
found	O
homozygous	O
in	O
any	O
of	O
the	O
5	O
databases	O
or	O
with	O
MAF	O
>	O
0	O
.	O
01	O
were	O
filtered	O
.	O

A	O
)	O
The	O
genomic	O
position	O
corresponding	O
to	O
variation	O
MYO7A	B-GENE
c	B-VARIANT
.	I-VARIANT
3827C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
shows	O
a	O
good	O
score	O
for	O
primate	O
,	O
mammal	O
and	O
vertebrate	O
conservation	O
.	O

High	O
-	O
throughput	O
sequencing	O
yielded	O
large	O
amounts	O
of	O
high	O
quality	O
data	O
for	O
each	O
pool	O
(	O
Supplementary	O
Table	O
3	O
)	O
.	O

Sequence	O
analysis	O
of	O
the	O
27	O
coding	O
exons	O
of	O
the	O
USH1C	B-GENE
gene	O
,	O
including	O
exon	O
-	O
intron	O
boundaries	O
,	O
revealed	O
a	O
deletion	O
of	O
an	O
A	O
nucleotide	O
at	O
position	O
-	O
2	O
of	O
intron	O
5	O
,	O
within	O
the	O
conserved	O
acceptor	O
splice	O
-	O
site	O
(	O
c	B-VARIANT
.	I-VARIANT
497	I-VARIANT
-	I-VARIANT
2delA	I-VARIANT
)	O
(	O
Figure	O
2A	O
)	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
(	O
0	O
-	O
100	O
)	O
is	O
in	O
dB	O
,	O
and	O
frequencies	O
(	O
500	O
-	O
8000	O
)	O
are	O
in	O
Hz	O
.	O

See	O
also	O
Figure	O
1a	O
.	O

Linear	O
regression	O
analyses	O
of	O
threshold	O
on	O
age	O
were	O
used	O
to	O
evaluate	O
progression	O
of	O
hearing	O
impairment	O
at	O
individual	O
frequencies	O
.	O

Statistical	O
analyses	O
were	O
performed	O
with	O
the	O
Rv	O
.	O
1	O
.	O
3	O
.	O
1	O
software	O
(	O
The	O
free	O
software	O
Fundation	O
,	O
Inc	O
)	O
.	O

We	O
would	O
like	O
to	O
acknowledge	O
the	O
Spanish	O
families	O
of	O
patients	O
for	O
taking	O
part	O
in	O
this	O
research	O
and	O
Dr	O
.	O

Multiplexing	O
12	O
samples	O
per	O
run	O
yielded	O
between	O
100	O
and	O
140X	O
of	O
coverage	O
,	O
similar	O
to	O
the	O
predicted	O
theoretical	O
coverage	O
of	O
120X	O
for	O
this	O
1	O
.	O
44	O
Mb	O
panel	O
.	O

Two	O
of	O
the	O
three	O
patients	O
were	O
borne	O
by	O
the	O
couples	O
in	O
consanguineous	O
marriages	O
who	O
have	O
normal	O
hearing	O
otherwise	O
.	O

One	O
hopes	O
that	O
modulation	O
of	O
the	O
UPR	O
cascade	O
with	O
external	O
synthetic	O
chaperones	O
might	O
alleviate	O
the	O
negative	O
features	O
by	O
promoting	O
secretion	O
of	O
partly	O
functional	O
mutant	O
collagen	O
trimers	O
.	O

The	O
pathogeneses	O
underlying	O
these	O
sensitivities	O
are	O
not	O
understood	O
or	O
is	O
it	O
clear	O
whether	O
they	O
originate	O
in	O
the	O
central	O
or	O
peripheral	O
auditory	O
system	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
the	O
only	O
common	O
feature	O
between	O
the	O
three	O
disorders	O
and	O
the	O
only	O
symptom	O
observed	O
in	O
DFN2	B-DISEASE
.	O

Under	O
Justification	O
,	O
"	O
Known	O
AA	O
"	O
indicates	O
that	O
the	O
amino	O
acid	O
substitution	O
is	O
known	O
to	O
cause	O
disease	O
while	O
"	O
Known	O
"	O
indicates	O
this	O
specific	O
DNA	O
change	O
is	O
known	O
to	O
cause	O
disease	O
.	O

This	O
finding	O
is	O
lower	O
than	O
the	O
result	O
in	O
Norway	O
,	O
where	O
,	O
4	O
.	O
7	O
(	O
305	O
/	O
66	O
)	O
patients	O
per	O
family	O
carried	O
a	O
heterozygote	O
mutation	O
[	O
8	O
]	O
.	O

The	O
remaining	O
12	O
novel	O
mutations	O
are	O
well	O
justified	O
,	O
and	O
novel	O
mutations	O
were	O
either	O
completely	O
absent	O
or	O
extremely	O
rare	O
in	O
controls	O
.	O

Unaffected	O
phenotype	O
status	O
was	O
defined	O
by	O
threshold	O
lower	O
than	O
age	O
-	O
and	O
gender	O
-	O
matched	O
50	O
th	O
percentile	O
values	O
for	O
all	O
frequencies	O
measured	O
.	O

Pure	O
tone	O
audiometry	O
was	O
performed	O
.	O

In	O
total	O
,	O
we	O
identified	O
52	O
distinct	O
,	O
pathogenic	O
,	O
or	O
likely	O
pathogenic	O
mutations	O
in	O
our	O
cohort	O
,	O
23	O
missense	O
,	O
15	O
nonsense	O
,	O
2	O
splicing	O
mutations	O
,	O
and	O
10	O
small	O
insertions	O
or	O
deletions	O
(	O
Table	O
1	O
)	O
.	O

To	O
confirm	O
the	O
common	O
ancestry	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
all	O
patients	O
from	O
our	O
study	O
,	O
as	O
well	O
as	O
among	O
the	O
Pakistani	O
and	O
Czech	O
subjects	O
where	O
the	O
mutation	O
was	O
first	O
detected	O
,	O
we	O
analyzed	O
21	O
SNPs	O
located	O
within	O
approximately	O
5	O
.	O
34	O
megabase	O
region	O
around	O
the	O
mutation	O
.	O

We	O
performed	O
exome	O
sequencing	O
on	O
a	O
cohort	O
of	O
30	O
non	O
-	O
aneuploid	O
fetuses	O
and	O
neonates	O
(	O
along	O
with	O
their	O
parents	O
)	O
with	O
diverse	O
structural	B-DISEASE
abnormalities	I-DISEASE
first	O
identified	O
by	O
prenatal	O
ultrasound	O
.	O

Variants	O
were	O
filtered	O
to	O
exclude	O
those	O
more	O
than	O
5	O
bp	O
beyond	O
the	O
splice	O
site	O
junction	O
.	O

For	O
example	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
a	O
statistically	O
significant	O
enrichment	O
of	O
de	O
novo	O
hot	O
zone	O
mutations	O
in	O
rare	O
disease	O
exomes	O
(	O
69	O
%	O
excess	O
;	O
P	O
=	O
2	O
.	O
3	O
x	O
10	O
-	O
7	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
an	O
Arg668His	B-VARIANT
change	O
in	O
the	O
myosin	B-GENE
VIIA	I-GENE
gene	O
product	O
leads	O
to	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
observed	O
in	O
the	O
family	O
we	O
studied	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
mutation	O
was	O
previously	O
identified	O
in	O
a	O
Korean	O
family	O
[	O
13	O
]	O
.	O

Haplotype	O
analysis	O
was	O
performed	O
analysing	O
14	O
SNP	O
'	O
s	O
surrounding	O
the	O
OPA1	B-GENE
gene	O
(	O
position	O
chr3	O
:	O
188	O
,	O
391	O
,	O
767	O
-	O
196	O
,	O
005	O
,	O
479	O
,	O
human	O
genome	O
version	O
hg19	O
/	O
GRCh37	O
)	O
(	O
Table	O
1	O
)	O
.	O

The	O
simultaneous	O
screening	O
of	O
target	O
genes	O
of	O
interest	O
allows	O
for	O
an	O
efficient	O
and	O
cost	O
-	O
effective	O
method	O
of	O
analyzing	O
panels	O
of	O
genes	O
concurrently	O
,	O
as	O
opposed	O
to	O
testing	O
on	O
a	O
gene	O
-	O
by	O
-	O
gene	O
basis	O
as	O
occurs	O
in	O
Sanger	O
sequencing	O
.	O

Based	O
on	O
these	O
facts	O
,	O
our	O
working	O
hypothesis	O
was	O
that	O
family	O
TB128	O
might	O
segregate	O
recessive	O
mutations	O
of	O
two	O
different	O
genes	O
,	O
independently	O
causing	O
RP	B-DISEASE
and	O
HL	B-DISEASE
,	O
and	O
mimicking	O
the	O
USH1	B-DISEASE
phenotype	O
.	O

performed	O
linkage	O
,	O
RT	O
-	O
PCR	O
,	O
mutational	O
analyses	O
,	O
and	O
cloned	O
isoforms	O
,	O
and	O
provided	O
bioinformatic	O
evaluations	O
;	O
I	O
.	O
A	O
.	O
B	O
.	O

As	O
with	O
the	O
cases	O
of	O
fibrochondrogenesis	B-DISEASE
described	O
by	O
Tompson	O
et	O
al	O
,	O
19	O
one	O
patient	O
characterised	O
here	O
possesses	O
similar	O
null	O
/	O
missense	O
mutations	O
,	O
but	O
has	O
Stickler	B-DISEASE
syndrome	I-DISEASE
instead	O
.	O

variants	O
within	O
2	O
base	O
pairs	O
from	O
splice	O
sites	O
)	O
were	O
considered	O
as	O
more	O
likely	O
to	O
be	O
deleterious	O
.	O

This	O
high	O
genetic	O
heterogeneity	O
mirrors	O
the	O
structural	O
and	O
functional	O
complexity	O
of	O
the	O
hearing	O
process	O
and	O
it	O
is	O
a	O
major	O
hurdle	O
for	O
the	O
successful	O
genetic	O
diagnosis	O
of	O
subjects	O
with	O
NSHI	B-DISEASE
.	O

This	O
tight	O
junction	O
protein	O
is	O
tetra	O
-	O
membrane	O
spanning	O
that	O
localizes	O
to	O
the	O
apical	O
tight	O
junctions	O
of	O
organ	O
of	O
Corti	O
hair	O
cells	O
and	O
in	O
many	O
other	O
tissues	O
.	O

Although	O
we	O
can	O
'	O
t	O
provide	O
a	O
definitive	O
proof	O
of	O
the	O
pathogenicity	O
for	O
the	O
identified	O
variants	O
,	O
some	O
elements	O
support	O
their	O
causative	O
role	O
in	O
producing	O
PEO	B-DISEASE
:	I-DISEASE
i	O
)	O
they	O
are	O
not	O
found	O
in	O
a	O
wide	O
number	O
of	O
ethnic	O
-	O
matched	O
and	O
pan	O
-	O
ethnics	O
control	O
subjects	O
;	O
ii	O
)	O
healthy	O
siblings	O
of	O
the	O
patients	O
don	O
'	O
t	O
harbour	O
the	O
mutations	O
;	O
iii	O
)	O
the	O
variants	O
affect	O
residues	O
located	O
in	O
regions	O
important	O
for	O
a	O
proper	O
structure	O
and	O
function	O
of	O
Twinkle	O
;	O
iv	O
)	O
the	O
signs	O
of	O
mitochondrial	O
pathology	O
disclosed	O
in	O
our	O
patients	O
are	O
related	O
to	O
an	O
impairment	O
in	O
mtDNA	O
replication	O
and	O
their	O
early	O
age	O
of	O
onset	O
is	O
compatible	O
with	O
PEO1	B-GENE
mutations	O
;	O
v	O
)	O
the	O
screening	O
of	O
other	O
PEO	O
-	O
associated	O
genes	O
was	O
negative	O
.	O

The	O
Mini	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
on	O
the	O
three	O
patients	O
(	O
III	O
:	O
1	O
,	O
III	O
:	O
9	O
and	O
III	O
:	O
11	O
)	O
of	O
family	O
2423	O
was	O
conducted	O
to	O
assess	O
the	O
cognitive	O
function	O
.	O

Thirteen	O
pathologic	O
PCDH15	B-GENE
alleles	O
out	O
of	O
the	O
38	O
screened	O
alleles	O
were	O
detected	O
(	O
34	O
.	O
2	O
%	O
)	O
.	O

We	O
previously	O
reported	O
that	O
the	O
quantity	O
of	O
the	O
mRNA	O
expression	O
level	O
of	O
mutant	O
COL4A5	B-GENE
gene	O
was	O
correlated	O
with	O
the	O
phenotypic	O
severity	O
of	O
XLAS	B-DISEASE
females	O
[	O
26	O
]	O
.	O

Three	O
years	O
of	O
following	O
this	O
patient	O
indicated	O
that	O
the	O
boy	O
had	O
periodic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
was	O
particularly	O
salient	O
when	O
he	O
suffered	O
fever	B-DISEASE
,	O
at	O
which	O
times	O
he	O
would	O
lose	O
communication	O
ability	O
and	O
was	O
characterized	O
by	O
normal	O
otoacoustic	O
emission	O
,	O
but	O
no	O
evoked	O
ABR	O
.	O

The	O
increase	O
of	O
ATP	O
/	O
ADP	O
ratio	O
leads	O
to	O
the	O
closure	O
of	O
K	O
ATP	O
channels	O
,	O
to	O
the	O
depolarization	O
of	O
the	O
plasma	O
membrane	O
and	O
to	O
the	O
subsequent	O
activation	O
of	O
VDCC	O
promoting	O
influx	O
of	O
calcium	O
into	O
the	O
cell	O
.	O

The	O
colour	O
representation	O
for	O
the	O
bars	O
is	O
the	O
same	O
as	O
(	O
D	O
)	O
.	O

In	O
USH1	B-DISEASE
patients	O
,	O
sign	O
language	O
becomes	O
a	O
less	O
and	O
less	O
efficient	O
mode	O
of	O
communication	O
as	O
the	O
visual	B-DISEASE
defect	I-DISEASE
progresses	O
,	O
and	O
ultimately	O
,	O
the	O
patients	O
may	O
become	O
unable	O
to	O
communicate	O
except	O
by	O
tactile	O
exchanges	O
.	O

33	O
Our	O
(	O
Caucasian	O
)	O
patient	O
had	O
overlapping	O
clinical	O
features	O
with	O
Bohring	B-DISEASE
-	I-DISEASE
Opitz	I-DISEASE
syndrome	I-DISEASE
,	O
including	O
growth	B-DISEASE
failure	I-DISEASE
,	O
developmental	B-DISEASE
delay	I-DISEASE
,	O
microcephaly	B-DISEASE
,	O
strabismus	B-DISEASE
,	O
hypotonia	B-DISEASE
,	O
and	O
seizures	B-DISEASE
;	O
therefore	O
,	O
the	O
de	O
novo	O
ASXL1	B-GENE
nonsense	O
mutation	O
is	O
highly	O
likely	O
to	O
explain	O
the	O
clinical	O
presentations	O
in	O
our	O
patient	O
.	O

52	O
It	O
must	O
be	O
expected	O
,	O
due	O
to	O
the	O
large	O
genetic	O
diversity	O
of	O
African	O
populations	O
,	O
as	O
is	O
evident	O
from	O
the	O
Exome	O
Sequencing	O
Project	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
,	O
that	O
comprehensive	O
genetic	O
screening	O
of	O
at	O
least	O
five	O
genes	O
will	O
be	O
necessary	O
to	O
provide	O
an	O
adequate	O
genetic	O
diagnosis	O
in	O
these	O
populations	O
.	O

In	O
contrast	O
,	O
the	O
MYO7A	B-GENE
compound	O
heterozygous	O
variants	O
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G25R	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
C154X	I-VARIANT
)	O
co	O
-	O
segregated	O
in	O
all	O
affected	O
family	O
members	O
tested	O
.	O

Nonsyndromic	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
NSHI	B-DISEASE
)	O
is	O
the	O
most	O
frequent	O
hereditary	B-DISEASE
sensory	I-DISEASE
defect	I-DISEASE
in	O
humans	O
worldwide	O
.	O

MYH9	B-GENE
genetic	O
variants	O
in	O
109	O
patients	O
.	O

Details	O
of	O
the	O
bioinformatics	O
analysis	O
methods	O
have	O
been	O
published	O
[	O
29	O
]	O
.	O

She	O
reported	O
a	O
reasonably	O
good	O
quality	O
of	O
life	O
during	O
the	O
second	O
trimester	O
but	O
in	O
the	O
32nd	O
week	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
to	O
induce	O
foetal	O
lung	O
maturation	O
by	O
corticosteroids	O
.	O

On	O
average	O
,	O
70	O
%	O
of	O
each	O
genome	O
and	O
80	O
%	O
of	O
each	O
exome	O
had	O
>	O
40x	O
coverage	O
.	O

Nonradioactive	O
DIG	O
-	O
labeled	O
(	O
Roche	O
)	O
oligodeoxynucleotides	O
(	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
:	O
5	O
'	O
-	O
CTAGACCAATGGGACTTAAA	O
-	O
3	O
'	O
and	O
5S	B-GENE
-	I-GENE
rRNA	I-GENE
:	O
5	O
'	O
-	O
GGGTGGTATGGCGGTAGAC	O
-	O
3	O
'	O
)	O
were	O
used	O
on	O
the	O
same	O
membrane	O
after	O
stripping	O
in	O
50	O
%	O
formamide	O
,	O
5	O
%	O
SDS	O
,	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7	O
.	O
5	O
and	O
extensive	O
washes	O
in	O
2x	O
SSC	O
[	O
67	O
]	O
.	O

Biallelic	O
mutations	O
in	O
SLC11A2	B-GENE
cause	O
autosomal	B-DISEASE
recessive	I-DISEASE
hypochromic	I-DISEASE
microcytic	I-DISEASE
anemia	I-DISEASE
with	O
iron	O
overload	O
but	O
there	O
is	O
no	O
mention	O
of	O
any	O
hearing	B-DISEASE
impairment	I-DISEASE
[	O
35	O
]	O
.	O

Family	O
history	O
and	O
clinical	O
questionnaire	O
was	O
obtained	O
from	O
all	O
subjects	O
or	O
their	O
parents	O
.	O

While	O
originally	O
described	O
in	O
muscle	O
tissue	O
,	O
another	O
form	O
of	O
myosin	O
,	O
called	O
unconventional	O
myosin	O
,	O
has	O
been	O
found	O
in	O
many	O
other	O
tissues	O
[	O
1	O
,	O
2	O
]	O
.	O

One	O
explanation	O
for	O
these	O
discrepancies	O
could	O
be	O
the	O
presence	O
of	O
population	O
-	O
specific	O
modifiers	O
,	O
genetic	O
or	O
other	O
,	O
such	O
as	O
the	O
recently	O
described	O
polymorphisms	O
in	O
the	O
3	O
'	O
-	O
UTR	O
of	O
KCNQ1	B-GENE
,	O
mitigating	O
the	O
effect	O
of	O
the	O
mutated	O
allele	O
by	O
reduced	O
expression	O
[	O
30	O
]	O
.	O

Click	O
here	O
for	O
file	O
Figure	O
S1	O
.	O

Pedigrees	O
of	O
the	O
four	O
families	O
of	O
six	O
ADOA	B-DISEASE
patients	O
.	O

Nonetheless	O
,	O
this	O
work	O
has	O
demonstrated	O
that	O
genetic	O
causes	O
of	O
deafness	B-DISEASE
could	O
be	O
found	O
in	O
a	O
higher	O
percentage	O
of	O
patients	O
when	O
considering	O
a	O
combined	O
analysis	O
of	O
both	O
DNA	O
sequence	O
variations	O
and	O
CNVs	O
.	O

The	O
DFNB15	B-GENE
locus	O
segregating	O
in	O
a	O
two	O
-	O
generation	O
consanguineous	O
Indian	O
family	O
with	O
prelingual	O
,	O
profound	O
autosomal	O
recessive	O
hearing	B-DISEASE
impairment	I-DISEASE
was	O
reported	O
previously	O
24	O
.	O

Results	O
showed	O
that	O
some	O
patients	O
in	O
the	O
family	O
display	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

On	O
orbital	O
high	O
-	O
resolution	O
MRI	O
with	O
fast	O
spin	O
-	O
echo	O
,	O
there	O
was	O
no	O
obvious	O
change	O
in	O
signal	O
intensity	O
in	O
the	O
retrobulbar	O
portion	O
of	O
the	O
right	O
optic	O
nerve	O
.	O

The	O
data	O
were	O
quantified	O
by	O
measuring	O
total	O
protein	O
band	O
intensities	O
ratios	O
using	O
UVP	O
multispectral	O
imaging	O
system	O
and	O
normalized	O
to	O
control	O
alpha	O
-	O
actin	O
band	O
.	O

Exome	O
sequencing	O
was	O
conducted	O
on	O
one	O
affected	O
individual	O
from	O
family	O
PKDF468	O
and	O
was	O
enriched	O
using	O
the	O
Nimblegen	O
SeqCap	O
EZ	O
Exome	O
v2	O
.	O
0	O
Library	O
(	O
Roche	O
Diagnostics	O
;	O
San	O
Francisco	O
,	O
CA	O
)	O
.	O

Absorbancies	O
were	O
detected	O
at	O
450	O
nm	O
.	O

For	O
exome	O
analysis	O
,	O
we	O
followed	O
the	O
guidelines	O
from	O
the	O
Genome	O
Analysis	O
ToolKit	O
(	O
GATK	O
)	O
best	O
practice	O
recommendations	O
v3	O
to	O
process	O
an	O
average	O
of	O
118	O
.	O
7	O
million	O
paired	O
-	O
end	O
reads	O
per	O
sample	O
.	O

On	O
whole	O
-	O
mount	O
organ	O
of	O
Corti	O
preparations	O
,	O
we	O
noted	O
abundant	O
staining	O
in	O
the	O
cytoplasm	O
of	O
IHCs	O
and	O
OHCs	O
characterized	O
by	O
fine	O
punctate	O
staining	O
apparent	O
at	O
the	O
base	O
,	O
around	O
the	O
nucleus	O
and	O
throughout	O
the	O
apical	O
part	O
of	O
the	O
hair	O
cells	O
(	O
Fig	O
.	O

Laboratory	O
data	O
on	O
admission	O
were	O
as	O
follows	O
:	O
albumin	O
,	O
29	O
g	O
/	O
L	O
;	O
total	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
,	O
135	O
IU	O
/	O
L	O
;	O
calcium	O
,	O
9	O
.	O
4	O
mg	O
/	O
dL	O
;	O
albumin	O
-	O
adjusted	O
calcium	O
using	O
serum	O
albumin	O
(	O
calcium	O
[	O
mg	O
/	O
dL	O
]	O
-	O
albumin	O
[	O
g	O
/	O
dL	O
]	O
+	O
-	O
4	O
.	O
0	O
)	O
,	O
10	O
.	O
5	O
mg	O
/	O
dL	O
;	O
phosphate	O
9	O
.	O
3	O
mg	O
/	O
dL	O
;	O
calcium	O
x	O
phosphate	O
product	O
,	O
98	O
mg	O
2	O
/	O
dL	O
2	O
;	O
iPTH	O
<	O
1	O
.	O
4	O
pg	O
/	O
mL	O
;	O
serum	O
level	O
of	O
1	O
,	O
25	O
-	O
dihydroxycholecalciferol	O
,	O
7	O
ng	O
/	O
L	O
(	O
reference	O
range	O
,	O
20	O
-	O
60	O
ng	O
/	O
L	O
)	O
;	O
25	O
-	O
hydroxycholecalciferol	O
,	O
16	O
.	O
9	O
mu	O
g	O
/	O
L	O
:	O
magnesium	O
,	O
2	O
.	O
3	O
mg	O
/	O
dL	O
(	O
reference	O
range	O
1	O
.	O
7	O
-	O
2	O
.	O
3	O
mg	O
/	O
dL	O
)	O
;	O
and	O
bone	O
-	O
specific	O
ALP	O
,	O
11	O
.	O
5	O
U	O
/	O
mL	O
(	O
reference	O
range	O
,	O
9	O
.	O
6	O
-	O
35	O
.	O
4	O
U	O
/	O
mL	O
)	O
.	O

The	O
critical	O
mutation	O
in	O
the	O
proband	O
is	O
TECTA	B-GENE
c	B-VARIANT
.	I-VARIANT
5597C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T1866M	I-VARIANT
)	O
(	O
Tables	O
2	O
and	O
3	O
)	O
,	O
which	O
encodes	O
alpha	O
-	O
tectorin	O
[	O
20	O
]	O
.	O

1C	O
)	O
.	O

She	O
reported	O
to	O
have	O
nyctalopia	O
at	O
age	O
12	O
and	O
constricted	O
VF	O
since	O
age	O
14	O
.	O

C	O
,	O
Sequence	O
alignment	O
of	O
the	O
mutation	O
location	O
across	O
multiple	O
species	O
(	O
using	O
Clustal	O
Omega	O
)	O
.	O

Genomic	O
DNA	O
of	O
all	O
patients	O
was	O
enriched	O
for	O
this	O
target	O
region	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
,	O
followed	O
by	O
single	O
-	O
read	O
cluster	O
generation	O
on	O
a	O
Cluster	O
Station	O
(	O
Illumina	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
homozygous	O
region	O
that	O
is	O
found	O
only	O
in	O
ARNSHI	B-DISEASE
individuals	O
is	O
bounded	O
by	O
rs917284	B-VARIANT
(	O
chr14	O
:	O
71	O
.	O
8	O
Mb	O
)	O
and	O
rs2043585	B-VARIANT
(	O
chr14	O
:	O
79	O
.	O
0	O
Mb	O
)	O
.	O

Within	O
the	O
linkage	O
region	O
,	O
the	O
only	O
gene	O
already	O
known	O
to	O
be	O
involved	O
in	O
NSHHL	B-DISEASE
,	O
MARVELD2	B-GENE
,	O
was	O
then	O
analysed	O
.	O

,	O
2009	O
a	O
)	O
.	O

Top	O
left	O
:	O
fundus	O
image	O
with	O
scan	O
cube	O
overlay	O
.	O

Family	O
pedigrees	O
in	O
which	O
the	O
co	O
-	O
segregation	O
of	O
the	O
detected	O
mutations	O
was	O
performed	O
.	O

In	O
addition	O
,	O
three	O
probands	O
had	O
CHARGE	B-DISEASE
syndrome	O
-	O
associated	O
features	O
.	O

Blood	O
samples	O
from	O
patients	O
,	O
relatives	O
and	O
unrelated	O
controls	O
were	O
mixed	O
with	O
an	O
RNA	O
stabilizer	O
solution	O
(	O
RNALater	O
;	O
Ambion	O
)	O
in	O
a	O
1	O
:	O
4	O
ratio	O
.	O

These	O
patients	O
will	O
undergo	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
applied	O
to	O
"	O
Usher	O
-	O
exome	O
"	O
(	O
i	O
.	O
e	O
.	O
,	O
targeted	O
exome	O
of	O
the	O
Usher	O
genes	O
)	O
as	O
this	O
approach	O
is	O
becoming	O
available	O
.	O

Assuming	O
that	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
results	O
from	O
a	O
loss	O
of	O
WFS1	B-GENE
function	O
,	O
patients	O
were	O
grouped	O
as	O
follows	O
:	O
Group	O
1	O
:	O
individuals	O
carrying	O
mutations	O
with	O
a	O
predicted	O
complete	O
loss	O
of	O
function	O
,	O
including	O
N	O
-	O
terminal	O
nonsense	O
and	O
frameshift	O
mutations	O
;	O
Group	O
2	O
:	O
individuals	O
carrying	O
mutations	O
with	O
a	O
predicted	O
partial	O
loss	O
of	O
function	O
,	O
including	O
COOH	O
-	O
terminal	O
nonsense	O
and	O
frameshift	O
mutations	O
or	O
small	O
in	O
-	O
frame	O
deletions	O
and	O
individuals	O
compound	O
heterozygous	O
for	O
a	O
predicted	O
complete	O
and	O
partial	O
loss	O
of	O
function	O
mutation	O
;	O
and	O
Group	O
3	O
:	O
individuals	O
carrying	O
mutations	O
with	O
a	O
putative	O
minor	O
loss	O
of	O
function	O
,	O
including	O
missense	O
mutations	O
and	O
individuals	O
compound	O
heterozygous	O
for	O
a	O
predicted	O
partial	O
and	O
minor	O
loss	O
of	O
function	O
mutation	O
(	O
Fig	O
.	O

Additional	O
software	O
analyses	O
(	O
Polyphen	O
-	O
2	O
[	O
37	O
]	O
,	O
MutationTaster	O
[	O
38	O
]	O
,	O
and	O
MutationAssessor	O
[	O
39	O
]	O
)	O
gave	O
similar	O
overall	O
predictions	O
based	O
on	O
their	O
own	O
parameters	O
.	O

Genetic	O
analysis	O
demonstrates	O
co	O
-	O
segregation	O
of	O
a	O
mutation	O
of	O
USH1G	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
206	I-VARIANT
-	I-VARIANT
207insC	I-VARIANT
)	O
with	O
USH1	B-DISEASE
.	O

As	O
shown	O
in	O
the	O
Fig	O
2	O
,	O
alleles	O
forming	O
the	O
risk	O
haplotypes	O
are	O
present	O
in	O
the	O
affected	O
and	O
carrier	O
individuals	O
.	O

Taken	O
together	O
,	O
we	O
identified	O
an	O
OPA1	B-GENE
mutation	O
in	O
a	O
family	O
with	O
ADOA	B-DISEASE
by	O
filling	O
the	O
missing	O
CNGS	O
data	O
.	O

We	O
report	O
here	O
four	O
patients	O
,	O
who	O
had	O
probable	O
pathogenic	O
mutations	O
in	O
two	O
different	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
genes	O
,	O
and	O
one	O
case	O
of	O
MYO7A	B-GENE
/	O
PCDH15	B-GENE
digenic	O
inheritance	O
.	O

The	O
solid	O
regression	O
line	O
covers	O
the	O
cross	O
-	O
sectional	O
analysis	O
.	O

We	O
failed	O
to	O
detect	O
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
in	O
our	O
first	O
pass	O
of	O
mutation	O
screening	O
using	O
the	O
SNaPshot	O
multiplex	O
assays	O
,	O
as	O
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
was	O
not	O
included	O
in	O
the	O
screening	O
panels	O
because	O
it	O
had	O
never	O
been	O
detected	O
in	O
our	O
previous	O
genetic	O
epidemiological	O
survey	O
[	O
8	O
]	O
.	O

The	O
segregation	O
analysis	O
for	O
the	O
variants	O
c	B-VARIANT
.	I-VARIANT
1086	I-VARIANT
-	I-VARIANT
12G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
red	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
G379D	I-VARIANT
(	O
green	O
)	O
is	O
also	O
shown	O
.	O

The	O
potential	O
role	O
of	O
the	O
inwardly	O
rectifying	O
potassium	O
channel	O
KCNJ10	B-GENE
in	O
PDS	B-DISEASE
/	O
EVA	B-DISEASE
was	O
also	O
suggested	O
from	O
studies	O
in	O
mice	O
.	O

Meyer	O
et	O
al	O
.	O

N	O
in	O
bleeders	O
[	O
43	O
and	O
15	O
-	O
68	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
42	O
+	O
-	O
16	O
)	O
;	O
N	O
in	O
nonbleeders	O
[	O
39	O
and	O
11	O
-	O
86	O
]	O
,	O
(	O
mean	O
+	O
-	O
SD	O
:	O
45	O
+	O
-	O
21	O
)	O
;	O
(	O
NS	O
)	O
:	O
P	O
=	O
0	O
.	O
74	O
.	O

The	O
lod	O
score	O
for	O
linkage	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
to	O
the	O
D16S3045	O
-	O
TTA	O
(	O
21	O
.	O
603	O
)	O
haplotype	O
was	O
3	O
.	O
49	O
.	O

The	O
C	O
-	O
terminal	O
region	O
has	O
significant	O
sequence	O
homology	O
with	O
the	O
sterile	O
-	O
motif	O
(	O
SAM	O
)	O
domains	O
[	O
12	O
]	O
.	O

In	O
all	O
cases	O
,	O
filtering	O
queries	O
were	O
created	O
as	O
specific	O
presets	O
that	O
allowed	O
in	O
silico	O
reduction	O
of	O
variant	O
lists	O
down	O
to	O
candidates	O
with	O
correlation	O
to	O
phenotype	O
,	O
transmission	O
mode	O
of	O
inheritance	O
and	O
alteration	O
classification	O
of	O
pathogenicity	O
.	O

Positive	O
controls	O
not	O
included	O
.	O

F	O
:	O
Japanese	O
monosyllable	O
test	O
(	O
65dB	O
SPL	O
in	O
quiet	O
)	O
showing	O
dramatic	O
improvement	O
with	O
bilateral	O
EAS	O
.	O

For	O
MA6	O
,	O
family	O
history	O
suggested	O
recessive	O
inheritance	O
of	O
RP	B-DISEASE
with	O
an	O
autozygous	O
mutation	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Project	O
of	O
the	O
National	O
Natural	O
Science	O
Foundation	O
of	O
China	O
(	O
Grant	O
No	O
.	O

Three	O
missense	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
V63L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V153A	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
V198M	I-VARIANT
,	O
are	O
located	O
in	O
extracelluar	O
domain	O
1	O
,	O
2	O
,	O
and	O
transmembrane	O
span	O
4	O
,	O
respectively	O
,	O
of	O
connexin	O
26	O
protein	O
.	O

As	O
a	O
result	O
,	O
we	O
detected	O
a	O
heterozygous	O
single	O
nucleotide	O
deletion	O
in	O
the	O
exon	O
13	O
of	O
the	O
USH2A	B-GENE
,	O
which	O
was	O
expected	O
to	O
result	O
in	O
a	O
frameshift	O
leading	O
to	O
premature	O
termination	O
at	O
the	O
787th	O
codon	O
(	O
c	B-VARIANT
.	I-VARIANT
2310delA	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
Glu771LysfsX17	I-VARIANT
)	O
(	O
Fig	O
.	O

In	O
our	O
family	O
,	O
the	O
presentation	O
of	O
the	O
optic	B-DISEASE
atrophy	I-DISEASE
and	O
the	O
bilateral	O
progressive	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
is	O
similar	O
to	O
the	O
presentation	O
of	O
the	O
families	O
with	O
autosomal	O
dominant	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
deafness	B-DISEASE
and	O
a	O
mutation	O
in	O
OPA1	B-GENE
.	O

In	O
2008	O
,	O
Bhuiyan	O
ZA	O
et	O
al	O
.	O
,	O
[	O
28	O
]	O
described	O
a	O
homozygous	O
intronic	O
mutation	O
(	O
c387	B-VARIANT
-	I-VARIANT
5T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
that	O
led	O
to	O
an	O
incomplete	O
skipping	O
of	O
exon	O
-	O
2	O
in	O
KCNQ1	B-GENE
and	O
rescued	O
hearing	O
in	O
an	O
Arabian	O
JLNS	B-DISEASE
patient	O
.	O

After	O
CLRN1	B-GENE
sequencing	O
,	O
we	O
found	O
two	O
novel	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
R207X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
I168N	I-VARIANT
.	O

Similarly	O
,	O
heterozygous	O
carriers	O
of	O
WFS1	B-GENE
mutations	O
have	O
an	O
increased	O
incidence	O
of	O
psychiatric	B-DISEASE
disorders	I-DISEASE
including	O
endogenous	B-DISEASE
depression	I-DISEASE
,	O
suicide	B-DISEASE
attempts	I-DISEASE
,	O
short	B-DISEASE
-	I-DISEASE
term	I-DISEASE
memory	I-DISEASE
loss	I-DISEASE
,	O
and	O
anxiety	B-DISEASE
[	O
22	O
]	O
.	O

Fagang	O
Jiang	O
and	O
Dr	O
.	O

Boycott	O
(	O
University	O
of	O
Ottawa	O
)	O
,	O
J	O
.	O

e	O
)	O
In	O
males	O
and	O
females	O
who	O
inherit	O
glomerulopathy	O
with	O
fibronectin	O
deposits	O
because	O
they	O
carry	O
heterozygous	O
mutations	O
in	O
the	O
FN1	B-GENE
gene	O
for	O
fibronectin	O
[	O
39	O
]	O
.	O

In	O
contrast	O
to	O
454	O
sequencing	O
(	O
GS	O
FLX	O
)	O
,	O
analysis	O
of	O
homopolymer	O
stretches	O
is	O
not	O
problematic	O
in	O
Solexa	O
sequencing	O
(	O
MiSeq	O
)	O
.	O

The	O
residual	O
PRS	O
-	O
I	O
activity	O
in	O
the	O
female	O
carriers	O
(	O
I	O
-	O
1	O
;	O
II	O
-	O
1	O
)	O
might	O
be	O
explained	O
by	O
compensation	O
through	O
the	O
second	O
(	O
intact	O
)	O
X	O
chromosome	O
.	O

Patients	O
carrying	O
a	O
mutation	O
in	O
the	O
DFNA1	B-DISEASE
locus	O
typically	O
experience	O
a	O
rapidly	O
deteriorating	O
hearing	B-DISEASE
loss	I-DISEASE
progressing	O
from	O
low	O
to	O
involve	O
all	O
higher	O
frequencies	O
[	O
39	O
]	O
.	O

See	O
clinodactyly	B-DISEASE
in	O
proband	O
4	O
(	O
4E	O
)	O
.	O

For	O
that	O
purpose	O
,	O
some	O
essential	O
,	O
so	O
far	O
missing	O
information	O
was	O
gathered	O
by	O
:	O
i	O
)	O
comparing	O
the	O
strategy	O
for	O
mutation	O
detection	O
currently	O
in	O
use	O
with	O
the	O
here	O
developed	O
USH	B-DISEASE
exome	O
sequencing	O
(	O
including	O
splice	O
sites	O
)	O
,	O
ii	O
)	O
determination	O
of	O
whether	O
the	O
phenotype	O
can	O
restrict	O
the	O
mutation	O
screening	O
to	O
the	O
USH	B-DISEASE
genes	O
corresponding	O
to	O
the	O
clinical	O
subtype	O
in	O
a	O
given	O
patient	O
,	O
and	O
iii	O
)	O
defining	O
the	O
possible	O
existence	O
of	O
digenic	O
/	O
oligogenic	O
inheritance	O
of	O
the	O
disease	O
in	O
some	O
patients	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
mutation	O
G25V	B-VARIANT
is	O
located	O
in	O
the	O
extracellular	O
N	O
-	O
terminus	O
of	O
the	O
channel	O
protein	O
.	O

1	O
)	O
.	O

ANOVA	O
for	O
repeated	O
measures	O
was	O
carried	O
out	O
to	O
analyse	O
ECochG	O
measures	O
.	O

His	O
parents	O
and	O
younger	O
brother	O
paid	O
a	O
visit	O
for	O
family	O
study	O
and	O
had	O
their	O
blood	O
drawn	O
for	O
cell	O
counts	O
and	O
molecular	O
genetic	O
analyses	O
(	O
Fig	O
.	O

A	O
.	O

Individuals	O
were	O
diagnosed	O
with	O
JLNS	B-DISEASE
based	O
on	O
QT	B-DISEASE
prolongation	I-DISEASE
in	O
the	O
presence	O
of	O
profound	O
sensorineural	B-DISEASE
deafness	I-DISEASE
.	O

US	O
examination	O
at	O
17	O
,	O
18	O
and	O
20	O
weeks	O
revealed	O
fetal	B-DISEASE
macrocephaly	I-DISEASE
,	O
a	O
narrow	B-DISEASE
thorax	I-DISEASE
,	O
and	O
shortening	B-DISEASE
and	I-DISEASE
bowing	I-DISEASE
of	I-DISEASE
long	I-DISEASE
bones	I-DISEASE
.	O

Until	O
now	O
,	O
43	O
mutations	O
in	O
14	O
different	O
exons	O
have	O
been	O
described	O
.	O

Black	O
,	O
red	O
,	O
and	O
green	O
dots	O
denote	O
signals	O
indicative	O
of	O
the	O
normal	O
,	O
the	O
increased	O
(	O
>	O
+	O
0	O
.	O
5	O
)	O
,	O
and	O
the	O
decreased	O
(	O
<	O
-	O
0	O
.	O
8	O
)	O
copy	O
numbers	O
,	O
respectively	O
.	O

Ruiz	O
for	O
technical	O
assistance	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

In	O
early	O
studies	O
using	O
impedance	O
analyzers	O
,	O
the	O
platelet	O
count	O
was	O
controlled	O
by	O
light	O
microscopy	O
"	O
(	O
microscope	O
count	O
)	O
"	O
.	O

Ziaugra	O
for	O
genotyping	O
assistance	O
,	O
M	O
.	O

While	O
both	O
SALL2	B-GENE
and	O
MYH9	B-GENE
mutations	O
likely	O
contribute	O
to	O
the	O
complex	O
phenotype	O
in	O
this	O
patient	O
,	O
biological	O
studies	O
using	O
model	O
systems	O
would	O
be	O
needed	O
to	O
support	O
if	O
these	O
are	O
sufficient	O
or	O
necessary	O
for	O
the	O
phenotype	O
observed	O
.	O

At	O
examination	O
,	O
his	O
visual	O
acuity	O
was	O
20	O
/	O
400	O
that	O
improved	O
after	O
refraction	O
to	O
20	O
/	O
300	O
in	O
the	O
right	O
eye	O
,	O
and	O
3	O
/	O
200	O
that	O
improved	O
to	O
20	O
/	O
400	O
in	O
the	O
left	O
eye	O
.	O

We	O
identified	O
the	O
CERKL	B-GENE
founder	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
13	O
of	O
the	O
YJ	O
families	O
.	O

The	O
actin	O
-	O
activated	O
ATPase	O
activity	O
of	O
the	O
wild	O
type	O
(	O
M6	O
Full	O
WT	O
)	O
in	O
0	O
.	O
1	O
mM	O
CaCl	O
2	O
showed	O
a	O
K	O
ATPase	O
value	O
that	O
was	O
similar	O
to	O
the	O
tail	O
-	O
truncated	O
mouse	O
myosin	B-GENE
VI	I-GENE
(	O
M6S1	O
)	O
previously	O
reported	O
[	O
20	O
]	O
,	O
and	O
the	O
V	O
max	O
was	O
approximately	O
half	O
of	O
the	O
V	O
max	O
of	O
M6S1	O
.	O

Genetic	O
hearing	B-DISEASE
loss	I-DISEASE
has	O
been	O
estimated	O
to	O
be	O
responsible	O
for	O
more	O
than	O
half	O
of	O
congenital	O
bilateral	O
profound	O
deafness	B-DISEASE
cases	O
[	O
10	O
,	O
11	O
]	O
,	O
however	O
no	O
definitive	O
means	O
of	O
confirming	O
this	O
estimate	O
so	O
far	O
.	O

In	O
the	O
two	O
probands	O
presenting	O
with	O
progressive	O
lower	B-DISEASE
limb	I-DISEASE
spasticity	I-DISEASE
(	O
UK	O
-	O
3	O
and	O
UK	O
-	O
5	O
)	O
,	O
no	O
underlying	O
metabolic	O
,	O
inflammatory	O
or	O
compressive	O
causes	O
were	O
found	O
despite	O
extensive	O
investigations	O
over	O
several	O
years	O
.	O

This	O
suggests	O
that	O
the	O
WS	B-DISEASE
-	O
causing	O
mutant	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
increases	O
ER	O
stress	O
,	O
whereas	O
the	O
less	O
severely	O
affected	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
mutant	O
may	O
be	O
pathogenic	O
due	O
to	O
a	O
defect	O
in	O
its	O
ability	O
to	O
suppress	O
the	O
ER	O
stress	O
response	O
after	O
the	O
pathway	O
is	O
activated	O
.	O

Enzyme	O
restriction	O
sites	O
used	O
in	O
this	O
study	O
are	O
indicated	O
in	O
italics	O
.	O

These	O
results	O
,	O
as	O
well	O
as	O
previous	O
genetic	O
studies	O
performed	O
by	O
our	O
group	O
,	O
suggest	O
that	O
there	O
are	O
no	O
mutational	O
hot	O
spots	O
for	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
Korean	O
population	O
[	O
33	O
,	O
47	O
-	O
50	O
]	O
.	O

Pedigrees	O
of	O
families	O
ARRP01	O
,	O
ARRP02	O
,	O
ARRP03	O
,	O
ARRP04	O
and	O
SU01	O
are	O
demonstrated	O
.	O

As	O
to	O
allele	O
frequency	O
,	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutation	O
was	O
most	O
commonly	O
observed	O
(	O
46	O
.	O
8	O
%	O
,	O
118	O
/	O
252	O
)	O
,	O
followed	O
by	O
the	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
40	O
.	O
1	O
%	O
,	O
101	O
/	O
252	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
299	I-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
mutations	O
(	O
4	O
.	O
76	O
%	O
,	O
12	O
/	O
252	O
)	O
.	O

Anders	O
B	O
.	O

The	O
four	O
recessive	O
mutations	O
of	O
CIB2	B-GENE
co	O
-	O
segregate	O
with	O
deafness	B-DISEASE
or	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
while	O
carriers	O
have	O
normal	O
hearing	O
.	O

The	O
DNA	O
variant	O
was	O
not	O
only	O
found	O
in	O
all	O
affected	O
individuals	O
(	O
II	O
-	O
1	O
,	O
II	O
-	O
3	O
,	O
II	O
-	O
5	O
,	O
III	O
-	O
3	O
)	O
but	O
was	O
also	O
present	O
in	O
three	O
unaffected	O
individuals	O
(	O
I	O
-	O
2	O
,	O
III	O
-	O
5	O
,	O
III	O
-	O
7	O
)	O
(	O
Table	O
1	O
;	O
Figure	O
1	O
)	O
.	O

Note	O
:	O
NA	O
:	O
Not	O
available	O
because	O
they	O
are	O
too	O
young	O
.	O

[	O
7	O
]	O
concluded	O
that	O
the	O
patients	O
also	O
had	O
impaired	B-DISEASE
glucose	I-DISEASE
tolerance	I-DISEASE
.	O

We	O
therefore	O
conducted	O
a	O
systematic	O
clinical	O
and	O
molecular	O
study	O
of	O
OPA1	B-GENE
positive	O
families	O
to	O
establish	O
the	O
frequency	O
of	O
DOA	B-DISEASE
plus	O
syndrome	O
(	O
DOA	O
+	O
)	O
in	O
OPA1	B-GENE
disease	O
,	O
describe	O
the	O
phenotypic	O
spectrum	O
and	O
the	O
natural	O
history	O
of	O
these	O
additional	O
neuromuscular	O
features	O
,	O
and	O
define	O
any	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Only	O
a	O
few	O
studies	O
have	O
screened	O
large	O
cohorts	O
of	O
CAKUT	B-DISEASE
patients	O
for	O
disease	O
-	O
causing	O
mutations	O
35	O
-	O
40	O
.	O

Eleven	O
patients	O
presenting	O
with	O
NSHL	B-DISEASE
were	O
selected	O
.	O

He	O
came	O
to	O
our	O
hospital	O
complaining	O
of	O
decreased	O
vision	O
.	O

Computer	O
analysis	O
to	O
predict	O
the	O
effect	O
of	O
missense	O
variants	O
on	O
CDH23	B-GENE
protein	O
function	O
was	O
performed	O
with	O
Sorting	O
Intolerant	O
from	O
Tolerant	O
(	O
SIFT	O
;	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
,	O
and	O
Polymorphism	O
Phenotyping	O
(	O
PolyPhen2	O
;	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
.	O

However	O
,	O
as	O
suggested	O
in	O
the	O
literature	O
(	O
Balduini	O
et	O
al	O
.	O

Taking	O
another	O
view	O
of	O
such	O
analyses	O
,	O
disease	O
onset	O
and	O
progression	O
were	O
relatively	O
similar	O
in	O
patients	O
in	O
whom	O
WFS1	B-GENE
function	O
was	O
thought	O
to	O
be	O
virtually	O
abolished	O
(	O
Figure	O
S2	O
in	O
File	O
S1	O
)	O
.	O

Two	O
of	O
the	O
missense	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
[	O
43	O
]	O
and	O
p	B-VARIANT
.	I-VARIANT
K101E	I-VARIANT
[	O
44	O
]	O
,	O
were	O
found	O
in	O
five	O
and	O
two	O
"	O
unrelated	O
"	O
families	O
,	O
respectively	O
.	O

In	O
the	O
Hungarian	O
subgroup	O
,	O
all	O
homozygous	O
probands	O
had	O
bilateral	B-DISEASE
severe	I-DISEASE
to	I-DISEASE
profound	I-DISEASE
deafness	I-DISEASE
with	O
minimal	O
residual	O
hearing	O
.	O

The	O
MYO7A	B-GENE
sequence	O
(	O
accession	O
number	O
Q13402	O
in	O
the	O
UniProtKB	O
/	O
Swiss	O
-	O
Protdatabase	O
)	O
was	O
submitted	O
to	O
a	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
(	O
BLAST	O
)	O
[	O
14	O
]	O
search	O
against	O
the	O
structures	O
in	O
the	O
protein	O
data	O
bank	O
(	O
PDB	O
)	O
to	O
find	O
suitable	O
templates	O
for	O
homology	O
modeling	O
.	O

Direct	O
sequencing	O
identified	O
novel	O
mutations	O
(	O
c	B-VARIANT
.	I-VARIANT
1931	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S532I	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R581S	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V659L	I-VARIANT
)	O
in	O
the	O
patients	O
with	O
a	O
single	O
mutation	O
by	O
Invader	O
assay	O
and	O
c	B-VARIANT
.	I-VARIANT
1219delCT	I-VARIANT
mutation	O
in	O
a	O
patient	O
with	O
EVA	B-DISEASE
(	O
Table	O
3	O
)	O
.	O

Targeted	O
exome	O
capture	O
of	O
COL4A3	B-GENE
/	O
COL4A4	B-GENE
/	O
COL4A5	B-GENE
followed	O
by	O
NGS	O
has	O
also	O
been	O
used	O
clinically	O
to	O
screen	O
clinically	O
suspected	O
AS	B-DISEASE
patients	O
[	O
9	O
,	O
10	O
]	O
.	O

Figure	O
4	O
.	O

Fig	O
.	O

Genomic	O
DNA	O
of	O
the	O
proband	O
was	O
sheared	O
by	O
sonication	O
and	O
hybridized	O
to	O
the	O
Nimblegen	O
SeqCap	O
EZ	O
Library	O
for	O
enrichment	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Plain	O
radiographic	O
findings	O
of	O
the	O
lumbar	O
spine	O
,	O
shoulder	O
and	O
hand	O
.	O

Trios	O
2	O
and	O
3	O
:	O
protein	O
-	O
altering	O
and	O
splice	O
-	O
site	O
variants	O
absent	O
from	O
dbSNP	O
(	O
build	O
132	O
)	O
,	O
1000	O
Genomes	O
Project	O
data	O
,	O
and	O
332	O
other	O
exomes	O
.	O

In	O
general	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
DFNA6	O
/	O
14	O
is	O
not	O
progressive	O
,	O
however	O
,	O
some	O
families	O
were	O
reported	O
to	O
have	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
that	O
could	O
be	O
attributed	O
to	O
presbycusis	O
[	O
28	O
,	O
29	O
]	O
.	O

The	O
methodology	O
provides	O
a	O
reliable	O
strategy	O
for	O
routine	O
gene	O
diagnosis	O
of	O
USH	B-DISEASE
.	O

Membranes	O
were	O
then	O
incubated	O
2	O
h	O
at	O
room	O
temperature	O
with	O
monoclonal	O
mouse	O
anti	O
-	O
OPA1	O
antibody	O
(	O
BD	O
Bioscience	O
PharMingen	O
,	O
Milan	O
,	O
Italy	O
)	O
and	O
mouse	O
monoclonal	O
anti	O
-	O
Hsp60	O
antibody	O
(	O
Stressgene	O
,	O
Victoria	O
,	O
Canada	O
)	O
.	O

New	O
genetic	O
diagnoses	O
for	O
13	O
patients	O
with	O
CI	B-DISEASE
deficiency	I-DISEASE
affected	O
sibling	O
pairs	O
novel	O
variant	O
,	O
not	O
previously	O
reported	O
Bold	O
indicates	O
likely	O
causal	O
variants	O
.	O

(	O
c	O
)	O
Patients	O
suspected	O
of	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
were	O
tested	O
for	O
CHD7	B-GENE
.	O

,	O
1983	O
)	O
.	O

USH1C	B-GENE
mutations	O
are	O
the	O
main	O
cause	O
of	O
USH1	B-DISEASE
in	O
Acadian	O
and	O
Quebecois	O
patients	O
,	O
due	O
to	O
a	O
mutation	O
founder	O
effect	O
[	O
10	O
,	O
11	O
]	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
mutation	O
of	O
MYO7A	B-GENE
,	O
found	O
in	O
family	O
TB114	O
,	O
has	O
been	O
reported	O
previously	O
in	O
a	O
USH1	B-DISEASE
patient	O
of	O
unknown	O
ethnicity	O
[	O
10	O
,	O
12	O
]	O
.	O

5	O
and	O
Supplementary	O
Table	O
5	O
)	O
affecting	O
integrin	O
activation	O
9	O
and	O
perhaps	O
the	O
efficiency	O
of	O
Ca	O
2	O
+	O
sequestering	O
by	O
CIB2	B-GENE
due	O
to	O
potential	O
subtle	O
changes	O
in	O
subcellular	O
localization	O
.	O

Hearing	B-DISEASE
impairment	I-DISEASE
is	O
the	O
most	O
common	O
neurosensory	O
disorder	O
in	O
humans	O
,	O
with	O
an	O
incidence	O
of	O
1	O
in	O
300	O
to	O
1	O
in	O
1	O
,	O
000	O
children	O
[	O
1	O
-	O
3	O
]	O
and	O
approximately	O
half	O
of	O
all	O
cases	O
are	O
caused	O
by	O
genetic	O
defects	O
.	O

Unmarked	O
cells	O
(	O
control	O
)	O
were	O
used	O
as	O
negative	O
controls	O
in	O
both	O
non	O
-	O
conjugated	O
and	O
conjugated	O
antibodies	O
.	O

Presumably	O
,	O
other	O
genetic	O
factors	O
and	O
environmental	O
factors	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
EVA	B-DISEASE
in	O
Caucasians	O
.	O

We	O
also	O
identified	O
a	O
deleterious	O
SALL2	B-GENE
mutation	O
as	O
a	O
potential	O
cause	O
of	O
her	O
VUR	B-DISEASE
and	O
an	O
unexpected	O
novel	O
MYH9	B-GENE
mutation	O
in	O
the	O
same	O
patient	O
.	O

Measurement	O
using	O
a	O
radioisotope	O
technique	O
showed	O
that	O
their	O
transport	O
activity	O
was	O
significantly	O
reduced	O
.	O

The	O
up	O
-	O
regulated	O
expression	O
of	O
TNC	B-GENE
gene	O
in	O
tissue	O
repair	O
and	O
neural	O
regeneration	O
was	O
seen	O
in	O
human	O
and	O
zebrafish	O
,	O
and	O
in	O
sensory	O
receptor	O
recovery	O
in	O
the	O
vestibular	O
organ	O
after	O
ototoxic	O
injury	O
in	O
birds	O
.	O

Secondary	O
antibody	O
incubation	O
was	O
for	O
1hr	O
at	O
room	O
temperature	O
.	O

This	O
work	O
was	O
supported	O
by	O
NSF	O
Graduate	O
Research	O
Fellowship	O
(	O
DSL	O
)	O
,	O
DOD	O
National	O
Defense	O
Science	O
and	O
Engineering	O
Graduate	O
Fellowship	O
(	O
SGH	O
)	O
,	O
grant	O
RC2HG005556	O
and	O
R01GM97136	O
from	O
the	O
NGHRI	O
/	O
NIH	O
(	O
VKM	O
)	O
,	O
the	O
Marriott	O
Mitochondrial	O
Disorders	O
Clinical	O
Research	O
Fund	O
(	O
VKM	O
)	O
,	O
and	O
the	O
Birmingham	O
and	O
MINDlink	O
Foundations	O
(	O
JDS	O
)	O
.	O
To	O
describe	O
the	O
clinical	O
and	O
genetic	O
findings	O
in	O
one	O
Chinese	O
family	O
with	O
autosomal	O
recessive	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
arRP	B-DISEASE
)	O
and	O
in	O
three	O
unrelated	O
Chinese	O
families	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
II	I-DISEASE
(	O
USH2	B-DISEASE
)	O
.	O

This	O
candidate	O
region	O
showed	O
partial	O
overlap	O
with	O
the	O
critical	O
intervals	O
identified	O
in	O
DFNB31	B-GENE
(	O
9q32	O
-	O
34	O
)	O
and	O
DFNB79	B-GENE
(	O
9q34	O
.	O
3	O
)	O
loci	O
(	O
Figure	O
.	O

Summary	O
of	O
possible	O
pathogenic	O
mutations	O
*	O
n	O
.	O
t	O
.	O

For	O
investigation	O
of	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
variant	O
pathogenicity	O
,	O
a	O
89	O
bp	O
fragment	O
of	O
exon	O
7	O
harbouring	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
location	O
was	O
amplified	O
with	O
primers	O
7K1F	O
and	O
7K1R	O
.	O

David	O
H	O
.	O

We	O
found	O
that	O
both	O
the	O
normal	O
and	O
mutated	O
CD164	B-GENE
transcripts	O
were	O
expressed	O
in	O
peripheral	O
blood	O
cells	O
(	O
Fig	O
7B	O
)	O
,	O
demonstrating	O
that	O
the	O
CD164	B-GENE
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
transcript	O
escapes	O
NMD	O
.	O

DFNB1	B-GENE
mutations	O
were	O
identified	O
in	O
only	O
4	O
of	O
the	O
130	O
families	O
.	O

Additional	O
exon	O
(	O
s	O
)	O
refers	O
to	O
the	O
number	O
of	O
exons	O
differing	O
from	O
the	O
main	O
isoform	O
.	O
Communicated	O
by	O
David	O
Rimoin	O
Both	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
.	O

Deafness	B-DISEASE
caused	O
by	O
otitis	B-DISEASE
media	I-DISEASE
,	O
meningitis	B-DISEASE
,	O
viral	B-DISEASE
encephalitis	I-DISEASE
,	O
parotitis	B-DISEASE
,	O
and	O
general	O
infection	B-DISEASE
were	O
also	O
excluded	O
for	O
both	O
siblings	O
.	O

For	O
example	O
,	O
in	O
Caucasians	O
,	O
mutation	O
of	O
a	O
single	O
gene	O
,	O
GJB2	B-GENE
,	O
accounts	O
for	O
up	O
to	O
50	O
%	O
of	O
all	O
cases	O
of	O
ARNSHL	B-DISEASE
[	O
3	O
]	O
.	O

Verbal	O
consents	O
were	O
obtained	O
from	O
all	O
enrolled	O
subjects	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
Institutional	O
Review	O
Board	O
of	O
the	O
American	O
University	O
of	O
Beirut	O
that	O
were	O
in	O
place	O
between	O
1994	O
-	O
1998	O
and	O
before	O
the	O
implementation	O
of	O
written	O
consent	O
forms	O
.	O

Once	O
again	O
these	O
referrals	O
came	O
almost	O
exclusively	O
from	O
geneticists	O
within	O
clinical	O
genetics	O
and	O
/	O
or	O
pediatrics	O
departments	O
and	O
included	O
nine	O
referrals	O
from	O
members	O
of	O
the	O
ESDN	O
panel	O
.	O

Sixty	O
-	O
seven	O
patients	O
were	O
identified	O
nationally	O
for	O
a	O
prevalence	O
of	O
one	O
per	O
710	O
,	O
000	O
,	O
with	O
33	O
patients	O
(	O
49	O
%	O
)	O
having	O
all	O
4	O
components	O
of	O
DIDMOAD	B-DISEASE
.	O

A	O
total	O
of	O
10	O
.	O
77	O
GB	O
data	O
on	O
target	O
genomic	O
regions	O
was	O
generated	O
for	O
the	O
three	O
samples	O
,	O
with	O
a	O
mean	O
coverage	O
of	O
target	O
region	O
of	O
78	O
.	O
23X	O
.	O

Testing	O
this	O
hypothesis	O
on	O
patient	O
samples	O
is	O
not	O
possible	O
since	O
the	O
level	O
of	O
transcription	O
of	O
TMPRSS3	B-GENE
is	O
low	O
in	O
blood	O
cells	O
.	O

All	O
predicted	O
variants	O
were	O
filtered	O
to	O
remove	O
false	O
positives	O
related	O
to	O
potential	O
homopolymer	O
artifacts	O
(	O
variants	O
found	O
in	O
homopolymers	O
having	O
sequence	O
length	O
>	O
=	O
5	O
were	O
removed	O
)	O
,	O
strand	O
specific	O
sequence	O
artifacts	O
,	O
ambiguously	O
mapped	O
data	O
(	O
average	O
mapping	O
quality	O
difference	O
between	O
the	O
reference	O
supporting	O
reads	O
and	O
variant	O
supporting	O
reads	O
>	O
=	O
30	O
)	O
,	O
and	O
low	O
quality	O
data	O
at	O
the	O
beginning	O
and	O
end	O
of	O
reads	O
(	O
variants	O
supported	O
exclusively	O
by	O
bases	O
observed	O
in	O
first	O
or	O
last	O
10	O
%	O
of	O
the	O
reads	O
)	O
.	O

The	O
non	O
-	O
synonymous	O
variant	O
c	B-VARIANT
.	I-VARIANT
829G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
discovered	O
in	O
42	O
heterozygous	O
patients	O
and	O
7	O
homozygous	O
patients	O
.	O

The	O
mutations	O
have	O
been	O
all	O
confirmed	O
by	O
direct	O
Sanger	O
sequencing	O
(	O
data	O
not	O
shown	O
)	O
.	O

Sequence	O
variations	O
were	O
found	O
on	O
both	O
strands	O
and	O
confirmed	O
in	O
a	O
separate	O
PCR	O
analysis	O
.	O

We	O
took	O
(	O
1	O
-	O
P	O
)	O
as	O
a	O
measure	O
of	O
the	O
statistical	O
confidence	O
of	O
the	O
data	O
and	O
conventionally	O
set	O
a	O
threshold	O
of	O
the	O
statistical	O
confidence	O
to	O
be	O
99	O
.	O
9	O
%	O
.	O

In	O
one	O
USH1	B-DISEASE
case	O
detailed	O
clinical	O
data	O
could	O
not	O
be	O
obtained	O
,	O
whereas	O
in	O
the	O
remaining	O
cases	O
clinical	O
information	O
was	O
revised	O
and	O
the	O
USH	B-DISEASE
diagnosis	O
was	O
confirmed	O
.	O

J	O
.	O
B	O
.	O
R	O
.	O

Light	O
microscopy	O
(	O
LM	O
)	O
showed	O
segmental	B-DISEASE
sclerosis	I-DISEASE
with	O
hyalinosis	B-DISEASE
and	O
adhesion	O
to	O
Bowman	O
'	O
s	O
capsule	O
.	O

B	O
,	O
Membrane	O
and	O
cytoplasm	O
protein	O
fractions	O
isolated	O
from	O
of	O
HEK	O
-	O
293	O
cells	O
transiently	O
transfected	O
with	O
empty	O
vectors	O
(	O
control	O
)	O
,	O
wild	O
-	O
type	O
KCNQ1	B-GENE
(	O
WT	O
)	O
,	O
or	O
mutant	O
KCNQ1	B-GENE
(	O
R397Q	B-VARIANT
)	O
.	O

Cormand	O
for	O
his	O
guidance	O
and	O
invaluable	O
advice	O
on	O
WES	O
.	O

One	O
affected	O
male	O
(	O
IIA	O
:	O
3	O
)	O
had	O
a	O
history	O
of	O
aminoglycoside	O
exposure	O
(	O
Table	O
1	O
;	O
Fig	O
.	O

At	O
last	O
,	O
Gold	O
antifade	O
reagent	O
was	O
added	O
to	O
mount	O
onto	O
coverslips	O
.	O

The	O
TBX1	B-GENE
G310S	B-VARIANT
variant	O
seems	O
to	O
affect	O
the	O
interaction	O
of	O
TBX1	B-GENE
with	O
other	O
factors	O
.	O

His	O
full	O
-	O
field	O
ERGs	O
were	O
nonrecordable	O
.	O

The	O
sequences	O
obtained	O
were	O
compared	O
with	O
the	O
consensus	O
genomic	O
sequence	O
NG_009168	O
.	O
1	O
using	O
the	O
BLAST	O
program	O
.	O

The	O
mutational	O
sites	O
are	O
indicated	O
with	O
an	O
asterisk	O
,	O
and	O
amino	O
acid	O
codes	O
are	O
depicted	O
with	O
a	O
line	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MTS	O
MFDA	O
PKHT	O
.	O

Mutations	O
in	O
CDH23	B-GENE
were	O
determined	O
as	O
the	O
cause	O
of	O
USH1	B-DISEASE
in	O
five	O
(	O
10	O
.	O
6	O
%	O
)	O
families	O
.	O

(	O
I	O
)	O
OCTs	O
display	O
atrophy	B-DISEASE
of	I-DISEASE
photoreceptors	I-DISEASE
layer	I-DISEASE
in	O
the	O
perifoveal	O
region	O
and	O
normal	O
foveal	O
thickness	O
.	O

'	O
+	O
'	O
,	O
deleterious	O
or	O
damaging	O
;	O
'	O
-	O
'	O
,	O
benign	O
;	O
'	O
?	O
'	O
,	O
not	O
avaiable	O
.	O

The	O
existence	O
of	O
LSDBs	O
for	O
nine	O
Usher	B-DISEASE
genes	O
(	O
USHbases	O
)	O
combining	O
international	O
datasets	O
is	O
a	O
valuable	O
tool	O
for	O
molecular	O
genetic	O
studies	O
of	O
USH	B-DISEASE
.	O

Of	O
eleven	O
heterozygous	O
patients	O
(	O
c	O
.	O
-	O
137	O
TC	O
and	O
c	O
.	O
-	O
53	O
GC	O
)	O
,	O
six	O
were	O
heterozygous	O
for	O
the	O
insertion	O
c	B-VARIANT
.	I-VARIANT
2097_2098insT	I-VARIANT
.	O

We	O
categorized	O
the	O
phenotypes	O
at	O
72	O
hours	O
post	O
-	O
fertilization	O
(	O
hpf	O
)	O
into	O
class	O
I	O
(	O
normal	O
like	O
)	O
,	O
class	O
II	O
(	O
tail	B-DISEASE
defect	I-DISEASE
)	O
,	O
class	O
III	O
(	O
tail	B-DISEASE
defect	I-DISEASE
,	O
micro	B-DISEASE
-	I-DISEASE
ophthalmia	I-DISEASE
,	O
blood	B-DISEASE
pooling	I-DISEASE
)	O
and	O
class	O
IV	O
(	O
hypo	B-DISEASE
-	I-DISEASE
pigmentation	I-DISEASE
,	O
micro	B-DISEASE
-	I-DISEASE
ophthalmia	I-DISEASE
,	O
tail	B-DISEASE
defects	I-DISEASE
and	O
retarded	B-DISEASE
development	I-DISEASE
;	O
Fig	O
.	O

With	O
the	O
advent	O
of	O
exome	O
sequencing	O
,	O
it	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
allelic	O
heterogeneity	O
in	O
genes	O
encoding	O
essential	O
proteins	O
,	O
such	O
as	O
those	O
involved	O
in	O
transcription	O
,	O
results	O
in	O
highly	O
variable	O
phenotypes	O
.	O

Similar	O
analysis	O
on	O
the	O
second	O
family	O
resulted	O
in	O
a	O
maximum	O
LOD	O
score	O
of	O
2	O
.	O
7	O
(	O
Figure	O
1	O
)	O
and	O
identified	O
a	O
disease	O
locus	O
on	O
chromosome	O
21q22	O
.	O
3	O
,	O
which	O
spanned	O
approximately	O
1	O
.	O
5	O
Mb	O
.	O

The	O
8	O
missense	O
mutations	O
are	O
p	B-VARIANT
.	I-VARIANT
G4D	I-VARIANT
(	O
3	O
heterozygous	O
patients	O
)	O
,	O
p	B-VARIANT
.	I-VARIANT
R32C	I-VARIANT
(	O
one	O
patient	O
in	O
compound	O
heterozygosity	O
with	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
)	O
,	O
p	B-VARIANT
.	I-VARIANT
R143W	I-VARIANT
(	O
4	O
compound	O
heterozygotes	O
)	O
,	O
p	B-VARIANT
.	I-VARIANT
T86R	I-VARIANT
(	O
all	O
compound	O
heterozygous	O
,	O
6	O
with	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
and	O
1	O
with	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
)	O
,	O
p	B-VARIANT
.	I-VARIANT
R127H	I-VARIANT
(	O
one	O
compound	O
with	O
p	B-VARIANT
.	I-VARIANT
Y152X	I-VARIANT
,	O
31	O
single	O
heterozygotes	O
)	O
,	O
p	B-VARIANT
.	I-VARIANT
S139N	I-VARIANT
(	O
2	O
single	O
heterozygotes	O
)	O
,	O
p	B-VARIANT
.	I-VARIANT
E47K	I-VARIANT
(	O
one	O
compound	O
with	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
)	O
,	O
p	B-VARIANT
.	I-VARIANT
S85P	I-VARIANT
(	O
single	O
heterozygote	O
)	O
.	O

TABLE	O
3	O
Overview	O
of	O
the	O
literature	O
on	O
mutations	O
in	O
the	O
TMPRRS3	B-GENE
gene	O
The	O
gray	O
rows	O
represent	O
families	O
with	O
postlingual	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
DFNB8	B-DISEASE
)	O
and	O
the	O
blank	O
rows	O
the	O
families	O
with	O
prelingual	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
DFNB10	B-DISEASE
)	O
.	O

None	O
of	O
the	O
individuals	O
are	O
first	O
degree	O
relatives	O
,	O
as	O
confirmed	O
by	O
genomic	O
analysis	O
.	O

Unfortunately	O
he	O
lost	O
the	O
opportunity	O
to	O
operation	O
because	O
of	O
pulmonary	B-DISEASE
hypertension	I-DISEASE
and	O
died	O
at	O
the	O
age	O
of	O
13	O
.	O

14	O
,	O
19	O
In	O
this	O
study	O
,	O
we	O
identified	O
two	O
novel	O
nonsense	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Q136X	I-VARIANT
)	O
and	O
(	O
p	B-VARIANT
.	I-VARIANT
W114X	I-VARIANT
)	O
in	O
POU3F4	B-GENE
as	O
a	O
cause	O
of	O
nonsyndromic	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
two	O
large	O
Pakistani	O
families	O
.	O

+	O
+	O
Patient	O
7	O
has	O
severe	O
microcephaly	O
(	O
head	O
circumference	O
of	O
15	O
cm	O
at	O
20	O
weeks	O
)	O
,	O
hydrocephaly	O
,	O
and	O
severe	O
disruption	O
of	O
the	O
telencephalic	O
architecture	O
.	O

Since	O
individuals	O
who	O
harbor	O
OPA1	B-GENE
mutations	O
may	O
have	O
mild	O
phenotypes	O
that	O
the	O
individuals	O
are	O
unaware	O
of	O
,	O
it	O
is	O
important	O
to	O
keep	O
OPA1	B-GENE
in	O
mind	O
for	O
patients	O
with	O
suspected	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
without	O
a	O
family	O
history	O
and	O
evaluate	O
the	O
family	O
members	O
of	O
these	O
singleton	O
cases	O
carefully	O
.	O

However	O
,	O
half	O
of	O
the	O
patients	O
included	O
in	O
this	O
study	O
demonstrated	O
various	O
degrees	O
of	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
also	O
sudden	O
aggravation	O
of	O
hearing	O
was	O
demonstrated	O
in	O
one	O
patient	O
.	O

As	O
shown	O
in	O
table	O
1	O
,	O
two	O
patients	O
carried	O
apparently	O
homozygous	O
DNA	O
sequence	O
variations	O
.	O

The	O
tubular	O
bones	O
are	O
short	O
and	O
broad	O
with	O
splayed	O
ends	O
and	O
cupped	O
metaphyses	O
and	O
mild	O
bowing	B-DISEASE
of	I-DISEASE
the	I-DISEASE
tibiae	I-DISEASE
.	O

This	O
required	O
578	O
primer	O
reactions	O
(	O
Le	O
Quesne	O
Stabej	O
et	O
al	O
.	O

Primers	O
and	O
PCR	O
conditions	O
are	O
described	O
elsewhere	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

Roche	O
454	O
data	O
were	O
initially	O
processed	O
using	O
the	O
GSMapper	O
software	O
package	O
(	O
Roche	O
Inc	O
.	O
)	O
supplied	O
with	O
the	O
GS	O
FLX	O
instrument	O
.	O

One	O
is	O
a	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
D458V	I-VARIANT
)	O
involving	O
the	O
PDZ	O
binding	O
motif	O
of	O
the	O
SANS	O
protein	O
,	O
and	O
is	O
predicted	O
to	O
reduce	O
the	O
strength	O
of	O
its	O
interaction	O
with	O
harmonin	O
,	O
the	O
protein	O
encoded	O
by	O
the	O
USH1C	B-GENE
gene	O
[	O
15	O
]	O
.	O

All	O
subjects	O
were	O
patients	O
at	O
the	O
National	O
Hospital	O
Organization	O
Tokyo	O
Medical	O
Center	O
or	O
a	O
collaborating	O
hospital	O
.	O

As	O
goiter	B-DISEASE
does	O
not	O
usually	O
manifest	O
until	O
adulthood	O
and	O
even	O
after	O
that	O
,	O
the	O
patient	O
VI	O
-	O
1	O
may	O
show	O
goiter	B-DISEASE
at	O
an	O
advanced	O
age	O
.	O

The	O
potential	O
effectiveness	O
of	O
such	O
genotype	O
-	O
driven	O
treatments	O
is	O
often	O
deducible	O
from	O
the	O
assayed	O
biological	O
consequence	O
of	O
the	O
disease	O
-	O
causing	O
mutation	O
and	O
known	O
mechanisms	O
of	O
action	O
of	O
candidate	O
drugs	O
,	O
and	O
is	O
further	O
testable	O
from	O
the	O
behavior	O
of	O
mutant	O
proteins	O
in	O
in	O
vitro	O
assays	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
candidate	O
drugs	O
.	O

This	O
individual	O
may	O
be	O
related	O
to	O
family	O
TB114	O
;	O
alternatively	O
,	O
p	B-VARIANT
.	I-VARIANT
Q234X	I-VARIANT
may	O
be	O
a	O
recurrent	O
mutation	O
.	O

Nationally	O
,	O
inherited	O
retinal	O
disease	O
accounts	O
for	O
4	O
.	O
2	O
%	O
of	O
all	O
sight	O
impairment	O
certifications	O
and	O
5	O
.	O
5	O
%	O
of	O
blindness	O
cases	O
[	O
1	O
]	O
.	O

The	O
mechanism	O
underlying	O
this	O
significant	O
difference	O
could	O
be	O
that	O
some	O
genetic	O
modifiers	O
(	O
yet	O
unknown	O
)	O
,	O
when	O
combined	O
with	O
a	O
primary	O
mutation	O
,	O
may	O
exacerbate	O
a	O
patient	O
'	O
s	O
phenotype	O
.	O
[	O
30	O
31	O
]	O
The	O
allele	O
frequencies	O
of	O
KCNE1	B-GENE
-	O
D85N	B-VARIANT
i	O
.	O
e	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
adult	O
subjects	O
and	O
parents	O
of	O
minor	O
subjects	O
.	O

did	O
however	O
find	O
a	O
novel	O
missense	O
variant	O
in	O
FOXI1	B-GENE
p	B-VARIANT
.	I-VARIANT
Pro239Leu	I-VARIANT
,	O
and	O
3	O
patients	O
with	O
the	O
variant	O
p	B-VARIANT
.	I-VARIANT
Arg271Cys	I-VARIANT
in	O
KCNJ10	B-GENE
out	O
of	O
19	O
patients	O
with	O
PDS	B-DISEASE
/	O
EVA	B-DISEASE
,	O
but	O
functional	O
analysis	O
of	O
p	B-VARIANT
.	I-VARIANT
Pro239Leu	I-VARIANT
showed	O
no	O
significant	O
impairment	O
in	O
the	O
transcriptional	O
activation	O
of	O
SLC26A4	B-GENE
,	O
and	O
,	O
p	B-VARIANT
.	I-VARIANT
Arg271Cys	I-VARIANT
was	O
classified	O
as	O
polymorphism	O
[	O
38	O
]	O
.	O

The	O
degree	O
of	O
HI	O
was	O
assessed	O
by	O
pure	O
tone	O
air	O
conduction	O
audiometry	O
at	O
frequencies	O
ranging	O
from	O
250	O
to	O
8000	O
Hz	O
.	O

Brain	O
NMR	O
revealed	O
reducing	O
the	O
thickness	O
of	O
the	O
nerve	O
and	O
chiasm	O
and	O
optic	O
tracts	O
,	O
a	B-DISEASE
nodule	I-DISEASE
of	I-DISEASE
heterotopic	I-DISEASE
gray	I-DISEASE
matter	I-DISEASE
in	I-DISEASE
the	I-DISEASE
left	I-DISEASE
anterior	I-DISEASE
frontal	I-DISEASE
periventricular	I-DISEASE
.	O

The	O
remaining	O
missense	O
mutations	O
interfere	O
with	O
conserved	O
residues	O
and	O
have	O
not	O
been	O
found	O
in	O
controls	O
;	O
further	O
the	O
mutations	O
p	B-VARIANT
.	I-VARIANT
F1596I	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
V1597M	I-VARIANT
,	O
are	O
located	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
SCN5A	B-GENE
,	O
where	O
mutations	O
causing	O
LQTS	B-DISEASE
are	O
particularly	O
frequent	O
[	O
2	O
]	O
.	O

None	O
of	O
the	O
other	O
patients	O
in	O
Branch	O
B	O
had	O
self	O
-	O
reported	O
goiter	B-DISEASE
either	O
,	O
consistent	O
with	O
the	O
rarity	O
of	O
Pendred	B-DISEASE
syndrome	I-DISEASE
among	O
Chinese	O
patients	O
.	O

In	O
the	O
present	O
family	O
,	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
phenotype	O
is	O
similar	O
to	O
that	O
which	O
has	O
been	O
reported	O
for	O
DFNA10	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
i	O
.	O
e	O
.	O
,	O
late	O
-	O
onset	O
,	O
progressive	O
,	O
sensorineural	O
and	O
non	O
-	O
syndromic	O
,	O
and	O
the	O
novel	O
c	B-VARIANT
.	I-VARIANT
T1301A	I-VARIANT
mutation	O
creates	O
a	O
p	B-VARIANT
.	I-VARIANT
I411K	I-VARIANT
substitution	O
in	O
the	O
eyaHR	O
.	O

Both	O
macular	B-DISEASE
hole	I-DISEASE
and	O
posterior	B-DISEASE
lenticonus	I-DISEASE
are	O
rare	O
ocular	O
manifestations	O
in	O
AS	B-DISEASE
[	O
12	O
-	O
16	O
]	O
.	O

DNA	O
samples	O
were	O
analysed	O
for	O
patients	O
with	O
a	O
high	O
suspicion	O
of	O
an	O
underlying	O
mitochondrial	O
genetic	O
disease	O
due	O
to	O
the	O
multi	O
-	O
system	O
pattern	O
of	O
their	O
clinical	O
presentations	O
,	O
evidence	O
of	O
a	O
mitochondrial	O
biochemical	O
defect	O
,	O
and	O
/	O
or	O
the	O
presence	O
of	O
multiple	O
mtDNA	O
deletions	O
.	O

In	O
brief	O
,	O
the	O
quality	O
of	O
each	O
sample	O
was	O
verified	O
by	O
gel	O
electrophoresis	O
prior	O
to	O
fragmentation	O
.	O

None	O
of	O
them	O
was	O
found	O
in	O
200	O
ethnically	O
-	O
matched	O
normal	O
hearing	O
controls	O
.	O

It	O
is	O
diagnosed	O
in	O
young	O
boys	O
when	O
they	O
are	O
neonates	O
or	O
infants	O
,	O
or	O
at	O
pubertal	O
age	O
.	O

Based	O
on	O
10	O
-	O
fold	O
cross	O
-	O
validation	O
,	O
the	O
error	O
rates	O
for	O
genotypes	O
passing	O
these	O
filters	O
were	O
estimated	O
to	O
be	O
<	O
1	O
.	O
3	O
%	O
for	O
false	O
negatives	O
and	O
<	O
2	O
.	O
3	O
%	O
for	O
false	O
positives	O
.	O

The	O
molecular	O
defects	O
of	O
more	O
than	O
80	O
%	O
of	O
the	O
mutant	O
alleles	O
for	O
NSHI	B-DISEASE
in	O
China	O
remain	O
to	O
be	O
identified	O
.	O

None	O
of	O
the	O
affected	O
individuals	O
displayed	O
symptoms	O
of	O
tinnitus	B-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
or	O
other	O
clinical	O
abnormalities	O
indicating	O
syndromic	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

We	O
focused	O
on	O
protein	O
-	O
altering	O
variants	O
(	O
missense	O
,	O
nonsense	O
,	O
splice	O
-	O
site	O
variants	O
,	O
and	O
coding	O
indels	O
)	O
absent	O
from	O
dbSNP	O
(	O
build	O
132	O
)	O
,	O
1000	O
Genomes	O
Project	O
data	O
19	O
,	O
and	O
101	O
other	O
exomes	O
.	O

For	O
these	O
patients	O
,	O
we	O
first	O
applied	O
the	O
Invader	O
assay	O
for	O
screening	O
47	O
known	O
mutations	O
of	O
13	O
known	O
deafness	B-DISEASE
genes	O
,	O
followed	O
by	O
direct	O
sequencing	O
as	O
necessary	O
.	O

Kazuma	O
Sugahara	O
and	O
Hiroshi	O
Yamashita	O
(	O
Yamaguchi	O
University	O
)	O
,	O
Drs	O
.	O

Wrote	O
the	O
paper	O
:	O
CB	O
MCP	O
GDB	O
.	O

Structural	O
and	O
sequence	O
homology	O
with	O
the	O
synaptic	O
protein	O
stargazin	O
suggest	O
a	O
role	O
for	O
CLRN1	B-GENE
in	O
the	O
plasma	O
membranes	O
surrounding	O
ribbon	O
synapses	O
of	O
the	O
inner	O
ear	O
and	O
retina	O
[	O
23	O
]	O
.	O

We	O
identified	O
a	O
homozygous	O
insertion	O
of	O
a	O
C	O
nucleotide	O
between	O
positions	O
206	O
and	O
207	O
of	O
USH1G	B-GENE
cDNA	O
,	O
located	O
in	O
exon	O
2	O
(	O
c	B-VARIANT
.	I-VARIANT
206	I-VARIANT
-	I-VARIANT
207insC	I-VARIANT
;	O
Figure	O
2D	O
)	O
.	O

Hearing	O
was	O
assessed	O
by	O
pure	O
-	O
tone	O
audiometry	O
and	O
/	O
or	O
auditory	O
evoked	O
responses	O
,	O
and	O
the	O
presence	O
of	O
SNHL	B-DISEASE
was	O
graded	O
according	O
to	O
the	O
"	O
Bureau	O
International	O
d	O
'	O
Audiophonologie	O
"	O
recommendations	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
biap	O
.	O
org	O
)	O
.	O

Cases	O
with	O
only	O
one	O
definitely	O
pathogenic	O
mutation	O
after	O
TRS	O
-	O
204	O
was	O
not	O
considered	O
as	O
explained	O
.	O

In	O
addition	O
to	O
the	O
expected	O
mutations	O
,	O
i	O
.	O
e	O
.	O
,	O
those	O
identified	O
by	O
microarray	O
analysis	O
,	O
two	O
unreported	O
mutations	O
were	O
identified	O
(	O
Table	O
2	O
)	O
.	O

Two	O
fragments	O
of	O
455	O
bp	O
and	O
217	O
bp	O
from	O
genotype	O
TT	O
were	O
unaffected	O
by	O
enzyme	O
digestion	O
,	O
while	O
three	O
fragments	O
of	O
672	O
bp	O
(	O
solid	O
arrow	O
)	O
,	O
455	O
bp	O
,	O
and	O
217	O
bp	O
were	O
observed	O
from	O
heterozygotes	O
carrying	O
genotype	O
TC	O
as	O
I	O
:	O
2	O
,	O
II	O
:	O
1	O
,	O
II	O
:	O
3	O
and	O
one	O
normal	O
control	O
(	O
C	O
indicated	O
by	O
the	O
open	O
arrow	O
)	O
.	O

We	O
also	O
thank	O
all	O
the	O
referring	O
physicians	O
who	O
have	O
helped	O
and	O
devoted	O
their	O
time	O
to	O
this	O
project	O
.	O

Targeted	O
or	O
whole	O
exome	O
sequencing	O
has	O
been	O
proved	O
to	O
be	O
a	O
powerful	O
tool	O
to	O
discover	O
novel	O
disease	O
-	O
related	O
genes	O
or	O
genetic	O
mutations	O
in	O
large	O
genomic	O
regions	O
[	O
3	O
]	O
.	O

This	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
7255	O
)	O
and	O
the	O
majority	O
of	O
individuals	O
in	O
both	O
groups	O
(	O
~	O
95	O
%	O
)	O
were	O
symptomatic	O
by	O
the	O
age	O
of	O
15	O
years	O
(	O
Fig	O
.	O

in	O
2009	O
determined	O
that	O
p	B-VARIANT
.	I-VARIANT
G572S	I-VARIANT
causes	O
a	O
dominant	O
negative	O
trafficking	O
defect	O
.	O

Therefore	O
,	O
we	O
believe	O
that	O
the	O
possibility	O
of	O
hearing	O
progression	O
should	O
be	O
explained	O
to	O
the	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
,	O
and	O
regular	O
auditory	O
tests	O
should	O
be	O
performed	O
in	O
order	O
to	O
treat	O
these	O
patients	O
with	O
proper	O
modality	O
of	O
auditory	O
rehabilitation	O
at	O
an	O
appropriate	O
timing	O
.	O

The	O
PCR	O
products	O
were	O
digested	O
with	O
2	O
units	O
of	O
NlaIII	O
restriction	O
enzyme	O
(	O
New	O
England	O
Biolabs	O
,	O
Inc	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
at	O
37	O
deg	O
C	O
for	O
5	O
h	O
.	O

This	O
will	O
disclose	O
compound	O
and	O
double	O
heterozygotes	O
.	O

Primary	O
tones	O
were	O
presented	O
at	O
70	O
dB	O
SPL	O
and	O
the	O
f2	O
/	O
f1	O
ratio	O
was	O
kept	O
at	O
1	O
.	O
21	O
.	O

H	O
.	O
K	O
.	O

This	O
mutation	O
was	O
absent	O
in	O
all	O
100	O
normal	O
controls	O
,	O
and	O
none	O
of	O
the	O
healthy	O
controls	O
in	O
the	O
1000	O
Genomes	O
Project	O
carried	O
this	O
mutation	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

In	O
contrast	O
,	O
Gipc3	B-GENE
343A	O
/	O
A	O
homozygotes	O
with	O
the	O
transgene	O
(	O
tg	O
+	O
A	O
/	O
A	O
)	O
showed	O
a	O
significant	O
delay	O
(	O
108	O
s	O
)	O
;	O
none	O
of	O
the	O
animals	O
seized	O
at	O
the	O
90	O
dB	O
stimulus	O
and	O
two	O
animals	O
showed	O
a	O
complete	O
resistance	O
(	O
Fig	O
.	O

QHF	O
and	O
FL	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
.	O

Novel	O
pathogenic	O
mutations	O
described	O
in	O
this	O
study	O
are	O
in	O
bold	O
.	O

To	O
know	O
if	O
the	O
altered	O
splicing	O
is	O
due	O
to	O
the	O
unique	O
mutation	O
found	O
in	O
exon	O
16	O
,	O
we	O
used	O
a	O
transfected	O
minigene	O
approach	O
to	O
address	O
the	O
functional	O
impact	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
1935G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
on	O
exon	O
16	O
splicing	O
.	O

16	O
-	O
18	O
These	O
tight	O
junctions	O
contain	O
a	O
high	O
amount	O
of	O
claudin	O
14	O
and	O
are	O
prominently	O
stained	O
with	O
anti	O
-	O
claudin	O
14	O
antibody	O
(	O
Figure	O
1b	O
-	O
c	O
)	O
.	O

Arg668His	B-VARIANT
is	O
located	O
in	O
a	O
region	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
that	O
is	O
highly	O
conserved	O
among	O
different	O
species	O
.	O

Furthermore	O
,	O
we	O
performed	O
direct	O
sequencing	O
of	O
all	O
the	O
exons	O
and	O
the	O
exon	O
/	O
intron	O
borders	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
in	O
seven	O
families	O
that	O
did	O
not	O
have	O
NGS	O
data	O
.	O

in	O
the	O
United	O
Kingdom	O
.	O

To	O
test	O
for	O
a	O
defect	O
in	O
the	O
stria	O
vascularis	O
,	O
we	O
measured	O
the	O
endocochlear	O
potential	O
(	O
EP	O
)	O
.	O

(	O
R3	O
)	O
Compound	O
heterozygous	O
USH2A	B-GENE
c	B-VARIANT
.	I-VARIANT
1841	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
left	O
)	O
and	O
c	B-VARIANT
.	I-VARIANT
2440C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gln814	I-VARIANT
*	I-VARIANT
)	O
(	O
right	O
)	O
mutations	O
.	O

Fig	O
.	O

2007	O
;	O
Roux	O
et	O
al	O
.	O

We	O
have	O
identified	O
an	O
additional	O
nine	O
novel	O
OPA1	B-GENE
mutations	O
in	O
this	O
study	O
,	O
adding	O
to	O
the	O
list	O
of	O
>	O
200	O
pathogenic	O
variants	O
so	O
far	O
catalogued	O
on	O
the	O
e	O
OPA1	B-GENE
database	O
(	O
Ferre	O
et	O
al	O
.	O

The	O
mutation	O
frequencies	O
of	O
GJB2	B-GENE
were	O
1	O
.	O
94	O
%	O
(	O
2	O
/	O
103	O
)	O
and	O
4	O
.	O
28	O
%	O
(	O
3	O
/	O
70	O
)	O
in	O
Uyghur	O
and	O
Han	O
Chinese	O
control	O
subjects	O
(	O
chi	O
2	O
=	O
4	O
.	O
495	O
,	O
P	O
>	O
0	O
.	O

Similarly	O
,	O
for	O
family	O
E	O
,	O
the	O
unaffected	O
mother	O
and	O
four	O
affected	O
and	O
five	O
unaffected	O
siblings	O
were	O
genotyped	O
.	O

MYO6	B-GENE
is	O
located	O
on	O
chromosome	O
6	O
[	O
10	O
,	O
12	O
]	O
.	O

Nucleotide	O
alteration	O
(	O
s	O
)	O
were	O
identified	O
by	O
sequence	O
alignment	O
with	O
the	O
MYO15A	B-GENE
GenBank	O
sequence	O
(	O
NM_016239	O
)	O
using	O
Genetool	O
software	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
OPA1	B-GENE
mutations	O
in	O
Greek	O
patients	O
with	O
ADOA	B-DISEASE
.	O

The	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
variable	O
in	O
patients	O
with	O
BOR	B-DISEASE
/	O
BO	B-DISEASE
syndrome	O
included	O
in	O
this	O
study	O
.	O

MRI	O
shows	O
diffuse	O
parietal	O
atrophy	O
(	O
arrows	O
in	O
A	O
,	O
C	O
)	O
and	O
mild	O
cerebellar	O
atrophy	O
(	O
arrows	O
in	O
B	O
,	O
D	O
)	O
in	O
the	O
index	O
patient	O
II	O
-	O
2	O
at	O
age	O
31	O
years	O
(	O
upper	O
row	O
)	O
as	O
well	O
as	O
in	O
his	O
sister	O
II	O
-	O
1	O
at	O
age	O
38	O
years	O
(	O
lower	O
row	O
)	O
(	O
A	O
,	O
C	O
T1	O
axial	O
;	O
B	O
,	O
FLAIR	O
coronar	O
;	O
D	O
T2	O
axial	O
)	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
(	O
RFLP	O
)	O
analysis	O
was	O
performed	O
to	O
exclude	O
the	O
alternative	O
conclusion	O
that	O
the	O
mutations	O
are	O
non	O
-	O
pathogenic	O
rare	O
polymorphisms	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
genetically	O
confirmed	O
case	O
of	O
USH	B-DISEASE
in	O
Korea	O
.	O

Four	O
of	O
the	O
patients	O
(	O
patient_ID	O
:	O
J246	O
,	O
J256	O
,	O
J267	O
,	O
J319	O
)	O
carried	O
homozygous	O
CNV	O
deletions	O
that	O
may	O
directly	O
disrupt	O
the	O
functions	O
of	O
deafness	B-DISEASE
genes	O
.	O

Considering	O
only	O
the	O
39	O
selected	O
ARNSHL	O
-	O
related	O
genes	O
the	O
percentage	O
of	O
mappable	O
bases	O
was	O
93	O
%	O
,	O
84	O
%	O
and	O
73	O
%	O
,	O
respectively	O
(	O
Fig	O
.	O

The	O
PS	B-DISEASE
phenotypes	O
are	O
related	O
with	O
mutations	O
in	O
two	O
fibroblast	O
growth	O
factor	O
receptors	O
(	O
FGFRs	O
)	O
,	O
FGFR1	B-GENE
and	O
FGFR2	B-GENE
(	O
8	O
,	O
11	O
)	O
.	O

Abnormal	O
ear	O
functions	O
of	O
cochlea	O
and	O
vestibule	O
,	O
have	O
been	O
shown	O
in	O
caspase	O
-	O
3	O
-	O
deficient	O
mice	O
(	O
18	O
)	O
.	O

PCR	O
amplifications	O
were	O
performed	O
in	O
a	O
Gene	O
Amp	O
PCR	O
System	O
9700	O
(	O
Applied	O
Biosystems	O
)	O
with	O
an	O
initial	O
denaturation	O
step	O
at	O
95	O
deg	O
C	O
for	O
10	O
min	O
and	O
then	O
36	O
cycles	O
at	O
95	O
deg	O
C	O
for	O
30	O
s	O
,	O
60	O
deg	O
C	O
for	O
30	O
s	O
,	O
72	O
deg	O
C	O
for	O
45	O
s	O
,	O
followed	O
by	O
7	O
min	O
of	O
final	O
extension	O
at	O
72	O
deg	O
C	O
.	O

The	O
first	O
one	O
had	O
not	O
yet	O
been	O
described	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
following	O
primers	O
were	O
designed	O
to	O
amplify	O
exon	O
6	O
of	O
TMPRSS3	B-GENE
:	O
TMPRSS3	B-GENE
-	O
ex6	O
-	O
Forward	O
,	O
5	O
'	O
-	O
TCTCCCACCATCTTCCTA	O
-	O
3	O
'	O
;	O
TMPRSS3	B-GENE
-	O
ex6	O
-	O
Reverse	O
,	O
5	O
'	O
-	O
ACTGATGCCAACACCAAC	O
-	O
3	O
'	O
.	O

We	O
identified	O
four	O
different	O
mutations	O
as	O
follows	O
:	O
a	O
previously	O
undescribed	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
784	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
in	O
intron	O
7	O
,	O
a	O
previously	O
reported	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
876_878delTGT	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Val294del	I-VARIANT
)	O
,	O
in	O
exon	O
9	O
leading	O
to	O
a	O
one	O
amino	O
acid	O
deletion	O
,	O
a	O
previously	O
reported	O
frameshift	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
2366delA	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
(	I-VARIANT
Asn789Metfs	I-VARIANT
*	I-VARIANT
11	I-VARIANT
)	O
,	O
in	O
exon	O
24	O
and	O
a	O
previously	O
reported	O
splice	O
-	O
site	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
1140	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
in	O
intron	O
11	O
of	O
the	O
OPA1	B-GENE
gene	O
.	O

Based	O
on	O
phenotypic	O
variability	O
,	O
it	O
has	O
been	O
suggested	O
that	O
AIFM	B-DISEASE
-	I-DISEASE
related	I-DISEASE
diseases	I-DISEASE
have	O
differing	O
pathogenic	O
mechanisms	O
.	O

IIIa	O
,	O
IIIb	O
and	O
IIIc	O
denote	O
exons	O
of	O
FGFR2	B-GENE
encoding	O
the	O
3	O
rd	O
immunoglobulin	O
-	O
like	O
domain	O
;	O
note	O
that	O
physiological	O
skipping	O
of	O
exon	O
IIIb	O
normally	O
occurs	O
in	O
blood	O
mRNA	O
.	O
TM	O
,	O
exon	O
encoding	O
transmembrane	O
domain	O
.	O

Hanno	O
J	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
is	O
located	O
close	O
to	O
one	O
of	O
the	O
active	O
residues	O
,	O
Asp304	O
,	O
and	O
therefore	O
this	O
substitution	O
can	O
be	O
predicted	O
to	O
directly	O
disturb	O
the	O
function	O
of	O
the	O
serine	O
protease	O
domain	O
.	O

For	O
MA19	O
family	O
history	O
suggested	O
recessive	O
inheritance	O
of	O
RCD	B-DISEASE
with	O
recessive	O
inheritance	O
with	O
an	O
autozygous	O
mutation	O
.	O

2	O
,	O
3	O
,	O
4	O
However	O
,	O
a	O
limitation	O
of	O
most	O
current	O
studies	O
,	O
and	O
indeed	O
clinical	O
analyses	O
,	O
is	O
that	O
a	O
diagnosis	O
is	O
only	O
possible	O
if	O
the	O
gene	O
has	O
been	O
previously	O
implicated	O
in	O
a	O
similar	O
condition	O
.	O

Mundlos	O
(	O
0313911	O
)	O
,	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
DFG	O
)	O
through	O
grants	O
to	O
P	O
.	O

Black	O
circles	O
,	O
mutations	O
detected	O
in	O
this	O
study	O
;	O
black	O
bars	O
,	O
copy	O
number	O
variations	O
detected	O
in	O
this	O
study	O
;	O
white	O
circles	O
and	O
grey	O
bars	O
,	O
previously	O
published	O
mutations	O
and	O
deletions	O
.	O

Although	O
mutations	O
in	O
the	O
SLC26A4	B-GENE
gene	O
were	O
frequently	O
found	O
in	O
Chinese	O
EVA	B-DISEASE
patients	O
with	O
and	O
without	O
MD	B-DISEASE
,	O
there	O
was	O
no	O
evidence	O
to	O
show	O
a	O
relationship	O
between	O
isolated	O
MD	B-DISEASE
and	O
the	O
SLC26A4	B-GENE
gene	O
in	O
the	O
Chinese	O
population	O
examined	O
.	O

Of	O
note	O
,	O
both	O
our	O
index	O
probands	O
had	O
an	O
ECG	O
pattern	O
of	O
IRBBB	B-DISEASE
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
be	O
associated	O
with	O
early	O
-	O
onset	O
lone	O
AF	B-DISEASE
[	O
15	O
]	O
supporting	O
the	O
AF	B-DISEASE
phenotype	O
in	O
the	O
patients	O
.	O

The	O
epiphyses	O
in	O
the	O
wrist	O
and	O
hands	O
are	O
too	O
small	O
for	O
age	O
.	O

Since	O
the	O
patients	O
were	O
referred	O
for	O
LQTS	B-DISEASE
screening	O
in	O
ordinary	O
health	O
care	O
,	O
the	O
clinical	O
data	O
were	O
collected	O
retrospectively	O
and	O
is	O
thus	O
not	O
complete	O
for	O
all	O
families	O
.	O

WS3	B-DISEASE
or	O
Klein	O
-	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
is	O
similar	O
to	O
WS1	B-DISEASE
,	O
but	O
includes	O
upper	O
limb	O
abnormalities	O
.	O

The	O
OPA1	B-GENE
mutation	O
is	O
described	O
according	O
to	O
the	O
OPA1	B-GENE
transcript	O
variant	O
1	O
(	O
RefSeq	O
:	O
NM_015560	O
)	O
.	O

Blood	O
samples	O
were	O
taken	O
from	O
a	O
subset	O
of	O
patients	O
for	O
mutation	O
analysis	O
.	O

8a	O
,	O
b	O
)	O
.	O

All	O
patients	O
were	O
previously	O
tested	O
and	O
all	O
resulted	O
to	O
be	O
negative	O
for	O
known	O
autosomal	B-DISEASE
recessive	I-DISEASE
retinitis	I-DISEASE
pigmentosa	I-DISEASE
(	O
ARRP	B-DISEASE
)	O
or	O
Leber	B-DISEASE
Congenital	I-DISEASE
Amaurosis	I-DISEASE
(	O
LCA	B-DISEASE
)	O
mutations	O
by	O
microarray	O
screening	O
,	O
based	O
on	O
the	O
Arrayed	O
Primer	O
EXtension	O
(	O
APEX	O
)	O
technology	O
[	O
Asper	O
Ophthalmics	O
,	O
Tartu	O
,	O
Estonia	O
]	O
[	O
21	O
]	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

This	O
suggests	O
that	O
it	O
may	O
be	O
unrelated	O
to	O
any	O
of	O
these	O
phenotypes	O
,	O
consistent	O
with	O
its	O
frequency	O
in	O
the	O
population	O
(	O
present	O
in	O
1	O
in	O
57	O
European	O
Americans	O
in	O
EVS	O
(	O
148	O
in	O
8452	O
European	O
Americans	O
(	O
0	O
.	O
0175	O
)	O
)	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
.	O

High	O
-	O
confidence	O
SNVs	O
were	O
detected	O
within	O
each	O
pooled	O
sample	O
using	O
the	O
Syzygy	O
algorithm	O
on	O
targeted	O
bases	O
with	O
a	O
minimum	O
of	O
100	O
high	O
-	O
quality	O
aligned	O
reads	O
(	O
base	O
quality	O
>	O
=	O
20	O
,	O
mapping	O
quality	O
>	O
0	O
,	O
>	O
=	O
30	O
reads	O
on	O
each	O
strand	O
)	O
.	O

528	O
of	O
these	O
3	O
516	O
spots	O
were	O
also	O
analyzed	O
in	O
the	O
R2	O
fragment	O
(	O
position	O
190	O
to	O
500	O
of	O
the	O
CDS	O
)	O
.	O

Previously	O
,	O
various	O
mutations	O
in	O
the	O
ZP	O
domain	O
(	O
C1837G	B-VARIANT
,	O
R2021H	B-VARIANT
,	O
and	O
Y1870C	B-VARIANT
)	O
of	O
TECTA	B-GENE
had	O
been	O
shown	O
within	O
the	O
cytoplasm	O
,	O
suggesting	O
the	O
defect	O
for	O
the	O
mutants	O
to	O
be	O
secreted	O
outside	O
of	O
the	O
cell	O
properly	O
[	O
20	O
]	O
.	O

We	O
then	O
subjected	O
the	O
mutation	O
-	O
negative	O
cases	O
to	O
exome	O
sequencing	O
and	O
identified	O
novel	O
causative	O
variants	O
in	O
the	O
MYH14	B-GENE
and	O
WFS1	B-GENE
genes	O
.	O

This	O
similarity	O
is	O
remarkable	O
considering	O
the	O
variations	O
in	O
marriage	O
rates	O
and	O
patterns	O
of	O
deafness	B-DISEASE
and	O
sibship	O
sizes	O
between	O
populations	O
.	O

Predicted	O
exonic	O
splicing	O
enhancer	O
(	O
ESE	O
)	O
motifs	O
were	O
screened	O
using	O
the	O
ESEfinder	O
web	O
-	O
interface	O
(	O
http	O
:	O
/	O
/	O
rulai	O
.	O
cshl	O
.	O
edu	O
/	O
tools	O
/	O
ESE	O
)	O
,	O
which	O
provided	O
a	O
score	O
based	O
on	O
the	O
frequency	O
of	O
nucleotides	O
at	O
each	O
position	O
in	O
the	O
sequence	O
of	O
the	O
motif	O
specifically	O
recognized	O
by	O
the	O
four	O
SR	O
proteins	O
SF2	O
/	O
ASF	O
,	O
SC35	O
,	O
SRp40	O
,	O
and	O
SRp55	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
D1663V	I-VARIANT
mutation	O
substituted	O
the	O
second	O
aspartic	O
acid	O
(	O
D	O
)	O
of	O
the	O
DXD	O
motif	O
at	O
EC16	O
domain	O
to	O
a	O
hydrophobic	O
valine	O
residue	O
.	O

Interestingly	O
,	O
in	O
the	O
sixth	O
patient	O
with	O
p	B-VARIANT
.	I-VARIANT
L46F	I-VARIANT
(	O
listed	O
as	O
single	O
nucleotide	O
polymorphism	O
[	O
SNP	O
]	O
in	O
NCBI	O
)	O
abnormal	O
structures	O
typical	O
of	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
were	O
found	O
using	O
EM	O
(	O
Fig	O
.	O

RNA	O
was	O
analysed	O
by	O
RT	O
-	O
PCR	O
and	O
sequenced	O
in	O
the	O
forward	O
(	O
A	O
)	O
and	O
reverse	O
(	O
B	O
)	O
directions	O
.	O

(	O
b	O
)	O
Genomic	O
structure	O
of	O
the	O
USH1C	B-GENE
gene	O
and	O
haplotype	O
bearing	O
the	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
in	O
different	O
patients	O
.	O

"	O
For	O
a	O
classification	O
based	O
on	O
evolutionary	O
conservation	O
,	O
all	O
variants	O
with	O
a	O
PhyloP	O
(	O
44	O
vertebrate	O
species	O
)	O
score	O
of	O
less	O
than	O
1	O
were	O
considered	O
"	O
benign	O
,	O
"	O
all	O
variants	O
with	O
a	O
PhyloP	O
value	O
above	O
2	O
.	O
5	O
were	O
considered	O
to	O
be	O
"	O
pathogenic	O
,	O
"	O
and	O
variants	O
with	O
intermediary	O
values	O
were	O
classified	O
as	O
"	O
unknown	O
"	O
(	O
cutoffs	O
were	O
based	O
upon	O
a	O
comparison	O
of	O
evolutionary	O
conservation	O
scores	O
of	O
dbSNP	O
[	O
build	O
130	O
]	O
and	O
HGMD	O
,	O
as	O
described	O
in	O
Vissers	O
et	O
al	O
.	O

Matched	O
APA	O
and	O
venous	O
blood	O
DNAs	O
were	O
obtained	O
from	O
patients	O
undergoing	O
adrenalectomy	O
for	O
hypertension	B-DISEASE
with	O
primary	O
aldosteronism	B-DISEASE
and	O
adrenocortical	O
tumor	O
at	O
Yale	O
New	O
Haven	O
Hospital	O
,	O
Uppsala	O
University	O
Hospital	O
,	O
and	O
Montefiore	O
Medical	O
Center	O
and	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
,	O
and	O
were	O
evaluated	O
as	O
previously	O
described	O
1	O
.	O

USH2	B-DISEASE
was	O
diagnosed	O
based	O
on	O
the	O
clinical	O
history	O
,	O
typical	O
RP	B-DISEASE
fundus	O
appearance	O
,	O
sensorineural	B-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
,	O
and	O
intact	O
vestibular	O
function	O
.	O

Notably	O
,	O
these	O
missense	O
mutations	O
only	O
affect	O
the	O
longer	O
whirlin	B-GENE
isoform	O
[	O
19	O
]	O
,	O
which	O
is	O
a	O
component	O
of	O
the	O
ankle	O
link	O
molecular	O
complex	O
together	O
with	O
VLGR1	B-GENE
and	O
usherin	O
[	O
40	O
,	O
41	O
]	O
.	O

Wolfram	B-DISEASE
syndrome	I-DISEASE
(	O
WFS	B-DISEASE
)	O
(	O
OMIM	O
#	O
222300	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
genetic	O
disease	O
characterized	O
by	O
insulin	O
dependent	O
diabetes	B-DISEASE
mellitus	I-DISEASE
,	O
optic	B-DISEASE
atrophy	I-DISEASE
,	O
blindness	B-DISEASE
,	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
other	O
neurological	B-DISEASE
dysfunctions	I-DISEASE
resulting	O
in	O
death	B-DISEASE
from	O
widespread	O
neurodegeneration	B-DISEASE
in	O
the	O
third	O
or	O
fourth	O
decade	O
[	O
1	O
]	O
.	O

(	O
a	O
)	O
Representative	O
experiment	O
of	O
reverse	O
transcription	O
-	O
PCR	O
using	O
XBP1	O
mRNA	O
as	O
template	O
,	O
from	O
AB8	O
/	O
13	O
cells	O
transiently	O
expressing	O
COL4A3	B-GENE
-	O
WT	O
(	O
A3	O
/	O
WT	O
)	O
or	O
the	O
mutant	O
chains	O
G1334E	B-VARIANT
,	O
G871C	B-VARIANT
,	O
G484R	B-VARIANT
(	O
COL4A3	B-GENE
)	O
.	O

We	O
have	O
deposited	O
our	O
dataset	O
in	O
NIH	O
Short	O
Read	O
Archive	O
and	O
the	O
accession	O
number	O
is	O
SRR1296682	O
.	O

The	O
splicing	O
mutation	O
maybe	O
skip	O
the	O
exon	O
32	O
,	O
which	O
contains	O
162	O
nucleotides	O
,	O
and	O
lead	O
to	O
a	O
deletion	O
of	O
54	O
amino	O
acid	O
residues	O
in	O
USH2A	B-GENE
.	O

Before	O
being	O
introduced	O
into	O
THP	O
-	O
1	O
cells	O
(	O
10	O
6	O
)	O
using	O
a	O
Cell	O
Line	O
Nucleofector	O
Kit	O
V	O
(	O
Amaxa	O
Biosystems	O
,	O
Cologne	O
,	O
Germany	O
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
10	O
ng	O
/	O
ml	O
)	O
was	O
added	O
to	O
enhance	O
transient	O
expression	O
of	O
NLRP3	B-GENE
gene	O
with	O
minimizing	O
spontaneous	O
cell	O
death	O
.	O

Representative	O
current	O
traces	O
recorded	O
(	O
left	O
:	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
;	O
right	O
:	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
)	O
using	O
the	O
60	O
bpm	O
(	O
black	O
)	O
and	O
120	O
bpm	O
(	O
gray	O
)	O
protocols	O
are	O
shown	O
on	O
the	O
right	O
.	O

This	O
study	O
includes	O
76	O
propositi	O
with	O
a	O
genotype	O
confirming	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
and	O
85	O
family	O
members	O
from	O
39	O
unrelated	O
families	O
.	O

Ninety	O
-	O
nine	O
variants	O
were	O
identified	O
within	O
the	O
AUNX1	B-GENE
locus	O
.	O

We	O
do	O
not	O
know	O
the	O
origin	O
of	O
our	O
three	O
patients	O
,	O
but	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
they	O
are	O
descendant	O
of	O
those	O
Sephardic	O
Jews	O
that	O
were	O
expelled	O
from	O
Spain	O
in	O
1492	O
[	O
40	O
]	O
.	O

Flexor	O
and	O
extensor	O
muscle	O
strength	O
were	O
assessed	O
manually	O
using	O
the	O
Medical	O
Research	O
Council	O
(	O
MRC	O
)	O
scale	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
BC	O
WP	O
KH	O
.	O

Using	O
WES	O
,	O
we	O
identified	O
two	O
heterozygous	O
novel	O
mutations	O
in	O
USH2A	B-GENE
as	O
the	O
most	O
likely	O
disease	O
-	O
causing	O
variants	O
in	O
a	O
Spanish	O
family	O
diagnosed	O
with	O
arRP	B-DISEASE
in	O
which	O
the	O
cause	O
of	O
the	O
disease	O
had	O
not	O
yet	O
been	O
identified	O
with	O
commonly	O
used	O
techniques	O
.	O

Ethnically	O
,	O
the	O
patients	O
included	O
193	O
Han	O
(	O
82	O
.	O
1	O
%	O
)	O
,	O
13	O
Bai	O
(	O
5	O
.	O
5	O
%	O
)	O
,	O
5	O
Dai	O
(	O
2	O
.	O
1	O
%	O
)	O
,	O
7	O
Yi	O
(	O
3	O
.	O
0	O
%	O
)	O
,	O
2	O
Hani	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
3	O
Hui	O
(	O
1	O
.	O
3	O
%	O
)	O
,	O
1	O
Jingpo	O
(	O
0	O
.	O
4	O
%	O
)	O
,	O
2	O
Lahu	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
2	O
Lisu	O
(	O
0	O
.	O
9	O
%	O
)	O
,	O
5	O
Nazi	O
(	O
2	O
.	O
1	O
%	O
)	O
,	O
1	O
Wa	O
(	O
0	O
.	O
4	O
%	O
)	O
,	O
and	O
1	O
Yao	O
(	O
0	O
.	O
4	O
%	O
)	O
Chinese	O
.	O

Genet	O
Med	O
17	O
10	O
,	O
774	O
-	O
781	O
.	O

Despite	O
the	O
power	O
of	O
WES	O
,	O
validation	O
by	O
Sanger	O
sequencing	O
and	O
,	O
if	O
possible	O
,	O
of	O
additional	O
genetic	O
investigation	O
in	O
family	O
members	O
of	O
the	O
patient	O
remain	O
key	O
elements	O
for	O
the	O
success	O
of	O
this	O
screening	O
technique	O
.	O

The	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
accounted	O
for	O
64	O
.	O
63	O
%	O
(	O
53	O
/	O
82	O
,	O
counting	O
only	O
the	O
definite	O
pathogenic	O
and	O
most	O
likely	O
pathogenic	O
variants	O
)	O
of	O
all	O
SLC26A4	B-GENE
mutant	O
alleles	O
in	O
this	O
population	O
(	O
Table	O
2	O
)	O
.	O

We	O
also	O
present	O
the	O
allelic	O
frequencies	O
of	O
some	O
GJB2	B-GENE
mutations	O
in	O
individuals	O
referred	O
for	O
NSHL	O
with	O
respect	O
to	O
the	O
frequency	O
in	O
the	O
general	O
population	O
(	O
Table	O
5	O
)	O
.	O

(	O
Figure	O
3	O
)	O
.	O

(	O
D5	O
)	O
MYO1A	B-GENE
c	B-VARIANT
.	I-VARIANT
2032A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ile678Phe	I-VARIANT
)	O
.	O

The	O
model	O
for	O
MYO1A	B-GENE
was	O
constructed	O
using	O
the	O
PDB	O
file	O
2dfs	O
[	O
39	O
]	O
as	O
a	O
template	O
.	O

Our	O
error	O
map	O
shows	O
that	O
98	O
.	O
1	O
%	O
of	O
base	O
positions	O
(	O
3343	O
out	O
of	O
3407	O
target	O
positions	O
)	O
in	O
the	O
NLRP3	B-GENE
exonic	O
amplicons	O
can	O
be	O
detected	O
with	O
~	O
1	O
%	O
mosaicism	O
when	O
more	O
than	O
~	O
350	O
reads	O
were	O
accumulated	O
for	O
each	O
strand	O
.	O

The	O
80	O
-	O
gene	O
panel	O
produced	O
222	O
.	O
8	O
kb	O
of	O
targeted	O
sequence	O
,	O
covering	O
1	O
,	O
258	O
exons	O
and	O
flanking	O
sequence	O
,	O
and	O
yielded	O
an	O
average	O
of	O
8	O
.	O
2	O
+	O
-	O
1	O
.	O
5	O
million	O
reads	O
per	O
sample	O
,	O
with	O
approximately	O
86	O
%	O
mapping	O
to	O
the	O
targeted	O
regions	O
.	O

Both	O
siblings	O
underwent	O
clinical	O
reevaluation	O
revealing	O
symptoms	O
and	O
signs	O
of	O
RP	B-DISEASE
,	O
such	O
as	O
bone	O
spicule	O
-	O
like	O
pigmentation	O
in	O
the	O
midperiphery	O
of	O
both	O
eyes	O
,	O
attenuation	O
of	O
the	O
retinal	O
vessels	O
and	O
pale	O
waxy	O
discs	O
.	O

(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Consistent	O
with	O
the	O
results	O
of	O
deglycosylation	O
experiments	O
,	O
the	O
G48S	B-VARIANT
,	O
R209H	B-VARIANT
,	O
and	O
E670A	B-VARIANT
mutants	O
had	O
similar	O
cell	O
-	O
surface	O
expression	O
levels	O
as	O
WT	O
(	O
Figure	O
2B	O
)	O
.	O

and	O
H	O
.	O
K	O
.	O

Otoscopy	O
showed	O
no	O
abnormalities	O
in	O
all	O
patients	O
.	O

11	O
%	O
of	O
the	O
mutations	O
)	O
,	O
specifically	O
,	O
c	B-VARIANT
.	I-VARIANT
1996C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
223delG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
1556G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
494C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
3719G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
5749G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
MYO7A	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
238_239dupC	I-VARIANT
in	O
USH1C	B-GENE
,	O
and	O
c	B-VARIANT
.	I-VARIANT
2299delG	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
10712C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
USH2A	B-GENE
.	O

Exons	O
and	O
flanking	O
sequences	O
were	O
amplified	O
by	O
PCR	O
using	O
578	O
primer	O
sets	O
and	O
sequenced	O
at	O
the	O
Wellcome	O
Trust	O
Sanger	O
Institute	O
as	O
part	O
of	O
the	O
ExoSeq	O
project	O
.	O

It	O
also	O
shows	O
a	O
high	O
frequency	O
of	O
associated	O
malformations	O
(	O
39	O
%	O
)	O
with	O
HH	B-DISEASE
including	O
the	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
in	O
4	O
boys	O
.	O

Briefly	O
,	O
5	O
x	O
10	O
5	O
cells	O
were	O
transfected	O
with	O
the	O
plasmid	O
in	O
a	O
6	O
well	O
plate	O
.	O

After	O
direct	O
sequencing	O
for	O
CDH23	B-GENE
mutations	O
,	O
three	O
subjects	O
were	O
identified	O
with	O
homozygous	O
or	O
compound	O
heterozygous	O
pathogenic	O
CDH23	B-GENE
mutations	O
(	O
20	O
.	O
0	O
%	O
of	O
tested	O
subjects	O
)	O
,	O
and	O
three	O
subjects	O
were	O
shown	O
to	O
have	O
heterozygous	O
mutations	O
(	O
20	O
.	O
0	O
%	O
of	O
tested	O
subjects	O
)	O
.	O

The	O
predicted	O
structural	O
effects	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Gln277Pro	I-VARIANT
mutation	O
fall	O
in	O
between	O
those	O
of	O
the	O
CMTX5	B-DISEASE
and	O
Arts	B-DISEASE
syndrome	I-DISEASE
PRPS1	B-GENE
mutations	O
(	O
Table	O
2	O
)	O
,	O
thus	O
explaining	O
the	O
CMTX	B-GENE
/	O
Arts	B-DISEASE
syndrome	I-DISEASE
overlapping	O
phenotype	O
in	O
the	O
male	O
index	O
patient	O
II	O
-	O
2	O
.	O

As	O
described	O
above	O
,	O
we	O
revealed	O
that	O
a	O
read	O
depth	O
of	O
~	O
350	O
for	O
each	O
strand	O
of	O
each	O
amplicon	O
would	O
be	O
sufficient	O
to	O
detect	O
somatic	O
mosaicism	O
as	O
low	O
as	O
1	O
%	O
with	O
statistical	O
confidence	O
.	O

In	O
this	O
study	O
,	O
272	O
Spanish	O
families	O
affected	O
by	O
arRP	B-DISEASE
were	O
analyzed	O
by	O
a	O
genotyping	O
microarray	O
,	O
followed	O
by	O
sequence	O
analysis	O
of	O
the	O
candidate	O
genes	O
to	O
establish	O
a	O
fast	O
and	O
effective	O
genetic	O
diagnosis	O
.	O

Six	O
MYO7A	B-GENE
variants	O
have	O
already	O
been	O
reported	O
in	O
the	O
literature	O
[	O
15	O
,	O
22	O
,	O
24	O
]	O
and	O
are	O
therefore	O
considered	O
pathogenic	O
.	O

All	O
qPCR	O
data	O
was	O
performed	O
in	O
triplicate	O
.	O

HMW	O
and	O
BYK	O
performed	O
the	O
sequencing	O
analyses	O
.	O

paniscus	O
,	O
XP_003825527	O
.	O
1	O
;	O
E	O
.	O

Mutations	O
in	O
the	O
POU4F3	B-GENE
gene	O
have	O
been	O
described	O
in	O
patients	O
with	O
nonsyndromic	B-DISEASE
sensorineural	I-DISEASE
deafness	I-DISEASE
autosomal	I-DISEASE
dominant	I-DISEASE
type	I-DISEASE
15	I-DISEASE
(	O
DFNA15	B-DISEASE
)	O
.	O

Parents	O
were	O
nonconsanguineous	O
and	O
originated	O
from	O
distant	O
regions	O
of	O
the	O
country	O
.	O

There	O
was	O
no	O
response	O
to	O
oral	O
corticosteroids	O
given	O
for	O
3	O
months	O
.	O

TargetP	O
1	O
.	O
1	O
server	O
prediction	O
results	O
.	O

Multiple	O
mtDNA	O
deletions	O
in	O
homogenate	O
skeletal	O
muscle	O
DNA	O
were	O
identified	O
by	O
Southern	O
blot	O
and	O
/	O
or	O
long	O
-	O
range	O
PCR	O
(	O
Amati	O
-	O
Bonneau	O
et	O
al	O
.	O

Similar	O
ophthalmologic	O
examination	O
results	O
were	O
detected	O
in	O
the	O
other	O
two	O
affected	O
siblings	O
(	O
III	O
:	O
1	O
,	O
III	O
:	O
3	O
)	O
of	O
the	O
proband	O
,	O
but	O
the	O
symptom	O
of	O
RP	B-DISEASE
in	O
IV	O
:	O
1	O
and	O
IV	O
:	O
2	O
were	O
mild	O
.	O

Most	O
of	O
these	O
mutations	O
were	O
just	O
reported	O
in	O
DGI	B-DISEASE
affected	O
individuals	O
by	O
sequence	O
analysis	O
,	O
but	O
not	O
further	O
functionally	O
confirmed	O
.	O

The	O
eight	O
remaining	O
Usher	B-DISEASE
variants	O
,	O
representing	O
0	O
.	O
17	O
%	O
of	O
the	O
original	O
pool	O
of	O
candidate	O
variants	O
,	O
underwent	O
specific	O
analysis	O
as	O
detailed	O
below	O
.	O

This	O
simple	O
filtering	O
strategy	O
rapidly	O
led	O
to	O
the	O
identification	O
of	O
causative	O
variants	O
in	O
the	O
MYH14	B-GENE
and	O
WFS1	B-GENE
genes	O
,	O
and	O
effectively	O
demonstrates	O
the	O
potential	O
of	O
this	O
combined	O
approach	O
to	O
identify	O
disease	O
causative	O
mutations	O
in	O
both	O
novel	O
and	O
known	O
genes	O
in	O
families	O
with	O
a	O
small	O
number	O
of	O
affected	O
individuals	O
.	O

USH3	B-DISEASE
is	O
rare	O
except	O
in	O
certain	O
populations	O
,	O
and	O
the	O
gene	O
responsible	O
for	O
this	O
type	O
is	O
USH3A	B-GENE
.	O

Critical	O
reading	O
anddiscussion	O
of	O
manuscript	O
:	O
WY	O
XH	O
XW	O
NL	O
YL	O
CP	O
Jun	O
Wang	O
HY	O
Jian	O
Wang	O
QW	O
.	O

Visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
was	O
severe	O
in	O
this	O
patient	O
.	O

However	O
,	O
revision	O
ossiculoplasty	O
was	O
performed	O
after	O
8	O
months	O
due	O
to	O
failure	O
of	O
hearing	O
gain	O
and	O
the	O
location	O
of	O
the	O
previously	O
inserted	O
PORP	O
was	O
adjusted	O
.	O

Lysates	O
from	O
HEK293	O
cells	O
transfected	O
with	O
GFP	O
-	O
MyoVIIa	O
and	O
tdTomato	O
-	O
CIB2	B-GENE
constructs	O
were	O
co	O
-	O
immuno	O
-	O
precipitated	O
with	O
anti	O
-	O
GFP	O
antibody	O
.	O

C	O
.	O

HEK293	O
cells	O
were	O
cultured	O
in	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
.	O

the	O
regulation	O
of	O
PRPS1	B-GENE
by	O
microRNA	O
-	O
376	O
[	O
17	O
]	O
and	O
difference	O
in	O
expression	O
levels	O
and	O
function	O
of	O
the	O
other	O
three	O
PRS	O
isoforms	O
[	O
6	O
]	O
.	O

This	O
suggests	O
increased	O
intracellular	O
Ca	O
2	O
+	O
as	O
a	O
final	O
common	O
pathway	O
to	O
APA	B-DISEASE
formation	O
.	O

We	O
thank	O
Pia	O
Hagman	O
and	O
Amer	O
Mujezinovic	O
for	O
technical	O
assistance	O
.	O

R	O
.	O
C	O
.	O

Table	O
1	O
describes	O
the	O
pathogenic	O
variants	O
,	O
with	O
characteristic	O
hearing	B-DISEASE
impairment	I-DISEASE
for	O
each	O
variant	O
.	O

Third	O
,	O
the	O
severity	O
of	O
the	O
phenotype	O
of	O
the	O
son	O
could	O
,	O
at	O
least	O
partly	O
,	O
reflect	O
the	O
addictive	O
effect	O
of	O
the	O
mutation	O
from	O
his	O
mother	O
.	O

The	O
patients	O
were	O
recruited	O
from	O
the	O
Federaci	O
o	O
n	O
de	O
Afectados	O
de	O
Retinosis	O
Pigmentaria	O
de	O
Espa	O
n	O
a	O
(	O
FARPE	O
)	O
and	O
also	O
from	O
the	O
Ophthalmology	O
and	O
ENT	O
Services	O
of	O
several	O
Spanish	O
Hospitals	O
as	O
part	O
of	O
a	O
large	O
-	O
scale	O
study	O
on	O
the	O
genetics	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
in	O
the	O
Spanish	O
population	O
.	O

Moreover	O
,	O
among	O
the	O
recessive	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
,	O
the	O
high	O
prevalence	O
genes	O
of	O
GJB2	B-GENE
or	O
SLC26A4	B-GENE
also	O
can	O
be	O
found	O
only	O
one	O
mutant	O
allele	O
in	O
the	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
or	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
syndrome	I-DISEASE
patients	O
.	O

In	O
addition	O
,	O
we	O
emphasize	O
that	O
candidate	O
variants	O
and	O
genes	O
nominated	O
by	O
our	O
study	O
will	O
require	O
extensive	O
experimental	O
functional	O
validation	O
as	O
well	O
as	O
replication	O
in	O
additional	O
ovarian	B-DISEASE
cancer	I-DISEASE
datasets	O
.	O

289350	O
.	O
These	O
authors	O
equally	O
contributed	O
to	O
this	O
study	O
.	O

The	O
latter	O
was	O
not	O
found	O
in	O
control	O
chromosomes	O
(	O
0	O
/	O
836	O
)	O
and	O
always	O
appeared	O
in	O
trans	O
with	O
a	O
pathogenic	O
variant	O
.	O

The	O
structure	O
of	O
the	O
wild	O
type	O
and	O
the	O
mutant	O
USH2A	B-GENE
protein	O
were	O
predicted	O
using	O
Swiss	O
Pdb	O
-	O
Viewer	O
4	O
.	O
0	O
.	O
1	O
.	O

Ages	O
at	O
onset	O
of	O
both	O
diabetes	B-DISEASE
mellitus	I-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
are	O
shown	O
in	O
the	O
same	O
graph	O
.	O

For	O
MA9	O
,	O
family	O
history	O
suggested	O
dominant	O
inheritance	O
of	O
a	O
macular	O
dystrophy	O
phenotype	O
.	O

In	O
our	O
study	O
population	O
,	O
the	O
frequency	O
of	O
SCL26A4	B-GENE
mutation	O
was	O
9	O
.	O
52	O
%	O
in	O
minority	O
patients	O
,	O
which	O
was	O
not	O
different	O
from	O
that	O
of	O
Han	O
patients	O
(	O
9	O
.	O
84	O
%	O
;	O
chi	O
2	O
=	O
0	O
.	O
0498	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

(	O
c	O
)	O
A	O
novel	O
c	B-VARIANT
.	I-VARIANT
5051C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
variant	O
and	O
six	O
previously	O
reported	O
mutations	O
in	O
USH2A	B-GENE
exon	O
25	O
.	O

E	O
.	O

Mundlos	O
(	O
0313911	O
)	O
,	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
(	O
DFG	O
)	O
through	O
grants	O
to	O
P	O
.	O

Fluctuations	O
in	O
mitochondrial	O
tRNA	O
levels	O
have	O
significant	O
influence	O
on	O
disease	O
expression	O
.	O

A	O
III	O
,	O
The	O
DFNB49	B-GENE
locus	O
(	O
bracket	O
)	O
on	O
chromosome	O
5	O
overlapping	O
the	O
linkage	O
region	O
(	O
arrow	O
)	O
is	O
displayed	O
in	O
the	O
Figure	O
.	O

Text	O
sequence	O
represents	O
the	O
sequence	O
seen	O
in	O
uninhibited	O
cells	O
(	O
upper	O
)	O
and	O
the	O
additional	O
sequence	O
obtained	O
from	O
inhibited	O
cells	O
(	O
lower	O
)	O
.	O

For	O
instance	O
,	O
although	O
similar	O
in	O
age	O
,	O
a	O
62	O
-	O
year	O
-	O
old	O
affected	O
member	O
of	O
the	O
KNUF25	O
family	O
had	O
substantially	O
better	O
hearing	B-DISEASE
(	O
particularly	O
overall	O
frequencies	O
)	O
than	O
a	O
57	O
-	O
year	O
-	O
old	O
affected	O
member	O
of	O
the	O
YS	O
-	O
149	O
family	O
.	O

It	O
seems	O
likely	O
that	O
there	O
are	O
additional	O
ARNSHL	B-DISEASE
-	O
causing	O
MYO15A	B-GENE
mutations	O
,	O
as	O
the	O
gene	O
is	O
large	O
and	O
mutation	O
analysis	O
is	O
rare	O
,	O
since	O
complementary	O
linkage	O
analysis	O
has	O
not	O
been	O
performed	O
in	O
East	O
Asian	O
populations	O
.	O

The	O
CTD	O
mutations	O
p	B-VARIANT
.	I-VARIANT
Thr529Ile	I-VARIANT
,	O
pGly719Ser	B-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
Thr585Arg	I-VARIANT
,	O
which	O
we	O
and	O
others	O
have	O
previously	O
described	O
[	O
Briggs	O
et	O
al	O
.	O
,	O
1998	O
;	O
Jakkula	O
et	O
al	O
.	O
,	O
2003	O
;	O
Kennedy	O
et	O
al	O
.	O
,	O
2005b	O
]	O
,	O
were	O
identified	O
in	O
four	O
patients	O
thus	O
confirming	O
the	O
clustering	O
of	O
the	O
CTD	O
mutations	O
into	O
distinct	O
regions	O
[	O
Kennedy	O
et	O
al	O
.	O
,	O
2005b	O
]	O
.	O

Assuming	O
a	O
minimum	O
incidence	O
of	O
1	O
per	O
1	O
,	O
000	O
for	O
children	O
with	O
congenital	O
profound	O
hearing	O
impairment	O
[	O
24	O
]	O
,	O
0	O
.	O
5	O
%	O
of	O
these	O
children	O
may	O
develop	O
additional	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
due	O
to	O
homozygosity	O
for	O
the	O
USH1C	B-GENE
mutation	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
.	O

After	O
excluding	O
frequent	O
variants	O
(	O
>	O
1	O
%	O
)	O
in	O
public	O
databases	O
,	O
12	O
variants	O
of	O
9	O
genes	O
co	O
-	O
segregated	O
with	O
symptoms	O
and	O
were	O
selected	O
as	O
possible	O
pathogenic	O
mutations	O
(	O
Table	O
3	O
)	O
or	O
variants	O
with	O
uncertain	O
pathogenicity	O
in	O
7	O
families	O
(	O
Table	O
4	O
)	O
.	O

It	O
would	O
have	O
been	O
very	O
interesting	O
to	O
examine	O
the	O
distortion	O
product	O
-	O
evoked	O
otoacoustic	O
or	O
transient	O
-	O
evoked	O
otoacoustic	O
emission	O
results	O
from	O
subjects	O
II	O
-	O
4	O
and	O
III	O
-	O
1	O
,	O
who	O
carry	O
p	B-VARIANT
.	I-VARIANT
T237I	I-VARIANT
of	O
the	O
TECTA	B-GENE
gene	O
.	O

Mutations	O
in	O
this	O
gene	O
at	O
the	O
DFNA36	B-GENE
and	O
DFNB7	B-GENE
/	I-GENE
11	I-GENE
loci	O
have	O
previously	O
been	O
reported	O
to	O
cause	O
nonsyndromic	O
autosomal	O
dominant	O
and	O
recessive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
respectively	O
[	O
15	O
]	O
.	O

The	O
selected	O
variants	O
were	O
prevalent	O
in	O
the	O
following	O
European	O
countries	O
:	O
Belgium	O
,	O
Denmark	O
,	O
UK	O
,	O
Germany	O
,	O
Italy	O
,	O
Spain	O
,	O
Switzerland	O
and	O
Netherlands	O
,	O
and	O
in	O
the	O
USA	O
.	O

Goldmann	O
Kinetic	O
Perimetry	O
(	O
GKP	O
)	O
showed	O
concentric	O
reduction	O
of	O
20	O
to	O
30	O
degrees	O
mainly	O
at	O
the	O
nasal	O
sector	O
of	O
the	O
visual	O
field	O
as	O
well	O
as	O
an	O
enlarged	O
blind	O
spot	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Gly1800Cys	I-VARIANT
was	O
inherited	O
from	O
her	O
mother	O
who	O
is	O
also	O
shown	O
.	O

ABRs	O
were	O
measured	O
using	O
an	O
Etymotic	O
Research	O
ER10B	O
+	O
probe	O
microphone	O
(	O
Etymotic	O
Research	O
,	O
Elk	O
Grove	O
,	O
IL	O
,	O
USA	O
)	O
coupled	O
to	O
two	O
Tucker	O
-	O
Davis	O
Technologies	O
MF1	O
multi	O
-	O
field	O
magnetic	O
speakers	O
(	O
Tucker	O
-	O
Davis	O
Technologies	O
,	O
Alachua	O
,	O
FL	O
,	O
USA	O
)	O
.	O

No	O
mutation	O
was	O
identified	O
among	O
families	O
with	O
an	O
autosomal	O
dominant	O
mode	O
of	O
inheritance	O
.	O

The	O
CACNA1A	B-GENE
gene	O
encodes	O
the	O
alpha	O
1A	O
subunit	O
of	O
the	O
voltage	O
-	O
dependent	O
(	O
VDCC	O
)	O
,	O
P	O
/	O
Q	O
type	O
calcium	O
channel	O
.	O

Residues	O
associated	O
with	O
known	O
gain	O
of	O
function	O
mutations	O
in	O
human	O
diseases	O
14	O
-	O
17	O
,	O
22	O
are	O
marked	O
in	O
purple	O
.	O

PCR	O
and	O
direct	O
sequencing	O
were	O
used	O
to	O
prescreen	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
and	O
to	O
confirm	O
the	O
variants	O
in	O
the	O
candidate	O
genes	O
that	O
had	O
been	O
identified	O
by	O
exome	O
sequencing	O
.	O

a	O
Pedigree	O
of	O
family	O
FC417	O
.	O

The	O
other	O
three	O
patients	O
did	O
not	O
reveal	O
any	O
abnormality	O
on	O
renal	O
ultrasonography	O
or	O
blood	O
testing	O
.	O

,	O
2005	O
;	O
Huang	O
et	O
al	O
.	O

To	O
protect	O
the	O
identity	O
of	O
individuals	O
,	O
these	O
confidential	O
data	O
are	O
not	O
publically	O
available	O
.	O

Given	O
the	O
large	O
effect	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
R192	I-VARIANT
*	I-VARIANT
mutation	O
on	O
CD164	B-GENE
subcellular	O
trafficking	O
in	O
our	O
cell	O
based	O
assays	O
,	O
we	O
speculated	O
whether	O
the	O
transcript	O
containing	O
the	O
mutation	O
was	O
expressed	O
in	O
cells	O
from	O
the	O
affected	O
family	O
members	O
.	O

PRS	O
enzymatic	O
activity	O
was	O
determined	O
in	O
erythrocytes	O
from	O
III	O
:	O
2	O
,	O
III	O
:	O
3	O
,	O
IV	O
:	O
1	O
,	O
IV	O
:	O
2	O
,	O
and	O
IV	O
:	O
3	O
,	O
according	O
to	O
the	O
method	O
previously	O
described	O
by	O
Torres	O
et	O
al	O
.	O

Jinyu	O
Wu	O
(	O
Institute	O
of	O
Genomic	O
Medicine	O
,	O
Wenzhou	O
Medical	O
University	O
,	O
China	O
)	O
for	O
scanning	O
the	O
present	O
mutation	O
in	O
in	O
-	O
house	O
exome	O
database	O
and	O
Dr	O
.	O
Ji	O
Sun	O
(	O
Department	O
of	O
Pharmacology	O
,	O
University	O
of	O
Washington	O
,	O
Seattle	O
,	O
WA	O
,	O
USA	O
)	O
for	O
structural	O
modeling	O
.	O

Amplicons	O
with	O
depth	O
of	O
coverage	O
of	O
less	O
than	O
20x	O
were	O
additionally	O
examined	O
by	O
Sanger	O
sequencing	O
.	O

The	O
cone	O
mediated	O
ERG	O
a	O
-	O
waves	O
were	O
within	O
normal	O
amplitudes	O
in	O
OU	O
and	O
b	O
-	O
waves	O
within	O
lower	O
limits	O
of	O
normal	O
amplitude	O
.	O

After	O
anesthesia	O
with	O
pentobarbital	O
,	O
two	O
Albino	O
guinea	O
pigs	O
(	O
250	O
g	O
)	O
were	O
decapitated	O
and	O
the	O
temporal	O
bones	O
and	O
otic	O
capsules	O
were	O
removed	O
.	O

AR	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
(	O
rMED	B-DISEASE
)	O
can	O
result	O
from	O
homozygosity	O
or	O
compound	O
heterozygosity	O
for	O
mutations	O
in	O
the	O
gene	O
encoding	O
SLC26A2	B-GENE
(	O
EDM4	O
;	O
MIM	O
#	O
226900	O
)	O
[	O
Hastbacka	O
et	O
al	O
.	O
,	O
1999	O
;	O
Rossi	O
and	O
Superti	O
-	O
Furga	O
,	O
2001	O
;	O
Superti	O
-	O
Furga	O
et	O
al	O
.	O
,	O
1999	O
]	O
and	O
is	O
the	O
mild	O
end	O
of	O
the	O
phenotypic	O
spectrum	O
that	O
includes	O
achondrogenesis	O
1B	O
and	O
diastrophic	O
dysplasia	O
[	O
Rossi	O
and	O
Superi	O
-	O
Furga	O
,	O
2001	O
]	O
.	O

The	O
constellation	O
of	O
these	O
abnormalities	O
is	O
suggested	O
as	O
the	O
most	O
severe	O
phenotype	O
of	O
ACTG1	B-GENE
mutations	O
[	O
24	O
,	O
25	O
]	O
.	O

It	O
was	O
determined	O
to	O
be	O
severe	O
to	O
profound	O
,	O
sensorineural	O
and	O
bilateral	O
.	O

All	O
patients	O
presented	O
with	O
mixed	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Genetic	O
analysis	O
showed	O
the	O
mutation	O
Val359Leu	B-VARIANT
in	O
the	O
exon	O
10	O
of	O
FGFR2	B-GENE
in	O
heterozygosis	O
(	O
Fig	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
duplicate	O
.	O

The	O
mutation	O
found	O
in	O
each	O
family	O
is	O
illustrated	O
by	O
a	O
sequence	O
below	O
the	O
appropriate	O
pedigree	O
,	O
with	O
mutations	O
indicated	O
on	O
the	O
sequences	O
by	O
red	O
arrows	O
.	O

Fitmaster	O
was	O
used	O
to	O
collect	O
data	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
appeared	O
to	O
be	O
progressive	O
.	O

The	O
remained	O
variants	O
were	O
further	O
screened	O
within	O
212	O
genes	O
registered	O
as	O
retinal	O
disease	O
-	O
causing	O
genes	O
in	O
the	O
RetNet	O
database	O
updated	O
on	O
March	O
10	O
,	O
2014	O
.	O

Shown	O
in	O
green	O
are	O
the	O
amino	O
acids	O
that	O
are	O
mutated	O
(	O
red	O
)	O
in	O
the	O
DFNB29	B-GENE
families	O
,	O
while	O
blue	O
color	O
represent	O
the	O
non	O
-	O
deleterious	O
change	O
found	O
in	O
family	O
PKDF361	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
HT	O
.	O

Patients	O
1	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
were	O
previously	O
described	O
.	O

As	O
above	O
,	O
we	O
performed	O
a	O
complementation	O
experiment	O
in	O
patient	O
fibroblasts	O
to	O
assess	O
the	O
role	O
of	O
FOXRED1	B-GENE
in	O
CI	O
activity	O
.	O

A	O
total	O
of	O
277	O
variants	O
passed	O
the	O
filters	O
,	O
only	O
one	O
of	O
which	O
was	O
within	O
a	O
genomic	O
region	O
that	O
was	O
homozygously	O
shared	O
by	O
the	O
two	O
affected	O
individuals	O
in	O
the	O
whole	O
genome	O
SNP	O
array	O
analysis	O
:	O
a	O
deletion	O
of	O
guanine	O
(	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
)	O
leading	O
to	O
a	O
frameshift	O
(	O
p	B-VARIANT
.	I-VARIANT
Gly407Glufs	I-VARIANT
*	I-VARIANT
56	I-VARIANT
)	O
in	O
an	O
alternative	O
exon	O
(	O
#	O
15	O
)	O
of	O
USH1C	B-GENE
.	O

After	O
drawing	O
the	O
required	O
layers	O
for	O
all	O
spaces	O
with	O
a	O
computer	O
mouse	O
,	O
the	O
software	O
generates	O
thickness	O
and	O
volume	O
values	O
for	O
each	O
of	O
the	O
nine	O
subfields	O
of	O
the	O
Early	O
Treatment	O
of	O
Diabetic	O
Retinopathy	O
Study	O
(	O
ETDRS	O
)	O
grid	O
.	O

Next	O
-	O
generation	O
sequencing	O
enables	O
the	O
simultaneous	O
analysis	O
of	O
multiple	O
genes	O
in	O
a	O
single	O
test	O
.	O

Partial	O
or	O
total	O
gene	O
deletions	O
have	O
been	O
reported	O
in	O
10	O
%	O
of	O
patients	O
without	O
identified	O
point	O
mutations	O
[	O
30	O
-	O
35	O
]	O
.	O

Among	O
the	O
three	O
patients	O
carrying	O
pathogenic	O
mutations	O
in	O
GPR98	B-GENE
,	O
two	O
(	O
U1093	O
and	O
U1178	O
)	O
were	O
homozygotes	O
for	O
truncating	O
mutations	O
and	O
the	O
other	O
(	O
U1171	O
)	O
was	O
compound	O
heterozygous	O
for	O
two	O
truncating	O
mutations	O
.	O

Patients	O
with	O
USH	B-DISEASE
are	O
classified	O
into	O
three	O
clinical	O
subtypes	O
(	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
,	O
or	O
USH3	B-DISEASE
)	O
,	O
based	O
on	O
the	O
severity	O
and	O
progression	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
presence	O
or	O
absence	O
of	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
3	O
,	O
4	O
]	O
.	O

High	O
resolution	O
computed	O
tomography	O
(	O
HRCT	O
)	O
was	O
also	O
performed	O
on	O
some	O
subjects	O
to	O
verify	O
whether	O
the	O
family	O
members	O
had	O
other	O
complications	O
other	O
than	O
hearing	O
disorders	O
.	O

Multi	O
-	O
gene	O
related	O
disease	O
and	O
epigenetic	O
imprinting	O
could	O
be	O
two	O
possible	O
explanations	O
.	O

In	O
China	O
,	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
was	O
the	O
most	O
common	O
form	O
accounting	O
for	O
57	O
.	O
63	O
%	O
of	O
the	O
mutant	O
alleles	O
[	O
27	O
]	O
.	O

Selected	O
variants	O
were	O
classified	O
as	O
known	O
mutations	O
,	O
possible	O
pathogenic	O
mutations	O
,	O
or	O
variants	O
with	O
unknown	O
pathogenicity	O
;	O
the	O
latter	O
classification	O
was	O
made	O
if	O
there	O
were	O
reports	O
of	O
a	O
controversial	O
finding	O
of	O
pathogenicity	O
or	O
>	O
1	O
%	O
allele	O
frequency	O
in	O
the	O
in	O
-	O
house	O
database	O
of	O
95	O
(	O
up	O
to	O
189	O
)	O
Japanese	O
subjects	O
with	O
normal	O
hearing	O
.	O

The	O
affected	O
woman	O
and	O
her	O
two	O
sons	O
suffer	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
carry	O
the	O
c	B-VARIANT
.	I-VARIANT
2508G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
WFS1	B-GENE
mutation	O
.	O

They	O
observed	O
gradual	O
mislocalization	O
of	O
tricellulin	B-GENE
at	O
TCs	O
after	O
the	O
first	O
postnatal	O
week	O
in	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
deficient	O
mice	O
[	O
31	O
]	O
.	O

The	O
comparatively	O
favorable	O
results	O
of	O
the	O
current	O
study	O
that	O
identified	O
83	O
%	O
of	O
the	O
causes	O
of	O
RD	B-DISEASE
may	O
be	O
attributable	O
to	O
a	O
few	O
specific	O
elements	O
,	O
including	O
the	O
size	O
of	O
the	O
cohort	O
analyzed	O
,	O
the	O
methods	O
and	O
extensiveness	O
of	O
the	O
genetic	O
screenings	O
carried	O
out	O
in	O
the	O
past	O
,	O
the	O
clinical	O
phenotype	O
of	O
the	O
patients	O
,	O
and	O
/	O
or	O
the	O
sequencing	O
/	O
mapping	O
methods	O
of	O
NGS	O
itself	O
.	O

The	O
identified	O
mutation	O
is	O
covered	O
by	O
83	O
reads	O
.	O

The	O
current	O
report	O
reinforces	O
the	O
genetic	O
heterogeneity	O
of	O
RP	B-DISEASE
,	O
and	O
demonstrates	O
how	O
consanguinity	O
could	O
increase	O
intrafamilial	O
clustering	O
of	O
multiple	O
hereditary	O
diseases	O
.	O

F	O
-	O
actin	O
is	O
visualized	O
by	O
rhodamine	O
-	O
phalloidin	O
(	O
red	O
)	O
.	O

Human	O
embryonic	O
kidney	O
(	O
HEK	O
)	O
cells	O
were	O
cultured	O
in	O
DMEM	O
solution	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
.	O

Moreover	O
,	O
mutations	O
in	O
genes	O
encoding	O
subunits	O
of	O
RNA	O
polymerases	O
I	O
and	O
III	O
(	O
POLR1C	B-GENE
and	O
POLR1D	B-GENE
)	O
cause	O
TCS	B-DISEASE
,	O
too	O
[	O
7	O
]	O
.	O

The	O
ESRR	O
proteins	O
have	O
DNA	O
-	O
binding	O
and	O
ligand	O
-	O
binding	O
domains	O
,	O
which	O
are	O
both	O
required	O
for	O
transcriptional	O
regulation	O
of	O
ER	O
target	O
genes	O
.	O

For	O
example	O
,	O
p	B-VARIANT
.	I-VARIANT
Val85Asp	I-VARIANT
impairs	O
the	O
ability	O
of	O
claudin	O
14	O
to	O
form	O
tight	O
junction	O
strands	O
.	O

Immunostaining	O
with	O
Pb877	O
revealed	O
a	O
similar	O
expression	O
and	O
localization	O
profile	O
,	O
showing	O
staining	O
of	O
the	O
cytoplasm	O
of	O
vestibular	O
and	O
cochlear	O
hair	O
cells	O
and	O
spiral	O
ganglion	O
neurons	O
(	O
Supplementary	O
Fig	O
.	O

The	O
prevalence	O
of	O
HDR	B-DISEASE
patients	O
who	O
develop	O
renal	O
dysfunction	O
resulting	O
in	O
hemodialysis	O
and	O
their	O
clinical	O
descriptions	O
has	O
not	O
been	O
reported	O
.	O

DNA	O
mutation	O
numbering	O
is	O
based	O
on	O
cDNA	O
sequence	O
with	O
a	O
'	O
c	O
.	O

Captured	O
PCR	O
products	O
were	O
subjected	O
to	O
Agilent	O
2100	O
Bioanalyzer	O
to	O
evaluate	O
the	O
magnitude	O
of	O
enrichment	O
.	O

Brainstem	B-DISEASE
atrophy	I-DISEASE
frequently	O
leads	O
to	O
central	B-DISEASE
respiratory	I-DISEASE
failure	I-DISEASE
,	O
which	O
is	O
the	O
most	O
common	O
cause	O
of	O
death	O
in	O
WS	B-DISEASE
individuals	O
,	O
usually	O
during	O
the	O
fourth	O
decade	O
of	O
life	O
[	O
2	O
]	O
.	O

Our	O
study	O
is	O
the	O
first	O
genetic	O
analysis	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
in	O
south	O
China	O
,	O
and	O
revealed	O
that	O
a	O
clear	O
genetic	O
etiology	O
accounted	O
for	O
32	O
.	O
0	O
%	O
of	O
non	O
-	O
syndromic	O
hearing	O
cases	O
in	O
patients	O
from	O
these	O
regions	O
.	O

Bottom	O
:	O
A	O
comparison	O
of	O
amino	O
acid	O
sequences	O
of	O
each	O
gene	O
in	O
multiple	O
vertebrate	O
species	O
.	O

Authors	O
'	O
contributions	O
MJA	O
performed	O
the	O
sequence	O
capture	O
,	O
variant	O
analysis	O
and	O
confirmation	O
of	O
point	O
mutations	O
by	O
Sanger	O
sequencing	O
;	O
EA	O
contributed	O
to	O
the	O
sequence	O
capture	O
,	O
copy	O
number	O
variant	O
analysis	O
,	O
MLPA	O
and	O
manuscript	O
preparation	O
;	O
CFG	O
contributed	O
to	O
variant	O
analysis	O
and	O
confirmation	O
of	O
point	O
mutations	O
by	O
Sanger	O
sequencing	O
;	O
GGG	O
performed	O
a	O
-	O
CGH	O
analysis	O
;	O
AFR	O
contributed	O
to	O
a	O
-	O
CGH	O
analysis	O
and	O
manuscript	O
preparation	O
,	O
RR	O
performed	O
the	O
functional	O
in	O
silico	O
analysis	O
of	O
mutations	O
;	O
RPVM	O
contributed	O
to	O
targeted	O
next	O
generation	O
sequencing	O
panel	O
design	O
and	O
validation	O
;	O
FBK	O
contributed	O
to	O
patients	O
recruitment	O
and	O
DNA	O
samples	O
validation	O
;	O
CA	O
contributed	O
to	O
patients	O
recruitment	O
and	O
manuscript	O
preparation	O
;	O
TJ	O
designed	O
the	O
targeted	O
next	O
generation	O
sequencing	O
panel	O
,	O
supervised	O
the	O
experiments	O
and	O
redacted	O
the	O
manuscript	O
JMM	O
supervised	O
the	O
design	O
and	O
experiments	O
and	O
redacted	O
the	O
manuscript	O
.	O

Cover	O
glasses	O
were	O
mounted	O
in	O
ProLong	O
anti	O
-	O
fade	O
media	O
(	O
Life	O
Technologies	O
)	O
and	O
visualized	O
with	O
100x	O
oil	O
objective	O
on	O
inverted	O
microscope	O
(	O
Zeiss	O
)	O
fitted	O
with	O
spinning	O
disc	O
confocal	O
scanner	O
(	O
Perkin	O
-	O
Elmer	O
)	O
.	O

Finally	O
,	O
it	O
is	O
clear	O
that	O
deployment	O
of	O
bioinformatic	O
prioritization	O
tools	O
provides	O
important	O
pointers	O
toward	O
apparent	O
phenotype	O
expansion	O
of	O
known	O
genes	O
(	O
seven	O
potential	O
examples	O
reported	O
here	O
)	O
,	O
as	O
well	O
as	O
pointers	O
toward	O
novel	O
disease	O
genes	O
(	O
four	O
potential	O
examples	O
reported	O
here	O
)	O
.	O

The	O
polymorphic	O
constellations	O
identified	O
in	O
this	O
study	O
(	O
TT	O
CC	O
,	O
TC	O
GG	O
,	O
CC	O
GG	O
,	O
and	O
TC	O
CC	O
)	O
are	O
four	O
of	O
a	O
total	O
of	O
nine	O
possible	O
constellations	O
.	O

Although	O
type	O
XI	O
collagen	O
is	O
a	O
quantitatively	O
minor	O
component	O
of	O
the	O
fibrils	O
it	O
has	O
an	O
important	O
role	O
in	O
regulating	O
fibrillogenesis	O
.	O

In	O
our	O
study	O
,	O
there	O
were	O
no	O
consistent	O
GBM	O
ultrastructural	O
findings	O
in	O
the	O
families	O
with	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
variants	O
.	O

(	O
C	O
)	O
Two	O
previously	O
indicated	O
hydrogen	O
bonds	O
are	O
eliminated	O
due	O
to	O
the	O
change	O
of	O
the	O
wide	O
type	O
threonine	O
into	O
the	O
mutant	O
methionine	O
.	O

Direct	O
exonic	O
sequence	O
revealed	O
a	O
novel	O
missense	O
mutation	O
in	O
SNRNP200	B-GENE
,	O
c	B-VARIANT
.	I-VARIANT
2042G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R681L	I-VARIANT
)	O
(	O
Table	O
1	O
B	O
)	O
in	O
a	O
codon	O
also	O
mutated	O
in	O
other	O
adRP	B-DISEASE
cases	O
(	O
c	B-VARIANT
.	I-VARIANT
2041C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R681C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
2042G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R681H	I-VARIANT
)	O
[	O
28	O
]	O
.	O

Approximately	O
350	O
children	O
have	O
been	O
tested	O
by	O
transtympanic	O
ECochG	O
at	O
our	O
department	O
over	O
the	O
past	O
15	O
years	O
.	O

The	O
controls	O
show	O
only	O
a	O
few	O
variants	O
,	O
resulting	O
in	O
a	O
much	O
higher	O
similarity	O
of	O
these	O
individuals	O
and	O
a	O
homogeneous	O
cluster	O
around	O
zero	O
.	O

Until	O
now	O
,	O
this	O
technology	O
has	O
mainly	O
been	O
used	O
for	O
research	O
purposes	O
.	O

[	O
36	O
]	O
used	O
two	O
different	O
approaches	O
:	O
whole	O
exome	O
sequencing	O
with	O
the	O
use	O
of	O
the	O
SOLiD	O
system	O
and	O
long	O
-	O
PCR	O
sequencing	O
on	O
nine	O
USH	B-DISEASE
genes	O
with	O
two	O
different	O
platforms	O
,	O
Illumina	O
(	O
Genome	O
Analyzer	O
II	O
)	O
and	O
the	O
Roche	O
454	O
(	O
GS	O
FLX	O
)	O
.	O

Yann	O
-	O
Jinn	O
Lee	O
for	O
designing	O
and	O
providing	O
primers	O
for	O
WFS1	B-GENE
exon	O
8	O
.	O

Patients	O
were	O
clinically	O
diagnosed	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

Important	O
success	O
factors	O
in	O
dominant	O
investigations	O
would	O
be	O
represented	O
by	O
the	O
detection	O
of	O
clear	O
-	O
cut	O
mutations	O
,	O
such	O
as	O
indels	O
and	O
nonsense	O
variants	O
,	O
in	O
known	O
disease	O
genes	O
and	O
the	O
use	O
of	O
control	O
population	O
data	O
analyzed	O
with	O
WES	O
,	O
in	O
order	O
to	O
systematically	O
subtract	O
the	O
noise	O
and	O
enhance	O
the	O
signal	O
throughout	O
the	O
genome	O
.	O

The	O
patients	O
were	O
clinically	O
examined	O
,	O
and	O
reversal	O
of	O
HH	B-DISEASE
was	O
assessed	O
after	O
treatment	O
withdrawal	O
.	O

Nonsense	O
mutations	O
,	O
splice	O
-	O
site	O
mutations	O
,	O
and	O
missense	O
mutations	O
were	O
chosen	O
according	O
to	O
this	O
algorithm	O
.	O

,	O
2005	O
)	O
;	O
FI	O
-	O
1	O
:	O
(	O
Puomila	O
et	O
al	O
.	O

Type	O
II	O
(	O
USH2	B-DISEASE
)	O
is	O
characterized	O
by	O
postpuberal	O
onset	O
RP	B-DISEASE
and	O
moderate	O
deafness	B-DISEASE
without	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Damhuis	O
,	O
A	O
.	O

A	O
cohort	O
of	O
44	O
patients	O
suffering	O
from	O
Usher	B-DISEASE
syndrome	I-DISEASE
was	O
selected	O
for	O
this	O
study	O
.	O

We	O
sequenced	O
MYO15A	B-GENE
exon	O
2	O
containing	O
these	O
variant	O
sites	O
and	O
detected	O
a	O
2	O
-	O
bp	O
deletion	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
373delCG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R125VfsX101	I-VARIANT
)	O
.	O

A	O
GFP	O
-	O
fused	O
wild	O
-	O
type	O
or	O
mutant	O
NLRP3	B-GENE
was	O
transfected	O
into	O
THP	O
-	O
1	O
cells	O
and	O
incubated	O
with	O
PMA	O
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
4	O
h	O
.	O

This	O
subgroup	O
also	O
included	O
a	O
trio	O
(	O
samples	O
R169	O
,	O
R169_1	O
,	O
R169_2	O
)	O
,	O
being	O
a	O
case	O
of	O
idiopathic	O
shortening	O
of	O
the	O
metatarsals	O
,	O
and	O
unaffected	O
parents	O
and	O
no	O
candidate	O
mutations	O
were	O
found	O
.	O

The	O
identification	O
of	O
a	O
large	O
KCNH2	B-GENE
p	B-VARIANT
.	I-VARIANT
F29L	I-VARIANT
founder	O
family	O
,	O
comprising	O
7	O
.	O
1	O
%	O
of	O
Danish	O
LQTS	B-DISEASE
families	O
,	O
is	O
interesting	O
,	O
and	O
the	O
location	O
of	O
the	O
family	O
in	O
the	O
Northern	O
part	O
of	O
Jutland	O
,	O
where	O
it	O
constitutes	O
ca	O
.	O

The	O
recently	O
identified	O
causal	O
Usher	B-DISEASE
genes	O
ABHD12	B-GENE
(	O
Fiskerstrand	O
et	O
al	O
.	O

3B	O
)	O
and	O
hypothetically	O
results	O
in	O
a	O
truncated	O
protein	O
of	O
323	O
amino	O
acids	O
.	O

No	O
affected	O
individuals	O
were	O
identified	O
among	O
close	O
relatives	O
of	O
the	O
family	O
.	O

No	O
mutational	O
hot	O
-	O
spots	O
were	O
revealed	O
in	O
these	O
Korean	O
families	O
.	O

Abbreviations	O
:	O
C	O
,	O
conserved	O
;	O
N	O
,	O
not	O
-	O
conserved	O
or	O
neutral	O
D	O
,	O
damaging	O
or	O
deleterious	O
;	O
B	O
,	O
benign	O
;	O
NA	O
,	O
not	O
applicable	O
.	O

The	O
method	O
described	O
is	O
faster	O
,	O
more	O
reliable	O
and	O
cheaper	O
than	O
the	O
Sanger	O
method	O
(	O
per	O
gene	O
/	O
case	O
)	O
and	O
avoids	O
the	O
need	O
for	O
several	O
sub	O
-	O
panels	O
of	O
genes	O
.	O

Both	O
5	O
'	O
polymorphisms	O
,	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
137	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
53	I-VARIANT
C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
have	O
been	O
described	O
as	O
5	O
'	O
UTR	O
polymorphisms	O
implying	O
they	O
become	O
part	O
of	O
the	O
mRNA	O
.	O

The	O
EYA1	B-GENE
gene	O
located	O
on	O
chromosome	O
8q13	O
.	O
3	O
encodes	O
a	O
transcriptional	O
co	O
-	O
activator	O
required	O
for	O
eye	O
morphogenesis	O
which	O
consists	O
of	O
three	O
isoforms	O
(	O
a	O
,	O
b	O
,	O
c	O
)	O
and	O
four	O
transcript	O
variants	O
(	O
EYA1A	O
-	O
1D	O
)	O
as	O
a	O
result	O
of	O
alternative	O
splicing	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

in	O
2003	O
[	O
5	O
]	O
.	O

Sometimes	O
,	O
it	O
would	O
be	O
difficult	O
for	O
clinicians	O
to	O
make	O
proper	O
clinical	O
diagnosis	O
due	O
to	O
the	O
atypical	O
manifestations	O
.	O

ANSD	B-DISEASE
is	O
closely	O
related	O
to	O
the	O
OTOF	B-GENE
gene	O
,	O
which	O
contains	O
47	O
coding	O
exons	O
and	O
spans	O
approximately	O
90	O
kb	O
,	O
encoding	O
protein	O
otoferlin	O
[	O
12	O
]	O
.	O

WFS1	B-GENE
,	O
on	O
chromosome	O
4p16	O
.	O
3	O
,	O
contains	O
eight	O
exons	O
.	O

Excluding	O
the	O
four	O
patients	O
without	O
an	O
identified	O
pathogenic	O
mutation	O
,	O
we	O
obtained	O
similar	O
results	O
(	O
~	O
18	O
.	O
5	O
%	O
,	O
p	O
=	O
0	O
.	O
0039	O
)	O
.	O

PCR	O
products	O
were	O
sequenced	O
according	O
to	O
standard	O
procedures	O
(	O
Big	O
Dye	O
Terminator	O
Sequencing	O
Kit	O
v3	O
.	O
1	O
,	O
Life	O
Technologies	O
,	O
USA	O
)	O
and	O
analyzed	O
on	O
the	O
ABI	O
3500	O
genetic	O
analyzer	O
(	O
Life	O
Technologies	O
,	O
USA	O
)	O
.	O

To	O
evaluate	O
the	O
enrichment	O
efficiencies	O
of	O
the	O
SureSelect	O
50	O
Mb	O
kit	O
and	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
,	O
we	O
compared	O
the	O
proportion	O
of	O
on	O
-	O
target	O
bases	O
.	O

CIBERER	O
is	O
an	O
initiative	O
of	O
the	O
Institute	O
of	O
Health	O
Carlos	O
III	O
,	O
Ministry	O
of	O
Economy	O
and	O
Competitiveness	O
.	O

The	O
demographics	O
(	O
age	O
,	O
sex	O
,	O
QTc	O
,	O
symptoms	O
,	O
family	O
history	O
,	O
and	O
treatment	O
with	O
beta	O
-	O
blockers	O
)	O
of	O
all	O
available	O
patients	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

We	O
speculate	O
that	O
targeted	O
deafness	B-DISEASE
gene	O
capture	O
and	O
NGS	O
provides	O
opportunities	O
to	O
identify	O
causative	O
mutations	O
and	O
new	O
Usher	B-DISEASE
syndrome	I-DISEASE
genes	O
efficiently	O
.	O

L	O
.	O
T	O
.	O
T	O
.	O

Constitutive	O
exons	O
are	O
given	O
in	O
black	O
,	O
alternatively	O
spliced	O
exons	O
in	O
grey	O
.	O

Here	O
,	O
three	O
high	O
confidence	O
germline	O
deletion	O
events	O
in	O
BRCA1	B-GENE
were	O
identified	O
in	O
three	O
cases	O
(	O
TCGA	O
-	O
36	O
-	O
2539	O
,	O
TCGA	O
-	O
31	O
-	O
1959	O
,	O
and	O
TCGA	O
-	O
23	O
-	O
1028	O
)	O
(	O
Fig	O
.	O

Consistently	O
,	O
we	O
found	O
GC	O
squared	O
was	O
a	O
significant	O
predictor	O
for	O
the	O
target	O
depth	O
of	O
the	O
SureSelect	O
50	O
Mb	O
kit	O
but	O
not	O
for	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
(	O
Table	O
6	O
)	O
.	O

We	O
therefore	O
deduced	O
that	O
the	O
USH2A	B-GENE
monogenic	O
recessive	O
mutation	O
failed	O
to	O
cause	O
the	O
Usher	B-DISEASE
phenotype	O
but	O
may	O
have	O
contributed	O
to	O
the	O
pathogenesis	O
of	O
the	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
mutation	O
,	O
resulting	O
in	O
phenotypic	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
two	O
patients	O
.	O

In	O
the	O
future	O
,	O
critical	O
gene	O
mutations	O
may	O
be	O
accurately	O
and	O
quickly	O
identified	O
in	O
families	O
with	O
hereditary	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
by	O
targeted	O
genomic	O
capture	O
and	O
MPS	O
.	O

Primers	O
were	O
designed	O
to	O
amplify	O
total	O
CD164	B-GENE
transcripts	O
(	O
recognising	O
both	O
transcripts	O
)	O
as	O
well	O
as	O
the	O
mutated	O
and	O
wild	O
-	O
type	O
transcript	O
(	O
allele	O
specific	O
primers	O
)	O
.	O

Seven	O
families	O
were	O
consanguineous	O
.	O

There	O
are	O
no	O
definitive	O
reports	O
regarding	O
the	O
specific	O
frequency	O
of	O
psychiatric	B-DISEASE
disorders	I-DISEASE
in	O
RSTS	B-DISEASE
due	O
to	O
its	O
low	O
prevalence	O
.	O

In	O
five	O
patients	O
that	O
were	O
initially	O
diagnosed	O
with	O
RP	B-DISEASE
(	O
individuals	O
7	O
,	O
554	O
,	O
9	O
,	O
437	O
,	O
21	O
,	O
141	O
,	O
21	O
,	O
334	O
,	O
and	O
31	O
,	O
723	O
)	O
,	O
identification	O
of	O
the	O
genetic	O
defect	O
led	O
to	O
a	O
reappraisal	O
of	O
the	O
phenotype	O
to	O
either	O
a	O
different	O
subtype	O
of	O
nonsyndromic	O
RD	B-DISEASE
or	O
to	O
a	O
(	O
mild	O
)	O
syndromic	O
form	O
of	O
RP	B-DISEASE
(	O
Supp	O
.	O

Mid	O
-	O
frequencies	O
are	O
more	O
severely	O
affected	O
than	O
lower	O
and	O
higher	O
frequencies	O
termed	O
basin	O
shaped	O
or	O
cookie	O
bite	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Alternatively	O
,	O
PS	B-DISEASE
-	O
related	O
phenotypes	O
in	O
the	O
patient	O
might	O
be	O
progressive	O
and	O
could	O
be	O
more	O
severe	O
with	O
age	O
.	O

Analysis	O
using	O
the	O
program	O
NNSPLICE	O
available	O
at	O
did	O
not	O
predict	O
gain	O
or	O
loss	O
of	O
a	O
splice	O
site	O
with	O
this	O
variant	O
,	O
and	O
it	O
was	O
therefore	O
also	O
considered	O
benign	O
.	O

EVA	B-DISEASE
can	O
also	O
be	O
associated	O
with	O
other	O
forms	O
of	O
syndromic	B-DISEASE
and	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
(	O
DFBN4	O
(	O
OMIM	O
600791	O
)	O
)	O
[	O
8	O
,	O
9	O
]	O
,	O
particularly	O
non	O
-	O
syndromic	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueducts	I-DISEASE
.	O

Congenital	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
(	O
HH	B-DISEASE
)	O
is	O
a	O
rare	O
cause	O
for	O
delayed	B-DISEASE
or	I-DISEASE
absent	I-DISEASE
puberty	I-DISEASE
.	O

In	O
a	O
minority	O
of	O
cases	O
,	O
however	O
,	O
the	O
correct	O
diagnosis	O
can	O
improve	O
patient	O
management	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
they	O
occur	O
in	O
compound	O
heterozygotes	O
with	O
a	O
missense	O
p	B-VARIANT
.	I-VARIANT
G163R	I-VARIANT
and	O
a	O
nonsense	O
p	B-VARIANT
.	I-VARIANT
R150X	I-VARIANT
mutation	O
,	O
respectively	O
.	O

Thus	O
,	O
the	O
carrier	O
frequency	O
of	O
GJB2	B-GENE
mutations	O
in	O
the	O
control	O
population	O
is	O
3	O
%	O
.	O

Implantation	O
was	O
uneventful	O
and	O
the	O
implant	O
was	O
fully	O
inserted	O
on	O
the	O
left	O
side	O
in	O
all	O
cases	O
.	O

Incidental	O
findings	O
are	O
a	O
direct	O
consequence	O
of	O
exhaustive	O
screening	O
with	O
NGS	O
.	O

A	O
recent	O
study	O
in	O
a	O
cohort	O
of	O
272	O
Spanish	O
patients	O
with	O
non	O
-	O
syndromic	O
RP	B-DISEASE
resulted	O
in	O
the	O
identification	O
of	O
two	O
mutant	O
alleles	O
of	O
the	O
USH2A	B-GENE
gene	O
in	O
nine	O
patients	O
,	O
with	O
seven	O
of	O
them	O
carrying	O
either	O
homozygous	O
missense	O
mutations	O
or	O
two	O
heterozygous	O
missense	O
mutations	O
[	O
18	O
]	O
.	O

Palmer	O
;	O
Dr	O
.	O

Genetic	O
cause	O
of	O
sensorineural	O
disorders	O
such	O
as	O
mental	B-DISEASE
retardation	I-DISEASE
,	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
and	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
extraordinarily	O
heterogeneous	O
.	O

Similar	O
craniofacial	O
features	O
were	O
also	O
exhibited	O
by	O
subjects	O
II	O
-	O
2	O
,	O
III	O
-	O
1	O
,	O
III	O
-	O
6	O
,	O
and	O
III	O
-	O
7	O
,	O
and	O
hypocalcemia	B-DISEASE
was	O
also	O
identified	O
in	O
subjects	O
II	O
-	O
2	O
and	O
III	O
-	O
7	O
.	O

Middle	O
right	O
:	O
3days	O
surface	O
maps	O
:	O
the	O
ILM	O
-	O
RPE	O
,	O
displaying	O
the	O
retinal	O
thickness	O
in	O
three	O
dimensions	O
.	O

Our	O
subjects	O
for	O
genome	O
analysis	O
are	O
Israeli	O
Jewish	O
and	O
Palestinian	O
Arab	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
that	O
varies	O
in	O
mode	O
of	O
inheritance	O
and	O
severity	O
.	O

Family	O
TB109	O
(	O
Figure	O
1D	O
)	O
is	O
a	O
Bedouin	O
family	O
from	O
northern	O
Israel	O
.	O

However	O
,	O
OPA1	B-GENE
(	O
NM_130837	O
)	O
is	O
the	O
major	O
gene	O
responsible	O
for	O
ADOA	B-DISEASE
,	O
which	O
was	O
first	O
localized	O
on	O
3q28	O
in	O
1996	O
,	O
followed	O
by	O
the	O
discovery	O
of	O
the	O
OPA1	B-GENE
gene	O
sequence	O
5	O
6	O
.	O

We	O
identified	O
a	O
novel	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
257	I-VARIANT
-	I-VARIANT
262CCTTTC	I-VARIANT
>	I-VARIANT
GCT	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT

Molecular	O
sequencing	O
revealed	O
5	O
heterozygous	O
compound	O
and	O
3	O
homozygous	O
mutations	O
.	O

The	O
English	O
in	O
this	O
document	O
has	O
been	O
checked	O
by	O
at	O
least	O
two	O
professional	O
editors	O
,	O
both	O
native	O
speakers	O
of	O
English	O
.	O

2012	O
;	O
Ishida	O
et	O
al	O
.	O

For	O
the	O
64	O
cases	O
without	O
a	O
clear	O
molecular	O
diagnosis	O
,	O
either	O
no	O
interesting	O
variants	O
were	O
detected	O
among	O
the	O
111	O
targeted	O
genes	O
(	O
eight	O
cases	O
)	O
,	O
the	O
identified	O
variants	O
were	O
predicted	O
to	O
be	O
benign	O
or	O
did	O
not	O
segregate	O
completely	O
(	O
48	O
cases	O
)	O
,	O
or	O
segregating	O
variants	O
were	O
identified	O
,	O
but	O
their	O
pathogenicity	O
remained	O
uncertain	O
(	O
eight	O
samples	O
)	O
.	O

Radiographs	O
of	O
hands	O
.	O

The	O
TBX1	B-GENE
cDNA	O
was	O
digested	O
and	O
inserted	O
into	O
the	O
plasmid	O
pcDNA3	O
.	O
1	O
(	O
+	O
)	O
at	O
the	O
KpnI	O
and	O
XhoI	O
sites	O
.	O

For	O
example	O
,	O
NGS	O
provided	O
genetic	O
diagnosis	O
in	O
36	O
%	O
(	O
36	O
out	O
of	O
100	O
)	O
of	O
patients	O
with	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
[	O
33	O
]	O
.	O

Peripheral	O
blood	O
samples	O
were	O
obtained	O
from	O
available	O
members	O
of	O
these	O
families	O
,	O
and	O
genomic	O
DNA	O
was	O
extracted	O
using	O
a	O
blood	O
genomic	O
DNA	O
extraction	O
kit	O
(	O
TianGen	O
,	O
Beijing	O
,	O
China	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Conserved	O
amino	O
acid	O
sequence	O
.	O

N	O
-	O
STORM	O
imaging	O
was	O
performed	O
with	O
a	O
Nikon	O
N	O
-	O
STORM	O
super	O
-	O
resolution	O
microscope	O
system	O
(	O
Nikon	O
Instruments	O
Ltd	O
,	O
Melville	O
,	O
NY	O
)	O
based	O
on	O
an	O
inverted	O
microscope	O
Nikon	O
A1Rsi	O
equipped	O
with	O
a	O
perfect	O
-	O
focusing	O
system	O
and	O
a	O
100	O
x	O
TIRF	O
APO	O
NA	O
1	O
.	O
49	O
oil	O
objective	O
.	O

Then	O
,	O
we	O
compared	O
these	O
variants	O
with	O
reported	O
Nonsyndromic	B-DISEASE
Hereditary	I-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
genes	O
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O

These	O
findings	O
reveal	O
that	O
these	O
two	O
variants	O
cannot	O
be	O
considered	O
as	O
disease	O
-	O
causing	O
.	O

That	O
demonstrates	O
once	O
again	O
the	O
mutation	O
-	O
specific	O
nature	O
of	O
PRS	B-GENE
-	I-GENE
I	I-GENE
phenotypes	O
[	O
7	O
,	O
11	O
]	O
.	O

All	O
other	O
probands	O
had	O
prelingual	O
or	O
early	O
-	O
onset	O
,	O
severe	O
-	O
to	O
-	O
profound	O
sensorineural	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

All	O
indels	O
and	O
failing	O
variants	O
were	O
removed	O
.	O

However	O
,	O
the	O
MCVs	O
and	O
CMAPs	O
of	O
all	O
patients	O
were	O
normal	O
(	O
see	O
online	O
supplementary	O
figure	O
S3	O
)	O
.	O

Click	O
here	O
for	O
file	O
We	O
would	O
like	O
to	O
gratefully	O
acknowledge	O
the	O
patients	O
and	O
their	O
relatives	O
.	O

E	O
shows	O
the	O
heterozygous	O
,	O
one	O
-	O
base	O
-	O
deletion	O
mutation	O
c	B-VARIANT
.	I-VARIANT
6249delT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT

Five	O
deletions	O
were	O
identified	O
,	O
one	O
of	O
21	O
nucleotides	O
(	O
c	B-VARIANT
.	I-VARIANT
3202_3222del	I-VARIANT
)	O
affecting	O
exon	O
25	O
predicted	O
a	O
deletion	O
of	O
seven	O
amino	O
acids	O
in	O
the	O
protein	O
(	O
p	B-VARIANT
.	I-VARIANT
Q1068_L1074del	I-VARIANT
)	O
.	O

3	O
Genetic	O
map	O
positions	O
based	O
on	O
Rutgers	O
linkage	O
physical	O
map	O
of	O
the	O
human	O
genome	O
.	O
The	O
first	O
two	O
authors	O
contributed	O
equally	O
to	O
this	O
work	O
To	O
identify	O
the	O
genetic	O
defect	O
in	O
Spanish	O
families	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
and	O
probable	O
involvement	O
of	O
the	O
CLRN1	B-GENE
gene	O
.	O

The	O
slash	O
symbol	O
indicates	O
deceased	O
individuals	O
.	O

This	O
disease	O
is	O
particularly	O
devastating	O
because	O
affected	O
individuals	O
lose	O
central	O
vision	O
,	O
which	O
is	O
necessary	O
common	O
tasks	O
including	O
reading	O
,	O
schooling	O
,	O
driving	O
and	O
recognizing	O
faces	O
.	O

The	O
first	O
was	O
a	O
36	O
-	O
year	O
-	O
old	O
woman	O
with	O
proximal	O
myopathy	B-DISEASE
,	O
peripheral	B-DISEASE
neuropathy	I-DISEASE
,	O
complicated	O
migraine	B-DISEASE
and	O
the	O
c	B-VARIANT
.	I-VARIANT
870	I-VARIANT
+	I-VARIANT
5g	I-VARIANT
>	I-VARIANT
a	I-VARIANT
splice	O
-	O
site	O
mutation	O
(	O
UK	O
-	O
2	O
)	O
.	O

After	O
first	O
excluding	O
plausible	O
variants	O
in	O
known	O
deafness	B-DISEASE
-	O
causing	O
genes	O
using	O
TGE	O
+	O
MPS	O
,	O
we	O
completed	O
whole	O
exome	O
sequencing	O
in	O
three	O
hearing	B-DISEASE
-	I-DISEASE
impaired	I-DISEASE
family	O
members	O
.	O

Two	O
different	O
groups	O
of	O
patients	O
-	O
-	O
86	O
families	O
with	O
juvenile	O
RP	B-DISEASE
and	O
186	O
families	O
with	O
typical	O
RP	B-DISEASE
(	O
onset	O
after	O
the	O
age	O
of	O
10	O
)	O
-	O
-	O
were	O
formed	O
and	O
studied	O
independently	O
,	O
according	O
to	O
their	O
clinical	O
ophthalmic	O
diagnosis	O
.	O

TECTA	B-GENE
has	O
been	O
reported	O
to	O
be	O
responsible	O
for	O
both	O
autosomal	B-DISEASE
dominant	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
(	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
)	O
and	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
(	O
DFNB21	B-GENE
)	O
.	O

After	O
explaining	O
the	O
nature	O
of	O
this	O
study	O
,	O
informed	O
consents	O
adhering	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
were	O
obtained	O
from	O
all	O
patients	O
and	O
their	O
relatives	O
.	O

Clinical	O
investigation	O
revealed	O
nonsyndromic	O
deafness	B-DISEASE
segregating	O
in	O
families	O
PKDF536	O
and	O
PKDF1132	O
.	O

S2	O
)	O
,	O
and	O
that	O
98	O
%	O
of	O
variants	O
previously	O
identified	O
by	O
Sanger	O
sequencing	O
were	O
correctly	O
found	O
by	O
NGS	O
(	O
Fig	O
.	O

Co	O
-	O
segregated	O
regions	O
of	O
CNVs	O
were	O
also	O
analyzed	O
by	O
Fisher	O
'	O
s	O
exact	O
test	O
(	O
D	O
)	O
.	O

The	O
other	O
disorders	O
,	O
FTNS	B-DISEASE
,	O
EPTS	B-DISEASE
,	O
and	O
APSMT	B-DISEASE
,	O
were	O
said	O
to	O
be	O
"	O
syndromic	O
"	O
because	O
the	O
hematological	O
symptoms	O
,	O
macrothrombocytopenia	B-DISEASE
and	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
,	O
also	O
called	O
D	O
o	O
hle	O
-	O
like	O
bodies	O
,	O
were	O
associated	O
with	O
various	O
combinations	O
of	O
extrahematological	O
symptoms	O
:	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
and	O
nephritis	B-DISEASE
in	O
EPTS	B-DISEASE
with	O
,	O
in	O
addition	O
,	O
cataracts	B-DISEASE
in	O
FTNS	B-DISEASE
.	O

PCR	O
primers	O
(	O
Supplementary	O
Table	O
5	O
)	O
were	O
designed	O
to	O
amplify	O
the	O
entire	O
cDNA	O
in	O
either	O
one	O
PCR	O
product	O
or	O
in	O
overlapping	O
segments	O
.	O

Thawing	O
was	O
performed	O
at	O
4	O
deg	O
C	O
and	O
room	O
temperature	O
successively	O
.	O

The	O
hydroxide	O
group	O
introduced	O
by	O
the	O
p	B-VARIANT
.	I-VARIANT
Ile308Thr	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
I308T	I-VARIANT
)	O
mutation	O
causes	O
a	O
conformational	O
change	O
in	O
the	O
Arginine	O
residue	O
at	O
323	O
(	O
C	O
)	O
.	O

In	O
22	O
out	O
of	O
47	O
families	O
(	O
46	O
.	O
8	O
%	O
)	O
we	O
identified	O
two	O
MYO7A	B-GENE
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variants	O
and	O
in	O
three	O
families	O
(	O
6	O
.	O
4	O
%	O
)	O
only	O
one	O
such	O
variant	O
.	O

The	O
intrafamilial	O
variation	O
indicates	O
that	O
these	O
data	O
do	O
not	O
allow	O
prediction	O
of	O
the	O
phenotypic	O
outcome	O
for	O
individual	O
cases	O
.	O

N1	O
,	O
N2	O
,	O
P1	O
,	O
P2	O
indicate	O
the	O
different	O
waves	O
and	O
decreased	O
P2	O
peak	O
indicates	O
the	O
blocking	O
of	O
optic	O
nerve	O
.	O

"	O
For	O
the	O
splice	O
-	O
site	O
prediction	O
programs	O
(	O
Splice	O
Site	O
Finder	O
,	O
MaxEntScan	O
,	O
NNSplice	O
)	O
,	O
wild	O
-	O
type	O
score	O
(	O
wt	O
)	O
and	O
mutation	O
score	O
(	O
mut	O
)	O
were	O
compared	O
using	O
the	O
following	O
cutoffs	O
.	O

Individuals	O
from	O
130	O
families	O
of	O
Saudi	O
Arabian	O
tribal	O
origin	O
diagnosed	O
with	O
an	O
autosomal	O
recessive	O
non	O
-	O
syndromic	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
screened	O
for	O
mutations	O
at	O
the	O
DFNB1	B-GENE
locus	O
by	O
direct	O
sequencing	O
.	O

For	O
SNP	O
typing	O
,	O
two	O
cycling	O
probes	O
labeled	O
with	O
two	O
different	O
fluorescent	O
dyes	O
(	O
6	O
-	O
carboxyfluorescein	O
(	O
FAM	O
)	O
or	O
6	O
-	O
carboxy	O
-	O
X	O
-	O
rhodamine	O
(	O
ROX	O
)	O
)	O
were	O
used	O
,	O
with	O
each	O
probe	O
harboring	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
corresponding	O
to	O
the	O
wild	O
-	O
type	O
nucleotide	O
or	O
the	O
nucleotide	O
with	O
a	O
mutation	O
at	O
the	O
SNP	O
position	O
.	O

But	O
given	O
the	O
carrier	O
frequency	O
in	O
normal	O
controls	O
,	O
the	O
number	O
of	O
heterozygous	O
deafness	B-DISEASE
cases	O
was	O
greater	O
than	O
would	O
be	O
expected	O
.	O

We	O
transfected	O
pRK5	O
-	O
WT	O
and	O
MT	O
CEACAM16	B-GENE
-	O
flag	O
plasmids	O
into	O
both	O
COS7	O
cells	O
and	O
HEK293	O
cells	O
.	O

Marchuk	O
;	O
D	O
.	O

Muscle	O
histochemistry	O
on	O
Patient	O
1	O
revealed	O
absence	B-DISEASE
of	I-DISEASE
COX	I-DISEASE
activity	I-DISEASE
in	O
several	O
scattered	O
muscle	O
fibres	O
,	O
many	O
of	O
which	O
also	O
showed	O
mitochondrial	O
proliferation	O
(	O
intense	O
SDH	O
-	O
positivity	O
,	O
RRFs	O
)	O
.	O

C	O
.	O

We	O
report	O
the	O
detailed	O
clinical	O
phenotype	O
of	O
a	O
group	O
of	O
WFS	B-DISEASE
subjects	O
seen	O
at	O
our	O
annual	O
multidisciplinary	O
Wolfram	B-DISEASE
Syndrome	I-DISEASE
Research	O
Clinic	O
at	O
Washington	O
University	O
,	O
Eighteen	O
participants	O
,	O
3	O
of	O
whom	O
were	O
siblings	O
,	O
aged	O
5	O
to	O
25	O
were	O
recruited	O
through	O
the	O
Washington	O
University	O
Wolfram	O
Syndrome	O
International	O
Registry	O
website	O
(	O
http	O
:	O
/	O
/	O
wolframsyndrome	O
.	O
dom	O
.	O
wustl	O
.	O
edu	O
/	O
medical	O
-	O
research	O
/	O
Wolfram	O
-	O
Syndrome	O
-	O
Home	O
.	O
aspx	O
)	O
to	O
participate	O
in	O
standardized	O
evaluations	O
across	O
domains	O
known	O
to	O
be	O
associated	O
with	O
WFS	B-DISEASE
.	O

This	O
predominant	O
localisation	O
in	O
exons	O
2	O
-	O
6	O
has	O
previously	O
been	O
described	O
.	O

We	O
also	O
identified	O
20	O
silent	O
variants	O
,	O
17	O
were	O
previously	O
described	O
as	O
neutral	O
[	O
[	O
36	O
]	O
,	O
https	O
:	O
/	O
/	O
grenada	O
.	O
lumc	O
.	O
nl	O
/	O
LOVD2	O
/	O
Usher_montpellier	O
,	O
[	O
35	O
]	O
]	O
and	O
three	O
were	O
novel	O
(	O
See	O
Table	O
3	O
)	O
.	O

The	O
point	O
mutations	O
in	O
MYO6	B-GENE
were	O
analysed	O
using	O
this	O
model	O
.	O

Fundus	O
examination	O
showed	O
attenuation	B-DISEASE
of	I-DISEASE
the	I-DISEASE
retinal	I-DISEASE
vessels	I-DISEASE
,	O
waxy	B-DISEASE
pallor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
nerve	I-DISEASE
head	I-DISEASE
,	O
and	O
bone	B-DISEASE
speckle	I-DISEASE
-	I-DISEASE
like	I-DISEASE
pigmentation	I-DISEASE
clumps	I-DISEASE
in	I-DISEASE
her	I-DISEASE
peripheral	I-DISEASE
retina	I-DISEASE
(	O
Figure	O
2	O
)	O
.	O

At	O
T0	O
,	O
CD164	B-GENE
was	O
present	O
at	O
the	O
plasma	O
membrane	O
in	O
both	O
cell	O
lines	O
,	O
as	O
expected	O
(	O
Fig	O
4A	O
and	O
4B	O
)	O
.	O

We	O
examined	O
LOH	O
patterns	O
indicating	O
retained	O
germline	O
missense	O
variants	O
in	O
BRCA1	B-GENE
Here	O
we	O
identified	O
two	O
known	O
pathogenic	O
missense	O
variants	O
,	O
G1788V	B-VARIANT
and	O
R1699W	B-VARIANT
31	O
(	O
Supplementary	O
Figure	O
4	O
)	O
;	O
R1699W	B-VARIANT
has	O
VAFs	O
of	O
42	O
%	O
and	O
79	O
%	O
and	O
G1788V	B-VARIANT
has	O
VAFs	O
of	O
57	O
%	O
and	O
98	O
%	O
in	O
the	O
germline	O
and	O
tumor	O
samples	O
,	O
respectively	O
.	O

2012	O
)	O
.	O

Unfortunately	O
,	O
no	O
mutation	O
was	O
found	O
in	O
any	O
candidate	O
(	O
the	O
pedigree	O
is	O
not	O
included	O
in	O
Figure	O
2	O
)	O
.	O

PRS	O
-	O
I	O
activity	O
was	O
not	O
detectable	O
in	O
erythrocytes	O
the	O
index	O
patient	O
II	O
-	O
2	O
(	O
<	O
0	O
.	O
005	O
nmol	O
/	O
[	O
min	O
.	O
mg	O
protein	O
]	O
;	O
reference	O
value	O
:	O
0	O
.	O
41	O
-	O
1	O
.	O
46	O
nmol	O
/	O
[	O
min	O
.	O
mg	O
protein	O
]	O
)	O
,	O
reduced	O
to	O
0	O
.	O
10	O
nmol	O
/	O
[	O
min	O
.	O
mg	O
protein	O
]	O
in	O
his	O
sister	O
(	O
II	O
-	O
1	O
)	O
,	O
and	O
normal	O
in	O
their	O
mother	O
(	O
I	O
-	O
1	O
;	O
1	O
.	O
04	O
nmol	O
/	O
[	O
min	O
.	O
mg	O
protein	O
]	O
)	O
(	O
Figure	O
1	O
B	O
)	O
.	O

F	O
-	O
actin	O
was	O
immuno	O
-	O
stained	O
with	O
Alexa	O
-	O
Fluor	O
-	O
647	O
-	O
phalloidin	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
;	O
1	O
:	O
500	O
)	O
.	O

These	O
results	O
,	O
once	O
more	O
,	O
confirmed	O
that	O
both	O
sequence	O
variations	O
correspond	O
to	O
non	O
-	O
pathogenic	O
polymorphisms	O
and	O
(	O
that	O
their	O
high	O
rates	O
)	O
represent	O
a	O
distinctive	O
feature	O
of	O
particular	O
Asian	O
populations	O
[	O
10	O
-	O
12	O
,	O
25	O
,	O
33	O
-	O
36	O
]	O
.	O

Thus	O
,	O
it	O
is	O
reasonable	O
for	O
us	O
to	O
explore	O
MPS	O
as	O
a	O
new	O
tool	O
for	O
this	O
purpose	O
.	O

2	O
.	O
7	O
.	O
5	O
)	O
software	O
(	O
http	O
:	O
/	O
/	O
rasmol	O
.	O
org	O
/	O
)	O
.	O

MED	B-DISEASE
patient	O
ESDN	O
-	O
00521	O
was	O
heterozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
500G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
which	O
is	O
predicted	O
to	O
result	O
in	O
a	O
p	B-VARIANT
.	I-VARIANT
Gly167Glu	I-VARIANT
substitution	O
in	O
the	O
second	O
EGF	O
-	O
like	O
repeat	O
of	O
COMP	B-GENE
.	O

Boxplot	O
for	O
average	O
mean	O
depth	O
.	O

Seven	O
to	O
ten	O
SNPs	O
were	O
selected	O
for	O
each	O
candidate	O
(	O
100	O
genes	O
in	O
total	O
)	O
,	O
and	O
genotyped	O
on	O
a	O
customized	O
Golden	O
Gate	O
Genotyping	O
Assay	O
(	O
Illumina	O
)	O
.	O

In	O
bold	O
:	O
Variants	O
not	O
previously	O
reported	O
.	O

A	O
gene	O
qualified	O
as	O
expressed	O
if	O
it	O
had	O
at	O
least	O
3	O
reads	O
in	O
at	O
least	O
70	O
%	O
of	O
samples	O
.	O

The	O
quality	O
of	O
the	O
reads	O
and	O
the	O
consensus	O
sequence	O
were	O
calculated	O
by	O
SOAPsnp	O
.	O

Click	O
here	O
for	O
file	O
Results	O
of	O
exome	O
sequencing	O
in	O
two	O
individuals	O
with	O
ARNSHL	B-DISEASE
.	O

Concerning	O
family	O
E5	O
,	O
most	O
recessive	O
RD	B-DISEASE
genes	O
were	O
discarded	O
under	O
the	O
assumption	O
of	O
claimed	O
consanguinity	O
(	O
I	O
.	O
1	O
and	O
I	O
.	O
2	O
)	O
,	O
and	O
the	O
rest	O
of	O
candidates	O
was	O
excluded	O
by	O
Sanger	O
sequencing	O
.	O

They	O
reported	O
that	O
the	O
overall	O
prevalence	O
of	O
cryptorchidism	B-DISEASE
was	O
50	O
%	O
and	O
this	O
was	O
bilateral	O
in	O
69	O
%	O
of	O
the	O
cases	O
.	O

Ocular	B-DISEASE
abnormalities	I-DISEASE
may	O
involve	O
the	O
cornea	O
,	O
iris	O
,	O
lens	O
,	O
or	O
retina	O
in	O
AS	B-DISEASE
[	O
2	O
,	O
4	O
]	O
,	O
among	O
which	O
anterior	B-DISEASE
lenticonus	I-DISEASE
and	O
the	O
dot	B-DISEASE
-	I-DISEASE
and	I-DISEASE
-	I-DISEASE
fleck	I-DISEASE
retinopathy	I-DISEASE
are	O
characteristic	O
of	O
AS	B-DISEASE
.	O

With	O
the	O
Roche	O
platform	O
,	O
90	O
%	O
of	O
the	O
target	O
exons	O
were	O
covered	O
more	O
than	O
15	O
-	O
fold	O
,	O
with	O
an	O
average	O
coverage	O
of	O
75	O
-	O
fold	O
per	O
sample	O
.	O

Wrote	O
the	O
paper	O
:	O
DLB	O
JGV	O
.	O

Array	O
CGH	O
similarly	O
shows	O
adequate	O
resolution	O
to	O
detect	O
a	O
45	O
kb	O
deletion	O
.	O

Specifically	O
,	O
there	O
were	O
238	O
cases	O
from	O
Guangdong	O
,	O
92	O
cases	O
from	O
Jiangxi	O
,	O
98	O
cases	O
from	O
Guangxi	O
,	O
96	O
cases	O
from	O
Fujian	O
,	O
98	O
cases	O
from	O
Hainan	O
,	O
and	O
79	O
cases	O
from	O
Hu	O
'	O
nan	O
.	O

To	O
increase	O
the	O
specificity	O
and	O
sensitivity	O
of	O
PCR	O
amplification	O
,	O
the	O
technique	O
of	O
touchdown	O
-	O
PCR	O
was	O
employed	O
:	O
one	O
cycle	O
at	O
95	O
deg	O
C	O
for	O
1	O
min	O
;	O
95	O
deg	O
C	O
for	O
30	O
s	O
,	O
62	O
deg	O
C	O
for	O
30	O
s	O
,	O
and	O
72	O
deg	O
C	O
for	O
45	O
s	O
,	O
followed	O
by	O
13	O
cycles	O
at	O
decreasing	O
annealing	O
temperatures	O
in	O
decrements	O
of	O
0	O
.	O
5	O
deg	O
C	O
;	O
21	O
cycles	O
of	O
95	O
deg	O
C	O
for	O
30	O
s	O
,	O
56	O
deg	O
C	O
for	O
30	O
s	O
,	O
and	O
72	O
deg	O
C	O
for	O
45	O
s	O
,	O
with	O
a	O
final	O
extension	O
at	O
72	O
deg	O
C	O
for	O
7	O
min	O
.	O

(	O
A	O
)	O
SDS	O
PAGE	O
followed	O
by	O
Western	O
Blot	O
of	O
fibroblast	O
cell	O
lysate	O
from	O
patient	O
II	O
.	O
1	O
does	O
not	O
show	O
lower	O
levels	O
of	O
mitochondrial	O
complex	O
I	O
(	O
COI	O
)	O
subunit	O
NDUFA13	B-GENE
(	O
Grim19	B-GENE
)	O
.	O

Her	O
best	O
-	O
corrected	O
visual	O
acuity	O
was	O
0	O
.	O
4	O
in	O
both	O
eyes	O
,	O
but	O
she	O
experienced	O
a	O
rapid	O
progression	O
of	O
visual	O
loss	O
in	O
the	O
last	O
year	O
.	O

Consistent	O
with	O
this	O
,	O
another	O
DGS	O
/	O
VCFS	O
locus	O
has	O
been	O
assigned	O
to	O
chromosome	O
10p13	O
-	O
14	O
region	O
[	O
9	O
]	O
.	O

The	O
residual	O
expression	O
of	O
wild	O
-	O
type	O
connection	B-GENE
-	I-GENE
26	I-GENE
encoded	O
by	O
these	O
transcripts	O
probably	O
underlies	O
the	O
mild	O
severity	O
and	O
late	O
onset	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
of	O
these	O
subjects	O
.	O

All	O
detected	O
mutations	O
result	O
in	O
a	O
truncated	O
protein	O
;	O
deleterious	O
missense	O
mutations	O
were	O
not	O
found	O
.	O

Table	O
S1	O
.	O

Family	O
structure	O
,	O
genetic	O
analysis	O
and	O
histological	O
features	O
.	O

All	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
parents	O
of	O
each	O
patient	O
and	O
control	O
.	O

With	O
respect	O
to	O
vestibular	O
function	O
,	O
one	O
subject	O
had	O
reduced	O
gain	O
of	O
the	O
vestibulo	O
-	O
ocular	O
reflex	O
to	O
steps	O
of	O
angular	O
acceleration	O
and	O
reduced	O
gain	O
and	O
increased	O
low	O
-	O
frequency	O
phase	O
lead	O
on	O
sinusoidal	O
harmonic	O
testing	O
over	O
the	O
range	O
0	O
.	O
025	O
-	O
0	O
.	O
5	O
Hz	O
.	O

Mutations	O
in	O
USH2A	B-GENE
account	O
for	O
over	O
70	O
%	O
of	O
cases	O
affected	O
with	O
USH	B-DISEASE
type	I-DISEASE
2	I-DISEASE
.	O

Ninety	O
-	O
two	O
35delG	B-VARIANT
heterozygotes	O
and	O
2	O
35delG	B-VARIANT
homozygotes	O
were	O
identified	O
,	O
resulting	O
in	O
a	O
carrier	O
frequency	O
of	O
1	O
/	O
66	O
(	O
1	O
.	O
53	O
%	O
)	O
for	O
35delG	B-VARIANT
.	O

Macular	B-DISEASE
hole	I-DISEASE
accompanied	O
with	O
both	O
anterior	O
and	O
posterior	B-DISEASE
lenticonus	I-DISEASE
has	O
not	O
previously	O
been	O
reported	O
.	O

The	O
location	O
of	O
the	O
AIFM1	B-GENE
gene	O
is	O
indicated	O
(	O
Mb	O
,	O
million	O
bps	O
)	O
.	O

Complex	O
I	O
(	O
CI	O
)	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
is	O
a	O
large	O
~	O
1MDa	O
macromolecular	O
machine	O
composed	O
of	O
45	O
protein	O
subunits	O
encoded	O
by	O
both	O
the	O
nuclear	O
and	O
mitochondrial	O
(	O
mtDNA	O
)	O
genomes	O
.	O

At	O
2	O
years	O
of	O
age	O
concerns	O
about	O
visual	O
development	O
and	O
a	O
very	O
pale	O
fundal	O
reflex	O
led	O
to	O
referral	O
for	O
investigation	O
of	O
a	O
possible	O
retinal	B-DISEASE
dystrophy	I-DISEASE
.	O

We	O
developed	O
in	O
-	O
house	O
software	O
called	O
"	O
GS	O
data	O
online	O
treatment	O
"	O
(	O
GSdot	O
)	O
,	O
available	O
at	O
https	O
:	O
/	O
/	O
neuro	O
-	O
2	O
.	O
iurc	O
.	O
montp	O
.	O
inserm	O
.	O
fr	O
/	O
454	O
/	O
to	O
automate	O
the	O
calculations	O
and	O
filters	O
described	O
above	O
.	O

Two	O
missense	O
changes	O
were	O
identified	O
,	O
p	B-VARIANT
.	I-VARIANT
E1611A	I-VARIANT
(	O
located	O
in	O
exon	O
35	O
,	O
CD2	O
)	O
and	O
p	B-VARIANT
.	I-VARIANT
Q1654P	I-VARIANT
(	O
exon	O
36	O
,	O
CD3	O
)	O
.	O

This	O
would	O
suggest	O
that	O
there	O
are	O
forms	O
of	O
familial	B-DISEASE
hip	I-DISEASE
dysplasia	I-DISEASE
,	O
variably	O
described	O
in	O
the	O
literature	O
as	O
Meyer	B-DISEASE
'	I-DISEASE
s	I-DISEASE
disease	I-DISEASE
(	O
dysplasia	B-DISEASE
epiphysealis	I-DISEASE
capitis	I-DISEASE
femoris	I-DISEASE
)	O
,	O
familial	B-DISEASE
hip	I-DISEASE
dysplasia	I-DISEASE
(	O
Beukes	O
)	O
,	O
and	O
bilateral	B-DISEASE
LCPD	I-DISEASE
,	O
that	O
are	O
genetically	O
distinct	O
from	O
the	O
classical	O
forms	O
of	O
MED	B-DISEASE
and	O
do	O
not	O
result	O
from	O
mutations	O
in	O
COMP	B-GENE
,	O
MATN3	B-GENE
,	O
or	O
type	B-GENE
IX	I-GENE
collagen	I-GENE
.	O

A	O
total	O
of	O
4	O
genetic	O
variants	O
in	O
the	O
EYA4	B-GENE
gene	O
were	O
identified	O
,	O
including	O
the	O
2	O
nonsense	O
mutations	O
p	B-VARIANT
.	I-VARIANT
S288X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Q393X	I-VARIANT
.	O

The	O
red	O
square	O
indicates	O
the	O
location	O
of	O
the	O
deletion	O
and	O
missense	O
mutation	O
we	O
identified	O
in	O
OPA1	B-GENE
(	O
B	O
)	O
Alpha	O
helical	O
structure	O
of	O
OPA1	B-GENE
.	O

In	O
contrast	O
,	O
the	O
CLRN1	B-GENE
mutants	O
showed	O
reduced	O
stability	O
.	O

In	O
family	O
5	O
,	O
double	O
heterozygous	O
mutations	O
of	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
were	O
detected	O
as	O
a	O
candidate	O
cause	O
.	O

For	O
each	O
high	O
-	O
confidence	O
interacting	O
protein	O
,	O
a	O
two	O
-	O
tailed	O
one	O
-	O
sample	O
t	O
-	O
test	O
was	O
performed	O
on	O
the	O
spectral	O
count	O
ratios	O
(	O
MUT	O
/	O
WT	O
)	O
.	O

Neither	O
the	O
maternal	O
grandparents	O
nor	O
the	O
uncle	O
of	O
the	O
proband	O
had	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

The	O
audiograms	O
at	O
age	O
31	O
and	O
at	O
age	O
35	O
were	O
similar	O
,	O
with	O
40	O
dB	O
HL	O
at	O
500	O
Hz	O
,	O
increasing	O
to	O
70	O
dB	O
HL	O
at	O
the	O
frequencies	O
1000	O
-	O
4000	O
Hz	O
,	O
and	O
improving	O
to	O
20	O
dB	O
HL	O
at	O
8000	O
Hz	O
(	O
Fig	O
1B	O
)	O
.	O

TCGA	O
ovarian	B-DISEASE
cancer	I-DISEASE
cases	O
were	O
classified	O
with	O
respect	O
to	O
ancestry	O
using	O
their	O
SNP	O
array	O
data	O
4	O
and	O
the	O
multi	O
-	O
dimensional	O
scaling	O
(	O
MDS	O
)	O
analysis	O
program	O
in	O
PLINK	O
.	O

The	O
notion	O
of	O
a	O
continuous	O
disease	O
spectrum	O
of	O
PRS1	B-DISEASE
-	I-DISEASE
hypoactivity	I-DISEASE
disorders	I-DISEASE
is	O
further	O
supported	O
by	O
our	O
observation	O
that	O
a	O
CMTX5	B-DISEASE
/	O
Arts	B-GENE
overlapping	O
phenotype	O
can	O
co	O
-	O
occur	O
within	O
the	O
same	O
family	O
as	O
a	O
DFN2	B-DISEASE
phenotype	O
(	O
subject	O
II	O
-	O
1	O
)	O
,	O
demonstrating	O
an	O
intrafamilial	O
continuum	O
of	O
these	O
three	O
clusters	O
of	O
PRS	O
-	O
I	O
hypoactivity	O
diseases	O
.	O

The	O
second	O
most	O
frequent	O
mutation	O
is	O
the	O
insertion	O
2097_2098insT	B-VARIANT
leading	O
to	O
a	O
frameshift	O
and	O
nonsense	O
mutation	O
after	O
I700	O
[	O
9	O
,	O
18	O
]	O
.	O

We	O
used	O
ABI	O
SOLiD	O
optimized	O
kits	O
(	O
Agilent	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
,	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
pathogenicity	O
of	O
novel	O
missense	O
variants	O
was	O
analyzed	O
with	O
the	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
bii	O
.	O
a	O
-	O
star	O
.	O
edu	O
.	O
sg	O
/	O
)	O
and	O
PolyPhen	O
-	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
algorithms	O
.	O

Park	O
)	O
,	O
and	O
by	O
the	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
Research	O
Fund	O
04	O
-	O
2010	O
-	O
003	O
(	O
to	O
B	O
.	O
Y	O
.	O

Use	O
of	O
the	O
pre	B-DISEASE
-	I-DISEASE
term	I-DISEASE
cohort	O
,	O
with	O
34	O
%	O
of	O
the	O
genomes	O
from	O
parents	O
of	O
a	O
pre	B-DISEASE
-	I-DISEASE
term	I-DISEASE
baby	O
,	O
could	O
introduce	O
bias	O
if	O
variation	O
in	O
the	O
cancer	O
-	O
predisposition	O
genes	O
influences	O
prematurity	O
.	O

They	O
are	O
classified	O
as	O
hypomyelinating	B-DISEASE
and	I-DISEASE
non	I-DISEASE
-	I-DISEASE
hypomyelinating	I-DISEASE
leukodystrophies	I-DISEASE
based	O
on	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
characteristics	O
2	O
,	O
depending	O
on	O
whether	O
the	O
principal	O
problem	O
appears	O
to	O
be	O
a	O
lack	O
of	O
myelin	O
deposition	O
during	O
development	O
or	O
altered	O
myelin	O
homeostasis	O
.	O

wt	O
:	O
wild	O
-	O
type	O
.	O

However	O
,	O
due	O
to	O
difficulties	O
to	O
collect	O
large	O
samples	O
for	O
such	O
a	O
rare	O
disease	O
,	O
our	O
results	O
may	O
be	O
useful	O
for	O
future	O
meta	O
-	O
analyses	O
that	O
will	O
combine	O
genetic	O
data	O
provided	O
by	O
other	O
individual	O
studies	O
.	O

Gaps	O
are	O
marked	O
with	O
a	O
dot	O
.	O

Panels	O
A	O
and	O
B	O
are	O
of	O
fundus	O
photos	O
showing	O
a	O
normal	O
-	O
looking	O
macula	O
and	O
an	O
abnormally	B-DISEASE
mottled	I-DISEASE
retinal	I-DISEASE
pigment	I-DISEASE
epithelium	I-DISEASE
in	I-DISEASE
the	I-DISEASE
periphery	I-DISEASE
.	O

Pierides	O
.	O

His	O
pedigree	O
was	O
compatible	O
with	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

We	O
would	O
like	O
to	O
thank	O
the	O
patients	O
and	O
their	O
families	O
for	O
their	O
collaboration	O
.	O

(	O
A	O
-	O
C	O
)	O
Immunolabeling	O
for	O
F	O
-	O
actin	O
(	O
A	O
)	O
and	O
EPS8	B-GENE
(	O
B	O
)	O
in	O
the	O
mouse	O
cochlea	O
.	O

Approximately	O
one	O
-	O
half	O
of	O
the	O
OPA1	B-GENE
mutations	O
lead	O
to	O
premature	O
termination	O
codons	O
from	O
nonsense	O
mutations	O
or	O
frameshifts	O
from	O
small	O
insertions	O
,	O
deletions	O
,	O
or	O
splice	O
site	O
mutations	O
[	O
45	O
]	O
.	O

Despite	O
previous	O
intensive	O
linkage	O
analysis	O
and	O
candidate	O
gene	O
screening	O
,	O
a	O
large	O
proportion	O
of	O
ARNSHL	B-DISEASE
remain	O
genetically	O
unexplained	O
.	O

5	O
6	O
PAX3	B-GENE
mutations	O
associated	O
with	O
WS1	B-DISEASE
include	O
substitutions	O
of	O
conserved	O
amino	O
acids	O
in	O
the	O
paired	O
domain	O
or	O
the	O
homeodomain	O
of	O
the	O
protein	O
,	O
splice	O
site	O
mutations	O
,	O
non	O
-	O
sense	O
mutations	O
and	O
insertions	O
or	O
deletions	O
leading	O
to	O
frame	O
shifts	O
.	O

1987	O
)	O
.	O

Examination	O
of	O
the	O
family	O
members	O
included	O
a	O
medical	O
history	O
guided	O
by	O
a	O
questionnaire	O
,	O
otoscopy	O
,	O
pure	O
tone	O
audiometry	O
,	O
and	O
drawing	O
blood	O
samples	O
for	O
DNA	O
isolation	O
.	O

This	O
mutation	O
causes	O
a	O
frameshift	O
and	O
extension	O
of	O
the	O
protein	O
beyond	O
the	O
normal	O
stopcodon	O
(	O
p	B-VARIANT
.	I-VARIANT

Our	O
initial	O
cohort	O
was	O
assembled	O
as	O
part	O
of	O
an	O
ongoing	O
epidemiological	O
study	O
of	O
inherited	O
optic	O
neuropathies	O
in	O
the	O
North	O
of	O
England	O
.	O

French	O
Canadian	O
subjects	O
from	O
Quebec	O
with	O
USH1	B-DISEASE
were	O
identified	O
through	O
the	O
McGill	O
Ocular	O
Genetics	O
Laboratory	O
,	O
Montreal	O
Children	O
'	O
s	O
Hospital	O
Research	O
Institute	O
,	O
McGill	O
University	O
Health	O
Center	O
,	O
Montreal	O
,	O
Quebec	O
,	O
Canada	O
(	O
see	O
Additional	O
data	O
file	O
4	O
for	O
precise	O
origin	O
of	O
each	O
patient	O
)	O
.	O

Each	O
proband	O
carried	O
4	O
.	O
8	O
variants	O
that	O
were	O
not	O
synonymous	O
and	O
had	O
the	O
occurring	O
frequency	O
of	O
less	O
than	O
three	O
among	O
the	O
20	O
probands	O
.	O

Multiple	O
mutations	O
responsible	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
identified	O
by	O
the	O
combination	O
of	O
targeted	O
capture	O
and	O
MPS	O
technology	O
.	O

Kerns	O
and	O
H	O
.	O

is	O
a	O
recipient	O
of	O
a	O
fellowship	O
from	O
the	O
Spanish	O
Ministry	O
of	O
Education	O
(	O
Ref	O
:	O
AP2008	O
-	O
02760	O
)	O
.	O

The	O
present	O
analysis	O
confirms	O
these	O
results	O
by	O
showing	O
a	O
major	O
implication	O
of	O
MYO7A	B-GENE
in	O
USH1	B-DISEASE
(	O
55	O
%	O
of	O
the	O
cases	O
)	O
,	O
and	O
of	O
USH2A	B-GENE
in	O
USH2	B-DISEASE
(	O
62	O
%	O
of	O
the	O
cases	O
)	O
.	O

We	O
obtained	O
a	O
highly	O
heterogeneous	O
coverage	O
using	O
a	O
custom	O
HaloPlex	O
Target	O
Enrichment	O
System	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Among	O
subjects	O
selected	O
for	O
RYR2	B-GENE
screening	O
(	O
n	O
=	O
36	O
)	O
the	O
average	O
QTc	O
was	O
432	O
ms	O
(	O
range	O
347	O
-	O
477	O
ms	O
)	O
,	O
of	O
which	O
five	O
of	O
them	O
had	O
a	O
QTc	O
prolongation	O
>	O
460	O
ms	O
(	O
25	O
available	O
ECG	O
)	O
.	O

Treatment	O
histories	O
and	O
testicular	O
volumes	O
,	O
sex	O
hormone	O
and	O
gonadotropin	O
levels	O
at	O
the	O
diagnosis	O
of	O
HH	B-DISEASE
and	O
after	O
TRT	O
pause	O
in	O
these	O
6	O
probands	O
with	O
HH	B-DISEASE
reversal	O
are	O
summarized	O
in	O
Figure	O
2	O
and	O
Table	O
1	O
.	O

4	O
In	O
contrast	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
,	O
which	O
results	O
from	O
a	O
c	B-VARIANT
.	I-VARIANT
1190	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
transversion	O
in	O
the	O
KCNQ1	B-GENE
gene	O
(	O
Figure	O
1	O
A	O
)	O
,	O
was	O
predicted	O
to	O
be	O
probably	O
damaging	O
or	O
disease	O
-	O
related	O
and	O
therefore	O
,	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

A	O
further	O
seven	O
had	O
both	O
RP	B-DISEASE
and	O
hearing	B-DISEASE
loss	I-DISEASE
which	O
were	O
considered	O
atypical	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
.	O

Among	O
the	O
clinically	O
documented	O
patients	O
(	O
n	O
=	O
44	O
)	O
,	O
HL	B-DISEASE
was	O
severe	O
to	O
profound	O
in	O
32	O
patients	O
,	O
moderate	O
in	O
10	O
,	O
and	O
mild	O
in	O
2	O
patients	O
.	O

Solid	O
histograms	O
(	O
black	O
)	O
show	O
marker	O
expression	O
;	O
open	O
histograms	O
(	O
grey	O
)	O
show	O
no	O
marker	O
expression	O
.	O

CDH23	B-GENE
is	O
expressed	O
in	O
the	O
outer	O
and	O
inner	O
hair	O
cells	O
.	O

Zhou	O
unpublished	O
data	O
)	O
.	O

3	O
)	O
.	O

Temporal	O
computed	O
tomography	O
(	O
CT	O
)	O
examination	O
was	O
conducted	O
in	O
664	O
patients	O
.	O

DNA	O
was	O
not	O
available	O
for	O
screening	O
of	O
all	O
five	O
genes	O
in	O
some	O
of	O
the	O
individuals	O
,	O
and	O
therefore	O
it	O
is	O
possible	O
that	O
some	O
double	O
mutations	O
might	O
have	O
been	O
missed	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
DM	O
QHX	O
LH	O
QLL	O
XZZ	O
LJ	O
.	O

Variants	O
(	O
SNPs	O
and	O
indels	O
)	O
were	O
called	O
with	O
vcftools	O
of	O
SAMTools	O
software	O
[	O
25	O
]	O
,	O
and	O
SNPs	O
with	O
a	O
read	O
coverage	O
>	O
=	O
4	O
x	O
and	O
quality	O
score	O
>	O
=	O
20	O
x	O
were	O
considered	O
in	O
the	O
initial	O
analysis	O
.	O

The	O
BLAST	O
protein	O
algorithm	O
(	O
http	O
:	O
/	O
/	O
blast	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
Blast	O
.	O
cgi	O
)	O
was	O
also	O
used	O
to	O
search	O
for	O
homologies	O
of	O
the	O
tail	O
,	O
but	O
did	O
not	O
detect	O
any	O
significant	O
hit	O
in	O
Eukaryotes	O
.	O

a	O
N	O
for	O
each	O
combination	O
of	O
two	O
reported	O
characteristics	O
for	O
all	O
combinations	O
.	O

Defects	O
in	O
these	O
genes	O
have	O
previously	O
been	O
described	O
to	O
cause	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

may	O
have	O
been	O
related	O
to	O
a	O
similar	O
error	O
in	O
interpretation	O
.	O

Y4801X	I-VARIANT
)	O
detected	O
in	O
patient	O
019092	O
.	O

2009	O
)	O
.	O

However	O
,	O
the	O
missense	O
mutations	O
p	B-VARIANT
.	I-VARIANT

The	O
incidence	O
of	O
WS	B-DISEASE
is	O
around	O
1	O
in	O
42	O
,	O
000	O
in	O
the	O
general	O
population	O
.	O

Fundus	O
examination	O
of	O
patient	O
II	O
:	O
5	O
showed	O
typical	O
signs	O
of	O
RP	B-DISEASE
with	O
intraretinal	O
bone	O
spicule	O
-	O
like	O
pigment	O
formation	O
and	O
preserved	O
posterior	O
pole	O
.	O

For	O
example	O
,	O
the	O
mutation	O
detection	O
rates	O
in	O
the	O
Tibetan	O
population	O
and	O
minorities	O
in	O
the	O
Southwest	O
region	O
and	O
Uygur	O
populations	O
were	O
significantly	O
lower	O
than	O
that	O
in	O
the	O
Han	O
,	O
Hui	O
and	O
Mongolian	O
populations	O
.	O

One	O
male	O
(	O
IV	O
-	O
5	O
)	O
,	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
first	O
diagnosed	O
at	O
about	O
age	O
10	O
y	O
,	O
was	O
examined	O
several	O
times	O
.	O

She	O
presented	O
the	O
distinctive	O
mannerism	O
of	O
repetitively	O
waving	O
her	O
hand	O
whenever	O
emotionally	O
disturbed	O
.	O

The	O
family	O
was	O
screened	O
for	O
copy	O
number	O
variations	O
(	O
CNVs	O
)	O
using	O
Illumina	O
-	O
HumanOmni2	O
.	O
5	O
-	O
Beadchip	O
and	O
for	O
coding	O
sequence	O
mutations	O
in	O
WS4	B-DISEASE
genes	O
(	O
EDN3	B-GENE
,	O
EDNRB	B-GENE
,	O
or	O
SOX10	B-GENE
)	O
and	O
in	O
the	O
main	O
HSCR	B-DISEASE
gene	O
(	O
RET	B-GENE
)	O
.	O

In	O
one	O
pool	O
,	O
for	O
example	O
,	O
96	O
%	O
of	O
the	O
mtDNA	O
came	O
from	O
a	O
single	O
patient	O
.	O

Similarly	O
,	O
the	O
V37I	B-VARIANT
variation	O
does	O
not	O
show	O
any	O
significant	O
difference	O
in	O
frequency	O
between	O
the	O
general	O
and	O
deaf	O
populations	O
.	O

Oligo	O
sequences	O
are	O
listed	O
in	O
S3	O
Table	O
.	O

There	O
were	O
five	O
large	O
deletions	O
and	O
one	O
duplication	O
that	O
could	O
only	O
be	O
detected	O
by	O
MLPA	O
analysis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
frequent	O
disease	O
-	O
causing	O
gene	O
mutations	O
in	O
autosomal	B-DISEASE
recessive	I-DISEASE
retinitis	I-DISEASE
pigmentosa	I-DISEASE
(	O
arRP	B-DISEASE
)	O
in	O
the	O
Japanese	O
population	O
.	O

Original	O
magnifications	O
:	O
a	O
x	O
400	O
;	O
c	O
x	O
5	O
,	O
000	O
;	O
and	O
d	O
x	O
12	O
,	O
000	O
An	O
MRI	O
revealed	O
hyperintense	O
signal	O
abnormalities	O
in	O
the	O
brains	O
of	O
both	O
patients	O
(	O
Fig	O
.	O

Fig	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
demonstrate	O
that	O
a	O
KS	B-DISEASE
patient	O
with	O
a	O
truncating	O
CHD7	B-GENE
mutation	O
can	O
undergo	O
reversal	O
of	O
hypogonadotropism	B-DISEASE
.	O

It	O
appeared	O
to	O
slowly	O
progress	O
,	O
and	O
by	O
age	O
25	O
she	O
suffered	O
inconvenience	O
in	O
hearing	O
and	O
communication	O
.	O

He	O
received	O
a	O
diagnosis	O
of	O
diabetes	B-DISEASE
mellitus	I-DISEASE
type	I-DISEASE
1	I-DISEASE
when	O
he	O
was	O
5	O
years	O
old	O
.	O

Amplicons	O
were	O
inserted	O
in	O
the	O
pSPL3	O
exon	O
-	O
trapping	O
vector	O
between	O
the	O
Not	O
I	O
and	O
Xho	O
I	O
restriction	O
sites	O
and	O
the	O
constructs	O
were	O
transfected	O
in	O
a	O
human	O
retinal	O
pigment	O
epithelial	O
cells	O
line	O
(	O
ARPE	O
-	O
19	O
)	O
as	O
previously	O
described	O
(	O
Gu	O
e	O
dard	O
-	O
M	O
e	O
reuze	O
et	O
al	O
.	O

List	O
of	O
131	O
Deafness	B-DISEASE
genes	O
.	O

The	O
sequence	O
data	O
were	O
processed	O
with	O
standard	O
Ion	O
Torrent	O
Suite	O
(	O
tm	O
)	O
Software	O
and	O
Torrent	O
Server	O
successively	O
mapped	O
to	O
human	O
genome	O
sequence	O
(	O
build	O
GRCh37	O
/	O
hg19	O
)	O
with	O
Torrent	O
Mapping	O
Alignment	O
Program	O
optimized	O
to	O
Ion	O
Torrent	O
(	O
tm	O
)	O
data	O
.	O

2010	O
)	O
and	O
that	O
did	O
not	O
have	O
an	O
effect	O
on	O
the	O
protein	O
level	O
were	O
removed	O
.	O

Although	O
analysis	O
for	O
these	O
mutations	O
should	O
be	O
performed	O
to	O
identify	O
the	O
molecular	O
nature	O
of	O
deafness	B-DISEASE
as	O
the	O
first	O
deafness	B-DISEASE
screening	O
step	O
,	O
a	O
different	O
strategy	O
may	O
be	O
necessary	O
for	O
screening	O
for	O
them	O
.	O

Interspecies	O
conservation	O
of	O
amino	O
acid	O
residues	O
mutated	O
in	O
patients	O
carrying	O
presumably	O
pathogenic	O
mutations	O
in	O
several	O
USH	B-DISEASE
genes	O
.	O

(	O
a	O
)	O
Western	O
blot	O
of	O
cochlear	O
tissues	O
from	O
guinea	O
pigs	O
.	O

In	O
the	O
inner	O
ear	O
,	O
TJs	O
are	O
essential	O
for	O
the	O
maintenance	O
of	O
compartmentalization	O
and	O
modulation	O
of	O
intercellular	O
permeability	O
[	O
25	O
-	O
]	O
,	O
both	O
of	O
which	O
are	O
required	O
for	O
normal	O
functioning	O
of	O
the	O
organ	O
of	O
Corti	O
.	O

He	O
had	O
normal	O
speech	O
acquisition	O
and	O
normal	O
motor	O
milestones	O
(	O
he	O
started	O
gait	O
at	O
9	O
months	O
old	O
)	O
.	O

8	O
)	O
,	O
with	O
a	O
detrimental	O
effect	O
on	O
the	O
ability	O
of	O
the	O
Opa1	B-GENE
protein	O
to	O
form	O
oligomers	O
,	O
which	O
is	O
critical	O
for	O
its	O
normal	O
function	O
.	O

At	O
cellular	O
level	O
,	O
this	O
behavior	O
agrees	O
with	O
previous	O
knowledge	O
according	O
to	O
which	O
the	O
proper	O
chain	O
folding	O
and	O
protein	O
quality	O
control	O
commence	O
immediately	O
after	O
the	O
entry	O
of	O
the	O
nascent	O
polypeptide	O
chain	O
in	O
the	O
ER	O
,	O
exiting	O
the	O
ribosomal	O
complex	O
.	O

Table	O
3	O
Details	O
of	O
final	O
candidates	O
from	O
eleven	O
deaf	O
subjects	O
molecular	O
genetically	O
diagnosed	O
and	O
three	O
subjects	O
with	O
only	O
one	O
mutant	O
allele	O
of	O
recessive	O
genes	O
after	O
targeted	O
exome	O
sequencing	O
of	O
204	O
deafness	B-DISEASE
genes	O
*	B-VARIANT
rs1219083	I-VARIANT
(	O
flagged	O
)	O
;	O
SS	O
rs121908349	B-VARIANT
(	O
flagged	O
)	O
.	O

Although	O
study	O
participants	O
were	O
counselled	O
primarily	O
for	O
NSHL	B-DISEASE
,	O
additional	O
symptoms	O
were	O
found	O
in	O
a	O
limited	O
minority	O
.	O

Identification	O
of	O
the	O
genetic	O
defects	O
in	O
patients	O
is	O
currently	O
labor	O
intensive	O
and	O
expensive	O
.	O

We	O
particularly	O
thank	O
the	O
families	O
and	O
individuals	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
for	O
their	O
time	O
and	O
support	O
.	O

BDP1	B-GENE
expression	O
has	O
been	O
reported	O
in	O
many	O
different	O
tissues	O
(	O
see	O
UniGene	O
/	O
ESTProfile	O
database	O
)	O
,	O
but	O
in	O
this	O
case	O
the	O
abnormality	O
of	O
the	O
protein	O
apparently	O
affects	O
only	O
the	O
auditory	O
system	O
.	O

The	O
preferential	O
involvement	O
of	O
the	O
anterior	O
lens	O
capsule	O
in	O
AS	B-DISEASE
remains	O
to	O
be	O
investigated	O
.	O

The	O
popularity	O
of	O
aCGH	O
in	O
prenatal	O
diagnostics	O
is	O
increasing	O
.	O

This	O
step	O
has	O
been	O
automated	O
with	O
GSdot	O
software	O
.	O

Phylogenetic	O
alignments	O
for	O
the	O
novel	O
missense	O
mutations	O
are	O
presented	O
in	O
Additional	O
file	O
1	O
,	O
showing	O
that	O
the	O
mutations	O
affected	O
highly	O
conserved	O
residues	O
.	O

HSD17B4	B-GENE
,	O
also	O
known	O
as	O
D	O
-	O
bifunctional	O
protein	O
(	O
DBP	O
)	O
,	O
is	O
a	O
peroxisomal	O
enzyme	O
that	O
catalyzes	O
multiple	O
steps	O
of	O
beta	O
-	O
oxidation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
.	O

One	O
of	O
the	O
EYS	B-GENE
variants	O
(	O
c	B-VARIANT
.	I-VARIANT
7558T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
F2520L	I-VARIANT
)	O
disrupts	O
the	O
second	O
laminin	O
G	O
subdomain	O
which	O
is	O
essential	O
for	O
normal	O
protein	O
function	O
[	O
20	O
]	O
.	O

Informed	O
written	O
consent	O
of	O
minors	O
was	O
obtained	O
from	O
their	O
guardians	O
.	O

We	O
amplified	O
a	O
346	O
-	O
bp	O
fragment	O
from	O
exon	O
14	O
to	O
exon	O
17	O
of	O
MYO7A	B-GENE
in	O
a	O
healthy	O
control	O
individual	O
.	O

In	O
this	O
regard	O
,	O
comparison	O
between	O
group	O
1	O
with	O
hypocalcemia	B-DISEASE
and	O
group	O
2	O
without	O
hypocalcemia	B-DISEASE
revealed	O
a	O
large	O
number	O
of	O
non	O
-	O
synonymous	O
and	O
synonymous	O
variants	O
that	O
exclusively	O
belonged	O
to	O
either	O
group	O
1	O
(	O
Table	O
S4	O
)	O
or	O
group	O
2	O
(	O
Table	O
S5	O
)	O
,	O
although	O
the	O
lists	O
did	O
not	O
contain	O
a	O
c	B-VARIANT
.	I-VARIANT
2968A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R990G	I-VARIANT
)	O
SNP	O
in	O
CASR	B-GENE
(	O
calcium	O
sensing	O
receptor	O
)	O
that	O
has	O
a	O
gain	O
-	O
of	O
-	O
function	O
effect	O
and	O
appears	O
to	O
raise	O
the	O
susceptibility	O
to	O
hypocalcemia	B-DISEASE
(	O
Fig	O
.	O

In	O
the	O
MYO1A	B-GENE
gene	O
,	O
we	O
identified	O
one	O
variant	O
with	O
a	O
G	O
to	O
A	O
substitution	O
at	O
nucleotide	O
position	O
1630	O
(	O
c	B-VARIANT
.	I-VARIANT
1630	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
in	O
patient	O
FTM	O
-	O
01	O
.	O

Of	O
course	O
,	O
it	O
is	O
possible	O
that	O
genes	O
that	O
fell	O
within	O
the	O
low	O
-	O
or	O
no	O
-	O
coverage	O
region	O
on	O
whole	O
-	O
exome	O
sequencing	O
might	O
harbor	O
a	O
causative	O
variant	O
.	O

The	O
average	O
number	O
of	O
variants	O
was	O
4	O
.	O
8	O
+	O
-	O
0	O
.	O
42	O
per	O
patient	O
after	O
basic	O
filtering	O
.	O

Altogether	O
,	O
the	O
yield	O
of	O
diagnostic	O
testing	O
has	O
remained	O
disappointingly	O
low	O
for	O
RP	B-DISEASE
patients	O
,	O
despite	O
many	O
important	O
disease	O
gene	O
discoveries	O
in	O
the	O
last	O
two	O
decades	O
[	O
Berger	O
et	O
al	O
.	O
,	O
2010	O
]	O
.	O

Thirty	O
-	O
three	O
of	O
the	O
37	O
mutations	O
detected	O
were	O
novel	O
.	O

HEK	O
-	O
293	O
cells	O
were	O
transiently	O
transfected	O
with	O
either	O
WT	O
or	O
mutant	O
KCNQ1	B-GENE
clones	O
using	O
Lipofectamine	O
2000	O
.	O

Without	O
a	O
substantial	O
increase	O
of	O
the	O
number	O
of	O
the	O
sequencing	O
reads	O
and	O
hence	O
of	O
the	O
sequencing	O
costs	O
/	O
sample	O
,	O
the	O
whole	O
exome	O
approach	O
can	O
be	O
insufficient	O
for	O
USH	B-DISEASE
diagnosis	O
.	O

None	O
of	O
the	O
members	O
had	O
sensorineural	B-DISEASE
deafness	I-DISEASE
.	O

In	O
conclusion	O
,	O
our	O
study	O
analyzes	O
for	O
the	O
first	O
time	O
the	O
WFS1	B-GENE
gene	O
status	O
in	O
a	O
Latin	O
American	O
family	O
with	O
WS	B-DISEASE
and	O
adds	O
to	O
the	O
mutational	O
spectrum	O
of	O
the	O
disease	O
.	O

Mutations	O
in	O
PCDH15	B-GENE
are	O
responsible	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
(	O
USH1F	B-GENE
)	O
and	O
DFNB23	B-DISEASE
.	O

The	O
mutations	O
detected	O
in	O
kindred	O
L151	O
.	O

Bockenhauer	O
(	O
London	O
)	O
,	O
H	O
.	O

Classically	O
,	O
microsatellite	O
markers	O
have	O
been	O
used	O
for	O
linkage	O
analysis	O
,	O
and	O
now	O
millions	O
of	O
dimorphic	O
SNP	O
markers	O
can	O
be	O
used	O
to	O
provide	O
higher	O
resolution	O
in	O
order	O
to	O
pinpoint	O
candidate	O
loci	O
[	O
8	O
]	O
.	O

Cell	O
cultures	O
,	O
expression	O
of	O
chimeras	O
and	O
microscopy	O
were	O
carried	O
out	O
as	O
previously	O
described	O
[	O
12	O
]	O
.	O

Pedigree	O
of	O
JSNY	O
-	O
023	O
.	O

(	O
B	O
and	O
C	O
)	O
IF	O
blood	O
smears	O
(	O
n	O
=	O
79	O
,	O
positive	O
73	O
)	O
.	O

7	O
)	O
.	O

Some	O
RNA	B-DISEASE
polymerase	I-DISEASE
(	I-DISEASE
POLR	I-DISEASE
)	I-DISEASE
3	I-DISEASE
-	I-DISEASE
related	I-DISEASE
leukodystrophy	I-DISEASE
cases	O
do	O
not	O
have	O
the	O
causal	O
mutations	O
in	O
POLR3A	B-GENE
and	O
POLR3B	B-GENE
.	O

The	O
arrow	O
shows	O
site	O
of	O
the	O
novel	O
c	B-VARIANT
.	I-VARIANT
499delC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro167Gln	I-VARIANT
fs	I-VARIANT
*	I-VARIANT
36	I-VARIANT
)	O
deletion	O
mutation	O
in	O
the	O
COL4A5	B-GENE
gene	O
.	O

The	O
frequency	O
of	O
patients	O
with	O
single	O
mutations	O
in	O
ABCA4	B-GENE
is	O
higher	O
than	O
controls	O
,	O
indicating	O
these	O
mutations	O
contribute	O
to	O
disease	O
.	O

Gene	O
numbers	O
in	O
brackets	O
include	O
additionally	O
screened	O
candidate	O
genes	O
that	O
are	O
not	O
yet	O
proven	O
retinal	O
disease	O
genes	O
.	O

lupus	O
familiaris	O
,	O
XP_003433659	O
.	O
1	O
.	O

34	O
members	O
,	O
including	O
13	O
deaf	O
(	O
III	O
:	O
2	O
,	O
III	O
:	O
12	O
,	O
III	O
:	O
15	O
,	O
III	O
:	O
17	O
,	O
III	O
:	O
19	O
,	O
IV	O
:	O
13	O
,	O
IV	O
:	O
16	O
,	O
IV	O
:	O
22	O
,	O
IV	O
:	O
24	O
,	O
IV	O
:	O
26	O
,	O
IV	O
:	O
31	O
,	O
V	O
:	O
10	O
and	O
V	O
:	O
13	O
)	O
,	O
17	O
normal	O
hearing	O
(	O
II	O
:	O
8	O
,	O
III	O
:	O
4	O
,	O
III	O
:	O
6	O
,	O
III	O
:	O
8	O
,	O
III	O
:	O
13	O
,	O
III	O
:	O
14	O
,	O
III	O
:	O
16	O
,	O
III	O
:	O
18	O
,	O
IV	O
:	O
14	O
,	O
IV	O
:	O
15	O
,	O
IV	O
:	O
17	O
,	O
IV	O
:	O
18	O
,	O
IV	O
:	O
20	O
,	O
IV	O
:	O
21	O
,	O
IV	O
:	O
29	O
,	O
IV	O
:	O
30	O
and	O
IV	O
:	O
32	O
)	O
,	O
and	O
4	O
subjects	O
younger	O
than	O
the	O
onset	O
age	O
whose	O
hearing	O
status	O
is	O
ambiguous	O
(	O
V	O
:	O
11	O
,	O
V	O
:	O
12	O
,	O
V	O
:	O
14	O
,	O
V	O
:	O
16	O
)	O
,	O
were	O
recruited	O
(	O
Figure	O
1	O
-	O
a	O
;	O
Table	O
1	O
)	O
.	O

The	O
'	O
otoacoustic	O
emissions	O
'	O
test	O
is	O
typically	O
normal	O
,	O
whereas	O
'	O
auditory	O
brainstem	O
response	O
'	O
is	O
typically	O
abnormal	O
.	O

The	O
Regional	O
Ethical	O
Review	O
Board	O
of	O
Ume	O
a	O
University	O
approved	O
this	O
study	O
.	O

Variations	O
were	O
considered	O
as	O
high	O
-	O
quality	O
differences	O
when	O
either	O
(	O
1	O
)	O
the	O
variation	O
was	O
sequenced	O
in	O
at	O
least	O
three	O
nonduplicate	O
reads	O
including	O
at	O
least	O
one	O
forward	O
and	O
one	O
reverse	O
read	O
,	O
or	O
(	O
2	O
)	O
the	O
variation	O
was	O
seen	O
in	O
at	O
least	O
five	O
reads	O
with	O
quality	O
scores	O
greater	O
than	O
20	O
.	O

(	O
XLS	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
pedigrees	O
showed	O
perfect	O
co	O
-	O
segregation	O
between	O
the	O
novel	O
sequence	O
variant	O
and	O
the	O
disease	O
in	O
six	O
families	O
,	O
whereas	O
in	O
four	O
families	O
no	O
interpretation	O
was	O
possible	O
due	O
to	O
non	O
-	O
penetrant	O
or	O
borderline	O
QTc	O
,	O
and	O
in	O
five	O
other	O
families	O
there	O
was	O
no	O
samples	O
available	O
or	O
missing	O
data	O
(	O
data	O
not	O
shown	O
)	O
.	O

MCM2	B-GENE
is	O
expressed	O
in	O
both	O
the	O
nuclei	O
and	O
cytoplasm	O
in	O
various	O
kinds	O
of	O
human	O
cell	O
lines	O
and	O
tissues	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O

The	O
findings	O
of	O
a	O
mutation	O
in	O
RYR2	B-GENE
among	O
8	O
%	O
of	O
the	O
selected	O
cases	O
,	O
as	O
well	O
as	O
CNVs	O
among	O
2	O
%	O
of	O
all	O
genotype	O
-	O
negative	O
cases	O
suggest	O
that	O
mutation	O
analysis	O
of	O
RYR2	B-GENE
and	O
MLPA	O
analysis	O
in	O
a	O
genotype	O
-	O
negative	O
LQTS	B-DISEASE
population	O
is	O
of	O
importance	O
and	O
might	O
give	O
a	O
higher	O
yield	O
than	O
screening	O
of	O
the	O
less	O
common	O
LQTS	O
-	O
associated	O
genes	O
.	O

27	O
The	O
ATP	O
analogue	O
(	O
AMPPCP	O
)	O
and	O
wild	O
-	O
type	O
residues	O
of	O
positions	O
490	O
,	O
623	O
,	O
628	O
and	O
721	O
,	O
722	O
,	O
725	O
and	O
726	O
are	O
pictured	O
in	O
stick	O
representation	O
.	O

3	O
.	O
36Mb	O
)	O
.	O

Observe	O
the	O
broad	O
thumb	O
in	O
ID	O
;	O
Note	O
clinodactyly	B-DISEASE
in	O
father	O
of	O
the	O
family	O
5	O
(	O
IID	O
)	O
.	O

The	O
raw	O
sequence	O
reads	O
were	O
aligned	O
to	O
the	O
reference	O
genome	O
(	O
hg19	O
,	O
NCBI	O
build	O
37	O
)	O
using	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA	O
)	O
[	O
32	O
]	O
.	O

His	O
phenotype	O
was	O
considered	O
unknown	O
through	O
the	O
study	O
.	O

When	O
looking	O
for	O
the	O
possible	O
common	O
ancestry	O
,	O
key	O
historical	O
events	O
concerning	O
the	O
Central	O
European	O
Roma	O
population	O
must	O
be	O
taken	O
into	O
account	O
.	O

2013	O
)	O
,	O
from	O
UV1	O
to	O
UV4	O
,	O
with	O
UV1	O
being	O
the	O
least	O
likely	O
to	O
be	O
disease	O
causing	O
.	O

4	O
B	O
)	O
.	O

cDNA	O
was	O
amplified	O
using	O
intron	O
-	O
spanning	O
primers	O
G403RTF	O
/	O
R	O
and	O
I770RTF	O
/	O
R	O
and	O
sequenced	O
with	O
forward	O
and	O
reverse	O
primers	O
.	O

Total	O
RNA	O
was	O
prepared	O
from	O
fresh	O
-	O
frozen	O
tissue	O
using	O
the	O
AllPrep	O
DNA	O
/	O
RNA	O
/	O
Protein	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
or	O
the	O
TRIzol	O
Reagent	O
(	O
Invitrogen	O
)	O
,	O
followed	O
by	O
column	O
purification	O
and	O
DNase	O
digestion	O
using	O
the	O
RNeasy	O
Mini	O
Kit	O
(	O
Qiagen	O
)	O
.	O

The	O
online	O
version	O
of	O
this	O
article	O
(	O
doi	O
:	O
10	O
.	O
1186	O
/	O
s13023	O
-	O
015	O
-	O
0238	O
-	O
5	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Those	O
cases	O
that	O
remain	O
"	O
mutation	O
negative	O
"	O
should	O
be	O
carefully	O
re	O
-	O
reviewed	O
and	O
alternative	O
diagnoses	O
possibly	O
considered	O
.	O

No	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
could	O
be	O
deduced	O
from	O
the	O
pure	O
-	O
tone	O
audiograms	O
of	O
study	O
participants	O
II	O
:	O
2	O
and	O
III	O
:	O
2	O
.	O

1c	O
)	O
were	O
found	O
to	O
be	O
homozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
192G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Glu64Asp	I-VARIANT
)	O
in	O
CIB2	B-GENE
.	O

In	O
this	O
study	O
,	O
we	O
were	O
able	O
to	O
identify	O
53	O
different	O
mutations	O
,	O
of	O
which	O
24	O
were	O
novel	O
.	O

Individual	O
III	O
-	O
1	O
(	O
Figure	O
1	O
A	O
)	O
was	O
born	O
after	O
a	O
normal	O
pregnancy	O
and	O
was	O
referred	O
for	O
craniofacial	O
assessment	O
at	O
two	O
years	O
of	O
age	O
because	O
prominent	O
eyes	O
and	O
a	O
head	O
tilt	O
.	O

The	O
same	O
mutation	O
was	O
not	O
detected	O
in	O
101	O
control	O
Tibetan	O
individuals	O
.	O

This	O
may	O
be	O
due	O
an	O
incorrect	O
initial	O
clinical	O
diagnosis	O
or	O
genetic	O
heterogeneity	O
of	O
disease	O
.	O

It	O
is	O
possible	O
that	O
a	O
conformational	O
change	O
or	O
loss	O
of	O
stable	O
interactions	O
may	O
target	O
Gipc3	B-GENE
(	O
115Arg	O
)	O
for	O
early	O
degradation	O
.	O

However	O
,	O
we	O
excluded	O
two	O
variants	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
E737K	I-VARIANT
variant	O
in	O
WFS1	B-GENE
and	O
the	O
p	B-VARIANT
.	I-VARIANT
P1422L	I-VARIANT
variant	O
in	O
COL11A2	B-GENE
from	O
the	O
candidate	O
mutations	O
,	O
because	O
these	O
two	O
variants	O
were	O
detected	O
in	O
5	O
and	O
2	O
normal	O
controls	O
,	O
respectively	O
(	O
Table	O
3	O
)	O
.	O

For	O
PhyloP	O
prediction	O
,	O
C	O
:	O
Conserved	O
,	O
NC	O
:	O
Not	O
conserved	O
.	O

Enrichment	O
of	O
histone	O
H3	O
lysine	O
4	O
trimethyl	O
(	O
H3K4me3	O
)	O
and	O
H3	O
lysine	O
27	O
acetylation	O
(	O
H3K72ac	O
)	O
modifications	O
that	O
mark	O
active	O
promoters	O
and	O
enhancers	O
in	O
nine	O
ENCODE	O
cell	O
types	O
and	O
islets	O
strongly	O
suggests	O
that	O
this	O
targeted	O
WFS1	B-GENE
region	O
contains	O
the	O
promoter	O
and	O
potential	O
enhancers	O
.	O

The	O
mutations	O
observed	O
in	O
TCS	B-DISEASE
are	O
predominantly	O
sporadic	O
,	O
and	O
the	O
vast	O
majority	O
results	O
in	O
the	O
introduction	O
of	O
a	O
premature	O
termination	O
codon	O
that	O
can	O
lead	O
to	O
the	O
truncation	O
of	O
protein	O
or	O
to	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
[	O
10	O
,	O
11	O
]	O
.	O

(	O
E	O
-	O
F	O
)	O
Typical	O
RP	B-DISEASE
fundus	O
is	O
shown	O
by	O
patient	O
USH03	O
-	O
II1	O
,	O
including	O
bone	O
spicule	O
-	O
like	O
pigmentation	O
,	O
retinal	O
vascular	O
attenuation	O
,	O
pallor	O
of	O
optic	O
disk	O
,	O
and	O
chorioretinal	O
atrophy	O
.	O

Otoferlin	O
,	O
encoded	O
by	O
OTOF	B-GENE
,	O
is	O
a	O
FER	O
-	O
1	O
-	O
like	O
protein	O
and	O
is	O
critical	O
for	O
exocytosis	O
at	O
the	O
auditory	O
ribbon	O
synapse	O
.	O

Of	O
the	O
10	O
remaining	O
cases	O
diagnosed	O
with	O
syndromes	O
for	O
which	O
there	O
is	O
as	O
yet	O
no	O
known	O
gene	O
(	O
S1	O
Table	O
)	O
,	O
no	O
strong	O
candidate	O
mutations	O
were	O
identified	O
,	O
suggesting	O
that	O
at	O
least	O
some	O
cases	O
of	O
these	O
syndromes	O
are	O
caused	O
by	O
mutations	O
in	O
genes	O
not	O
yet	O
associated	O
with	O
skeletal	B-DISEASE
disorders	I-DISEASE
.	O

In	O
some	O
circumstances	O
,	O
establishing	O
an	O
early	O
genetic	O
diagnosis	O
can	O
also	O
predict	O
the	O
possible	O
phenotypic	O
outcomes	O
and	O
suggest	O
personalized	O
preventative	O
and	O
therapeutic	O
options	O
.	O

A	O
4	O
-	O
year	O
-	O
old	O
boy	O
with	O
severe	O
ocular	O
phenotype	O
was	O
found	O
to	O
be	O
compound	O
heterozygous	O
for	O
two	O
OPA1	B-GENE
mutations	O
,	O
a	O
p	B-VARIANT
.	I-VARIANT
S64fs	I-VARIANT
frameshift	O
deletion	O
and	O
a	O
p	B-VARIANT
.	I-VARIANT
V377I	I-VARIANT
missense	O
mutation	O
,	O
possibly	O
implying	O
an	O
additive	O
effect	O
.	O

Upon	O
sound	O
stimulation	O
,	O
the	O
relative	O
displacement	O
of	O
the	O
tectorial	O
membrane	O
with	O
regards	O
to	O
the	O
hair	O
cells	O
provokes	O
a	O
deflection	O
of	O
their	O
stererociliary	O
bundles	O
,	O
thereby	O
leading	O
to	O
the	O
opening	O
of	O
their	O
mechanotransduction	O
channel	O
[	O
2	O
]	O
.	O

PCR	O
primers	O
complementary	O
to	O
each	O
arm	O
of	O
the	O
probe	O
amplify	O
the	O
hybridised	O
oligonucleotide	O
target	O
.	O

Bilateral	O
EVA	B-DISEASE
was	O
detected	O
in	O
16	O
patients	O
(	O
14	O
patients	O
with	O
SLC26A4	B-GENE
mutation	O
,	O
2	O
without	O
SLC26A4	B-GENE
mutation	O
)	O
(	O
Table	O
2	O
)	O
.	O

The	O
type	O
,	O
degree	O
,	O
onset	O
,	O
progressiveness	O
and	O
/	O
or	O
fluctuation	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
were	O
evaluated	O
in	O
each	O
patient	O
.	O

Whole	O
-	O
exome	O
sequencing	O
has	O
recently	O
been	O
used	O
to	O
detect	O
disease	O
-	O
causing	O
mutations	O
underlying	O
rare	O
sporadic	O
syndromes	O
in	O
just	O
a	O
few	O
unrelated	O
individuals	O
8	O
-	O
10	O
.	O

Small	O
indel	O
detection	O
was	O
performed	O
using	O
the	O
UnifiedGenotyper	O
tool	O
from	O
GATK	O
(	O
version	O
v1	O
.	O
0	O
.	O
4705	O
)	O
[	O
22	O
]	O
after	O
all	O
the	O
high	O
-	O
quality	O
reads	O
were	O
aligned	O
to	O
the	O
human	O
reference	O
genome	O
using	O
BWA	O
(	O
version	O
0	O
.	O
5	O
.	O
9	O
-	O
r16	O
)	O
[	O
23	O
]	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Therefore	O
,	O
when	O
singleton	O
cases	O
of	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
encountered	O
in	O
the	O
Korean	O
population	O
,	O
it	O
can	O
be	O
presumed	O
that	O
deafness	B-DISEASE
is	O
due	O
to	O
a	O
monogenic	O
Mendelian	O
genetic	O
disorder	O
at	O
least	O
in	O
half	O
of	O
cases	O
.	O

Each	O
variation	O
was	O
sequenced	O
by	O
the	O
Sanger	O
sequencing	O
method	O
using	O
an	O
ABI	O
PRISM	O
Big	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
v3	O
.	O
1	O
and	O
an	O
ABI	O
3130xl	O
DNA	O
sequencer	O
(	O
Applied	O
Biosystems	O
Corps	O
.	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Finally	O
,	O
variants	O
were	O
annotated	O
with	O
predictions	O
from	O
SIFT	O
19	O
,	O
POLYPHEN2	O
20	O
,	O
and	O
various	O
other	O
annotation	O
programs	O
using	O
dbNSFP	O
version	O
2	O
.	O
0b4	O
21	O
.	O

The	O
generation	O
number	O
is	O
shown	O
on	O
the	O
left	O
.	O

The	O
vestibular	O
system	O
and	O
the	O
cochlea	O
were	O
separately	O
dissected	O
and	O
immediately	O
frozen	O
in	O
TriReagent	O
(	O
Ambion	O
)	O
.	O

Circles	O
indicate	O
females	O
and	O
fully	O
shaded	O
squares	O
represent	O
males	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
;	I-DISEASE
and	O
the	O
central	O
dot	O
in	O
the	O
female	O
symbol	O
indicate	O
the	O
carrier	O
of	O
the	O
affected	O
X	O
chromosome	O
.	O

All	O
the	O
PCR	O
products	O
of	O
affected	O
and	O
unaffected	O
members	O
were	O
completely	O
sequenced	O
.	O

Ethics	O
approval	O
:	O
The	O
Ethics	O
Reviewing	O
Committee	O
of	O
the	O
Chinese	O
PLA	O
General	O
Hospital	O
.	O

Moreover	O
,	O
acoustically	O
-	O
evoked	O
brainstem	O
responses	O
were	O
absent	O
or	O
showed	O
profound	O
alteration	O
in	O
all	O
OPA1	B-GENE
-	O
M	O
patients	O
irrespective	O
of	O
the	O
severity	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Retention	O
of	O
pendrin	B-GENE
in	O
the	O
endoplasmic	O
reticulum	O
is	O
a	O
major	O
mechanism	O
for	O
Pendred	B-DISEASE
syndrome	I-DISEASE
,	O
[	O
12	O
]	O
suggesting	O
that	O
V239D	B-VARIANT
is	O
probably	O
the	O
pathogenic	O
mutation	O
in	O
Family	O
Y	O
.	O

Bleeders	O
were	O
defined	O
as	O
suffering	O
from	O
spontaneous	O
muco	O
-	O
cutaneous	O
manifestations	O
including	O
easy	O
bruising	O
,	O
epistaxis	B-DISEASE
,	O
gum	O
bleeding	B-DISEASE
,	O
hematomas	B-DISEASE
,	O
ecchymosis	B-DISEASE
,	O
petechial	B-DISEASE
purpura	I-DISEASE
,	O
menometrorrhagias	B-DISEASE
,	O
or	O
provoked	O
bleeding	B-DISEASE
during	O
/	O
after	O
trauma	O
,	O
tooth	O
extraction	O
,	O
minor	O
or	O
major	O
surgery	O
,	O
pregnancy	O
,	O
delivery	O
and	O
postpartum	O
.	O

One	O
hundred	O
twenty	O
five	O
patients	O
carried	O
one	O
heterozygous	O
pathogenic	O
mutation	O
without	O
an	O
identified	O
second	O
mutant	O
allele	O
.	O

Type	O
XI	O
collagen	O
along	O
with	O
type	O
II	O
collagen	O
,	O
forms	O
the	O
heterotypic	O
fibrillar	O
collagen	O
fibrils	O
found	O
in	O
cartilage	O
and	O
vitreous	O
.	O

The	O
average	O
QTc	O
among	O
all	O
available	O
index	O
patients	O
was	O
463	O
ms	O
(	O
+	O
-	O
44	O
)	O
.	O

The	O
capacity	O
to	O
simultaneously	O
screen	O
thousands	O
of	O
target	O
genes	O
makes	O
this	O
technique	O
an	O
especially	O
powerful	O
tool	O
for	O
detecting	O
pathogenic	O
mutations	O
that	O
cause	O
heterogeneous	O
disorders	O
such	O
as	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Our	O
result	O
indicated	O
that	O
mutation	O
in	O
TECTA	B-GENE
gene	O
is	O
responsible	O
for	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
Mongolian	O
family	O
.	O

The	O
criteria	O
used	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
the	O
putative	O
membrane	O
location	O
for	O
each	O
chain	O
was	O
plausible	O
(	O
i	O
.	O
e	O
.	O
,	O
the	O
C	O
-	O
terminus	O
of	O
each	O
domain	O
was	O
not	O
buried	O
inside	O
the	O
complex	O
)	O
,	O
(	O
ii	O
)	O
the	O
interface	O
energy	O
score	O
,	O
and	O
(	O
iii	O
)	O
the	O
number	O
of	O
polar	O
interactions	O
between	O
interface	O
residues	O
capable	O
of	O
forming	O
hydrogen	O
bonds	O
.	O

Among	O
them	O
,	O
five	O
(	O
p	B-VARIANT
.	I-VARIANT
W3X	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
99delT	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
155_c	I-VARIANT
.	I-VARIANT
158delTCTG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
512_c	I-VARIANT
.	I-VARIANT
513insAACG	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
Y152X	I-VARIANT
)	O
are	O
novel	O
.	O

Consequently	O
,	O
this	O
might	O
be	O
considered	O
in	O
future	O
experiments	O
for	O
functional	O
evaluation	O
of	O
COL4	O
mutations	O
that	O
could	O
be	O
extended	O
to	O
the	O
final	O
patient	O
prognosis	O
.	O

The	O
mental	B-DISEASE
retardation	I-DISEASE
and	O
cognitive	O
phenotype	O
in	O
patients	O
with	O
RSTS	B-DISEASE
may	O
be	O
derived	O
from	O
impairments	O
to	O
the	O
function	O
of	O
CREB	B-GENE
-	I-GENE
binding	I-GENE
protein	I-GENE
[	O
2	O
,	O
13	O
]	O
.	O

PCR	O
with	O
H	O
taq	O
polymerase	O
was	O
performed	O
using	O
fluorescently	O
tagged	O
primers	O
.	O

The	O
observed	O
constellations	O
resulted	O
in	O
different	O
deductions	O
regarding	O
the	O
pathogenicity	O
of	O
the	O
respective	O
RP1	B-GENE
allele	O
:	O
RP1	B-GENE
mutations	O
are	O
mostly	O
truncating	O
and	O
may	O
cause	O
adRP	B-DISEASE
[	O
27	O
]	O
or	O
arRP	B-DISEASE
[	O
28	O
]	O
.	O

"	O
STGD	B-DISEASE
-	O
like	O
"	O
autosomal	O
dominant	O
diseases	O
can	O
be	O
caused	O
by	O
mutations	O
in	O
PROM1	B-GENE
4	O
and	O
ELOVL4	B-GENE
5	O
.	O

Small	O
insertions	O
and	O
deletions	O
were	O
detected	O
using	O
the	O
SOLiD	O
Small	O
InDel	O
Tool	O
.	O

For	O
more	O
than	O
5	O
,	O
000	O
years	O
and	O
continuing	O
to	O
the	O
present	O
,	O
the	O
eastern	O
shores	O
of	O
the	O
Mediterranean	O
have	O
seen	O
immigration	O
of	O
people	O
from	O
a	O
wide	O
variety	O
of	O
cultures	O
.	O

Since	O
there	O
was	O
no	O
autosomal	O
recessive	O
inheritance	O
,	O
they	O
did	O
not	O
present	O
with	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
spectrum	O
.	O

Exon	O
number	O
was	O
named	O
based	O
on	O
ENST00000403946	O
.	O

This	O
gene	O
produces	O
a	O
5	O
Kb	O
transcript	O
and	O
a	O
86	O
kDa	O
protein	O
with	O
780	O
amino	O
acids	O
,	O
called	O
pendrin	O
,	O
which	O
is	O
a	O
member	O
of	O
solute	O
carrier	O
family	O
26A	O
(	O
SLC26A	O
)	O
.	O

Diagram	O
of	O
the	O
human	O
MYH14	B-GENE
consisting	O
of	O
a	O
N	O
-	O
terminal	O
myosin	O
domain	O
,	O
a	O
myosin	O
head	O
region	O
,	O
a	O
motor	O
domain	O
,	O
two	O
IQ	O
motifs	O
,	O
a	O
coiled	O
-	O
coil	O
region	O
and	O
a	O
tail	O
domain	O
(	O
C	O
)	O
.	O

This	O
variant	O
,	O
c	B-VARIANT
.	I-VARIANT
8187G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Lys2729Asn	I-VARIANT
)	O
,	O
is	O
predicted	O
to	O
be	O
probably	O
damaging	O
by	O
PolyPhen	O
and	O
has	O
somewhat	O
reduced	O
homology	O
-	O
directed	O
repair	O
activity	O
in	O
vitro	O
,	O
but	O
the	O
degree	O
of	O
activity	O
is	O
significantly	O
greater	O
than	O
that	O
of	O
BRCA2	B-GENE
constructs	O
with	O
known	O
pathogenic	O
mutations	O
[	O
55	O
]	O
.	O

40	O
We	O
identified	O
three	O
heterozygous	O
mutations	O
affecting	O
amino	O
acid	O
residues	O
located	O
in	O
the	O
ATP	O
binding	O
pocket	O
of	O
the	O
intracellular	O
tyrosine	O
kinase	O
domain	O
(	O
TKD	O
,	O
amino	O
acids	O
478	O
-	O
767	O
)	O
:	O
G490R	B-VARIANT
(	O
patient	O
3	O
,	O
moderate	O
phenotype	O
)	O
,	O
D623Y	B-VARIANT
(	O
patient	O
4	O
,	O
mild	O
phenotype	O
)	O
,	O
and	O
N628K	B-VARIANT
(	O
patient	O
5	O
,	O
moderate	O
phenotype	O
)	O
.	O

At	O
the	O
time	O
of	O
this	O
study	O
,	O
no	O
subjects	O
were	O
diagnosed	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
which	O
,	O
in	O
addition	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
is	O
associated	O
with	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
and	O
visual	B-DISEASE
impairment	I-DISEASE
due	O
to	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Significant	O
linkage	O
was	O
found	O
with	O
markers	O
D9S164	O
and	O
D9S1826	O
(	O
positive	O
two	O
-	O
point	O
LOD	O
scores	O
of	O
3	O
.	O
44	O
and	O
3	O
.	O
31	O
at	O
=	O
0	O
,	O
respectively	O
,	O
Table	O
1	O
)	O
within	O
the	O
chromosomal	O
region	O
9q31	O
.	O
3	O
-	O
34	O
.	O
3	O
(	O
Figure	O
2C	O
)	O
.	O

Mutation	O
segregation	O
was	O
confirmed	O
for	O
six	O
of	O
these	O
cases	O
,	O
parental	O
samples	O
were	O
unavailable	O
for	O
the	O
other	O
four	O
cases	O
.	O

One	O
hypothesis	O
for	O
this	O
interesting	O
pattern	O
of	O
restricted	O
allelic	O
heterogeneity	O
is	O
that	O
some	O
disease	O
-	O
causing	O
mutations	O
more	O
frequently	O
arise	O
from	O
specific	O
mutagenic	O
mechanisms	O
.	O

Tests	O
were	O
administered	O
at	O
70	O
dB	O
(	O
A	O
)	O
in	O
quiet	O
,	O
and	O
in	O
the	O
presence	O
of	O
competing	O
noise	O
presented	O
at	O
two	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
(	O
+	O
10	O
,	O
+	O
5	O
)	O
.	O

Where	O
a	O
live	O
birth	O
occurred	O
,	O
neonatal	O
DNA	O
was	O
usually	O
collected	O
from	O
cord	O
blood	O
at	O
delivery	O
(	O
Supplementary	O
Material	O
,	O
Appendix	O
and	O
Table	O
2	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
an	O
eighth	O
mutation	O
in	O
a	O
family	O
in	O
which	O
progressive	O
non	O
-	O
syndromic	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
segregates	O
with	O
the	O
DFNA11	B-DISEASE
locus	O
.	O

The	O
heterogeneous	O
multi	O
-	O
system	O
manifestations	O
seen	O
in	O
DOA	O
+	O
families	O
and	O
the	O
remarkable	O
variable	O
penetrance	O
among	O
carriers	O
with	O
the	O
same	O
pathogenic	O
variant	O
clearly	O
implicate	O
the	O
influence	O
of	O
secondary	O
modulatory	O
factors	O
on	O
the	O
phenotypic	O
expression	O
of	O
the	O
'	O
primary	O
'	O
OPA1	B-GENE
mutation	O
.	O

(	O
c	O
)	O
Localization	O
of	O
claudin	O
14	O
(	O
green	O
)	O
in	O
the	O
tight	O
junctions	O
between	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
and	O
pillar	O
cells	O
and	O
between	O
two	O
adjacent	O
pillar	O
cells	O
.	O

Among	O
the	O
six	O
cases	O
where	O
inclusions	O
could	O
not	O
be	O
detected	O
even	O
using	O
IF	O
procedures	O
,	O
one	O
presented	O
abnormal	O
structures	O
using	O
electron	O
microscopy	O
(	O
EM	O
)	O
typical	O
of	O
MYH9	B-DISEASE
-	I-DISEASE
RD	I-DISEASE
.	O

The	O
disease	O
is	O
genetically	O
heterogeneous	O
and	O
currently	O
134	O
loci	O
have	O
been	O
determined	O
and	O
80	O
genes	O
identified	O
for	O
the	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
type	I-DISEASE
(	O
Hereditary	O
Hearing	B-DISEASE
Loss	I-DISEASE
Homepage	O
,	O
URL	O
:	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
.	O

The	O
haplotype	O
spanning	O
18	O
SNPs	O
was	O
not	O
detected	O
in	O
a	O
homozygous	O
state	O
in	O
any	O
of	O
the	O
analyzed	O
control	O
samples	O
,	O
supporting	O
the	O
hypothesis	O
of	O
a	O
common	O
ancestry	O
of	O
this	O
mutation	O
among	O
these	O
patients	O
.	O

All	O
four	O
components	O
of	O
DIDMOAD	B-DISEASE
were	O
present	O
in	O
33	O
patients	O
(	O
49	O
%	O
)	O
.	O

The	O
cutoff	O
for	O
the	O
maximum	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
was	O
set	O
to	O
1	O
%	O
[	O
12	O
]	O
.	O

Thirty	O
-	O
nine	O
(	O
48	O
%	O
)	O
of	O
these	O
mutations	O
,	O
i	O
.	O
e	O
.	O

Cases	O
one	O
and	O
two	O
were	O
sequenced	O
using	O
PerkinElmer	O
'	O
s	O
sequencing	O
service	O
using	O
the	O
Agilent	O
Sure	O
Select	O
Human	O
All	O
Exon	O
Capture	O
V4	O
Kit	O
and	O
exome	O
sequencing	O
for	O
these	O
two	O
cases	O
was	O
performed	O
(	O
two	O
paired	O
-	O
end	O
100	O
-	O
bp	O
reads	O
)	O
with	O
the	O
Illumina	O
HiSeq	O
2000	O
system	O
.	O

CONFLICT	O
OF	O
INTEREST	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Difficult	O
cases	O
of	O
a	O
heterozygous	O
state	O
without	O
a	O
second	O
mutation	O
are	O
also	O
seen	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
13	O
]	O
,	O
[	O
14	O
]	O
.	O

Shafique	O
S	O
.	O

If	O
a	O
novel	O
variant	O
fulfilled	O
the	O
above	O
criteria	O
,	O
but	O
segregated	O
with	O
USH	B-DISEASE
in	O
only	O
one	O
family	O
,	O
it	O
was	O
deemed	O
to	O
be	O
probably	O
pathogenic	O
and	O
was	O
classified	O
as	O
'	O
UV4	O
'	O
.	O

At	O
intensities	O
lower	O
than	O
100	O
dB	O
,	O
the	O
prolonged	O
potential	O
was	O
recorded	O
for	O
both	O
ECochG	O
patterns	O
with	O
increased	O
peak	O
latency	O
and	O
reduced	O
amplitude	O
compared	O
to	O
the	O
compound	O
action	O
potential	O
recorded	O
from	O
the	O
normal	O
control	O
.	O

The	O
depth	O
of	O
coverage	O
on	O
given	O
target	O
regions	O
was	O
calculated	O
using	O
the	O
DepthOfCoverage	O
module	O
of	O
GATK	O
.	O

The	O
amino	O
acid	O
substitution	O
is	O
predicted	O
to	O
be	O
damaging	O
if	O
the	O
score	O
is	O
<	O
0	O
.	O
05	O
,	O
and	O
tolerated	O
if	O
the	O
score	O
is	O
>	O
0	O
.	O
05	O
.	O

T461P	I-VARIANT
were	O
novel	O
(	O
Table	O
2	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
detect	O
OPA1	B-GENE
gene	O
mutations	O
and	O
associated	O
phenotypes	O
in	O
Chinese	O
patients	O
with	O
suspected	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
.	O

In	O
five	O
patients	O
,	O
we	O
identified	O
heterozygous	O
PRPF31	B-GENE
mutations	O
,	O
including	O
deletions	O
of	O
multiple	O
(	O
patient	O
116	O
)	O
or	O
even	O
all	O
coding	O
exons	O
(	O
patient	O
113	O
)	O
(	O
see	O
Figure	O
S1	O
and	O
Figure	O
S2C	O
in	O
File	O
S1	O
)	O
.	O

The	O
variants	O
were	O
then	O
annotated	O
by	O
the	O
ANNOVAR	O
software	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
openbioinformatics	O
.	O
org	O
/	O
annovar	O
/	O
annovar_db	O
.	O
html	O
)	O
,	O
for	O
filtering	O
common	O
variants	O
reported	O
in	O
dbSNP132	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
)	O
,	O
in	O
1000	O
Genomes	O
Project	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
1000genomes	O
.	O
org	O
/	O
)	O
,	O
and	O
in	O
-	O
house	O
database	O
.	O

Variants	O
(	O
SNPs	O
and	O
indels	O
)	O
were	O
called	O
with	O
MAQ	O
.	O

The	O
exons	O
and	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
known	O
candidate	O
genes	O
(	O
BSND	B-GENE
(	O
NM_057176	O
.	O
2	O
)	O
,	O
GJB2	B-GENE
(	O
NM_004004	O
.	O
5	O
)	O
,	O
HGF	B-GENE
(	O
NM_000601	O
)	O
,	O
MYO15A	B-GENE
(	O
NM_016239	O
.	O
3	O
)	O
,	O
MSRB3	B-GENE
(	O
NM_001031679	O
.	O
2	O
)	O
,	O
SLC26A4	B-GENE
(	O
NM_000441	O
.	O
1	O
)	O
,	O
TMC1	B-GENE
(	O
NM_138691	O
.	O
2	O
)	O
,	O
TMPRSS3	B-GENE
(	O
NM_024022	O
.	O
2	O
)	O
and	O
TMIE	B-GENE
(	O
NM_147196	O
)	O
)	O
present	O
in	O
the	O
homozygous	O
regions	O
were	O
sequenced	O
in	O
the	O
proband	O
of	O
the	O
families	O
.	O

Conversely	O
,	O
dominantly	O
inherited	O
mutations	O
account	O
for	O
autosomal	B-DISEASE
dominant	I-DISEASE
progressive	I-DISEASE
external	I-DISEASE
ophthalmoplegia	I-DISEASE
(	O
adPEO	B-DISEASE
)	O
characterised	O
by	O
ptosis	B-DISEASE
and	O
ophthalmoparesis	B-DISEASE
,	O
with	O
COX	O
-	O
deficient	O
and	O
ragged	O
-	O
red	O
fibres	O
and	O
multiple	O
mtDNA	O
deletions	O
in	O
muscle	O
[	O
12	O
]	O
.	O

Note	O
broad	O
medially	O
deviated	O
/	O
great	B-DISEASE
toes	I-DISEASE
in	O
the	O
father	O
of	O
family	O
5	O
(	O
IIC	O
)	O
.	O

Next	O
,	O
intergenic	O
or	O
intronic	O
variants	O
were	O
discarded	O
,	O
and	O
only	O
non	O
-	O
synonymous	O
variants	O
in	O
coding	O
sequences	O
and	O
splice	O
-	O
site	O
variants	O
were	O
sorted	O
out	O
as	O
probable	O
pathogenic	O
variants	O
,	O
based	O
on	O
their	O
direct	O
association	O
with	O
the	O
protein	O
expression	O
or	O
function	O
.	O

Identification	O
of	O
the	O
PEX1	B-GENE
transcriptional	O
start	O
is	O
of	O
importance	O
because	O
a	O
transcriptional	O
start	O
at	O
around	O
c	O
.	O
-	O
123	O
would	O
render	O
the	O
upstream	O
polymorphism	O
at	O
c	O
.	O
-	O
137	O
a	O
promotor	O
polymorphism	O
.	O

,	O
2008	O
)	O
.	O

Two	O
-	O
point	O
LOD	O
(	O
logarithm	O
of	O
odds	O
)	O
scores	O
were	O
calculated	O
by	O
the	O
Merlin	O
programs	O
(	O
version	O
5	O
.	O
2	O
)	O
under	O
an	O
autosomal	O
dominant	O
inheritance	O
model	O
with	O
a	O
mutant	O
allele	O
frequency	O
of	O
0	O
.	O
0001	O
and	O
complete	O
penetrance	O
.	O

2012	O
)	O
and	O
sequencing	O
of	O
366	O
exons	O
(	O
Bonnet	O
et	O
al	O
.	O

As	O
no	O
DSPP	B-GENE
transcript	O
was	O
able	O
to	O
be	O
detected	O
in	O
gingiva	O
or	O
peripheral	O
blood	O
sample	O
by	O
RT	O
-	O
PCR	O
,	O
we	O
decided	O
to	O
confirm	O
the	O
function	O
of	O
this	O
causal	O
mutation	O
by	O
in	O
vitro	O
splicing	O
analysis	O
using	O
the	O
vector	O
pLRT	O
which	O
contained	O
the	O
splicing	O
reporter	O
LTR	O
-	O
SD1	O
-	O
SAExon	O
-	O
SD	O
-	O
SA5opt	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

In	O
209	O
unrelated	O
early	O
-	O
onset	O
lone	O
AF	B-DISEASE
patients	O
(	O
<	O
40	O
years	O
)	O
the	O
entire	O
coding	O
sequence	O
of	O
KCNE1	B-GENE
was	O
bidirectionally	O
sequenced	O
.	O

Undetected	O
large	O
genomic	O
rearrangements	O
,	O
undetected	O
pathogenic	O
variants	O
in	O
the	O
promoter	O
and	O
intronic	O
regions	O
,	O
misdiagnosed	O
USH	B-DISEASE
syndrome	I-DISEASE
,	O
and	O
human	O
as	O
well	O
as	O
computer	O
software	O
errors	O
during	O
sequence	O
analysis	O
are	O
likely	O
to	O
underlie	O
these	O
'	O
missing	O
alleles	O
'	O
.	O

It	O
affects	O
about	O
1	O
in	O
100	O
,	O
000	O
individuals	O
1	O
)	O
,	O
but	O
is	O
more	O
rare	O
in	O
the	O
Asian	O
population	O
,	O
with	O
only	O
a	O
few	O
cases	O
reported	O
in	O
Korea	O
5	O
-	O
8	O
)	O
.	O

Only	O
Bonnet	O
et	O
al	O
has	O
identified	O
biallelic	O
MYO7A	B-GENE
mutations	O
in	O
a	O
sporadic	O
Caucasian	O
patient	O
[	O
36	O
]	O
,	O
but	O
with	O
no	O
clinical	O
data	O
provided	O
in	O
their	O
paper	O
in	O
addition	O
to	O
diagnosis	O
.	O

Several	O
examples	O
have	O
been	O
identified	O
[	O
11	O
,	O
13	O
,	O
20	O
,	O
21	O
]	O
.	O

This	O
experiment	O
demonstrated	O
that	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
was	O
trapped	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
other	O
four	O
variants	O
[	O
c	B-VARIANT
.	I-VARIANT
4798G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly1600Arg	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
5810T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu1937Pro	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
977T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Leu326Pro	I-VARIANT
)	O
,	O
c	B-VARIANT
.	I-VARIANT
4039C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg1347Ser	I-VARIANT
)	O
]	O
were	O
novel	O
and	O
could	O
not	O
be	O
found	O
in	O
the	O
1000	O
Genomes	O
Database	O
.	O

Case	O
42	O
has	O
an	O
interesting	O
phenotype	O
.	O

Circles	O
indicate	O
females	O
and	O
fully	O
shaded	O
squares	O
represent	O
males	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
;	I-DISEASE
and	O
the	O
central	O
dot	O
in	O
a	O
female	O
symbol	O
indicates	O
a	O
carrier	O
of	O
a	O
X	O
-	O
linked	O
mutation	O
.	O

These	O
data	O
might	O
suggest	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
186	I-VARIANT
+	I-VARIANT
2t	I-VARIANT
>	I-VARIANT
c	I-VARIANT
mutation	O
in	O
COL9A2	B-GENE
is	O
another	O
ancestral	O
mutation	O
in	O
the	O
Dutch	O
population	O
;	O
however	O
,	O
haplotype	O
analysis	O
should	O
be	O
performed	O
to	O
test	O
this	O
hypothesis	O
further	O
.	O

The	O
normalized	O
ratio	O
of	O
GFP	O
-	O
ELMOD3	B-GENE
and	O
ZO1	O
signal	O
intensities	O
at	O
the	O
cell	O
membrane	O
(	O
n	O
=	O
30	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
)	O
confirmed	O
the	O
internalization	O
of	O
ELMOD3	B-GENE
following	O
Cyto	O
-	O
D	O
treatment	O
.	O

NF	O
-	O
kappa	O
B	O
induction	O
is	O
shown	O
as	O
the	O
fold	O
-	O
change	O
compared	O
with	O
cells	O
that	O
were	O
transfected	O
with	O
a	O
control	O
vector	O
without	O
ASC	O
(	O
set	O
equal	O
to	O
one	O
)	O
.	O

Commercially	O
available	O
genotyping	O
microarrays	O
are	O
based	O
on	O
arrayed	O
primer	O
extension	O
technology	O
(	O
APEX	O
,	O
Asper	O
Ophthalmics	O
,	O
Tartu	O
,	O
Estonia	O
)	O
,	O
which	O
enable	O
the	O
simultaneous	O
screening	O
of	O
multiple	O
genes	O
,	O
but	O
they	O
can	O
detect	O
only	O
a	O
fixed	O
number	O
of	O
known	O
mutations	O
[	O
21	O
]	O
.	O

These	O
are	O
gene	O
-	O
specific	O
,	O
meaning	O
that	O
only	O
patients	O
for	O
whom	O
mutations	O
have	O
been	O
identified	O
will	O
benefit	O
from	O
these	O
novel	O
approaches	O
to	O
stratified	O
medicine	O
.	O

We	O
predicted	O
deleterious	O
effects	O
of	O
each	O
missense	O
mutation	O
in	O
silico	O
by	O
using	O
PolyPhen2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
)	O
and	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
www	O
/	O
SIFT_enst_submit	O
.	O
html	O
)	O
.	O

But	O
these	O
variations	O
did	O
not	O
cosegregate	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
.	O

15	O
By	O
previously	O
described	O
criteria	O
,	O
16	O
17	O
the	O
low	O
-	O
quality	O
variations	O
were	O
filtered	O
out	O
.	O

1	O
.	O
5	O
)	O
software	O
(	O
Technelysium	O
,	O
Pty	O
Ltd	O
.	O
,	O
Tewantin	O
,	O
Queensland	O
,	O
Australia	O
)	O
and	O
S	O
eqscape	O
(	O
v	O
.	O

However	O
,	O
in	O
combination	O
with	O
the	O
p	B-VARIANT
.	I-VARIANT
Ala426Thr	I-VARIANT
or	O
p	B-VARIANT
.	I-VARIANT
Ala138Glu	I-VARIANT
mutations	O
,	O
a	O
milder	O
phenotype	O
with	O
postlingual	O
onset	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
seen	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
456_459dupTTCC	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
795_800delCTGGTT	I-VARIANT
mutations	O
were	O
only	O
present	O
in	O
the	O
probands	O
(	O
Figure	O
3	O
,	O
B	O
-	O
II	O
:	O
1	O
,	O
C	O
-	O
II	O
:	O
1	O
)	O
but	O
not	O
in	O
their	O
parents	O
,	O
demonstrating	O
de	O
novo	O
mutations	O
that	O
have	O
been	O
rarely	O
reported	O
in	O
PAX3	B-GENE
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

The	O
Capture	O
library	O
was	O
designed	O
with	O
Agilent	O
'	O
s	O
eArray	O
homepage	O
(	O
http	O
:	O
/	O
/	O
earray	O
.	O
vhem	O
.	O
agilent	O
.	O
com	O
/	O
earray	O
/	O
)	O
.	O

2008	O
)	O
.	O

The	O
molecular	O
genetic	O
etiology	O
of	O
ADNSHL	B-DISEASE
is	O
extremely	O
heterogeneous	O
.	O

To	O
date	O
,	O
more	O
than	O
60	O
pathogenic	O
variants	O
of	O
the	O
OTOF	B-GENE
gene	O
have	O
been	O
reported	O
in	O
familial	O
or	O
sporadic	O
patients	O
of	O
ANSD	B-DISEASE
and	O
congenital	O
SNHL	B-DISEASE
[	O
20	O
]	O
-	O
[	O
22	O
]	O
.	O

CT	O
scan	O
of	O
individual	O
V	O
:	O
2	O
revealed	O
all	O
three	O
semicircular	O
and	O
internal	O
auditory	O
canals	O
were	O
intact	O
on	O
both	O
sides	O
.	O

Collectively	O
,	O
the	O
five	O
USH1	B-DISEASE
genes	O
comprise	O
183	O
coding	O
exons	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
genome	O
.	O
ucsc	O
.	O
edu	O
/	O
)	O
.	O

Variants	O
identified	O
in	O
multiple	O
samples	O
were	O
considered	O
as	O
putative	O
polymorphisms	O
and	O
were	O
further	O
verified	O
by	O
testing	O
additional	O
control	O
samples	O
.	O

The	O
affected	O
individuals	O
did	O
not	O
have	O
delays	O
in	O
gross	O
motor	O
development	O
;	O
neither	O
did	O
they	O
have	O
balance	O
problems	O
.	O

However	O
,	O
InterProScan	O
[	O
31	O
]	O
and	O
SWISS	O
-	O
MODEL	O
[	O
32	O
]	O
molecular	O
modeling	O
softwares	O
predicted	O
that	O
NARS2	B-GENE
does	O
not	O
contain	O
this	O
additional	O
domain	O
(	O
Fig	O
.	O

Our	O
immunohistochemistry	O
detected	O
Bdp1	B-GENE
protein	O
in	O
the	O
proximity	O
of	O
blood	O
vessels	O
(	O
example	O
of	O
the	O
same	O
blood	O
vessel	O
in	O
adjacent	O
sections	O
is	O
indicated	O
with	O
an	O
arrow	O
in	O
B	O
,	O
C	O
,	O
D	O
)	O
.	O

Fundus	O
photographs	O
of	O
affected	O
individuals	O
from	O
family	O
TB109	O
.	O

Audiogram	O
of	O
affected	O
subjects	O
showed	O
hearing	B-DISEASE
loss	I-DISEASE
ranged	O
from	O
severe	O
to	O
profound	O
.	O
;	O
C	O
.	O

Nonetheless	O
,	O
it	O
is	O
regarded	O
as	O
probably	O
damaging	O
by	O
PolyPhen	O
-	O
2	O
and	O
has	O
a	O
Grantham	O
score	O
of	O
126	O
(	O
see	O
Table	O
4	O
)	O
.	O

4	O
To	O
remove	O
outliers	O
in	O
data	O
quality	O
,	O
we	O
required	O
that	O
WHISP	O
samples	O
have	O
read	O
mapping	O
rates	O
<	O
80	O
%	O
,	O
duplication	O
rates	O
<	O
40	O
%	O
,	O
and	O
at	O
least	O
10	O
,	O
000	O
SNVs	O
called	O
in	O
the	O
target	O
region	O
.	O

Patients	O
with	O
conductive	O
or	O
mixed	O
hearing	B-DISEASE
loss	I-DISEASE
had	O
a	O
decreased	O
likelihood	O
of	O
receiving	O
a	O
genetic	O
diagnosis	O
(	O
17	O
and	O
21	O
%	O
,	O
respectively	O
)	O
,	O
but	O
the	O
difference	O
was	O
not	O
significant	O
.	O

Whereas	O
the	O
normal	O
acquisition	O
of	O
potassium	O
currents	O
attenuates	O
the	O
IHC	O
receptor	O
potential	O
,	O
lack	O
of	O
those	O
currents	O
in	O
BLSW	O
allows	O
greater	O
depolarization	O
,	O
which	O
may	O
in	O
turn	O
enhance	O
Ca	O
2	O
+	O
-	O
dependent	O
neurotransmission	O
,	O
perhaps	O
leading	O
to	O
synchronized	O
cochlear	O
nerve	O
activity	O
,	O
enhanced	O
ABR	O
wave	O
I	O
amplitudes	O
and	O
seizure	B-DISEASE
susceptibility	O
.	O

Variants	O
c	B-VARIANT
.	I-VARIANT
881	I-VARIANT
-	I-VARIANT
882delAC	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
863	I-VARIANT
-	I-VARIANT
864insT	I-VARIANT
were	O
found	O
in	O
part	O
A	O
and	O
B	O
,	O
respectively	O
.	O

Overall	O
,	O
the	O
present	O
study	O
should	O
be	O
considered	O
as	O
a	O
starting	O
point	O
to	O
design	O
further	O
investigations	O
:	O
our	O
results	O
might	O
indeed	O
contribute	O
to	O
meta	O
-	O
analysis	O
studies	O
,	O
aimed	O
at	O
the	O
identification	O
/	O
confirmation	O
of	O
novel	O
causative	O
or	O
modifier	O
genes	O
.	O

In	O
vitro	O
analysis	O
revealed	O
that	O
MCM2	B-GENE
over	O
-	O
expression	O
induced	O
apoptosis	O
in	O
HL60	O
cells	O
[	O
23	O
]	O
.	O

There	O
was	O
no	O
difference	O
in	O
the	O
proportion	O
of	O
multiplex	O
hearing	B-DISEASE
loss	I-DISEASE
families	O
between	O
the	O
recruited	O
93	O
families	O
and	O
the	O
other	O
107	O
families	O
.	O

The	O
tagged	O
aliquots	O
were	O
pooled	O
prior	O
to	O
hybridisation	O
against	O
the	O
target	O
enrichment	O
reagent	O
and	O
run	O
on	O
a	O
single	O
lane	O
of	O
the	O
Illumina	O
GAIIx	O
DNA	O
sequencer	O
.	O

In	O
this	O
study	O
,	O
the	O
NSD	B-DISEASE
population	O
(	O
n	O
=	O
350	O
)	O
included	O
199	O
Uyghur	O
patients	O
(	O
86	O
males	O
and	O
113	O
females	O
)	O
,	O
aged	O
12	O
.	O
7	O
+	O
-	O
5	O
.	O
3	O
years	O
(	O
range	O
,	O
1	O
-	O
35	O
)	O
,	O
and	O
151	O
Han	O
Chinese	O
patients	O
(	O
86	O
males	O
and	O
65	O
females	O
)	O
,	O
aged	O
10	O
.	O
9	O
+	O
-	O
5	O
.	O
4	O
years	O
(	O
1	O
-	O
26	O
)	O
.	O

We	O
identified	O
one	O
M34T	B-VARIANT
homozygote	O
in	O
the	O
general	O
population	O
,	O
as	O
expected	O
from	O
the	O
carrier	O
frequency	O
(	O
1	O
/	O
4	O
,	O
444	O
)	O
.	O

TGE	O
+	O
MPS	O
have	O
been	O
used	O
in	O
several	O
small	O
cohorts	O
with	O
positive	O
diagnostic	O
rates	O
that	O
range	O
from	O
10	O
to	O
83	O
%	O
[	O
reviewed	O
in	O
(	O
Shearer	O
and	O
Smith	O
2015	O
)	O
]	O
.	O

Interestingly	O
,	O
the	O
patient	O
of	O
this	O
case	O
had	O
progressive	O
external	O
ophthalmoplegia	B-DISEASE
and	O
central	B-DISEASE
vision	I-DISEASE
loss	I-DISEASE
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
a	O
novel	O
missense	O
mutation	O
within	O
the	O
ILDR1	B-GENE
gene	O
associated	O
with	O
partial	B-DISEASE
deafness	I-DISEASE
,	O
and	O
identified	O
partial	O
mislocalization	O
of	O
the	O
mutant	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
protein	O
at	O
TCs	O
.	O

Boxes	O
list	O
genes	O
containing	O
'	O
likely	O
deleterious	O
'	O
variants	O
in	O
each	O
patient	O
.	O

A	O
cohort	O
of	O
587	O
subjects	O
with	O
SNHL	B-DISEASE
were	O
chosen	O
as	O
the	O
other	O
affected	O
set	O
for	O
further	O
analysis	O
.	O

The	O
region	O
encoded	O
by	O
exon	O
16	O
is	O
located	O
in	O
the	O
middle	O
of	O
this	O
domain	O
,	O
which	O
encodes	O
the	O
HW	O
helix	O
,	O
the	O
third	O
strand	O
of	O
the	O
central	O
seven	O
-	O
stranded	O
beta	O
sheet	O
,	O
and	O
two	O
loops	O
(	O
Figure	O
2	O
)	O
.	O

D	O
:	O
Scotopic	O
electrophysiological	O
responses	O
:	O
severely	O
abnormal	O
.	O

The	O
three	O
lanes	O
were	O
total	O
cochlear	O
protein	O
(	O
Total	O
)	O
,	O
cochlear	O
tissues	O
without	O
spiral	O
ligament	O
or	O
stria	O
vasculari	O
(	O
without	O
sl	O
.	O

Cook	O
,	O
Jr	O
.	O
,	O
Bernie	O
Devlin	O
,	O
Richard	O
A	O
.	O

Our	O
findings	O
indicate	O
that	O
CMTX5	B-DISEASE
,	O
Arts	B-DISEASE
syndrome	I-DISEASE
and	O
DFN2	B-DISEASE
are	O
phenotypic	O
clusters	O
on	O
a	O
continuous	O
intraindividual	O
and	O
intrafamilial	O
spectrum	O
of	O
PRPS1	B-GENE
-	O
disease	O
.	O

Thus	O
the	O
proportion	O
of	O
validated	O
de	O
novo	O
mutations	O
that	O
are	O
predicted	O
to	O
have	O
a	O
functional	O
consequence	O
of	O
the	O
encoded	O
protein	O
is	O
significantly	O
enriched	O
over	O
what	O
would	O
be	O
expected	O
by	O
chance	O
(	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
suggesting	O
that	O
an	O
appreciable	O
subset	O
of	O
these	O
functional	O
mutations	O
is	O
likely	O
to	O
be	O
pathogenic	O
.	O

SP	O
,	O
a	O
signal	O
peptide	O
;	O
mTP	O
,	O
a	O
mitochondrial	O
targeting	O
peptide	O
;	O
M	O
,	O
Mitochondrion	O
;	O
S	O
,	O
Secretory	O
pathway	O
;	O
RC	O
:	O
Reliability	O
class	O
,	O
from	O
1	O
to	O
5	O
,	O
where	O
1	O
indicates	O
the	O
strongest	O
prediction	O
.	O

This	O
work	O
was	O
supported	O
by	O
research	O
grants	O
from	O
Schwarzbach	O
Medical	O
Research	O
Fund	O
and	O
by	O
research	O
grant	O
612	O
/	O
09	O
from	O
the	O
Legacy	O
Heritage	O
Bio	O
-	O
Medical	O
program	O
of	O
the	O
Israel	O
Science	O
Foundation	O
to	O
T	O
.	O
B	O
.	O
This	O
study	O
investigated	O
the	O
genetic	O
basis	O
for	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
(	O
USH1	B-DISEASE
)	O
in	O
four	O
consanguineous	O
Israeli	O
Arab	O
families	O
.	O

Sequences	O
were	O
aligned	O
and	O
compared	O
with	O
published	O
sequences	O
from	O
the	O
NCBI	O
database	O
(	O
GJB2	B-GENE
:	O
NG_008358	O
.	O
1	O
;	O
SLC26A4	B-GENE
:	O
NG_008489	O
.	O
1	O
)	O
.	O

1	O
Diagnostic	O
rates	O
are	O
dependent	O
on	O
patient	O
-	O
specific	O
clinical	O
and	O
phenotypic	O
characteristics	O
and	O
are	O
shown	O
as	O
the	O
percentage	O
of	O
patients	O
with	O
the	O
noted	O
characteristic	O
.	O

To	O
investigate	O
and	O
define	O
its	O
expression	O
pattern	O
in	O
inner	O
ear	O
,	O
we	O
immuno	O
-	O
labeled	O
whole	O
mount	O
P2	O
mouse	O
cochlea	O
with	O
HOMER2	B-GENE
antibody	O
.	O

Wrote	O
the	O
paper	O
:	O
MM	O
SU	O
.	O

(	O
B	O
)	O
Pedigree	O
and	O
segregation	O
pattern	O
in	O
Family	O
DE3050	O
.	O

These	O
findings	O
are	O
valuable	O
for	O
genetic	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
prenatal	O
testing	O
and	O
pre	O
-	O
implantation	O
diagnosis	O
in	O
EVA	B-DISEASE
families	O
.	O

This	O
contrasts	O
with	O
the	O
affected	O
family	O
members	O
in	O
the	O
current	O
family	O
who	O
showed	O
a	O
flat	O
-	O
type	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
with	O
poor	O
speech	O
recognition	O
.	O

(	O
B	O
)	O
Chromatogram	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
574C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
showed	O
equal	O
expression	O
of	O
both	O
alleles	O
in	O
peripheral	O
blood	O
cells	O
,	O
demonstrating	O
that	O
the	O
nonsense	O
mutation	O
is	O
not	O
degraded	O
through	O
NMD	O
For	O
the	O
gene	O
to	O
have	O
a	O
likely	O
role	O
in	O
disease	O
pathology	O
,	O
it	O
should	O
be	O
expressed	O
in	O
the	O
relevant	O
tissue	O
.	O

The	O
gene	O
is	O
located	O
on	O
chromosome	O
11q13	O
.	O
5	O
and	O
has	O
49	O
exons	O
.	O

Subcloning	O
followed	O
by	O
the	O
capillary	O
DNA	O
sequencing	O
has	O
been	O
a	O
de	O
facto	O
standard	O
to	O
identify	O
somatic	O
mosaicism	O
,	O
but	O
this	O
is	O
not	O
the	O
method	O
of	O
choice	O
for	O
routine	O
diagnostics	O
because	O
it	O
is	O
laborious	O
,	O
time	O
consuming	O
,	O
and	O
costly	O
.	O

Of	O
these	O
variants	O
,	O
262	O
are	O
missense	O
,	O
four	O
are	O
frameshift	O
and	O
three	O
are	O
nonsense	O
(	O
Table	O
1	O
and	O
Supplementary	O
Material	O
,	O
Table	O
S3	O
)	O
.	O

This	O
insertion	O
is	O
produced	O
near	O
the	O
end	O
of	O
exon	O
11	O
.	O

For	O
example	O
,	O
p	B-VARIANT
.	I-VARIANT
V63A	I-VARIANT
has	O
been	O
reported	O
as	O
a	O
novel	O
variant	O
,	O
p	B-VARIANT
.	I-VARIANT
V153I	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
D159N	I-VARIANT
were	O
reported	O
as	O
a	O
polymorphism	O
[	O
29	O
]	O
.	O

Splice	O
site	O
mutations	O
were	O
predicted	O
with	O
the	O
Splice	O
Site	O
Prediction	O
by	O
Neural	O
Network	O
[	O
32	O
]	O
.	O

We	O
thank	O
Christian	O
Kubisch	O
and	O
Karin	O
Boss	O
for	O
discussion	O
and	O
comments	O
on	O
the	O
manuscript	O
and	O
Radu	O
Wirth	O
for	O
technical	O
support	O
.	O

For	O
USH2A	B-GENE
gene	O
cDNA	O
numbering	O
+	O
1	O
corresponds	O
to	O
A	O
in	O
the	O
ATG	O
translation	O
initiation	O
codon	O
in	O
RefSeq	O
(	O
AY481573	O
.	O
1	O
)	O
.	O

TF	O
-	O
ELMOD3	B-GENE
co	O
-	O
sedimented	O
,	O
albeit	O
weakly	O
or	O
incompletely	O
,	O
with	O
F	O
-	O
actin	O
in	O
this	O
assay	O
(	O
Figure	O
S9	O
)	O
.	O

Clinical	O
implementation	O
of	O
exome	O
sequencing	O
for	O
prenatal	O
diagnosis	O
of	O
structural	B-DISEASE
anomalies	I-DISEASE
identified	O
by	O
ultrasound	O
promises	O
to	O
improve	O
management	O
of	O
pregnancy	O
and	O
enable	O
more	O
informative	O
counseling	O
to	O
parents	O
.	O

Patricia	O
Fernandez	O
San	O
Jose	O
'	O
s	O
work	O
is	O
supported	O
by	O
a	O
Rio	O
Hortega	O
grant	O
(	O
CM12	O
/	O
00013	O
)	O
and	O
Marta	O
Corton	O
by	O
a	O
Miguel	O
Servet	O
grant	O
(	O
CP	O
/	O
03256	O
)	O
,	O
both	O
from	O
Instituto	O
de	O
Salud	O
Carlos	O
III	O
.	O

In	O
addition	O
we	O
obtained	O
consent	O
for	O
publication	O
of	O
individual	O
patient	O
data	O
from	O
all	O
of	O
the	O
study	O
participants	O
.	O

Finally	O
,	O
we	O
identified	O
COL9A2	B-GENE
mutations	O
in	O
five	O
MED	B-DISEASE
patients	O
and	O
a	O
COL9A3	B-GENE
mutation	O
in	O
a	O
single	O
MED	B-DISEASE
patient	O
(	O
Table	O
3	O
)	O
.	O

Ali	O
et	O
al	O
.	O

To	O
date	O
,	O
12	O
causative	O
genes	O
and	O
a	O
modifier	O
gene	O
have	O
been	O
identified	O
for	O
the	O
three	O
clinical	O
subtypes	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
,	O
and	O
USH3	B-DISEASE
)	O
,	O
whose	O
clinical	O
definition	O
is	O
based	O
on	O
the	O
progression	O
and	O
severity	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
and	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
(	O
Ebermann	O
et	O
al	O
.	O

All	O
of	O
these	O
variations	O
appeared	O
on	O
both	O
strands	O
at	O
the	O
expected	O
allele	O
frequencies	O
as	O
shown	O
in	O
Fig	O
.	O

We	O
focused	O
on	O
small	O
,	O
nonsynonymous	O
variations	O
-	O
substitutions	O
,	O
insertions	O
,	O
and	O
deletions	O
-	O
since	O
germline	O
variations	O
in	O
the	O
cancer	O
-	O
susceptibility	O
genes	O
are	O
mostly	O
of	O
this	O
type	O
[	O
20	O
]	O
.	O

Thus	O
,	O
in	O
order	O
to	O
link	O
with	O
certainty	O
the	O
Y669H	B-VARIANT
mutation	O
in	O
WFS1	B-GENE
with	O
symptoms	O
of	O
LFSNHL	B-DISEASE
,	O
future	O
research	O
will	O
involve	O
the	O
construction	O
of	O
a	O
transgenic	O
mouse	O
model	O
carrying	O
this	O
mutation	O
and	O
the	O
analysis	O
of	O
its	O
phenotypic	O
behavior	O
,	O
particularly	O
in	O
respect	O
to	O
symptoms	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

The	O
A684V	B-VARIANT
could	O
not	O
be	O
confirmed	O
in	O
her	O
parents	O
since	O
no	O
DNA	O
sample	O
from	O
their	O
was	O
available	O
at	O
the	O
time	O
of	O
the	O
screening	O
of	O
WFS1	B-GENE
gene	O
.	O

His	O
mother	O
was	O
39	O
years	O
old	O
,	O
and	O
his	O
father	O
was	O
40	O
years	O
old	O
.	O

Importantly	O
,	O
all	O
5	O
women	O
had	O
FGFR1	B-GENE
mutations	O
,	O
in	O
contrast	O
to	O
only	O
4	O
of	O
25	O
men	O
(	O
Table	O
1	O
)	O
(	O
p	O
=	O
0	O
.	O
0009	O
)	O
.	O

Haruo	O
Takahashi	O
(	O
Nagasaki	O
University	O
)	O
,	O
Dr	O
.	O

With	O
the	O
error	O
rate	O
q	O
i	O
,	O
j	O
,	O
d	O
,	O
the	O
upper	O
probability	O
(	O
P	O
)	O
that	O
the	O
number	O
of	O
reads	O
(	O
R	O
)	O
with	O
a	O
certain	O
sequence	O
alteration	O
of	O
category	O
j	O
in	O
position	O
i	O
is	O
equal	O
or	O
greater	O
than	O
the	O
number	O
of	O
observed	O
reads	O
r	O
out	O
of	O
N	O
reads	O
with	O
a	O
sequenced	O
direction	O
d	O
for	O
an	O
unknown	O
sample	O
was	O
defined	O
as	O
:	O
(	O
2	O
)	O
where	O
,	O
lamda	O
i	O
,	O
j	O
,	O
d	O
=	O
N	O
i	O
,	O
d	O
x	O
q	O
i	O
,	O
j	O
,	O
d	O
.	O

The	O
haplotype	O
associated	O
with	O
IVS45	B-VARIANT
-	I-VARIANT
9G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
Quebec	O
patients	O
matches	O
with	O
the	O
CDH23	B-GENE
haplotype	O
of	O
two	O
German	O
families	O
that	O
we	O
have	O
investigated	O
previously	O
[	O
19	O
]	O
.	O

In	O
total	O
46	O
individuals	O
were	O
screened	O
for	O
CD164	B-GENE
mutations	O
.	O

not	O
confirmed	O
by	O
segregation	O
study	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
primers	O
used	O
to	O
amplify	O
and	O
sequence	O
the	O
entire	O
mitochondrial	O
DNA	O
is	O
given	O
according	O
the	O
Revised	O
Cambridge	O
Reference	O
Sequence	O
of	O
the	O
Human	O
Mitochondrial	O
DNA	O
(	O
RefSeq	O
:	O
AC_000021	O
.	O
2	O
)	O
numbering	O
,	O
described	O
as	O
being	O
the	O
"	O
Light	O
strand	O
.	O

Asterisks	O
indicate	O
available	O
samples	O
.	O

To	O
characterize	O
the	O
cellular	O
localization	O
of	O
ELMOD3	B-GENE
,	O
we	O
produced	O
a	O
rabbit	O
polyclonal	O
antiserum	O
against	O
synthetic	O
peptide	O
immunogens	O
from	O
mouse	O
ELMOD3	B-GENE
isoform	O
b	O
.	O

A	O
28	O
year	O
old	O
primigravida	O
was	O
referred	O
to	O
us	O
at	O
17	O
weeks	O
for	O
counselling	O
with	O
an	O
undiagnosed	O
skeletal	B-DISEASE
dysplasia	I-DISEASE
with	O
specific	O
skeletal	B-DISEASE
anomalies	I-DISEASE
suggesting	O
the	O
collagen	B-DISEASE
2	I-DISEASE
disorder	I-DISEASE
,	O
spondyloperipheral	B-DISEASE
dysplasia	I-DISEASE
(	O
SPD	B-DISEASE
;	I-DISEASE
MIM	O
156550	O
)	O
.	O

The	O
major	O
clinical	O
features	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
literature	O
,	O
including	O
in	O
Brazilian	O
patients	O
(	O
7	O
,	O
22	O
,	O
23	O
)	O
.	O

Importantly	O
,	O
it	O
has	O
been	O
shown	O
that	O
rs2435357T	B-VARIANT
allele	O
(	O
RET	B-GENE
intron	O
1	O
)	O
as	O
well	O
as	O
the	O
RET	B-GENE
risk	O
haplotype	O
are	O
linked	O
to	O
reduced	O
RET	B-GENE
expression	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
35	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

Therefore	O
,	O
we	O
detected	O
the	O
proband	O
of	O
the	O
family	O
using	O
exome	O
sequencing	O
to	O
identify	O
the	O
gene	O
responsible	O
for	O
this	O
disease	O
.	O

We	O
utilized	O
another	O
cohort	O
comprising	O
280	O
normal	O
Korean	O
control	O
subjects	O
to	O
exclude	O
rare	O
TECTA	B-GENE
variants	O
.	O

1	O
and	O
Table	O
1	O
)	O
.	O

It	O
may	O
be	O
argued	O
that	O
their	O
clinical	O
presentation	O
resembled	O
extreme	O
constitutional	B-DISEASE
delay	I-DISEASE
of	I-DISEASE
puberty	I-DISEASE
(	O
CDP	B-DISEASE
)	O
.	O

B	O
)	O
Atypical	O
image	O
obtained	O
in	O
the	O
patient	O
RP	O
-	O
531	O
,	O
in	O
whom	O
CNV	O
analysis	O
could	O
not	O
be	O
performed	O
.	O

In	O
Family	O
Y	O
,	O
the	O
lod	O
score	O
for	O
linkage	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
to	O
the	O
D7S496	O
-	O
D7S2459	O
haplotype	O
was	O
2	O
.	O
11	O
,	O
close	O
to	O
the	O
maximum	O
lod	O
score	O
possible	O
in	O
this	O
family	O
.	O

In	O
two	O
families	O
,	O
we	O
did	O
not	O
find	O
mutations	O
in	O
the	O
regions	O
evaluated	O
,	O
but	O
we	O
only	O
sequenced	O
the	O
most	O
common	O
sites	O
for	O
mutations	O
described	O
for	O
PS	B-DISEASE
.	O

Treacher	B-DISEASE
Collins	I-DISEASE
syndrome	I-DISEASE
(	O
TCS	B-DISEASE
;	O
OMIM	O
#	O
154500	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
that	O
affects	O
the	O
craniofacial	O
development	O
during	O
early	O
embryogenesis	O
[	O
1	O
]	O
.	O

Asterisks	O
indicate	O
p	O
<	O
0	O
.	O
01	O
.	O

As	O
a	O
result	O
,	O
we	O
only	O
detected	O
two	O
clearly	O
pathogenic	O
mutations	O
in	O
two	O
USH1	B-DISEASE
families	O
of	O
Italian	O
and	O
Spanish	O
origins	O
.	O

Nucleotide	O
variations	O
were	O
considered	O
likely	O
to	O
be	O
splice	O
site	O
mutations	O
when	O
predicted	O
highly	O
confident	O
donor	O
or	O
acceptor	O
site	O
mutations	O
by	O
Netgene2	O
and	O
"	O
Splice	O
site	O
prediction	O
by	O
neural	O
network	O
"	O
programs	O
.	O

Of	O
the	O
five	O
OPA1	B-GENE
patients	O
who	O
had	O
electrically	O
-	O
evoked	O
ABRs	O
,	O
the	O
subject	O
with	O
profound	B-DISEASE
deafness	I-DISEASE
(	O
Subject	O
7	O
)	O
also	O
showed	O
neural	O
potentials	O
(	O
electrically	O
-	O
evoked	O
compound	O
action	O
potentials	O
)	O
and	O
both	O
waves	O
II	O
and	O
V	O
in	O
ABR	O
recordings	O
in	O
response	O
to	O
electrical	O
stimulation	O
consistent	O
with	O
cochlear	B-DISEASE
deafness	I-DISEASE
.	O

One	O
such	O
gene	O
,	O
the	O
TRIC	B-GENE
gene	O
,	O
encodes	O
tricellulin	O
and	O
is	O
known	O
to	O
cause	O
NSHL	B-DISEASE
(	O
DFNB49	B-DISEASE
)	O
[	O
22	O
]	O
.	O

USH1C	B-GENE
therefore	O
should	O
be	O
considered	O
a	O
candidate	O
gene	O
in	O
patients	O
with	O
USH1	B-GENE
,	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
young	O
(	O
<	O
40	O
years	O
)	O
RP	B-DISEASE
patients	O
with	O
normal	O
hearing	O
function	O
,	O
and	O
RP	B-DISEASE
patients	O
with	O
mild	O
or	O
late	O
-	O
onset	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

6	O
)	O
.	O

gene	O
-	O
specific	O
approach	O
based	O
on	O
Long	O
-	O
PCR	O
enrichment	O
.	O

The	O
individuals	O
in	O
this	O
manuscript	O
have	O
given	O
written	O
informed	O
consent	O
(	O
as	O
outlined	O
in	O
PLOS	O
consent	O
form	O
)	O
to	O
publish	O
these	O
case	O
details	O
.	O

We	O
therefore	O
chose	O
to	O
use	O
as	O
input	O
for	O
our	O
custom	O
software	O
GSdot	O
the	O
complete	O
list	O
of	O
aligned	O
DNA	O
alterations	O
,	O
which	O
explains	O
the	O
relatively	O
high	O
number	O
of	O
candidate	O
DNA	O
variants	O
at	O
the	O
very	O
beginning	O
of	O
the	O
workflow	O
(	O
mean	O
4674	O
)	O
,	O
the	O
majority	O
of	O
which	O
,	O
92	O
.	O
3	O
%	O
(	O
i	O
.	O
e	O
.	O
,	O
4316	O
/	O
4674	O
)	O
are	O
removed	O
/	O
excluded	O
by	O
the	O
first	O
filter	O
.	O

We	O
found	O
the	O
mutation	O
previously	O
described	O
p	B-VARIANT
.	I-VARIANT
Y63X	I-VARIANT
[	O
9	O
]	O
and	O
two	O
novel	O
pathogenic	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
R207X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
I168N	I-VARIANT
.	O

The	O
mutations	O
we	O
identified	O
in	O
MYO7A	B-GENE
and	O
PDE6B	B-GENE
are	O
truncating	O
and	O
consequently	O
expected	O
to	O
be	O
null	O
.	O

The	O
data	O
consistently	O
showed	O
normal	O
aminoacylation	O
for	O
both	O
patients	O
while	O
mt	B-GENE
-	I-GENE
tRNA	I-GENE
Asn	I-GENE
,	O
Lys	O
,	O
Asp	O
levels	O
varied	O
between	O
experiments	O
and	O
patients	O
and	O
a	O
clear	O
determination	O
would	O
not	O
be	O
made	O
.	O

Therefore	O
,	O
this	O
family	O
segregated	O
autosomal	O
recessive	O
DFNB1	B-GENE
HI	B-DISEASE
with	O
a	O
pseudo	O
-	O
dominant	O
pattern	O
and	O
presented	O
intra	O
-	O
familial	O
phenotypic	O
variability	O
.	O

Haplotype	O
and	O
sequence	O
analysis	O
were	O
performed	O
to	O
identify	O
the	O
second	O
mutated	O
allele	O
.	O

The	O
cochlea	O
and	O
vestibular	O
system	O
were	O
separated	O
from	O
the	O
inner	O
ear	O
,	O
and	O
the	O
total	O
RNA	O
was	O
extracted	O
from	O
each	O
tissue	O
using	O
TRIreagent	O
(	O
Life	O
Technologies	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

Our	O
screening	O
procedure	O
does	O
not	O
miss	O
this	O
mutation	O
because	O
we	O
sequence	O
both	O
GJB2	B-GENE
exons	O
and	O
exon	O
-	O
intron	O
junctions	O
in	O
all	O
cases	O
in	O
which	O
DFNB1	B-GENE
HI	B-DISEASE
is	O
suspected	O
.	O

There	O
are	O
three	O
affected	O
males	O
and	O
the	O
pedigree	O
is	O
consistent	O
with	O
X	O
-	O
Linked	O
recessive	O
inheritance	O
(	O
5B	O
)	O
.	O

One	O
heterozygous	O
p	B-VARIANT
.	I-VARIANT
Gly843Asp	I-VARIANT
patient	O
was	O
found	O
to	O
carry	O
the	O
rare	O
homozygous	O
c	O
.	O
-	O
137	O
CC	O
c	O
.	O
-	O
53	O
GG	O
constellation	O
.	O

Note	O
the	O
depigmented	B-DISEASE
retina	I-DISEASE
and	O
underlying	O
choroid	O
vessels	O
.	O

As	O
fluid	O
homeostasis	O
is	O
important	O
for	O
correct	O
hearing	O
,	O
this	O
could	O
be	O
one	O
possible	O
mechanism	O
through	O
which	O
CD164	B-GENE
is	O
involved	O
in	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
average	O
depth	O
of	O
coverage	O
for	O
each	O
exon	O
of	O
targeted	O
deafness	B-DISEASE
genes	O
was	O
used	O
in	O
the	O
calculation	O
of	O
CNVs	O
.	O

The	O
patients	O
'	O
father	O
carried	O
a	O
c	B-VARIANT
.	I-VARIANT
1485	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
splicing	O
-	O
site	O
mutation	O
,	O
while	O
the	O
mother	O
carried	O
the	O
c	B-VARIANT
.	I-VARIANT
1460C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
missense	O
mutation	O
.	O

In	O
our	O
cohort	O
of	O
patients	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg257Stop	I-VARIANT
mutation	O
in	O
the	O
CERKL	B-GENE
gene	O
accounted	O
for	O
4	O
.	O
8	O
%	O
(	O
9	O
out	O
of	O
186	O
)	O
of	O
typical	O
RP	B-DISEASE
cases	O
.	O

The	O
symbols	O
for	O
deceased	O
family	O
members	O
have	O
a	O
slash	O
.	O

The	O
macroaneurysm	B-DISEASE
was	O
demonstrated	O
by	O
early	O
point	O
hyperfluorescence	O
through	O
the	O
retinal	B-DISEASE
hemorrhage	I-DISEASE
with	O
a	O
feeder	O
artery	O
and	O
late	O
leakage	O
.	O

JDS	O
looked	O
after	O
the	O
patient	O
.	O

The	O
ATP	O
binding	O
site	O
was	O
analyzed	O
using	O
the	O
Research	O
Collaboratory	O
for	O
Structural	O
Bioinformatics	O
(	O
RCSB	O
)	O
Protein	O
Data	O
Bank	O
(	O
PDB	O
)	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
pdb	O
.	O
org	O
)	O
[	O
38	O
]	O
.	O

Myoclonic	O
movements	O
started	O
at	O
3	O
months	O
of	O
age	O
,	O
rapidly	O
worsened	O
,	O
eventually	O
involving	O
all	O
four	O
extremities	O
and	O
complex	B-DISEASE
partial	I-DISEASE
seizures	I-DISEASE
were	O
recorded	O
.	O

A	O
commercially	O
-	O
available	O
CNV	O
test	O
kit	O
based	O
on	O
SYBR	O
green	O
chemistry	O
(	O
DyNAmo	O
ColorFlash	O
SYBR	O
Green	O
qPCR	O
Kit	O
,	O
Thermo	O
Scientific	O
Inc	O
.	O
,	O
Pittsburgh	O
PA	O
)	O
was	O
used	O
.	O

USH	B-DISEASE
shows	O
great	O
clinical	O
and	O
genetic	O
heterogeneities	O
.	O

(	O
B	O
)	O
Sanger	O
sequencing	O
electropherograms	O
confirming	O
the	O
COL4A5	B-GENE
donor	O
splice	O
site	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
687	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
,	O
and	O
multiple	O
species	O
sequence	O
alignment	O
showing	O
conserved	O
GT	O
in	O
the	O
donor	O
splice	O
site	O
.	O

We	O
next	O
carried	O
out	O
a	O
hearing	O
-	O
loss	O
-	O
targeted	O
linkage	O
scan	O
of	O
the	O
ten	O
families	O
,	O
using	O
68	O
microsatellite	O
markers	O
within	O
and	O
flanking	O
the	O
36	O
autosomal	O
genes	O
known	O
to	O
be	O
responsible	O
for	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
Table	O
1	O
)	O
[	O
15	O
]	O
.	O

Conservation	O
of	O
residues	O
across	O
several	O
species	O
was	O
examined	O
.	O

Histopathological	O
analysis	O
of	O
the	O
muscle	O
biopsy	O
revealed	O
myopathies	B-DISEASE
harboring	O
small	O
,	O
angulated	O
,	O
or	O
elongated	O
degenerating	B-DISEASE
myofibers	I-DISEASE
containing	O
aggregated	O
,	O
enlarged	O
mitochondria	O
with	O
concentric	O
cristae	O
.	O

In	O
mutational	O
studies	O
of	O
the	O
linkers	O
between	O
two	O
contiguous	O
zinc	O
fingers	O
,	O
mutation	O
of	O
threonine	O
to	O
alanine	O
had	O
deleterious	O
effects	O
on	O
DNA	O
binding	O
[	O
33	O
]	O
.	O

The	O
pathogenicity	O
of	O
several	O
exonic	O
variants	O
found	O
in	O
our	O
patients	O
and	O
predicted	O
to	O
be	O
pathogenic	O
in	O
previous	O
studies	O
and	O
/	O
or	O
by	O
prediction	O
software	O
was	O
further	O
investigated	O
.	O

Finally	O
,	O
six	O
variants	O
were	O
successfully	O
confirmed	O
in	O
the	O
WFS1	B-GENE
(	O
n	O
=	O
2	O
)	O
,	O
COCH	B-GENE
,	O
ACTG1	B-GENE
,	O
TMC1	B-GENE
,	O
and	O
POU4F3	B-GENE
genes	O
(	O
Table	O
2	O
)	O
.	O

Using	O
targeted	O
genomic	O
capture	O
and	O
MPS	O
,	O
we	O
have	O
successfully	O
identified	O
causative	O
gene	O
mutations	O
in	O
six	O
families	O
with	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
,	O
and	O
in	O
patients	O
from	O
a	O
family	O
with	O
recessive	B-DISEASE
DFNB	I-DISEASE
,	O
we	O
detected	O
two	O
monoallelic	O
mutations	O
in	O
the	O
GJB2	B-GENE
and	O
USH2A	B-GENE
genes	O
,	O
respectively	O
.	O

In	O
summary	O
,	O
two	O
novel	O
compound	O
heterozygous	O
mutations	O
in	O
USH2A	B-GENE
have	O
been	O
identified	O
with	O
exome	O
sequencing	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
undertook	O
a	O
large	O
-	O
scale	O
mutation	O
screening	O
of	O
all	O
currently	O
known	O
USH	B-DISEASE
genes	O
in	O
a	O
cohort	O
of	O
54	O
USH	B-DISEASE
patients	O
.	O

HMW	O
,	O
MHP	O
and	O
WGY	O
analyzed	O
the	O
data	O
.	O

4	O
)	O
,	O
we	O
used	O
the	O
annotation	O
mode	O
of	O
the	O
Versatile	O
Aggregate	O
Profiler	O
with	O
the	O
transcription	O
start	O
site	O
as	O
the	O
only	O
reference	O
point	O
and	O
100	O
windows	O
of	O
10	O
base	O
pairs	O
each	O
on	O
both	O
sides	O
of	O
the	O
reference	O
point	O
52	O
.	O

The	O
other	O
sister	O
(	O
II	O
-	O
3	O
)	O
of	O
the	O
index	O
patient	O
developed	O
proteinuria	B-DISEASE
with	O
increased	O
serum	O
creatinine	O
(	O
150	O
umol	O
/	O
L	O
)	O
at	O
age	O
50	O
,	O
with	O
no	O
MH	B-DISEASE
.	O

All	O
the	O
23	O
patients	O
had	O
typical	O
clinical	O
features	O
of	O
the	O
syndrome	O
and	O
pathogenic	O
mutations	O
were	O
detected	O
in	O
19	O
of	O
them	O
.	O

When	O
all	O
variants	O
were	O
included	O
,	O
exome	O
sequencing	O
revealed	O
:	O
(	O
1	O
)	O
83	O
non	O
-	O
synonymous	O
and	O
86	O
synonymous	O
variants	O
that	O
were	O
present	O
in	O
groups	O
1	O
+	O
2	O
and	O
absent	O
from	O
group	O
3	O
(	O
Table	O
S2	O
)	O
;	O
(	O
2	O
)	O
54	O
non	O
-	O
synonymous	O
and	O
48	O
synonymous	O
variants	O
that	O
were	O
present	O
in	O
group	O
1	O
and	O
absent	O
from	O
groups	O
2	O
+	O
3	O
(	O
Table	O
S3	O
)	O
;	O
(	O
3	O
)	O
6	O
,	O
033	O
non	O
-	O
synonymous	O
and	O
6	O
,	O
667	O
synonymous	O
variants	O
that	O
were	O
present	O
in	O
groups	O
1	O
+	O
2	O
,	O
but	O
not	O
specific	O
to	O
groups	O
1	O
+	O
2	O
(	O
thus	O
,	O
they	O
may	O
be	O
present	O
in	O
group	O
3	O
or	O
absent	O
from	O
group	O
3	O
)	O
;	O
and	O
(	O
4	O
)	O
7	O
,	O
073	O
non	O
-	O
synonymous	O
and	O
7	O
,	O
861	O
synonymous	O
variants	O
that	O
were	O
present	O
in	O
group	O
1	O
,	O
but	O
not	O
specific	O
to	O
group	O
1	O
.	O

In	O
our	O
series	O
of	O
study	O
,	O
we	O
were	O
able	O
to	O
detect	O
biallelic	O
mutations	O
in	O
one	O
USH	B-DISEASE
gene	O
in	O
22	O
out	O
of	O
32	O
USH	B-DISEASE
patients	O
(	O
68	O
.	O
75	O
%	O
)	O
and	O
to	O
identify	O
51	O
out	O
of	O
the	O
64	O
expected	O
mutated	O
alleles	O
(	O
a	O
detection	O
ratio	O
of	O
79	O
.	O
7	O
%	O
)	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
combination	O
of	O
two	O
mutations	O
affecting	O
the	O
long	O
usherin	O
isoform	O
have	O
a	O
relatively	O
mild	O
effect	O
on	O
audition	O
.	O

The	O
asterisk	O
indicates	O
family	O
members	O
where	O
DNA	O
samples	O
were	O
available	O
for	O
molecular	O
analysis	O
.	O

Physiologically	O
,	O
the	O
slowly	O
activating	O
delayed	O
rectifier	O
K	O
+	O
current	O
(	O
I	O
Ks	O
)	O
is	O
crucial	O
in	O
maintaining	O
the	O
cardiac	O
responses	O
that	O
generate	O
a	O
normal	O
T	O
wave	O
and	O
QT	O
interval	O
.	O

Imaging	O
was	O
performed	O
on	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
using	O
40	O
x	O
oil	O
-	O
immersion	O
objective	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Helsinki	O
Committees	O
of	O
Tel	O
Aviv	O
University	O
,	O
the	O
Israel	O
Ministry	O
of	O
Health	O
,	O
the	O
Human	O
Subjects	O
Committees	O
of	O
Bethlehem	O
University	O
,	O
and	O
the	O
Committee	O
for	O
Protection	O
of	O
Human	O
Subjects	O
of	O
the	O
University	O
of	O
Washington	O
(	O
protocol	O
33486	O
)	O
.	O

Not	O
only	O
is	O
it	O
challenging	O
to	O
generate	O
accurate	O
sequencing	O
data	O
without	O
pseudogene	O
inclusion	O
,	O
it	O
is	O
even	O
more	O
difficult	O
interpreting	O
such	O
data	O
without	O
the	O
usual	O
reliable	O
resources	O
for	O
mutation	O
interpretation	O
,	O
as	O
these	O
databases	O
are	O
'	O
polluted	O
'	O
with	O
pseudogene	O
data	O
as	O
well	O
.	O

Novel	O
mutations	O
responsible	O
for	O
inherited	O
deafness	B-DISEASE
in	O
four	O
kindreds	O
.	O

Yumiko	O
Kobayashi	O
and	O
Hiroaki	O
Sato	O
(	O
Iwate	O
Medical	O
University	O
)	O
,	O
Drs	O
.	O

Four	O
variants	O
were	O
classified	O
as	O
pathogenic	O
variants	O
,	O
including	O
2	O
known	O
variants	O
(	O
GJB2	B-GENE
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
and	O
MYO7A	B-GENE
p	B-VARIANT
.	I-VARIANT
T381M	I-VARIANT
)	O
and	O
2	O
novel	O
variants	O
(	O
KCNQ4	B-GENE
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
and	O
MYH9	B-GENE
p	B-VARIANT
.	I-VARIANT
E1256K	I-VARIANT
)	O
.	O

Abdominal	O
examination	O
revealed	O
normal	O
bowel	O
sounds	O
,	O
without	O
tenderness	B-DISEASE
on	I-DISEASE
palpation	I-DISEASE
or	O
rebound	B-DISEASE
tenderness	I-DISEASE
.	O

This	O
variant	O
was	O
not	O
reported	O
in	O
the	O
1000	O
Genomes	O
Project	O
or	O
in	O
the	O
Exome	O
Variant	O
Server	O
but	O
was	O
considered	O
non	O
-	O
pathogenic	O
.	O

Inherited	B-DISEASE
retinal	I-DISEASE
dystrophies	I-DISEASE
(	O
IRDs	B-DISEASE
)	O
are	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
progressive	O
dysfunction	O
and	O
death	O
of	O
retinal	O
photoreceptors	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
both	O
parents	O
of	O
the	O
patient	O
.	O

PCR	O
products	O
were	O
analysed	O
on	O
agarose	O
gel	O
and	O
ethidium	O
bromide	O
staining	O
using	O
standard	O
methods	O
.	O

C	O
:	O
The	O
minimum	O
coverage	O
of	O
a	O
percentage	O
of	O
targets	O
.	O

All	O
images	O
were	O
acquired	O
using	O
a	O
Zeiss	O
LSM	O
700	O
scanning	O
confocal	O
microscope	O
that	O
was	O
equipped	O
with	O
63	O
x	O
and	O
100	O
x	O
objectives	O
,	O
and	O
the	O
analyses	O
were	O
performed	O
using	O
ImageJ	O
software	O
.	O

The	O
microsatellite	O
marker	O
D11S937	O
,	O
which	O
is	O
close	O
to	O
the	O
candidate	O
gene	O
MYO7A	B-GENE
(	O
USH1B	B-GENE
locus	O
)	O
,	O
was	O
selected	O
for	O
genotyping	O
.	O

We	O
then	O
screened	O
additional	O
family	O
members	O
(	O
available	O
to	O
our	O
study	O
)	O
,	O
who	O
had	O
not	O
been	O
exome	O
sequenced	O
,	O
for	O
the	O
two	O
validated	O
variants	O
.	O

Here	O
we	O
report	O
the	O
new	O
diagnostic	O
pipeline	O
combining	O
Sanger	O
sequencing	O
and	O
targeted	O
resequencing	O
to	O
find	O
mutations	O
in	O
familial	O
NSHL	B-DISEASE
cases	O
.	O

,	O
2010	O
;	O
Leruez	O
et	O
al	O
.	O

In	O
many	O
of	O
those	O
unsolved	O
cases	O
,	O
the	O
cause	O
may	O
involve	O
a	O
known	O
or	O
a	O
novel	O
mutation	O
in	O
currently	O
known	O
causative	O
genes	O
.	O

To	O
predict	O
whether	O
a	O
novel	O
missense	O
variant	O
was	O
deleterious	O
,	O
we	O
used	O
the	O
combined	O
results	O
of	O
two	O
different	O
computer	O
algorithms	O
:	O
SIFT	O
and	O
PolyPhen	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
use	O
whole	O
exome	O
sequencing	O
(	O
WES	O
)	O
to	O
evaluate	O
the	O
genetic	O
causes	O
of	O
RSTS	B-DISEASE
in	O
a	O
young	O
girl	O
presenting	O
with	O
an	O
Autism	B-DISEASE
phenotype	O
.	O

More	O
than	O
250	O
OPA1	B-GENE
mutations	O
have	O
been	O
reported	O
to	O
date	O
.	O

Performed	O
the	O
experiments	O
:	O
ODH	O
DD	O
JF	O
AS	O
.	O

2	O
Prelingual	B-DISEASE
HL	I-DISEASE
is	O
typically	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
with	O
or	O
without	O
accompanying	O
other	O
syndromic	O
features	O
.	O

Compute	O
pI	O
/	O
Mw	O
is	O
applied	O
for	O
the	O
computation	O
of	O
the	O
theoretical	O
isoelectric	O
point	O
(	O
http	O
:	O
/	O
/	O
web	O
.	O
expasy	O
.	O
org	O
/	O
compute_pi	O
/	O
)	O
[	O
28	O
]	O
.	O

So	O
far	O
,	O
family	O
based	O
analyses	O
have	O
proven	O
that	O
this	O
methodology	O
is	O
successful	O
and	O
the	O
results	O
have	O
shown	O
that	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
five	O
separate	O
families	O
was	O
caused	O
by	O
five	O
different	O
genes	O
(	O
Table	O
1	O
)	O
,	O
thus	O
tentatively	O
confirming	O
the	O
already	O
well	O
-	O
established	O
finding	O
of	O
genetic	O
heterogeneity	O
in	O
ARNSHL	B-DISEASE
worldwide	O
is	O
in	O
fact	O
analogous	O
in	O
the	O
Saudi	O
population	O
.	O

She	O
was	O
thoroughly	O
evaluated	O
to	O
assess	O
problems	O
related	O
to	O
delayed	O
development	O
and	O
dysmorphology	O
.	O

27	O
28	O
To	O
our	O
knowledge	O
,	O
none	O
of	O
these	O
FGFR1	B-GENE
mutations	O
have	O
been	O
previously	O
reported	O
in	O
dbSNP	O
,	O
Exome	O
Variant	O
Server	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
or	O
the	O
scientific	O
literature	O
,	O
and	O
all	O
heterozygous	O
mutations	O
have	O
occurred	O
de	O
novo	O
.	O

Secondly	O
,	O
the	O
frequency	O
of	O
mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
in	O
this	O
study	O
did	O
not	O
differ	O
from	O
what	O
was	O
previously	O
reported	O
in	O
the	O
Korean	O
population	O
,	O
suggesting	O
the	O
drop	O
out	O
in	O
this	O
study	O
was	O
not	O
significantly	O
biased	O
.	O

A	O
sub	O
-	O
group	O
of	O
32	O
probands	O
was	O
additionally	O
analysed	O
by	O
direct	O
DNA	O
sequencing	O
.	O

Note	O
recombination	O
event	O
for	O
marker	O
D10S1759	O
in	O
patient	O
1235	O
.	O

,	O
2004	O
)	O
.	O

He	O
harbored	O
in	O
-	O
frame	O
3	O
-	O
bp	O
deletion	O
,	O
nucleotides	O
1060_1062	O
,	O
in	O
exon	O
8	O
,	O
that	O
results	O
in	O
the	O
loss	O
of	O
Phenylalanine	O
354	O
residue	O
.	O

This	O
screening	O
resulted	O
in	O
the	O
identification	O
of	O
common	O
KCNJ10	B-GENE
mutations	O
in	O
the	O
Chinese	O
population	O
.	O

Smaller	O
clusters	O
were	O
aggregated	O
into	O
an	O
"	O
Other	O
"	O
group	O
,	O
which	O
was	O
excluded	O
from	O
allele	O
frequency	O
calculations	O
since	O
it	O
does	O
not	O
represent	O
an	O
ancestry	O
-	O
based	O
population	O
.	O

We	O
are	O
grateful	O
to	O
Paul	O
F	O
.	O

The	O
protocol	O
of	O
this	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
at	O
the	O
six	O
participating	O
institutions	O
(	O
National	O
Hospital	O
Organization	O
Tokyo	O
Medical	O
Center	O
,	O
Jikei	O
University	O
School	O
of	O
Medicine	O
,	O
Mie	O
University	O
School	O
of	O
Medicine	O
,	O
Nagoya	O
University	O
Graduate	O
School	O
of	O
Medicine	O
,	O
Teikyo	O
University	O
School	O
of	O
Medicine	O
and	O
Kinki	O
University	O
Faculty	O
of	O
Medicine	O
)	O
.	O

One	O
variant	O
in	O
our	O
cohort	O
,	O
c	B-VARIANT
.	I-VARIANT
847C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg283Cys	I-VARIANT
)	O
,	O
occurs	O
at	O
a	O
DNA	O
-	O
contacting	O
residue	O
and	O
was	O
previously	O
reported	O
as	O
cancer	O
-	O
associated	O
[	O
58	O
]	O
.	O

Copy	O
number	O
variants	O
(	O
CNVs	O
)	O
,	O
often	O
de	O
novo	O
and	O
covering	O
multiple	O
adjacent	O
genes	O
,	O
have	O
been	O
identified	O
as	O
conferring	O
risk	O
3	O
,	O
4	O
.	O

Variants	O
did	O
not	O
occur	O
with	O
the	O
86	O
in	O
-	O
house	O
exomes	O
with	O
a	O
frequency	O
greater	O
than	O
5	O
%	O
.	O

Four	O
unrelated	O
Tunisian	O
families	O
including	O
one	O
or	O
several	O
deaf	O
individuals	O
(	O
DF11	O
,	O
DF25	O
,	O
DF99	O
,	O
and	O
DF103	O
)	O
were	O
studied	O
(	O
Fig	O
.	O

Louis	O
,	O
St	O
.	O

In	O
families	O
1	O
and	O
2	O
,	O
the	O
staining	O
pattern	O
was	O
characterized	O
by	O
numerous	O
aggregates	O
of	O
small	O
size	O
(	O
<	O
0	O
.	O
5	O
mu	O
m	O
)	O
(	O
Fig	O
.	O

c	O
-	O
d	O
Electron	O
micrographs	O
revealed	O
degenerating	B-DISEASE
myofibers	I-DISEASE
containing	O
diffusely	O
scattered	O
autophagic	O
vacuoles	O
,	O
distorted	O
myofibrillar	O
arrangement	O
,	O
abnormal	O
membranous	O
structures	O
,	O
and	O
aggregated	O
enlarged	O
mitochondria	O
with	O
swelling	O
,	O
concentric	O
cristae	O
,	O
and	O
dense	O
inclusions	O
.	O

We	O
targeted	O
all	O
well	O
-	O
annotated	O
protein	O
-	O
coding	O
regions	O
as	O
defined	O
by	O
the	O
CCDS	O
(	O
September	O
2009	O
)	O
.	O

C	O
.	O

Using	O
targeted	O
genomic	O
capture	O
and	O
MPS	O
,	O
104	O
genes	O
and	O
three	O
microRNA	O
regions	O
were	O
selected	O
and	O
simultaneously	O
sequenced	O
in	O
23	O
unrelated	O
probands	O
of	O
Chinese	O
families	O
with	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

A	O
high	O
-	O
throughout	O
and	O
cost	O
-	O
effective	O
method	O
to	O
detect	O
the	O
genetic	O
defects	O
is	O
needed	O
.	O

Moreover	O
,	O
although	O
in	O
many	O
cases	O
the	O
genetic	O
origin	O
of	O
thrombocytopenia	B-DISEASE
can	O
be	O
easily	O
suspected	O
for	O
the	O
presence	O
of	O
a	O
low	O
platelet	O
count	O
in	O
one	O
of	O
the	O
parents	O
,	O
it	O
appears	O
important	O
the	O
awareness	O
that	O
about	O
35	O
%	O
of	O
MYH9	B-GENE
-	O
RD	O
patients	O
are	O
sporadic	O
cases	O
,	O
and	O
,	O
therefore	O
,	O
present	O
with	O
no	O
familial	O
history	O
of	O
thrombocytopenia	B-DISEASE
[	O
2	O
]	O
.	O

All	O
available	O
members	O
of	O
the	O
pedigree	O
and	O
200	O
matched	O
control	O
individuals	O
were	O
screened	O
for	O
the	O
USH2A	B-GENE
c	B-VARIANT
.	I-VARIANT
4325T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
15188T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutations	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

We	O
were	O
unable	O
to	O
assess	O
stability	O
of	O
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
mutant	O
protein	O
in	O
vivo	O
since	O
no	O
patient	O
tissue	O
is	O
available	O
,	O
but	O
the	O
protein	O
was	O
stable	O
in	O
vitro	O
.	O

dCib2	O
RNAi	O
flies	O
show	O
a	O
reduction	O
in	O
response	O
amplitude	O
of	O
over	O
30	O
%	O
compared	O
to	O
control	O
flies	O
.	O

Abnormal	B-DISEASE
pupillary	I-DISEASE
response	I-DISEASE
,	O
nystagmus	B-DISEASE
,	O
and	O
cataracts	B-DISEASE
were	O
present	O
in	O
11	O
(	O
61	O
%	O
)	O
,	O
five	O
(	O
28	O
%	O
)	O
,	O
and	O
five	O
(	O
28	O
%	O
)	O
,	O
respectively	O
.	O

5E	O
.	O

D	O
.	O

It	O
is	O
possible	O
that	O
the	O
proportion	O
of	O
the	O
various	O
isoforms	O
may	O
differ	O
from	O
tissue	O
to	O
tissue	O
,	O
depending	O
upon	O
the	O
expression	O
of	O
transacting	O
splicing	O
factors	O
,	O
but	O
this	O
has	O
not	O
been	O
investigated	O
.	O

The	O
sibling	O
recurrence	O
-	O
risk	O
of	O
SNHL	B-DISEASE
among	O
42	O
genetically	O
undiagnosed	O
families	O
with	O
0	O
.	O
03	O
(	O
1	O
/	O
38	O
)	O
was	O
significantly	O
lower	O
than	O
among	O
genetically	O
diagnosed	O
recessive	O
families	O
with	O
0	O
.	O
19	O
(	O
7	O
/	O
37	O
)	O
.	O

SH	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
,	O
participated	O
in	O
the	O
sequence	O
alignment	O
and	O
drafted	O
the	O
manuscript	O
,	O
and	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
performed	O
the	O
statistical	O
analysis	O
.	O

c	B-VARIANT
.	I-VARIANT
8375	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
V2792A	I-VARIANT
)	O
was	O
predicted	O
to	O
be	O
damaging	O
by	O
SIFT	O
and	O
Polyphen2	O
(	O
see	O
URL8	O
,	O
9	O
)	O
.	O

c	O
In	O
-	O
frame	O
skipping	O
of	O
exon	O
12	O
(	O
p	B-VARIANT
.	I-VARIANT
T381	I-VARIANT
-	I-VARIANT
N404del	I-VARIANT
)	O
.	O

All	O
constructs	O
were	O
verified	O
by	O
restriction	O
analysis	O
and	O
sequencing	O
.	O

A	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
v1	O
(	O
38	O
Mb	O
)	O
B	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
v2	O
(	O
44	O
Mb	O
)	O
C	O
)	O
Agilent	O
SureSelect	O
Human	O
all	O
Exon	O
(	O
50	O
Mb	O
)	O
D	O
)	O
TrueSeq	O
Exome	O
(	O
68	O
MB	O
)	O
.	O

His	O
sister	O
(	O
IV	O
-	O
1	O
)	O
also	O
did	O
not	O
have	O
this	O
mutation	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
both	O
Family	O
DE2827	O
and	O
Family	O
DE3281	O
,	O
heterozygosity	O
for	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
co	O
-	O
segregated	O
with	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
phenotype	O
in	O
the	O
pedigree	O
(	O
Figure	O
5B	O
and	O
5C	O
)	O
,	O
except	O
for	O
case	O
I	O
-	O
1	O
of	O
Family	O
DE2827	O
,	O
which	O
exhibited	O
normal	O
hearing	O
that	O
corresponded	O
to	O
his	O
age	O
.	O

Of	O
note	O
,	O
anosmia	B-DISEASE
or	O
hyposmia	B-DISEASE
had	O
been	O
diagnosed	O
on	O
the	O
basis	O
of	O
anamnestic	O
information	O
,	O
olfactometry	O
,	O
or	O
by	O
the	O
inability	B-DISEASE
to	I-DISEASE
recognize	I-DISEASE
familiar	I-DISEASE
odors	I-DISEASE
such	O
as	O
coffee	O
.	O

A	O
genome	O
-	O
wide	O
linkage	O
analysis	O
was	O
performed	O
using	O
Illumina	O
Cyto	O
-	O
12	O
Chip	O
containing	O
300	O
,	O
000	O
SNP	O
markers	O
.	O

As	O
seen	O
in	O
previous	O
mutation	O
screening	O
reports	O
,	O
we	O
encountered	O
a	O
significant	O
number	O
of	O
heterozygous	O
cases	O
without	O
a	O
second	O
mutation	O
even	O
after	O
direct	O
sequencing	O
of	O
the	O
coding	O
region	O
of	O
the	O
gene	O
.	O

In	O
previous	O
studies	O
,	O
families	O
with	O
consanguineous	O
marriages	O
and	O
large	O
sibships	O
were	O
preferentially	O
recruited	O
[	O
47	O
]	O
.	O

It	O
should	O
however	O
be	O
noted	O
that	O
the	O
first	O
available	O
audiograms	O
of	O
II	O
:	O
2	O
were	O
made	O
at	O
the	O
age	O
of	O
60	O
years	O
and	O
that	O
the	O
first	O
available	O
audiograms	O
of	O
III	O
:	O
2	O
were	O
made	O
at	O
the	O
age	O
of	O
60	O
years	O
.	O

Green	O
stars	O
,	O
individuals	O
whose	O
samples	O
were	O
subjected	O
to	O
WES	O
.	O

The	O
variants	O
c	B-VARIANT
.	I-VARIANT
721C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg241Gly	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
4411T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ser1471Pro	I-VARIANT
)	O
have	O
already	O
been	O
reported	O
in	O
Italian	O
patients	O
with	O
USH	B-DISEASE
(	O
[	O
15	O
]	O
and	O
[	O
22	O
]	O
respectively	O
)	O
,	O
and	O
the	O
repeated	O
detection	O
in	O
various	O
small	O
series	O
of	O
Italian	O
patients	O
suggests	O
that	O
these	O
variants	O
may	O
be	O
a	O
recurrent	O
variant	O
in	O
Italian	O
patients	O
with	O
USH	B-DISEASE
,	O
even	O
if	O
c	B-VARIANT
.	I-VARIANT
721C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg241Gly	I-VARIANT
)	O
has	O
been	O
reported	O
in	O
other	O
ethnic	O
groups	O
[	O
16	O
]	O
.	O

B	O
.	O

The	O
proband	O
(	O
II	O
-	O
1	O
;	O
Table	O
1	O
and	O
Fig	O
.	O

No	O
carrier	O
of	O
the	O
c	B-VARIANT
.	I-VARIANT
637G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
was	O
found	O
in	O
the	O
500	O
ancestry	O
-	O
matched	O
control	O
chromosomes	O
,	O
the	O
1000	O
Genome	O
Project	O
or	O
the	O
NHLBI	O
EVS	O
database	O
.	O

Genetic	O
analysis	O
revealed	O
four	O
novel	O
EYA1	B-GENE
mutations	O
and	O
a	O
large	O
deletion	O
encompassing	O
the	O
EYA1	B-GENE
gene	O
.	O

Amplification	O
was	O
performed	O
with	O
the	O
following	O
cycling	O
profile	O
:	O
incubation	O
at	O
94	O
deg	O
C	O
for	O
5	O
min	O
followed	O
by	O
36	O
cycles	O
of	O
45	O
s	O
denaturation	O
at	O
94	O
deg	O
C	O
,	O
45	O
s	O
annealing	O
at	O
58	O
deg	O
C	O
and	O
45	O
s	O
elongation	O
at	O
72	O
deg	O
C	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
(	O
highlighted	O
)	O
affects	O
a	O
highly	O
conserved	O
amino	O
acid	O
.	O

Speech	O
recognition	O
scores	O
as	O
evaluated	O
in	O
a	O
quiet	O
environment	O
(	O
Fig	O
.	O

Instead	O
,	O
a	O
skip	O
of	O
exon	O
3	O
(	O
p	B-VARIANT
.	I-VARIANT
V18_Q45del	I-VARIANT
)	O
was	O
hypothesized	O
.	O

However	O
,	O
since	O
the	O
A	O
>	O
G	O
mutation	O
did	O
not	O
support	O
use	O
of	O
the	O
normal	O
exon	O
IIIc	O
donor	O
splice	O
site	O
(	O
Figure	O
2	O
C	O
)	O
,	O
other	O
explanations	O
for	O
these	O
differences	O
are	O
possible	O
,	O
such	O
as	O
differing	O
proportions	O
of	O
cell	O
types	O
in	O
the	O
blood	O
samples	O
analysed	O
,	O
and	O
/	O
or	O
differences	O
in	O
genetic	O
background	O
.	O

Siddiqi	O
MS	O
JO	O
HA	O
AB	O
M	O
.	O

The	O
filled	O
symbols	O
and	O
open	O
symbols	O
indicate	O
affected	O
and	O
unaffected	O
individuals	O
,	O
respectively	O
.	O

Forty	O
-	O
three	O
mutations	O
have	O
been	O
reported	O
in	O
MYO15A	B-GENE
,	O
most	O
of	O
which	O
have	O
been	O
found	O
by	O
linkage	O
analysis	O
in	O
consanguineous	O
families	O
from	O
specific	O
countries	O
,	O
such	O
as	O
Pakistan	O
,	O
Turkey	O
,	O
and	O
Iran	O
[	O
5	O
-	O
7	O
]	O
.	O

The	O
analysis	O
of	O
protein	O
structure	O
by	O
molecular	O
modeling	O
suggests	O
that	O
the	O
mutation	O
may	O
change	O
the	O
structure	O
of	O
OPA1	B-GENE
by	O
formation	O
of	O
an	O
alpha	O
helix	O
protruding	O
into	O
an	O
existing	O
pocket	O
.	O

Nuclei	O
were	O
stained	O
with	O
4	O
'	O
,	O
6	O
-	O
Diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
and	O
mounted	O
on	O
SuperFrost	O
glass	O
slides	O
(	O
Hounisen	O
,	O
Risskov	O
,	O
Denmark	O
)	O
.	O

Thirteen	O
of	O
these	O
were	O
already	O
published	O
and	O
7	O
are	O
novel	O
(	O
Table	O
3	O
)	O
.	O

Clinical	O
and	O
genetic	O
data	O
of	O
4	O
COL4A5	B-GENE
c	B-VARIANT
.	I-VARIANT
499delC	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro167Gln	I-VARIANT
fs	I-VARIANT
*	I-VARIANT
36	I-VARIANT
)	O
mutation	O
carriers	O
.	O

In	O
addition	O
,	O
MYO7A	B-GENE
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
C154X	I-VARIANT
)	O
was	O
found	O
in	O
three	O
normal	O
hearing	O
family	O
members	O
,	O
including	O
the	O
father	O
and	O
two	O
grand	O
-	O
daughters	O
(	O
I	O
:	O
1	O
,	O
III	O
:	O
1	O
,	O
and	O
III	O
:	O
3	O
)	O
,	O
while	O
MYO7A	B-GENE
c	B-VARIANT
.	I-VARIANT
73G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
G25R	I-VARIANT
)	O
was	O
found	O
only	O
in	O
the	O
mother	O
(	O
I	O
:	O
2	O
)	O
(	O
Figure	O
1	O
)	O
.	O

However	O
,	O
probably	O
due	O
to	O
being	O
too	O
large	O
to	O
be	O
screened	O
by	O
conventional	O
direct	O
sequencing	O
,	O
the	O
routine	O
screening	O
of	O
this	O
particular	O
gene	O
was	O
hampered	O
in	O
spite	O
of	O
its	O
importance	O
in	O
this	O
particular	O
population	O
.	O

The	O
interpretation	O
of	O
these	O
data	O
requires	O
an	O
understanding	O
of	O
the	O
variation	O
in	O
cancer	B-DISEASE
risk	O
-	O
associated	O
genes	O
in	O
healthy	O
individuals	O
,	O
which	O
is	O
largely	O
uncharacterized	O
.	O

Deafness	B-DISEASE
was	O
defined	O
by	O
an	O
auditive	O
examination	O
and	O
could	O
lead	O
to	O
hearing	O
help	O
in	O
some	O
cases	O
.	O

He	O
noticed	O
his	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
around	O
age	O
20	O
.	O

CLC	O
Sequence	O
Viewer	O
v6	O
.	O
0	O
.	O
1	O
software	O
(	O
CLC	O
Bio	O
,	O
Aarhus	O
,	O
Denmark	O
)	O
was	O
used	O
to	O
determine	O
the	O
level	O
of	O
conservation	O
of	O
protein	O
sequences	O
between	O
humans	O
and	O
selected	O
vertebrates	O
.	O

Six	O
variations	O
were	O
described	O
in	O
five	O
families	O
with	O
autosomal	O
recessive	O
nonsyndromic	O
HL	B-DISEASE
.	O

We	O
identified	O
germline	O
truncation	O
variants	O
(	O
nonsense	O
,	O
nonstop	O
,	O
splice	O
site	O
,	O
and	O
frameshift	O
indels	O
)	O
in	O
these	O
429	O
matched	O
tumor	O
-	O
normal	O
cases	O
using	O
multiple	O
algorithms	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
accompanying	O
images	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1253delA	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Y418fsX459	I-VARIANT
)	O
mutation	O
is	O
predicted	O
to	O
yield	O
a	O
truncated	O
TBX1C	B-GENE
protein	O
missing	O
the	O
NLS	O
and	O
most	O
of	O
the	O
TAD	O
.	O

Haplotype	O
analysis	O
suggested	O
linkage	O
of	O
the	O
family	O
to	O
the	O
WS4B	O
(	O
EDN3	B-GENE
)	O
locus	O
.	O

We	O
included	O
149	O
patients	O
with	O
USH2	B-DISEASE
,	O
29	O
patients	O
with	O
USH1	B-DISEASE
,	O
and	O
six	O
patients	O
with	O
USHA	B-DISEASE
in	O
this	O
study	O
.	O

One	O
affected	O
male	O
was	O
in	O
the	O
family	O
(	O
3D	O
)	O
.	O

To	O
further	O
confirm	O
the	O
abnormality	O
in	O
exon	O
45	O
detected	O
at	O
the	O
cDNA	O
level	O
,	O
genomic	O
DNAs	O
of	O
II	O
-	O
2	O
,	O
III	O
-	O
1	O
,	O
and	O
I	O
-	O
2	O
were	O
amplified	O
using	O
the	O
published	O
PCR	O
primers	O
and	O
conditions	O
for	O
exon	O
45	O
[	O
18	O
]	O
and	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
.	O

To	O
generate	O
fluorescence	O
constructs	O
containing	O
the	O
C	O
-	O
terminal	O
(	O
CTR	O
)	O
of	O
CD164	B-GENE
,	O
wild	O
-	O
type	O
and	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
(	O
with	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
lacking	O
the	O
last	O
six	O
residues	O
RNYHTL	O
)	O
,	O
mCherry	O
and	O
eGFP	O
were	O
amplified	O
by	O
PCR	O
and	O
subcloned	O
into	O
pSECTAG2bzeo	O
(	O
Invitrogen	O
)	O
in	O
reading	O
frame	O
with	O
the	O
ER	O
signal	O
peptide	O
present	O
in	O
this	O
vector	O
.	O

Luciferase	O
reporter	O
assays	O
in	O
HEK293T	O
cells	O
transfected	O
with	O
the	O
ERSE	O
reporter	O
together	O
with	O
control	O
(	O
pcDNA	O
)	O
,	O
wild	O
-	O
type	O
WFS1	B-GENE
(	O
WT	O
)	O
,	O
mutant	O
c	B-VARIANT
.	I-VARIANT
937C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
WFS1	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
)	O
,	O
or	O
mutant	O
c	B-VARIANT
.	I-VARIANT
940T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
WFS1	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
)	O
expression	O
plasmid	O
.	O

However	O
,	O
to	O
confirm	O
that	O
c	B-VARIANT
.	I-VARIANT
794T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
did	O
not	O
affect	O
splicing	O
of	O
ELMOD3	B-GENE
transcripts	O
,	O
we	O
generated	O
cDNA	O
libraries	O
using	O
the	O
total	O
RNA	O
extracted	O
from	O
the	O
white	O
blood	O
cells	O
of	O
two	O
affected	O
and	O
one	O
normal	O
hearing	O
individual	O
.	O

Visual	O
acuity	O
was	O
poor	O
except	O
the	O
younger	O
patient	O
,	O
RP	O
-	O
1850	O
,	O
who	O
is	O
19	O
years	O
old	O
,	O
but	O
she	O
experienced	O
a	O
considerable	O
loss	O
of	O
vision	O
in	O
the	O
last	O
year	O
.	O

76bp	O
reads	O
were	O
aligned	O
to	O
the	O
genome	O
using	O
MAQ	O
algorithm	O
44	O
within	O
the	O
Picard	O
analysis	O
pipeline	O
,	O
and	O
further	O
processed	O
using	O
the	O
SAMtools	O
software	O
45	O
and	O
custom	O
scripts	O
.	O

The	O
major	O
difference	O
between	O
the	O
two	O
disorders	O
is	O
thyroid	O
abnormality	O
(	O
goiter	B-DISEASE
)	O
which	O
is	O
observed	O
to	O
be	O
segregating	O
with	O
PS	B-DISEASE
[	O
2	O
]	O
.	O

The	O
error	O
rate	O
for	O
next	O
-	O
generation	O
sequencing	O
is	O
estimated	O
to	O
be	O
1	O
%	O
[	O
10	O
]	O
and	O
therefore	O
multiple	O
reads	O
are	O
required	O
to	O
obtain	O
equivalent	O
sensitivity	O
to	O
Sanger	O
sequencing	O
.	O

These	O
findings	O
indicate	O
that	O
missense	O
and	O
truncating	O
mutations	O
of	O
USH1G	B-GENE
can	O
result	O
in	O
a	O
milder	O
USH	B-DISEASE
phenotype	O
,	O
and	O
that	O
the	O
severity	O
of	O
the	O
phenotype	O
induced	O
by	O
USH1G	B-GENE
mutations	O
may	O
be	O
modified	O
by	O
unknown	O
genetic	O
or	O
environmental	O
factors	O
[	O
16	O
]	O
.	O

[	O
17	O
]	O
,	O
who	O
compared	O
peripapillary	O
RNFL	B-DISEASE
thickness	I-DISEASE
of	O
33	O
patients	O
to	O
healthy	O
controls	O
using	O
Stratus	O
OCT	O
.	O

Additionally	O
,	O
we	O
screened	O
for	O
the	O
three	O
mutations	O
mentioned	O
above	O
in	O
93	O
Korean	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
by	O
Sanger	O
sequencing	O
.	O

For	O
cascade	O
screening	O
of	O
relatives	O
,	O
mutation	O
analysis	O
was	O
performed	O
by	O
sequencing	O
as	O
described	O
above	O
,	O
or	O
by	O
directed	O
mutation	O
analysis	O
with	O
MGB	O
probes	O
using	O
the	O
TaqMan	O
7000	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

In	O
Chinese	O
Hans	O
,	O
for	O
example	O
,	O
bi	O
-	O
allelic	O
GJB2	B-GENE
mutations	O
were	O
reported	O
in	O
19	O
.	O
1	O
%	O
of	O
patients	O
with	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
deafness	I-DISEASE
,	O
followed	O
by	O
bi	O
-	O
allelic	O
SLC26A4	B-GENE
mutations	O
in	O
12	O
.	O
1	O
%	O
and	O
the	O
mitochondrial	O
A1555G	B-VARIANT
mutation	O
of	O
MT	B-GENE
-	I-GENE
RNR	I-GENE
in	O
1	O
.	O
6	O
%	O
[	O
4	O
-	O
6	O
]	O
.	O

Pathogenic	O
variants	O
identified	O
by	O
whole	O
exome	O
sequencing	O
a	O
A	O
SIFT	O
score	O
of	O
<	O
0	O
.	O
05	O
is	O
predicted	O
to	O
be	O
deleterious	O
.	O

Plain	O
radiographs	O
of	O
our	O
patient	O
'	O
s	O
grandmother	O
(	O
A	O
)	O
and	O
father	O
(	O
B	O
)	O
show	O
end	O
-	O
stage	O
OA	B-DISEASE
,	O
while	O
a	O
radiograph	O
of	O
our	O
patient	O
'	O
s	O
mother	O
(	O
C	O
)	O
appears	O
almost	O
normal	O
.	O

*	O
*	O
*	O
DAMAGING	O
by	O
SIFT	O
,	O
PolyPhen2	O
result	O
:	O
Unknown	O
WARNING	O
:	O
BLAST	O
search	O
results	O
for	O
PCDH15	B-GENE
truncated	O
due	O
to	O
total	O
number	O
of	O
HSPs	O
>	O
2000	O
.	O

3B	O
and	O
3C	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
results	O
of	O
our	O
project	O
,	O
which	O
we	O
term	O
"	O
Mito10K	O
"	O
reflecting	O
the	O
103	O
candidate	O
genes	O
sequenced	O
in	O
103	O
patients	O
with	O
CI	B-DISEASE
deficiency	I-DISEASE
.	O

In	O
our	O
study	O
,	O
only	O
93	O
subjects	O
participated	O
in	O
the	O
molecular	O
genetic	O
test	O
among	O
initially	O
eligible	O
236	O
patients	O
.	O

3	O
)	O
.	O

4d	O
-	O
f	O
)	O
.	O

The	O
ESP	O
dataset	O
showed	O
a	O
striking	O
ratio	O
of	O
synonymous	O
to	O
non	O
-	O
synonymous	O
substitutions	O
of	O
79	O
:	O
1	O
for	O
the	O
covered	O
portion	O
of	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
combined	O
.	O

2013	O
)	O
.	O

In	O
addition	O
,	O
despite	O
the	O
wide	O
geographic	O
distribution	O
of	O
these	O
families	O
,	O
a	O
common	O
ancestry	O
was	O
described	O
[	O
13	O
]	O
,	O
as	O
all	O
the	O
affected	O
members	O
of	O
the	O
seven	O
families	O
studied	O
shared	O
the	O
same	O
haplotype	O
.	O

The	O
cell	O
lysates	O
and	O
the	O
immunoprecipitates	O
were	O
processed	O
for	O
Western	O
blot	O
analysis	O
[	O
66	O
]	O
.	O

Table	O
1	O
.	O

We	O
used	O
GATK	O
over	O
the	O
six	O
samples	O
together	O
to	O
call	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
indels	O
.	O

1	O
)	O
had	O
enlarged	B-DISEASE
testes	I-DISEASE
;	O
however	O
,	O
they	O
did	O
not	O
want	O
to	O
cease	O
TRT	O
to	O
further	O
assess	O
the	O
reversal	O
of	O
HH	B-DISEASE
.	O

It	O
is	O
also	O
noteworthy	O
that	O
abnormal	O
nerve	O
conduction	O
studies	O
were	O
documented	O
in	O
two	O
DOA	O
+	O
patients	O
with	O
no	O
overt	O
neuropathic	O
features	O
.	O

Of	O
note	O
,	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
not	O
detected	O
;	O
this	O
resembles	O
the	O
rhodopsin	B-GENE
p	B-VARIANT
.	I-VARIANT
P23H	I-VARIANT
mutation	O
,	O
which	O
has	O
been	O
found	O
in	O
12	O
%	O
of	O
Irish	O
-	O
American	O
families	O
with	O
autosomal	O
dominant	O
RP	O
,	O
but	O
not	O
in	O
Europe	O
[	O
22	O
]	O
.	O

This	O
is	O
a	O
subgroup	O
(	O
12	O
%	O
)	O
of	O
a	O
larger	O
cohort	O
described	O
previously	O
(	O
2	O
)	O
.	O

A	O
detailed	O
clinical	O
history	O
of	O
each	O
affected	O
member	O
was	O
collected	O
to	O
ensure	O
that	O
hearing	B-DISEASE
loss	I-DISEASE
was	O
not	O
due	O
to	O
infections	O
,	O
ototoxic	O
drugs	O
,	O
trauma	O
or	O
premature	O
birth	O
and	O
was	O
not	O
accompanied	O
by	O
any	O
apparent	O
ear	O
,	O
eye	O
,	O
head	O
,	O
neck	O
,	O
skin	O
,	O
skeletal	O
or	O
neurological	O
abnormalities	O
.	O

Percentages	O
of	O
giant	O
,	O
intermediate	O
-	O
sized	O
,	O
or	O
normal	O
platelets	O
were	O
compared	O
in	O
four	O
groups	O
of	O
patients	O
defined	O
by	O
their	O
platelet	O
count	O
(	O
x	O
10	O
9	O
/	O
L	O
)	O
:	O
<	O
10	O
,	O
11	O
-	O
50	O
,	O
51	O
-	O
99	O
,	O
and	O
100	O
-	O
136	O
using	O
the	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
test	O
(	O
Kruskal	O
-	O
Wallis	O
test	O
)	O
.	O

B	O
:	O
SSCP	O
analysis	O
for	O
c	B-VARIANT
.	I-VARIANT
11806A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
T3936P	I-VARIANT
)	O
showed	O
that	O
the	O
mutant	O
pattern	O
(	O
three	O
bands	O
)	O
cosegregated	O
with	O
the	O
affected	O
individuals	O
and	O
carriers	O
,	O
but	O
not	O
with	O
the	O
unaffected	O
individuals	O
and	O
normal	O
control	O
(	O
two	O
bands	O
)	O
.	O

In	O
addition	O
,	O
the	O
cases	O
with	O
heterozygous	O
or	O
no	O
causative	O
mutation	O
were	O
fully	O
sequenced	O
by	O
Sanger	O
sequencing	O
for	O
USH1	B-DISEASE
genes	O
in	O
order	O
to	O
verify	O
the	O
MPS	O
results	O
.	O

For	O
the	O
remaining	O
25	O
missense	O
variants	O
and	O
2	O
in	O
-	O
frame	O
deletions	O
,	O
all	O
of	O
them	O
changed	O
evolutionarily	O
conserved	O
amino	O
acids	O
with	O
positive	O
PhyloP	O
scores	O
and	O
were	O
predicted	O
to	O
be	O
disease	O
-	O
causing	O
by	O
at	O
least	O
one	O
of	O
the	O
Mutation	O
Taster	O
,	O
PROVEAN	O
and	O
SIFT	O
programs	O
.	O

One	O
affected	O
subject	O
from	O
each	O
branch	O
was	O
subject	O
to	O
targeted	O
NGS	O
whose	O
genomic	O
DNA	O
was	O
enriched	O
either	O
by	O
whole	O
-	O
exome	O
capture	O
(	O
Agilent	O
SureSelect	O
All	O
Exon	O
50	O
Mb	O
)	O
or	O
by	O
candidate	O
genes	O
capture	O
(	O
Agilent	O
SureSelect	O
custom	O
kit	O
)	O
.	O

As	O
mentioned	O
above	O
,	O
this	O
family	O
was	O
nonconsanguineous	O
and	O
homozygosity	O
mapping	O
did	O
not	O
reveal	O
large	O
homozygous	O
regions	O
,	O
we	O
therefore	O
considered	O
both	O
homozygous	O
changes	O
and	O
two	O
heterozygous	O
changes	O
affecting	O
the	O
same	O
gene	O
.	O

Several	O
mutations	O
(	O
7444G	B-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
7445A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
7472insC	B-VARIANT
,	O
7510T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
7511T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
and	O
7512T	B-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
in	O
the	O
mitochondrial	B-GENE
tRNA	I-GENE
ser	I-GENE
(	I-GENE
UCN	I-GENE
)	I-GENE
gene	O
are	O
also	O
known	O
to	O
cause	O
maternally	O
inherited	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
by	O
disrupting	O
the	O
tRNA	O
structure	O
and	O
function	O
[	O
33	O
-	O
35	O
]	O
.	O

The	O
family	O
is	O
characterized	O
by	O
a	O
recessive	O
pattern	O
of	O
inheritance	O
.	O

This	O
study	O
was	O
supported	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
-	O
National	O
Institute	O
on	O
Deafness	B-DISEASE
and	O
Other	O
Communication	O
Disorders	O
grant	O
R01DC012836	O
to	O
MT	O
and	O
the	O
University	O
of	O
Ibadan	O
Tertiary	O
Education	O
Trust	O
Fund	O
to	O
AOL	O
.	O
Academic	O
Editor	O
:	O
Karen	O
Friderici	O
Mutations	O
in	O
the	O
estrogen	B-GENE
-	I-GENE
related	I-GENE
receptor	I-GENE
beta	I-GENE
(	O
ESRRB	B-GENE
)	O
gene	O
is	O
the	O
underlying	O
cause	O
of	O
autosomal	B-DISEASE
recessive	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
impairment	I-DISEASE
(	O
ARNSHI	B-DISEASE
)	O
due	O
to	O
the	O
DFNB35	O
locus	O
which	O
maps	O
to	O
14q24	O
.	O
3	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

On	O
the	O
basis	O
of	O
this	O
study	O
we	O
advise	O
to	O
perform	O
extensive	O
genetic	O
testing	O
of	O
at	O
least	O
WFS1	B-GENE
and	O
OPA1	B-GENE
in	O
cases	O
of	O
autosomal	O
dominant	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
deafness	B-DISEASE
.	O

In	O
the	O
last	O
decade	O
,	O
the	O
use	O
of	O
electrocochleography	O
(	O
ECochG	O
)	O
recording	O
has	O
been	O
proposed	O
in	O
the	O
diagnosis	O
of	O
auditory	B-DISEASE
neuropathy	I-DISEASE
for	O
defining	O
the	O
details	O
of	O
both	O
receptor	O
and	O
neural	O
responses	O
in	O
the	O
various	O
forms	O
of	O
the	O
disorder	O
(	O
Santarelli	O
and	O
Arslan	O
,	O
2002	O
;	O
McMahon	O
et	O
al	O
.	O

Time	O
'	O
0	O
'	O
refers	O
to	O
cochlear	O
microphonic	O
onset	O
.	O

Identification	O
of	O
the	O
responsible	O
mutation	O
in	O
families	O
with	O
autosomal	B-DISEASE
-	I-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
is	O
difficult	O
because	O
mutations	O
in	O
27	O
different	O
genes	O
have	O
been	O
identified	O
as	O
causing	O
this	O
common	O
form	O
of	O
deafness	B-DISEASE
(	O
Hereditary	O
Hearing	O
Loss	O
Homepage	O
)	O
.	O

The	O
most	O
common	O
molecular	O
cause	O
of	O
CHI	B-DISEASE
is	O
the	O
dysfunction	O
of	O
the	O
pancreatic	O
K	O
+	O
ATP	O
channel	O
encoded	O
by	O
the	O
sulfonylurea	O
receptor	O
gene	O
(	O
SUR1	B-GENE
,	O
alias	O
ABCC8	B-GENE
)	O
and	O
the	O
inward	O
-	O
rectifying	O
potassium	O
channel	O
gene	O
(	O
KIR6	B-GENE
.	I-GENE
2	I-GENE
,	O
alias	O
KCNJ11	B-GENE
)	O
.	O

Sequencing	O
reactions	O
and	O
mutational	O
analyses	O
were	O
performed	O
as	O
described	O
previously	O
.	O

We	O
used	O
Kcnj10	B-GENE
as	O
a	O
marker	O
of	O
intermediate	O
cells	O
(	O
C	O
)	O
and	O
laminin	O
as	O
a	O
marker	O
of	O
the	O
basal	O
lamina	O
surrounding	O
blood	O
vessels	O
(	O
D	O
)	O
in	O
the	O
stria	O
vascularis	O
in	O
the	O
sections	O
shown	O
in	O
A	O
.	O

We	O
sequenced	O
PCR	O
products	O
containing	O
coding	O
exons	O
from	O
CRKL	B-GENE
using	O
the	O
sanger	O
method	O
,	O
and	O
no	O
mutations	O
were	O
detected	O
.	O

ConSeq	O
[	O
19	O
]	O
and	O
GetArea	O
version	O
1	O
.	O
1	O
using	O
a	O
sphere	O
probe	O
radius	O
of	O
1	O
.	O
4	O
A	O
[	O
20	O
]	O
were	O
used	O
to	O
analyze	O
solvent	O
accessibility	O
surface	O
.	O

In	O
Acadians	O
,	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
is	O
responsible	O
for	O
virtually	O
all	O
USH1	B-DISEASE
cases	O
(	O
only	O
one	O
out	O
of	O
44	O
Acadian	O
USH1	B-DISEASE
cases	O
has	O
been	O
shown	O
not	O
to	O
be	O
homozygous	O
,	O
but	O
compound	O
heterozygous	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
238	I-VARIANT
-	I-VARIANT
239insC	I-VARIANT
[	O
17	O
]	O
)	O
.	O

Our	O
results	O
show	O
that	O
rare	O
causative	O
mutations	O
in	O
known	O
ARNSHL	B-DISEASE
genes	O
can	O
be	O
reliably	O
identified	O
via	O
WES	O
.	O

Genetic	O
and	O
molecular	O
mechanism	O
of	O
the	O
missense	O
mutation	O
c	B-VARIANT
.	I-VARIANT
5765	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
A	I-VARIANT
at	O
the	O
donor	O
splice	O
site	O
of	O
intron	O
40	O
.	O

Etiological	O
studies	O
have	O
shown	O
that	O
approximately	O
two	O
-	O
thirds	O
of	O
congenital	O
/	O
early	O
-	O
onset	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
developed	O
countries	O
is	O
estimated	O
to	O
be	O
due	O
to	O
genetic	O
causes	O
[	O
1	O
]	O
.	O

18	O
In	O
this	O
respect	O
,	O
families	O
1	O
and	O
2	O
were	O
distinctive	O
in	O
their	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
may	O
be	O
an	O
indication	O
that	O
it	O
is	O
associated	O
with	O
a	O
recessive	O
mode	O
of	O
inheritance	O
.	O

These	O
patients	O
carrying	O
this	O
variation	O
presented	O
a	O
clinical	O
feature	O
of	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

control	O
exomes	O
from	O
the	O
WHISP	O
.	O

Figure	O
1	O
Flow	O
diagram	O
of	O
our	O
hierarchical	O
molecular	O
genetic	O
test	O
in	O
cochlear	O
implantees	O
.	O

Other	O
members	O
of	O
the	O
OSBPL	O
family	O
should	O
be	O
considered	O
as	O
potential	O
candidates	O
in	O
future	O
studies	O
aimed	O
at	O
the	O
identification	O
of	O
novel	O
deafness	B-DISEASE
genes	O
.	O

This	O
experiment	O
was	O
repeated	O
with	O
a	O
different	O
preparation	O
,	O
and	O
essentially	O
identical	O
results	O
were	O
obtained	O
.	O

The	O
median	O
gestational	O
age	O
at	O
confirmation	O
of	O
diagnosis	O
was	O
21	O
weeks	O
(	O
range	O
11	O
-	O
35	O
)	O
.	O

Hereditary	B-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
(	O
HHL	B-DISEASE
)	O
includes	O
a	O
broad	O
range	O
of	O
disorders	O
that	O
affect	O
infants	O
,	O
children	O
and	O
adults	O
[	O
1	O
]	O
.	O

This	O
procedure	O
allowed	O
for	O
a	O
horizontal	O
and	O
vertical	O
overlap	O
of	O
at	O
least	O
2	O
degree	O
between	O
successive	O
images	O
.	O

Key	O
words	O
:	O
Craniosynostosis	B-DISEASE
,	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
,	O
mutation	O
,	O
FGFR2	B-GENE
.	O

Targeted	O
or	O
WES	O
has	O
proved	O
to	O
be	O
a	O
robust	O
and	O
powerful	O
tool	O
to	O
discover	O
mutations	O
or	O
genes	O
for	O
both	O
nonsyndromic	O
and	O
complex	O
syndromic	O
forms	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
especially	O
in	O
small	O
families	O
with	O
a	O
distinct	O
and	O
particular	O
phenotypic	O
expression	O
that	O
were	O
once	O
too	O
small	O
to	O
map	O
[	O
2	O
]	O
-	O
[	O
4	O
]	O
.	O

Eleven	O
USH	B-DISEASE
patients	O
were	O
included	O
in	O
the	O
test	O
group	O
to	O
verify	O
the	O
reliability	O
of	O
our	O
NGS	O
custom	O
panel	O
.	O

The	O
mean	O
somatic	O
mutation	O
rate	O
was	O
3	O
.	O
0	O
x	O
10	O
-	O
7	O
per	O
base	O
,	O
with	O
a	O
mean	O
of	O
1	O
.	O
7	O
silent	O
and	O
6	O
.	O
1	O
protein	O
-	O
altering	O
somatic	O
mutations	O
per	O
tumor	O
(	O
median	O
1	O
and	O
3	O
.	O
5	O
,	O
respectively	O
;	O
Supplementary	O
Fig	O
.	O

Figure	O
S5	O
.	O

S2	O
)	O
.	O

To	O
test	O
the	O
feasibility	O
of	O
identifying	O
pathogenic	O
mutations	O
in	O
genomic	O
DNA	O
from	O
patients	O
with	O
retinal	B-DISEASE
degeneration	I-DISEASE
,	O
we	O
selected	O
four	O
patients	O
in	O
whom	O
,	O
by	O
Sanger	O
sequencing	O
of	O
candidate	O
genes	O
,	O
we	O
had	O
identified	O
mutation	O
(	O
s	O
)	O
deemed	O
clearly	O
causative	O
based	O
on	O
exclusion	O
from	O
control	O
cohorts	O
,	O
predicted	O
pathogenicity	O
and	O
segregation	O
in	O
additional	O
family	O
members	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NGS	O
panel	O
provides	O
a	O
fast	O
,	O
accurate	O
and	O
cost	O
-	O
effective	O
molecular	O
diagnostic	O
tool	O
for	O
identifying	O
mutations	O
in	O
a	O
highly	O
genetically	O
heterogeneous	O
set	O
of	O
disorders	O
such	O
as	O
genetic	O
skeletal	B-DISEASE
disorders	I-DISEASE
.	O

This	O
exceptional	O
case	O
was	O
a	O
7	O
-	O
year	O
-	O
old	O
boy	O
(	O
Subject	O
No	O
.	O

,	O
1984	O
;	O
Jiang	O
et	O
al	O
.	O

"	O
This	O
study	O
has	O
been	O
performed	O
with	O
the	O
approval	O
of	O
the	O
ethics	O
committee	O
of	O
Shandong	O
Academy	O
of	O
Medical	O
Science	O
.	O

Two	O
pathogenic	O
or	O
presumably	O
pathogenic	O
mutations	O
in	O
PCDH15	B-GENE
,	O
specifically	O
,	O
a	O
nonsense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
R991X	I-VARIANT
)	O
[	O
27	O
]	O
and	O
a	O
novel	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
R1273S	I-VARIANT
)	O
,	O
were	O
found	O
in	O
two	O
patients	O
.	O

NUBPL	B-GENE
(	O
nucleotide	O
binding	O
protein	O
-	O
like	O
)	O
,	O
also	O
known	O
as	O
IND1	O
,	O
was	O
recently	O
shown	O
to	O
be	O
an	O
assembly	O
factor	O
for	O
CI	O
38	O
.	O

However	O
,	O
the	O
use	O
of	O
WGS	O
for	O
assessment	O
of	O
cancer	B-DISEASE
risk	O
in	O
the	O
general	O
population	O
could	O
strongly	O
benefit	O
from	O
a	O
better	O
understanding	O
of	O
the	O
clinical	O
significance	O
of	O
many	O
of	O
the	O
genetic	O
variants	O
in	O
cancer	B-DISEASE
genes	O
.	O

Wrote	O
the	O
paper	O
:	O
JZ	O
YY	O
.	O

On	O
the	O
whole	O
,	O
this	O
study	O
suggests	O
that	O
ESDN	O
receives	O
a	O
significant	O
number	O
of	O
referrals	O
from	O
geneticists	O
and	O
/	O
or	O
pediatricians	O
with	O
an	O
interest	O
in	O
,	O
and	O
knowledge	O
of	O
,	O
skeletal	B-DISEASE
dysplasias	I-DISEASE
,	O
which	O
is	O
reflected	O
in	O
the	O
relatively	O
high	O
level	O
of	O
correct	O
diagnosis	O
on	O
referral	O
.	O

Greek	O
patients	O
with	O
suspected	O
ADOA	B-DISEASE
have	O
never	O
been	O
screened	O
for	O
OPA1	B-GENE
mutations	O
.	O

Consanguineous	O
family	O
demonstrating	O
linkage	O
to	O
Usher	B-DISEASE
type1	I-DISEASE
genes	O
.	O

The	O
family	O
history	O
was	O
also	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
and	O
this	O
prompted	O
OPA1	B-GENE
genetic	O
screening	O
,	O
which	O
uncovered	O
a	O
c	B-VARIANT
.	I-VARIANT
2613	I-VARIANT
+	I-VARIANT
1g	I-VARIANT
>	I-VARIANT
a	I-VARIANT
splice	O
-	O
site	O
mutation	O
within	O
intron	O
25	O
segregating	O
with	O
affected	O
disease	O
status	O
in	O
both	O
the	O
proband	O
and	O
her	O
two	O
brothers	O
.	O

The	O
speciments	O
were	O
next	O
immersed	O
in	O
Alexa	O
-	O
488	O
-	O
conjugated	O
phalloindin	O
(	O
1	O
:	O
200	O
,	O
Cat	O
#	O
A12379	O
,	O
Invitrogen	O
)	O
for	O
40	O
min	O
to	O
label	O
the	O
stereocilia	O
and	O
cuticular	O
plate	O
of	O
the	O
cochlear	O
and	O
vestibular	O
sensory	O
hair	O
cells	O
,	O
and	O
the	O
F	O
-	O
actin	O
in	O
the	O
gap	O
-	O
junction	O
of	O
marginal	O
cells	O
of	O
stria	O
vascularis	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
duplicate	O
.	O

ADNSHL	B-DISEASE
patients	O
with	O
mutations	O
in	O
alpha	B-GENE
-	I-GENE
tectorin	I-GENE
display	O
various	O
severity	O
and	O
onset	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
13	O
]	O
.	O

Hearing	O
impairment	O
had	O
a	O
typical	O
onset	O
in	O
the	O
first	O
decade	O
of	O
life	O
in	O
the	O
high	O
frequencies	O
,	O
with	O
significant	O
subsequent	O
progression	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
over	O
all	O
frequencies	O
.	O

The	O
ratio	O
of	O
exon	O
8	O
of	O
the	O
DIAPH1	B-GENE
gene	O
was	O
close	O
to	O
2	O
,	O
suggesting	O
that	O
the	O
DNA	O
segment	O
containing	O
this	O
exon	O
was	O
doubled	O
compared	O
to	O
the	O
normal	O
copy	O
number	O
.	O

The	O
SNPs	O
were	O
selected	O
following	O
:	O
i	O
)	O
high	O
informativity	O
according	O
to	O
SNPbrowser	O
Software	O
Version	O
4	O
.	O
0	O
.	O
1	O
and	O
dbSNP	O
database	O
(	O
www	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
projects	O
/	O
SNP	O
/	O
)	O
;	O
ii	O
)	O
physical	O
location	O
(	O
covering	O
upstream	O
,	O
intragenic	O
and	O
downstream	O
regions	O
)	O
;	O
iii	O
)	O
inclusion	O
in	O
different	O
haplotypic	O
blocks	O
.	O

Inclusion	O
criteria	O
and	O
determination	O
of	O
affection	O
status	O
are	O
as	O
previously	O
reported	O
27	O
.	O

As	O
a	O
final	O
step	O
,	O
these	O
variants	O
were	O
screened	O
against	O
the	O
control	O
group	O
and	O
were	O
removed	O
unless	O
already	O
established	O
as	O
a	O
deafness	B-DISEASE
-	I-DISEASE
associated	I-DISEASE
damaging	O
mutation	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

The	O
program	O
is	O
accessible	O
at	O
splice	O
.	O

The	O
ring	O
analysis	O
(	O
see	O
schematic	O
)	O
goes	O
from	O
the	O
centre	O
to	O
the	O
periphery	O
.	O

In	O
the	O
case	O
of	O
KCNQ1	B-GENE
:	O
pA344V	B-VARIANT
,	O
two	O
cases	O
had	O
been	O
detected	O
by	O
SSCP	O
,	O
but	O
an	O
additional	O
case	O
was	O
identified	O
by	O
direct	O
sequencing	O
.	O

We	O
describe	O
a	O
hemodialysis	O
patient	O
with	O
hypoparathyroidism	B-DISEASE
due	O
to	O
HDR	B-DISEASE
(	O
hypoparathyroidism	B-DISEASE
,	O
sensorineural	B-DISEASE
deafness	I-DISEASE
,	O
and	O
renal	B-DISEASE
dysplasia	I-DISEASE
)	O
syndrome	O
caused	O
by	O
GATA3	B-GENE
mutation	O
.	O

We	O
searched	O
for	O
variants	O
that	O
were	O
not	O
listed	O
in	O
dbSNP137	O
,	O
NHLBI	O
(	O
http	O
:	O
/	O
/	O
evs	O
.	O
gs	O
.	O
washington	O
.	O
edu	O
/	O
EVS	O
/	O
)	O
or	O
that	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
less	O
than	O
1	O
%	O
in	O
these	O
databases	O
.	O

IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
was	O
the	O
hotspot	O
mutation	O
region	O
in	O
this	O
patient	O
cohort	O
,	O
for	O
which	O
five	O
patients	O
were	O
homozygous	O
,	O
six	O
were	O
compound	O
heterozygous	O
,	O
and	O
four	O
were	O
heterozygous	O
(	O
Table	O
2	O
)	O
.	O

The	O
previously	O
undescribed	O
splice	O
-	O
site	O
mutation	O
c	O
.	O
784	O
-	O
1G	O
>	O
T	O
detected	O
in	O
family	O
F2	O
affects	O
the	O
critical	O
guanine	O
at	O
the	O
3	O
'	O
acceptor	O
splice	O
site	O
of	O
intron	O
7	O
.	O

The	O
first	O
screening	O
using	O
304	O
Japanese	O
probands	O
compatible	O
with	O
autosomal	O
recessive	O
inheritance	O
identified	O
26	O
candidates	O
for	O
disease	O
causing	O
mutations	O
.	O

Pedigrees	O
of	O
the	O
seven	O
families	O
are	O
shown	O
in	O
Figure	O
1	O
;	O
clinical	O
features	O
are	O
described	O
in	O
Table	O
1	O
and	O
supplemental	O
materials	O
[	O
Additional	O
file	O
2	O
and	O
Additional	O
file	O
3	O
]	O
.	O

The	O
tests	O
of	O
vestibular	O
function	O
in	O
four	O
additional	O
affected	O
individuals	O
(	O
B3	O
,	O
C4	O
,	O
E10	O
,	O
and	O
E13	O
)	O
demonstrated	O
no	O
abnormalities	O
.	O

Although	O
we	O
did	O
not	O
find	O
common	O
clinical	O
features	O
among	O
reversal	O
variants	O
that	O
would	O
have	O
predicted	O
the	O
clinical	O
course	O
of	O
HH	B-DISEASE
after	O
adolescence	O
,	O
two	O
reversal	O
variants	O
had	O
mutations	O
in	O
GNRHR	B-GENE
.	O

The	O
mutation	O
was	O
named	O
following	O
the	O
nomenclature	O
recommended	O
by	O
the	O
Human	O
Genomic	O
Variation	O
Society	O
.	O

The	O
screening	O
was	O
performed	O
in	O
19	O
probands	O
with	O
USH	B-DISEASE
already	O
screened	O
for	O
mutations	O
in	O
the	O
most	O
prevalent	O
USH1	B-DISEASE
genes	O
,	O
myosin	B-GENE
VIIA	I-GENE
(	O
MYO7A	B-GENE
)	O
and	O
cadherin	B-GENE
-	I-GENE
23	I-GENE
(	O
CDH23	B-GENE
)	O
,	O
and	O
for	O
copy	O
number	O
variants	O
in	O
PCDH15	B-GENE
.	O

The	O
most	O
accepted	O
criterion	O
for	O
definition	O
of	O
a	O
large	O
vestibular	O
aqueduct	O
is	O
that	O
suggested	O
by	O
Valvassori	O
[	O
7	O
]	O
:	O
a	O
vestibular	O
aqueduct	O
is	O
considered	O
to	O
be	O
enlarged	O
if	O
its	O
diameter	O
is	O
>	O
1	O
.	O
5	O
mm	O
at	O
the	O
midpoint	O
between	O
the	O
common	O
crus	O
and	O
the	O
external	O
aperture	O
of	O
the	O
vestibular	O
aqueduct	O
on	O
CT	O
images	O
.	O

The	O
TJP2	B-GENE
gene	O
,	O
mutation	O
of	O
which	O
causes	O
autosomal	B-DISEASE
dominant	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ADNSHL	B-DISEASE
)	O
,	O
lies	O
at	O
the	O
DFNA51	B-GENE
locus	O
on	O
chromosome	O
9	O
.	O

4A	O
)	O
.	O

Sequence	O
inspection	O
revealed	O
that	O
the	O
alternative	O
translation	O
initiation	O
codon	O
is	O
likely	O
to	O
be	O
located	O
between	O
Gly26	O
and	O
Arg64	O
,	O
where	O
,	O
within	O
a	O
sequence	O
compatible	O
with	O
the	O
Kozak	O
consensus	O
,	O
there	O
is	O
a	O
methionine	O
in	O
codon	O
46	O
(	O
Met46	O
)	O
.	O

A	O
full	O
-	O
shaded	O
icon	O
denotes	O
ESRD	B-DISEASE
;	O
a	O
3	O
/	O
4	O
-	O
shaded	O
icon	O
denotes	O
impaired	O
renal	O
function	O
;	O
individual	O
with	O
unknown	O
phenotype	O
is	O
indicated	O
in	O
gray	O
.	O

6e	O
,	O
f	O
)	O
.	O

Ho	O
provided	O
critical	O
feedback	O
on	O
the	O
manuscript	O
.	O

USH2A	B-GENE
(	O
MIM	O
:	O
608400	O
)	O
,	O
located	O
on	O
chromosome	O
1	O
and	O
sublocation	O
1q41	O
,	O
encodes	O
the	O
usherin	B-GENE
,	O
which	O
demonstrates	O
a	O
wide	O
but	O
not	O
ubiquitous	O
tissue	O
distribution	O
[	O
5	O
]	O
.	O

Scale	O
bar	O
;	O
10	O
mu	O
m	O
.	O

The	O
amino	O
acids	O
A181	O
in	O
MYH14	B-GENE
and	O
A150	O
in	O
WFS1	B-GENE
are	O
conserved	O
in	O
all	O
sequenced	O
vertebrates	O
,	O
from	O
zebrafish	O
to	O
mammals	O
(	O
Fig	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
applied	O
a	O
sequence	O
-	O
alignment	O
method	O
that	O
detects	O
remote	O
homology	O
and	O
builds	O
consensus	O
profiles	O
of	O
highly	O
diverse	O
sequences	O
19	O
.	O

The	O
verbal	O
consents	O
of	O
the	O
subjects	O
were	O
witnessed	O
by	O
at	O
least	O
three	O
study	O
participants	O
.	O

The	O
two	O
variants	O
described	O
in	O
this	O
paper	O
are	O
indicated	O
by	O
black	O
arrows	O
.	O

Five	O
patients	O
underwent	O
middle	O
ear	O
surgeries	O
without	O
successful	O
hearing	O
gain	O
.	O

Studies	O
have	O
shown	O
that	O
EDN3	B-GENE
/	O
EDNRB	B-GENE
interaction	O
is	O
required	O
for	O
the	O
proper	O
development	O
of	O
neural	O
crest	O
derived	O
melanocytes	O
and	O
enteric	O
neurons	O
[	O
34	O
-	O
36	O
]	O
.	O

This	O
missense	O
mutation	O
was	O
also	O
absent	O
from	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgmd	O
.	O
org	O
/	O
)	O
and	O
has	O
not	O
been	O
reported	O
in	O
any	O
published	O
literature	O
,	O
to	O
our	O
knowledge	O
.	O

No	O
other	O
mutations	O
in	O
KCNJ10	B-GENE
were	O
detected	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
is	O
characterized	O
by	O
specific	O
phenotypic	O
traits	O
that	O
allow	O
a	O
clear	O
clinical	O
characterization	O
in	O
three	O
main	O
forms	O
,	O
being	O
USH	B-DISEASE
II	I-DISEASE
the	O
most	O
frequent	O
type	O
(	O
between	O
half	O
and	O
two	O
thirds	O
of	O
all	O
cases	O
)	O
,	O
and	O
USH2A	B-GENE
the	O
major	O
causative	O
gene	O
(	O
75	O
-	O
80	O
%	O
of	O
USH	B-DISEASE
II	I-DISEASE
cases	O
)	O
[	O
27	O
]	O
.	O

Members	O
of	O
the	O
Wolfram	B-DISEASE
Syndrome	I-DISEASE
Diabetes	B-DISEASE
Writing	O
Group	O
:	O
Germany	O
:	O
Mathias	O
Herr	O
,	O
Berlin	O
;	O
Ulrike	O
Menzel	O
,	O
Hamburg	O
;	O
Ina	O
Knerr	O
,	O
Erlangen	O
;	O
Ursula	O
Strier	O
,	O
M	O
o	O
nchengladbach	O
;	O
Ursula	O
Reiners	O
-	O
Franz	O
,	O
Koblenz	O
;	O
Albert	O
Otten	O
,	O
Hamm	O
;	O
Henrik	O
Bennink	O
,	O
Lingen	O
;	O
Renate	O
D	O
u	O
rr	O
,	O
Waiblingen	O
;	O
Hartmut	O
Koch	O
,	O
Vechta	O
;	O
Nicolin	O
Datz	O
,	O
Hannover	O
;	O
Dietrich	O
Adam	O
,	O
Passau	O
;	O
Michael	O
Witsch	O
,	O
Mannheim	O
;	O
Ishani	O
Siccar	O
,	O
Frankfurt	O
;	O
Ralph	O
Ziegler	O
,	O
M	O
u	O
nster	O
;	O
Ilse	O
Engelsberger	O
,	O
M	O
u	O
nchen	O
.	O

(	O
IA	O
and	O
IIA	O
)	O
Anterior	O
view	O
of	O
craniofacial	O
features	O
of	O
PS	B-DISEASE
parents	O
;	O
(	O
IB	O
and	O
IIB	O
)	O
Showing	O
lateral	O
view	O
of	O
craniofacial	O
features	O
.	O

Seven	O
pedigrees	O
were	O
compatible	O
with	O
an	O
autosomal	O
dominant	O
(	O
ad	O
)	O
pattern	O
,	O
but	O
one	O
(	O
11NCE	O
)	O
could	O
also	O
be	O
explained	O
by	O
an	O
X	O
-	O
linked	O
inheritance	O
,	O
as	O
all	O
affected	O
women	O
showed	O
a	O
less	O
severe	O
phenotype	O
.	O

3	O
Solve	O
rate	O
and	O
implicated	O
genes	O
across	O
ethnicities	O
.	O

Targeted	O
next	O
generation	O
sequencing	O
allowed	O
us	O
to	O
detect	O
both	O
point	O
mutations	O
and	O
large	O
rearrangements	O
in	O
a	O
single	O
experiment	O
,	O
minimizing	O
the	O
economic	O
cost	O
of	O
the	O
study	O
,	O
increasing	O
the	O
detection	O
ratio	O
of	O
the	O
genetic	O
cause	O
of	O
the	O
disease	O
and	O
improving	O
the	O
genetic	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
patients	O
.	O

The	O
eluted	O
protein	O
was	O
concentrated	O
to	O
0	O
.	O
25	O
mL	O
in	O
a	O
spin	O
concentrator	O
(	O
Amicon	O
Ultra	O
-	O
4	O
;	O
EMD	O
Millipore	O
)	O
.	O

It	O
should	O
be	O
mentioned	O
that	O
in	O
a	O
minority	O
of	O
cells	O
,	O
we	O
observed	O
slow	O
or	O
no	O
internalization	O
of	O
both	O
wild	O
-	O
type	O
and	O
truncated	O
CD164	B-GENE
.	O

Note	O
the	O
normal	O
appearance	O
of	O
organ	O
of	O
Corti	O
(	O
arrows	O
point	O
to	O
OHC	O
and	O
arrowhead	O
to	O
IHC	O
)	O
and	O
spiral	O
ganglion	O
neurons	O
(	O
arrow	O
)	O
in	O
8	O
-	O
week	O
-	O
old	O
BLSW	O
mice	O
,	O
but	O
base	O
to	O
mid	O
-	O
apex	O
degeneration	O
(	O
red	O
star	O
)	O
in	O
52	O
-	O
week	O
-	O
old	O
BLSW	O
cochleae	O
.	O

Yanamadala	O
,	O
and	O
the	O
Carol	O
Woods	O
and	O
Crosdaile	O
Retirement	O
Communities	O
;	O
R	O
.	O

Individual	O
II	O
:	O
3	O
was	O
heterozygous	O
for	O
this	O
mutation	O
,	O
and	O
no	O
other	O
MYO7A	B-GENE
mutation	O
was	O
detected	O
.	O

All	O
seven	O
mutations	O
identified	O
in	O
the	O
present	O
study	O
locate	O
within	O
isoform	O
b	O
,	O
among	O
which	O
,	O
p	B-VARIANT
.	I-VARIANT
Y3745	I-VARIANT
*	I-VARIANT
in	O
family	O
ARRP01	O
,	O
p	B-VARIANT
.	I-VARIANT
G4763R	I-VARIANT
in	O
family	O
ARRP02	O
,	O
p	B-VARIANT
.	I-VARIANT
P2762A	I-VARIANT
in	O
family	O
ARRP03	O
,	O
p	B-VARIANT
.	I-VARIANT
Y2854_R2896del43	I-VARIANT
in	O
family	O
ARRP04	O
,	O
and	O
p	B-VARIANT
.	I-VARIANT
R3719H	I-VARIANT
in	O
family	O
SU01	O
,	O
locate	O
within	O
the	O
fibronectin	O
type	O
-	O
III	O
repeats	O
,	O
while	O
another	O
mutation	O
in	O
family	O
ARRP04	O
,	O
p	B-VARIANT
.	I-VARIANT
G3320C	I-VARIANT
,	O
was	O
found	O
in	O
the	O
interval	O
between	O
the	O
18	O
th	O
and	O
the	O
19	O
th	O
fibronectin	O
type	O
-	O
III	O
domains	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
average	O
age	O
of	O
onset	O
of	O
other	O
patients	O
is	O
0	O
.	O
97	O
+	O
-	O
1	O
.	O
42	O
.	O

To	O
answer	O
the	O
first	O
question	O
,	O
screening	O
of	O
the	O
SLC26A4	B-GENE
mutations	O
in	O
a	O
large	O
NSHI	O
population	O
without	O
EVA	B-DISEASE
is	O
necessary	O
.	O

The	O
technology	O
described	O
herein	O
will	O
contribute	O
to	O
the	O
development	O
of	O
a	O
retinal	B-DISEASE
dystrophy	I-DISEASE
diagnostic	O
screening	O
service	O
by	O
reducing	O
costs	O
associated	O
with	O
using	O
a	O
single	O
capture	O
reagent	O
to	O
analyse	O
up	O
to	O
four	O
samples	O
in	O
a	O
single	O
experiment	O
.	O

GJB2	B-GENE
mutation	O
spectrum	O
in	O
patients	O
with	O
NSHI	B-DISEASE
from	O
south	O
China	O
GJB2	B-GENE
mono	O
-	O
allelic	O
mutations	O
are	O
shown	O
in	O
Table	O
2	O
.	O

Dashed	O
line	O
represents	O
the	O
calculated	O
mean	O
audiogram	O
.	O

He	O
was	O
unable	O
to	O
perceive	O
and	O
describe	O
his	O
own	O
physical	O
problems	O
during	O
medical	O
visits	O
,	O
rejected	O
social	O
contacts	O
,	O
and	O
neglected	O
the	O
need	O
for	O
medical	O
and	O
rehabilitative	O
treatment	O
.	O

At	O
re	O
-	O
evaluation	O
,	O
his	O
52	O
-	O
years	O
-	O
old	O
mother	O
had	O
30	O
x	O
10	O
9	O
/	O
L	O
platelets	O
,	O
no	O
bleeding	O
diathesis	O
,	O
and	O
a	O
history	O
of	O
bilateral	O
hearing	B-DISEASE
loss	I-DISEASE
since	O
the	O
age	O
of	O
40	O
.	O

Calls	O
were	O
further	O
evaluated	O
by	O
manual	O
inspection	O
of	O
the	O
read	O
alignments	O
.	O

The	O
last	O
objective	O
was	O
to	O
evaluate	O
the	O
nasal	O
ciliary	O
beat	O
frequency	O
in	O
patients	O
with	O
USH1	B-DISEASE
and	O
compare	O
it	O
with	O
control	O
subjects	O
.	O

2012	O
)	O
.	O

Structural	O
comparison	O
of	O
wild	O
-	O
type	O
versus	O
mutated	O
AIFM1	B-GENE
protein	O
showed	O
that	O
mutations	O
in	O
the	O
two	O
flavin	O
adenine	O
dinucleotide	O
(	O
FAD	O
)	O
and	O
reduced	O
nicotinamide	O
adenine	O
dinucleotide	O
(	O
NADH	O
)	O
domains	O
have	O
greater	O
impact	O
on	O
the	O
protein	O
surface	O
than	O
mutations	O
in	O
C	O
-	O
terminus	O
(	O
see	O
online	O
supplementary	O
figures	O
S6	O
and	O
S7	O
)	O
.	O

9	O
A	O
Topo	O
TA	O
cloning	O
kit	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
to	O
subclone	O
each	O
of	O
the	O
14	O
amplicons	O
.	O

Thus	O
,	O
wolframin	B-GENE
may	O
be	O
involved	O
in	O
regulation	O
of	O
inner	O
ear	O
ion	O
homeostasis	O
as	O
maintained	O
by	O
the	O
canalicular	O
reticulum	O
[	O
33	O
,	O
34	O
]	O
.	O

Adult	O
family	O
members	O
gave	O
written	O
informed	O
consent	O
and	O
for	O
minors	O
,	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
their	O
parents	O
.	O

In	O
addition	O
,	O
50	O
randomly	O
selected	O
DNA	O
samples	O
(	O
100	O
chromosomes	O
each	O
)	O
were	O
taken	O
from	O
a	O
healthy	O
Spanish	O
control	O
population	O
and	O
analyzed	O
to	O
establish	O
the	O
prevalence	O
of	O
the	O
new	O
mutations	O
identified	O
in	O
this	O
study	O
.	O

2007	O
)	O
.	O

TMC1	B-GENE
is	O
predicted	O
to	O
be	O
involved	O
in	O
the	O
functional	O
maturation	O
of	O
cochlear	O
hair	O
cells	O
[	O
13	O
]	O
.	O

Moreover	O
,	O
MCM2	B-GENE
has	O
also	O
been	O
proven	O
to	O
have	O
a	O
pro	O
-	O
apoptotic	O
effect	O
lately	O
.	O

Novel	O
variants	O
identified	O
by	O
sequencing	O
analysis	O
We	O
identified	O
four	O
novel	O
pathogenic	O
variants	O
in	O
three	O
different	O
genes	O
.	O

Each	O
mutation	O
was	O
within	O
a	O
homozygous	O
run	O
documented	O
via	O
WES	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
as	O
previously	O
described	O
[	O
21	O
]	O
.	O

(	O
b	O
)	O
Two	O
brothers	O
with	O
homozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
which	O
was	O
also	O
found	O
in	O
patients	O
367	O
,	O
1116	O
,	O
and	O
1172	O
.	O

It	O
has	O
been	O
suggested	O
that	O
an	O
abnormality	O
in	O
type	O
II	O
collagen	O
is	O
an	O
important	O
factor	O
in	O
the	O
development	O
of	O
both	O
diseases	O
,	O
and	O
they	O
may	O
represent	O
multiple	O
phenotypes	O
resulting	O
from	O
a	O
single	O
underlying	O
mechanism	O
present	O
with	O
a	O
family	O
.	O

Sequence	O
data	O
were	O
analysed	O
for	O
the	O
presence	O
of	O
base	O
substitutions	O
,	O
small	O
insertions	O
or	O
deletions	O
(	O
indels	O
)	O
and	O
exonic	O
deletions	O
or	O
duplications	O
.	O

Phenotypic	O
variability	O
was	O
associated	O
with	O
the	O
known	O
p	B-VARIANT
.	I-VARIANT
Val85Asp	I-VARIANT
mutation	O
(	O
Figure	O
4	O
)	O
,	O
an	O
allele	O
we	O
reported	O
in	O
two	O
large	O
multi	O
-	O
generation	O
Pakistani	O
families	O
segregating	O
pre	O
-	O
lingual	O
,	O
severe	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Mayumi	O
Sugamura	O
and	O
Takashi	O
Nakagawa	O
(	O
Fukuoka	O
University	O
)	O
,	O
Dr	O
.	O

Histopathological	O
studies	O
indicate	O
that	O
ADOA	B-DISEASE
is	O
caused	O
by	O
the	O
degeneration	B-DISEASE
of	I-DISEASE
retinal	I-DISEASE
ganglion	I-DISEASE
cells	I-DISEASE
followed	O
by	O
the	O
ascending	B-DISEASE
atrophy	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
nerve	I-DISEASE
[	O
6	O
]	O
.	O

It	O
also	O
included	O
one	O
known	O
ovarian	O
susceptibility	O
gene	O
(	O
FANCM	B-GENE
;	O
P	O
=	O
4	O
.	O
04	O
-	O
06	O
,	O
CAST	O
greater	O
)	O
as	O
well	O
as	O
three	O
cancer	O
genes	O
(	O
ARID1A	B-GENE
,	O
EGFR	B-GENE
,	O
and	O
DNMT1	B-GENE
)	O
,	O
not	O
previously	O
implicated	O
in	O
ovarian	B-DISEASE
cancer	I-DISEASE
(	O
Supplementary	O
Data	O
6	O
and	O
9	O
)	O
.	O

(	O
C	O
)	O
pEGFP	O
-	O
C2	O
empty	O
vector	O
,	O
which	O
was	O
used	O
as	O
a	O
control	O
.	O

2002	O
)	O
.	O

The	O
nucleotide	O
change	O
was	O
a	O
heterozygous	O
G	O
>	O
T	O
at	O
position	O
833	O
(	O
arrow	O
)	O
,	O
resulting	O
in	O
Cys278Phe	B-VARIANT
.	O

average	O
of	O
2000	O
,	O
4000	O
,	O
and	O
8000	O
Hz	O
.	O

Her	O
son	O
developed	O
ESKD	B-DISEASE
at	O
45	O
years	O
and	O
was	O
transplanted	O
at	O
46	O
years	O
.	O

To	O
date	O
,	O
seven	O
mutations	O
of	O
myosin	B-GENE
VIIA	I-GENE
which	O
cause	O
DFNA11	B-DISEASE
have	O
been	O
described	O
.	O

2010	O
)	O
.	O

HL	B-DISEASE
caused	O
by	O
a	O
mutation	O
in	O
the	O
MYO6	B-GENE
gene	O
was	O
first	O
reported	O
in	O
Snell	O
'	O
s	O
waltzer	O
mouse	O
.	O

The	O
OPA1	B-GENE
protein	O
is	O
a	O
dynamin	O
-	O
related	O
GTPase	O
targeted	O
to	O
mitochondria	O
,	O
where	O
it	O
is	O
anchored	O
to	O
the	O
mitochondrial	O
inner	O
membrane	O
[	O
11	O
,	O
30	O
]	O
.	O

The	O
ability	O
of	O
spontaneous	O
recovery	O
after	O
spinal	O
lesion	O
in	O
adult	O
zebrafish	O
could	O
also	O
be	O
explained	O
by	O
the	O
promotion	O
of	O
tenascin	O
-	O
C	O
[	O
16	O
]	O
.	O

Both	O
c	B-VARIANT
.	I-VARIANT
907G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
1699G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
variants	O
were	O
reported	O
as	O
CINCA	B-DISEASE
/	O
NOMID	B-DISEASE
-	O
associated	O
mutations	O
in	O
Infevers	O
database	O
(	O
http	O
:	O
/	O
/	O
fmf	O
.	O
igh	O
.	O
cnrs	O
.	O
fr	O
/	O
ISSAID	O
/	O
infevers	O
/	O
)	O
and	O
in	O
the	O
dbSNP	O
database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
projects	O
/	O
SNP	O
/	O
)	O
.	O

Variants	O
were	O
filtered	O
using	O
GATK	O
,	O
SnpSift	O
and	O
in	O
-	O
house	O
perl	O
scripts	O
.	O

compound	O
(	O
Miles	O
Laboratories	O
,	O
Elkhart	O
,	O
IN	O
)	O
.	O

1987	O
)	O
.	O

As	O
the	O
clinical	O
presentation	O
may	O
be	O
sudden	O
death	B-DISEASE
in	O
cLQTS	B-DISEASE
mutation	O
carriers	O
,	O
this	O
is	O
a	O
serious	O
clinical	O
problem	O
.	O

Although	O
the	O
natural	O
NLS	O
has	O
been	O
disrupted	O
,	O
a	O
new	O
NLS	O
-	O
compatible	O
motif	O
(	O
RGRRRRCR	O
)	O
has	O
been	O
created	O
on	O
the	O
added	O
amino	O
acid	O
sequence	O
.	O

Attenuated	O
retinal	O
vessels	O
and	O
pale	O
optic	O
disc	O
are	O
observed	O
.	O

The	O
progression	O
of	O
RP	B-DISEASE
resulted	O
in	O
a	O
severe	O
visual	O
handicap	O
at	O
20	O
-	O
30	O
years	O
.	O

Second	O
,	O
while	O
most	O
mutations	O
have	O
loss	O
-	O
of	O
-	O
function	O
effects	O
,	O
gain	O
-	O
of	O
-	O
function	O
effects	O
have	O
been	O
suggested	O
for	O
p	B-VARIANT
.	I-VARIANT
F148Y	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
H194Q	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
310S	I-VARIANT
by	O
in	O
vitro	O
studies	O
[	O
8	O
]	O
.	O

USH	B-DISEASE
type	I-DISEASE
1	I-DISEASE
,	O
accounting	O
for	O
30	O
%	O
to	O
40	O
%	O
of	O
total	O
USH	B-DISEASE
,	O
is	O
the	O
most	O
severe	O
clinical	O
form	O
typified	O
by	O
profound	O
congenital	B-DISEASE
deafness	I-DISEASE
,	O
early	O
onset	O
of	O
visual	B-DISEASE
impairment	I-DISEASE
(	O
usually	O
within	O
the	O
first	O
decade	O
of	O
life	O
)	O
,	O
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
9	O
]	O
.	O

described	O
a	O
USH2	B-DISEASE
patient	O
with	O
"	O
digenic	O
inheritance	O
.	O

,	O
2008	O
)	O
.	O

Average	O
of	O
500	O
,	O
1000	O
,	O
2000	O
and	O
4000	O
Hz	O
.	O

We	O
thus	O
report	O
both	O
clinical	O
and	O
genetic	O
features	O
of	O
Japanese	O
patients	O
with	O
WFS	B-DISEASE
.	O

has	O
received	O
a	O
Research	O
Scholar	O
Junior	O
1	O
award	O
from	O
the	O
Fonds	O
de	O
Recherche	O
du	O
Qu	O
e	O
bec	O
en	O
Sant	O
e	O
(	O
FRQS	O
)	O
.	O

The	O
combined	O
whole	O
genome	O
SNP	O
array	O
and	O
WES	O
analysis	O
in	O
the	O
two	O
families	O
revealed	O
the	O
same	O
mutation	O
-	O
c	B-VARIANT
.	I-VARIANT
1220delG	I-VARIANT
in	O
USH1C	B-GENE
.	O

Variants	O
were	O
also	O
filtered	O
for	O
presence	O
in	O
less	O
than	O
five	O
samples	O
in	O
our	O
internal	O
database	O
that	O
includes	O
1010	O
exomes	O
,	O
including	O
69	O
ethnicity	O
matched	O
unrelated	O
samples	O
.	O

Previously	O
reported	O
heterozygous	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
mutations	O
in	O
humans	O
also	O
suggest	O
a	O
more	O
severe	O
phenotype	O
for	O
ACTB	B-GENE
mutations	O
33	O
-	O
35	O
(	O
phenotype	O
reviewed	O
in	O
Supplementary	O
note	O
and	O
Supplementary	O
Table	O
5	O
)	O
.	O

Further	O
studies	O
may	O
identify	O
the	O
molecular	O
mechanism	O
of	O
the	O
two	O
mutations	O
in	O
the	O
cochlea	O
and	O
the	O
retina	O
.	O

Recently	O
,	O
two	O
spontaneous	O
mutations	O
(	O
rda	O
and	O
rda	O
2J	O
)	O
in	O
mouse	O
Elmod1	B-GENE
were	O
shown	O
to	O
result	O
in	O
profound	O
deafness	B-DISEASE
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
[	O
7	O
]	O
,	O
demonstrating	O
that	O
the	O
function	O
of	O
ELMOD1	B-GENE
is	O
essential	O
for	O
regulating	O
the	O
shape	O
and	O
maintenance	O
of	O
inner	O
ear	O
hair	O
cell	O
stereocilia	O
in	O
mice	O
[	O
7	O
]	O
.	O

Variations	O
contained	O
in	O
VCF	O
reports	O
were	O
filtered	O
by	O
a	O
custom	O
knowledge	O
database	O
in	O
order	O
to	O
identify	O
candidate	O
disease	O
-	O
causing	O
mutations	O
.	O

The	O
mutation	O
frequencies	O
of	O
mtDNA	B-GENE
12S	I-GENE
rRNA	I-GENE
and	O
GJB3	B-GENE
were	O
relatively	O
low	O
in	O
both	O
Uyghur	O
and	O
Han	O
Chinese	O
patients	O
(	O
Fisher	O
'	O
s	O
exact	O
probability	O
test	O
,	O
P	O
>	O
0	O
.	O

[	O
13	O
,	O
17	O
]	O
described	O
DFNB23	B-DISEASE
families	O
homozygous	O
for	O
variant	O
p	B-VARIANT
.	I-VARIANT
R134G	I-VARIANT
.	O

These	O
data	O
suggest	O
that	O
c	B-VARIANT
.	I-VARIANT
256A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
is	O
a	O
rare	O
and	O
benign	O
variant	O
while	O
p	B-VARIANT
.	I-VARIANT
Ser87Ile	I-VARIANT
is	O
predicted	O
to	O
be	O
deleterious	O
(	O
Table	O
1	O
)	O
.	O

Communicated	O
by	O
Hamish	O
S	O
.	O

(	O
A	O
)	O
Sanger	O
sequence	O
of	O
the	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
variant	O
.	O

Three	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
167delT	I-VARIANT
,	O
and	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
are	O
found	O
to	O
be	O
the	O
most	O
frequent	O
mutations	O
in	O
Caucasian	O
,	O
Ashkenazi	O
Jewish	O
,	O
and	O
Asian	O
populations	O
,	O
respectively	O
[	O
6	O
,	O
7	O
,	O
9	O
-	O
13	O
,	O
20	O
,	O
23	O
-	O
26	O
]	O
.	O

This	O
portion	O
of	O
the	O
protein	O
is	O
highly	O
conserved	O
among	O
myosin	B-GENE
VIIA	I-GENE
homologs	O
and	O
seems	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
communication	O
between	O
the	O
actin	O
interface	O
and	O
nucleotide	O
-	O
binding	O
pocket	O
[	O
22	O
]	O
.	O

The	O
literature	O
that	O
studied	O
patients	O
with	O
WS1	B-DISEASE
caused	O
by	O
mutations	O
in	O
PAX3	B-GENE
was	O
reviewed	O
in	O
2009	O
by	O
Pingault	O
et	O
al	O
.	O
,	O
and	O
no	O
relationship	O
was	O
found	O
between	O
the	O
severity	O
of	O
disease	O
and	O
the	O
type	O
of	O
mutation	O
[	O
17	O
]	O
.	O

In	O
the	O
cochlea	O
,	O
glutamate	O
receptors	O
mediate	O
fast	O
synaptic	O
transmission	O
at	O
the	O
IHC	O
afferent	O
synapse	O
and	O
glutamate	O
excitotoxicity	O
is	O
central	O
to	O
the	O
neural	O
damage	O
during	O
acoustic	O
trauma	O
35	O
36	O
.	O

Because	O
WFS	B-DISEASE
is	O
a	O
progressive	O
disorder	O
,	O
affected	O
individuals	O
experience	O
a	O
wide	O
spectrum	O
of	O
symptoms	O
during	O
their	O
lifetimes	O
[	O
3	O
]	O
.	O

To	O
ensure	O
reliable	O
capture	O
of	O
shorter	O
exons	O
,	O
we	O
specifically	O
generated	O
longer	O
hybridization	O
probes	O
from	O
gDNA	O
for	O
those	O
exons	O
that	O
were	O
shorter	O
than	O
50	O
bp	O
by	O
including	O
about	O
100	O
bp	O
gDNA	O
flanking	O
the	O
exons	O
on	O
both	O
sides	O
.	O

Patients	O
were	O
evaluated	O
using	O
a	O
multidisciplinary	O
team	O
approach	O
that	O
included	O
otolaryngologists	O
,	O
clinical	O
geneticists	O
,	O
audiologists	O
,	O
speech	O
and	O
language	O
therapists	O
,	O
and	O
others	O
,	O
as	O
appropriate	O
for	O
each	O
patient	O
,	O
thus	O
enhancing	O
phenotypic	O
assessment	O
.	O

DNA	O
samples	O
of	O
the	O
affected	O
members	O
of	O
our	O
cohort	O
of	O
USH	B-DISEASE
families	O
were	O
tested	O
using	O
an	O
USH	B-DISEASE
genotyping	O
array	O
,	O
and	O
/	O
or	O
genotyped	O
with	O
polymorphic	O
markers	O
specific	O
for	O
the	O
USH3A	B-GENE
locus	O
.	O

This	O
result	O
is	O
in	O
agreement	O
with	O
a	O
recent	O
study	O
[	O
41	O
]	O
that	O
reported	O
large	O
genomic	O
rearrangements	O
(	O
mainly	O
consisting	O
of	O
deletions	O
)	O
in	O
35	O
%	O
of	O
patients	O
with	O
USH	B-DISEASE
previously	O
identified	O
as	O
carriers	O
of	O
a	O
monoallelic	O
USH2A	B-GENE
mutation	O
and	O
suggest	O
that	O
in	O
USH	B-DISEASE
MLPA	O
analysis	O
can	O
detect	O
a	O
significant	O
fraction	O
of	O
mutations	O
not	O
identified	O
with	O
exon	O
sequencing	O
.	O

Tight	O
junctions	O
(	O
TJs	O
)	O
are	O
essential	O
components	O
of	O
eukaryotic	O
cells	O
,	O
and	O
serve	O
as	O
paracellular	O
barriers	O
and	O
zippers	O
between	O
adjacent	O
tissues	O
.	O

Similar	O
expression	O
domains	O
were	O
observed	O
in	O
the	O
BLSW	O
cochlea	O
(	O
Fig	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
-	O
in	O
-	O
Chief	O
of	O
this	O
journal	O
.	O

The	O
arrow	O
and	O
box	O
designate	O
the	O
location	O
of	O
the	O
mutation	O
.	O

Comparable	O
with	O
other	O
labs	O
[	O
5	O
]	O
,	O
[	O
9	O
]	O
-	O
[	O
11	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
,	O
when	O
measured	O
at	O
a	O
minimum	O
depth	O
of	O
8	O
x	O
,	O
82	O
%	O
of	O
the	O
target	O
region	O
was	O
covered	O
with	O
an	O
average	O
depth	O
of	O
68	O
x	O
(	O
Figure	O
2A	O
)	O
.	O

The	O
proband	O
'	O
s	O
parents	O
and	O
siblings	O
(	O
I	O
-	O
1	O
,	O
I	O
-	O
2	O
,	O
II	O
-	O
3	O
,	O
and	O
II	O
-	O
4	O
)	O
had	O
no	O
history	O
of	O
microscopic	O
hematuria	B-DISEASE
and	O
proteinuria	B-DISEASE
.	O

The	O
39	O
remaining	O
DFNB	B-DISEASE
families	O
were	O
also	O
investigated	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
EPS8	B-GENE
,	O
and	O
we	O
did	O
not	O
find	O
any	O
.	O

It	O
consists	O
of	O
a	O
polypeptide	O
of	O
2	O
,	O
155	O
amino	O
acids	O
and	O
is	O
composed	O
of	O
3	O
distinct	O
modules	O
:	O
entactin	O
G1	O
domain	O
,	O
zonadhesin	O
domain	O
(	O
with	O
von	O
Willebrand	O
factor	O
type	O
D	O
repeat	O
)	O
,	O
and	O
zona	O
pellucida	O
domain	O
.	O

Detection	O
of	O
mutations	O
in	O
COL4A5	B-GENE
gene	O
in	O
males	O
with	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
AS	I-DISEASE
can	O
be	O
up	O
to	O
95	O
%	O
using	O
contemporary	O
techniques	O
[	O
5	O
]	O
.	O

It	O
has	O
been	O
hypothesized	O
by	O
some	O
that	O
such	O
patients	O
might	O
have	O
inherited	O
a	O
late	O
onset	O
form	O
of	O
ARAS	B-DISEASE
due	O
to	O
inheritance	O
of	O
a	O
second	O
in	O
-	O
trans	O
mutation	O
in	O
the	O
same	O
gene	O
that	O
was	O
missed	O
during	O
screening	O
by	O
several	O
methods	O
.	O

Two	O
men	O
with	O
reversal	O
of	O
HH	B-DISEASE
had	O
fathered	O
a	O
child	O
while	O
on	O
TRT	O
and	O
one	O
became	O
a	O
father	O
when	O
off	O
Rx	O
.	O

Family	O
5	O
.	O

Three	O
hundred	O
and	O
seven	O
patients	O
carry	O
two	O
confirmed	O
pathogenic	O
mutations	O
,	O
including	O
178	O
homozygotes	O
and	O
129	O
compound	O
heterozygotes	O
.	O

35	O
Nevertheless	O
,	O
the	O
data	O
are	O
scant	O
and	O
insufficient	O
to	O
consider	O
KCNQ1	B-GENE
as	O
a	O
causal	O
gene	O
for	O
hereditary	B-DISEASE
cardiomyopathies	I-DISEASE
.	O

We	O
sequenced	O
CACNA1D	B-GENE
S6	O
segments	O
of	O
domains	O
I	O
and	O
II	O
in	O
100	O
unrelated	O
subjects	O
with	O
unexplained	O
early	O
-	O
onset	O
primary	O
aldosteronism	B-DISEASE
.	O

(	O
http	O
:	O
/	O
/	O
www	O
.	O
ch	O
.	O
embnet	O
.	O
org	O
/	O
software	O
/	O
COILS_form	O
.	O
html	O
)	O
.	O

The	O
minigene	O
construct	O
was	O
transiently	O
transfected	O
into	O
ARPE	O
-	O
19	O
cells	O
(	O
ATCC	O
,	O
CRL	O
-	O
2502TM	O
)	O
during	O
24	O
h	O
.	O

A	O
Graphical	O
view	O
of	O
the	O
LOD	O
score	O
calculation	O
of	O
genome	O
-	O
wide	O
SNP	O
mapping	O
.	O

McEvoy	O
;	O
K	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
natural	O
history	O
of	O
Wolfram	B-DISEASE
syndrome	I-DISEASE
,	O
we	O
conducted	O
a	O
large	O
-	O
scale	O
phenotypic	O
study	O
of	O
WSD	B-DISEASE
compared	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
,	O
delineated	O
the	O
role	O
of	O
glycemic	O
control	O
in	O
disease	O
progression	O
,	O
and	O
examined	O
genotype	O
-	O
phenotype	O
relationships	O
.	O

(	O
B	O
)	O
cDNA	O
analysis	O
.	O

Glutathione	O
Sepharose	O
4B	O
(	O
GE	O
Healthcare	O
)	O
beads	O
were	O
added	O
and	O
incubated	O
at	O
4	O
deg	O
C	O
for	O
3	O
hrs	O
with	O
mixing	O
.	O

not	O
all	O
affected	O
family	O
members	O
have	O
the	O
variant	O
.	O

4F	O
)	O
.	O

The	O
mutation	O
spectrum	O
and	O
prevalence	O
of	O
mutations	O
vary	O
significantly	O
among	O
different	O
ethnic	O
groups	O
.	O

The	O
protein	O
encoded	O
by	O
the	O
GPR98	B-GENE
gene	O
at	O
the	O
USH2C	B-GENE
locus	O
is	O
a	O
member	O
of	O
the	O
serpentine	O
G	O
-	O
protein	O
coupled	O
receptor	O
superfamily	O
[	O
24	O
]	O
.	O

Specifically	O
,	O
we	O
could	O
confirm	O
that	O
missense	O
mutations	O
in	O
USH2A	B-GENE
,	O
a	O
gene	O
found	O
to	O
be	O
mutated	O
in	O
patients	O
suffering	O
from	O
the	O
blindness	B-DISEASE
-	I-DISEASE
deafness	I-DISEASE
disease	O
known	O
as	O
Usher	B-DISEASE
syndrome	I-DISEASE
,	O
cause	O
in	O
general	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
without	O
hearing	B-DISEASE
loss	I-DISEASE
(	O
patient	O
08	O
-	O
177	O
)	O
[	O
35	O
]	O
.	O

Where	O
these	O
approaches	O
did	O
not	O
lead	O
to	O
the	O
identification	O
of	O
the	O
genetic	O
subtype	O
,	O
we	O
sequenced	O
the	O
entire	O
coding	O
regions	O
of	O
all	O
USH1	B-DISEASE
genes	O
,	O
in	O
the	O
order	O
of	O
mutation	O
prevalences	O
in	O
other	O
populations	O
:	O
MYO7A	B-GENE
(	O
USH1B	B-GENE
)	O
,	O
CDH23	B-GENE
(	O
USH1D	B-GENE
)	O
,	O
USH1C	B-GENE
,	O
and	O
PCDH15	B-GENE
(	O
USH1F	B-GENE
)	O
.	O

Our	O
patient	O
had	O
hypoplasia	B-DISEASE
of	O
the	O
right	O
kidney	O
,	O
but	O
urinalysis	O
did	O
not	O
show	O
proteinuria	B-DISEASE
,	O
hematuria	B-DISEASE
,	O
or	O
hypercalciuria	B-DISEASE
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Gln277Pro	I-VARIANT
change	O
will	O
result	O
in	O
a	O
loss	O
of	O
this	O
hydrogen	O
bonding	O
interaction	O
potentially	O
destabilizing	O
the	O
region	O
surrounding	O
the	O
ribose	O
-	O
5	O
-	O
P	O
binding	O
site	O
,	O
thus	O
affecting	O
the	O
PRPS1	B-GENE
catalytic	O
active	O
site	O
.	O

We	O
analyzed	O
the	O
nine	O
USH	B-DISEASE
genes	O
in	O
a	O
cohort	O
of	O
54	O
French	O
patients	O
,	O
of	O
whom	O
27	O
were	O
affected	O
by	O
USH1	B-DISEASE
,	O
21	O
by	O
USH2	B-DISEASE
,	O
and	O
six	O
by	O
USH3	B-DISEASE
.	O

'	O
symbol	O
before	O
the	O
number	O
and	O
uses	O
the	O
A	O
of	O
the	O
ATG	O
translation	O
initiation	O
start	O
site	O
as	O
nucleotide	O
1	O
.	O

To	O
date	O
,	O
more	O
than	O
120	O
different	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
reported	O
in	O
the	O
USH2A	B-GENE
gene	O
,	O
which	O
are	O
widely	O
distributed	O
over	O
the	O
coding	O
regions	O
of	O
all	O
72	O
exons	O
.	O

PCR	O
products	O
were	O
sequenced	O
using	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
(	O
Applied	O
Biosystems	O
)	O
.	O

However	O
,	O
when	O
assayed	O
for	O
Arl2	O
GAP	O
activity	O
,	O
the	O
mutant	O
was	O
inactive	O
(	O
Figure	O
8	O
)	O
.	O

There	O
were	O
27	O
men	O
and	O
23	O
women	O
whose	O
age	O
ranged	O
from	O
18	O
to	O
57	O
years	O
(	O
mean	O
,	O
38	O
.	O
1	O
+	O
-	O
8	O
.	O
3	O
years	O
)	O
in	O
this	O
normal	O
control	O
group	O
.	O

The	O
WS	B-DISEASE
is	O
caused	O
by	O
a	O
novel	O
missense	O
mutation	O
,	O
whereas	O
DMD	B-DISEASE
resulted	O
due	O
to	O
a	O
deletion	O
.	O

15	O
,	O
16	O
We	O
show	O
that	O
CIB2	B-GENE
can	O
multimerize	O
and	O
interacts	O
with	O
whirlin	O
,	O
which	O
is	O
localized	O
at	O
the	O
tips	O
of	O
stereocilia	O
,	O
17	O
and	O
myosin	O
VIIa	O
(	O
Fig	O
.	O

Mutations	O
of	O
neighbouring	O
residues	O
(	O
P722S	B-VARIANT
,	O
P722H	B-VARIANT
,	O
and	O
N724K	B-VARIANT
)	O
have	O
been	O
previously	O
suggested	O
to	O
alter	O
the	O
conformation	O
of	O
this	O
region	O
(	O
figures	O
3	O
and	O
4	O
,	O
see	O
online	O
supplementary	O
table	O
S3	O
)	O
and	O
shown	O
to	O
decrease	O
kinase	O
activity	O
.	O

(	O
Psychiatry	O
)	O
Linda	O
Manwaring	O
,	O
M	O
.	O
S	O
.	O

The	O
FGFR2	B-GENE
protein	O
is	O
a	O
transmembrane	O
receptor	O
with	O
an	O
extra	O
cellular	O
ligand	O
-	O
binding	O
region	O
(	O
IgI	O
,	O
IgII	O
,	O
and	O
IgIII	O
)	O
,	O
a	O
transmembrane	O
region	O
,	O
and	O
a	O
tyrosine	O
kinase	O
domain	O
.	O

'	O
Neutral	O
'	O
variants	O
did	O
not	O
segregate	O
with	O
disease	O
,	O
were	O
either	O
previously	O
published	O
as	O
neutral	O
,	O
or	O
were	O
found	O
in	O
controls	O
with	O
a	O
frequency	O
>	O
0	O
.	O
236	O
%	O
.	O

Besides	O
the	O
clinical	O
findings	O
,	O
several	O
matters	O
are	O
also	O
notable	O
in	O
the	O
nine	O
apparently	O
pathologic	O
TBX1	B-GENE
mutations	O
identified	O
to	O
date	O
(	O
Table	O
2	O
)	O
.	O

Among	O
them	O
,	O
KCNQ4	B-GENE
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
and	O
MYH9	B-GENE
p	B-VARIANT
.	I-VARIANT
E1256K	I-VARIANT
were	O
novel	O
.	O

Our	O
patient	O
'	O
s	O
successful	O
performance	O
after	O
EAS	O
is	O
compatible	O
with	O
the	O
intra	O
-	O
membranous	O
labyrinth	O
etiology	O
.	O

Recently	O
,	O
whole	O
exome	O
sequencing	O
has	O
substantially	O
aided	O
the	O
detection	O
of	O
a	O
series	O
of	O
new	O
causative	O
deafness	B-DISEASE
genes	O
[	O
49	O
-	O
55	O
]	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
is	O
consistent	O
with	O
autosomal	O
recessive	O
inheritance	O
.	O

However	O
,	O
as	O
the	O
heterozygous	O
variant	O
p	B-VARIANT
.	I-VARIANT
G1220R	I-VARIANT
was	O
present	O
in	O
the	O
Korean	O
control	O
exome	O
data	O
,	O
we	O
regard	O
it	O
as	O
a	O
polymorphism	O
.	O

Two	O
relatives	O
(	O
07	O
-	O
0430	O
-	O
02009	O
and	O
07	O
-	O
0430	O
-	O
01590	O
)	O
were	O
included	O
and	O
the	O
same	O
COL4A5	B-GENE
-	O
G1161E	B-VARIANT
mutation	O
was	O
independently	O
identified	O
providing	O
credence	O
to	O
our	O
approach	O
.	O

Their	O
father	O
had	O
a	O
high	O
arched	O
palate	O
and	O
mild	O
,	O
asymptomatic	O
high	O
tone	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

100	O
%	O
of	O
our	O
patients	O
with	O
two	O
mutant	O
alleles	O
(	O
17	O
/	O
17	O
)	O
and	O
only	O
33	O
.	O
3	O
%	O
(	O
3	O
/	O
9	O
)	O
of	O
patients	O
with	O
one	O
mutant	O
allele	O
were	O
confirmed	O
to	O
have	O
EVA	B-DISEASE
manifestation	O
.	O

(	O
1	O
)	O
[	O
McMillan	O
et	O
al	O
.	O
,	O
2012	O
]	O
;	O
(	O
2	O
)	O
Unpublished	O
;	O
(	O
3	O
)	O
[	O
Berryer	O
et	O
al	O
.	O
,	O
2013	O
]	O
.	O

The	O
two	O
hydrogen	O
bonds	O
,	O
which	O
link	O
an	O
alpha	O
-	O
helix	O
with	O
beta	O
-	O
sheets	O
according	O
to	O
the	O
predicted	O
crystal	O
structure	O
,	O
are	O
generally	O
critical	O
for	O
the	O
tertiary	O
structure	O
of	O
the	O
protein	O
.	O

The	O
hearing	O
level	O
in	O
all	O
of	O
the	O
participants	O
was	O
evaluated	O
by	O
audiological	O
tests	O
,	O
including	O
pure	O
-	O
tone	O
audiometry	O
(	O
PTA	O
)	O
and	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
.	O

MLPA	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
:	O
denaturation	O
at	O
98	O
deg	O
C	O
for	O
5	O
minutes	O
;	O
stabilization	O
at	O
25	O
deg	O
C	O
;	O
hybridization	O
at	O
95	O
deg	O
C	O
for	O
1	O
minute	O
and	O
at	O
60	O
deg	O
C	O
for	O
16	O
-	O
20	O
hours	O
,	O
stabilization	O
at	O
54	O
deg	O
C	O
;	O
ligation	O
at	O
54	O
deg	O
C	O
for	O
15	O
minutes	O
,	O
inactivation	O
at	O
98	O
deg	O
C	O
for	O
5	O
minutes	O
,	O
and	O
stabilization	O
at	O
20	O
deg	O
C	O
.	O

However	O
,	O
her	O
anosmic	O
father	O
carrying	O
the	O
same	O
mutation	O
had	O
had	O
four	O
children	O
during	O
testosterone	O
therapy	O
,	O
consistent	O
with	O
active	O
spermatogenesis	O
,	O
and	O
her	O
brother	O
had	O
normosmic	O
HH	B-DISEASE
.	O

Whole	O
venous	O
blood	O
samples	O
(	O
10	O
ml	O
)	O
were	O
collected	O
and	O
immediately	O
processed	O
for	O
genomic	O
DNA	O
extraction	O
from	O
peripheral	O
blood	O
leucocytes	O
,	O
using	O
the	O
standard	O
protocols	O
.	O

The	O
genotyping	O
results	O
did	O
not	O
exclude	O
MYO7A	B-GENE
,	O
suggesting	O
that	O
one	O
or	O
more	O
mutation	O
(	O
s	O
)	O
in	O
MYO7A	B-GENE
likely	O
caused	O
the	O
phenotype	O
observed	O
in	O
the	O
two	O
patients	O
.	O

We	O
considered	O
the	O
latter	O
to	O
possibly	O
be	O
a	O
disease	O
modifier	O
.	O

En	O
face	O
OCT	O
imaging	O
of	O
Patient	O
1	O
-	O
II	O
-	O
1	O
revealed	O
that	O
cysts	O
were	O
located	O
in	O
the	O
superior	O
,	O
nasal	O
,	O
and	O
inferior	O
macular	O
quadrants	O
in	O
both	O
eyes	O
(	O
Figures	O
6	O
(	O
a	O
)	O
and	O
6	O
(	O
b	O
)	O
)	O
.	O

Usherin	B-GENE
shows	O
two	O
alternatively	O
spliced	O
isoforms	O
that	O
comprise	O
of	O
short	O
"	O
isoform	O
a	O
"	O
and	O
longer	O
"	O
isoform	O
b	O
"	O
variants	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
the	O
p	B-VARIANT
.	I-VARIANT
F1442S	I-VARIANT
change	O
affects	O
long	O
and	O
short	O
isoforms	O
while	O
the	O
p	B-VARIANT
.	I-VARIANT
L5063R	I-VARIANT
variant	O
affects	O
only	O
the	O
long	O
isoform	O
of	O
USH2A	B-GENE
.	O

Interestingly	O
,	O
Pineda	O
et	O
al	O
.	O

This	O
additional	O
DFNA67	B-DISEASE
family	O
strongly	O
supports	O
the	O
association	O
of	O
OSBPL2	B-GENE
mutations	O
with	O
ADNSHL	B-DISEASE
.	O

Agarose	O
gel	O
examination	O
of	O
genomic	O
DNA	O
quality	O
.	O

Targeted	O
NGS	O
for	O
84	O
deafness	B-DISEASE
genes	O
resulted	O
in	O
identification	O
of	O
candidate	O
genes	O
in	O
7	O
of	O
15	O
families	O
and	O
revealed	O
the	O
diverse	O
spectrum	O
of	O
rare	O
deafness	B-DISEASE
genes	O
in	O
Japanese	O
subjects	O
with	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
the	O
first	O
time	O
.	O

The	O
function	O
of	O
OSBPL2	B-GENE
in	O
the	O
hearing	O
process	O
remains	O
to	O
be	O
determined	O
.	O

There	O
are	O
three	O
affected	O
males	O
and	O
the	O
pedigree	O
is	O
consistent	O
with	O
X	O
-	O
Linked	O
recessive	O
inheritance	O
(	O
5B	O
)	O
.	O

The	O
disease	O
prevalence	O
is	O
between	O
1	O
:	O
12	O
000	O
to	O
1	O
:	O
50	O
000	O
in	O
different	O
populations	O
3	O
4	O
.	O

3	O
,	O
overlapping	O
audiograms	O
of	O
the	O
patients	O
with	O
only	O
one	O
mutation	O
was	O
similar	O
to	O
that	O
with	O
the	O
patients	O
with	O
two	O
mutations	O
(	O
high	O
frequency	O
involved	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
with	O
residual	O
hearing	O
at	O
the	O
lower	O
frequencies	O
)	O
.	O

and	O
S	O
.	O
L	O
.	O

They	O
play	O
essential	O
roles	O
in	O
the	O
initiation	O
and	O
elongation	O
of	O
DNA	O
synthesis	O
and	O
the	O
assembly	O
and	O
activation	O
of	O
the	O
pre	O
-	O
replicative	O
complex	O
[	O
15	O
-	O
17	O
]	O
.	O

These	O
amplified	O
fragments	O
were	O
inserted	O
into	O
a	O
cloning	O
vector	O
followed	O
by	O
sequencing	O
the	O
individual	O
clones	O
carrying	O
the	O
amplified	O
fragments	O
.	O

3	O
)	O
,	O
while	O
in	O
two	O
DFNB48	B-DISEASE
families	O
(	O
DEM4025	O
,	O
DEM4225	O
)	O
a	O
c	B-VARIANT
.	I-VARIANT
297C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Cys99Trp	I-VARIANT
)	O
CIB2	B-GENE
mutation	O
co	O
-	O
segregated	O
with	O
deafness	B-DISEASE
(	O
Figs	O
.	O

For	O
i	O
n	O
vivo	O
mRNA	O
synthesis	O
,	O
HOMER2	B-GENE
WT	O
and	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
plasmids	O
were	O
transferred	O
into	O
the	O
expression	O
vector	O
pCS2	O
+	O
with	O
Gateway	O
LR	O
Clonase	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Life	O
Technologies	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Several	O
of	O
the	O
substitution	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
V116M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G243R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
C386R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
V372M	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R445C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R63W	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R89H	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R620C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
D918N	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E1701K	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
S2527L	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
E31G	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R84W	I-VARIANT
)	O
were	O
predicted	O
to	O
have	O
severe	O
detrimental	O
effects	O
by	O
SIFT	O
and	O
POLYPHEN	O
analysis	O
(	O
Table	O
2	O
)	O
.	O

We	O
detected	O
at	O
least	O
one	O
pathogenic	O
/	O
likely	O
pathogenic	O
mutant	O
allele	O
in	O
86	O
%	O
of	O
all	O
Usher	B-DISEASE
probands	O
studied	O
,	O
indicating	O
that	O
there	O
is	O
no	O
other	O
Usher	B-DISEASE
gene	O
of	O
major	O
impact	O
in	O
the	O
population	O
.	O

Genetic	O
testing	O
confirmed	O
that	O
both	O
mother	O
and	O
son	O
had	O
a	O
novel	O
c	B-VARIANT
.	I-VARIANT
685A	I-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Lys229X	I-VARIANT
mutation	O
in	O
the	O
COL4A5	B-GENE
gene	O
(	O
Figure	O
1	O
C	O
)	O
,	O
which	O
is	O
predicted	O
to	O
be	O
pathogenic	O
,	O
confirming	O
X	B-DISEASE
-	I-DISEASE
linked	I-DISEASE
AS	I-DISEASE
.	O

To	O
determine	O
the	O
parental	O
origin	O
in	O
the	O
cases	O
in	O
which	O
the	O
microarray	O
detected	O
two	O
mutated	O
alleles	O
,	O
cosegregation	O
analysis	O
of	O
the	O
variants	O
was	O
performed	O
by	O
sequence	O
analysis	O
.	O

Proof	O
of	O
pathogenicity	O
is	O
defined	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
criteria	O
;	O
(	O
1	O
)	O
a	O
previously	O
published	O
mutation	O
with	O
family	O
studies	O
or	O
absent	O
in	O
controls	O
(	O
indicated	O
by	O
parenthesis	O
)	O
,	O
(	O
2	O
)	O
a	O
de	O
novo	O
mutation	O
or	O
co	O
-	O
segregation	O
in	O
this	O
study	O
,	O
(	O
3	O
)	O
alteration	O
of	O
an	O
evolutionary	O
conserved	O
functional	O
residue	O
in	O
either	O
the	O
N	O
-	O
type	O
motif	O
or	O
C	O
-	O
type	O
motif	O
of	O
the	O
type	O
III	O
repeat	O
region	O
of	O
COMP	B-GENE
.	O

The	O
remaining	O
50	O
%	O
of	O
congenital	O
cases	O
are	O
attributable	O
to	O
other	O
factors	O
such	O
as	O
prenatal	O
exposure	O
to	O
measles	O
,	O
cytomegalovirus	O
,	O
premature	O
birth	O
,	O
and	O
newborn	O
meningitis	O
.	O

Shown	O
are	O
four	O
Israeli	O
Arab	O
families	O
segregating	O
USH1	B-DISEASE
.	O

Our	O
findings	O
suggest	O
that	O
the	O
USH1C	B-GENE
mutation	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
is	O
one	O
of	O
only	O
a	O
handful	O
of	O
common	O
single	O
USH1	B-DISEASE
mutations	O
,	O
along	O
with	O
founder	O
mutations	O
in	O
USH3A	B-GENE
in	O
the	O
Finnish	O
and	O
the	O
Ashkenazi	O
Jewish	O
population	O
and	O
a	O
PCDH15	B-GENE
/	O
USH1F	B-GENE
founder	O
allele	O
in	O
Ashkenazi	O
Jews	O
[	O
12	O
,	O
25	O
,	O
26	O
]	O
;	O
moreover	O
,	O
it	O
is	O
predominant	O
in	O
two	O
populations	O
.	O

But	O
more	O
recently	O
,	O
the	O
mutation	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
IVS4	O
+	O
2T	O
>	O
C	O
)	O
has	O
also	O
been	O
identified	O
in	O
the	O
European	O
Roma	O
population	O
,	O
possibly	O
contributing	O
significantly	O
to	O
the	O
deafness	B-DISEASE
etiology	O
within	O
this	O
ethnic	O
group	O
[	O
10	O
]	O
.	O

A	O
deletion	O
of	O
21	O
nucleotides	O
,	O
c	B-VARIANT
.	I-VARIANT
3202_3222del	I-VARIANT
in	O
exon	O
24	O
(	O
p	B-VARIANT
.	I-VARIANT
Q1068_L1074	I-VARIANT
del	I-VARIANT
)	O
,	O
was	O
identified	O
in	O
a	O
59	O
year	O
-	O
old	O
-	O
woman	O
who	O
had	O
a	O
moderate	O
thrombocytopenia	B-DISEASE
(	O
platelet	O
count	O
:	O
50	O
-	O
90	O
x	O
10	O
9	O
/	O
L	O
)	O
but	O
spontaneous	O
and	O
provoked	O
bleeding	B-DISEASE
,	O
large	O
platelets	O
(	O
giant	O
:	O
46	O
%	O
,	O
intermediate	O
-	O
size	O
increase	O
:	O
47	O
%	O
)	O
,	O
leukocyte	B-DISEASE
inclusions	I-DISEASE
type	O
II	O
/	O
III	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
since	O
childhood	O
,	O
congenital	O
cataracts	B-DISEASE
(	O
operated	O
at	O
4	O
years	O
)	O
,	O
and	O
mild	O
proteinuria	B-DISEASE
(	O
0	O
.	O
22	O
g	O
/	O
L	O
)	O
.	O

Mutations	O
were	O
found	O
in	O
9	O
/	O
49	O
patients	O
(	O
18	O
%	O
)	O
with	O
neonatal	B-DISEASE
diabetes	I-DISEASE
(	O
Table	O
1	O
)	O
.	O

Three	O
probands	O
had	O
mutations	O
in	O
KAL1	B-GENE
(	O
Table	O
1	O
)	O
.	O

The	O
sequencing	O
runs	O
performed	O
here	O
showed	O
60	O
-	O
90	O
%	O
of	O
reads	O
on	O
target	O
,	O
consistent	O
with	O
the	O
proportion	O
of	O
sequences	O
on	O
target	O
in	O
custom	O
capture	O
kits	O
in	O
the	O
literature	O
that	O
report	O
70	O
-	O
80	O
%	O
capture	O
,	O
depending	O
on	O
the	O
size	O
of	O
the	O
panel	O
and	O
the	O
capture	O
kit	O
used	O
[	O
71	O
,	O
72	O
,	O
83	O
]	O
.	O

Kausar	O
for	O
technical	O
assistance	O
and	O
Drs	O
.	O

As	O
indicated	O
by	O
several	O
exceptional	O
findings	O
in	O
our	O
study	O
,	O
scientific	O
gain	O
of	O
knowledge	O
will	O
strongly	O
benefit	O
from	O
the	O
recent	O
advent	O
of	O
NGS	O
in	O
routine	O
diagnostics	O
and	O
the	O
"	O
byproducts	O
"	O
of	O
such	O
unprecedented	O
large	O
-	O
scale	O
analyses	O
-	O
not	O
only	O
for	O
RD	O
,	O
but	O
for	O
many	O
other	O
genetically	O
heterogeneous	O
conditions	O
.	O

The	O
F013	O
has	O
been	O
mapped	O
to	O
9q33	O
by	O
linkage	O
analysis	O
six	O
years	O
ago	O
by	O
our	O
team	O
,	O
but	O
the	O
causative	O
gene	O
was	O
not	O
identified	O
because	O
of	O
too	O
many	O
candidate	O
genes	O
involved	O
in	O
this	O
mapped	O
locus	O
.	O

The	O
Bioanalyzer	O
High	O
Sensitivity	O
chip	O
(	O
Agilent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
was	O
used	O
to	O
check	O
the	O
size	O
range	O
of	O
the	O
enriched	O
fragment	O
libraries	O
.	O

Liver	O
transaminase	O
levels	O
were	O
normal	O
:	O
the	O
AST	O
level	O
was	O
23	O
mu	O
/	O
L	O
,	O
and	O
the	O
ALT	O
level	O
was	O
38	O
mu	O
/	O
L	O
.	O

To	O
identify	O
pathogenic	O
variants	O
,	O
we	O
filtered	O
out	O
polymorphisms	O
using	O
the	O
Single	O
Nucleotide	O
Polymorphism	O
Database	O
dbSNP131	O
and	O
the	O
Korean	O
exome	O
data	O
,	O
which	O
includes	O
exome	O
data	O
for	O
30	O
Koreans	O
from	O
another	O
study	O
[	O
13	O
]	O
,	O
and	O
the	O
Korean	O
genome	O
database	O
,	O
TIARA	O
[	O
14	O
]	O
.	O

Data	O
quality	O
control	O
was	O
performed	O
using	O
PedCheck	O
[	O
3	O
]	O
to	O
check	O
for	O
genotyping	O
error	O
which	O
resulted	O
in	O
Mendelian	O
inconsistencies	O
,	O
while	O
MERLIN	O
[	O
4	O
]	O
was	O
used	O
to	O
detect	O
occurrence	O
of	O
double	O
recombination	O
events	O
over	O
short	O
genetic	O
distances	O
,	O
which	O
are	O
most	O
likely	O
due	O
to	O
genotyping	O
error	O
.	O

Currently	O
,	O
few	O
reports	O
have	O
observed	O
the	O
dynamic	O
evolution	O
of	O
macular	B-DISEASE
holes	I-DISEASE
,	O
except	O
that	O
Shah	O
et	O
al	O
.	O

PTA	O
was	O
calculated	O
as	O
the	O
average	O
of	O
the	O
hearing	O
level	O
at	O
0	O
.	O
5	O
,	O
1	O
.	O
0	O
,	O
2	O
.	O
0	O
and	O
4	O
.	O
0	O
KHz	O
for	O
the	O
better	O
ear	O
.	O

Nine	O
individuals	O
were	O
found	O
to	O
be	O
heterozygous	O
carriers	O
of	O
GJB2	B-GENE
pathogenic	O
mutations	O
;	O
three	O
had	O
the	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
three	O
had	O
the	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
,	O
and	O
the	O
c	B-VARIANT
.	I-VARIANT
512_c	I-VARIANT
.	I-VARIANT
513insAACG	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
E47X	I-VARIANT
mutation	O
have	O
been	O
detected	O
in	O
single	O
individuals	O
(	O
see	O
Supplemental	O
Table	O
3	O
)	O
.	O

*	O
Average	O
of	O
500	O
,	O
1000	O
,	O
2000	O
,	O
and	O
4000	O
Hz	O
.	O

All	O
students	O
with	O
moderate	O
to	O
profound	O
hearing	B-DISEASE
loss	I-DISEASE
from	O
Chifeng	O
city	O
and	O
within	O
500	O
km	O
diameter	O
of	O
its	O
neighboring	O
area	O
come	O
to	O
this	O
school	O
.	O

2	O
)	O
.	O

Using	O
ESEfinder	O
,	O
the	O
two	O
motifs	O
SRp40	O
and	O
SRp55	O
of	O
the	O
SR	O
proteins	O
were	O
predicted	O
to	O
bind	O
the	O
new	O
site	O
.	O

The	O
mouse	O
genes	O
will	O
be	O
sequenced	O
from	O
DNA	O
of	O
many	O
more	O
human	O
families	O
in	O
the	O
future	O
.	O

Yan	O
et	O
al	O
.	O

(	O
DOCX	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

On	O
the	O
other	O
hand	O
,	O
other	O
phenotypes	O
have	O
also	O
been	O
reported	O
.	O

The	O
arrow	O
designates	O
the	O
proband	O
.	O

Clinical	O
history	O
and	O
physical	O
examinations	O
of	O
family	O
members	O
ruled	O
out	O
the	O
implication	O
of	O
environmental	O
factors	O
in	O
the	O
etiology	O
of	O
HL	B-DISEASE
and	O
RP	B-DISEASE
.	O

A	O
majority	O
of	O
patients	O
had	O
a	O
mean	O
platelet	O
count	O
between	O
11	O
and	O
50	O
x	O
10	O
9	O
/	O
L	O
(	O
44	O
.	O
8	O
%	O
)	O
or	O
between	O
51	O
and	O
99	O
x	O
10	O
9	O
/	O
L	O
(	O
37	O
.	O
3	O
%	O
)	O
.	O

The	O
former	O
is	O
responsible	O
for	O
about	O
30	O
%	O
of	O
prelingual	O
deafness	B-DISEASE
in	O
combination	O
with	O
abnormalities	O
of	O
other	O
organs	O
.	O

34	O
47	O
48	O
To	O
analyse	O
such	O
rearrangements	O
reliably	O
,	O
other	O
methods	O
such	O
as	O
MLPA	O
and	O
oligonucleotide	O
array	O
based	O
comparative	O
genomic	O
hybridisation	O
could	O
be	O
used	O
in	O
future	O
.	O

Thus	O
,	O
more	O
studies	O
are	O
required	O
to	O
determine	O
whether	O
the	O
biologically	O
relevant	O
substrate	O
of	O
ELMOD3	O
'	O
s	O
GAP	O
activity	O
in	O
the	O
inner	O
ear	O
is	O
Arl2	O
or	O
a	O
related	O
GTPase	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
there	O
are	O
only	O
74	O
WS4	B-DISEASE
cases	O
described	O
(	O
2012	O
)	O
in	O
the	O
English	O
literature	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
,	O
[	O
4	O
]	O
,	O
[	O
5	O
]	O
,	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
,	O
[	O
8	O
]	O
.	O

The	O
generated	O
products	O
were	O
analysed	O
on	O
a	O
1	O
%	O
agarose	O
gel	O
and	O
sequenced	O
with	O
BigDye	O
TM	O
terminator	O
cycle	O
chemistries	O
.	O

Pure	O
tone	O
audiogram	O
for	O
the	O
left	O
and	O
right	O
ears	O
of	O
the	O
HL	O
-	O
01	O
patient	O
(	O
III	O
-	O
2	O
)	O
(	O
lower	O
panel	O
)	O
.	O

(	O
2012	O
)	O
had	O
shown	O
that	O
ABI	O
Sanger	O
sequencing	O
of	O
all	O
exons	O
of	O
nine	O
genes	O
that	O
were	O
known	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
at	O
that	O
date	O
had	O
a	O
diagnostic	O
yield	O
of	O
about	O
80	O
%	O
.	O

This	O
higher	O
resolution	O
should	O
help	O
in	O
detecting	O
and	O
evaluating	O
en	O
face	O
images	O
of	O
MME	B-DISEASE
.	O

Currently	O
mutations	O
in	O
eight	O
genes	O
explain	O
approximatively	O
25	O
-	O
35	O
%	O
of	O
KS	B-DISEASE
cases	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

Analyzing	O
number	O
of	O
the	O
diseases	O
revealed	O
an	O
imbalance	O
in	O
the	O
distribution	O
of	O
areas	O
and	O
hospitals	O
diagnosing	O
rare	O
diseases	O
,	O
which	O
suggests	O
that	O
a	O
multi	O
-	O
level	O
network	O
should	O
be	O
created	O
to	O
meet	O
the	O
specific	O
challenge	O
of	O
healthcare	O
for	O
rare	O
diseases	O
in	O
China	O
.	O

The	O
National	O
Research	O
Ethics	O
Service	O
Committee	O
(	O
West	O
Midlands	O
-	O
-	O
Staffordshire	O
,	O
UK	O
)	O
approved	O
this	O
study	O
(	O
REC	O
reference	O
09	O
/	O
H1203	O
/	O
74	O
)	O
.	O

The	O
results	O
showed	O
that	O
all	O
7	O
of	O
these	O
variants	O
were	O
highly	O
conserved	O
among	O
multiple	O
vertebrate	O
species	O
(	O
Figure	O
2	O
d	O
,	O
Additional	O
file	O
3	O
:	O
Figure	O
S1	O
)	O
.	O

We	O
identified	O
a	O
novel	O
missense	O
c	B-VARIANT
.	I-VARIANT
788T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
in	O
PAX3	B-GENE
in	O
a	O
family	O
with	O
Waardenburg	B-DISEASE
syndrome	I-DISEASE
with	O
intrafamilial	O
phenotypic	O
heterogeneity	O
.	O

Seven	O
USH2A	B-GENE
mutations	O
,	O
including	O
four	O
missense	O
substitutions	O
(	O
p	B-VARIANT
.	I-VARIANT
P2762A	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
G3320C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R3719H	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
G4763R	I-VARIANT
)	O
,	O
two	O
splice	O
site	O
variants	O
(	O
c	B-VARIANT
.	I-VARIANT
8223	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
8559	I-VARIANT
-	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
,	O
and	O
a	O
nonsense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
Y3745	I-VARIANT
*	I-VARIANT
)	O
,	O
were	O
identified	O
as	O
disease	O
causative	O
in	O
the	O
five	O
investigated	O
families	O
,	O
of	O
which	O
three	O
reported	O
to	O
have	O
consanguineous	O
marriage	O
.	O

The	O
mutation	O
was	O
not	O
observed	O
in	O
both	O
of	O
his	O
normal	O
parents	O
.	O

Deletions	O
or	O
duplications	O
were	O
not	O
detected	O
in	O
any	O
of	O
these	O
patients	O
,	O
supporting	O
the	O
non	O
-	O
pathogenicity	O
of	O
the	O
two	O
missense	O
variants	O
,	O
which	O
remained	O
UV1	O
or	O
UV2	O
.	O

1	O
/	O
770	O
,	O
000	O
)	O
[	O
2	O
]	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
find	O
this	O
mutation	O
in	O
110	O
Tunisian	O
healthy	O
subjects	O
.	O

In	O
case	O
of	O
three	O
different	O
votes	O
,	O
the	O
variant	O
was	O
predicted	O
as	O
"	O
unknown	O
.	O

The	O
incomplete	O
penetrance	O
of	O
the	O
clinical	O
symptoms	O
in	O
the	O
obligate	O
carrier	O
females	O
has	O
been	O
documented	O
in	O
a	O
few	O
studies	O
.	O

The	O
mRNA	O
from	O
normal	O
human	O
adenoid	O
specimens	O
was	O
extracted	O
,	O
and	O
cDNA	O
was	O
synthesized	O
.	O

SignalP	O
4	O
.	O
0	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
cbs	O
.	O
dtu	O
.	O
dk	O
/	O
services	O
/	O
SignalP	O
-	O
4	O
.	O
0	O
/	O
)	O
was	O
employed	O
to	O
predict	O
the	O
presence	O
and	O
location	O
of	O
the	O
signal	O
peptide	O
/	O
non	O
-	O
signal	O
peptide	O
cleavage	O
sites	O
[	O
20	O
]	O
.	O

All	O
exons	O
and	O
their	O
flanking	O
intronic	O
sequences	O
of	O
MYH9	B-GENE
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
by	O
pairs	O
of	O
primers	O
designed	O
by	O
the	O
authors	O
(	O
available	O
upon	O
request	O
)	O
.	O

The	O
data	O
was	O
analyzed	O
utilizing	O
Sequencing	O
analysis	O
v5	O
.	O
2	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
and	O
Chromas	O
Pro	O
v1	O
.	O
5	O
software	O
(	O
Technelysium	O
,	O
Pty	O
Ltd	O
.	O
,	O
Tewantin	O
,	O
QLD	O
,	O
Australia	O
)	O
.	O

The	O
only	O
exception	O
is	O
a	O
patient	O
who	O
is	O
a	O
compound	O
heterozygous	O
for	O
a	O
null	O
and	O
a	O
missense	O
mutation	O
but	O
no	O
clinical	O
data	O
were	O
presented	O
by	O
the	O
authors	O
[	O
23	O
]	O
.	O

p	B-VARIANT
.	I-VARIANT
C3358Y	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
P4818L	I-VARIANT
were	O
classified	O
by	O
McGee	O
et	O
al	O
.	O

These	O
data	O
confirm	O
recent	O
studies	O
showing	O
that	O
COMP	B-GENE
mutations	O
are	O
the	O
predominant	O
cause	O
of	O
MED	B-DISEASE
[	O
Zankl	O
et	O
al	O
.	O
,	O
2007	O
]	O
,	O
while	O
type	O
IX	O
collagen	O
gene	O
mutations	O
account	O
for	O
only	O
about	O
10	O
%	O
of	O
the	O
currently	O
known	O
mutations	O
in	O
AD	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
.	O

Therefore	O
,	O
the	O
observations	O
made	O
in	O
our	O
limited	O
sample	O
suggested	O
that	O
the	O
order	O
in	O
which	O
symptoms	O
emerge	O
in	O
the	O
course	O
of	O
WFS	B-DISEASE
is	O
difficult	O
to	O
discern	O
.	O

For	O
TMIE	B-GENE
,	O
all	O
eight	O
mutation	O
positive	O
families	O
were	O
homozygous	O
for	O
the	O
observed	O
mutations	O
.	O

A	O
targeted	O
NGS	O
approach	O
was	O
conducted	O
on	O
patients	O
ARRP01	O
-	O
IV	O
:	O
4	O
,	O
ARRP02	O
-	O
II	O
:	O
3	O
,	O
ARRP03	O
-	O
IV	O
:	O
3	O
,	O
and	O
ARRP04	O
-	O
IV	O
:	O
4	O
using	O
a	O
microarray	O
that	O
targeted	O
180	O
IRDs	B-DISEASE
causative	O
and	O
9	O
candidate	O
genes	O
,	O
while	O
on	O
patient	O
SU	O
-	O
II	O
:	O
2	O
using	O
a	O
different	O
microarray	O
that	O
targeted	O
319	O
ophthalmic	O
disease	O
relevant	O
genes	O
.	O

The	O
HEK293T	O
and	O
COS7	O
cells	O
were	O
maintained	O
in	O
DMEM	O
medium	O
(	O
Invitrogen	O
,	O
California	O
,	O
USA	O
)	O
with	O
10	O
%	O
foetal	O
calf	O
serum	O
(	O
Invitrogen	O
,	O
California	O
,	O
USA	O
)	O
and	O
were	O
then	O
co	O
-	O
transfected	O
with	O
100	O
ng	O
of	O
the	O
wild	O
-	O
type	O
or	O
mutant	O
TBX1	B-GENE
constructs	O
,	O
500	O
ng	O
of	O
the	O
4XT	O
/	O
2	O
-	O
minP	O
reporter	O
construct	O
,	O
and	O
a	O
renilla	O
luciferase	O
pGL4	O
.	O
74	O
[	O
hRluc	O
/	O
TK	O
]	O
vector	O
(	O
Promega	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
USA	O
)	O
.	O

This	O
case	O
demonstrates	O
the	O
importance	O
of	O
a	O
correct	O
diagnosis	O
even	O
in	O
adulthood	O
,	O
enabling	O
individuals	O
affected	O
by	O
rare	O
conditions	O
to	O
be	O
made	O
aware	O
about	O
recurrence	O
and	O
pregnancy	O
-	O
associated	O
risks	O
,	O
and	O
potential	O
complications	O
in	O
the	O
newborn	O
.	O

The	O
bar	O
graph	O
summarizes	O
the	O
amount	O
of	O
charge	O
conducted	O
by	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
-	O
WT	O
/	O
KCNE1	B-GENE
(	O
black	O
;	O
n	O
=	O
10	O
)	O
or	O
K	B-GENE
V	I-GENE
7	I-GENE
.	I-GENE
1	I-GENE
/	O
KCNE1	B-GENE
-	O
G60D	B-VARIANT
(	O
white	O
;	O
n	O
=	O
15	O
)	O
channels	O
in	O
the	O
first	O
130	O
ms	O
after	O
the	O
capacitive	O
spike	O
(	O
10	O
ms	O
)	O
of	O
the	O
pulse	O
at	O
the	O
7th	O
second	O
when	O
normalized	O
to	O
the	O
charge	O
carried	O
at	O
60	O
bpm	O
.	O

The	O
CLRN1	B-GENE
protein	O
is	O
thought	O
to	O
be	O
expressed	O
in	O
mouse	O
cochlea	O
transiently	O
from	O
E18	O
to	O
postnatal	O
day	O
(	O
P	O
)	O
6	O
in	O
basal	O
parts	O
of	O
the	O
hair	O
cells	O
,	O
whereas	O
in	O
apical	O
parts	O
(	O
stereocilia	O
)	O
the	O
CLRN1	B-GENE
expression	O
is	O
lost	O
already	O
at	O
P1	O
.	O

No	O
mutational	O
hotspots	O
or	O
recurrent	O
mutations	O
have	O
been	O
identified	O
in	O
the	O
PCDH15	B-GENE
gene	O
,	O
with	O
the	O
exception	O
of	O
p	B-VARIANT
.	I-VARIANT
R245X	I-VARIANT
,	O
a	O
founder	O
mutation	O
responsible	O
for	O
about	O
50	O
%	O
-	O
60	O
%	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
I	I-DISEASE
cases	O
in	O
the	O
Ashkenazi	O
Jewish	O
population	O
[	O
24	O
,	O
26	O
]	O
.	O

(	O
a	O
)	O
Pedigree	O
of	O
family	O
PKDF1132	O
with	O
six	O
affected	O
individuals	O
present	O
in	O
three	O
sibships	O
.	O

Patient	O
DT35	O
presented	O
with	O
mitochondrial	B-DISEASE
encephalomyopathy	I-DISEASE
and	O
was	O
found	O
to	O
contain	O
an	O
apparent	O
homozygous	O
NUBPL	B-GENE
:	B-VARIANT
c	I-VARIANT
.	I-VARIANT
166G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
mutation	O
(	O
Supplementary	O
Fig	O
.	O

The	O
overlap	O
between	O
phenotypes	O
resulting	O
from	O
knockdown	O
of	O
PARD3	B-GENE
and	O
the	O
phenotypes	O
in	O
F9	O
and	O
F19	O
is	O
interesting	O
,	O
however	O
we	O
judged	O
that	O
the	O
current	O
knowledge	O
of	O
the	O
function	O
of	O
PARD3B	B-GENE
is	O
insufficient	O
to	O
categorize	O
the	O
mutations	O
identified	O
in	O
our	O
cohort	O
as	O
being	O
possibly	O
causal	O
.	O

Additionally	O
,	O
some	O
Brn4	O
null	O
mice	O
display	O
a	O
reduction	O
in	O
cochlear	O
coiling	O
.	O

The	O
stability	O
of	O
F	O
-	O
actin	O
in	O
these	O
cells	O
was	O
probed	O
using	O
latrunculin	O
A	O
,	O
which	O
binds	O
actin	O
monomers	O
thereby	O
preventing	O
their	O
incorporation	O
into	O
growing	O
filaments	O
36	O
.	O

Primary	O
care	O
physicians	O
,	O
ophthalmologists	O
,	O
and	O
endocrinologists	O
were	O
all	O
likely	O
to	O
be	O
the	O
caregivers	O
first	O
proposing	O
the	O
diagnosis	O
and	O
school	O
screening	O
programs	O
were	O
instrumental	O
in	O
identifying	O
vision	O
and	O
hearing	O
losses	O
in	O
several	O
.	O

This	O
is	O
a	O
particular	O
problem	O
when	O
family	O
data	O
are	O
not	O
sufficient	O
to	O
establish	O
linkage	O
.	O

All	O
data	O
was	O
smoothed	O
with	O
[	O
filter	O
{	O
ones	O
(	O
1	O
,	O
windowsize	O
)	O
/	O
windowsize	O
,	O
1	O
,	O
data	O
}	O
]	O
with	O
the	O
following	O
window	O
sizes	O
:	O
Amplitude	O
:	O
5	O
sec	O
stimuli	O
1000	O
;	O
300	O
ms	O
stimuli	O
100	O
;	O
Frequency	O
:	O
10	O
%	O
of	O
cycle	O
length	O
,	O
Sustainability	O
:	O
100	O
.	O

After	O
the	O
Ion	O
Sphere	O
Particle	O
preparation	O
,	O
MPS	O
was	O
performed	O
with	O
an	O
Ion	O
Torrent	O
Personal	O
Genome	O
Machine	O
(	O
PGM	O
)	O
system	O
using	O
the	O
Ion	O
PGM	O
(	O
tm	O
)	O
200	O
Sequencing	O
Kit	O
and	O
Ion	O
318	O
(	O
tm	O
)	O
Chip	O
(	O
Life	O
Technologies	O
)	O
according	O
to	O
the	O
established	O
procedures	O
(	O
Publication	O
Part	O
Number	O
4474596	O
Rev	O
.	O

A	O
second	O
subnetwork	O
containing	O
somatic	O
mutations	O
and	O
germline	O
variants	O
in	O
EGFR	B-GENE
,	O
ERRB2	B-GENE
,	O
ERBB3	B-GENE
,	O
and	O
other	O
genes	O
is	O
shown	O
in	O
(	O
Fig	O
.	O

Structural	O
analysis	O
of	O
USH2A	B-GENE
performed	O
with	O
the	O
HOPE	O
server	O
[	O
28	O
]	O
suggests	O
that	O
the	O
original	O
wild	O
-	O
type	O
residues	O
and	O
the	O
newly	O
introduced	O
mutant	O
residues	O
differ	O
in	O
size	O
,	O
charge	O
,	O
and	O
hydrophobicity	O
values	O
.	O

Table	O
2	O
summarizes	O
the	O
number	O
of	O
variants	O
detected	O
from	O
the	O
61	O
or	O
84	O
targeted	O
genes	O
for	O
each	O
subject	O
.	O

Audiometry	O
results	O
of	O
the	O
proband	O
.	O

DNA	O
microarray	O
was	O
performed	O
on	O
nine	O
loci	O
of	O
four	O
deafness	O
-	O
associated	O
genes	O
,	O
including	O
35delG	B-VARIANT
,	O
176	B-VARIANT
-	I-VARIANT
191del16	I-VARIANT
,	O
235delC	B-VARIANT
,	O
299	B-VARIANT
-	I-VARIANT
300delAT	I-VARIANT
,	O
538C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
1494C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
,	O
2168A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
,	O
and	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

3	O
)	O
.	O

SCN1	B-GENE
-	I-GENE
3B	I-GENE
(	O
involved	O
in	O
I	O
Na	O
)	O
[	O
6	O
,	O
9	O
]	O
,	O
or	O
cardiac	O
repolarisation	O
,	O
e	O
.	O
g	O
.	O

Visual	O
fields	O
were	O
markedly	O
constricted	O
in	O
patients	O
in	O
their	O
twenties	O
(	O
Fig	O
.	O

Although	O
for	O
many	O
decades	O
,	O
genome	O
wide	O
linkage	O
analysis	O
has	O
been	O
used	O
for	O
disease	O
gene	O
identification	O
,	O
this	O
approach	O
is	O
time	O
consuming	O
and	O
unsuitable	O
for	O
small	O
families	O
with	O
an	O
inadequate	O
number	O
of	O
affected	O
individuals	O
.	O

In	O
addition	O
,	O
both	O
Leu262	O
and	O
Trp301	O
residues	O
are	O
highly	O
conserved	O
among	O
metazoan	O
GIPC	O
proteins	O
.	O

reported	O
SCN5A	B-GENE
p	B-VARIANT
.	I-VARIANT
A572D	I-VARIANT
as	O
a	O
mutation	O
in	O
3	O
of	O
their	O
patients	O
[	O
13	O
]	O
.	O

The	O
map	O
illustrates	O
the	O
location	O
of	O
the	O
places	O
given	O
in	O
the	O
table	O
(	O
cities	O
associated	O
with	O
patients	O
carrying	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
red	O
)	O
.	O

These	O
test	O
results	O
suggested	O
profound	B-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Indeed	O
,	O
two	O
siblings	O
(	O
cases	O
16	O
.	O
1	O
and	O
16	O
.	O
2	O
)	O
carrying	O
ATP6V0A4	B-GENE
mutations	O
had	O
dRTA	B-DISEASE
with	O
SNHL	B-DISEASE
since	O
childhood	O
,	O
as	O
described	O
[	O
11	O
]	O
.	O

(	O
1B	O
-	O
5B	O
)	O
Showing	O
lateral	O
view	O
of	O
craniofacial	O
features	O
.	O

Turning	O
to	O
diabetes	B-DISEASE
insipidus	I-DISEASE
(	O
DI	B-DISEASE
)	O
,	O
the	O
average	O
age	O
of	O
onset	O
for	O
the	O
entire	O
group	O
was	O
10	O
.	O
6	O
+	O
-	O
3	O
.	O
3	O
years	O
,	O
and	O
13	O
subjects	O
(	O
72	O
%	O
)	O
had	O
DI	B-DISEASE
.	O

DSL	O
,	O
SGH	O
,	O
JDS	O
,	O
and	O
VKM	O
wrote	O
the	O
report	O
.	O

Sequencing	O
alignment	O
data	O
for	O
the	O
homozygous	O
mutation	O
TMPRSS3	B-GENE
:	O
c	B-VARIANT
.	I-VARIANT
535G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
is	O
shown	O
in	O
the	O
left	O
panel	O
.	O

Simultaneously	O
,	O
we	O
used	O
RFLP	O
to	O
detect	O
the	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
in	O
85	O
Hungarian	O
deaf	B-DISEASE
Roma	O
patients	O
,	O
control	O
groups	O
of	O
702	O
normal	O
hearing	O
Romanies	O
from	O
both	O
countries	O
and	O
375	O
hearing	B-DISEASE
impaired	I-DISEASE
Slovak	O
Caucasians	O
.	O

To	O
identify	O
pathogenic	O
variants	O
,	O
we	O
filtered	O
out	O
polymorphisms	O
using	O
the	O
dbSNP131	O
and	O
the	O
Korean	O
exome	O
data	O
.	O

holds	O
a	O
postdoctoral	O
fellowship	O
from	O
Fonds	O
de	O
Recherche	O
du	O
Qu	O
e	O
bec	O
-	O
-	O
Nature	O
et	O
Technologies	O
.	O

D	O
,	O
H	O
)	O
OCT	O
shows	O
bilateral	O
loss	O
of	O
IS	O
/	O
OS	O
junctions	O
and	O
decreased	O
retinal	O
thickness	O
.	O

Using	O
confocal	O
microscopy	O
,	O
images	O
of	O
live	O
cells	O
were	O
captured	O
two	O
days	O
after	O
transfection	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
accordance	O
with	O
the	O
approved	O
guidelines	O
.	O

Sanger	O
sequencing	O
of	O
RT	O
-	O
PCR	O
products	O
evidences	O
the	O
absence	O
of	O
the	O
wild	O
-	O
type	O
allele	O
in	O
the	O
cDNA	O
of	O
the	O
proband	O
(	O
IV	O
:	O
3	O
)	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
myosin	B-GENE
VI	I-GENE
transports	O
cargo	O
molecules	O
at	O
the	O
base	O
of	O
stereocilia	O
,	O
anchors	O
actin	O
filaments	O
to	O
the	O
membrane	O
of	O
stereocilia	O
by	O
cargo	O
molecules	O
in	O
the	O
inner	O
ear	O
and	O
is	O
a	O
mechanism	O
for	O
HL	B-DISEASE
in	O
myosin	O
VI	O
-	O
null	O
mice	O
[	O
15	O
,	O
16	O
]	O
.	O

Optical	O
coherence	O
tomographs	O
of	O
a	O
normal	O
control	O
and	O
three	O
USH3	B-DISEASE
patients	O
.	O

Some	O
PDS	B-DISEASE
cases	O
can	O
also	O
exhibit	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
which	O
involves	O
the	O
bilateral	O
enlargement	O
of	O
the	O
vestibular	O
aqueducts	O
(	O
EVA	B-DISEASE
)	O
with	O
cochlear	O
hypoplasia	O
[	O
7	O
]	O
.	O

The	O
nucleotide	O
(	O
A	O
,	O
adenine	O
)	O
and	O
amino	O
acid	O
(	O
Arg	O
,	O
arginine	O
)	O
changes	O
are	O
shown	O
in	O
red	O
.	O

Both	O
of	O
these	O
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Q136X	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
W114X	I-VARIANT
)	O
are	O
predicted	O
to	O
cause	O
premature	O
truncation	O
of	O
the	O
POU3F4	B-GENE
protein	O
prior	O
to	O
the	O
POU	O
and	O
homeobox	O
domains	O
,	O
hence	O
likely	O
representing	O
functional	O
null	O
alleles	O
.	O

The	O
age	O
of	O
the	O
individual	O
at	O
the	O
time	O
of	O
each	O
analysis	O
is	O
indicated	O
.	O

The	O
flexibility	O
of	O
our	O
approach	O
means	O
that	O
these	O
genes	O
can	O
be	O
incorporated	O
into	O
subsequent	O
versions	O
of	O
the	O
targeted	O
reagent	O
.	O

Group	O
3	O
showed	O
intermediate	O
values	O
.	O

Interestingly	O
,	O
among	O
the	O
identified	O
hearing	B-DISEASE
loss	I-DISEASE
-	O
associated	O
genes	O
,	O
nineteen	O
encode	O
proteins	O
that	O
interact	O
with	O
actin	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

A	O
.	O

A	O
:	O
32	O
-	O
year	O
-	O
old	O
healthy	O
control	O
with	O
visual	O
acuity	O
(	O
VA	O
)	O
of	O
20	O
/	O
20	O
.	O

The	O
main	O
assets	O
of	O
the	O
RD	B-DISEASE
-	O
chip	O
are	O
:	O
i	O
)	O
the	O
robustness	O
of	O
the	O
genetic	O
information	O
that	O
underscores	O
the	O
most	O
probable	O
candidates	O
,	O
ii	O
)	O
the	O
invaluable	O
clues	O
in	O
cases	O
of	O
shared	O
haplotypes	O
,	O
which	O
are	O
indicative	O
of	O
a	O
common	O
founder	O
effect	O
,	O
and	O
iii	O
)	O
the	O
detection	O
of	O
extended	O
haplotypes	O
over	O
closely	O
mapping	O
genes	O
,	O
which	O
substantiates	O
cosegregation	O
,	O
although	O
the	O
assumptions	O
in	O
which	O
the	O
genetic	O
analysis	O
is	O
based	O
could	O
exceptionally	O
lead	O
astray	O
.	O

IF	O
is	O
proposed	O
as	O
a	O
reliable	O
and	O
more	O
sensitive	O
technique	O
(	O
Savoia	O
et	O
al	O
.	O

Mutation	O
nomenclature	O
is	O
based	O
on	O
cDNA	O
sequence	O
(	O
GenBank	O
accession	O
number	O
NM_004004	O
.	O
5	O
)	O
and	O
follows	O
current	O
Human	O
Genome	O
Variation	O
Society	O
rules	O
as	O
implemented	O
by	O
the	O
Mutalyzer	O
2	O
.	O
0	O
beta	O
program	O
(	O
http	O
:	O
/	O
/	O
mutalyzer	O
.	O
nl	O
)	O
.	O

It	O
may	O
be	O
due	O
to	O
the	O
likelihood	O
of	O
incomplete	O
penetrance	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
R348C	I-VARIANT
mutation	O
influenced	O
by	O
additional	O
environmental	O
factors	O
,	O
genetic	O
modifiers	O
or	O
difference	O
in	O
genetic	O
/	O
ethnical	O
background	O
.	O

The	O
audiograms	O
showed	O
variable	O
patterns	O
with	O
either	O
a	O
flat	O
audiogram	O
affecting	O
all	O
frequencies	O
,	O
or	O
,	O
at	O
least	O
initially	O
,	O
a	O
basin	O
shape	O
with	O
the	O
most	O
severe	O
affection	O
on	O
the	O
mid	O
-	O
frequencies	O
.	O

Thirteen	O
novel	O
WSF1	B-GENE
mutations	O
were	O
identified	O
.	O

JL	O
and	O
DH	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
.	O

2	O
)	O
.	O

SDOCT	O
volume	O
scans	O
of	O
7	O
patients	O
with	O
ADOA	B-DISEASE
(	O
OPA	B-GENE
-	I-GENE
1	I-GENE
mutation	O
)	O
and	O
14	O
healthy	O
controls	O
were	O
quantitatively	O
analyzed	O
using	O
manual	O
grading	O
software	O
.	O

Mutations	O
that	O
were	O
not	O
yet	O
listed	O
in	O
the	O
human	O
genome	O
mutation	O
database	O
or	O
the	O
locus	O
specific	O
database	O
(	O
LSDB	O
)	O
were	O
subjected	O
to	O
MutationTaster	O
(	O
Schwarz	O
et	O
al	O
.	O

In	O
addition	O
,	O
all	O
variants	O
were	O
discarded	O
from	O
genes	O
suspected	O
to	O
have	O
pseudogenes	O
or	O
other	O
paralogs	O
missing	O
from	O
the	O
human	O
reference	O
sequence	O
,	O
such	O
as	O
PDE4DIP	O
,	O
CDC27	O
,	O
MUC4	O
,	O
DUX4	O
,	O
and	O
XPC	O
.	O

Considering	O
only	O
the	O
patients	O
clearly	O
diagnosed	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
II	I-DISEASE
,	O
and	O
results	O
obtained	O
in	O
this	O
and	O
previous	O
studies	O
,	O
we	O
can	O
state	O
that	O
mutations	O
in	O
USH2A	B-GENE
are	O
responsible	O
for	O
76	O
.	O
1	O
%	O
of	O
USH2	B-DISEASE
disease	O
in	O
patients	O
of	O
Spanish	O
origin	O
.	O

2001	O
;	O
Kunishima	O
et	O
al	O
.	O

The	O
abnormal	O
SEP	O
results	O
were	O
also	O
recorded	O
,	O
including	O
no	O
response	O
or	O
prolonged	O
latency	O
for	O
the	O
evoked	O
potential	O
P40	O
of	O
tibial	O
SEP	O
,	O
with	O
or	O
without	O
prolonged	O
latency	O
of	O
N9	O
potential	O
of	O
median	O
SEP	O
(	O
see	O
online	O
supplementary	O
figure	O
S4	O
)	O
.	O

Any	O
known	O
deafness	B-DISEASE
causing	O
gene	O
(	O
s	O
)	O
located	O
in	O
this	O
interval	O
were	O
assumed	O
the	O
likely	O
disease	O
-	O
causing	O
candidate	O
and	O
the	O
patients	O
were	O
screened	O
by	O
direct	O
sequencing	O
of	O
the	O
coding	O
sequence	O
for	O
the	O
particular	O
gene	O
(	O
s	O
)	O
.	O

All	O
genetic	O
screenings	O
were	O
done	O
on	O
a	O
custom	O
-	O
designed	O
TGE	O
+	O
MPS	O
panel	O
called	O
OtoSCOPE	O
(	O
r	O
)	O
(	O
Shearer	O
et	O
al	O
.	O

Interestingly	O
,	O
the	O
phenotype	O
of	O
the	O
mother	O
is	O
more	O
severe	O
than	O
that	O
of	O
her	O
son	O
.	O

As	O
Cx	O
-	O
26	O
is	O
highly	O
expressed	O
on	O
human	O
cochlear	O
hairy	O
cells	O
,	O
GJB2	B-GENE
gene	O
mutation	O
is	O
believed	O
to	O
be	O
closely	O
associated	O
with	O
NSD	B-DISEASE
.	O

The	O
Altaians	O
mainly	O
belong	O
to	O
the	O
Central	O
Asian	O
type	O
of	O
the	O
North	O
Asian	O
race	O
.	O

There	O
are	O
between	O
327	O
,	O
000	O
and	O
11	O
,	O
300	O
,	O
000	O
points	O
plotted	O
per	O
gene	O
,	O
depending	O
on	O
total	O
coding	O
length	O
.	O

(	O
C	O
)	O
The	O
amino	O
acid	O
changes	O
caused	O
by	O
the	O
changes	O
in	O
the	O
DNA	O
sequence	O
.	O

Using	O
PolyPhen	O
2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
and	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
to	O
predict	O
possible	O
functional	O
effects	O
,	O
both	O
COL4A4	B-GENE
c	B-VARIANT
.	I-VARIANT
G2636A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly879Glu	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
C4715T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Pro1572Leu	I-VARIANT
)	O
were	O
classified	O
as	O
pathogenic	O
and	O
are	O
highly	O
conserved	O
across	O
multiple	O
organisms	O
(	O
results	O
summarized	O
in	O
Table	O
1	O
)	O
.	O

Informed	O
consent	O
for	O
genetic	O
testing	O
was	O
obtained	O
from	O
all	O
participants	O
after	O
the	O
nature	O
and	O
possible	O
consequences	O
of	O
the	O
study	O
were	O
explained	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
YL	O
YQ	O
.	O

Some	O
studies	O
have	O
reported	O
the	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
female	O
siblings	O
or	O
mothers	O
of	O
affected	O
males	O
with	O
mutations	O
in	O
POU3F4	B-GENE
.	O

Patients	O
from	O
the	O
whole	O
-	O
exome	O
sequencing	O
trios	O
.	O

Exact	O
input	O
data	O
for	O
Hungary	O
and	O
Czech	O
Republic	O
are	O
not	O
available	O
,	O
although	O
similar	O
numbers	O
of	O
patients	O
(	O
adjusted	O
to	O
the	O
country	O
populations	O
)	O
could	O
be	O
expected	O
.	O

YC	O
,	O
HZ	O
,	O
and	O
JS	O
carried	O
out	O
the	O
molecular	O
genetic	O
studies	O
,	O
participated	O
in	O
the	O
collection	O
of	O
blood	O
samples	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

2013	O
;	O
Ji	O
et	O
al	O
.	O

Both	O
variants	O
co	O
-	O
segregated	O
with	O
the	O
clinical	O
phenotype	O
and	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
were	O
absent	O
in	O
219	O
ethnicity	O
-	O
matched	O
controls	O
.	O

Mahan	O
for	O
assistance	O
in	O
DNA	O
sample	O
preparation	O
,	O
J	O
.	O

In	O
this	O
group	O
,	O
the	O
prevalence	O
of	O
c	B-VARIANT
.	I-VARIANT
1331	I-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
homozygotes	O
was	O
8	O
.	O
23	O
%	O
.	O

To	O
date	O
,	O
nine	O
syndromic	O
or	O
nonsyndromic	O
deafness	B-DISEASE
genes	O
have	O
been	O
identified	O
using	O
targeted	O
genomic	O
enrichment	O
and	O
next	O
-	O
generation	O
sequencing	O
:	O
TPRN	B-GENE
,	O
GPSM2	B-GENE
,	O
CEACAM16	B-GENE
,	O
SMPX	B-GENE
,	O
HSD17B4	B-GENE
,	O
HARS2	B-GENE
,	O
MASP1	B-GENE
,	O
DNMT1	B-GENE
,	O
and	O
TSPEAR	B-GENE
[	O
4	O
-	O
12	O
]	O
.	O

Other	O
missense	O
mutations	O
:	O
K77I	B-VARIANT
,	O
S391R	B-VARIANT
,	O
N392Y	B-VARIANT
,	O
T410M	B-VARIANT
and	O
H723R	B-VARIANT
have	O
been	O
reported	O
in	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
other	O
studies	O
[	O
26	O
,	O
27	O
,	O
29	O
]	O
.	O

Mayor	O
for	O
sample	O
collection	O
,	O
helpful	O
discussions	O
and	O
constant	O
support	O
to	O
our	O
research	O
.	O

Since	O
the	O
clinical	O
data	O
provided	O
for	O
most	O
of	O
these	O
TMPRSS3	B-GENE
families	O
are	O
very	O
limited	O
,	O
a	O
thorough	O
comparison	O
with	O
our	O
data	O
is	O
not	O
possible	O
.	O

Both	O
missense	O
mutations	O
G48S	B-VARIANT
[	O
20	O
]	O
and	O
E670A	B-VARIANT
,	O
found	O
in	O
patients	O
with	O
familial	O
KS	B-DISEASE
,	O
displayed	O
impaired	O
downstream	O
signaling	O
as	O
assessed	O
by	O
MAPK	O
phosphorylation	O
.	O

High	O
-	O
molecular	O
-	O
weight	O
gDNA	O
(	O
~	O
5	O
u	O
g	O
)	O
was	O
fragmented	O
ultrasonically	O
with	O
a	O
Covaris	O
E210	O
DNA	O
shearing	O
instrument	O
(	O
Covaris	O
,	O
Woburn	O
,	O
MA	O
)	O
to	O
an	O
average	O
size	O
of	O
200	O
base	O
pairs	O
(	O
bp	O
)	O
.	O

He	O
came	O
to	O
our	O
attention	O
at	O
48	O
years	O
of	O
age	O
,	O
complaining	O
of	O
generalized	B-DISEASE
fatigue	I-DISEASE
and	O
progressive	O
visual	B-DISEASE
loss	I-DISEASE
since	O
childhood	O
.	O

Baux	O
et	O
al	O
.	O

Samples	O
were	O
refrigerated	O
to	O
4	O
deg	O
C	O
for	O
no	O
more	O
than	O
4	O
h	O
.	O

Unlike	O
most	O
JLNS	B-DISEASE
cases	O
,	O
he	O
showed	O
a	O
mild	O
QT	B-DISEASE
interval	I-DISEASE
prolongation	I-DISEASE
(	O
460	O
ms	O
)	O
and	O
has	O
been	O
event	O
-	O
free	O
for	O
the	O
last	O
16	O
years	O
.	O

Hypocalcemia	B-DISEASE
is	O
included	O
.	O

Misalignment	O
was	O
noted	O
not	O
only	O
in	O
homopolymeric	O
regions	O
but	O
also	O
in	O
some	O
neighboring	O
regions	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
USH2A	B-GENE
c	B-VARIANT
.	I-VARIANT
2299delG	I-VARIANT
mutation	O
lies	O
in	O
the	O
vicinity	O
of	O
a	O
stretch	O
of	O
6	O
A	O
and	O
could	O
not	O
be	O
detected	O
at	O
first	O
when	O
using	O
the	O
default	O
parameters	O
,	O
see	O
below	O
)	O
.	O

Although	O
WES	O
has	O
been	O
integral	O
in	O
identifying	O
more	O
than	O
1	O
,	O
000	O
novel	O
genes	O
in	O
Mendelian	O
disorders	O
[	O
1	O
]	O
,	O
there	O
is	O
still	O
a	O
need	O
for	O
increased	O
efficiency	O
of	O
gene	O
discovery	O
using	O
WES	O
data	O
.	O

Although	O
the	O
current	O
NGS	O
technique	O
is	O
too	O
expensive	O
to	O
be	O
widely	O
used	O
,	O
the	O
cost	O
of	O
NGS	O
is	O
gradually	O
decreasing	O
,	O
which	O
will	O
lead	O
to	O
the	O
increased	O
applicability	O
of	O
this	O
technology	O
.	O

Although	O
the	O
majority	O
of	O
cases	O
with	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
caused	O
by	O
nuclear	O
gene	O
defects	O
,	O
it	O
has	O
become	O
clear	O
that	O
mutations	O
in	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
can	O
also	O
cause	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
28	O
,	O
29	O
]	O
.	O

RX	O
and	O
KS	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
analyzed	O
the	O
data	O
and	O
helped	O
draft	O
and	O
revise	O
the	O
manuscript	O
.	O

The	O
presence	O
of	O
copy	O
number	O
variants	O
(	O
CNVs	O
)	O
within	O
the	O
LQTS	B-DISEASE
disease	O
genes	O
have	O
also	O
been	O
suggested	O
as	O
an	O
explanation	O
for	O
the	O
lack	O
of	O
identified	O
mutations	O
[	O
37	O
-	O
39	O
]	O
.	O

c	B-VARIANT
.	I-VARIANT
2868	I-VARIANT
+	I-VARIANT
5G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
was	O
detected	O
in	O
the	O
heterozygous	O
state	O
in	O
patient	O
RP	B-DISEASE
-	O
1323	O
,	O
who	O
is	O
also	O
a	O
carrier	O
of	O
a	O
nonsense	O
mutation	O
,	O
and	O
variant	O
c	B-VARIANT
.	I-VARIANT
3717	I-VARIANT
+	I-VARIANT
2dupT	I-VARIANT
was	O
found	O
homozygously	O
in	O
patient	O
RP	B-DISEASE
-	O
219	O
.	O

The	O
initiation	O
codon	O
is	O
Met	O
1	O
.	O

Identified	O
variants	O
were	O
checked	O
against	O
the	O
dbNSFP	O
v1	O
.	O
3	O
[	O
47	O
]	O
as	O
well	O
as	O
dbSNP	O
v135	O
and	O
HGMD	O
(	O
r	O
)	O
Professional	O
2011	O
.	O
4	O
database	O
(	O
released	O
December	O
9	O
,	O
2011	O
)	O
.	O

Three	O
wild	O
-	O
type	O
mice	O
at	O
postnatal	O
day	O
five	O
from	O
the	O
albino	O
C57BL	O
/	O
6J	O
-	O
Tyr	O
c	O
-	O
Brd	O
inbred	O
strain	O
were	O
used	O
for	O
the	O
expression	O
analysis	O
.	O

4	O
)	O
.	O

However	O
,	O
in	O
vivo	O
studies	O
and	O
computational	O
evidence	O
have	O
suggested	O
that	O
its	O
primary	O
role	O
is	O
likely	O
in	O
fatty	O
-	O
acid	O
metabolism	O
,	O
while	O
steroid	O
conversion	O
is	O
only	O
a	O
secondary	O
and	O
possibly	O
minor	O
activity	O
in	O
vivo	O
[	O
21	O
]	O
.	O

(	O
e	O
)	O
ABR	O
thresholds	O
(	O
dBSPL	O
)	O
at	O
click	O
(	O
orange	O
)	O
,	O
8	O
(	O
green	O
)	O
,	O
16	O
(	O
purple	O
)	O
and	O
32	O
kHz	O
(	O
red	O
)	O
of	O
NIH	O
Swiss	O
homozygous	O
for	O
the	O
wild	O
-	O
type	O
(	O
343G	O
/	O
G	O
;	O
n	O
=	O
9	O
)	O
and	O
mutant	O
(	O
343A	O
/	O
A	O
;	O
n	O
=	O
9	O
)	O
Gipc3	B-GENE
alleles	O
.	O

2010	O
)	O
.	O

The	O
study	O
subjects	O
have	O
an	O
average	O
of	O
14	O
HGMD	O
variants	O
(	O
range	O
:	O
4	O
-	O
25	O
)	O
,	O
2	O
variants	O
in	O
the	O
deleterious	O
class	O
(	O
range	O
:	O
0	O
-	O
4	O
)	O
,	O
and	O
52	O
VUS	O
(	O
range	O
:	O
34	O
-	O
78	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

SD	O
-	O
OCT	O
scan	O
was	O
performed	O
from	O
lower	O
to	O
upper	O
retina	O
.	O

These	O
valeues	O
were	O
then	O
divided	O
by	O
the	O
number	O
of	O
stereocilia	O
within	O
the	O
corresponding	O
ROIs	O
to	O
determine	O
the	O
labeling	O
intensity	O
per	O
stereocilium	O
.	O

The	O
subjects	O
younger	O
than	O
the	O
onset	O
age	O
whose	O
hearing	O
status	O
is	O
ambiguous	O
are	O
marked	O
by	O
question	O
mark	O
and	O
the	O
deceased	O
are	O
differentiated	O
by	O
a	O
slash	O
.	O

All	O
bioinformatics	O
processing	O
and	O
data	O
analysis	O
,	O
including	O
genome	O
alignment	O
,	O
variation	O
detection	O
,	O
filtering	O
and	O
visualization	O
,	O
were	O
performed	O
on	O
the	O
DNAnexus	O
platform	O
(	O
DNAnexus	O
,	O
Inc	O
.	O
,	O
Mountain	O
View	O
,	O
USA	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
dnanexus	O
.	O
com	O
)	O
.	O

Amino	O
acids	O
sequence	O
homology	O
alignment	O
reveals	O
that	O
all	O
missense	O
mutations	O
and	O
unclassified	O
variants	O
occur	O
at	O
an	O
evolutionarily	O
conserved	O
amino	O
acid	O
(	O
Figure	O
2	O
)	O
.	O

Substitution	O
of	O
the	O
cysteine	O
725	O
by	O
a	O
tyrosine	O
will	O
likely	O
affect	O
the	O
conformation	O
of	O
this	O
region	O
.	O

The	O
variants	O
described	O
in	O
five	O
of	O
the	O
seven	O
families	O
are	O
listed	O
in	O
the	O
NHLBI	O
Exome	O
Variant	O
Server	O
(	O
EVS	O
)	O
database	O
however	O
;	O
these	O
variants	O
are	O
found	O
at	O
very	O
low	O
frequencies	O
of	O
between	O
0	O
.	O
003	O
and	O
0	O
.	O
000085	O
in	O
over	O
11	O
,	O
000	O
chromosomes	O
.	O

Furthermore	O
,	O
detailed	O
clinical	O
information	O
was	O
variable	O
in	O
quality	O
,	O
therefore	O
it	O
can	O
not	O
be	O
excluded	O
that	O
,	O
in	O
some	O
cases	O
,	O
other	O
factors	O
,	O
e	O
.	O
g	O
.	O

We	O
observed	O
the	O
expression	O
of	O
the	O
mutant	O
alleles	O
in	O
two	O
patients	O
(	O
TCS16	B-DISEASE
and	O
23	O
)	O
,	O
but	O
in	O
patients	O
TCS21	B-DISEASE
and	O
22	O
we	O
could	O
only	O
detect	O
the	O
wild	O
-	O
type	O
allele	O
(	O
Figure	O
2	O
)	O
.	O

The	O
alteration	O
of	O
the	O
isoelectric	O
point	O
of	O
the	O
protein	O
might	O
contribute	O
to	O
the	O
change	O
of	O
the	O
protein	O
function	O
.	O

There	O
was	O
considerable	O
phenotypic	O
diversity	O
that	O
impacted	O
the	O
overall	O
diagnostic	O
rate	O
of	O
39	O
%	O
(	O
Fig	O
.	O

The	O
patient	O
had	O
late	O
onset	O
of	O
glomerular	O
disease	O
,	O
which	O
is	O
consistent	O
with	O
the	O
missense	O
COL4A	O
mutations	O
.	O

These	O
included	O
19	O
base	O
substitutions	O
,	O
ten	O
small	O
insertions	O
or	O
deletions	O
(	O
<	O
=	O
27	O
bases	O
)	O
and	O
five	O
partial	O
/	O
whole	O
gene	O
deletions	O
/	O
duplications	O
(	O
see	O
ESM	O
Fig	O
.	O

It	O
included	O
78	O
cases	O
with	O
nonsyndromic	O
isolated	O
RP	B-DISEASE
and	O
22	O
cases	O
with	O
autosomal	O
recessive	O
RP	B-DISEASE
(	O
e	O
.	O
g	O
.	O
,	O
unaffected	O
parents	O
and	O
two	O
or	O
more	O
affected	O
siblings	O
)	O
,	O
all	O
without	O
a	O
molecular	O
diagnosis	O
.	O

,	O
2005	O
)	O
.	O

All	O
the	O
patients	O
denied	O
any	O
history	O
of	O
ototoxic	O
drug	O
or	O
noise	O
exposure	O
.	O

The	O
effect	O
of	O
the	O
amino	O
acid	O
change	O
on	O
the	O
structure	O
of	O
PRPS1	B-GENE
was	O
predicted	O
using	O
the	O
crystal	O
structure	O
of	O
human	O
PRPS1	B-GENE
from	O
[	O
12	O
]	O
(	O
PDB	O
entry	O
2H06	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
pdb	O
.	O
org	O
/	O
)	O
as	O
described	O
before	O
[	O
4	O
]	O
.	O

Evolutionary	O
conservation	O
of	O
the	O
sequences	O
and	O
structures	O
of	O
the	O
proteins	O
and	O
nucleic	O
acids	O
was	O
assessed	O
using	O
the	O
ConSeq	O
server	O
(	O
http	O
:	O
/	O
/	O
conseq	O
.	O
tau	O
.	O
ac	O
.	O
il	O
/	O
)	O
.	O

(	O
C	O
-	O
D	O
)	O
Representative	O
results	O
of	O
the	O
transfection	O
of	O
P2	O
C57BL	O
/	O
6J	O
mouse	O
inner	O
ear	O
sensory	O
epithelial	O
explants	O
with	O
expression	O
vectors	O
that	O
encoded	O
either	O
GFP	O
-	O
ELMOD3	B-GENE
or	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
ELMOD3	B-GENE
.	O

We	O
would	O
like	O
to	O
thank	O
Dr	O
.	O

Performed	O
the	O
experiments	O
:	O
RR	O
.	O

Microsatellite	O
markers	O
were	O
analyzed	O
as	O
described	O
previously	O
[	O
12	O
]	O
and	O
Sanger	O
sequencing	O
was	O
performed	O
according	O
to	O
Schraders	O
et	O
al	O
.	O

Whenever	O
two	O
putative	O
pathologic	O
variants	O
were	O
identified	O
in	O
a	O
patient	O
,	O
segregation	O
analysis	O
was	O
performed	O
on	O
all	O
available	O
family	O
members	O
to	O
confirm	O
the	O
cosegregation	O
with	O
the	O
disease	O
and	O
to	O
determine	O
parental	O
origin	O
.	O

Numbers	O
(	O
except	O
42	O
)	O
correspond	O
to	O
low	O
concentrations	O
(	O
Tables	O
1	O
and	O
2	O
)	O
:	O
KS	B-DISEASE
in	O
cases	O
13	O
,	O
41	O
and	O
46	O
,	O
CHARGE	B-DISEASE
syndrome	I-DISEASE
in	O
case	O
27	O
,	O
FGFR1	B-GENE
mutation	O
in	O
cases	O
14	O
and	O
36	O
and	O
other	O
HH	B-DISEASE
in	O
the	O
others	O
.	O

The	O
best	O
evidence	O
for	O
a	O
possible	O
functional	O
role	O
of	O
either	O
KCNJ10	B-GENE
or	O
FOXI1	B-GENE
in	O
the	O
PDS	B-DISEASE
/	O
EVA	B-DISEASE
phenotype	O
in	O
humans	O
would	O
be	O
genetic	O
evidence	O
-	O
further	O
families	O
with	O
mutations	O
,	O
which	O
are	O
shown	O
to	O
have	O
a	O
functional	O
effect	O
and	O
which	O
are	O
present	O
in	O
a	O
lower	O
frequency	O
in	O
the	O
general	O
population	O
than	O
those	O
with	O
the	O
PDS	B-DISEASE
/	O
EVA	B-DISEASE
phenotype	O
.	O

The	O
V37I	B-VARIANT
variant	O
was	O
considered	O
a	O
pathogenic	O
mutation	O
in	O
Japanese	O
studies	O
,	O
but	O
it	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
Korean	O
control	O
or	O
patient	O
populations	O
reported	O
previously	O
[	O
6	O
,	O
10	O
,	O
46	O
]	O
.	O

Furthermore	O
,	O
those	O
thresholds	O
were	O
in	O
the	O
normal	O
range	O
and	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
tg	O
(	O
+	O
/	O
-	O
)	O
G	O
/	O
A	O
heterozygotes	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Herein	O
,	O
we	O
have	O
identified	O
six	O
novel	O
and	O
one	O
recurrent	O
USH2A	B-GENE
mutations	O
using	O
targeted	O
NGS	O
approaches	O
,	O
which	O
further	O
demonstrates	O
that	O
targeted	O
NGS	O
approaches	O
are	O
valuable	O
tools	O
for	O
genetic	O
diagnoses	O
.	O

A	O
multi	O
-	O
generational	O
family	O
from	O
Denmark	O
with	O
ADNSHI	B-DISEASE
,	O
affecting	O
17	O
individuals	O
in	O
five	O
generations	O
(	O
Fig	O
1A	O
)	O
participated	O
in	O
the	O
study	O
.	O

Haplotypes	O
for	O
selected	O
individuals	O
of	O
families	O
PKDF356	O
and	O
PKDF282	O
indicate	O
the	O
smallest	O
linkage	O
interval	O
.	O

(	O
Physical	O
Therapy	O
)	O
Tamara	O
Hershey	O
(	O
Psychiatry	O
,	O
Neurology	O
,	O
Radiology	O
)	O
James	O
Hoekel	O
,	O
O	O
.	O
D	O
.	O

Table	O
3	O
Comparison	O
of	O
the	O
clinical	O
phenotypes	O
of	O
IOSCA	B-DISEASE
patients	O
with	O
mutations	O
in	O
the	O
C10orf2	B-GENE
gene	O
NA	O
not	O
available	O
a	O
Abnormal	O
after	O
epileptic	B-DISEASE
encephalopathy	I-DISEASE
b	O
When	O
her	O
symptoms	O
worsen	O
,	O
liver	O
enzymes	O
were	O
elevated	O
c	O
Abnormal	O
in	O
patients	O
with	O
compound	O
heterozygote	O
mutation	O
d	O
Inconsistently	O
elevated	O
in	O
capillary	O
lactate	O
,	O
while	O
normal	O
in	O
CSF	O
lactate	O
Fig	O
.	O

The	O
residues	O
of	O
the	O
KMSKS	O
motif	O
are	O
coloured	O
pink	O
.	O

Of	O
the	O
target	O
bases	O
of	O
III	O
-	O
13	O
(	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
)	O
,	O
92	O
.	O
8	O
%	O
were	O
covered	O
at	O
least	O
once	O
,	O
83	O
.	O
3	O
%	O
were	O
covered	O
at	O
>	O
=	O
10	O
x	O
and	O
76	O
.	O
5	O
%	O
were	O
at	O
>	O
=	O
20	O
x	O
.	O

7162	O
)	O
with	O
USH1	B-DISEASE
.	O

There	O
are	O
three	O
families	O
(	O
Families	O
DUK6534	O
,	O
DUK6630	O
and	O
DUK6527	O
)	O
with	O
missense	O
variants	O
at	O
glycine	O
residues	O
in	O
the	O
collagenous	O
domain	O
of	O
alpha	O
3	O
or	O
alpha	O
4	O
collagen	O
(	O
IV	O
)	O
,	O
two	O
families	O
(	O
Families	O
DUK6531	O
and	O
DUK6585	O
)	O
with	O
missense	O
variants	O
in	O
the	O
NC1	O
domains	O
and	O
two	O
families	O
(	O
Families	O
DUK6696	O
and	O
DUK6669	O
)	O
with	O
truncating	O
variants	O
in	O
COL4A3	B-GENE
and	O
COL4A4	B-GENE
(	O
Table	O
2	O
)	O
.	O

Because	O
no	O
experimentally	O
solved	O
structures	O
exist	O
for	O
either	O
MYO1A	B-GENE
or	O
MOY6	B-GENE
,	O
we	O
built	O
homology	O
models	O
for	O
these	O
proteins	O
.	O

BLSW	O
.	O
CAST	O
-	O
+	O
/	O
+	O
mice	O
showed	O
normal	O
hearing	O
at	O
2	O
and	O
12	O
months	O
of	O
age	O
with	O
mean	O
thresholds	O
of	O
12	O
+	O
-	O
4	O
and	O
16	O
+	O
-	O
5	O
dBSPL	O
for	O
the	O
16	O
kHz	O
stimulus	O
,	O
respectively	O
(	O
Fig	O
.	O

Detailed	O
analysis	O
of	O
a	O
selected	O
subset	O
of	O
5	O
clinically	O
important	O
cancer	B-DISEASE
genes	O
,	O
BRCA1	B-GENE
,	O
BRCA2	B-GENE
,	O
KRAS	B-GENE
,	O
TP53	B-GENE
,	O
and	O
PTEN	B-GENE
,	O
highlights	O
differences	O
between	O
germline	O
variants	O
and	O
reported	O
somatic	O
mutations	O
.	O

FA	O
did	O
not	O
show	O
any	O
leakage	O
in	O
Patients	O
1	O
-	O
II	O
-	O
1	O
and	O
2	O
-	O
II	O
-	O
1	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
asterisks	O
indicate	O
a	O
non	O
-	O
specific	O
band	O
.	O

As	O
a	O
whole	O
,	O
the	O
Altaian	O
population	O
was	O
shown	O
to	O
be	O
genetic	O
heterogeneous	O
resulted	O
from	O
its	O
territorial	O
subdivision	O
and	O
the	O
specific	O
Altaian	O
clan	O
compositions	O
in	O
different	O
localities	O
[	O
20	O
-	O
22	O
]	O
.	O

This	O
interaction	O
regulates	O
the	O
activity	O
of	O
proteins	O
involved	O
in	O
Ca	O
2	O
+	O
signaling	O
complexes	O
including	O
metabotropic	O
glutamate	O
receptors	O
(	O
mGluR	O
)	O
[	O
12	O
]	O
,	O
inositol	O
tri	O
-	O
phosphate	O
receptors	O
(	O
IP	O
3	O
R	O
)	O
[	O
8	O
]	O
and	O
transient	O
receptor	O
potential	O
canonical	O
channels	O
(	O
TRPC	O
)	O
[	O
13	O
]	O
.	O

Also	O
in	O
this	O
study	O
exons	O
10	O
,	O
15	O
,	O
and	O
16	O
were	O
revealed	O
as	O
pathogenic	O
gene	O
regions	O
.	O

We	O
also	O
Sanger	O
-	O
sequenced	O
NARS2	B-GENE
in	O
14	O
unrelated	O
Perrault	B-DISEASE
syndrome	I-DISEASE
probands	O
to	O
assess	O
whether	O
mutations	O
in	O
NARS2	B-GENE
are	O
a	O
common	O
finding	O
in	O
this	O
patient	O
population	O
,	O
but	O
did	O
not	O
find	O
any	O
pathogenic	O
variants	O
.	O

Differences	O
between	O
ancestry	O
groups	O
are	O
also	O
reflected	O
in	O
the	O
allele	O
frequencies	O
of	O
cancer	O
-	O
gene	O
variants	O
.	O

Other	O
mutations	O
near	O
the	O
FGFR2	B-GENE
exon	O
IIIc	O
splice	O
donor	O
site	O
have	O
also	O
been	O
described	O
(	O
Table	O
1	O
)	O
,	O
all	O
associated	O
with	O
a	O
mild	O
Crouzon	B-DISEASE
phenotype	O
.	O

As	O
such	O
high	O
average	O
coverage	O
is	O
not	O
necessary	O
for	O
reliable	O
variant	O
analysis	O
;	O
the	O
next	O
run	O
was	O
modified	O
accordingly	O
.	O

The	O
pupils	O
were	O
dilated	O
fully	O
using	O
10	O
%	O
phenylephrine	O
HCl	O
and	O
1	O
%	O
tropicamide	O
,	O
and	O
Burian	O
-	O
Allen	O
bipolar	O
corneal	O
electrodes	O
were	O
applied	O
after	O
topical	O
anesthesia	O
with	O
5	O
%	O
proparacaine	O
HCl	O
.	O

A	O
genetic	O
diagnosis	O
is	O
important	O
since	O
it	O
defines	O
the	O
diagnostic	O
subtype	O
,	O
determines	O
the	O
most	O
appropriate	O
treatment	O
and	O
informs	O
the	O
sibling	O
recurrence	O
risk	O
or	O
risk	O
of	O
diabetes	B-DISEASE
in	O
offspring	O
.	O

However	O
,	O
simulations	O
(	O
Supplementary	O
Information	O
)	O
show	O
that	O
two	O
such	O
hits	O
are	O
inadequate	O
to	O
define	O
a	O
gene	O
as	O
a	O
conclusive	O
risk	O
factor	O
given	O
the	O
number	O
of	O
observed	O
events	O
in	O
the	O
study	O
.	O

After	O
washing	O
for	O
1	O
h	O
,	O
the	O
sensory	O
epithelial	O
layer	O
was	O
carefully	O
spread	O
on	O
a	O
slide	O
and	O
mounted	O
with	O
fluorescent	O
mounting	O
medium	O
containing	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
(	O
DAPI	O
)	O
.	O

H6908	O
,	O
Sigma	O
)	O
.	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Since	O
both	O
the	O
wild	O
-	O
type	O
and	O
mutant	O
alleles	O
appear	O
to	O
be	O
transcribed	O
,	O
we	O
counted	O
the	O
numbers	O
of	O
wild	O
type	O
and	O
mutant	O
clones	O
we	O
obtained	O
,	O
and	O
found	O
no	O
significant	O
difference	O
in	O
their	O
numbers	O
(	O
30	O
clones	O
of	O
wild	O
type	O
versus	O
22	O
mutant	O
)	O
(	O
Fig	O
.	O

The	O
localization	O
of	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
at	O
TCs	O
was	O
reported	O
recently	O
[	O
8	O
]	O
.	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2350	O
/	O
13	O
/	O
24	O
/	O
prepub	O
The	O
additional	O
file	O
(	O
PDF	O
)	O
contains	O
a	O
detailed	O
description	O
of	O
the	O
methods	O
,	O
three	O
additional	O
figures	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
:	O
Conservation	O
of	O
KCNE1	B-GENE
G25	O
and	O
G60	O
within	O
different	O
species	O
;	O
Additional	O
file	O
1	O
:	O
Figure	O
S2	O
:	O
Comparison	O
of	O
I	B-GENE
Ks	I-GENE
-	O
WT	O
and	O
I	B-GENE
Ks	I-GENE
-	O
G25V	B-VARIANT
channel	O
currents	O
in	O
Xenopus	O
laevis	O
oocytes	O
;	O
Additional	O
file	O
1	O
:	O
Figure	O
S3	O
:	O
Comparison	O
of	O
I	B-GENE
Ks	I-GENE
-	O
WT	O
and	O
I	B-GENE
Ks	I-GENE
-	O
G60D	B-VARIANT
and	O
I	B-GENE
Ks	I-GENE
-	O
WT	O
/	O
G60D	B-VARIANT
channel	O
currents	O
.	O
)	O
,	O
and	O
additional	O
references	O
.	O

Fourth	O
,	O
we	O
searched	O
for	O
genes	O
where	O
variants	O
were	O
present	O
in	O
all	O
four	O
patients	O
,	O
and	O
for	O
which	O
the	O
variant	O
found	O
in	O
the	O
patient	O
of	O
the	O
case	O
-	O
parents	O
trio	O
was	O
de	O
novo	O
.	O

Linkage	O
analysis	O
was	O
also	O
performed	O
with	O
SNP	O
microarray	O
by	O
adding	O
three	O
more	O
subjects	O
in	O
the	O
family	O
.	O

In	O
vitro	O
functional	O
studies	O
(	O
Born	O
'	O
s	O
method	O
)	O
showed	O
normal	O
platelet	O
aggregation	O
after	O
stimulation	O
with	O
ADP	O
,	O
collagen	O
,	O
and	O
ristocetin	O
.	O

The	O
remaining	O
predictions	O
,	O
combined	O
with	O
all	O
the	O
known	O
CI	O
structural	O
subunits	O
and	O
assembly	O
factors	O
,	O
comprise	O
a	O
focused	O
set	O
of	O
103	O
candidate	O
genes	O
for	O
human	O
CI	B-DISEASE
deficiency	I-DISEASE
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

S2	O
)	O
.	O

Table	O
S1	O
)	O
.	O

(	O
H	O
)	O
Statistical	O
analysis	O
of	O
FLAG	O
and	O
tricellulin	B-GENE
localization	O
at	O
TCs	O
.	O

In	O
addition	O
,	O
the	O
reduction	O
of	O
TCOF1	B-GENE
expression	O
(	O
18	O
-	O
31	O
%	O
)	O
in	O
adult	O
cells	O
of	O
TCS	B-DISEASE
patients	O
as	O
compared	O
to	O
controls	O
is	O
in	O
accordance	O
to	O
the	O
observed	O
5	O
-	O
25	O
%	O
reduction	O
of	O
transcript	O
levels	O
caused	O
by	O
NMD	B-DISEASE
in	O
the	O
presence	O
of	O
premature	O
stop	O
codon	O
mutations	O
in	O
mRNA	O
molecules	O
[	O
26	O
]	O
.	O

Click	O
here	O
for	O
file	O
We	O
would	O
like	O
to	O
thank	O
all	O
the	O
referring	O
clinicians	O
and	O
their	O
patients	O
.	O

Visual	B-DISEASE
failure	I-DISEASE
was	O
a	O
prominent	O
feature	O
of	O
their	O
phenotypes	O
and	O
when	O
initial	O
screens	O
for	O
POLG1	B-GENE
,	O
POLG2	B-GENE
,	O
PEO1	B-GENE
and	O
SLC25A4	B-GENE
were	O
found	O
to	O
be	O
negative	O
,	O
OPA1	B-GENE
sequencing	O
was	O
performed	O
.	O

A	O
possible	O
dominant	O
negative	O
effect	O
was	O
therefore	O
suggested	O
with	O
the	O
mutant	O
Opa1	B-GENE
protein	O
disrupting	O
mitochondrial	O
inner	O
membrane	O
function	O
and	O
/	O
or	O
the	O
delicate	O
balance	O
of	O
the	O
intra	O
-	O
mitochondrial	O
nucleotide	O
pool	O
required	O
for	O
efficient	O
mtDNA	O
replication	O
(	O
Zeviani	O
,	O
2008	O
)	O
.	O

qPCR	O
data	O
was	O
captured	O
and	O
analyzed	O
using	O
StepOne	O
software	O
(	O
ver	O
.	O

All	O
patients	O
were	O
heterozygous	O
carriers	O
of	O
a	O
single	O
mutation	O
,	O
except	O
one	O
double	O
heterozygous	O
proband	O
(	O
1	O
.	O
4	O
%	O
of	O
families	O
)	O
,	O
who	O
carried	O
p	B-VARIANT
.	I-VARIANT
R583G	I-VARIANT
in	O
KCNQ1	B-GENE
and	O
p	B-VARIANT
.	I-VARIANT
A93T	I-VARIANT
in	O
KCNE1	B-GENE
.	O

Retinal	B-DISEASE
dystrophies	I-DISEASE
result	O
from	O
degeneration	O
of	O
photoreceptor	O
and	O
retinal	O
pigment	O
epithelium	O
cells	O
.	O

Performed	O
the	O
experiments	O
:	O
T	O
-	O
JK	O
HRK	O
J	O
-	O
IB	O
.	O

Thus	O
,	O
while	O
these	O
results	O
support	O
the	O
findings	O
on	O
the	O
internalization	O
of	O
wild	O
-	O
type	O
and	O
lack	O
thereof	O
for	O
mutant	O
CD164	B-GENE
presented	O
in	O
Fig	O
4	O
,	O
they	O
do	O
not	O
support	O
the	O
idea	O
that	O
mutant	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
negatively	O
affects	O
internalization	O
of	O
wild	O
-	O
type	O
CD164	B-GENE
.	O

A	O
model	O
covering	O
the	O
myosin	O
motor	O
domain	O
from	O
residue	O
Val2	O
to	O
Gln752	O
was	O
built	O
using	O
the	O
crystal	O
structure	O
of	O
the	O
myosin	O
-	O
II	O
heavy	O
chain	O
from	O
D	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Thus	O
,	O
novel	O
missense	O
variant	O
in	O
SLC26A4	B-GENE
is	O
possibly	O
pathogenic	O
.	O

The	O
prelingual	O
-	O
onset	O
,	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
phenotype	O
segregating	O
in	O
this	O
Chinese	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
family	O
is	O
similar	O
to	O
that	O
of	O
reported	O
DFNA8	B-GENE
/	I-GENE
12	I-GENE
families	O
.	O

Second	O
,	O
CMTX5	B-DISEASE
/	O
Arts	B-GENE
and	O
(	O
prelingual	O
,	O
severe	O
)	O
DFN2	B-DISEASE
can	O
present	O
within	O
one	O
and	O
the	O
same	O
family	O
,	O
revealing	O
an	O
intrafamilial	O
continuum	O
of	O
these	O
disorders	O
.	O

Patient	O
1598	O
is	O
heterozygous	O
at	O
chr1	B-VARIANT
:	I-VARIANT
216258194G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
rs56110889	B-VARIANT
)	O
.	O

M	O
e	O
ndez	O
and	O
S	O
.	O

(	O
A	O
)	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
of	O
the	O
optic	O
disc	O
.	O

Together	O
with	O
the	O
fact	O
that	O
a	O
large	O
number	O
of	O
coding	O
exons	O
exist	O
in	O
these	O
genes	O
,	O
traditional	O
screening	O
of	O
each	O
region	O
is	O
infeasible	O
for	O
clinical	O
application	O
.	O

The	O
five	O
TBX1	B-GENE
mutation	O
positive	O
subjects	O
in	O
groups	O
1	O
+	O
2	O
lacked	O
cardiovascular	O
lesion	O
and	O
manifested	O
borderline	O
to	O
mild	O
developmental	B-DISEASE
retardation	I-DISEASE
(	O
while	O
they	O
had	O
no	O
susceptibility	O
to	O
infection	O
,	O
assessment	O
of	O
thymic	B-DISEASE
hypoplasia	I-DISEASE
remained	O
fragmentary	O
)	O
.	O

The	O
Taiwanese	O
family	O
examined	O
herein	O
showed	O
an	O
autosomal	O
dominant	O
hereditary	O
pattern	O
with	O
a	O
full	O
penetrance	O
,	O
which	O
strongly	O
suggests	O
that	O
an	O
underlying	O
genetic	O
factor	O
is	O
involved	O
(	O
Figure	O
1	O
)	O
.	O

B	O
)	O
Amino	O
acid	O
sequence	O
conservation	O
of	O
p	O
.	O
Phe2741	O
across	O
11	O
species	O
.	O

However	O
,	O
the	O
available	O
clinical	O
data	O
seem	O
to	O
be	O
in	O
line	O
with	O
those	O
of	O
the	O
present	O
families	O
.	O

The	O
axial	O
3D	O
T2	O
-	O
weighted	O
MRI	O
images	O
from	O
the	O
region	O
of	O
the	O
inner	O
ear	O
of	O
(	O
A	O
)	O
a	O
KS	B-DISEASE
patient	O
with	O
normal	O
semicircular	O
canals	O
(	O
asterisk	O
)	O
,	O
and	O
(	O
B	O
)	O
a	O
KS	B-DISEASE
patient	O
with	O
hypoplastic	B-DISEASE
semicircular	I-DISEASE
canals	I-DISEASE
(	O
arrow	O
)	O
,	O
and	O
an	O
unspecified	O
atrophic	O
area	O
(	O
arrow	O
head	O
)	O
in	O
his	O
retina	O
(	O
C	O
)	O
.	O

In	O
this	O
family	O
,	O
we	O
could	O
not	O
confirm	O
association	O
of	O
the	O
disease	O
with	O
any	O
USH	B-DISEASE
gene	O
by	O
SNP	O
analysis	O
as	O
the	O
proband	O
has	O
no	O
sibs	O
.	O

g	O
.	O

The	O
proband	O
#	O
20	O
,	O
and	O
his	O
brother	O
with	O
normosmic	O
HH	B-DISEASE
,	O
had	O
the	O
same	O
missense	O
mutation	O
(	O
c	B-VARIANT
.	I-VARIANT
2009A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
[	O
p	B-VARIANT
.	I-VARIANT
E670A	I-VARIANT
]	O
)	O
;	O
the	O
brother	O
also	O
had	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
,	O
and	O
limb	B-DISEASE
malformations	I-DISEASE
manifested	O
as	O
a	O
fusion	B-DISEASE
of	I-DISEASE
3	I-DISEASE
rd	I-DISEASE
and	I-DISEASE
4	I-DISEASE
th	I-DISEASE
metatarsal	I-DISEASE
bones	I-DISEASE
,	O
and	O
missing	B-DISEASE
of	I-DISEASE
the	I-DISEASE
2	I-DISEASE
nd	I-DISEASE
and	I-DISEASE
3	I-DISEASE
rd	I-DISEASE
toe	I-DISEASE
in	O
both	O
feet	O
(	O
see	O
Table	O
1	O
)	O
.	O

Substantial	O
input	O
on	O
the	O
the	O
manuscript	O
:	O
SJM	O
JC	O
SIK	O
ARK	O
JK	O
SHL	O
SHO	O
.	O

Since	O
identification	O
of	O
USH2A	B-GENE
,	O
several	O
studies	O
have	O
indicated	O
that	O
mutations	O
of	O
this	O
gene	O
can	O
cause	O
a	O
significant	O
proportion	O
of	O
non	O
-	O
syndromic	O
recessive	O
RP	B-DISEASE
[	O
12	O
-	O
20	O
]	O
.	O

(	O
2003	O
)	O
.	O

A	O
control	O
population	O
of	O
216	O
healthy	O
blood	O
donors	O
was	O
collected	O
(	O
52	O
%	O
male	O
gender	O
,	O
median	O
age	O
of	O
39	O
years	O
(	O
interquartile	O
range	O
30	O
-	O
48	O
years	O
)	O
)	O
.	O

Moreover	O
,	O
microtubule	O
polymerization	O
depends	O
on	O
Arl2	O
activity	O
[	O
33	O
]	O
,	O
and	O
we	O
have	O
shown	O
that	O
ELMOD3	B-GENE
exhibits	O
a	O
GAP	O
activity	O
against	O
Arl2	O
.	O

Nucleotide	O
sequencing	O
of	O
the	O
entire	O
WFS1	B-GENE
coding	O
region	O
confirmed	O
the	O
presence	O
of	O
two	O
different	O
mutations	O
in	O
the	O
four	O
affected	O
patients	O
:	O
one	O
allele	O
carried	O
a	O
novel	O
R177P	B-VARIANT
missense	O
mutation	O
resulting	O
from	O
a	B-VARIANT
G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
transversion	I-VARIANT
at	I-VARIANT
nucleotide	I-VARIANT
position	I-VARIANT
530	I-VARIANT
in	I-VARIANT
exon	I-VARIANT
5	I-VARIANT
(	O
Figure	O
3	O
)	O
.	O

wrote	O
the	O
manuscript	O
.	O

Mutations	O
adjacent	O
to	O
residue	O
T487	O
have	O
been	O
associated	O
with	O
both	O
dominant	O
and	O
recessive	O
phenotypes	O
:	O
T405I	B-VARIANT
,	O
L456V	B-VARIANT
,	O
R463W	B-VARIANT
,	O
and	O
Y508	O
mutations	O
cause	O
IOSCA	B-DISEASE
[	O
6	O
,	O
7	O
,	O
18	O
]	O
,	O
while	O
W474C	B-VARIANT
,	O
A475P	B-VARIANT
,	O
F478I	B-VARIANT
,	O
E479K	B-VARIANT
,	O
and	O
F485L	O
cause	O
PEO	B-DISEASE
[	O
19	O
]	O
.	O

Study	O
participants	O
gave	O
informed	O
consent	O
and	O
these	O
investigations	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
as	O
revised	O
in	O
2000	O
.	O

Two	O
homology	O
models	O
of	O
CIB2	B-GENE
were	O
constructed	O
;	O
the	O
templates	O
were	O
the	O
high	O
resolution	O
crystal	O
structure	O
of	O
human	O
CIB1	B-GENE
(	O
1XO5A	O
.	O
PDB	O
)	O
,	O
5	O
and	O
the	O
solution	O
structure	O
of	O
a	O
Ca	O
2	O
+	O
-	O
CIB1	B-GENE
complex	O
(	O
Fig	O
.	O

No	O
.	O

The	O
crystal	O
structure	O
of	O
Limulus	O
polyphemus	O
filamentous	O
actin	O
(	O
PDB	O
:	O
3B63	O
)	O
and	O
the	O
4	O
.	O
1	O
protein	O
-	O
ezrin	O
-	O
radixin	O
-	O
moesin	O
(	O
FERM	O
)	O
domain	O
of	O
Mus	O
musculus	O
myosin	O
VIIa	O
in	O
complex	O
with	O
Sans	O
protein	O
(	O
PDB	O
:	O
3PVL	O
)	O
were	O
utilized	O
as	O
the	O
templates	O
to	O
model	O
ACTG1	B-GENE
with	O
the	O
p	B-VARIANT
.	I-VARIANT
G268S	I-VARIANT
mutation	O
and	O
MYO7A	B-GENE
with	O
the	O
p	B-VARIANT
.	I-VARIANT
W2160G	I-VARIANT
mutation	O
,	O
respectively	O
.	O

LOD	O
,	O
logarithm	O
of	O
odds	O
.	O

Clinical	O
findings	O
in	O
proband	O
of	O
families	O
with	O
Pfeiffer	B-DISEASE
syndrome	I-DISEASE
(	O
PS	B-DISEASE
)	O
.	O

Signal	O
-	O
to	O
-	O
noise	O
ratios	O
of	O
greater	O
than	O
6	O
dB	O
was	O
shown	O
in	O
a	O
specific	O
frequency	O
band	O
in	O
distortion	O
product	O
otoacoustic	O
emissions	O
(	O
lower	O
panel	O
)	O
.	O

Green	O
line	O
=	O
window	O
14	O
;	O
Blue	O
line	O
=	O
window	O
21	O
;	O
Red	O
line	O
=	O
window	O
28	O
.	O

This	O
unreported	O
rearrangement	O
results	O
in	O
the	O
activation	O
of	O
an	O
exonic	O
cryptic	O
donor	O
site	O
leading	O
to	O
an	O
in	O
-	O
frame	O
six	O
nucleotide	O
-	O
long	O
skipping	O
of	O
exon	O
28	O
(	O
r	B-VARIANT
.	I-VARIANT
2819_2824del	I-VARIANT
)	O
and	O
producing	O
a	O
microdeletion	O
within	O
the	O
GED	O
domain	O
(	O
p	B-VARIANT
.	I-VARIANT
Lys940_Val942delinsIle	I-VARIANT
)	O
.	O

Osbpl2	B-GENE
was	O
detected	O
in	O
stereocilia	O
of	O
both	O
OHCs	O
(	O
Figure	O
4	O
A	O
,	O
B	O
)	O
and	O
IHCs	O
(	O
Figure	O
4	O
C	O
,	O
D	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
confirmed	O
that	O
two	O
transcription	O
factors	O
in	O
87	O
Korean	O
patients	O
caused	O
autosomal	B-DISEASE
dominant	I-DISEASE
NSHL	I-DISEASE
.	O

2005	O
)	O
.	O

Molecular	O
investigation	O
of	O
more	O
samples	O
of	O
WS	B-DISEASE
patients	O
from	O
our	O
country	O
will	O
help	O
to	O
identify	O
if	O
compound	O
heterozygosity	O
occurs	O
commonly	O
or	O
if	O
there	O
are	O
recurrent	O
or	O
founder	O
WFS1	B-GENE
mutations	O
in	O
this	O
particular	O
ethnic	O
group	O
.	O

The	O
boy	O
presented	O
with	O
heterochromia	B-DISEASE
iridis	I-DISEASE
and	O
bilateral	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
but	O
did	O
not	O
show	O
dystopia	B-DISEASE
canthorum	I-DISEASE
.	O

Three	O
alpha	O
1	O
chains	O
encoded	O
by	O
the	O
COL2A1	B-GENE
gene	O
are	O
folded	O
together	O
in	O
a	O
triple	O
-	O
helical	O
configuration	O
to	O
form	O
the	O
procollagen	O
homotrimer	O
.	O

The	O
average	O
QTc	O
among	O
index	O
cases	O
without	O
an	O
identified	O
mutation	O
was	O
445	O
ms	O
(	O
+	O
-	O
41	O
)	O
(	O
Table	O
1	O
)	O
.	O

Among	O
the	O
6	O
probands	O
with	O
verified	O
reversal	O
,	O
the	O
median	O
age	O
at	O
reversal	O
of	O
HH	B-DISEASE
was	O
23	O
yrs	O
,	O
ranging	O
from	O
21	O
to	O
39	O
yrs	O
.	O

In	O
conclusion	O
,	O
by	O
applying	O
the	O
MPS	O
diagnostic	O
panel	O
targeting	O
80	O
deafness	B-DISEASE
genes	O
to	O
12	O
multiplex	O
Han	O
Chinese	O
families	O
with	O
idiopathic	O
nonsyndromic	O
SNHI	B-DISEASE
,	O
we	O
identified	O
4	O
variants	O
in	O
4	O
different	O
genes	O
,	O
which	O
might	O
have	O
led	O
to	O
SNHI	B-DISEASE
in	O
4	O
families	O
compatible	O
with	O
autosomal	O
dominant	O
inheritance	O
,	O
including	O
GJB2	B-GENE
p	B-VARIANT
.	I-VARIANT
R75Q	I-VARIANT
,	O
MYO7A	B-GENE
p	B-VARIANT
.	I-VARIANT
T381M	I-VARIANT
,	O
KCNQ4	B-GENE
p	B-VARIANT
.	I-VARIANT
S680F	I-VARIANT
,	O
and	O
MYH9	B-GENE
p	B-VARIANT
.	I-VARIANT
E1256K	I-VARIANT
.	O

D	O
:	O
c	B-VARIANT
.	I-VARIANT
1991C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
/	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
TIF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Bilateral	O
transtympanic	O
recording	O
methods	O
are	O
part	O
of	O
our	O
audiological	O
evaluation	O
of	O
hearing	B-DISEASE
disorders	I-DISEASE
in	O
children	O
when	O
the	O
reliability	O
of	O
ABRs	O
in	O
hearing	O
threshold	O
estimation	O
could	O
be	O
significantly	O
reduced	O
,	O
possibly	O
resulting	O
from	O
dysfunction	O
or	O
immaturity	O
of	O
brainstem	O
generators	O
of	O
ABRs	O
(	O
Kraus	O
et	O
al	O
.	O

(	O
F	O
-	O
K	O
)	O
These	O
images	O
are	O
temporal	O
bone	O
CT	O
in	O
normal	O
control	O
.	O

1	O
;	O
Table	O
1	O
)	O
.	O

The	O
age	O
of	O
RP	B-DISEASE
onset	O
is	O
earlier	O
in	O
the	O
patients	O
with	O
more	O
than	O
two	O
pathogenic	O
mutations	O
.	O

TMC1	B-GENE
has	O
been	O
implicated	O
both	O
in	O
autosomal	O
recessive	O
(	O
DFNB7	B-DISEASE
/	I-DISEASE
11	I-DISEASE
)	O
and	O
autosomal	O
dominant	O
(	O
DFNA36	B-DISEASE
)	O
deafness	B-DISEASE
forms	O
.	O

There	O
are	O
two	O
of	O
the	O
female	O
subjects	O
who	O
developed	O
hearing	B-DISEASE
loss	I-DISEASE
late	O
,	O
at	O
ages	O
25	O
.	O
8	O
and	O
16	O
.	O
3	O
years	O
,	O
and	O
the	O
remaining	O
group	O
of	O
four	O
developed	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
an	O
average	O
age	O
of	O
7	O
.	O
5	O
+	O
-	O
2	O
.	O
4	O
years	O
.	O

These	O
CNVs	O
included	O
homozygous	O
deletions	O
,	O
which	O
may	O
directly	O
give	O
rise	O
to	O
deleterious	O
effects	O
on	O
protein	O
functions	O
known	O
to	O
be	O
essential	O
for	O
hearing	O
,	O
as	O
well	O
as	O
heterozygous	O
deletions	O
and	O
CNV	O
gains	O
,	O
which	O
when	O
compounded	O
with	O
sequence	O
mutations	O
in	O
deafness	B-DISEASE
genes	O
could	O
potentially	O
harm	O
gene	O
functions	O
known	O
to	O
be	O
essential	O
for	O
hearing	O
.	O

The	O
RP1	B-GENE
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
Gln2102	I-VARIANT
*	I-VARIANT
locates	O
near	O
the	O
C	O
-	O
terminus	O
and	O
likely	O
represents	O
an	O
NMD	O
-	O
insensitive	O
non	O
-	O
pathogenic	O
variant	O
.	O

2	O
)	O
.	O

To	O
generate	O
epitope	O
-	O
tagged	O
versions	O
of	O
CD164	B-GENE
,	O
the	O
HA	O
tag	O
(	O
YPYDVPDYA	O
)	O
,	O
triple	O
FLAG	O
tag	O
(	O
DYKDHDGDYKDHDIDYKDDDDK	O
)	O
or	O
the	O
myc	O
tag	O
(	O
EQKLISEEDL	O
)	O
were	O
inserted	O
in	O
a	O
phylogenetically	O
poorly	O
conserved	O
34	O
amino	O
acid	O
region	O
C	O
-	O
terminal	O
to	O
the	O
signal	O
peptide	O
at	O
the	O
indicated	O
positions	O
:	O
DKN	O
(	O
FLAG1	O
)	O
TTQ	O
(	O
HA2	O
,	O
myc2	O
)	O
HPNVTTLAPISNVTSA	O
(	O
FLAG3	O
)	O
PVTSLPLVTT	O
(	O
HA4	O
,	O
FLAG4	O
)	O
PA	O
,	O
with	O
arbitrary	O
numerals	O
referring	O
to	O
the	O
position	O
of	O
insertion	O
.	O

The	O
Opa1	B-GENE
protein	O
has	O
multiple	O
functions	O
and	O
plays	O
a	O
key	O
role	O
in	O
the	O
fusion	O
of	O
mitochondria	O
and	O
thus	O
in	O
organizing	O
the	O
mitochondrial	O
network	O
[	O
13	O
,	O
14	O
]	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
venous	O
leukocytes	O
.	O

Additional	O
genes	O
for	O
DNA	O
sequence	O
analysis	O
were	O
selected	O
for	O
each	O
patient	O
based	O
on	O
clinical	O
findings	O
.	O

The	O
reproductive	O
phenotype	O
of	O
30	O
probands	O
(	O
25	O
men	O
;	O
5	O
women	O
)	O
ranged	O
from	O
severe	O
HH	B-DISEASE
to	O
partial	O
puberty	O
.	O

In	O
the	O
11	O
subjects	O
who	O
did	O
not	O
display	O
obvious	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
most	O
were	O
less	O
than	O
5	O
years	O
old	O
at	O
the	O
time	O
of	O
this	O
study	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
according	O
to	O
standard	O
procedures	O
.	O

At	O
age	O
of	O
9	O
years	O
he	O
started	O
to	O
suffer	O
from	O
nocturnal	B-DISEASE
apnea	I-DISEASE
.	O

Reads	O
were	O
aligned	O
to	O
the	O
NCBI	O
human	O
reference	O
genome	O
(	O
NCBI	O
build	O
37	O
.	O
1	O
)	O
for	O
SNP	O
analysis	O
with	O
Short	O
Oligonucleotide	O
Alignment	O
Program	O
(	O
SOAP	O
;	O
http	O
:	O
/	O
/	O
soap	O
.	O
genomics	O
.	O
org	O
.	O
cn	O
)	O
[	O
21	O
]	O
,	O
and	O
for	O
Indel	O
detection	O
using	O
Burrows	O
-	O
Wheeler	O
Aligner	O
(	O
BWA	O
;	O
http	O
:	O
/	O
/	O
bio	O
-	O
bwa	O
.	O
sourceforge	O
.	O
net	O
/	O
)	O
[	O
22	O
]	O
.	O

Thirty	O
-	O
six	O
of	O
these	O
sequence	O
variants	O
have	O
not	O
been	O
previously	O
described	O
in	O
the	O
literature	O
and	O
were	O
not	O
presented	O
in	O
the	O
LSDB	O
for	O
USH	O
genes	O
(	O
Roux	O
et	O
al	O
.	O

In	O
the	O
human	O
retina	O
,	O
myosin	B-GENE
VIIa	I-GENE
functions	O
actively	O
in	O
the	O
migration	O
of	O
retinal	O
pigment	O
epithelium	O
,	O
photoreceptor	O
cells	O
,	O
and	O
opsin	O
transport	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
.	O

This	O
patient	O
had	O
coccygeal	O
eversion	O
leading	O
to	O
a	O
tail	O
.	O

We	O
compared	O
these	O
results	O
with	O
the	O
results	O
of	O
our	O
two	O
reference	O
groups	O
12	O
months	O
after	O
use	O
.	O

Some	O
,	O
but	O
not	O
all	O
,	O
pendrin	B-GENE
mis	O
-	O
sense	O
mutations	O
are	O
more	O
diverged	O
from	O
wild	O
-	O
type	O
pendrin	B-GENE
than	O
are	O
other	O
SLC26A	O
transporters	O
.	O

(	O
O	O
)	O
Head	O
MRI	O
scan	O
of	O
individual	O
III	O
:	O
2	O
exhibits	O
a	O
mild	O
cerebellar	B-DISEASE
atrophy	I-DISEASE
(	O
white	O
arrow	O
)	O
.	O

1888	I-VARIANT
G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
was	O
identified	O
.	O

The	O
density	O
of	O
myelinated	O
fibers	O
(	O
MFs	O
)	O
,	O
axonal	O
diameter	O
,	O
myelin	O
thickness	O
,	O
and	O
the	O
g	O
-	O
ratio	O
of	O
MFs	O
were	O
determined	O
from	O
semi	O
-	O
thin	O
transverse	O
sections	O
using	O
a	O
computer	O
-	O
assisted	O
image	O
analyzer	O
(	O
AnalySIS	O
,	O
Soft	O
Imaging	O
System	O
,	O
Germany	O
)	O
.	O

The	O
hearing	B-DISEASE
loss	I-DISEASE
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
variant	O
is	O
moderately	O
conserved	O
with	O
a	O
GERP	O
score	O
of	O
3	O
.	O
89	O
.	O

,	O
2004	O
)	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
family	O
was	O
late	O
onset	O
and	O
the	O
high	O
frequency	O
was	O
initially	O
decreased	O
(	O
Figure	O
S6	O
)	O
.	O

1	O
-	O
4	O
Distinct	O
physical	O
findings	O
associated	O
with	O
many	O
syndromic	B-DISEASE
forms	I-DISEASE
of	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
direct	O
targeted	O
DNA	O
sequence	O
analysis	O
towards	O
particular	O
genes	O
.	O

The	O
characteristic	O
physical	O
features	O
and	O
growth	O
curve	O
of	O
the	O
patient	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

Critical	O
dosage	O
of	O
Tcof1	B-GENE
for	O
appropriate	O
craniofacial	O
development	O
has	O
been	O
further	O
demonstrated	O
in	O
Tcof1	O
+	O
/	O
-	O
mice	O
[	O
12	O
,	O
13	O
]	O
.	O

performed	O
experiments	O
.	O

Mean	O
depth	O
(	O
X	O
)	O
:	O
the	O
sequencing	O
depth	O
of	O
each	O
exon	O
.	O

All	O
CNV	O
deletion	O
events	O
were	O
annotated	O
to	O
identify	O
those	O
overlapping	O
coding	O
exons	O
and	O
those	O
that	O
were	O
intronic	O
,	O
intergenic	O
,	O
or	O
affected	O
UTR	O
exons	O
were	O
removed	O
.	O

coli	O
4AQ7	O
pdb	O
structure	O
)	O
,	O
showing	O
the	O
different	O
domains	O
coloured	O
as	O
follows	O
:	O
grey	O
,	O
N	O
-	O
terminal	O
;	O
yellow	O
,	O
catalytic	O
;	O
cyan	O
,	O
editing	O
;	O
red	O
,	O
anticodon	O
-	O
binding	O
;	O
orange	O
,	O
C	O
-	O
terminal	O
.	O

Her	O
family	O
history	O
revealed	O
eight	O
affected	O
members	O
in	O
three	O
generations	O
(	O
Figure	O
1	O
)	O
.	O

Finally	O
,	O
we	O
excluded	O
the	O
variants	O
that	O
we	O
can	O
detect	O
from	O
our	O
276	O
Korean	O
normal	O
hearing	O
control	O
chromosomes	O
.	O

Reads	O
were	O
aligned	O
to	O
hg19	O
using	O
BWA	O
12	O
.	O

reported	O
11	O
%	O
patients	O
with	O
multiple	O
mutations	O
among	O
the	O
genotype	O
-	O
positive	O
patients	O
[	O
8	O
,	O
13	O
,	O
14	O
]	O
.	O

One	O
affected	O
individual	O
displays	O
mild	O
intellectual	B-DISEASE
disability	I-DISEASE
and	O
epilepsy	B-DISEASE
,	O
while	O
another	O
sibling	O
has	O
severe	O
myopathy	B-DISEASE
,	O
fatigability	O
and	O
ptosis	O
[	O
8	O
]	O
.	O

The	O
pedigree	O
was	O
taken	O
notice	O
of	O
in	O
our	O
clinical	O
work	O
.	O

The	O
pedigrees	O
indicate	O
the	O
inheritance	O
of	O
each	O
mutation	O
in	O
three	O
different	O
families	O
.	O

Proteins	O
predicted	O
to	O
interact	O
with	O
human	O
TMPRSS3	B-GENE
include	O
multiple	O
known	O
deafness	B-DISEASE
proteins	O
such	O
as	O
MYO7A	B-GENE
,	O
GJB2	B-GENE
,	O
DFNB59	B-GENE
and	O
SLC26A4	B-GENE
.	O

While	O
both	O
of	O
these	O
hypotheses	O
are	O
attractive	O
,	O
further	O
functional	O
studies	O
are	O
needed	O
to	O
identify	O
the	O
partner	O
proteins	O
of	O
HOMER2	B-GENE
in	O
inner	O
ear	O
and	O
investigate	O
the	O
effect	O
of	O
the	O
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
mutation	O
on	O
these	O
interactions	O
.	O

In	O
74	O
%	O
of	O
the	O
patients	O
,	O
optic	B-DISEASE
atrophy	I-DISEASE
was	O
the	O
first	O
neurodegenerative	B-DISEASE
symptom	I-DISEASE
after	O
diabetes	B-DISEASE
onset	O
.	O

More	O
specifically	O
,	O
of	O
those	O
16	O
patients	O
,	O
13	O
(	O
13	O
/	O
15	O
,	O
~	O
86	O
%	O
)	O
were	O
homozygous	O
for	O
the	O
common	O
p	B-VARIANT
.	I-VARIANT
Arg279Trp	I-VARIANT
AR	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
mutation	O
[	O
Superti	O
-	O
Furga	O
et	O
al	O
.	O
,	O
1999	O
]	O
,	O
while	O
one	O
patient	O
was	O
compound	O
heterozygous	O
(	O
p	B-VARIANT
.	I-VARIANT
Arg279Trp	I-VARIANT
and	O
IVS1	B-VARIANT
+	I-VARIANT
2T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
.	O

2000	O
;	O
Heath	O
et	O
al	O
.	O

Besides	O
the	O
efficiency	O
and	O
cost	O
considerations	O
we	O
also	O
analyzed	O
the	O
prerequisites	O
for	O
the	O
sequencing	O
data	O
to	O
detect	O
exon	O
deletions	O
.	O

Here	O
,	O
we	O
identify	O
a	O
novel	O
missense	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
progressive	O
low	O
and	O
middle	O
frequency	O
DFNA11	B-DISEASE
.	O

This	O
variant	O
resides	O
in	O
the	O
entactin	O
(	O
ENT	O
)	O
domain	O
and	O
co	O
-	O
segregated	O
perfectly	O
with	O
non	O
-	O
progressive	O
high	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
.	O

[	O
29	O
]	O
,	O
and	O
Kaiserman	O
et	O
al	O
.	O

Pure	O
tone	O
and	O
speech	O
audiometry	O
and	O
physical	O
examinations	O
were	O
performed	O
for	O
nine	O
members	O
of	O
the	O
cohort	O
(	O
Figure	O
1	O
B	O
)	O
.	O

Although	O
a	O
recent	O
report	O
recommended	O
GJB2	B-GENE
screening	O
in	O
cases	O
of	O
progressive	O
and	O
recurrent	O
sudden	O
HL	O
[	O
31	O
]	O
)	O
,	O
no	O
GJB2	B-GENE
and	O
/	O
or	O
GJB6	B-GENE
biallelic	O
mutations	O
were	O
identified	O
in	O
patients	O
with	O
progressive	O
,	O
postlingual	O
,	O
asymmetrical	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
this	O
study	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
in	O
the	O
family	O
is	O
dominant	O
(	O
Figure	O
2	O
)	O
.	O

The	O
expression	O
of	O
GFP	O
-	O
ELMOD3	B-GENE
harboring	O
the	O
p	B-VARIANT
.	I-VARIANT
Leu265Ser	I-VARIANT
mutation	O
in	O
MDCK	O
cells	O
resulted	O
in	O
a	O
protein	O
that	O
failed	O
to	O
target	O
or	O
accumulate	O
at	O
the	O
plasma	O
membrane	O
and	O
instead	O
,	O
appeared	O
to	O
concentrate	O
in	O
the	O
nuclei	O
(	O
Figure	O
S8B	O
)	O
.	O

All	O
subjects	O
were	O
tested	O
for	O
GJB2	B-GENE
[	O
4	O
]	O
by	O
standard	O
Sanger	O
sequencing	O
.	O

Note	O
rounding	O
,	O
variation	O
in	O
diameter	O
,	O
central	O
nuclei	O
,	O
regenerating	O
fibers	O
and	O
fibrosis	O
in	O
panel	O
E	O
(	O
hematoxylin	O
and	O
eosin	O
staining	O
)	O
,	O
and	O
total	O
absence	O
of	O
DMD	B-DISEASE
staining	O
in	O
all	O
the	O
fibers	O
in	O
panel	O
F	O
.	O

Contributors	O
:	O
GW	O
and	O
DS	O
were	O
responsible	O
for	O
study	O
concept	O
and	O
design	O
and	O
acquisition	O
of	O
genetic	O
data	O
and	O
interpretation	O
.	O

Interestingly	O
,	O
only	O
one	O
of	O
the	O
three	O
variants	O
that	O
are	O
highly	O
likely	O
to	O
be	O
causal	O
would	O
have	O
been	O
detected	O
by	O
aCGH	O
alone	O
(	O
the	O
CNV	O
overlapping	O
OFD1	B-GENE
in	O
F14	O
)	O
,	O
and	O
only	O
one	O
could	O
have	O
been	O
suspected	O
as	O
a	O
candidate	O
gene	O
from	O
the	O
ultrasound	O
findings	O
alone	O
(	O
FGFR3	B-GENE
variants	O
in	O
F23	O
with	O
thanataphoric	B-DISEASE
dysplasia	I-DISEASE
)	O
.	O

There	O
are	O
8	O
reported	O
missense	O
pathogenic	O
mutations	O
and	O
1	O
in	O
-	O
frame	O
deletion	O
of	O
1	O
single	O
amino	O
acid	O
,	O
c	B-VARIANT
.	I-VARIANT
424_c	I-VARIANT
.	I-VARIANT
426del3	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
del142F	I-VARIANT
)	O
,	O
which	O
occurs	O
in	O
4	O
heterozygous	O
patients	O
(	O
Supplemental	O
Table	O
1	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
both	O
this	O
p	B-VARIANT
.	I-VARIANT
Trp314Arg	I-VARIANT
variant	O
and	O
another	O
rare	O
variant	O
(	O
p	B-VARIANT
.	I-VARIANT
His313Tyr	I-VARIANT
)	O
in	O
an	O
adjacent	O
codon	O
,	O
which	O
was	O
identified	O
as	O
de	O
novo	O
mutations	O
in	O
two	O
unrelated	O
Danish	O
individuals	O
with	O
WS	B-DISEASE
(	O
18	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
when	O
an	O
autosomal	O
recessive	O
ataxia	B-DISEASE
is	O
suspected	O
,	O
a	O
single	O
exome	O
will	O
provide	O
a	O
genetic	O
diagnosis	O
at	O
least	O
30	O
%	O
of	O
the	O
time	O
in	O
a	O
known	O
disease	O
gene	O
and	O
that	O
this	O
diagnostic	O
rate	O
will	O
increase	O
to	O
~	O
50	O
%	O
if	O
there	O
is	O
an	O
affected	O
sibling	O
or	O
a	O
history	O
of	O
consanguinity	O
.	O

However	O
,	O
our	O
understanding	O
of	O
HDR	B-DISEASE
syndrome	I-DISEASE
to	O
date	O
is	O
not	O
complete	O
,	O
and	O
future	O
research	O
is	O
needed	O
on	O
this	O
disease	O
.	O

ESEFinder	O
[	O
33	O
,	O
34	O
]	O
was	O
used	O
to	O
determine	O
whether	O
p	B-VARIANT
.	I-VARIANT
Ser16Pro	I-VARIANT
could	O
alter	O
the	O
normal	O
splicing	O
of	O
the	O
mRNA	O
.	O

After	O
linkage	O
analysis	O
,	O
we	O
mapped	O
the	O
disease	O
-	O
causing	O
gene	O
in	O
the	O
USH2A	B-GENE
region	O
.	O

AL	O
,	O
alobar	O
;	O
CCA	O
,	O
corpus	B-DISEASE
callosum	I-DISEASE
agenesis	I-DISEASE
;	O
CDI	O
,	O
central	B-DISEASE
diabetes	I-DISEASE
insipidus	I-DISEASE
;	O
CLP	O
,	O
cleft	B-DISEASE
lip	I-DISEASE
and	I-DISEASE
palate	I-DISEASE
;	O
DD	O
,	O
developmental	O
delay	O
;	O
F	O
,	O
female	O
;	O
GH	O
,	O
growth	O
hormone	O
;	O
HH	O
,	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
;	O
HPE	B-DISEASE
,	O
holoprosencephaly	B-DISEASE
;	O
ID	O
,	O
intellectual	O
disability	O
;	O
L	O
,	O
lobar	O
;	O
M	O
,	O
male	O
;	O
na	O
,	O
not	O
applicable	O
;	O
nr	O
,	O
not	O
reported	O
;	O
SL	O
,	O
semilobar	O
;	O
TOP	O
,	O
termination	O
of	O
pregnancy	O
;	O
TRH	O
,	O
thyrotropin	O
releasing	O
hormone	O
.	O

6	O
-	O
9	O
The	O
claudin	O
proteins	O
are	O
predicted	O
to	O
have	O
four	O
transmembrane	O
domains	O
and	O
short	O
cytosolic	O
amino	O
and	O
carboxy	O
termini	O
.	O

Hospital	O
distribution	O
of	O
reported	O
cases	O
of	O
genetic	B-DISEASE
skeletal	I-DISEASE
disorders	I-DISEASE
in	O
Chinese	O
biomedical	O
literatures	O
.	O

The	O
coding	O
length	O
of	O
a	O
gene	O
is	O
defined	O
as	O
the	O
total	O
number	O
of	O
bases	O
predicted	O
to	O
be	O
translated	O
in	O
any	O
of	O
the	O
associated	O
transcripts	O
.	O

The	O
main	O
pattern	O
of	O
inheritance	O
in	O
severe	O
childhood	O
deafness	B-DISEASE
is	O
autosomal	O
recessive	O
(	O
over	O
75	O
%	O
)	O
while	O
autosomal	O
dominant	O
(	O
12	O
-	O
24	O
%	O
)	O
,	O
X	O
-	O
linked	O
(	O
1	O
-	O
3	O
%	O
)	O
and	O
mitochondrial	O
is	O
also	O
involved	O
[	O
3	O
]	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
was	O
the	O
first	O
report	O
of	O
USH	B-DISEASE
mutation	O
analysis	O
using	O
MPS	O
and	O
the	O
frequency	O
of	O
USH1	B-DISEASE
genes	O
in	O
Japanese	O
.	O

Table	O
2	O
shows	O
the	O
clinical	O
details	O
for	O
the	O
100	O
subjects	O
.	O

After	O
incubation	O
at	O
room	O
temperature	O
,	O
we	O
added	O
the	O
transfection	O
reagent	O
to	O
the	O
cells	O
in	O
a	O
drop	O
-	O
wise	O
manner	O
.	O

In	O
vitro	O
functional	O
analysis	O
of	O
the	O
identified	O
NLRP3	B-GENE
mosaic	O
mutations	O
.	O

This	O
gene	O
is	O
so	O
far	O
the	O
most	O
common	O
responsible	O
gene	O
for	O
congenital	O
deafness	B-DISEASE
worldwide	O
[	O
7	O
]	O
.	O

The	O
melting	O
temperature	O
used	O
to	O
amplify	O
these	O
fragments	O
was	O
55	O
deg	O
C	O
.	O

B	O
:	O
Fundus	O
appearance	O
of	O
patient	O
019092	O
from	O
family	O
F8	O
.	O

The	O
USH2A	B-GENE
p	B-VARIANT
.	I-VARIANT
P1684L	I-VARIANT
mutation	O
occurs	O
at	O
an	O
evolutionarily	O
conserved	O
amino	O
acid	O
(	O
in	O
red	O
box	O
)	O
.	O

reported	O
a	O
lack	O
of	O
deafness	O
among	O
their	O
Chinese	O
patients	O
with	O
WS1	B-DISEASE
,	O
and	O
indicated	O
a	O
possible	O
ethnic	O
specific	O
variation	O
in	O
clinical	O
expression	O
of	O
the	O
syndrome	O
[	O
43	O
]	O
.	O

Mutation	O
screening	O
is	O
rarely	O
offered	O
to	O
patients	O
,	O
owing	O
to	O
the	O
extreme	O
clinical	O
and	O
genetic	O
heterogeneity	O
of	O
ADNSHL	B-DISEASE
.	O

Sanger	O
sequencing	O
confirmed	O
the	O
co	O
-	O
segregation	O
of	O
the	O
homozygote	O
mutation	O
with	O
HL	B-DISEASE
in	O
Branch	O
B	O
(	O
Figure	O
1a	O
)	O
.	O

Mutation	O
c	B-VARIANT
.	I-VARIANT
462C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
is	O
a	O
novel	O
mutation	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
umd	O
.	O
be	O
/	O
MYO7A	B-GENE
/	O
)	O
located	O
within	O
exon	O
4	O
that	O
results	O
in	O
the	O
nonsense	O
mutation	O
C154X	B-VARIANT
.	O

20	O
Mutations	O
in	O
CDH23	B-GENE
gene	O
cause	O
both	O
USH1D	B-DISEASE
and	O
DFNB12	B-DISEASE
.	O

PolyPhen	O
stablish	O
three	O
classifications	O
:	O
"	O
Probably	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
most	O
likely	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Possibly	O
damaging	O
"	O
(	O
it	O
is	O
believed	O
to	O
affect	O
protein	O
function	O
or	O
structure	O
)	O
,	O
"	O
Benign	O
"	O
(	O
most	O
likely	O
lacking	O
any	O
phenotypic	O
effect	O
)	O
.	O

Otoscopy	O
,	O
physical	O
examination	O
,	O
and	O
pure	O
tone	O
audiometry	O
(	O
at	O
frequencies	O
from	O
250	O
to	O
8	O
,	O
000	O
Hz	O
)	O
were	O
performed	O
.	O

Although	O
the	O
majority	O
of	O
cases	O
of	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
are	O
caused	O
by	O
nuclear	O
gene	O
defects	O
,	O
it	O
has	O
become	O
clear	O
that	O
mutations	O
in	O
mtDNA	O
can	O
also	O
cause	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

4c	O
)	O
.	O

For	O
sample	O
B	O
,	O
though	O
a	O
number	O
of	O
changes	O
were	O
observed	O
,	O
only	O
compound	O
heterozygosity	O
for	O
a	O
premature	O
stop	O
codon	O
and	O
a	O
high	O
pathogenicity	O
missense	O
mutation	O
in	O
CRB1	B-GENE
fitted	O
with	O
the	O
LCA	B-DISEASE
diagnosis	O
in	O
this	O
patient	O
.	O

The	O
ligated	O
product	O
(	O
20	O
ng	O
)	O
was	O
amplified	O
for	O
14	O
PCR	O
cycles	O
with	O
Illumina	O
PCR	O
primers	O
InPE1	O
.	O
0	O
and	O
indexing	O
primer	O
following	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

These	O
disorders	O
often	O
affect	O
the	O
entire	O
skeletal	O
system	O
.	O

[	O
11	O
]	O
,	O
and	O
PDE6A	B-GENE
from	O
Chavan	O
a	O
s	O
et	O
al	O
.	O

Two	O
connexons	O
from	O
adjacent	O
cells	O
dock	O
to	O
form	O
a	O
functional	O
channel	O
that	O
will	O
allow	O
,	O
among	O
other	O
small	O
molecules	O
,	O
the	O
diffusion	O
of	O
potassium	O
ions	O
critical	O
for	O
the	O
normal	O
sensory	O
hair	O
cell	O
excitation	O
[	O
3	O
]	O
.	O

2007	O
;	O
Besnard	O
et	O
al	O
.	O

Slow	O
Potassium	O
(	O
IKs	O
)	O
currents	O
were	O
obtained	O
by	O
depolarizing	O
voltage	O
steps	O
from	O
a	O
holding	O
potential	O
of	O
-	O
80	O
mV	O
to	O
various	O
test	O
potentials	O
.	O

First	O
,	O
RNA	O
from	O
cells	O
uninhibited	O
for	O
NMD	O
had	O
the	O
normal	O
and	O
variant	O
sequence	O
,	O
demonstrating	O
that	O
the	O
variant	O
allele	O
could	O
be	O
spliced	O
normally	O
,	O
although	O
there	O
appeared	O
to	O
be	O
unequal	O
peak	O
heights	O
in	O
the	O
sequence	O
chromatogram	O
(	O
figure	O
4	O
)	O
.	O

Another	O
deceased	O
individual	O
in	O
this	O
family	O
also	O
has	O
similar	O
clinical	O
features	O
.	O

5	O
-	O
10mL	O
of	O
peripheral	O
blood	O
sample	O
from	O
each	O
of	O
20	O
family	O
members	O
was	O
collected	O
(	O
III	O
4	O
,	O
III	O
6	O
,	O
III	O
11	O
,	O
III	O
15	O
,	O
IV	O
1	O
,	O
IV	O
2	O
,	O
IV	O
3	O
,	O
IV	O
6	O
,	O
IV	O
7	O
,	O
IV	O
8	O
,	O
IV	O
9	O
,	O
IV	O
12	O
,	O
IV	O
15	O
,	O
IV	O
16	O
,	O
V	O
1	O
,	O
V	O
2	O
,	O
V	O
4	O
,	O
V	O
6	O
,	O
V	O
7	O
,	O
V	O
8	O
,	O
consisting	O
of	O
16	O
affected	O
and	O
four	O
unaffected	O
members	O
)	O
.	O

POU3F4	B-GENE
gene	O
product	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
has	O
a	O
critical	O
role	O
in	O
inner	O
ear	O
morphogenesis	O
.	O

GJB2	B-GENE
mutations	O
are	O
a	O
frequent	O
cause	O
of	O
arNSHI	B-DISEASE
,	O
as	O
in	O
most	O
populations	O
;	O
however	O
,	O
the	O
relative	O
contribution	O
varies	O
per	O
country	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
German	O
Research	O
Foundation	O
(	O
HA	O
1374	O
/	O
7	O
-	O
2	O
)	O
.	O

To	O
date	O
,	O
61	O
genes	O
and	O
more	O
than	O
100	O
genetic	O
loci	O
have	O
been	O
implicated	O
in	O
ARNSHL	B-DISEASE
(	O
http	O
:	O
/	O
/	O
hereditaryhearingloss	O
.	O
org	O
/	O
)	O
.	O

In	O
the	O
mammalian	O
inner	O
ear	O
,	O
an	O
optimal	O
intracellular	O
Ca	O
2	O
+	O
concentration	O
is	O
critical	O
for	O
MET	O
,	O
adaptation	O
,	O
frequency	O
tuning	O
,	O
hair	O
bundle	O
twitching	O
,	O
outer	O
hair	O
cell	O
electromotility	O
,	O
and	O
afferent	O
synaptic	O
transmission	O
.	O

originally	O
reported	O
by	O
Chen	O
et	O
al	O
.	O

The	O
existence	O
of	O
DFNB2	B-GENE
is	O
controversial	O
,	O
and	O
often	O
there	O
is	O
no	O
relationship	O
between	O
the	O
type	O
and	O
location	O
of	O
the	O
MYO7A	B-GENE
mutations	O
corresponding	O
to	O
the	O
USH1B	B-DISEASE
and	O
DFNB2	B-GENE
phenotype	O
.	O

Medical	O
treatments	O
of	O
CHI	B-DISEASE
include	O
different	O
drugs	O
such	O
as	O
oral	O
diazoxide	O
(	O
channel	O
activator	O
)	O
,	O
somatostatin	O
analogue	O
(	O
octreotide	O
)	O
injections	O
,	O
and	O
appropriate	O
diet	O
.	O

Summary	O
of	O
the	O
79	O
targeted	O
deafness	B-DISEASE
genes	O
.	O

SLC26A4	B-GENE
Site	O
-	O
Directed	O
Mutation	O
Primers	O
.	O

The	O
most	O
upstream	O
functional	O
primer	O
extended	O
up	O
to	O
c	O
.	O
-	O
123	O
suggesting	O
that	O
the	O
polymorphism	O
at	O
c	O
.	O
-	O
137	O
is	O
not	O
necessarily	O
part	O
of	O
the	O
mRNA	O
.	O

These	O
channels	O
feature	O
four	O
homologous	O
repeats	O
(	O
I	O
-	O
IV	O
)	O
with	O
6	O
transmembrane	O
segments	O
(	O
S1	O
-	O
S6	O
)	O
and	O
a	O
membrane	O
-	O
associated	O
loop	O
between	O
segments	O
S5	O
and	O
S6	O
.	O

Knockout	O
of	O
the	O
mouse	O
orthologue	O
causes	O
defects	O
in	O
axonal	O
extension	O
(	O
31	O
)	O
.	O

Visual	B-DISEASE
failure	I-DISEASE
was	O
a	O
prominent	O
feature	O
of	O
their	O
phenotypes	O
and	O
when	O
initial	O
screens	O
for	O
POLG1	B-GENE
,	O
POLG2	B-GENE
,	O
PEO1	B-GENE
and	O
SLC25A4	B-GENE
were	O
found	O
to	O
be	O
negative	O
,	O
OPA1	B-GENE
sequencing	O
was	O
performed	O
.	O

The	O
Moroccan	O
Jewish	O
community	O
is	O
an	O
ancient	O
population	O
that	O
until	O
recently	O
was	O
highly	O
endogamous	O
.	O

We	O
identified	O
7	O
KCNQ1	B-GENE
mutations	O
.	O

Stable	O
HeLa	O
cell	O
lines	O
expressing	O
FLAG	O
-	O
tagged	O
POLR1C	B-GENE
(	O
WT	O
or	O
mutated	O
)	O
were	O
cultured	O
to	O
80	O
%	O
confluence	O
and	O
crosslinked	O
with	O
1	O
%	O
formaldehyde	O
directly	O
in	O
the	O
cell	O
medium	O
for	O
5	O
min	O
followed	O
by	O
a	O
5	O
-	O
min	O
quenching	O
in	O
125	O
mM	O
glycine	O
.	O

In	O
our	O
study	O
,	O
the	O
mutation	O
frequencies	O
of	O
GJB2	B-GENE
are	O
9	O
.	O
05	O
%	O
Uyghur	O
patients	O
and	O
16	O
.	O
56	O
%	O
for	O
Han	O
Chinese	O
patients	O
,	O
in	O
consistence	O
with	O
the	O
report	O
of	O
Dai	O
et	O
al	O
.	O

This	O
is	O
the	O
only	O
family	O
member	O
who	O
had	O
neurological	O
problems	O
.	O

Eye	O
fundus	O
revealed	O
attenuation	B-DISEASE
of	I-DISEASE
vessels	I-DISEASE
,	O
waxy	B-DISEASE
pallor	I-DISEASE
of	I-DISEASE
the	I-DISEASE
optic	I-DISEASE
nerve	I-DISEASE
head	I-DISEASE
,	O
and	O
bone	B-DISEASE
spicules	I-DISEASE
deposits	I-DISEASE
(	O
typical	O
RP	B-DISEASE
)	O
.	O

and	O
Rattus	O
sp	O
.	O

Next	O
-	O
generation	O
sequencing	O
technology	O
provides	O
the	O
potential	O
for	O
simultaneous	O
analysis	O
of	O
all	O
the	O
known	O
disease	O
genes	O
in	O
a	O
single	O
assay	O
at	O
a	O
similar	O
cost	O
to	O
testing	O
a	O
few	O
genes	O
by	O
Sanger	O
sequencing	O
.	O

Brain	O
MRI	O
was	O
normal	O
.	O

Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
TJJ	O
EMR	O
AAI	O
RAK	O
SaR	O
.	O

Snow	O
Fund	O
at	O
Washington	O
University	O
,	O
the	O
American	O
Diabetes	O
Association	O
,	O
the	O
George	O
Decker	O
and	O
Julio	O
V	O
.	O

By	O
2009	O
,	O
about	O
70	O
mutations	O
of	O
PAX3	B-GENE
related	O
to	O
WS	B-DISEASE
had	O
been	O
introduced	O
[	O
17	O
]	O
.	O

By	O
this	O
additional	O
diagnostic	O
approach	O
they	O
could	O
identify	O
the	O
second	O
pathogenic	O
mutation	O
in	O
about	O
a	O
third	O
of	O
the	O
cases	O
.	O

GenBank	O
reference	O
sequences	O
:	O
GPR98	B-GENE
:	O
NM_32119	O
.	O
3	O
;	O
DFNB31	B-GENE
:	O
NM_015404	O
.	O
2	O
.	O

Models	O
of	O
peroxisome	O
protein	O
import	O
have	O
been	O
reviewed	O
recently	O
[	O
7	O
,	O
8	O
]	O
.	O

The	O
revised	O
version	O
was	O
approved	O
by	O
all	O
authors	O
before	O
re	O
-	O
submission	O
.	O

For	O
family	O
E	O
,	O
three	O
regions	O
with	O
suggestive	O
linkage	O
were	O
found	O
with	O
a	O
LOD	O
score	O
of	O
~	O
2	O
.	O
42	O
.	O

The	O
present	O
report	O
describes	O
the	O
phenotype	O
of	O
a	O
third	O
family	O
with	O
autosomal	O
dominant	O
optic	B-DISEASE
neuropathy	I-DISEASE
and	O
deafness	B-DISEASE
that	O
is	O
associated	O
with	O
a	O
novel	O
missense	O
mutation	O
in	O
WFS1	B-GENE
.	O

Analyzed	O
the	O
data	O
:	O
MM	O
TN	O
SN	O
.	O

Ethnic	O
differences	O
impacted	O
the	O
diagnostic	O
rate	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

Data	O
provided	O
by	O
the	O
Genome	O
Database	O
[	O
29	O
]	O
were	O
used	O
as	O
references	O
for	O
allele	O
sizes	O
.	O

Our	O
analysis	O
of	O
the	O
mitochondrial	O
network	O
showed	O
that	O
fibroblasts	O
with	O
the	O
c	B-VARIANT
.	I-VARIANT
2794C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
contained	O
a	O
larger	O
proportion	O
of	O
short	O
mitochondria	O
than	O
controls	O
(	O
Figure	O
6	O
)	O
.	O

SNP	O
data	O
with	O
poor	O
quality	O
(	O
quality	O
value	O
<	O
20	O
)	O
and	O
low	O
coverage	O
(	O
depth	O
<	O
10	O
)	O
were	O
filtered	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
variations	O
allowed	O
us	O
to	O
infer	O
the	O
pathogenic	O
role	O
for	O
3	O
out	O
of	O
9	O
variants	O
,	O
thanks	O
to	O
the	O
availability	O
of	O
secondary	O
and	O
3D	O
structure	O
analysis	O
of	O
the	O
corresponding	O
protein	O
regions	O
(	O
Table	O
S1	O
)	O
.	O

They	O
established	O
genetic	O
diagnosis	O
in	O
2	O
ADNSHL	B-DISEASE
and	O
4	O
ARNSHL	B-DISEASE
families	O
,	O
and	O
identified	O
4	O
novel	O
mutations	O
.	O

2012	O
;	O
Dai	O
et	O
al	O
.	O

Understanding	O
the	O
evolution	O
of	O
these	O
symptoms	O
over	O
time	O
in	O
WFS	B-DISEASE
is	O
a	O
necessary	O
step	O
towards	O
preparing	O
for	O
future	O
clinical	O
trials	O
.	O

Participant	O
identification	O
number	O
is	O
given	O
above	O
each	O
lane	O
.	O

In	O
addition	O
,	O
as	O
can	O
be	O
seen	O
in	O
the	O
current	O
study	O
,	O
recurrent	O
as	O
well	O
as	O
novel	O
mutations	O
in	O
known	O
genes	O
define	O
the	O
disease	O
in	O
the	O
families	O
which	O
seem	O
to	O
have	O
some	O
population	O
specificity	O
.	O

Prior	O
mutation	O
screening	O
using	O
the	O
SNaPshot	O
multiplex	O
assays	O
,	O
which	O
targeted	O
20	O
common	O
deafness	B-DISEASE
-	O
associated	O
mutations	O
in	O
the	O
Han	O
Chinese	O
population	O
of	O
Taiwan	O
[	O
14	O
]	O
,	O
did	O
not	O
detect	O
mutations	O
in	O
these	O
12	O
families	O
.	O

Subject	O
III	O
-	O
1	O
(	O
F	O
/	O
8yr	O
)	O
did	O
not	O
complain	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
however	O
her	O
pronunciation	O
was	O
mildly	O
abnormal	O
.	O

Karen	O
Friis	O
Henriksen	O
(	O
ICMM	O
,	O
Copenhagen	O
)	O
is	O
acknowledged	O
for	O
preparing	O
the	O
library	O
and	O
Targeted	O
NimbleGen	O
array	O
capture	O
for	O
NGS	O
.	O

2	O
C	O
)	O
,	O
suggesting	O
a	O
mutation	O
affecting	O
the	O
motor	O
domain	O
of	O
myosin	B-GENE
-	I-GENE
9	I-GENE
[	O
2	O
,	O
4	O
]	O
.	O

This	O
mutation	O
screening	O
study	O
further	O
confirms	O
that	O
the	O
OTOF	B-GENE
gene	O
contributes	O
to	O
ANs	B-DISEASE
and	O
to	O
TS	B-DISEASE
-	I-DISEASE
NSRAN	I-DISEASE
.	O

In	O
this	O
large	O
cohort	O
,	O
the	O
high	O
genetic	O
informativity	O
allowed	O
us	O
to	O
exclude	O
most	O
candidates	O
after	O
the	O
RD	B-DISEASE
cosegregation	O
chip	O
,	O
and	O
Sanger	O
sequencing	O
ruled	O
out	O
the	O
few	O
remaining	O
genes	O
.	O

The	O
admixture	O
proportions	O
distinguishing	O
the	O
African	O
subpopulation	O
(	O
>	O
=	O
78	O
%	O
African	O
)	O
from	O
the	O
African	O
-	O
European	O
group	O
result	O
from	O
a	O
breakpoint	O
in	O
the	O
data	O
and	O
are	O
comparable	O
to	O
the	O
proportions	O
of	O
the	O
dominant	O
ancestry	O
in	O
the	O
East	O
Asian	O
,	O
Central	O
Asian	O
,	O
and	O
European	O
groups	O
(	O
>	O
=	O
79	O
%	O
,	O
>	O
=	O
79	O
%	O
,	O
>	O
=	O
83	O
%	O
,	O
respectively	O
)	O
.	O

In	O
this	O
study	O
,	O
three	O
novel	O
missense	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
S298N	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A115V	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R290Q	I-VARIANT
,	O
are	O
reported	O
for	O
the	O
first	O
time	O
in	O
association	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
and	O
two	O
of	O
these	O
,	O
p	B-VARIANT
.	I-VARIANT
S298N	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R290Q	I-VARIANT
,	O
affect	O
the	O
GTPase	O
domain	O
.	O

It	O
'	O
s	O
possible	O
that	O
the	O
second	O
mutant	O
allele	O
has	O
not	O
yet	O
been	O
identified	O
due	O
to	O
a	O
)	O
mutations	O
deep	O
in	O
introns	O
or	O
promoter	O
regions	O
that	O
are	O
not	O
sequenced	O
,	O
b	O
)	O
intragenic	O
exon	O
deletions	O
,	O
c	O
)	O
mutations	O
in	O
genes	O
other	O
than	O
SLC26A4	B-GENE
may	O
involve	O
in	O
the	O
pathogenesis	O
(	O
digenic	O
)	O
.	O

Our	O
biological	O
interest	O
in	O
WFS1	B-GENE
was	O
high	O
,	O
as	O
coding	O
variants	O
in	O
this	O
gene	O
have	O
been	O
associated	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
in	O
candidate	O
gene	O
studies	O
(	O
20	O
,	O
21	O
)	O
and	O
common	O
noncoding	O
variants	O
nearby	O
this	O
gene	O
have	O
been	O
associated	O
with	O
increased	O
risk	O
for	O
type	B-DISEASE
2	I-DISEASE
diabetes	I-DISEASE
in	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
22	O
,	O
23	O
)	O
.	O

To	O
identify	O
pathogenic	O
variants	O
,	O
we	O
consecutively	O
filtered	O
these	O
variants	O
by	O
subjecting	O
them	O
to	O
an	O
analytical	O
pipeline	O
for	O
high	O
-	O
confidence	O
variant	O
calling	O
and	O
annotation	O
and	O
identified	O
novel	O
compound	O
heterozygous	O
mutations	O
in	O
TMC1	B-GENE
.	O

4B	O
,	O
D	O
)	O
.	O

The	O
case	O
with	O
the	O
V1637L	B-VARIANT
variant	O
in	O
BRCA1	B-GENE
also	O
had	O
a	O
truncation	O
in	O
BRCA2	B-GENE
and	O
V1637L	B-VARIANT
has	O
previously	O
been	O
predicted	O
to	O
be	O
functionally	O
neutral	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

For	O
the	O
number	O
of	O
variants	O
in	O
each	O
position	O
,	O
we	O
assumed	O
a	O
binomial	O
distribution	O
with	O
the	O
probability	O
parameter	O
of	O
1	O
/	O
24	O
,	O
and	O
the	O
size	O
parameter	O
of	O
the	O
number	O
of	O
coverage	O
.	O

Genes	O
are	O
listed	O
by	O
chromosome	O
and	O
physical	O
location	O
.	O

Among	O
the	O
two	O
patients	O
carrying	O
one	O
or	O
more	O
VUS	O
in	O
SLC26A4	B-GENE
,	O
one	O
patient	O
carrying	O
two	O
VUS	O
had	O
unilateral	O
hearing	B-DISEASE
loss	I-DISEASE
despite	O
having	O
bilateral	O
inner	B-DISEASE
ear	I-DISEASE
malformations	I-DISEASE
involving	O
the	O
vestibule	O
and	O
semicircular	O
canals	O
,	O
and	O
one	O
patient	O
carrying	O
a	O
single	O
VUS	O
had	O
bilateral	O
Mondini	B-DISEASE
malformation	I-DISEASE
with	O
bilateral	O
semicircular	B-DISEASE
canal	I-DISEASE
abnormalities	I-DISEASE
and	O
multiple	B-DISEASE
congenital	I-DISEASE
anomalies	I-DISEASE
of	O
unknown	O
but	O
presumably	O
independent	O
aetiology	O
.	O

17	O
,	O
18	O
In	O
this	O
report	O
,	O
we	O
described	O
a	O
patient	O
with	O
MHA	B-DISEASE
due	O
to	O
a	O
missense	O
mutation	O
in	O
the	O
MYH9	B-GENE
gene	O
.	O

The	O
conditions	O
in	O
a	O
proportion	O
of	O
individuals	O
with	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
particularly	O
in	O
the	O
undiagnosed	O
group	O
,	O
may	O
have	O
been	O
caused	O
or	O
modified	O
by	O
an	O
accumulation	O
of	O
unfavorable	O
variants	O
across	O
multiple	O
genes	O
.	O

25	O
,	O
36	O
Previous	O
studies	O
have	O
identified	O
mutations	O
in	O
TECTA	B-GENE
can	O
lead	O
to	O
DFNA12	B-DISEASE
or	O
DFNB21	B-DISEASE
.	O

Residual	O
hearing	O
for	O
acoustic	O
amplification	O
could	O
be	O
preserved	O
,	O
and	O
hearing	O
level	O
with	O
bilateral	O
EAS	O
was	O
around	O
30dB	O
(	O
Fig	O
.	O

The	O
age	O
at	O
the	O
time	O
of	O
audiological	O
examination	O
with	O
dotted	O
line	O
was	O
18	O
years	O
old	O
.	O

These	O
CNVs	O
may	O
affect	O
regulatory	O
regions	O
anywhere	O
in	O
the	O
genome	O
offsetting	O
the	O
synchronization	O
and	O
balance	O
of	O
the	O
signaling	O
network	O
implicated	O
in	O
the	O
disorder	O
.	O

3	O
)	O
.	O

Wild	O
-	O
type	O
and	O
mutant	O
myosin	B-GENE
VIIA	I-GENE
HMM	O
were	O
transfected	O
into	O
baculovirus	O
-	O
Sf9	O
cells	O
using	O
lipo2000	O
(	O
Invitrogen	O
)	O
.	O

,	O
2009	O
;	O
Santarelli	O
,	O
2010	O
)	O
.	O

See	O
also	O
Figure	O
1a	O
.	O

Cirulli	O
,	O
Dr	O
.	O

The	O
proband	O
(	O
III	O
-	O
6	O
)	O
,	O
a	O
41	O
-	O
year	O
-	O
old	O
woman	O
with	O
LCPD	B-DISEASE
accompanied	O
by	O
osteoporosis	O
(	O
OP	O
)	O
,	O
came	O
to	O
our	O
hospital	O
for	O
genetic	O
counseling	O
with	O
regard	O
to	O
bone	O
disease	O
.	O

While	O
enrichment	O
and	O
NGS	O
of	O
RP2	B-GENE
is	O
uncomplicated	O
,	O
the	O
mutational	O
hot	O
spot	O
exon	O
of	O
RPGR	B-GENE
,	O
ORF15	B-GENE
,	O
is	O
not	O
accessible	O
by	O
our	O
NGS	O
approach	O
due	O
to	O
its	O
highly	O
repetitive	O
sequence	O
.	O

Broader	O
sequencing	O
,	O
combined	O
with	O
functional	O
validation	O
,	O
will	O
be	O
required	O
to	O
fully	O
elucidate	O
the	O
molecular	O
basis	O
of	O
these	O
remaining	O
cases	O
.	O

WS	B-DISEASE
-	O
associated	O
DM	B-DISEASE
shows	O
clear	O
differences	O
respect	O
to	O
autoimmune	B-DISEASE
type	I-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
.	O

The	O
previously	O
published	O
audiograms	O
of	O
family	O
E	O
were	O
also	O
included	O
(	O
Cremers	O
et	O
al	O
.	O

Most	O
published	O
methods	O
on	O
CNV	O
detections	O
from	O
NGS	O
data	O
are	O
designed	O
for	O
examining	O
CNVs	O
on	O
the	O
whole	O
genome	O
or	O
whole	O
exome	O
scale	O
,	O
with	O
specific	O
mathematical	O
models	O
applied	O
in	O
the	O
algorithms	O
[	O
9	O
]	O
.	O

At	O
P6	O
,	O
we	O
found	O
no	O
difference	O
in	O
transduction	O
currents	O
recorded	O
from	O
OHCs	O
and	O
IHCs	O
between	O
BLSW	O
and	O
Swiss	O
Webster	O
control	O
mice	O
.	O

For	O
patients	O
with	O
a	O
family	O
history	O
of	O
deafness	B-DISEASE
,	O
the	O
frequencies	O
of	O
gene	O
mutations	O
in	O
the	O
nine	O
loci	O
studied	O
were	O
significantly	O
higher	O
in	O
Han	O
Chinese	O
patients	O
than	O
in	O
Uyghur	O
patients	O
(	O
Fisher	O
'	O
s	O
exact	O
probability	O
test	O
,	O
P	O
<	O
0	O
.	O

Mice	O
carrying	O
a	O
mutation	O
of	O
the	O
orthologous	O
gene	O
(	O
COMT2	B-GENE
)	O
suffer	O
from	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
,	O
profound	B-DISEASE
deafness	I-DISEASE
and	O
progressive	O
degeneration	B-DISEASE
of	I-DISEASE
the	I-DISEASE
organ	I-DISEASE
of	I-DISEASE
Corti	I-DISEASE
[	O
19	O
]	O
.	O

This	O
is	O
in	O
line	O
with	O
the	O
essentiality	O
of	O
the	O
interaction	O
between	O
EDN3	B-GENE
with	O
ENDRB	B-GENE
for	O
the	O
development	O
of	O
epidermal	O
melanocytes	O
and	O
enteric	O
neurons	O
[	O
40	O
]	O
.	O

All	O
the	O
patients	O
were	O
of	O
Chinese	O
Han	O
ethnicity	O
living	O
in	O
northwest	O
China	O
.	O

The	O
recent	O
finding	O
that	O
mutations	O
in	O
DFNB31	B-GENE
cause	O
USH2	B-DISEASE
prompted	O
us	O
to	O
screen	O
the	O
12	O
exons	O
of	O
this	O
gene	O
in	O
195	O
patients	O
from	O
diverse	O
origins	O
who	O
have	O
USH1	B-DISEASE
,	O
USH2	B-DISEASE
,	O
and	O
USHA	B-DISEASE
.	O

Mutational	O
screening	O
revealed	O
five	O
novel	O
heterozygous	O
mutations	O
(	O
Table	O
1	O
)	O
.	O

Verbal	O
IQ	O
was	O
overall	O
very	O
high	O
,	O
with	O
15	O
of	O
the	O
16	O
tested	O
performing	O
at	O
the	O
average	O
range	O
or	O
above	O
.	O

Electron	O
microscopy	O
revealed	O
irregular	O
thickening	O
and	O
splitting	O
of	O
the	O
glomerular	O
basement	O
membranes	O
(	O
GBMs	O
)	O
.	O

This	O
is	O
compared	O
with	O
the	O
15	O
.	O
5	O
%	O
of	O
cases	O
(	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
P	O
=	O
3	O
.	O
4	O
x	O
10	O
-	O
8	O
;	O
88	O
%	O
excess	O
observations	O
among	O
cases	O
)	O
.	O
Current	O
genetic	O
tests	O
for	O
diagnosing	O
monogenic	O
diabetes	B-DISEASE
rely	O
on	O
selection	O
of	O
the	O
appropriate	O
gene	O
for	O
analysis	O
according	O
to	O
the	O
patient	O
'	O
s	O
phenotype	O
.	O

Louis	O
Children	O
'	O
s	O
Hospital	O
,	O
Dr	O
.	O

Based	O
on	O
the	O
phenotypic	O
characterization	O
,	O
the	O
disease	O
has	O
been	O
classified	O
into	O
three	O
subtypes	O
.	O

Even	O
though	O
p	B-VARIANT
.	I-VARIANT
S2161F	I-VARIANT
was	O
not	O
the	O
causative	O
mutation	O
in	O
this	O
family	O
,	O
it	O
has	O
the	O
potential	O
to	O
exert	O
pathogenic	O
effects	O
on	O
protein	O
function	O
in	O
other	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
as	O
supported	O
by	O
the	O
in	O
silico	O
analysis	O
.	O

For	O
ABR	O
,	O
acoustic	O
stimuli	O
were	O
generated	O
from	O
a	O
high	O
frequency	O
transducer	O
and	O
presented	O
at	O
varying	O
intensity	O
at	O
a	O
rate	O
of	O
19	O
.	O
1	O
times	O
per	O
s	O
for	O
a	O
total	O
of	O
350	O
presentations	O
.	O

Assessment	O
of	O
her	O
parents	O
revealed	O
insignificant	O
,	O
age	O
-	O
compatible	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
for	O
her	O
mother	O
(	O
25	O
dB	O
/	O
4000	O
Hz	O
)	O
and	O
mild	O
to	O
moderate	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
her	O
father	O
(	O
40	O
dB	O
/	O
1000	O
-	O
4000	O
Hz	O
)	O
.	O

Although	O
fundus	O
hypopigmentation	B-DISEASE
was	O
recorded	O
in	O
WS	B-DISEASE
in	O
previous	O
reports	O
,	O
it	O
has	O
not	O
been	O
described	O
in	O
WS1	B-DISEASE
patients	O
with	O
PAX3	B-GENE
mutations	O
before	O
.	O

Sequencing	O
of	O
the	O
complete	O
CDS	O
of	O
the	O
EDNRB	B-GENE
gene	O
revealed	O
a	O
c	B-VARIANT
.	I-VARIANT
1A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
heterozygous	O
DNA	O
change	O
in	O
the	O
NM_000115	O
.	O
3	O
sequence	O
.	O

Non	O
-	O
synonymous	O
variants	O
were	O
evaluated	O
by	O
four	O
algorithms	O
,	O
including	O
PolyPhen	O
,	O
SIFT	O
,	O
PANTHER	O
and	O
Pmut	O
,	O
to	O
determine	O
pathogenicity	O
[	O
13	O
]	O
.	O

Analysis	O
of	O
the	O
5	O
'	O
region	O
of	O
PEX1	B-GENE
.	O

Only	O
patient	O
8	O
revealed	O
homozygous	O
alleles	O
for	O
all	O
4	O
markers	O
,	O
while	O
all	O
12	O
normal	O
controls	O
showed	O
heterozygous	O
alleles	O
for	O
at	O
least	O
one	O
of	O
the	O
microsatellite	O
markers	O
(	O
Table	O
S2	O
)	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
Igor	O
Pro	O
(	O
Wavemetrics	O
,	O
Lake	O
Oswego	O
,	O
OR	O
,	O
USA	O
)	O
and	O
GraphPad	O
Prism	O
(	O
GraphPad	O
Software	O
Inc	O
.	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

total	O
number	O
of	O
coding	O
bases	O
for	O
each	O
of	O
the	O
158	O
cancer	O
-	O
susceptibility	O
genes	O
.	O

3B	O
)	O
.	O

Further	O
,	O
mother	O
of	O
17	O
.	O
1	O
,	O
father	O
of	O
18	O
.	O
1	O
and	O
both	O
parents	O
of	O
20	O
.	O
1	O
were	O
found	O
to	O
be	O
heterozygous	O
for	O
the	O
mutation	O
.	O

All	O
ANSD	B-DISEASE
cases	O
were	O
sporadic	O
(	O
compatible	O
with	O
autosomal	O
recessive	O
inheritance	O
)	O
.	O

To	O
increase	O
the	O
yield	O
,	O
we	O
amplified	O
5	O
u	O
L	O
eluted	O
solution	O
with	O
12	O
PCR	O
cycles	O
using	O
Illumina	O
PCR	O
primers	O
InpE1	O
.	O
0	O
and	O
InpE2	O
.	O
0	O
.	O

For	O
wild	O
-	O
type	O
recombinant	O
myosin	B-GENE
VI	I-GENE
(	O
M6	O
Full	O
WT	O
)	O
,	O
a	O
c	O
-	O
myc	O
and	O
FLAG	O
tag	O
sequence	O
(	O
ACGCGTGAGCAAAAGCTCATTTCTGAAGAGGACTTGTCGCGTGATTATAAAGATGATGATGATAAA	O
)	O
was	O
introduced	O
between	O
the	O
3	O
'	O
end	O
of	O
the	O
myosin	B-GENE
VI	I-GENE
cDNA	O
and	O
the	O
stop	O
codon	O
to	O
aid	O
purification	O
of	O
the	O
recombinant	O
protein	O
.	O

Novel	O
mutations	O
and	O
variants	O
were	O
defined	O
as	O
those	O
not	O
present	O
in	O
the	O
literature	O
,	O
dbSNP	O
database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
SNP	O
/	O
)	O
,	O
Human	O
Genetic	O
Variation	O
Browser	O
,	O
1000	O
Genome	O
project	O
database	O
or	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
hgmd	O
.	O
cf	O
.	O
ac	O
.	O
uk	O
)	O
.	O

Our	O
results	O
provided	O
a	O
new	O
example	O
of	O
prelingual	B-DISEASE
deafness	I-DISEASE
caused	O
by	O
a	O
TMPRSS3	B-GENE
mutation	O
.	O

Although	O
having	O
the	O
same	O
pathogenic	O
alleles	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
one	O
of	O
the	O
sisters	O
is	O
more	O
severe	O
and	O
the	O
onset	O
of	O
HL	B-DISEASE
and	O
RP	B-DISEASE
differ	O
by	O
3	O
years	O
.	O

This	O
is	O
consistent	O
with	O
the	O
report	O
that	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
is	O
the	O
primary	O
mutation	O
of	O
SLC26A4	B-GENE
in	O
Han	O
Chinese	O
NSD	B-DISEASE
patients	O
.	O

Finally	O
,	O
since	O
the	O
Tunisian	O
population	O
shares	O
a	O
common	O
genetic	O
background	O
with	O
other	O
populations	O
of	O
the	O
Mediterranean	O
basin	O
and	O
Middle	O
-	O
East	O
[	O
25	O
]	O
,	O
direct	O
screening	O
of	O
the	O
identified	O
mutations	O
in	O
profoundly	O
deaf	B-DISEASE
patients	O
from	O
those	O
regions	O
would	O
be	O
useful	O
to	O
get	O
an	O
estimate	O
of	O
their	O
prevalence	O
.	O

CV	O
,	O
GS	O
,	O
DCdS	O
,	O
BD	O
,	O
CH	O
,	O
BK	O
,	O
GM	O
,	O
SJ	O
,	O
and	O
GVV	O
recruited	O
subjects	O
,	O
gathered	O
clinical	O
data	O
and	O
contributed	O
DNA	O
samples	O
.	O

Based	O
upon	O
our	O
preliminary	O
data	O
of	O
molecular	O
epidemiology	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
China	O
[	O
28	O
,	O
39	O
-	O
41	O
]	O
,	O
Li	O
has	O
combined	O
allele	O
-	O
specific	O
PCR	O
and	O
universal	O
array	O
(	O
ASPUA	O
)	O
methodologies	O
for	O
the	O
detection	O
of	O
mutations	O
causing	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Sanger	O
sequencing	O
confirmed	O
that	O
all	O
7	O
variations	O
in	O
the	O
7	O
DFNA	B-DISEASE
families	O
were	O
heterozygous	O
in	O
the	O
patients	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
which	O
was	O
consistent	O
with	O
the	O
inheritance	O
pattern	O
of	O
the	O
disorder	O
.	O

At	O
age	O
19	O
,	O
his	O
audiogram	O
showed	O
50	O
dB	O
HL	O
at	O
500	O
Hz	O
,	O
and	O
a	O
60	O
dB	O
HL	O
at	O
1000	O
-	O
8000	O
HZ	O
,	O
thus	O
illustrating	O
progression	O
(	O
S1	O
Fig	O
)	O
.	O

The	O
top	O
panels	O
represent	O
a	O
single	O
confocal	O
microscopy	O
section	O
of	O
the	O
cells	O
at	O
the	O
nuclei	O
level	O
and	O
the	O
bottom	O
panels	O
a	O
projection	O
of	O
all	O
the	O
confocal	O
microscopy	O
sections	O
from	O
the	O
base	O
to	O
the	O
apex	O
of	O
the	O
cells	O
.	O

For	O
USH1	B-DISEASE
,	O
early	O
diagnosis	O
has	O
many	O
immediate	O
and	O
several	O
long	O
-	O
term	O
advantages	O
for	O
patients	O
and	O
their	O
families	O
[	O
1	O
]	O
.	O

The	O
wolframin	B-GENE
(	O
WFS1	B-GENE
)	O
gene	O
was	O
screened	O
for	O
mutations	O
in	O
39	O
patients	O
.	O

The	O
father	O
carried	O
a	O
heterozygous	O
c	B-VARIANT
.	I-VARIANT
1032_1117dup	I-VARIANT
(	O
blue	O
)	O
,	O
while	O
the	O
mother	O
a	O
heterozygous	O
1319	B-VARIANT
delT	I-VARIANT
(	O
red	O
)	O
.	O

To	O
evaluate	O
the	O
mutations	O
in	O
the	O
general	O
population	O
,	O
we	O
also	O
applied	O
Sanger	O
sequencing	O
for	O
these	O
mutations	O
to	O
80	O
normal	O
subjects	O
belonging	O
to	O
the	O
Korean	O
ethnic	O
group	O
.	O

6	O
)	O
.	O

Figure	O
1	O
shows	O
the	O
pedigree	O
of	O
this	O
family	O
.	O

In	O
addition	O
,	O
the	O
CUHK	O
-	O
HL	B-DISEASE
V1	O
kit	O
also	O
included	O
the	O
full	O
length	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
as	O
a	O
single	O
target	O
.	O

The	O
combined	O
ribbon	O
and	O
stick	O
-	O
sphere	O
representation	O
indicate	O
the	O
predicted	O
structure	O
model	O
of	O
the	O
myosin	B-GENE
VIIA	I-GENE
motor	O
domain	O
.	O

This	O
assay	O
is	O
based	O
on	O
a	O
reaction	O
in	O
which	O
the	O
regeneration	O
of	O
hydrolyzed	O
ATP	O
is	O
coupled	O
to	O
the	O
oxidation	O
of	O
NADH	O
.	O

In	O
our	O
cohort	O
,	O
we	O
observed	O
3	O
KRAS	B-GENE
variants	O
,	O
c	B-VARIANT
.	I-VARIANT
565A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Met189Leu	I-VARIANT
)	O
in	O
two	O
individuals	O
,	O
and	O
c	B-VARIANT
.	I-VARIANT
535G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Gly179Ser	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
531_533del	I-VARIANT
in	O
one	O
individual	O
each	O
.	O

The	O
ERSE	O
reporter	O
reflects	O
activation	O
levels	O
of	O
the	O
ER	O
stress	O
response	O
.	O

Our	O
rate	O
of	O
molecular	O
resolution	O
for	O
patients	O
with	O
a	O
defined	O
clinical	O
diagnosis	O
at	O
the	O
beginning	O
was	O
22	O
%	O
(	O
8	O
/	O
36	O
)	O
,	O
similar	O
to	O
the	O
success	O
rate	O
for	O
clinical	O
genome	O
and	O
exome	O
sequencing	O
of	O
25	O
%	O
[	O
8	O
-	O
10	O
]	O
.	O

By	O
10	O
months	O
of	O
age	O
,	O
he	O
had	O
developed	O
laryngomalacia	B-DISEASE
with	O
pharyngeal	B-DISEASE
hypotonia	I-DISEASE
,	O
his	O
condition	O
progressed	O
and	O
he	O
died	O
of	O
respiratory	B-DISEASE
failure	I-DISEASE
at	O
15	O
months	O
of	O
age	O
.	O

The	O
mutation	O
frequency	O
of	O
1494C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
is	O
even	O
lower	O
than	O
that	O
of	O
1555A	B-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

LZ	O
,	O
ML	O
,	O
XW	O
,	O
WZ	O
collected	O
clinical	O
data	O
,	O
carried	O
out	O
genetic	O
studies	O
,	O
participated	O
in	O
the	O
sequence	O
alignment	O
and	O
revised	O
the	O
manuscript	O
.	O

The	O
majority	O
of	O
nonconfirmed	O
variants	O
(	O
76	O
%	O
)	O
were	O
falsely	O
called	O
indels	O
,	O
many	O
in	O
the	O
vicinity	O
of	O
homopolymer	O
stretches	O
,	O
a	O
known	O
pitfall	O
of	O
the	O
Roche	O
454	O
pyrosequencing	O
technology	O
.	O

The	O
MLPA	O
analysis	O
,	O
applied	O
to	O
65	O
of	O
the	O
probands	O
,	O
resulted	O
in	O
the	O
identification	O
of	O
a	O
single	O
three	O
exon	O
(	O
7	O
-	O
9	O
)	O
deletion	O
,	O
IVS6_IVS10del	B-VARIANT
,	O
in	O
KCNQ1	B-GENE
.	O

Clinical	O
features	O
of	O
patients	O
in	O
8	O
Korean	O
families	O
carrying	O
autosomal	O
dominant	O
hearing	B-DISEASE
loss	I-DISEASE
*	O
The	O
hearing	O
test	O
for	O
III	O
-	O
1	O
(	O
KNUF21	O
)	O
was	O
performed	O
by	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
.	O

The	O
variant	O
list	O
derived	O
from	O
analysing	O
case	O
530	O
(	O
a	O
female	O
)	O
identified	O
heterozygous	O
variants	O
in	O
HMCN1	B-GENE
and	O
the	O
previously	O
reported	O
GUCY2D	B-GENE
[	O
24	O
]	O
,	O
[	O
25	O
]	O
as	O
the	O
most	O
likely	O
candidates	O
.	O

38	O
39	O
Although	O
mutations	O
in	O
the	O
C	O
-	O
propeptide	O
of	O
other	O
fibrillar	O
collagens	O
have	O
been	O
described	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
a	O
C	O
-	O
propeptide	O
mutation	O
in	O
alpha	O
1	O
(	O
XI	O
)	O
collagen	O
.	O

The	O
imaging	O
protocol	O
consisted	O
of	O
T2	O
-	O
weighted	O
spin	O
echo	O
(	O
SE	O
)	O
(	O
repetition	O
time	O
(	O
TR	O
)	O
/	O
echo	O
time	O
(	O
TE	O
)	O
=	O
4	O
,	O
700	O
/	O
120	O
ms	O
)	O
,	O
T1	O
-	O
weighted	O
SE	O
(	O
TR	O
/	O
TE	O
=	O
550	O
/	O
12	O
ms	O
)	O
,	O
and	O
fluid	O
-	O
attenuated	O
inversion	O
recovery	O
(	O
FLAIR	O
)	O
(	O
TR	O
/	O
TE	O
=	O
9	O
,	O
000	O
/	O
119	O
ms	O
;	O
inversion	O
time	O
=	O
2	O
,	O
609	O
ms	O
)	O
images	O
.	O

We	O
report	O
here	O
the	O
diagnostic	O
yield	O
of	O
WES	O
for	O
the	O
subset	O
of	O
FORGE	O
patients	O
with	O
a	O
phenotypic	O
description	O
of	O
cerebellar	O
ataxia	B-DISEASE
.	O

It	O
allows	O
direct	O
estimates	O
of	O
recurrence	O
risk	O
in	O
relatives	O
and	O
helps	O
family	O
planning	O
.	O

In	O
contrast	O
,	O
neither	O
IVS7	B-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
nor	O
p	B-VARIANT
.	I-VARIANT
H723R	I-VARIANT
were	O
found	O
in	O
the	O
Tibetan	B-DISEASE
and	I-DISEASE
Uygur	I-DISEASE
patients	O
.	O

In	O
cells	O
transfected	O
with	O
wild	O
-	O
type	O
EDNRB	B-GENE
isoform	O
1	O
/	O
GFP	O
,	O
signals	O
were	O
detected	O
at	O
the	O
plasma	O
membrane	O
only	O
(	O
Figure	O
2A	O
)	O
.	O

Analyzed	O
the	O
data	O
:	O
BYC	O
JK	O
JC	O
SJM	O
SIK	O
.	O

In	O
the	O
present	O
study	O
,	O
no	O
genetic	O
linkage	O
analysis	O
was	O
performed	O
prior	O
to	O
exome	O
sequencing	O
in	O
order	O
to	O
identify	O
candidate	O
chromosomal	O
regions	O
and	O
to	O
reduce	O
the	O
analysis	O
to	O
those	O
regions	O
.	O

In	O
addition	O
,	O
the	O
prevalence	O
of	O
mutations	O
varies	O
among	O
ethnic	O
groups	O
.	O

We	O
then	O
applied	O
a	O
NimbleGen	O
customized	O
targeted	O
capture	O
array	O
and	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
in	O
order	O
to	O
sequence	O
the	O
entire	O
locus	O
in	O
one	O
affected	O
individual	O
(	O
IV	O
-	O
31	O
)	O
(	O
Fig	O
1A	O
)	O
.	O

Therefore	O
,	O
the	O
mutation	O
will	O
lead	O
to	O
extra	O
ionic	O
interactions	O
and	O
other	O
possible	O
interactions	O
of	O
the	O
arginine	O
residue	O
in	O
the	O
mutated	O
-	O
type	O
MYO7A	B-GENE
,	O
such	O
as	O
creating	O
additional	O
hydrogen	O
bonds	O
,	O
loss	O
of	O
structural	O
flexibility	O
conferred	O
by	O
Glycine	O
,	O
or	O
alternation	O
in	O
protein	O
localization	O
.	O

Analyzed	O
the	O
data	O
:	O
RC	O
MH	O
PC	O
SS	O
HL	O
SJ	O
.	O

The	O
latter	O
,	O
c	B-VARIANT
.	I-VARIANT
2831delA	I-VARIANT
(	O
Figure	O
1G	O
)	O
,	O
identified	O
in	O
the	O
exon	O
16	O
of	O
patient	O
TCS	B-DISEASE
9	O
,	O
causes	O
a	O
frameshift	O
.	O

Under	O
these	O
conditions	O
,	O
no	O
staining	O
has	O
been	O
observed	O
in	O
utricule	O
(	O
A	O
)	O
,	O
saccule	O
(	O
B	O
)	O
or	O
the	O
organ	O
of	O
Corti	O
(	O
C	O
)	O
epithelia	O
.	O

This	O
was	O
comparable	O
to	O
previous	O
direct	O
sequence	O
analysis	O
results	O
such	O
as	O
Bonnet	O
et	O
al	O
.	O

The	O
tectorial	O
membrane	O
of	O
the	O
inner	O
ear	O
is	O
a	O
ribbon	O
-	O
like	O
strip	O
of	O
extracellular	O
matrix	O
that	O
spirals	O
along	O
the	O
entire	O
length	O
of	O
the	O
cochlea	O
.	O

The	O
retinal	O
phenotype	O
seen	O
in	O
patient	O
II	O
:	O
4	O
,	O
who	O
is	O
homozygous	O
for	O
mutations	O
in	O
both	O
genes	O
,	O
results	O
from	O
overlapping	O
pathologies	O
that	O
include	O
a	O
combination	O
of	O
cellular	O
defects	O
affecting	O
RPE	O
function	O
,	O
visual	O
cycle	O
,	O
and	O
photoreceptor	O
cell	O
structure	O
and	O
survival	O
.	O

The	O
five	O
USH1	B-DISEASE
,	O
three	O
USH2	B-DISEASE
,	O
and	O
one	O
USH3	B-DISEASE
genes	O
are	O
collectively	O
composed	O
of	O
183	O
,	O
173	O
,	O
and	O
five	O
coding	O
exons	O
,	O
respectively	O
[	O
23	O
]	O
.	O

USH2	B-DISEASE
is	O
characterized	O
by	O
variable	O
degrees	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
progressive	O
visual	O
troubles	O
beginning	O
in	O
adolescence	O
or	O
early	O
adulthood	O
.	O

Genomic	O
DNA	O
samples	O
from	O
58	O
subjects	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
from	O
15	O
unrelated	O
Japanese	O
families	O
were	O
subjected	O
to	O
NGS	O
to	O
identify	O
the	O
genetic	O
causes	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

Further	O
,	O
considering	O
that	O
TCOF1	B-GENE
deficiency	O
in	O
adult	O
cells	O
could	O
be	O
associated	O
to	O
pathologic	O
clinical	O
findings	O
,	O
it	O
will	O
be	O
important	O
to	O
verify	O
if	O
TCS	B-DISEASE
patients	O
have	O
an	O
impairment	O
in	O
adult	O
stem	O
cell	O
properties	O
,	O
as	O
this	O
can	O
reduce	O
the	O
efficiency	O
of	O
plastic	O
surgery	O
results	O
during	O
rehabilitation	O
of	O
these	O
patients	O
.	O

All	O
parents	O
and	O
participants	O
provided	O
informed	O
written	O
consent	O
.	O

Segregation	O
analyses	O
of	O
mutations	O
were	O
performed	O
on	O
patients	O
with	O
available	O
family	O
members	O
.	O

Oligo	O
dT	O
and	O
randomly	O
primed	O
first	O
strand	O
cDNA	O
libraries	O
were	O
generated	O
using	O
SMART	O
1	O
st	O
strand	O
cDNA	O
synthesis	O
kit	O
(	O
Clontech	O
)	O
.	O

reported	O
that	O
~	O
5	O
%	O
of	O
recessive	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
might	O
be	O
caused	O
by	O
mutation	O
of	O
CDH23	B-GENE
[	O
6	O
]	O
.	O

Among	O
the	O
three	O
genes	O
described	O
for	O
USH2	B-DISEASE
,	O
USH2A	B-GENE
is	O
the	O
most	O
commonly	O
mutated	O
gene	O
.	O

Finally	O
,	O
the	O
results	O
were	O
discussed	O
with	O
the	O
medical	O
collaborators	O
and	O
molecular	O
diagnosis	O
was	O
defined	O
in	O
cases	O
in	O
which	O
the	O
candidate	O
mutations	O
matched	O
with	O
diagnosis	O
.	O

Original	O
magnifications	O
:	O
a	O
x	O
100	O
;	O
b	O
x	O
200	O
;	O
c	O
x	O
20	O
,	O
000	O
;	O
d	O
x	O
40	O
,	O
000	O
;	O
e	O
x	O
100	O
;	O
f	O
x	O
100	O
;	O
g	O
x	O
200	O
;	O
and	O
h	O
x	O
200	O
Light	O
microscopic	O
examination	O
of	O
longitudinal	O
and	O
cross	O
sections	O
of	O
nerve	O
fibers	O
showed	O
markedly	O
decreased	O
size	O
of	O
nerve	O
fascicles	O
with	O
marked	O
subperineurial	O
edema	O
and	O
multifocal	O
variable	O
-	O
sized	O
Renaut	O
bodies	O
,	O
which	O
consists	O
of	O
loose	O
EMA	O
-	O
positive	O
spindle	O
cells	O
.	O

Clinical	O
and	O
ethical	O
issues	O
of	O
the	O
study	O
:	O
AS	O
MCN	O
PSV	O
SDC	O
SM	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
using	O
SAS	O
9	O
.	O
1	O
.	O
3	O
software	O
(	O
SAS	O
,	O
Cary	O
,	O
North	O
Carolina	O
,	O
USA	O
)	O
.	O

During	O
the	O
experiment	O
three	O
control	O
patients	O
and	O
one	O
studied	O
patient	O
failed	O
in	O
the	O
capture	O
step	O
of	O
the	O
target	O
DNA	O
of	O
the	O
HaloPlex	O
protocol	O
.	O

Rescue	O
was	O
not	O
complete	O
for	O
mitochondrial	O
complexes	O
I	O
and	O
IV	O
.	O

This	O
analysis	O
led	O
us	O
to	O
amplify	O
a	O
5	O
.	O
5	O
kb	O
PCR	O
fragment	O
containing	O
the	O
deletion	O
flanking	O
regions	O
(	O
Figure	O
2C	O
,	O
2D	O
)	O
.	O

Copy	O
number	O
variant	O
analysis	O
was	O
performed	O
as	O
described	O
(	O
Nord	O
et	O
al	O
.	O

Histopathological	O
studies	O
of	O
human	O
eyes	O
with	O
ADOA	B-DISEASE
showed	O
diffuse	O
atrophy	O
of	O
the	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
layer	O
that	O
predominated	O
in	O
the	O
central	O
retina	O
[	O
7	O
,	O
8	O
]	O
.	O

Mutation	O
profile	O
of	O
TECTA	B-GENE
gene	O
(	O
located	O
on	O
chr11	O
)	O
.	O

Run	O
statistics	O
and	O
target	O
coverage	O
of	O
NGS	O
in	O
each	O
individual	O
After	O
heterozygous	O
variations	O
were	O
sorted	O
according	O
to	O
the	O
inheritance	O
patterns	O
of	O
each	O
family	O
,	O
quality	O
control	O
filtering	O
was	O
performed	O
based	O
on	O
the	O
PHRED	O
score	O
(	O
>	O
20	O
)	O
and	O
variant	O
allele	O
frequency	O
(	O
higher	O
than	O
20	O
%	O
)	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
/	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
compound	O
heterozygous	O
subject	O
II	O
:	O
4	O
.	O

The	O
results	O
shown	O
are	O
the	O
mean	O
+	O
-	O
s	O
.	O
e	O
.	O
m	O
of	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

Table	O
S1	O
)	O
.	O

27	O
%	O
to	O
100	O
%	O
of	O
the	O
mutations	O
found	O
in	O
each	O
USH	B-DISEASE
gene	O
,	O
had	O
not	O
been	O
previously	O
reported	O
(	O
Tables	O
2	O
,	O
3	O
and	O
4	O
,	O
Figure	O
1	O
)	O
.	O

White	O
M	O
.	O
D	O
.	O
,	O
CDE	O
(	O
Pediatrics	O
)	O
Fumihiko	O
Urano	O
,	O
M	O
.	O
D	O
.	O
,	O
Ph	O
.	O
D	O
.	O

PGM1	O
RT	O
-	O
PCR	O
was	O
used	O
as	O
a	O
control	O
(	O
bottom	O
panel	O
)	O
.	O

The	O
additional	O
feature	O
-	O
iris	B-DISEASE
heterochromia	I-DISEASE
-	O
presented	O
by	O
one	O
affected	O
individual	O
could	O
have	O
resulted	O
from	O
an	O
independent	O
genetic	O
event	O
,	O
such	O
a	O
de	O
novo	O
CNV	O
affecting	O
genes	O
involved	O
in	O
eye	O
development	O
.	O

All	O
variants	O
passing	O
this	O
QC	O
were	O
indicated	O
as	O
PASS	O
in	O
the	O
VCF	O
file	O
.	O

A	O
I	O
,	O
Pedigree	O
of	O
the	O
Qatari	O
family	O
carrying	O
the	O
p	B-VARIANT
.	I-VARIANT
*	I-VARIANT
2625Gluext	I-VARIANT
*	I-VARIANT
11	I-VARIANT
mutation	O
in	O
BDP1	B-GENE
gene	O
.	O

We	O
evaluated	O
these	O
strong	O
candidates	O
further	O
using	O
exome	O
sequencing	O
on	O
935	O
cases	O
and	O
870	O
controls	O
and	O
at	O
both	O
KATNAL2	B-GENE
and	O
CHD8	B-GENE
,	O
three	O
additional	O
LoF	O
mutations	O
were	O
observed	O
in	O
cases	O
with	O
none	O
in	O
controls	O
(	O
no	O
additional	O
LoF	O
mutations	O
were	O
seen	O
at	O
SCN2A	B-GENE
)	O
.	O

This	O
once	O
more	O
proves	O
the	O
value	O
of	O
genetic	O
testing	O
for	O
detecting	O
presymptomatic	O
carriers	O
or	O
excluding	O
the	O
risk	O
of	O
being	O
affected	O
.	O

In	O
general	O
,	O
the	O
ADNSHL	B-DISEASE
phenotypes	O
are	O
postlingual	O
hearing	B-DISEASE
loss	I-DISEASE
mostly	O
affecting	O
the	O
high	O
frequencies	O
,	O
although	O
some	O
hereditary	O
hearing	B-DISEASE
loss	I-DISEASE
involves	O
mainly	O
low	O
or	O
intermediate	O
frequencies	O
.	O

The	O
lysate	O
was	O
used	O
for	O
liquid	O
scintillation	O
counting	O
to	O
determine	O
the	O
[	O
14	O
C	O
]	O
formate	O
uptake	O
.	O

We	O
confirmed	O
that	O
the	O
c	B-VARIANT
.	I-VARIANT
5766	I-VARIANT
-	I-VARIANT
3del	I-VARIANT
had	O
no	O
effects	O
on	O
MYH9	B-GENE
transcription	O
(	O
data	O
not	O
shown	O
)	O
and	O
should	O
be	O
considered	O
as	O
a	O
SNP	O
.	O

*	O
confirmed	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
1083A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
.	O

Yang	O
et	O
al	O
.	O

For	O
family	O
4243	O
,	O
a	O
maximum	O
two	O
-	O
point	O
LOD	O
score	O
of	O
3	O
.	O
04	O
(	O
theta	O
=	O
0	O
)	O
was	O
observed	O
at	O
marker	O
rs935340	B-VARIANT
(	O
chr14	O
:	O
75	O
.	O
66	O
Mb	O
;	O
see	O
Table	O
1	O
)	O
.	O

All	O
sequences	O
were	O
analyzed	O
with	O
the	O
Sequencher	O
software	O
(	O
Gene	O
Codes	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
.	O

All	O
subjects	O
underwent	O
audiological	O
assessment	O
including	O
pure	O
tone	O
and	O
speech	O
audiometry	O
,	O
speech	O
perception	O
measures	O
and	O
otoacoustic	O
emissions	O
and	O
ABRs	O
recording	O
,	O
all	O
performed	O
in	O
the	O
same	O
session	O
.	O

List	O
of	O
the	O
mutations	O
excluded	O
by	O
Sanger	O
sequencing	O
in	O
ascertained	O
families	O
before	O
whole	O
exome	O
sequencing	O
.	O

Statistical	O
analyses	O
were	O
performed	O
using	O
one	O
-	O
way	O
ANOVA	O
(	O
Zebrafish	O
data	O
)	O
or	O
one	O
-	O
way	O
ANOVA	O
with	O
post	O
hoc	O
T	O
-	O
test	O
analysis	O
using	O
GraphPad	O
Prism	O
6	O
(	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
for	O
ABR	O
and	O
DPOAE	O
data	O
.	O

The	O
clinical	O
course	O
of	O
the	O
five	O
patients	O
with	O
compound	O
heterozygous	O
or	O
homozygous	O
CNGA1	B-GENE
mutations	O
included	O
night	B-DISEASE
blindness	I-DISEASE
from	O
childhood	O
,	O
visual	B-DISEASE
field	I-DISEASE
loss	I-DISEASE
in	O
middle	O
age	O
,	O
non	O
-	O
recordable	O
ERG	O
and	O
characteristic	O
retinal	B-DISEASE
degeneration	I-DISEASE
pattern	O
of	O
RP	B-DISEASE
,	O
which	O
were	O
consistent	O
with	O
previously	O
reported	O
phenotypes	O
of	O
CNGA1	B-GENE
mutations	O
[	O
32	O
]	O
,	O
[	O
34	O
]	O
.	O

For	O
each	O
mutation	O
category	O
,	O
we	O
found	O
a	O
similar	O
trend	O
in	O
the	O
error	O
distribution	O
rate	O
in	O
the	O
amplicon	O
sequences	O
among	O
the	O
control	O
samples	O
(	O
Supplementary	O
Figs	O
S2	O
-	O
S4	O
)	O
.	O

In	O
fact	O
,	O
some	O
reports	O
support	O
that	O
as	O
much	O
as	O
35	O
%	O
of	O
the	O
second	O
USH2A	B-GENE
mutant	O
alleles	O
are	O
duplications	O
,	O
deletions	O
and	O
deep	O
intronic	O
variants	O
,	O
which	O
are	O
extremely	O
difficult	O
to	O
detect	O
by	O
DNA	O
sequencing	O
[	O
27	O
]	O
.	O

Another	O
variant	O
,	O
more	O
recently	O
published	O
as	O
a	O
pathogenic	O
missense	O
change	O
,	O
CDH23	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Ala366Thr	I-VARIANT
,	O
42	O
44	O
-	O
46	O
occurred	O
in	O
1	O
/	O
96	O
CEPH	O
chromosomes	O
and	O
was	O
found	O
in	O
an	O
Usher	B-DISEASE
syndrome	I-DISEASE
type	I-DISEASE
1	I-DISEASE
patient	O
146	O
who	O
has	O
two	O
pathogenic	O
MYO7A	B-GENE
mutations	O
(	O
p	B-VARIANT
.	I-VARIANT
Asp521GlufsX8	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Lys1255ArgfsX8	I-VARIANT
)	O
.	O

Except	O
for	O
mutations	O
in	O
GJB2	B-GENE
,	O
which	O
are	O
the	O
cause	O
in	O
up	O
to	O
50	O
%	O
of	O
families	O
with	O
ARNSHL	B-DISEASE
in	O
some	O
populations	O
,	O
most	O
deafness	B-DISEASE
mutations	O
are	O
private	O
and	O
are	O
seen	O
in	O
only	O
a	O
single	O
or	O
few	O
families	O
[	O
4	O
]	O
.	O

E	O
:	O
RFLP	O
analysis	O
for	O
the	O
two	O
mutations	O
in	O
100	O
normal	O
controls	O
out	O
of	O
the	O
family	O
.	O

The	O
isoform	O
a	O
is	O
predicted	O
to	O
be	O
secreted	O
to	O
the	O
extracellular	O
matrix	O
,	O
whereas	O
the	O
isoform	O
b	O
is	O
anchored	O
on	O
the	O
cell	O
membrane	O
.	O

For	O
focused	O
molecular	O
analysis	O
that	O
aims	O
to	O
assist	O
in	O
diagnosis	O
,	O
false	O
negative	O
results	O
due	O
to	O
missed	O
nucleotides	O
must	O
be	O
avoided	O
.	O

Both	O
tagged	O
mutated	O
POLR1C	B-GENE
(	O
N32I	B-VARIANT
and	O
N74S	B-VARIANT
)	O
pulled	O
down	O
amounts	O
of	O
POLR1	O
-	O
specific	O
(	O
POLR1A	O
,	O
1B	O
,	O
1E	O
,	O
CD3EAP	O
,	O
TWISTNB	O
and	O
ZNRD1	O
)	O
and	O
POLR1	O
/	O
POLR3	O
-	O
shared	O
subunits	O
(	O
POLR2E	O
,	O
2F	O
,	O
2H	O
,	O
2K	O
,	O
2L	O
,	O
1C	O
and	O
1D	O
)	O
that	O
were	O
not	O
significantly	O
different	O
from	O
those	O
pulled	O
down	O
by	O
the	O
WT	O
(	O
this	O
is	O
especially	O
true	O
for	O
the	O
POLR1	O
-	O
specific	O
subunits	O
)	O
.	O

WS4	B-DISEASE
or	O
Waardenburg	B-DISEASE
-	I-DISEASE
Shah	I-DISEASE
syndrome	I-DISEASE
has	O
features	O
of	O
Hirschsprung	B-DISEASE
disease	I-DISEASE
in	O
addition	O
to	O
WS2	B-DISEASE
.	O

A	O
clinical	O
and	O
dysmorphological	O
examination	O
of	O
the	O
patients	O
was	O
carried	O
out	O
to	O
exclude	O
non	O
-	O
genetic	O
causes	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
(	O
for	O
example	O
syphilis	O
,	O
toxoplasmosis	O
,	O
cytomegalovirus	O
,	O
injuries	O
etc	O
.	O
)	O
or	O
the	O
presence	O
of	O
SHHL	B-DISEASE
,	O
but	O
no	O
other	O
relevant	O
feature	O
was	O
detected	O
.	O

Further	O
screening	O
of	O
the	O
coding	O
region	O
of	O
FOXI1	B-GENE
itself	O
revealed	O
five	O
further	O
non	O
-	O
synonymous	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT

The	O
ethnicity	O
was	O
determined	O
based	O
on	O
the	O
institutional	O
household	O
records	O
.	O

Plasma	O
amino	O
acids	O
,	O
as	O
well	O
as	O
,	O
lactic	O
acid	O
in	O
blood	O
were	O
within	O
normal	O
range	O
.	O

Pupils	O
were	O
mydriatic	O
with	O
decreased	O
light	O
reflex	O
.	O

Despite	O
modern	O
mobility	O
,	O
secularization	O
,	O
urbanization	O
and	O
immigration	O
in	O
the	O
second	O
half	O
of	O
the	O
20th	O
century	O
,	O
historical	O
founder	O
effects	O
still	O
have	O
a	O
strong	O
impact	O
on	O
medical	O
genetics	O
and	O
public	O
health	O
in	O
Quebec	O
.	O

Figure	O
2	O
shows	O
the	O
distribution	O
of	O
all	O
the	O
pathogenic	O
mutations	O
detected	O
in	O
the	O
present	O
study	O
,	O
along	O
the	O
different	O
domains	O
of	O
the	O
USH2A	B-GENE
protein	O
.	O

A	O
total	O
of	O
four	O
haplotypes	O
of	O
8p23	O
.	O
1	O
may	O
have	O
been	O
inherited	O
in	O
this	O
family	O
,	O
and	O
each	O
parent	O
may	O
have	O
had	O
both	O
under	O
-	O
and	O
over	O
-	O
amplified	O
alleles	O
of	O
8p23	O
.	O
1	O
.	O

C	O
.	O

Retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
is	O
the	O
most	O
common	O
form	O
of	O
hereditary	B-DISEASE
retinal	I-DISEASE
degeneration	I-DISEASE
(	O
HRD	B-DISEASE
)	O
with	O
a	O
worldwide	O
prevalence	O
of	O
1	O
in	O
4	O
,	O
000	O
.	O

However	O
,	O
due	O
to	O
young	O
age	O
of	O
this	O
patient	O
,	O
it	O
remained	O
unsure	O
whether	O
or	O
not	O
she	O
entered	O
puberty	O
later	O
in	O
life	O
.	O

Graphical	O
view	O
of	O
the	O
LOD	O
score	O
calculation	O
from	O
genomewide	O
SNP	O
mapping	O
for	O
this	O
family	O
previous	O
to	O
NGS	O
testing	O
:	O
Genomewide	O
homozygosity	O
mapping	O
prior	O
to	O
NGS	O
did	O
not	O
identify	O
a	O
clear	O
candidate	O
locus	O
.	O

Meta	O
-	O
analyses	O
of	O
larger	O
cohorts	O
are	O
needed	O
for	O
a	O
statistically	O
sound	O
analysis	O
of	O
further	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

Another	O
variant	O
was	O
found	O
in	O
PCDH15	B-GENE
in	O
380	O
out	O
of	O
381	O
reads	O
.	O

In	O
addition	O
,	O
50	O
(	O
race	O
matched	O
)	O
controls	O
with	O
normal	O
hearing	O
were	O
screened	O
for	O
SLC26A4	B-GENE
mutations	O
by	O
DHPLC	O
followed	O
by	O
sequencing	O
analysis	O
.	O

We	O
cannot	O
exclude	O
(	O
1	O
)	O
the	O
possibility	O
of	O
the	O
presence	O
of	O
large	O
rearrangements	O
undetectable	O
by	O
PCR	O
,	O
as	O
has	O
been	O
reported	O
for	O
the	O
PCDH15	B-GENE
gene	O
[	O
21	O
,	O
22	O
]	O
(	O
2	O
)	O
the	O
presence	O
of	O
mutations	O
responsible	O
for	O
clinical	O
type	O
I	O
in	O
USH2	B-DISEASE
genes	O
(	O
3	O
)	O
the	O
presence	O
of	O
mutations	O
located	O
in	O
promoter	O
regions	O
or	O
introns	O
far	O
from	O
the	O
consensus	O
sequences	O
of	O
splicing	O
and	O
(	O
4	O
)	O
mutations	O
associated	O
with	O
USH1	B-DISEASE
in	O
still	O
unknown	O
genes	O
in	O
these	O
unsolved	O
cases	O
.	O

In	O
a	O
total	O
of	O
57	O
consecutive	O
families	O
that	O
were	O
referred	O
to	O
our	O
center	O
during	O
the	O
period	O
of	O
2009	O
to	O
July	O
2011	O
,	O
eight	O
heterozygous	O
mutations	O
were	O
detected	O
in	O
87	O
patients	O
of	O
16	O
families	O
(	O
28	O
,	O
1	O
%	O
)	O
.	O

The	O
c	B-VARIANT
.	I-VARIANT
794T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
does	O
not	O
affect	O
the	O
splicing	O
of	O
ELMOD3	B-GENE
isoforms	O
.	O

The	O
mean	O
+	O
-	O
standard	O
deviation	O
(	O
SD	O
)	O
levels	O
of	O
hearing	B-DISEASE
impairment	I-DISEASE
at	O
250	O
,	O
500	O
,	O
1000	O
,	O
2000	O
,	O
4000	O
,	O
and	O
8000	O
Hz	O
from	O
three	O
older	O
subjects	O
were	O
described	O
(	O
Table	O
1	O
)	O
.	O

Attempts	O
to	O
sequence	O
this	O
GC	O
rich	O
region	O
(	O
chr6	O
:	O
99	O
,	O
282	O
,	O
960	O
-	O
99	O
,	O
283	O
,	O
007	O
)	O
were	O
performed	O
by	O
Sanger	O
sequencing	O
of	O
two	O
different	O
PCR	O
products	O
,	O
as	O
well	O
as	O
providing	O
the	O
purified	O
PCR	O
product	O
to	O
Eurofins	O
Genomics	O
for	O
direct	O
Sanger	O
sequencing	O
using	O
their	O
custom	O
service	O
for	O
difficult	O
templates	O
.	O

It	O
is	O
unclear	O
whether	O
DOA	B-DISEASE
is	O
rare	O
in	O
Chinese	O
or	O
may	O
not	O
be	O
easily	O
recognized	O
in	O
clinics	O
compared	O
to	O
LHON	B-DISEASE
.	O

Thus	O
,	O
although	O
our	O
study	O
included	O
a	O
limited	O
series	O
of	O
patients	O
,	O
we	O
suggest	O
caution	O
in	O
causally	O
relating	O
any	O
hearing	B-DISEASE
impairment	I-DISEASE
to	O
the	O
pathogenic	O
OPA1	B-GENE
-	O
H	O
mutations	O
due	O
to	O
the	O
possible	O
coexistence	O
of	O
unrelated	O
aetiologies	O
.	O

Age	O
and	O
sex	O
corrected	O
audiograms	O
(	O
ISO	O
7029	O
)	O
of	O
RP952	O
and	O
RP1068	O
mutated	O
in	O
GPR98	B-GENE
are	O
represented	O
along	O
with	O
the	O
median	O
audiogram	O
of	O
GPR98	B-GENE
-	O
mutated	O
patients	O
from	O
the	O
Abadie	O
et	O
al	O
.	O

We	O
performed	O
parametric	O
linkage	O
analysis	O
with	O
the	O
R	O
package	O
paramlink	O
[	O
37	O
]	O
.	O

For	O
this	O
,	O
we	O
performed	O
co	O
-	O
immunoprecipitation	O
studies	O
using	O
GFP	O
-	O
and	O
HA	O
-	O
tagged	O
wild	O
type	O
and	O
mutant	O
proteins	O
that	O
were	O
co	O
-	O
expressed	O
in	O
HEK293T	O
cells	O
.	O

In	O
contrast	O
,	O
no	O
mutations	O
were	O
identified	O
in	O
the	O
additional	O
exons	O
of	O
MATN1	B-GENE
,	O
MATN3	B-GENE
,	O
and	O
MATN4	B-GENE
that	O
we	O
screened	O
,	O
which	O
is	O
consistent	O
with	O
our	O
previous	O
studies	O
[	O
Jackson	O
et	O
al	O
.	O
,	O
2004	O
]	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
report	O
that	O
mutations	O
in	O
the	O
beta	O
-	O
subunit	O
KCNE1	B-GENE
are	O
associated	O
with	O
AF	B-DISEASE
.	O

Briefly	O
,	O
search	O
terms	O
included	O
genes	O
associated	O
with	O
CAKUT	B-DISEASE
and	O
/	O
or	O
other	O
kidney	O
related	O
phenotypes	O
such	O
as	O
renal	O
failure	O
,	O
abnormal	O
kidney	O
development	O
,	O
ectopic	O
kidney	O
,	O
atrophic	O
kidney	O
,	O
single	O
kidney	O
,	O
no	O
kidney	O
,	O
and	O
kidney	O
disease	O
.	O

This	O
was	O
done	O
to	O
detect	O
and	O
distinguish	O
the	O
subcellular	O
localization	O
of	O
wild	O
-	O
type	O
and	O
truncated	O
CD164	B-GENE
C	O
-	O
terminal	O
regions	O
simultaneously	O
in	O
the	O
same	O
experiment	O
.	O

A	O
substantial	O
proportion	O
of	O
USH	B-DISEASE
patients	O
thus	O
carry	O
a	O
third	O
,	O
presumably	O
pathogenic	O
mutation	O
which	O
,	O
in	O
some	O
cases	O
,	O
may	O
contribute	O
to	O
worsen	O
the	O
sensory	O
defects	O
resulting	O
from	O
missense	O
mutations	O
present	O
in	O
the	O
"	O
primary	O
"	O
USH	B-DISEASE
gene	O
.	O

Interestingly	O
,	O
the	O
newly	O
reported	O
mutations	O
occur	O
in	O
the	O
editing	O
and	O
near	O
the	O
Leucine	O
-	O
Specific	O
domain	O
,	O
consistent	O
with	O
two	O
of	O
the	O
three	O
previously	O
-	O
reported	O
mutations	O
(	O
Figure	O
1B	O
)	O
.	O

Those	O
with	O
point	O
mutations	O
displayed	O
goiter	B-DISEASE
18	O
)	O
,	O
unilateral	O
megaencephaly	B-DISEASE
with	O
seizures	B-DISEASE
19	O
)	O
,	O
familial	B-DISEASE
urological	I-DISEASE
abnormalities	I-DISEASE
12	O
)	O
,	O
bilateral	O
cataracts	B-DISEASE
,	O
basal	B-DISEASE
ganglia	I-DISEASE
calcification	I-DISEASE
,	O
and	O
psoriasis	B-DISEASE
20	O
)	O
.	O

possibly	O
more	O
than	O
1	O
in	O
4	O
-	O
5	O
individuals	O
[	O
3	O
]	O
.	O

About	O
50	O
%	O
of	O
ND	B-DISEASE
patients	O
show	O
progressive	O
mental	B-DISEASE
disorder	I-DISEASE
,	O
often	O
with	O
psychotic	O
features	O
,	O
and	O
approximately	O
one	O
-	O
third	O
of	O
the	O
cases	O
develop	O
bilateral	O
,	O
progressive	O
,	O
sensorineural	O
deafness	B-DISEASE
in	O
the	O
second	O
decade	O
.	O

Glomerular	B-DISEASE
MH	I-DISEASE
during	O
early	O
childhood	O
is	O
a	O
common	O
feature	O
of	O
a	O
heterogeneous	O
group	O
of	O
inherited	B-DISEASE
hematuric	I-DISEASE
nephropathies	I-DISEASE
.	O

A	O
parametric	O
linkage	O
analysis	O
under	O
a	O
recessive	O
model	O
was	O
performed	O
(	O
using	O
a	O
risk	O
allele	O
frequency	O
0	O
.	O
00001	O
and	O
complete	O
penetrance	O
)	O
using	O
Merlin	O
version	O
1	O
.	O
1	O
.	O
2	O
.	O

No	O
other	O
mutations	O
have	O
been	O
found	O
in	O
GJB2	B-GENE
or	O
GJB6	B-GENE
(	O
including	O
the	O
309	O
-	O
kb	O
deletion	O
)	O
in	O
this	O
largest	O
cohort	O
of	O
patients	O
from	O
this	O
population	O
.	O

The	O
prevalence	O
of	O
USH	B-DISEASE
is	O
estimated	O
at	O
3	O
to	O
6	O
/	O
100	O
,	O
000	O
[	O
6	O
]	O
.	O

in	O
1995	O
)	O
by	O
positional	O
candidate	O
gene	O
approach	O
.	O

Mutation	O
nomenclature	O
is	O
based	O
on	O
HGVS	O
nomenclature	O
guidelines	O
[	O
http	O
:	O
/	O
/	O
www	O
.	O
hgvs	O
.	O
org	O
/	O
mutnomen	O
]	O
[	O
15	O
]	O
.	O

Radiographs	O
of	O
patient	O
1	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
E1006K	I-VARIANT
mutation	O
substituted	O
the	O
negatively	O
charged	O
glutamic	O
acid	O
(	O
E	O
)	O
of	O
the	O
XEX	O
motif	O
at	O
EC10	O
domain	O
to	O
a	O
negatively	O
charged	O
lysine	O
residue	O
.	O

The	O
great	O
heterogeneity	O
comprising	O
NSHL	B-DISEASE
undoubtedly	O
contributes	O
to	O
molecular	O
diagnostic	O
challenges	O
.	O

Detected	O
variants	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
all	O
families	O
.	O

The	O
studies	O
suggest	O
that	O
sequencing	O
of	O
a	O
defined	O
set	O
of	O
genes	O
in	O
patients	O
with	O
glomerular	B-DISEASE
diseases	I-DISEASE
or	O
CAKUT	B-DISEASE
may	O
help	O
in	O
early	O
diagnosis	O
and	O
management	O
particularly	O
in	O
complex	O
cases	O
.	O

Prediction	O
of	O
the	O
effect	O
of	O
missense	O
variants	O
on	O
CDH23	B-GENE
protein	O
function	O
was	O
performed	O
using	O
Polymorphism	O
Phenotyping	O
[	O
PolyPhen2	O
[	O
20	O
]	O
and	O
Protein	O
Variation	O
Effect	O
Analyzer	O
(	O
PROVEAN	O
v1	O
.	O
1	O
.	O
3	O
.	O
)	O
[	O
21	O
]	O
.	O

Most	O
patients	O
with	O
OTOF	B-GENE
mutations	O
have	O
a	O
phenotype	O
of	O
stable	O
prelingual	O
and	O
severe	O
to	O
profound	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Therefore	O
,	O
another	O
possibility	O
could	O
be	O
that	O
the	O
other	O
mutation	O
might	O
lie	O
in	O
an	O
exon	O
that	O
has	O
not	O
been	O
characterized	O
yet	O
.	O

By	O
linkage	O
analysis	O
and	O
further	O
sequence	O
scan	O
,	O
the	O
dentin	O
sialophosphoprotein	O
(	O
DSPP	B-GENE
)	O
gene	O
was	O
identified	O
to	O
be	O
the	O
key	O
gene	O
associated	O
with	O
DGI	B-DISEASE
,	O
especially	O
type	O
II	O
and	O
type	O
III	O
[	O
1	O
]	O
.	O

Both	O
patients	O
with	O
p	B-VARIANT
.	I-VARIANT
W33R	I-VARIANT
developed	O
deafness	B-DISEASE
later	O
.	O

Dr	O
.	O

Functional	O
studies	O
on	O
this	O
EDN3	B-GENE
variant	O
were	O
not	O
performed	O
.	O

The	O
hearing	B-DISEASE
loss	I-DISEASE
could	O
be	O
moderate	O
to	O
profound	O
,	O
bilateral	O
or	O
unilateral	O
,	O
symmetrical	O
or	O
asymmetrical	O
,	O
stable	O
or	O
progressive	O
,	O
pre	O
or	O
post	O
-	O
lingual	O
,	O
syndromic	O
or	O
non	O
syndromic	O
.	O

It	O
was	O
found	O
that	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
137	I-VARIANT
T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
polymorphism	O
decreased	O
the	O
PEX1	B-GENE
gene	O
expression	O
by	O
50	O
%	O
(	O
|	O
)	O
,	O
whereas	O
the	O
c	B-VARIANT
.	I-VARIANT
-	I-VARIANT
53	I-VARIANT
C	I-VARIANT
>	I-VARIANT
G	I-VARIANT
polymorphism	O
increased	O
PEX1	B-GENE
expression	O
by	O
approximately	O
25	O
%	O
(	O
|	O
)	O
when	O
analyzed	O
in	O
a	O
luciferase	O
reporter	O
study	O
[	O
19	O
]	O
.	O

Furthermore	O
,	O
they	O
were	O
initially	O
misdiagnosed	O
as	O
nonsyndromic	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
.	O

Heterozygosity	O
for	O
a	O
pathogenic	O
mutation	O
of	O
any	O
of	O
these	O
genes	O
can	O
be	O
associated	O
with	O
microscopic	B-DISEASE
haematuria	I-DISEASE
,	O
thinning	O
of	O
the	O
glomerular	O
basement	O
membranes	O
and	O
a	O
low	O
,	O
but	O
non	O
-	O
negligible	O
,	O
risk	O
of	O
renal	O
impairment	O
.	O

Based	O
upon	O
the	O
decision	O
reached	O
at	O
Hearing	O
Group	O
Meeting	O
,	O
result	O
letters	O
were	O
generated	O
for	O
all	O
patients	O
,	O
reporting	O
all	O
variants	O
with	O
MAF	O
<	O
1	O
%	O
to	O
the	O
ordering	O
physician	O
.	O

Haplotype	O
analysis	O
of	O
the	O
chromosome	O
segments	O
encompassing	O
arRP	B-DISEASE
genes	O
in	O
those	O
arRP	B-DISEASE
families	O
(	O
A	O
-	O
H	O
)	O
in	O
which	O
the	O
microarray	O
detected	O
one	O
mutated	O
allele	O
.	O

In	O
contrast	O
,	O
only	O
low	O
levels	O
of	O
CD164	B-GENE
R192	B-VARIANT
*	I-VARIANT
were	O
internalized	O
after	O
10	O
and	O
30	O
minutes	O
(	O
Fig	O
4D	O
and	O
4F	O
)	O
.	O

Furthermore	O
,	O
Migliosi	O
et	O
al	O
.	O

Blood	O
samples	O
(	O
3	O
ml	O
)	O
were	O
drawn	O
from	O
18	O
participants	O
for	O
DNA	O
extraction	O
and	O
were	O
used	O
for	O
genetic	O
analysis	O
.	O

(	O
d	O
)	O
Compound	O
heterozygosity	O
for	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
and	O
the	O
novel	O
nonsense	O
mutation	O
p	B-VARIANT
.	I-VARIANT
R155X	I-VARIANT
(	O
patient	O
475	O
)	O
.	O

Tetramers	O
composed	O
of	O
purely	O
wild	O
-	O
type	O
monomers	O
in	O
this	O
family	O
would	O
occur	O
infrequently	O
(	O
1	O
/	O
16	O
)	O
.	O

A	O
c	B-VARIANT
.	I-VARIANT
815	I-VARIANT
-	I-VARIANT
27T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
mutation	O
was	O
identified	O
that	O
is	O
predicted	O
to	O
ablate	O
a	O
consensus	O
branch	O
sequence	O
.	O

Well	O
-	O
conserved	O
retinal	O
architecture	O
was	O
found	O
in	O
the	O
left	O
eye	O
(	O
LE	O
)	O
and	O
the	O
atrophy	B-DISEASE
is	O
restricted	O
to	O
RPE	O
and	O
external	O
layers	O
.	O

More	O
than	O
200	O
pathogenic	O
mutations	O
in	O
the	O
OPA1	B-GENE
gene	O
have	O
been	O
so	O
far	O
described	O
[	O
8	O
]	O
.	O

All	O
families	O
in	O
this	O
study	O
were	O
consanguineous	O
(	O
Table	O
S1	O
)	O
and	O
all	O
patients	O
in	O
these	O
families	O
were	O
diagnosed	O
with	O
severe	O
to	O
profound	O
congenital	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

Alternative	O
strategies	O
include	O
direct	O
sequencing	O
of	O
USH	B-DISEASE
gene	O
coding	O
exons	O
[	O
27	O
-	O
30	O
]	O
.	O

It	O
is	O
predicted	O
that	O
the	O
two	O
compound	O
heterozygous	O
mutations	O
in	O
the	O
same	O
subject	O
caused	O
complete	O
dysfunction	O
of	O
myosin	B-GENE
VIIa	I-GENE
,	O
leading	O
to	O
the	O
observed	O
phenotype	O
in	O
all	O
three	O
affected	O
family	O
members	O
[	O
9	O
]	O
.	O

Each	O
sample	O
had	O
more	O
than	O
98	O
.	O
0	O
%	O
targeted	O
regions	O
covered	O
.	O

L	O
=	O
left	O
.	O

Primers	O
that	O
do	O
not	O
yield	O
PCR	O
products	O
are	O
marked	O
in	O
dark	O
gray	O
.	O

Mice	O
were	O
culled	O
using	O
methods	O
approved	O
by	O
the	O
American	O
Veterinary	O
Medical	O
Association	O
(	O
AVMA	O
)	O
Guidelines	O
for	O
the	O
Euthanasia	O
of	O
Animals	O
.	O

The	O
plasma	O
AMH	O
concentrations	O
were	O
normal	O
in	O
15	O
boys	O
and	O
decreased	O
in	O
12	O
boys	O
.	O

However	O
,	O
in	O
the	O
patient	O
'	O
s	O
replicate	O
2	O
,	O
we	O
only	O
could	O
amplify	O
the	O
smallest	O
fragment	O
.	O

The	O
identification	O
of	O
pathogenic	O
missense	O
variants	O
in	O
high	O
-	O
throughput	O
sequencing	O
data	O
is	O
challenging	O
due	O
to	O
the	O
large	O
number	O
of	O
rare	O
variants	O
of	O
unknown	O
significance	O
and	O
inherent	O
uncertainties	O
associated	O
with	O
in	O
silico	O
based	O
functional	O
prediction	O
.	O

Identified	O
sequence	O
variants	O
were	O
annotated	O
according	O
to	O
the	O
guidelines	O
published	O
by	O
the	O
Human	O
Genome	O
Variation	O
Society	O
.	O

OSBPL2	B-GENE
binds	O
phosphatidylinositol	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
trisphosphate	O
(	O
PtdIns	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
P	O
3	O
)	O
[	O
46	O
]	O
,	O
a	O
phospholipid	O
of	O
the	O
plasma	O
membrane	O
that	O
is	O
crucial	O
for	O
defining	O
neuronal	O
polarity	O
[	O
47	O
,	O
48	O
]	O
,	O
a	O
possible	O
hint	O
that	O
OSBPL2	B-GENE
could	O
be	O
needed	O
to	O
establish	O
and	O
maintain	O
polarity	O
of	O
hair	O
cells	O
.	O

Summary	O
of	O
the	O
number	O
of	O
variants	O
detected	O
in	O
each	O
subject	O
*	O
SNV	O
,	O
single	O
nucleotide	O
variant	O
;	O
MNV	O
,	O
multiple	O
nucleotide	O
variant	O
.	O

The	O
trochanters	O
minor	O
are	O
well	O
ossified	O
and	O
prominent	O
present	O
.	O

The	O
asterisk	O
sign	O
indicates	O
individuals	O
both	O
clinically	O
and	O
genetically	O
examined	O
.	O

The	O
proband	O
is	O
indicated	O
by	O
an	O
arrow	O
.	O

Right	O
foot	O
:	O
central	O
large	O
gap	O
with	O
partial	O
syndactyly	O
of	O
toes	O
3	O
-	O
5	O
,	O
absence	O
of	O
the	O
third	O
phalange	O
of	O
digits	O
2	O
and	O
3	O
.	O

Then	O
,	O
the	O
cohort	O
data	O
were	O
used	O
to	O
mask	O
likely	O
nonpathogenic	O
variants	O
,	O
that	O
is	O
,	O
when	O
variants	O
were	O
present	O
in	O
more	O
than	O
four	O
patients	O
or	O
were	O
more	O
than	O
20	O
bp	O
away	O
from	O
exon	O
boundaries	O
.	O

Subsequently	O
,	O
100	O
mu	O
l	O
of	O
these	O
pools	O
were	O
purified	O
with	O
the	O
High	O
Pure	O
PCR	O
Cleanup	O
Micro	O
Kit	O
(	O
Roche	O
Diagnostics	O
)	O
.	O

Ears	O
were	O
pooled	O
into	O
different	O
classes	O
of	O
PTA	O
.	O

One	O
hundred	O
and	O
eight	O
variants	O
identified	O
in	O
the	O
USH1	B-DISEASE
genes	O
were	O
studied	O
with	O
bioinformatic	O
tools	O
(	O
SpliceView	O
,	O
NNSplice	O
,	O
NetGene2	O
and	O
HSF	O
)	O
in	O
order	O
to	O
analyze	O
the	O
effect	O
of	O
these	O
variants	O
in	O
the	O
splice	O
prediction	O
and	O
the	O
recognition	O
of	O
donor	O
and	O
acceptor	O
sites	O
.	O

None	O
declared	O
.	O

Band	O
B	O
is	O
the	O
skipping	O
of	O
exon	O
42	O
.	O

Signs	O
of	O
motor	B-DISEASE
neuropathy	I-DISEASE
and	O
myopathy	B-DISEASE
were	O
discovered	O
for	O
the	O
first	O
time	O
in	O
IOSCA	B-DISEASE
patients	O
with	O
C10orf2	B-GENE
mutations	O
.	O

The	O
current	O
findings	O
are	O
compatible	O
with	O
our	O
previous	O
report	O
that	O
this	O
mutation	O
is	O
a	O
frequently	O
encountered	O
cause	O
for	O
postlingual	O
deafness	B-DISEASE
in	O
patients	O
who	O
received	O
cochlear	O
implantation	O
[	O
18	O
]	O
.	O

Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
not	O
detected	O
in	O
the	O
Inner	O
Mongolia	O
deaf	O
population	O
.	O

As	O
primary	O
antibodies	O
we	O
used	O
:	O
anti	O
-	O
ORP	O
-	O
2	O
(	O
OSBPL2	B-GENE
)	O
antibody	O
(	O
goat	O
,	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
,	O
sc	O
-	O
66570	O
,	O
dilution	O
1	O
:	O
50	O
)	O
,	O
anti	O
-	O
prestin	O
antibody	O
(	O
rabbit	O
[	O
30	O
]	O
,	O
dilution	O
1	O
:	O
5000	O
)	O
,	O
and	O
anti	O
-	O
otoferlin	O
antibody	O
(	O
rabbit	O
[	O
31	O
]	O
,	O
dilution	O
1	O
:	O
10000	O
)	O
.	O

Eight	O
of	O
the	O
Danish	O
specific	O
mutations	O
were	O
deletions	O
,	O
or	O
frameshift	O
mutations	O
.	O

c	B-VARIANT
.	I-VARIANT
9959	I-VARIANT
-	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
,	O
predicted	O
change	O
at	O
acceptor	O
site	O
1	O
bps	O
downstream	O
:	O
-	O
100	O
.	O
0	O
%	O
(	O
MaxEnt	O
:	O
-	O
100	O
.	O
0	O
%	O
,	O
NNSPLICE	O
:	O
-	O
100	O
.	O
0	O
%	O
,	O
HSF	O
:	O
-	O
100	O
.	O
0	O
%	O
)	O
.	O

Based	O
on	O
stereocilia	O
tip	O
localization	O
,	O
one	O
may	O
hypothesize	O
that	O
CIB2	B-GENE
temporarily	O
sequesters	O
Ca	O
2	O
+	O
entering	O
the	O
stereocilia	O
through	O
MET	O
channels	O
until	O
Ca	O
2	O
+	O
exits	O
the	O
stereocilia	O
through	O
PMCA	O
,	O
35	O
,	O
43	O
-	O
46	O
or	O
is	O
taken	O
up	O
by	O
mitochondria	O
beneath	O
the	O
cuticular	O
plate	O
.	O

RPL	O
is	O
an	O
Investigator	O
of	O
the	O
Howard	O
Hughes	O
Medical	O
Institute	O
.	O

Genotypes	O
were	O
called	O
from	O
cell	O
intensity	O
data	O
by	O
the	O
BRLMM	O
(	O
Bayesian	O
Robust	O
Linear	O
Model	O
with	O
Mahalanobis	O
distance	O
)	O
algorithm	O
implemented	O
in	O
the	O
GeneChip	O
Analysis	O
Software	O
v	O
.	O
4	O
.	O
0	O
(	O
Affymetrix	O
)	O
using	O
default	O
parameter	O
settings	O
.	O

Genomic	O
DNA	O
was	O
immediately	O
isolated	O
from	O
these	O
samples	O
using	O
standard	O
techniques	O
.	O

S	O
,	O
severe	O
;	O
M	O
,	O
moderate	O
.	O

To	O
assess	O
the	O
effect	O
of	O
CACNA1D	B-GENE
mutations	O
on	O
channel	O
function	O
,	O
we	O
expressed	O
wildtype	O
(	O
WT	O
)	O
and	O
mutant	O
Ca	O
V	O
1	O
.	O
3	O
together	O
with	O
beta	O
2	O
(	O
beta	O
2a	O
isoform	O
)	O
and	O
alpha	O
2	O
delta	O
1	O
subunits	O
in	O
HEK293T	O
cells	O
.	O

RT	O
-	O
PCR	O
fragments	O
were	O
purified	O
and	O
directly	O
sequenced	O
.	O

Ajmal	O
.	O

[	O
13	O
]	O
showed	O
that	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
tagged	O
form	O
of	O
myosin	B-GENE
VIIa	I-GENE
containing	O
deletion	O
p	B-VARIANT
.	I-VARIANT
E1716del	I-VARIANT
localizes	O
properly	O
to	O
stereocilia	O
in	O
transfected	O
mouse	O
inner	O
ear	O
hair	O
cells	O
,	O
similarly	O
to	O
the	O
wild	O
-	O
type	O
protein	O
,	O
which	O
argues	O
for	O
the	O
residual	O
functional	O
activity	O
of	O
the	O
altered	O
protein	O
.	O

We	O
prioritized	O
candidate	O
genes	O
based	O
on	O
functional	O
clues	O
,	O
performed	O
pooled	O
DNA	O
sequencing	O
of	O
a	O
patient	O
cohort	O
,	O
and	O
identified	O
novel	O
variants	O
that	O
we	O
predict	O
to	O
be	O
deleterious	O
.	O

Unfortunately	O
,	O
several	O
obstacles	O
remain	O
,	O
including	O
methodologies	O
to	O
handle	O
variants	O
of	O
unknown	O
significance	O
and	O
standardized	O
pipelines	O
and	O
metrics	O
to	O
ensure	O
repeatability	O
and	O
reliability	O
of	O
data	O
.	O

At	O
present	O
,	O
no	O
specific	O
study	O
has	O
reported	O
the	O
complete	O
sequence	O
of	O
MYO7A	B-GENE
and	O
USH2A	B-GENE
,	O
the	O
most	O
common	O
USH	B-DISEASE
genes	O
,	O
involving	O
a	O
large	O
series	O
of	O
Italian	O
patients	O
with	O
USH	B-DISEASE
.	O

Stals	O
and	O
M	O
.	O

Probands	O
with	O
mutations	O
in	O
commonly	O
screened	O
deafness	B-DISEASE
genes	O
GJB2	B-GENE
,	O
SLC26A4	B-GENE
and	O
MT	B-GENE
-	I-GENE
RNR1	I-GENE
were	O
pre	O
-	O
excluded	O
by	O
Sanger	O
sequencing	O
.	O

Detection	O
rates	O
of	O
deafness	O
-	O
associated	O
gene	O
mutations	O
among	O
Uyghur	O
and	O
Han	O
Chinese	O
patients	O
with	O
nonsyndromic	O
deafness	B-DISEASE
Genotypes	O
of	O
prevalent	O
gene	O
mutations	O
in	O
nonsyndromic	O
deafness	B-DISEASE
patients	O
and	O
control	O
subjects	O
of	O
Uyghur	O
and	O
Han	O
Chinese	O
ethnicities	O
The	O
frequency	O
of	O
GJB2	B-GENE
multination	O
was	O
9	O
.	O
05	O
%	O
(	O
18	O
/	O
199	O
)	O
in	O
Uyghur	O
patients	O
,	O
involving	O
three	O
mutations	O
,	O
namely	O
,	O
235delC	B-VARIANT
,	O
35delG	B-VARIANT
,	O
and	O
187delG	B-VARIANT
.	O

Still	O
,	O
we	O
realize	O
that	O
the	O
cellular	O
system	O
used	O
here	O
has	O
limitations	O
,	O
mainly	O
stemming	O
from	O
the	O
single	O
chain	O
overexpression	O
in	O
podocytes	O
and	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

In	O
contrast	O
,	O
this	O
pathology	O
has	O
not	O
been	O
reported	O
in	O
mutant	O
mice	O
carrying	O
a	O
p	B-VARIANT
.	I-VARIANT
Tyr1870Cys	I-VARIANT
mutation	O
responsible	O
for	O
non	O
-	O
progressive	O
stable	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
41	O
]	O
,	O
[	O
46	O
]	O
.	O

Genome	O
-	O
wide	O
SNP	O
genotyping	O
was	O
performed	O
in	O
six	O
members	O
of	O
the	O
family	O
(	O
III	O
-	O
1	O
,	O
III	O
-	O
2	O
,	O
IV	O
-	O
3	O
,	O
IV	O
-	O
5	O
,	O
IV	O
-	O
6	O
,	O
and	O
IV	O
-	O
7	O
)	O
using	O
Affymetrix	O
6	O
.	O
0	O
arrays	O
.	O

(	O
B	O
)	O
Eye	O
fundus	O
photos	O
for	O
optic	O
disc	O
.	O

Up	O
to	O
now	O
more	O
than	O
200	O
pathogenic	O
mutations	O
,	O
along	O
OPA1	B-GENE
coding	O
region	O
,	O
have	O
been	O
associated	O
to	O
human	O
disease	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
monoclonal	O
Anti	O
-	O
FLAG	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
.	O

The	O
dotted	O
line	O
indicated	O
the	O
T	O
-	O
box	O
domain	O
.	O

Only	O
the	O
C725Y	B-VARIANT
mutation	O
lies	O
alone	O
at	O
the	O
TKD	O
C	O
-	O
terminal	O
extremity	O
,	O
among	O
mutations	O
reported	O
in	O
patients	O
with	O
IHH	B-DISEASE
/	O
KS	B-DISEASE
with	O
orofacial	O
features	O
.	O

Moreover	O
,	O
in	O
a	O
recent	O
study	O
involving	O
522	O
patients	O
with	O
CAKUT	B-DISEASE
,	O
72	O
distinct	O
known	O
or	O
novel	O
copy	O
-	O
number	O
variations	O
in	O
87	O
(	O
16	O
.	O
6	O
%	O
)	O
patients	O
were	O
identified	O
,	O
suggesting	O
that	O
kidney	O
malformations	O
can	O
,	O
in	O
part	O
,	O
result	O
from	O
pathogenic	O
genomic	O
imbalances	O
43	O
.	O

A	O
high	O
resolution	O
CT	O
scan	O
of	O
the	O
temporal	O
bone	O
was	O
obtained	O
in	O
one	O
affected	O
person	O
in	O
each	O
family	O
to	O
look	O
for	O
inner	O
ear	O
anomalies	O
.	O

Broken	O
lines	O
to	O
the	O
5	O
th	O
and	O
95	O
th	O
percentiles	O
[	O
16	O
]	O
.	O

As	O
has	O
been	O
pointed	O
by	O
Eisenberger	O
et	O
al	O
.	O
[	O
63	O
]	O
,	O
high	O
and	O
extensive	O
coverage	O
allows	O
for	O
systematic	O
analysis	O
for	O
CNVs	O
and	O
reduces	O
the	O
risk	O
of	O
mutations	O
escaping	O
detection	O
because	O
of	O
their	O
localization	O
in	O
regions	O
with	O
low	O
coverage	O
.	O

She	O
was	O
24	O
years	O
old	O
at	O
her	O
last	O
visit	O
to	O
our	O
hospital	O
and	O
she	O
complained	O
about	O
her	O
rapidly	O
decreased	O
visual	O
acuities	O
.	O

Variants	O
with	O
uncertain	O
pathogenicity	O
were	O
described	O
as	O
'	O
UV2	O
'	O
.	O

Patient	O
ARRP01	O
-	O
IV	O
:	O
3	O
suffered	O
from	O
poor	O
night	O
vision	O
in	O
her	O
early	O
10	O
s	O
,	O
which	O
was	O
relatively	O
early	O
when	O
compared	O
with	O
other	O
patients	O
investigated	O
in	O
this	O
study	O
.	O

Consistent	O
to	O
previous	O
reports	O
that	O
mutations	O
on	O
the	O
ZP	O
domains	O
are	O
associated	O
with	O
mid	B-DISEASE
-	I-DISEASE
frequency	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
the	O
hearing	O
of	O
affected	O
subjects	O
was	O
predominantly	O
affected	O
at	O
the	O
frequency	O
between	O
1000	O
Hz	O
and	O
2000	O
Hz	O
.	O

All	O
relevant	O
data	O
are	O
within	O
the	O
paper	O
and	O
its	O
Supporting	O
Information	O
files	O
.	O

Visual	O
acuity	O
was	O
0	O
.	O
05	O
in	O
both	O
eyes	O
,	O
and	O
he	O
presented	O
with	O
pseudophakia	O
.	O

Circles	O
indicate	O
females	O
,	O
and	O
squares	O
,	O
males	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
MYO15A	B-GENE
mutations	O
in	O
an	O
East	O
Asian	O
population	O
.	O

Schimpf	O
et	O
al	O
.	O

The	O
average	O
of	O
mean	O
depth	O
for	O
all	O
30	O
samples	O
reached	O
71	O
.	O
11	O
+	O
-	O
7	O
.	O
68	O
-	O
fold	O
and	O
the	O
average	O
of	O
coverage	O
at	O
4	O
-	O
and	O
12	O
-	O
fold	O
for	O
all	O
30	O
samples	O
reached	O
98	O
.	O
1	O
%	O
and	O
92	O
.	O
5	O
%	O
respectively	O
.	O

None	O
of	O
the	O
five	O
aforementioned	O
variants	O
identified	O
in	O
this	O
study	O
were	O
detected	O
in	O
any	O
of	O
the	O
hundred	O
normal	O
-	O
hearing	O
Korean	O
participants	O
who	O
were	O
examined	O
as	O
controls	O
.	O

Prior	O
to	O
whole	O
genome	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
mapping	O
all	O
families	O
were	O
pre	O
-	O
screened	O
for	O
mutations	O
in	O
GJB2	B-GENE
by	O
Sanger	O
sequence	O
analysis	O
.	O

(	O
2014b	O
)	O
)	O
,	O
mandating	O
comprehensive	O
TGE	O
+	O
MPS	O
and	O
thorough	O
data	O
analysis	O
.	O

A	O
non	O
-	O
consanguineous	O
three	O
-	O
generation	O
white	O
Brazilian	O
family	O
of	O
European	O
ancestry	O
(	O
14	O
individuals	O
)	O
with	O
Hirschsprung	O
phenotype	O
was	O
included	O
in	O
this	O
study	O
.	O

Novel	O
pathogenic	O
OTOF	B-GENE
mutations	O
in	O
this	O
work	O
.	O

The	O
arrow	O
beside	O
the	O
circles	O
represents	O
the	O
proband	O
.	O

The	O
EGA	O
ID	O
for	O
the	O
exome	O
sequencing	O
data	O
is	O
EGAS00001000167	O
(	O
https	O
:	O
/	O
/	O
www	O
.	O
ebi	O
.	O
ac	O
.	O
uk	O
/	O
ega	O
/	O
)	O
.	O

Additional	O
family	O
members	O
were	O
examined	O
both	O
during	O
the	O
initial	O
diagnostic	O
work	O
up	O
of	O
the	O
proband	O
,	O
and	O
at	O
the	O
time	O
of	O
active	O
contact	O
tracing	O
following	O
the	O
identification	O
of	O
a	O
pathogenic	O
OPA1	B-GENE
mutation	O
.	O

Interestingly	O
,	O
no	O
patient	O
with	O
the	O
p	B-VARIANT
.	I-VARIANT
R1165C	I-VARIANT
mutation	O
in	O
exon	O
27	O
presented	O
extrahematological	O
symptoms	O
.	O

Therefore	O
,	O
the	O
TMPRSS3	B-GENE
patients	O
tended	O
to	O
have	O
somewhat	O
higher	O
scores	O
than	O
the	O
presbyacusis	B-DISEASE
patients	O
at	O
similar	O
PTA	O
1	O
,	O
2	O
,	O
4	O
kHz	O
levels	O
.	O

(	O
b	O
)	O
Wild	O
type	O
and	O
homozygous	O
mutant	O
nucleotide	O
sequence	O
chromatograms	O
of	O
exon	O
3	O
of	O
CLDN14	B-GENE
illustrating	O
homozygosity	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
259_260TC	I-VARIANT
>	I-VARIANT
AT	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ser87Ile	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
281C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ala94Val	I-VARIANT
)	O
mutations	O
(	O
arrows	O
)	O
.	O

In	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
group	O
,	O
ages	O
ranged	O
from	O
8	O
months	O
to	O
29	O
years	O
and	O
the	O
average	O
age	O
was	O
11	O
years	O
.	O

The	O
mutation	O
is	O
classified	O
as	O
probably	O
damaging	O
by	O
Polyphen	O
,	O
is	O
not	O
tolerated	O
by	O
SIFT	O
(	O
Table	O
3	O
)	O
and	O
was	O
not	O
reported	O
before	O
,	O
nor	O
as	O
disease	O
causing	O
mutation	O
nor	O
as	O
a	O
SNP	O
.	O

To	O
identify	O
the	O
causative	O
variant	O
at	O
the	O
AUNX1	B-GENE
locus	O
,	O
we	O
completed	O
exome	O
sequencing	O
of	O
the	O
proband	O
in	O
family	O
AUNX1	B-GENE
.	O

Muscle	O
biopsy	O
appeared	O
unremarkable	O
on	O
light	O
and	O
electron	O
microscopy	O
.	O

17	O
To	O
validate	O
anti	O
-	O
CIB2	B-GENE
antibody	O
(	O
H00010518	O
-	O
A01	O
,	O
Abnova	O
)	O
,	O
we	O
performed	O
a	O
co	O
-	O
localization	O
assay	O
using	O
CIB2	B-GENE
-	O
GFP	O
,	O
DsRed	O
-	O
CIB1	B-GENE
,	O
GFP	O
-	O
CIB3	B-GENE
and	O
GFP	O
-	O
CIB4	B-GENE
transfected	O
COS	O
-	O
7	O
cells	O
(	O
Supplementary	O
Fig	O
.	O

In	O
the	O
control	O
experiment	O
,	O
the	O
anti	O
-	O
MCM2	B-GENE
antibody	O
was	O
omitted	O
.	O

(	O
A	O
-	O
B	O
)	O
Fundus	O
photographies	O
show	O
pale	B-DISEASE
and	I-DISEASE
atrophic	I-DISEASE
papilla	I-DISEASE
,	O
narrowed	O
vessels	O
,	O
diffuse	O
hypopigmentation	B-DISEASE
,	O
bone	B-DISEASE
spicules	I-DISEASE
,	O
and	O
retinal	B-DISEASE
pigment	I-DISEASE
epithelium	I-DISEASE
(	I-DISEASE
RPE	I-DISEASE
)	I-DISEASE
atrophy	I-DISEASE
in	O
the	O
mid	O
-	O
periphery	O
of	O
BE	O
,	O
and	O
a	O
well	O
-	O
defined	O
atrophic	O
macular	O
lesion	O
in	O
the	O
right	O
eye	O
(	O
RE	O
)	O
.	O

Of	O
these	O
,	O
DNA	O
samples	O
from	O
86	O
patients	O
came	O
from	O
DIABGENE	O
Laboratory	O
,	O
IEE	O
SAS	O
.	O

We	O
thank	O
Fatemeh	O
Alasti	O
for	O
providing	O
samples	O
1	O
and	O
2	O
.	O
Competing	O
Interests	O
:	O
The	O
authors	O
have	O
declared	O
that	O
no	O
competing	O
interests	O
exist	O
.	O

The	O
proband	O
and	O
her	O
family	O
were	O
evaluated	O
at	O
the	O
Medical	O
Genetics	O
Clinic	O
,	O
Dr	O
.	O

They	O
included	O
9	O
USH	B-DISEASE
genes	O
,	O
2	O
candidate	O
USH	B-DISEASE
genes	O
(	O
VEZT	B-GENE
and	O
PDZD7	B-GENE
)	O
,	O
seven	O
hearing	B-DISEASE
-	I-DISEASE
loss	I-DISEASE
genes	O
and	O
the	O
choroideremia	B-DISEASE
-	O
causative	O
gene	O
CHM	O
and	O
the	O
sequencing	O
was	O
carried	O
out	O
on	O
Roche	O
GS	O
Junior	O
sequencer	O
.	O

Only	O
the	O
variants	O
with	O
a	O
read	O
depth	O
greater	O
than	O
5	O
were	O
retained	O
.	O

Pedigrees	O
of	O
multiplex	O
families	O
that	O
were	O
employed	O
for	O
calculation	O
of	O
the	O
sibling	O
recurrence	O
risk	O
in	O
this	O
study	O
.	O

Giese	O
,	O
R	O
.	O

Mutant	O
mice	O
lacking	O
EPS8	B-GENE
(	O
Eps8	B-GENE
-	O
/	O
-	O
mice	O
)	O
,	O
which	O
is	O
present	O
in	O
the	O
hair	O
bundle	O
,	O
the	O
sensory	O
antenna	O
of	O
the	O
auditory	O
sensory	O
cells	O
that	O
operate	O
the	O
mechano	O
-	O
electrical	O
transduction	O
,	O
are	O
also	O
profoundly	O
deaf	O
and	O
have	O
abnormally	O
short	O
hair	O
bundle	O
stereocilia	O
.	O

The	O
identification	O
of	O
the	O
BDP1	B-GENE
mutation	O
increases	O
our	O
knowledge	O
of	O
the	O
molecular	O
bases	O
of	O
Nonsyndromic	B-DISEASE
Hereditary	I-DISEASE
Hearing	I-DISEASE
Loss	I-DISEASE
and	O
provides	O
new	O
opportunities	O
for	O
the	O
diagnosis	O
and	O
treatment	O
of	O
this	O
disease	O
in	O
the	O
Qatari	O
population	O
.	O

These	O
alpha	O
1	O
subunits	O
contain	O
4	O
repeated	O
domains	O
(	O
I	O
-	O
IV	O
)	O
(	O
Fig	O
.	O

Competing	O
financial	O
interests	O
The	O
authors	O
report	O
no	O
competing	O
financial	O
interests	O
.	O

The	O
subject	O
with	O
a	O
history	O
of	O
near	O
drowning	O
performed	O
in	O
the	O
borderline	O
range	O
.	O

(	O
C	O
)	O
Air	O
-	O
conduction	O
audiometric	O
curves	O
for	O
patients	O
IV	O
.	O
4	O
(	O
open	O
blue	O
circles	O
)	O
and	O
IV	O
.	O
5	O
(	O
closed	O
green	O
diamonds	O
)	O
at	O
the	O
ages	O
of	O
11	O
and	O
7	O
years	O
,	O
respectively	O
.	O

These	O
signs	O
can	O
be	O
isolated	O
(	O
isolated	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
(	O
HH	B-DISEASE
)	O
)	O
[	O
1	O
]	O
or	O
associated	O
with	O
symptoms	O
like	O
hypoglycemia	O
,	O
jaundice	O
and	O
decreased	O
growth	O
rate	O
in	O
cases	O
where	O
hypogonadotropic	B-DISEASE
hypogonadism	I-DISEASE
is	O
associated	O
with	O
other	O
hypothalamic	B-DISEASE
-	I-DISEASE
pituitary	I-DISEASE
deficiencies	I-DISEASE
[	O
2	O
]	O
.	O

Written	O
informed	O
consent	O
for	O
participation	O
in	O
the	O
study	O
was	O
obtained	O
from	O
participants	O
or	O
from	O
a	O
parent	O
/	O
guardian	O
in	O
the	O
case	O
of	O
child	O
participants	O
(	O
SH23	O
-	O
52	O
)	O
.	O

The	O
amplicons	O
from	O
individual	O
exon	O
were	O
purified	O
and	O
analyzed	O
by	O
cycle	O
sequencing	O
with	O
ABI	O
BigDye	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
v3	O
.	O
1	O
(	O
ABI	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
on	O
an	O
automatic	O
DNA	O
sequencer	O
(	O
ABI	O
3100	O
Genetic	O
Analyzer	O
,	O
Applied	O
Biosystems	O
)	O
.	O

However	O
,	O
it	O
is	O
of	O
utmost	O
importance	O
to	O
raise	O
awareness	O
about	O
the	O
possibility	O
that	O
congenital	B-DISEASE
deafness	I-DISEASE
reveals	O
USH	B-DISEASE
,	O
because	O
early	O
diagnosis	O
of	O
this	O
dual	O
sensory	B-DISEASE
disorder	I-DISEASE
is	O
crucial	O
and	O
urges	O
on	O
cochlear	O
implant	O
in	O
the	O
affected	O
children	O
.	O

[	O
10	O
]	O
,	O
CRB1	B-GENE
from	O
Vallesp	O
i	O
n	O
et	O
al	O
.	O

One	O
novel	O
mutation	O
in	O
actin	O
gamma	O
1	O
(	O
ACTG1	B-GENE
)	O
was	O
identified	O
,	O
consisting	O
of	O
a	O
methionine	O
to	O
threonine	O
substitution	O
at	O
amino	O
acid	O
305	O
(	O
p	B-VARIANT
.	I-VARIANT
M305T	I-VARIANT
)	O
,	O
This	O
candidate	O
variant	O
was	O
validated	O
by	O
Sanger	O
sequencing	O
and	O
co	O
-	O
segregated	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
all	O
family	O
members	O
(	O
Figure	O
4	O
A	O
and	O
B	O
)	O
.	O

1A	O
)	O
,	O
yielded	O
on	O
average	O
5	O
.	O
2	O
Gb	O
high	O
quality	O
sequence	O
data	O
per	O
exome	O
,	O
with	O
about	O
98	O
.	O
9	O
%	O
coverage	O
of	O
the	O
target	O
and	O
a	O
70	O
x	O
mean	O
coverage	O
(	O
range	O
51	O
x	O
-	O
81	O
x	O
)	O
,	O
with	O
more	O
than	O
93	O
%	O
of	O
target	O
covered	O
>	O
10	O
x	O
(	O
Supplementary	O
Table	O
S1	O
)	O
.	O

The	O
1933bp	O
DSPP	B-GENE
allele	O
containing	O
whole	O
exon3	O
-	O
intron3	O
-	O
exon4	O
and	O
partial	O
intron	O
2	O
and	O
intron	O
4	O
was	O
amplified	O
by	O
PCR	O
with	O
the	O
following	O
primers	O
:	O
DSPP1933_L_MunI	O
:	O
CCCCAATTGTCTGGTCACGCCTCCTGTTC	O
and	O
DSPP1933_R_XhoI	O
:	O
CCGCTCGAGCATCCTGGTGCTTAGATTCCTT	O
.	O

TGE	O
+	O
MPS	O
were	O
completed	O
on	O
DNA	O
prepared	O
from	O
whole	O
blood	O
using	O
a	O
Sciclone	O
NGS	O
workstation	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
for	O
sample	O
preparation	O
.	O

We	O
have	O
previously	O
established	O
a	O
screening	O
strategy	O
focusing	O
on	O
recurrent	O
mutations	O
and	O
demonstrated	O
its	O
benefits	O
for	O
clinical	O
application	O
[	O
2	O
]	O
.	O

Wolfram	B-GENE
syndrome	I-GENE
gene	I-GENE
1	I-GENE
(	O
WFS1	B-GENE
)	O
accounts	O
for	O
most	O
of	O
the	O
familial	B-DISEASE
nonsyndromic	I-DISEASE
low	I-DISEASE
-	I-DISEASE
frequency	I-DISEASE
sensorineural	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
LFSNHL	B-DISEASE
)	O
which	O
is	O
characterized	O
by	O
sensorineural	B-DISEASE
hearing	I-DISEASE
losses	I-DISEASE
equal	O
to	O
and	O
below	O
2000	O
Hz	O
.	O

We	O
are	O
able	O
to	O
complete	O
the	O
screening	O
in	O
a	O
relatively	O
short	O
period	O
of	O
time	O
.	O

"	O
This	O
will	O
initiate	O
the	O
download	O
of	O
a	O
pdf	O
file	O
that	O
contains	O
the	O
information	O
.	O

The	O
'	O
Acadian	O
allele	O
'	O
,	O
c	B-VARIANT
.	I-VARIANT
216G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
R155X	I-VARIANT
are	O
both	O
located	O
on	O
the	O
most	O
prevalent	O
haplotype	O
predicted	O
to	O
account	O
for	O
50	O
%	O
of	O
haplotypes	O
.	O

E	O
:	O
Activation	O
rise	O
time	O
,	O
determined	O
as	O
the	O
time	O
to	O
1	O
/	O
2	O
max	O
following	O
a	O
depolarization	O
to	O
0	O
or	O
+	O
20	O
mV	O
.	O

These	O
criteria	O
give	O
a	O
positive	O
predictive	O
value	O
for	O
WS	B-DISEASE
of	O
83	O
%	O
and	O
a	O
negative	O
predictive	O
value	O
of	O
1	O
%	O
[	O
2	O
]	O
.	O

The	O
mutation	O
spectrum	O
of	O
SLC26A4	B-GENE
varies	O
widely	O
among	O
ethnic	O
groups	O
[	O
12	O
]	O
.	O

The	O
cohort	O
includes	O
all	O
such	O
patients	O
diagnosed	O
in	O
Melbourne	O
from	O
1992	O
to	O
2007	O
,	O
with	O
the	O
exception	O
of	O
9	O
patients	O
from	O
whom	O
no	O
suitable	O
DNA	O
was	O
available	O
for	O
sequencing	O
.	O

ELMOD3	B-GENE
targeting	O
and	O
localization	O
with	O
F	O
-	O
actin	O
is	O
affected	O
by	O
the	O
DFNB88	B-GENE
allele	O
.	O

Dai	O
et	O
al	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
P	O
XG	O
and	O
GJW	O
are	O
co	O
-	O
first	O
authors	O
on	O
this	O
work	O
.	O

Resultantly	O
,	O
among	O
the	O
236	O
subjects	O
,	O
93	O
subjects	O
who	O
consented	O
to	O
the	O
molecular	O
genetic	O
test	O
and	O
went	O
through	O
at	O
least	O
one	O
molecular	O
genetic	O
test	O
were	O
finally	O
included	O
.	O

7	O
.	O
9	O
+	O
-	O
4	O
.	O
2	O
years	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
with	O
a	O
lower	O
prevalence	O
of	O
ketoacidosis	B-DISEASE
(	O
7	O
vs	O
.	O

For	O
the	O
probands	O
from	O
the	O
193	O
families	O
,	O
155	O
were	O
sporadic	O
cases	O
,	O
and	O
38	O
had	O
a	O
family	O
history	O
of	O
hereditary	O
optic	B-DISEASE
neuropathy	I-DISEASE
;	I-DISEASE
132	O
were	O
male	O
,	O
and	O
61	O
were	O
female	O
.	O

Large	O
-	O
scale	O
genetic	O
studies	O
make	O
clear	O
that	O
the	O
origins	O
of	O
ASD	B-DISEASE
risk	O
are	O
multifarious	O
,	O
and	O
recent	O
estimates	O
based	O
on	O
CNV	O
data	O
put	O
the	O
number	O
of	O
independent	O
risk	O
loci	O
in	O
the	O
hundreds	O
4	O
.	O

Furthermore	O
,	O
our	O
study	O
suggests	O
that	O
compound	O
heterozygosity	O
for	O
a	O
mild	O
and	O
severe	O
mutation	O
leads	O
to	O
postlingual	O
hearing	B-DISEASE
impairment	I-DISEASE
.	O

Hildebrand	O
et	O
al	O
.	O

We	O
also	O
thank	O
P	O
.	O

Existing	O
common	O
methods	O
to	O
diagnose	O
AS	B-DISEASE
include	O
DHPLC	O
and	O
Sanger	O
sequencing	O
.	O

Audiometric	O
studies	O
showed	O
low	O
-	O
frequency	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

In	O
female	O
XLAS	B-DISEASE
patients	O
,	O
the	O
explanation	O
for	O
the	O
wide	O
variability	O
in	O
outcomes	O
is	O
uncertain	O
,	O
as	O
genotype	O
-	O
phenotype	O
correlation	O
has	O
not	O
been	O
observed	O
.	O

Several	O
explanations	O
are	O
possible	O
for	O
deafness	B-DISEASE
in	O
this	O
child	O
:	O
he	O
may	O
carry	O
a	O
second	O
MYO7A	B-GENE
mutation	O
located	O
within	O
an	O
intron	O
or	O
in	O
a	O
regulatory	O
region	O
,	O
which	O
therefore	O
we	O
failed	O
to	O
detect	O
;	O
alternatively	O
,	O
his	O
deafness	B-DISEASE
may	O
be	O
due	O
to	O
mutation	O
(	O
s	O
)	O
in	O
a	O
different	O
gene	O
(	O
independent	O
segregation	O
of	O
mutations	O
in	O
more	O
than	O
one	O
deafness	B-DISEASE
-	O
causing	O
gene	O
within	O
the	O
same	O
family	O
has	O
been	O
previously	O
reported	O
[	O
4	O
]	O
)	O
.	O

Secondly	O
,	O
hybridization	O
based	O
enrichment	O
suffers	O
from	O
selection	O
bias	O
and	O
uneven	O
capture	O
efficiency	O
.	O

Numbering	O
commenced	O
with	O
the	O
A	O
of	O
the	O
ATG	O
initiation	O
codon	O
as	O
+	O
1	O
.	O

The	O
beta	O
-	O
satellite	O
insertion	O
in	O
TMPRSS3	B-GENE
was	O
analysed	O
by	O
PCR	O
,	O
as	O
published	O
[	O
5	O
]	O
.	O

Vector	O
NTI	O
Advance	O
11	O
software	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
was	O
applied	O
to	O
evaluate	O
the	O
evolutionary	O
conservation	O
of	O
the	O
mutated	O
amino	O
acids	O
through	O
alignment	O
of	O
the	O
MYO7A	B-GENE
orthologous	O
protein	O
sequences	O
of	O
the	O
following	O
species	O
:	O
Homo	O
sapiens	O
(	O
ENSP00000386331	O
)	O
,	O
Pan	O
troglodytes	O
(	O
ENSPTRP00000007055	O
)	O
,	O
Canis	O
lupus	O
familiaris	O
(	O
ENSCAFP00000007721	O
)	O
,	O
Bos	O
taurus	O
(	O
ENSBTAP00000005191	O
)	O
,	O
Sus	O
scrofa	O
(	O
ENSSSCP00000015796	O
)	O
,	O
Mus	O
musculus	O
(	O
ENSMUSP00000102745	O
)	O
,	O
Gallus	O
gallus	O
(	O
ENSGALP00000001044	O
)	O
,	O
Danio	O
rerio	O
(	O
ENSDARP00000083378	O
)	O
,	O
Drosophila	O
melanogaster	O
(	O
FBpp0080282	O
)	O
,	O
and	O
Caenorhabditis	O
elegans	O
(	O
T10H10	O
.	O
1	O
)	O
.	O

Further	O
detailed	O
functional	O
studies	O
are	O
needed	O
to	O
provide	O
further	O
insights	O
to	O
this	O
inherited	O
disease	O
.	O

This	O
mutation	O
was	O
tested	O
in	O
five	O
members	O
of	O
family	O
F3	O
,	O
including	O
the	O
affected	O
father	O
and	O
his	O
four	O
children	O
,	O
one	O
affected	O
son	O
15	O
years	O
old	O
,	O
one	O
son	O
under	O
the	O
age	O
of	O
onset	O
,	O
and	O
two	O
apparently	O
unaffected	O
daughters	O
in	O
their	O
early	O
20s	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
two	O
novel	O
mutations	O
,	O
p	B-VARIANT
.	I-VARIANT
S2161F	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
R2146Q	I-VARIANT
,	O
which	O
are	O
located	O
in	O
the	O
MyTH4	O
domain	O
.	O

According	O
to	O
the	O
present	O
data	O
,	O
screening	O
for	O
OTOF	B-GENE
is	O
necessary	O
not	O
only	O
for	O
the	O
patients	O
diagnosed	O
with	O
ANSD	B-DISEASE
,	O
but	O
also	O
should	O
be	O
extended	O
to	O
ARNSHL	B-DISEASE
cases	O
.	O

Family	O
4	O
.	O

If	O
necessary	O
,	O
we	O
requested	O
samples	O
of	O
family	O
members	O
after	O
informed	O
consent	O
was	O
obtained	O
.	O

are	O
supported	O
by	O
a	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
,	O
Australia	O
project	O
grant	O
(	O
APP1068278	O
)	O
.	O

Funding	O
:	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
grants	O
from	O
the	O
Science	O
and	O
Technology	O
Commission	O
of	O
Shanghai	O
Municipality	O
(	O
Grant	O
No	O
.	O

241995	O
)	O
.	O

Also	O
,	O
it	O
is	O
near	O
-	O
impossible	O
to	O
identify	O
pathogenic	O
mutations	O
by	O
traditional	O
linkage	O
analysis	O
when	O
DNA	O
is	O
available	O
from	O
only	O
small	O
families	O
.	O

traurus	O
,	O
M	O
.	O

The	O
genes	O
selected	O
for	O
this	O
study	O
resulted	O
from	O
searches	O
of	O
public	O
databases	O
such	O
as	O
PUBMED	O
and	O
GUDMAP	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
gudmap	O
.	O
org	O
/	O
)	O
and	O
abstracts	O
as	O
of	O
2010	O
(	O
Figure	O
1a	O
)	O
.	O

In	O
vivo	O
retinal	O
imaging	O
was	O
performed	O
by	O
the	O
Heidelberg	O
OCT	O
(	O
Heidelberg	O
Engineering	O
)	O
,	O
followed	O
by	O
fundus	O
auto	O
-	O
fluorescence	O
(	O
FAF	O
)	O
and	O
began	O
in	O
2009	O
,	O
thus	O
some	O
patients	O
did	O
not	O
receive	O
this	O
testing	O
until	O
after	O
their	O
molecular	O
diagnosis	O
was	O
confirmed	O
.	O

We	O
thank	O
the	O
staff	O
(	O
Mark	O
Haynes	O
,	O
Linda	O
Breuklander	O
,	O
Shantay	O
Brown	O
,	O
Libby	O
Beach	O
)	O
of	O
the	O
Pediatric	O
Clinical	O
Research	O
Unit	O
at	O
Washington	O
University	O
and	O
St	O
.	O

(	O
C	O
)	O
Dual	O
COX	O
-	O
SDH	O
histochemistry	O
performed	O
on	O
20	O
u	O
m	O
thick	O
cryostat	O
sections	O
showing	O
the	O
presence	O
of	O
COX	O
-	O
deficient	O
muscle	O
fibres	O
(	O
33	O
/	O
1100	O
,	O
3	O
.	O
00	O
%	O
)	O
.	O

Additional	O
Supporting	O
Information	O
may	O
be	O
found	O
in	O
the	O
online	O
version	O
of	O
this	O
article	O
:	O
Figure	O
S1	O
.	O

70	O
of	O
the	O
130	O
families	O
that	O
were	O
enrolled	O
in	O
the	O
study	O
had	O
2	O
or	O
more	O
affected	O
individuals	O
,	O
the	O
remaining	O
being	O
made	O
up	O
of	O
sporadic	O
cases	O
.	O

For	O
MA20	O
,	O
family	O
history	O
suggested	O
RP	B-DISEASE
with	O
recessive	O
inheritance	O
due	O
to	O
an	O
autozygous	O
mutation	O
.	O

This	O
mutation	O
was	O
found	O
in	O
all	O
the	O
affected	O
members	O
of	O
this	O
family	O
that	O
exhibited	O
LFSNHL	B-DISEASE
(	O
Figure	O
2c	O
)	O
,	O
but	O
not	O
in	O
any	O
of	O
the	O
control	O
subjects	O
,	O
nor	O
was	O
it	O
present	O
in	O
the	O
respective	O
WFS1	B-GENE
gene	O
products	O
of	O
Mus	O
sp	O
.	O

Therefore	O
,	O
it	O
is	O
not	O
surprising	O
that	O
we	O
found	O
one	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
homozygote	O
among	O
40	O
Canadian	O
USH	B-DISEASE
patients	O
,	O
and	O
one	O
compound	O
p	B-VARIANT
.	I-VARIANT
Y176X	I-VARIANT
/	O
p	B-VARIANT
.	I-VARIANT
N48K	I-VARIANT
heterozygote	O
in	O
Finland	O
.	O

We	O
applied	O
both	O
whole	O
gene	O
sequencing	O
and	O
MLPA	O
analysis	O
for	O
the	O
detection	O
of	O
point	O
mutations	O
and	O
copy	O
number	O
variations	O
in	O
the	O
genes	O
PAX3	B-GENE
and	O
MITF	B-GENE
,	O
and	O
describe	O
19	O
mutations	O
,	O
of	O
which	O
15	O
have	O
not	O
been	O
previously	O
reported	O
for	O
patients	O
with	O
features	O
of	O
WS	B-DISEASE
.	O

22	O
Moreover	O
,	O
nonsynchronous	O
regional	O
ventricular	O
contraction	O
resulting	O
from	O
intraventricular	O
conduction	O
delay	O
consequent	O
to	O
the	O
KCNQ1	B-GENE
mutation	O
might	O
offer	O
a	O
mechanical	O
explanation	O
for	O
cardiac	B-DISEASE
dysfunction	I-DISEASE
.	O

Allele	O
-	O
specific	O
sequencing	O
of	O
a	O
fragment	O
of	O
exon	O
8	O
allowed	O
the	O
identification	O
of	O
a	O
novel	O
16	O
bp	O
deletion	O
,	O
1355	B-VARIANT
-	I-VARIANT
1370delAGC	I-VARIANT
CCT	I-VARIANT
ACA	I-VARIANT
CGC	I-VARIANT
GCA	I-VARIANT
G	I-VARIANT
(	I-VARIANT
c	I-VARIANT
.	I-VARIANT
1354del16	I-VARIANT
)	O
,	O
that	O
predicts	O
the	O
introduction	O
of	O
a	O
premature	O
stop	O
signal	O
65	O
codons	O
downstream	O
,	O
P451fsX515	B-VARIANT
(	O
Figure	O
4	O
)	O
.	O

Figure	O
S5	O
shows	O
representative	O
images	O
of	O
membrane	O
expression	O
patterns	O
of	O
the	O
10	O
mutant	O
pendrins	O
.	O

RNA	O
from	O
a	O
cell	O
line	O
heterozygous	O
for	O
the	O
c	B-VARIANT
.	I-VARIANT
1191delT	I-VARIANT
mutation	O
was	O
analysed	O
by	O
RT	O
-	O
PCR	O
and	O
sequenced	O
(	O
A	O
)	O
.	O

For	O
instance	O
,	O
a	O
patient	O
with	O
a	O
germline	O
frameshift	O
mutation	O
(	O
M723fs	B-VARIANT
)	O
in	O
PALB2	B-GENE
also	O
harbored	O
a	O
somatic	O
nonsense	O
mutation	O
(	O
Q378	B-VARIANT
*	I-VARIANT
)	O
and	O
another	O
patient	O
with	O
a	O
germline	O
nonsense	O
variant	O
(	O
Q153	B-VARIANT
*	I-VARIANT
)	O
in	O
CDK5RAP1	B-GENE
acquired	O
a	O
somatic	O
splice	O
site	O
mutation	O
in	O
that	O
gene	O
(	O
e9	O
-	O
2	O
)	O
.	O

A	O
multiphasic	O
analysis	O
of	O
WES	O
data	O
.	O

These	O
truncated	O
mRNAs	O
are	O
unstable	O
and	O
get	O
degraded	O
by	O
specific	O
pathways	O
,	O
that	O
is	O
,	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
,	O
which	O
are	O
in	O
-	O
built	O
protective	O
cellular	O
mechanisms	O
against	O
mutant	O
proteins	O
with	O
possible	O
dominant	O
negative	O
effect	O
[	O
42	O
,	O
46	O
,	O
47	O
]	O
.	O

In	O
the	O
wild	O
type	O
H170	O
side	O
chain	O
is	O
pointing	O
away	O
from	O
the	O
core	O
and	O
the	O
resulting	O
side	O
chain	O
is	O
solvent	O
accessible	O
whilst	O
the	O
asparagine	O
side	O
chain	O
170	O
in	O
the	O
mutated	O
form	O
of	O
GIPC3	B-GENE
points	O
inwards	O
towards	O
the	O
hydrophobic	O
core	O
and	O
forms	O
a	O
tight	O
network	O
of	O
H	O
-	O
bonds	O
.	O

Patient	O
:	O
macrothrombocytopenia	B-DISEASE
,	O
platelet	O
count	O
:	O
90	O
x	O
10	O
9	O
/	O
L	O
,	O
hearing	B-DISEASE
loss	I-DISEASE
onset	O
at	O
10	O
years	O
,	O
menometrorrhagias	B-DISEASE
.	O

The	O
authors	O
thank	O
all	O
participants	O
in	O
this	O
study	O
for	O
their	O
cooperation	O
.	O

Antibodies	O
included	O
NDUFS4	B-GENE
(	O
MS104	O
,	O
Mitosciences	O
)	O
at	O
1	O
:	O
1000	O
,	O
Porin	O
(	O
529534	O
,	O
Calbiochem	O
)	O
at	O
1	O
:	O
10000	O
,	O
Complex	O
II	O
70kD	O
subunit	O
(	O
A	O
-	O
1142	O
.	O

Our	O
study	O
showed	O
that	O
exome	O
sequencing	O
is	O
a	O
fast	O
,	O
sensitive	O
,	O
and	O
relatively	O
low	O
-	O
cost	O
method	O
to	O
identify	O
gene	O
(	O
s	O
)	O
responsible	O
for	O
AS	B-DISEASE
.	O

We	O
are	O
very	O
grateful	O
to	O
all	O
participating	O
patients	O
and	O
their	O
relatives	O
.	O

Most	O
of	O
the	O
reported	O
EYA4	B-GENE
mutations	O
produce	O
truncated	O
proteins	O
missing	O
a	O
part	O
of	O
the	O
EYA	O
homolog	O
domain	O
[	O
25	O
]	O
.	O

Two	O
are	O
novel	O
missense	O
substitutions	O
(	O
p	B-VARIANT
.	I-VARIANT
Ser87Ile	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Ala94Val	I-VARIANT
)	O
while	O
p	B-VARIANT
.	I-VARIANT
Arg81His	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Val85Asp	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
Met133ArgfsX23	I-VARIANT
have	O
been	O
reported	O
previously	O
.	O

Of	O
these	O
,	O
142	O
were	O
new	O
TCGA	O
cases	O
and	O
287	O
cases	O
were	O
previously	O
reported	O
4	O
;	O
the	O
remaining	O
twenty	O
-	O
nine	O
cases	O
reported	O
in	O
that	O
study	O
4	O
did	O
not	O
meet	O
our	O
coverage	O
requirement	O
(	O
>	O
=	O
20x	O
coverage	O
for	O
at	O
least	O
50	O
%	O
of	O
target	O
exons	O
)	O
and	O
were	O
excluded	O
from	O
this	O
analysis	O
.	O

In	O
addition	O
,	O
both	O
polymorphisms	O
were	O
found	O
to	O
cosegregate	O
with	O
the	O
2097_2098insT	B-VARIANT
mutation	O
[	O
19	O
]	O
.	O

We	O
also	O
searched	O
for	O
the	O
previously	O
reported	O
684	O
kb	O
deletion	O
in	O
PCDH15	B-GENE
using	O
the	O
reported	O
primers	O
[	O
44	O
]	O
.	O

Details	O
of	O
neurological	O
and	O
genetic	O
findings	O
from	O
all	O
subjects	O
are	O
summarized	O
in	O
Supplementary	O
Table	O
1	O
,	O
whereas	O
clinical	O
and	O
audiological	O
results	O
are	O
reported	O
in	O
Supplementary	O
Table	O
2	O
and	O
Table	O
1	O
,	O
for	O
the	O
OPA1	B-GENE
-	O
H	O
and	O
OPA1	B-GENE
-	O
M	O
groups	O
.	O

However	O
,	O
Sanger	O
sequencing	O
of	O
these	O
genes	O
did	O
not	O
reveal	O
any	O
pathogenic	O
variants	O
.	O

An	O
audiometric	O
test	O
performed	O
in	O
patients	O
from	O
the	O
Tunisian	O
family	O
showed	O
severe	O
to	O
profound	O
bilateral	O
sensorineural	O
HL	B-DISEASE
.	O

Red	O
proteins	O
show	O
a	O
level	O
of	O
differential	O
interaction	O
with	O
POLR1C	B-GENE
that	O
is	O
statistically	O
significant	O
,	O
while	O
blue	O
proteins	O
do	O
not	O
.	O

Loss	O
of	O
Gipc1	B-GENE
function	O
(	O
Gipc1	B-GENE
tm1Mvc	O
)	O
results	O
in	O
a	O
reduction	B-DISEASE
in	I-DISEASE
pre	I-DISEASE
-	I-DISEASE
and	I-DISEASE
postsynaptic	I-DISEASE
transmission	I-DISEASE
in	I-DISEASE
hippocampal	I-DISEASE
neurons	I-DISEASE
19	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
MS	O
TMS	O
HK	O
RQ	O
.	O

Articulation	O
-	O
gain	O
curves	O
from	O
OPA1	B-GENE
patients	O
were	O
compared	O
to	O
the	O
mean	O
functions	O
with	O
95	O
%	O
confidence	O
limits	O
,	O
calculated	O
for	O
each	O
class	O
of	O
PTA	O
for	O
a	O
large	O
sample	O
of	O
subjects	O
,	O
including	O
normally	O
-	O
hearing	O
individuals	O
(	O
394	O
ears	O
,	O
range	O
18	O
-	O
50	O
years	O
)	O
and	O
patients	O
with	O
cochlear	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
583	O
ears	O
,	O
range	O
18	O
-	O
50	O
years	O
)	O
,	O
submitted	O
to	O
audiometric	O
evaluation	O
at	O
our	O
department	O
over	O
the	O
past	O
8	O
years	O
.	O

In	O
general	O
,	O
these	O
findings	O
raise	O
the	O
question	O
regarding	O
potential	O
mechanisms	O
involved	O
in	O
the	O
effect	O
of	O
different	O
subunit	O
mutations	O
of	O
the	O
same	O
proton	O
pump	O
over	O
hearing	O
ability	O
[	O
9	O
]	O
.	O

The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Prenatal	O
diagnosis	O
is	O
possible	O
analyzing	O
DNA	O
extracted	O
from	O
fetal	O
cells	O
by	O
amniocentesis	O
at	O
approximately	O
15	O
-	O
18	O
weeks	O
gestation	O
or	O
chorionic	O
villus	O
sampling	O
at	O
approximately	O
10	O
-	O
12	O
weeks	O
gestation	O
.	O

Variations	O
were	O
named	O
following	O
the	O
nomenclature	O
recommended	O
by	O
the	O
Human	O
Genomic	O
Variation	O
Society	O
(	O
HGVS	O
)	O
.	O

The	O
neutralized	O
DNA	O
was	O
desalted	O
and	O
concentrated	O
on	O
a	O
QIAquick	O
MinElute	O
column	O
and	O
eluted	O
into	O
30	O
u	O
L	O
EB	O
buffer	O
.	O

The	O
RESCUE	O
-	O
ESE	O
program	O
also	O
predicted	O
a	O
new	O
binding	O
site	O
.	O

Exon	O
libraries	O
were	O
sequenced	O
with	O
the	O
Illumina	O
Hiseq	O
2000	O
platform	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Illumina	O
)	O
,	O
providing	O
108	O
-	O
122	O
average	O
depth	O
for	O
each	O
sample	O
.	O

Despite	O
significant	O
advances	O
in	O
the	O
understanding	O
of	O
monogenic	O
deafness	B-DISEASE
,	O
the	O
molecular	O
genetics	O
of	O
the	O
more	O
common	O
and	O
complex	O
forms	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
poorly	O
characterized	O
.	O

Novel	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
2A	I-GENE
(	O
USH2A	B-GENE
)	O
compound	O
heterozygous	O
mutations	O
,	O
c	B-VARIANT
.	I-VARIANT
4325T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
F1442S	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
15188T	I-VARIANT
>	I-VARIANT
G	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
L5063R	I-VARIANT
)	O
,	O
located	O
in	O
exons	O
20	O
and	O
70	O
,	O
respectively	O
,	O
were	O
identified	O
as	O
probable	O
causative	O
mutations	O
for	O
RP	B-DISEASE
in	O
this	O
family	O
.	O

2001	O
)	O
.	O

6j	O
)	O
.	O

Although	O
historically	O
this	O
heterogeneity	O
restricted	O
genetic	O
testing	O
to	O
just	O
a	O
few	O
genes	O
(	O
Hilgert	O
et	O
al	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Asp2006Tyr	I-VARIANT
of	O
alpha	B-GENE
-	I-GENE
tectorin	I-GENE
and	O
p	B-VARIANT
.	I-VARIANT
Cys282Gly	I-VARIANT
of	O
SLC26A4	B-GENE
were	O
predicted	O
to	O
be	O
pathogenic	O
mutations	O
by	O
SIFT	O
and	O
PolyPhen	O
.	O

Secondary	O
antibodies	O
used	O
:	O
Alexa	O
-	O
Fluor	O
-	O
488	O
goat	O
anti	O
-	O
mouse	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
;	O
1	O
:	O
500	O
)	O
to	O
stain	O
FLAG	O
-	O
tagged	O
HOMER2	B-GENE
p	B-VARIANT
.	I-VARIANT
Arg185Pro	I-VARIANT
and	O
Alexa	O
-	O
Fluor	O
-	O
568	O
goat	O
anti	O
-	O
rabbit	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
;	O
1	O
:	O
500	O
)	O
to	O
stain	O
cMYC	O
-	O
tagged	O
HOMER2	B-GENE
WT	O
.	O

Nonetheless	O
,	O
the	O
deep	O
coverage	O
of	O
mtDNA	O
permitted	O
variant	O
discovery	O
even	O
in	O
some	O
poorly	O
represented	O
samples	O
.	O

Methodologically	O
,	O
the	O
procedures	O
used	O
were	O
in	O
general	O
rather	O
simple	O
.	O

Two	O
members	O
(	O
II	O
-	O
3	O
and	O
III	O
-	O
6	O
)	O
had	O
no	O
subjective	O
hearing	O
problems	O
,	O
but	O
pure	O
tone	O
audiometric	O
tests	O
were	O
abnormal	O
.	O

Behr	O
;	O
R	O
.	O

Primers	O
for	O
PCR	O
amplification	O
of	O
EPS8	B-GENE
exons	O
Click	O
here	O
for	O
file	O
We	O
thank	O
the	O
family	O
members	O
for	O
their	O
participation	O
in	O
this	O
study	O
.	O

We	O
also	O
calculated	O
the	O
mean	O
hearing	O
level	O
of	O
low	O
frequencies	O
,	O
mid	O
frequencies	O
,	O
and	O
high	O
frequencies	O
.	O

MME	B-DISEASE
was	O
originally	O
identified	O
in	O
patients	O
with	O
multiple	B-DISEASE
sclerosis	I-DISEASE
(	O
MS	B-DISEASE
)	O
by	O
Gelfand	O
et	O
al	O
.	O
,	O
and	O
it	O
was	O
characterized	O
by	O
cystic	O
lacunar	O
areas	O
of	O
hyporeflectivity	O
with	O
clear	O
boundaries	O
in	O
the	O
spectral	O
domain	O
optical	O
coherence	O
tomographic	O
(	O
SD	O
-	O
OCT	O
)	O
images	O
[	O
23	O
]	O
.	O

We	O
applied	O
customized	O
targeted	O
next	O
-	O
generation	O
exome	O
sequencing	O
(	O
NGS	O
)	O
to	O
determine	O
if	O
mutations	O
in	O
genes	O
associated	O
with	O
renal	B-DISEASE
malformations	I-DISEASE
,	O
Alport	B-DISEASE
syndrome	I-DISEASE
(	O
AS	B-DISEASE
)	O
or	O
nephrotic	B-DISEASE
syndrome	I-DISEASE
are	O
a	O
potential	O
cause	O
of	O
renal	O
abnormalities	O
in	O
patients	O
with	O
equivocal	O
or	O
atypical	O
presentation	O
.	O

We	O
thank	O
all	O
of	O
the	O
normal	O
-	O
hearing	O
subjects	O
who	O
participated	O
in	O
this	O
study	O
.	O

Two	O
days	O
post	O
transfection	O
the	O
medium	O
was	O
replaced	O
with	O
DMEM	O
without	O
phenol	O
red	O
and	O
live	O
pictures	O
was	O
captured	O
on	O
a	O
confocal	O
laser	O
scanning	O
microscope	O
(	O
LSM	O
780	O
,	O
Zeiss	O
,	O
Jena	O
,	O
Germany	O
)	O
using	O
63	O
x	O
water	O
-	O
immersion	O
objective	O
with	O
a	O
NA	O
of	O
1	O
.	O
2	O
.	O

We	O
also	O
included	O
samples	O
from	O
the	O
southwestern	O
provinces	O
of	O
Yunnan	O
and	O
Guizhou	O
,	O
where	O
the	O
populations	O
comprise	O
a	O
number	O
of	O
minorities	O
originating	O
from	O
various	O
native	O
tribes	O
.	O

LRAT	O
was	O
discarded	O
after	O
sequencing	O
of	O
all	O
exons	O
,	O
whereas	O
direct	O
screening	O
of	O
MERTK	B-GENE
exon	O
16	O
identified	O
the	O
expected	O
mutation	O
c	B-VARIANT
.	I-VARIANT
2189	I-VARIANT
+	I-VARIANT
1G	I-VARIANT
>	I-VARIANT
T	I-VARIANT
in	O
homozygosis	O
,	O
again	O
supporting	O
a	O
founder	O
effect	O
.	O

To	O
eliminate	O
alignment	O
artefacts	O
due	O
to	O
insertion	O
/	O
deletion	O
positions	O
,	O
the	O
lower	O
strand	O
reads	O
were	O
converted	O
to	O
the	O
reverse	O
complement	O
sequence	O
,	O
i	O
.	O
e	O
.	O

According	O
to	O
the	O
information	O
on	O
the	O
inheritance	O
,	O
we	O
could	O
significantly	O
reduce	O
the	O
average	O
numbers	O
of	O
candidate	O
mutations	O
to	O
1	O
.	O
95	O
+	O
-	O
0	O
.	O
29	O
per	O
patient	O
(	O
t	O
-	O
test	O
p	O
=	O
2	O
.	O
8	O
x	O
10	O
-	O
6	O
)	O
.	O

In	O
addition	O
,	O
the	O
pathogenic	O
nature	O
of	O
the	O
mutation	O
also	O
comes	O
from	O
the	O
fact	O
that	O
threonine	O
residue	O
at	O
position	O
98	O
is	O
conserved	O
in	O
different	O
EDN3	B-GENE
orthologs	O
from	O
human	O
to	O
zebra	O
fish	O
(	O
Figure	O
3C	O
)	O
.	O

Two	O
columns	O
are	O
sequencing	O
chromatograms	O
of	O
variants	O
carriers	O
and	O
control	O
.	O

(	O
e	O
)	O
Sequence	O
chromatogram	O
of	O
pathogenic	O
variant	O
,	O
c	B-VARIANT
.	I-VARIANT
341G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
W114X	I-VARIANT
)	O
,	O
along	O
with	O
a	O
homozygous	O
wild	O
type	O
allele	O
.	O

We	O
adopted	O
Agilent	O
(	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
SureSelect	O
TGE	O
technology	O
to	O
manufacture	O
the	O
assay	O
chemistries	O
.	O

In	O
the	O
Usher	O
cohorts	O
,	O
analysis	O
of	O
USH2A	B-GENE
rendered	O
2	O
new	O
missense	O
and	O
3	O
known	O
(	O
one	O
frameshift	O
and	O
2	O
missense	O
)	O
mutations	O
.	O

USH	B-DISEASE
is	O
the	O
most	O
common	O
form	O
of	O
deaf	B-DISEASE
-	I-DISEASE
blindness	I-DISEASE
(	O
Saihan	O
et	O
al	O
.	O

In	O
the	O
RDH12	B-GENE
gene	O
,	O
we	O
identified	O
the	O
p	B-VARIANT
.	I-VARIANT
Leu93Pro	I-VARIANT
variation	O
.	O

p	B-VARIANT
.	I-VARIANT
R412H	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
A1425V	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
N1667K	I-VARIANT
did	O
not	O
segregate	O
with	O
the	O
phenotype	O
in	O
the	O
families	O
studied	O
;	O
and	O
p	B-VARIANT
.	I-VARIANT
V66V	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
9510	I-VARIANT
+	I-VARIANT
13C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
and	O
p	B-VARIANT
.	I-VARIANT
D3253A	I-VARIANT
were	O
present	O
in	O
control	O
chromosomes	O
of	O
unaffected	O
individuals	O
,	O
implying	O
that	O
these	O
changes	O
were	O
unlikely	O
to	O
be	O
pathogenic	O
.	O

Figure	O
3A	O
shows	O
the	O
pedigree	O
of	O
each	O
family	O
and	O
the	O
pure	O
-	O
tone	O
audiograms	O
of	O
the	O
patients	O
.	O

The	O
authors	O
are	O
grateful	O
to	O
the	O
Finnish	O
individuals	O
participating	O
in	O
this	O
study	O
.	O

Contributed	O
reagents	O
/	O
materials	O
/	O
analysis	O
tools	O
:	O
IM	O
AS	O
LV	O
AF	O
MH	O
MS	O
DSB	O
SA	O
JB	O
SS	O
IJ	O
ZMA	O
PS	O
BM	O
MP	O
IK	O
SR	O
LK	O
DG	O
.	O

Kyoko	O
Nagai	O
and	O
Nobuhiko	O
Furuya	O
(	O
Gunma	O
University	O
)	O
,	O
Drs	O
.	O

E767fs	I-VARIANT
for	O
USH2	B-DISEASE
and	O
p	B-VARIANT
.	I-VARIANT
C759F	I-VARIANT
for	O
arRP	B-DISEASE
in	O
Caucasians	O
,	O
are	O
not	O
detected	O
in	O
Chinese	O
and	O
Japanese	O
patients	O
[	O
12	O
-	O
14	O
,	O
16	O
,	O
18	O
,	O
19	O
,	O
21	O
,	O
27	O
-	O
29	O
]	O
.	O

The	O
enrichment	O
reagent	O
was	O
designed	O
against	O
genes	O
listed	O
on	O
the	O
RetNet	O
database	O
(	O
July	O
2010	O
)	O
.	O

Nerve	O
conduction	O
velocity	O
studies	O
that	O
involved	O
right	O
median	O
,	O
ulnar	O
and	O
common	O
peroneal	O
,	O
and	O
sural	O
nerve	O
were	O
normal	O
.	O

Clinical	O
information	O
and	O
specimens	O
were	O
obtained	O
with	O
informed	O
consent	O
in	O
accordance	O
with	O
German	O
law	O
for	O
genetic	O
diagnostics	O
.	O

To	O
identify	O
further	O
genetic	O
risk	O
factors	O
,	O
we	O
assess	O
the	O
role	O
of	O
de	O
novo	O
mutations	O
in	O
ASD	B-DISEASE
by	O
sequencing	O
the	O
exomes	O
of	O
ASD	B-DISEASE
cases	O
and	O
their	O
parents	O
(	O
n	O
=	O
175	O
trios	O
)	O
.	O

Criteria	O
for	O
patients	O
being	O
included	O
in	O
the	O
study	O
were	O
juvenile	O
-	O
onset	O
diabetes	B-DISEASE
and	O
optic	B-DISEASE
atrophy	I-DISEASE
or	O
juvenile	O
-	O
onset	O
diabetes	B-DISEASE
and	O
molecular	O
evidence	O
of	O
WFS1	B-GENE
mutations	O
.	O

In	O
this	O
study	O
only	O
males	O
were	O
affected	O
while	O
carrier	O
females	O
did	O
not	O
present	O
with	O
any	O
clinical	O
findings	O
.	O

Brothers	O
of	O
Perrault	B-DISEASE
syndrome	I-DISEASE
females	O
have	O
been	O
reported	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
but	O
are	O
reportedly	O
fertile	O
[	O
13	O
]	O
.	O

Quantities	O
were	O
normalised	O
to	O
Hprt1	B-GENE
levels	O
.	O

Performed	O
the	O
experiments	O
:	O
ZR	O
CB	O
YB	O
NL	O
.	O

Electrophysiology	O
of	O
the	O
germline	O
p	B-VARIANT
.	I-VARIANT
Gly403Asp	I-VARIANT
mutation	O
(	O
Ca	O
V	O
1	O
.	O
3	O
G403D	B-VARIANT
)	O
in	O
subject	O
1444	O
-	O
1	O
demonstrated	O
activation	O
at	O
less	O
depolarizing	O
potentials	O
(	O
V	O
1	O
/	O
2	O
=	O
-	O
32	O
.	O
4	O
+	O
-	O
2	O
.	O
3	O
mV	O
(	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
001	O
versus	O
WT	O
)	O
)	O
and	O
markedly	O
impaired	O
inactivation	O
-	O
similar	O
to	O
Gly403Arg	B-VARIANT
(	O
Fig	O
.	O

Of	O
the	O
13	O
mutations	O
that	O
were	O
observed	O
more	O
than	O
once	O
,	O
the	O
six	O
most	O
common	O
were	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
Y111C	I-VARIANT
(	O
n	O
=	O
20	O
)	O
,	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
R518	I-VARIANT
*	I-VARIANT
(	O
n	O
=	O
6	O
)	O
,	O
SCN5A	B-GENE
p	B-VARIANT
.	I-VARIANT
V411M	I-VARIANT
(	O
n	O
=	O
4	O
)	O
,	O
SCN5A	B-GENE
c	B-VARIANT
.	I-VARIANT
4519_4527del	I-VARIANT
(	O
n	O
=	O
4	O
)	O
,	O
KCNQ1	B-GENE
p	B-VARIANT
.	I-VARIANT
Q530	I-VARIANT
*	I-VARIANT
(	O
n	O
=	O
3	O
)	O
,	O
and	O
KCNQ1	B-GENE
c	B-VARIANT
.	I-VARIANT
572_576del	I-VARIANT
(	O
n	O
=	O
3	O
)	O
.	O

[	O
14	O
]	O
described	O
a	O
novel	O
genetic	O
subtype	O
for	O
Usher	B-GENE
syndrome	I-GENE
type	I-GENE
II	I-GENE
(	O
USH2D	B-GENE
)	O
caused	O
by	O
truncating	O
mutations	O
in	O
the	O
long	O
isoform	O
of	O
whirlin	O
.	O

Homozygosity	O
for	O
35delG	B-VARIANT
was	O
found	O
in	O
33	O
.	O
3	O
%	O
(	O
10	O
/	O
30	O
)	O
of	O
the	O
genotyped	O
unrelated	O
deaf	O
patients	O
,	O
50	O
%	O
were	O
carrying	O
this	O
deletion	O
in	O
a	O
compound	O
heterozygous	O
state	O
and	O
16	O
.	O
7	O
%	O
had	O
other	O
mutations	O
.	O

We	O
evaluated	O
the	O
number	O
and	O
percentage	O
of	O
bleeders	O
according	O
to	O
the	O
affected	O
domain	O
.	O

Alleles	O
were	O
analyzed	O
with	O
ABI	O
GeneMapper	O
(	O
version	O
3	O
.	O
0	O
)	O
.	O

A	O
total	O
of	O
43	O
.	O
3	O
million	O
non	O
-	O
duplicated	O
reads	O
could	O
be	O
mapped	O
to	O
the	O
genome	O
.	O

The	O
resulting	O
P	O
values	O
were	O
adjusted	O
for	O
multiple	O
hypothesis	O
testing	O
using	O
the	O
Benjamini	O
-	O
Hochberg	O
procedure	O
42	O
.	O

Tenascin	B-GENE
C	I-GENE
(	O
TNC	B-GENE
)	O
,	O
encoded	O
by	O
TNC	B-GENE
,	O
is	O
a	O
glycoprotein	O
expressed	O
in	O
the	O
extracellular	O
matrix	O
of	O
various	O
tissues	O
during	O
development	O
,	O
disease	O
,	O
or	O
injury	O
,	O
as	O
well	O
as	O
in	O
restricted	O
areas	O
of	O
the	O
central	O
nervous	O
system	O
involved	O
in	O
neurogenesis	O
[	O
27	O
]	O
.	O

Type	B-GENE
IV	I-GENE
collagen	I-GENE
alpha	I-GENE
5	I-GENE
chain	I-GENE
contains	O
1	O
,	O
685	O
amino	O
acid	O
residues	O
,	O
which	O
consist	O
of	O
a	O
26	O
-	O
residue	O
signal	O
peptide	O
,	O
a	O
1	O
,	O
430	O
-	O
residue	O
collagenous	O
domain	O
starting	O
with	O
a	O
14	O
-	O
residue	O
noncollagenous	O
sequence	O
,	O
a	O
Gly	O
-	O
X	O
-	O
Y	O
-	O
repeat	O
sequence	O
interrupted	O
at	O
22	O
locations	O
,	O
and	O
a	O
229	O
-	O
residue	O
carboxyl	O
-	O
terminal	O
NC1	O
domain	O
[	O
19	O
]	O
.	O

Forty	O
-	O
two	O
unrelated	O
individuals	O
and	O
two	O
siblings	O
(	O
12	O
-	O
0878	O
,	O
12	O
-	O
0880	O
)	O
with	O
Usher	B-DISEASE
syndrome	I-DISEASE
were	O
screened	O
for	O
mutations	O
in	O
the	O
Usher	B-DISEASE
genes	O
CDH23	B-GENE
,	O
CLRN1	B-GENE
,	O
DFNB31	B-GENE
,	O
GPR98	B-GENE
,	O
MYO7A	B-GENE
,	O
PCDH15	B-GENE
,	O
USH1C	B-GENE
,	O
USH1G	B-GENE
,	O
and	O
USH2A	B-GENE
.	O

We	O
only	O
sequenced	O
the	O
coding	O
region	O
and	O
flanking	O
areas	O
between	O
exons	O
and	O
introns	O
.	O

For	O
example	O
,	O
in	O
addition	O
to	O
the	O
three	O
most	O
common	O
mutations	O
of	O
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
299_c	I-VARIANT
.	I-VARIANT
300delAT	I-VARIANT
,	O
c	B-VARIANT
.	I-VARIANT
176_c	I-VARIANT
.	I-VARIANT
191del16	I-VARIANT
,	O
for	O
minorities	O
in	O
Xinjiang	O
,	O
testing	O
of	O
Caucasian	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
mutation	O
should	O
be	O
included	O
.	O

,	O
2008	O
;	O
Hudson	O
et	O
al	O
.	O

To	O
functionally	O
characterize	O
the	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
variant	O
,	O
HEK293	O
cells	O
were	O
cotransfected	O
with	O
full	O
-	O
length	O
WT	O
or	O
variant	O
(	O
p	B-VARIANT
.	I-VARIANT
R397Q	I-VARIANT
)	O
KCNQ1	B-GENE
construct	O
along	O
with	O
the	O
full	O
-	O
length	O
KCNE1	B-GENE
clone	O
.	O

The	O
somatic	O
mutation	O
rate	O
was	O
calculated	O
from	O
the	O
observed	O
number	O
of	O
somatic	O
mutations	O
and	O
the	O
number	O
of	O
coding	O
bases	O
in	O
the	O
exome	O
capture	O
.	O

Functional	O
categorization	O
of	O
genes	O
that	O
were	O
found	O
to	O
carry	O
causative	O
mutations	O
in	O
our	O
study	O
.	O

Absence	O
of	O
an	O
early	O
diagnosis	O
of	O
USH	B-DISEASE
is	O
devastating	O
.	O

The	O
majority	O
of	O
the	O
patients	O
showed	O
congenital	O
,	O
high	O
frequency	O
involved	O
,	O
progressive	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

974C	I-VARIANT
>	I-VARIANT
F	I-VARIANT
)	O
in	O
SEC31B	B-GENE
(	O
MIM	O
610258	O
,	O
ENST00000370345	O
)	O
in	O
F33	O
(	O
Supplementary	O
Material	O
,	O
Table	O
S2	O
)	O
.	O

Interestingly	O
,	O
in	O
spite	O
of	O
the	O
widespread	O
expression	O
of	O
AIFM1	B-GENE
in	O
murine	O
inner	O
ear	O
,	O
which	O
is	O
consistent	O
with	O
a	O
role	O
in	O
normal	O
auditory	O
function	O
,	O
the	O
mutated	O
protein	O
did	O
not	O
affect	O
OHCs	O
function	O
as	O
measured	O
by	O
distortion	O
product	O
otoacoustic	O
emission	O
responses	O
(	O
figure	O
5	O
and	O
online	O
supplementary	O
table	O
S9	O
)	O
.	O

Recently	O
he	O
was	O
found	O
to	O
have	O
thrombocytopenia	B-DISEASE
on	O
routine	O
health	O
checkup	O
at	O
an	O
army	O
hospital	O
.	O

The	O
duplicated	O
sequence	O
is	O
marked	O
with	O
a	O
box	O
.	O

G	O
.	O

In	O
approximately	O
80	O
%	O
of	O
Crouzon	B-DISEASE
syndrome	I-DISEASE
and	O
PS	B-DISEASE
,	O
the	O
mutation	O
is	O
located	O
in	O
the	O
exon	O
8	O
and	O
10	O
of	O
FGFR2	B-GENE
,	O
which	O
encode	O
the	O
third	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
the	O
protein	O
(	O
IgIII	O
)	O
,	O
but	O
mutations	O
in	O
different	O
exxons	O
have	O
also	O
been	O
identified	O
(	O
13	O
,	O
14	O
,	O
22	O
)	O
.	O

Linkage	O
analysis	O
was	O
performed	O
to	O
prioritize	O
the	O
gene	O
to	O
study	O
,	O
followed	O
by	O
sequencing	O
of	O
exons	O
and	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
selected	O
gene	O
,	O
GPR98	B-GENE
(	O
90	O
exons	O
)	O
or	O
DFNB31	B-GENE
(	O
12	O
exons	O
)	O
.	O

Variations	O
in	O
the	O
TJP2	B-GENE
gene	O
were	O
evaluated	O
in	O
87	O
unrelated	O
Korean	O
patients	O
with	O
ADNSHL	B-DISEASE
.	O

They	O
include	O
Legg	B-DISEASE
-	I-DISEASE
Calv	I-DISEASE
e	I-DISEASE
-	I-DISEASE
Perthes	I-DISEASE
disease	I-DISEASE
(	O
LCPD	B-DISEASE
)	O
and	O
avascular	B-DISEASE
necrosis	I-DISEASE
of	I-DISEASE
the	I-DISEASE
femoral	I-DISEASE
head	I-DISEASE
(	O
ANFH	B-DISEASE
)	O
.	O

The	O
12	O
-	O
lead	O
electrocardiogram	O
(	O
ECG	O
)	O
for	O
probands	O
from	O
kindred	O
L148	O
.	O

After	O
duplicated	O
reads	O
were	O
removed	O
,	O
sequences	O
were	O
aligned	O
to	O
the	O
human	O
genome	O
reference	O
sequence	O
(	O
build	O
hg19	O
)	O
using	O
BFAST	O
[	O
29	O
]	O
(	O
0	O
.	O
7	O
.	O
0a	O
,	O
"	O
-	O
a	O
2	O
"	O
mode	O
)	O
and	O
a	O
maximum	O
of	O
two	O
mismatches	O
allowed	O
.	O

Using	O
additional	O
information	O
,	O
such	O
as	O
essential	O
gene	O
status	O
,	O
we	O
note	O
that	O
among	O
the	O
general	O
population	O
an	O
individual	O
will	O
rarely	O
have	O
a	O
hot	O
zone	O
de	O
novo	O
mutation	O
within	O
an	O
"	O
essential	O
"	O
gene	O
(	O
1	O
.	O
9	O
%	O
of	O
individuals	O
,	O
based	O
on	O
728	O
control	O
trios	O
)	O
,	O
yet	O
we	O
see	O
the	O
rate	O
among	O
our	O
patients	O
to	O
be	O
15	O
.	O
5	O
%	O
(	O
88	O
%	O
excess	O
;	O
P	O
=	O
3	O
.	O
4	O
x	O
10	O
-	O
8	O
)	O
.	O

The	O
project	O
is	O
approved	O
by	O
the	O
Human	O
Subjects	O
Division	O
of	O
the	O
University	O
of	O
Washington	O
,	O
by	O
the	O
Helsinki	O
Committee	O
of	O
Tel	O
Aviv	O
University	O
and	O
by	O
the	O
Human	O
Subjects	O
Committee	O
of	O
Bethlehem	O
University	O
.	O

USH1C	B-GENE
genotypes	O
identified	O
in	O
this	O
study	O
.	O

So	O
far	O
,	O
MARVELD2	B-GENE
positive	O
deafness	B-DISEASE
cases	O
are	O
only	O
known	O
from	O
Pakistan	O
,	O
Iran	O
and	O
Czech	O
Republic	O
(	O
Central	O
Europe	O
)	O
[	O
4	O
,	O
7	O
,	O
9	O
,	O
10	O
]	O
,	O
not	O
from	O
India	O
.	O

On	O
fundoscopy	O
,	O
half	O
of	O
the	O
patients	O
showed	O
typical	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
while	O
the	O
other	O
half	O
presented	O
an	O
atypical	O
clinical	O
picture	O
with	O
rare	O
or	O
absent	O
pigment	O
clumping	O
.	O

In	O
five	O
families	O
with	O
TMPRSS3	B-GENE
mutations	O
,	O
all	O
affected	O
members	O
were	O
homozygotes	O
and	O
in	O
one	O
family	O
all	O
affected	O
members	O
were	O
compound	O
heterozygotes	O
(	O
p	B-VARIANT
.	I-VARIANT
V116M	I-VARIANT
and	O
c	B-VARIANT
.	I-VARIANT
323	I-VARIANT
-	I-VARIANT
6G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
(	O
Table	O
2	O
)	O
.	O

Furthermore	O
,	O
a	O
recent	O
report	O
strongly	O
suggests	O
that	O
the	O
phenotypic	O
outcome	O
of	O
a	O
particular	O
mutation	O
in	O
a	O
genetic	O
region	O
that	O
causes	O
an	O
improper	O
functioning	O
of	O
the	O
hearing	O
apparatus	O
may	O
be	O
influenced	O
by	O
modifier	O
genes	O
that	O
affect	O
for	O
instance	O
disease	O
penetrance	O
and	O
progression	O
.	O

Autosomal	O
recessive	O
nonsyndromic	O
hearing	B-DISEASE
loss	I-DISEASE
is	O
a	O
genetically	O
heterogeneous	O
disorder	O
.	O

Elucidation	O
of	O
the	O
genetic	O
basis	O
of	O
human	O
disease	O
provides	O
crucial	O
information	O
for	O
diagnostics	O
,	O
and	O
for	O
understanding	O
mechanisms	O
of	O
disease	O
progression	O
and	O
options	O
for	O
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
applied	O
whole	O
-	O
exome	O
sequencing	O
(	O
WES	O
)	O
to	O
study	O
small	O
Korean	O
families	O
negative	O
for	O
mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
,	O
and	O
we	O
identified	O
CDH23	B-GENE
mutations	O
in	O
two	O
families	O
with	O
autosomal	B-DISEASE
recessive	I-DISEASE
non	I-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
ARNSHL	B-DISEASE
)	O
.	O

Aggregate	O
profile	O
produced	O
with	O
the	O
annotation	O
mode	O
of	O
the	O
Versatile	O
Aggregate	O
Profiler	O
shows	O
ChIP	O
-	O
Seq	O
data	O
sets	O
over	O
the	O
three	O
classes	O
of	O
POLR3	O
-	O
transcribed	O
genes	O
,	O
as	O
defined	O
by	O
the	O
promoter	O
structure	O
.	O

4	O
B	O
)	O
.	O

WXR	O
and	O
ZJ	O
performed	O
renal	O
pathological	O
analysis	O
.	O

Unlike	O
mutations	O
in	O
the	O
Cx26	B-GENE
gene	O
,	O
which	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
impairment	O
in	O
India	O
,	O
the	O
contribution	O
of	O
mutations	O
in	O
these	O
five	O
genes	O
is	O
rather	O
small	O
.	O

The	O
level	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
in	O
terms	O
of	O
PTA	O
,	O
was	O
described	O
as	O
follows	O
:	O
normal	O
hearing	O
,	O
<	O
20	O
dB	O
;	O
mild	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
21	O
-	O
40	O
dB	O
;	O
moderate	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
41	O
-	O
70	O
dB	O
;	O
severe	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
71	O
-	O
90	O
dB	O
;	O
and	O
profound	O
hearing	B-DISEASE
impairment	I-DISEASE
,	O
>	O
91	O
dB	O
.	O

(	O
D	O
)	O
Strand	O
-	O
wise	O
error	O
rate	O
for	O
each	O
amplicon	O
.	O

no	O
.	O

We	O
reported	O
a	O
clinical	O
and	O
molecular	O
study	O
of	O
five	O
Brazilian	O
families	O
with	O
PS	B-DISEASE
,	O
with	O
identification	O
of	O
genetic	O
mutations	O
in	O
three	O
families	O
.	O

Among	O
them	O
,	O
approximately	O
70	O
%	O
of	O
cases	O
are	O
non	O
-	O
syndromic	O
,	O
meaning	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
is	O
the	O
only	O
distinctive	O
clinical	O
feature	O
,	O
and	O
the	O
remaining	O
30	O
%	O
are	O
syndromic	O
with	O
other	O
abnormalities	O
[	O
3	O
]	O
.	O

Approved	O
calcium	O
channel	O
blockers	O
are	O
weak	O
antagonists	O
of	O
wildtype	O
Ca	O
V	O
1	O
.	O
3	O
although	O
potent	O
and	O
specific	O
Ca	O
V	O
1	O
.	O
3	O
inhibitors	O
have	O
been	O
identified	O
21	O
.	O

The	O
diagnostic	O
rate	O
varied	O
considerably	O
based	O
on	O
phenotype	O
and	O
was	O
highest	O
for	O
patients	O
with	O
a	O
positive	O
family	O
history	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
or	O
when	O
the	O
loss	O
was	O
congenital	O
and	O
symmetric	O
.	O

His	O
height	O
was	O
152	O
cm	O
,	O
and	O
weight	O
50	O
kg	O
on	O
admission	O
.	O

To	O
conclude	O
,	O
we	O
report	O
here	O
that	O
tagging	O
DNA	O
and	O
pooling	O
samples	O
prior	O
to	O
hybridisation	O
capture	O
and	O
next	O
generation	O
sequencing	O
is	O
a	O
viable	O
high	O
throughput	O
method	O
for	O
the	O
genetic	O
diagnosis	O
of	O
retinal	B-DISEASE
dystrophies	I-DISEASE
.	O

F	O
.	O

The	O
probands	O
of	O
the	O
founder	O
families	O
were	O
included	O
to	O
assess	O
the	O
frequency	O
of	O
compound	O
heterozygozity	O
in	O
our	O
cohort	O
.	O

Informed	O
consent	O
conforming	O
to	O
the	O
tenets	O
of	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
the	O
Guidance	O
of	O
Sample	O
Collection	O
of	O
Human	O
Genetic	O
Diseases	O
(	O
863	O
-	O
Plan	O
)	O
by	O
the	O
Ministry	O
of	O
Public	O
Health	O
of	O
China	O
was	O
obtained	O
from	O
the	O
participants	O
or	O
their	O
guardians	O
before	O
the	O
study	O
.	O

Human	O
myosin	B-GENE
VI	I-GENE
cDNA	O
clones	O
containing	O
nucleotides	O
1	O
-	O
1285	O
were	O
obtained	O
from	O
a	O
human	O
kidney	O
cDNA	O
library	O
and	O
inserted	O
into	O
the	O
pFastbac1	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
baculovirus	O
transfer	O
vector	O
at	O
the	O
polylinker	O
region	O
.	O

The	O
samples	O
were	O
clarified	O
by	O
centrifugation	O
,	O
and	O
400	O
u	O
L	O
was	O
taken	O
for	O
counting	O
in	O
a	O
liquid	O
scintillation	O
counter	O
.	O

Meanwhile	O
,	O
all	O
members	O
of	O
this	O
family	O
who	O
were	O
initially	O
misdiagnosed	O
as	O
having	O
nonsyndromic	O
RP	B-DISEASE
received	O
an	O
audiometric	O
vestibular	O
test	O
.	O

Mutation	O
screening	O
was	O
performed	O
on	O
members	O
of	O
33	O
USH	B-DISEASE
families	O
.	O

All	O
patients	O
underwent	O
a	O
complete	O
history	O
and	O
physical	O
exam	O
as	O
well	O
as	O
audiogram	O
including	O
air	O
and	O
bone	O
(	O
AC	O
/	O
BC	O
)	O
conduction	O
pure	O
tone	O
thresholds	O
,	O
auditory	O
brainstem	O
response	O
(	O
ABR	O
)	O
thresholds	O
,	O
and	O
auditory	O
steady	O
state	O
response	O
(	O
ASSR	O
)	O
.	O

(	O
DOC	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Libraries	O
were	O
then	O
sequenced	O
on	O
an	O
Illumina	O
Genome	O
Analyzer	O
IIx	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
recommendations	O
for	O
paired	O
-	O
end	O
76	O
-	O
bp	O
reads	O
.	O

They	O
were	O
first	O
seen	O
as	O
neonates	O
or	O
up	O
to	O
17	O
.	O
6	O
years	O
for	O
micropenis	B-DISEASE
,	O
unilateral	O
or	O
bilateral	O
cryptorchidism	B-DISEASE
and	O
/	O
or	O
pubertal	O
delay	O
.	O

This	O
is	O
the	O
second	O
report	O
in	O
the	O
literature	O
of	O
a	O
family	O
with	O
ADNSHL	B-DISEASE
caused	O
by	O
CEACAM16	B-GENE
mutation	O
.	O

Arrow	O
indicates	O
the	O
deaf	O
proband	O
.	O

In	O
addition	O
,	O
three	O
mutations	O
were	O
found	O
in	O
a	O
fragment	O
less	O
than	O
10	O
bp	O
around	O
the	O
5	O
'	O
end	O
of	O
exon	O
10	O
.	O

Images	O
were	O
acquired	O
using	O
a	O
CCD	O
camera	O
and	O
analyzed	O
with	O
cellSens	O
software	O
(	O
Olympus	O
Soft	O
Imaging	O
Solutions	O
,	O
OSIS	O
)	O
.	O

B	O
.	O

Band	O
intensities	O
were	O
quantified	O
with	O
Quantity	O
One	O
software	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
)	O
.	O

All	O
patients	O
in	O
our	O
cohort	O
,	O
76	O
propositi	O
and	O
33	O
family	O
members	O
,	O
were	O
heterozygous	O
for	O
a	O
variant	O
in	O
the	O
MYH9	B-GENE
gene	O
.	O

At	O
2	O
months	O
she	O
underwent	O
surgical	O
correction	O
of	O
club	B-DISEASE
feet	I-DISEASE
.	O

Specific	O
types	O
of	O
SNHL	B-DISEASE
were	O
determined	O
by	O
audiometric	O
curve	O
patterns	O
:	O
ascending	O
(	O
hearing	B-DISEASE
loss	I-DISEASE
greater	O
at	O
the	O
lower	O
frequencies	O
)	O
,	O
flat	O
,	O
descending	O
(	O
hearing	B-DISEASE
loss	I-DISEASE
greater	O
at	O
the	O
higher	O
frequencies	O
)	O
,	O
and	O
"	O
U	O
-	O
shaped	O
"	O
(	O
hearing	B-DISEASE
loss	I-DISEASE
at	O
mid	O
-	O
frequencies	O
)	O
curves	O
.	O

The	O
specificity	O
of	O
Sanger	O
sequencing	O
is	O
known	O
to	O
be	O
extremely	O
high	O
,	O
but	O
the	O
cost	O
of	O
analyzing	O
CDH23	B-GENE
by	O
Sanger	O
sequencing	O
is	O
also	O
extremely	O
high	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
ELMOD3	B-GENE
localizes	O
to	O
actin	O
-	O
based	O
microvilli	O
and	O
stereocilia	O
(	O
Figure	O
5	O
)	O
but	O
that	O
a	O
point	O
mutation	O
in	O
the	O
ELMO	O
domain	O
can	O
prevent	O
its	O
normal	O
localization	O
and	O
potentially	O
affect	O
its	O
function	O
in	O
the	O
stereocilia	O
.	O

Short	O
-	O
sequence	O
read	O
alignments	O
visualized	O
with	O
igv	O
.	O

At	O
age	O
33	O
in	O
2007	O
,	O
she	O
was	O
referred	O
to	O
our	O
hospital	O
.	O

Y81C	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
W87R	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
R98W	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
P127T	I-VARIANT
-	O
as	O
well	O
as	O
p	B-VARIANT
.	I-VARIANT
D76N	I-VARIANT
,	O
located	O
in	O
the	O
cytoplasmic	O
C	O
-	O
terminus	O
of	O
minK	O
,	O
have	O
previously	O
been	O
associated	O
with	O
LQTS	B-DISEASE
[	O
2	O
]	O
.	O

Apart	O
from	O
the	O
ability	O
to	O
analyze	O
all	O
known	O
RP	B-DISEASE
genes	O
simultaneously	O
,	O
thus	O
increasing	O
effectiveness	O
of	O
the	O
genetic	O
analysis	O
,	O
this	O
approach	O
has	O
added	O
value	O
and	O
superior	O
clinical	O
relevance	O
because	O
it	O
allowed	O
the	O
identification	O
of	O
a	O
substantial	O
number	O
of	O
cases	O
with	O
apparent	O
de	O
novo	O
mutations	O
,	O
and	O
it	O
has	O
the	O
potential	O
to	O
identify	O
additional	O
mutations	O
potentially	O
contributing	O
to	O
the	O
phenotype	O
-	O
-	O
that	O
is	O
,	O
to	O
determine	O
the	O
cumulative	O
mutational	O
load	O
.	O

For	O
relative	O
quantitative	O
analysis	O
of	O
Cib2	B-GENE
,	O
the	O
PCR	O
primers	O
were	O
located	O
in	O
exons	O
4	O
and	O
5	O
,	O
while	O
the	O
Taqman	O
probe	O
spanned	O
the	O
junction	O
of	O
exons	O
4	O
and	O
5	O
.	O

Initially	O
,	O
these	O
mutations	O
were	O
only	O
found	O
in	O
patients	O
of	O
Pakistani	O
origin	O
[	O
4	O
,	O
7	O
]	O
.	O

1	O
)	O
.	O

Among	O
those	O
,	O
AGILE	O
(	O
AliGnIng	O
Long	O
rEads	O
)	O
seems	O
to	O
be	O
promising	O
in	O
terms	O
of	O
accuracy	O
,	O
memory	O
usage	O
,	O
and	O
speed	O
(	O
Misra	O
et	O
al	O
.	O

The	O
curve	O
can	O
be	O
interpreted	O
as	O
the	O
achieved	O
coverage	O
proportions	O
(	O
y	O
axis	O
)	O
at	O
different	O
normalized	O
depths	O
(	O
x	O
axis	O
)	O
.	O

Proteins	O
in	O
supernatants	O
were	O
precipitated	O
by	O
100	O
%	O
trichloroacetic	O
acid	O
,	O
and	O
washed	O
by	O
acetone	O
for	O
4	O
times	O
.	O

The	O
amplicon	O
libraries	O
were	O
quantified	O
by	O
using	O
Ion	O
Library	O
Quantitation	O
Kit	O
(	O
Applied	O
Biosystems	O
,	O
Life	O
Technologies	O
)	O
and	O
the	O
StepOne	O
plus	O
realtime	O
PCR	O
system	O
(	O
Applied	O
Biosystems	O
,	O
Life	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturers	O
'	O
procedures	O
.	O

Target	O
enrichment	O
was	O
analysed	O
using	O
NGSrich	O
.	O

Lastly	O
,	O
patients	O
with	O
severe	O
ADOA	B-DISEASE
with	O
extraocular	O
symptom	O
were	O
found	O
to	O
harbor	O
multiple	O
mitochondrial	O
DNA	O
deletions	O
[	O
14	O
,	O
15	O
]	O
,	O
reinforcing	O
the	O
strong	O
links	O
existing	O
between	O
mitochondrial	O
structure	O
maintenance	O
and	O
mitochondrial	O
energetic	O
metabolism	O
in	O
neurodegenerative	B-DISEASE
diseases	I-DISEASE
.	O

FBK	O
,	O
MILM	O
,	O
BGS	O
,	O
JdV	O
performed	O
the	O
clinical	O
evaluation	O
of	O
the	O
patients	O
and	O
the	O
interpretation	O
of	O
the	O
phenotypic	O
analysis	O
.	O

He	O
didn	O
'	O
t	O
show	O
mental	O
retardation	O
.	O

Limitations	O
of	O
molecular	O
studies	O
to	O
the	O
sequencing	O
of	O
all	O
the	O
coding	O
exons	O
and	O
their	O
boundaries	O
together	O
with	O
the	O
CGH	O
array	O
leave	O
some	O
unresolved	O
cases	O
that	O
require	O
further	O
studies	O
at	O
the	O
RNA	O
level	O
.	O

Furthermore	O
,	O
most	O
disease	O
-	O
causing	O
mutations	O
are	O
located	O
in	O
highly	O
conserved	O
regions	O
,	O
which	O
exome	O
sequencing	O
is	O
expected	O
to	O
cover	O
.	O

There	O
are	O
two	O
exceptions	O
to	O
this	O
,	O
as	O
the	O
cohort	O
includes	O
two	O
sets	O
of	O
related	O
fetuses	O
.	O

Compound	O
heterozygous	O
mutations	O
c	B-VARIANT
.	I-VARIANT
1032G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Ala344Alasp	I-VARIANT
)	O
and	O
c	B-VARIANT
.	I-VARIANT
569G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg190Gln	I-VARIANT
)	O
were	O
identified	O
in	O
the	O
proband	O
.	O

In	O
our	O
series	O
,	O
three	O
(	O
12	O
%	O
)	O
men	O
had	O
KAL1	B-GENE
mutations	O
which	O
all	O
are	O
expected	O
to	O
cause	O
loss	O
-	O
of	O
-	O
function	O
of	O
anosmin	O
-	O
1	O
:	O
both	O
the	O
nonsense	O
mutation	O
R262X	B-VARIANT
[	O
43	O
]	O
,	O
and	O
the	O
frameshift	O
mutation	O
S158WfsX45	B-VARIANT
,	O
lead	O
to	O
premature	O
stop	O
codons	O
in	O
the	O
region	O
encoding	O
the	O
first	O
fibronectin	O
type	O
III	O
-	O
like	O
repeat	O
of	O
the	O
protein	O
[	O
44	O
]	O
,	O
and	O
the	O
deletion	O
of	O
the	O
last	O
nucleotide	O
of	O
exon	O
8	O
and	O
the	O
first	O
three	O
nucleotides	O
of	O
intron	O
8	O
(	O
g	B-VARIANT
.	I-VARIANT
2357_2360delAgta	I-VARIANT
)	O
abolishes	O
the	O
splice	O
site	O
,	O
and	O
most	O
likely	O
results	O
in	O
an	O
incorrect	O
transcript	O
.	O

Under	O
the	O
autosomal	O
recessive	O
model	O
,	O
we	O
identified	O
113	O
genes	O
with	O
homozygous	O
or	O
multiple	O
heterozygous	O
variants	O
(	O
216	O
SNPs	O
and	O
59	O
indels	O
)	O
common	O
to	O
both	O
affected	O
siblings	O
.	O

Detailed	O
genotype	O
and	O
phenotype	O
analyses	O
were	O
performed	O
to	O
provide	O
effective	O
risk	O
assessment	O
and	O
genetic	O
counseling	O
for	O
hearing	B-DISEASE
loss	I-DISEASE
patients	O
and	O
their	O
families	O
in	O
this	O
area	O
.	O

Protein	O
levels	O
and	O
morphology	O
of	O
lymphoblastoid	O
cell	O
lines	O
from	O
six	O
affected	O
individuals	O
were	O
examined	O
,	O
representative	O
examples	O
of	O
which	O
appear	O
in	O
Fig	O
.	O

We	O
first	O
searched	O
for	O
sequence	O
variants	O
of	O
the	O
coding	O
and	O
non	O
-	O
coding	O
exons	O
and	O
of	O
splice	O
sites	O
in	O
the	O
known	O
DFNB	B-DISEASE
and	O
DFNA	O
(	O
autosomal	O
dominant	O
non	O
-	O
syndromic	O
deafness	B-DISEASE
)	O
genes	O
.	O

These	O
preparations	O
were	O
stable	O
at	O
4	O
deg	O
C	O
and	O
against	O
freeze	O
-	O
thaw	O
cycles	O
,	O
as	O
judged	O
by	O
either	O
GAP	O
activity	O
or	O
lack	O
of	O
precipitation	O
.	O

As	O
USH1C	B-GENE
mutations	O
have	O
so	O
far	O
only	O
been	O
reported	O
in	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
and	O
6	O
,	O
these	O
exons	O
were	O
sequenced	O
first	O
.	O

Clarin	O
1	O
is	O
a	O
membrane	O
protein	O
with	O
four	O
transmembrane	O
domains	O
that	O
belongs	O
to	O
the	O
family	O
of	O
vertebrate	O
tetraspanins	O
.	O

Massively	O
parallel	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
two	O
patient	O
-	O
parent	O
trios	O
was	O
performed	O
at	O
the	O
Radboud	O
University	O
Nijmegen	O
Medical	O
Center	O
by	O
using	O
the	O
ABI	O
SOLiD	O
(	O
tm	O
)	O
4	O
platform	O
(	O
Life	O
Technologies	O
)	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
E385D	I-VARIANT
missense	O
mutation	O
is	O
considered	O
causative	O
largely	O
because	O
it	O
was	O
demonstrated	O
to	O
disrupt	O
actin	O
movement	O
by	O
lowering	O
ATPase	O
activity	O
[	O
37	O
]	O
.	O

We	O
present	O
the	O
genetic	O
analyses	O
conducted	O
on	O
a	O
three	O
-	O
generation	O
family	O
(	O
14	O
individuals	O
)	O
with	O
three	O
members	O
affected	O
with	O
isolated	B-DISEASE
-	I-DISEASE
Hirschsprung	I-DISEASE
disease	I-DISEASE
(	O
HSCR	B-DISEASE
)	O
and	O
one	O
with	O
HSCR	B-DISEASE
and	O
heterochromia	B-DISEASE
iridum	I-DISEASE
(	O
syndromic	B-DISEASE
-	I-DISEASE
HSCR	I-DISEASE
)	O
,	O
a	O
phenotype	O
reminiscent	O
of	O
Waardenburg	B-DISEASE
-	I-DISEASE
Shah	I-DISEASE
syndrome	I-DISEASE
(	O
WS4	B-DISEASE
)	O
.	O

G3PDH	O
amplification	O
was	O
used	O
as	O
a	O
control	O
.	O

In	O
addition	O
,	O
P240	O
of	O
CDH23	B-GENE
is	O
on	O
the	O
extracellular	O
cadherin	O
1	O
domain	O
,	O
and	O
R283	O
of	O
PCDH15	B-GENE
is	O
on	O
the	O
extracellular	O
cadherin	O
2	O
domain	O
,	O
which	O
are	O
considered	O
to	O
interact	O
with	O
each	O
other	O
for	O
tip	O
-	O
link	O
bound	O
[	O
49	O
]	O
,	O
raising	O
the	O
possibility	O
that	O
the	O
double	O
heterozygous	O
mutations	O
could	O
lead	O
to	O
a	O
destabilized	O
tip	O
-	O
link	O
.	O

c	B-VARIANT
.	I-VARIANT
5856G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
K1952K	I-VARIANT
,	O
MYO7A	B-GENE
)	O
was	O
previously	O
analyzed	O
by	O
Jaijo	O
et	O
al	O
.	O

(	O
c	O
)	O
Schematic	O
representation	O
of	O
the	O
subunit	O
composition	O
of	O
POLR1	O
(	O
Pol	O
I	O
)	O
and	O
POLR3	O
(	O
Pol	O
III	O
;	O
see	O
refs	O
53	O
for	O
details	O
)	O
.	O

The	O
order	O
of	O
markers	O
is	O
based	O
on	O
the	O
Marshfield	O
map	O
.	O

The	O
mutational	O
spectrum	O
included	O
missense	O
,	O
in	O
-	O
frame	O
deletion	O
,	O
nonsense	O
and	O
smaller	O
deletions	O
and	O
insertions	O
,	O
which	O
were	O
associated	O
with	O
a	O
shift	O
of	O
the	O
WFS1	B-GENE
reading	O
frame	O
.	O

Isoform	O
a	O
is	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
isoform	O
b	O
.	O

Nearly	O
a	O
third	O
of	O
all	O
the	O
DOA	O
+	O
patients	O
in	O
our	O
study	O
had	O
evidence	O
of	O
an	O
axonal	B-DISEASE
neuropathy	I-DISEASE
,	O
an	O
observation	O
with	O
important	O
parallels	O
to	O
a	O
specific	O
subtype	O
of	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
(	O
CMT	O
)	O
disease	O
or	O
,	O
hereditary	B-DISEASE
motor	I-DISEASE
and	I-DISEASE
sensory	I-DISEASE
neuropathy	I-DISEASE
type	I-DISEASE
VI	I-DISEASE
(	O
HMSN	B-DISEASE
VI	I-DISEASE
,	O
OMIM	O
601152	O
)	O
.	O

Pedigrees	O
and	O
sequence	O
chromatograms	O
of	O
the	O
autosomal	O
dominant	O
families	O
D1	O
through	O
D8	O
.	O

Band	O
A	O
is	O
the	O
correct	O
transcript	O
corresponding	O
to	O
the	O
exon	O
12	O
(	O
MYO7A	B-GENE
)	O
.	O

Thus	O
,	O
we	O
plan	O
to	O
study	O
the	O
interaction	O
between	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
and	O
other	O
components	O
that	O
drive	O
the	O
localization	O
of	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
at	O
TCs	O
by	O
modeling	O
their	O
complex	O
structure	O
,	O
although	O
any	O
additional	O
components	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

Although	O
apoptosis	O
of	O
hair	O
cells	O
is	O
a	O
major	O
cause	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
in	O
mammals	O
[	O
33	O
-	O
35	O
]	O
,	O
the	O
exact	O
relationship	O
between	O
variant	O
MCM2	B-GENE
and	O
patients	O
'	O
auditory	O
phenotype	O
is	O
uncertain	O
.	O

The	O
first	O
image	O
represents	O
the	O
patient	O
'	O
s	O
right	O
eye	O
fundus	O
examination	O
and	O
we	O
observe	O
optic	B-DISEASE
disk	I-DISEASE
atrophy	I-DISEASE
(	O
arrow	O
)	O
.	O

Among	O
(	O
a	O
)	O
controls	O
and	O
(	O
b	O
)	O
cases	O
who	O
had	O
at	O
least	O
one	O
protein	O
-	O
coding	O
de	O
novo	O
mutation	O
identified	O
,	O
the	O
gene	O
-	O
level	O
(	O
Residual	O
Variation	O
Intolerance	O
Score	O
(	O
RVIS	O
)	O
genic	O
intolerance	O
percentile	O
)	O
and	O
variant	O
-	O
level	O
(	O
PolyPhen	O
-	O
2	O
)	O
scores	O
are	O
plotted	O
in	O
two	O
-	O
dimensional	O
space	O
.	O

Vestibular	O
symptoms	O
were	O
not	O
reported	O
.	O

The	O
first	O
set	O
of	O
analysis	O
was	O
the	O
five	O
-	O
generation	O
Chinese	O
hearing	B-DISEASE
loss	I-DISEASE
family	O
,	O
F013	O
,	O
a	O
total	O
of	O
22	O
subjects	O
of	O
which	O
were	O
included	O
in	O
the	O
linkage	O
study	O
(	O
II	O
:	O
2	O
,	O
III	O
:	O
1	O
-	O
5	O
,	O
III	O
:	O
7	O
,	O
III	O
:	O
9	O
-	O
11	O
,	O
IV	O
:	O
1	O
-	O
3	O
,	O
IV	O
:	O
5	O
,	O
IV	O
:	O
9	O
,	O
IV	O
:	O
11	O
,	O
IV	O
:	O
13	O
,	O
IV	O
:	O
17	O
,	O
IV	O
:	O
29	O
,	O
IV	O
:	O
31	O
-	O
32	O
,	O
V	O
:	O
1	O
)	O
and	O
four	O
individuals	O
(	O
IV	O
:	O
3	O
,	O
IV	O
:	O
5	O
,	O
IV	O
:	O
17	O
,	O
IV	O
:	O
31	O
)	O
were	O
included	O
in	O
exome	O
sequencing	O
study	O
(	O
Figure	O
1	O
)	O
.	O

Taken	O
together	O
,	O
approximately	O
47	O
.	O
89	O
%	O
(	O
83	O
+	O
53	O
/	O
284	O
)	O
of	O
patients	O
with	O
NSHI	B-DISEASE
in	O
typical	O
Chinese	O
areas	O
had	O
molecular	O
defects	O
in	O
the	O
GJB2	B-GENE
or	O
SLC26A4	B-GENE
gene	O
,	O
whereas	O
about	O
33	O
.	O
1	O
%	O
and	O
3	O
.	O
5	O
%	O
of	O
European	O
patients	O
with	O
NSHI	B-DISEASE
carried	O
mutations	O
in	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
,	O
respectively	O
,	O
with	O
a	O
total	O
of	O
36	O
.	O
6	O
%	O
in	O
a	O
patient	O
cohort	O
of	O
142	O
sib	O
pairs	O
[	O
30	O
]	O
.	O

In	O
the	O
developing	O
central	O
nervous	O
system	O
,	O
it	O
is	O
involved	O
in	O
regulating	O
the	O
proliferation	O
of	O
both	O
oligodendrocyte	O
precursor	O
cells	O
and	O
astrocytes	O
[	O
28	O
]	O
.	O

The	O
genetics	O
team	O
then	O
communicated	O
directly	O
with	O
the	O
treating	O
clinicians	O
to	O
discuss	O
whether	O
a	O
relevant	O
qualifying	O
genotype	O
could	O
explain	O
the	O
clinical	O
presentation	O
of	O
the	O
patient	O
.	O

Exceptions	O
seen	O
for	O
five	O
patients	O
included	O
post	O
trauma	O
extradural	O
hematoma	B-DISEASE
at	O
5	O
years	O
,	O
amygdalectomy	O
at	O
4	O
years	O
,	O
a	O
neonatal	O
parietal	O
hematoma	B-DISEASE
in	O
unknown	O
circumstances	O
,	O
meningeal	B-DISEASE
bleeding	I-DISEASE
at	O
birth	O
,	O
and	O
neonatal	B-DISEASE
bleeding	I-DISEASE
for	O
which	O
no	O
details	O
were	O
available	O
.	O

Patients	O
'	O
genomic	O
DNA	O
was	O
extracted	O
either	O
from	O
fresh	O
or	O
frozen	O
whole	O
blood	O
samples	O
with	O
Puregene	O
(	O
tm	O
)	O
Genomic	O
DNA	O
Purification	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
MN	O
)	O
or	O
from	O
saliva	O
with	O
Oragene	O
(	O
tm	O
)	O
kits	O
(	O
DNA	O
Genotek	O
Inc	O
.	O
,	O
Ontario	O
,	O
Canada	O
)	O
.	O

3B	O
2	O
)	O
.	O

Capture	O
enrichment	O
was	O
measured	O
with	O
qPCR	O
according	O
to	O
the	O
NimbleGen	O
protocol	O
.	O

Spontaneous	O
testicular	O
growth	O
during	O
androgen	O
therapy	O
is	O
highly	O
indicative	O
for	O
reversal	O
of	O
HH	B-DISEASE
.	O

Quantitative	O
real	O
-	O
time	O
PCR	O
on	O
cDNA	O
generated	O
from	O
normalised	O
RNA	O
from	O
the	O
organs	O
of	O
Corti	O
of	O
4	O
-	O
day	O
-	O
old	O
wildtype	O
(	O
blue	O
)	O
and	O
diminuendo	O
homozygote	O
(	O
red	O
)	O
littermates	O
[	O
32	O
]	O
.	O

The	O
CNVs	O
and	O
the	O
rank	O
of	O
occurrences	O
found	O
in	O
targeted	O
deafness	B-DISEASE
genes	O
among	O
the	O
79	O
patient	O
samples	O
Results	O
presented	O
in	O
Table	O
1	O
show	O
that	O
,	O
under	O
the	O
most	O
relaxed	O
criteria	O
,	O
we	O
could	O
only	O
detect	O
pathogenic	O
genetic	O
mutations	O
in	O
29	O
of	O
the	O
79	O
samples	O
.	O

To	O
identify	O
SNPs	O
,	O
we	O
used	O
SOAPsnp	O
software	O
and	O
bioinformatics	O
pipeline	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
define	O
the	O
identity	O
and	O
frequency	O
of	O
CLDN14	B-GENE
mutations	O
and	O
associated	O
inner	O
ear	O
phenotypes	O
in	O
a	O
cohort	O
of	O
800	O
Pakistani	O
families	O
segregating	O
deafness	B-DISEASE
.	O

The	O
results	O
showed	O
that	O
the	O
sibling	O
possessed	O
the	O
same	O
genotype	O
as	O
the	O
proband	O
(	O
Figure	O
2	O
b	O
)	O
,	O
while	O
the	O
parents	O
were	O
each	O
unaffected	O
heterozygotes	O
carrying	O
a	O
GJB2	B-GENE
c	B-VARIANT
.	I-VARIANT
235delC	I-VARIANT
monoallelic	O
mutation	O
(	O
the	O
father	O
)	O
or	O
a	O
USH2A	B-GENE
c	B-VARIANT
.	I-VARIANT
5051C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
monoallelic	O
mutation	O
(	O
the	O
mother	O
)	O
.	O

Following	O
discussion	O
,	O
DNA	O
samples	O
from	O
the	O
patient	O
,	O
and	O
when	O
available	O
affected	O
and	O
unaffected	O
family	O
members	O
,	O
were	O
sent	O
for	O
mutation	O
screening	O
in	O
Manchester	O
(	O
for	O
PSACH	B-DISEASE
and	O
AD	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
)	O
or	O
Lausanne	O
(	O
AR	B-DISEASE
-	I-DISEASE
MED	I-DISEASE
)	O
.	O

Afterwards	O
,	O
ATP6V0A4	B-GENE
gene	O
study	O
in	O
dRTA	B-DISEASE
patients	O
with	O
normal	O
hearing	O
,	O
and	O
in	O
those	O
without	O
any	O
structural	O
mutation	O
in	O
the	O
ATP6V1B1	B-GENE
gene	O
despite	O
presenting	O
SNHL	B-DISEASE
.	O

Orthologs	O
or	O
close	O
paralogs	O
of	O
CACNA1D	B-GENE
in	O
vertebrate	O
and	O
invertebrate	O
species	O
were	O
identified	O
by	O
a	O
BLAST	O
search	O
1	O
.	O

We	O
identified	O
five	O
different	O
mutations	O
,	O
all	O
of	O
them	O
lying	O
in	O
the	O
coding	O
exon	O
:	O
three	O
known	O
as	O
recessive	O
mutations	O
(	O
35delG	B-VARIANT
,	O
235delC	B-VARIANT
and	O
312del14	B-VARIANT
)	O
,	O
one	O
as	O
a	O
dominant	O
mutation	O
(	O
R75Q	B-VARIANT
)	O
,	O
the	O
fifth	O
mutation	O
is	O
a	O
newly	O
identified	O
missense	O
mutation	O
,	O
W172C	B-VARIANT
.	O

The	O
neural	O
network	O
splice	O
site	O
predictor	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
fruitfly	O
.	O
org	O
/	O
seq_tools	O
/	O
splice	O
.	O
html	O
)	O
generates	O
a	O
score	O
for	O
the	O
wild	O
type	O
donor	O
of	O
0	O
.	O
88	O
,	O
which	O
is	O
reduced	O
to	O
0	O
.	O
37	O
by	O
the	O
A	O
>	O
G	O
transition	O
,	O
and	O
to	O
0	O
.	O
19	O
by	O
the	O
A	O
>	O
T	O
transversion	O
.	O

Aided	O
thresholds	O
were	O
obtained	O
from	O
all	O
implanted	O
patients	O
in	O
the	O
free	O
-	O
field	O
at	O
frequencies	O
from	O
0	O
.	O
25	O
to	O
4	O
kHz	O
.	O

Ophthalmological	O
evaluation	O
revealed	O
hypopigmented	B-DISEASE
iris	I-DISEASE
and	O
choroid	O
with	O
visualization	O
of	O
the	O
choroidal	O
vessels	O
.	O

In	O
the	O
human	O
cochlea	O
,	O
myosin	B-GENE
VIIA	I-GENE
is	O
involved	O
in	O
hair	O
bundle	O
morphogenesis	O
and	O
mechanotransduction	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
[	O
3	O
]	O
.	O

End	O
repair	O
of	O
DNA	O
fragments	O
,	O
addition	O
of	O
a	O
3	O
'	O
adenine	O
(	O
A	O
)	O
,	O
adaptor	O
ligation	O
,	O
and	O
reaction	O
clean	O
-	O
up	O
were	O
carried	O
out	O
following	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

18	O
Variants	O
were	O
filtered	O
against	O
1000	O
Genomes	O
data	O
,	O
and	O
all	O
variants	O
with	O
a	O
minor	O
allele	O
frequency	O
(	O
MAF	O
)	O
>	O
1	O
%	O
were	O
removed	O
from	O
the	O
analysis	O
.	O

Variants	O
post	O
filtration	O
and	O
primers	O
used	O
for	O
mutation	O
validation	O
.	O

Using	O
this	O
method	O
we	O
identified	O
a	O
novel	O
frameshift	O
mutation	O
in	O
an	O
alternative	O
exon	O
of	O
USH1C	B-GENE
as	O
the	O
cause	O
of	O
RP	B-DISEASE
with	O
late	O
onset	O
hearing	B-DISEASE
loss	I-DISEASE
rather	O
than	O
the	O
classic	O
USH1	O
phenotype	O
which	O
manifests	O
with	O
profound	O
congenital	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

The	O
c	B-VARIANT
.	I-VARIANT
1253delA	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Y418fsX459	I-VARIANT
)	O
identified	O
in	O
this	O
family	O
resides	O
on	O
exon	O
9C	O
.	O

We	O
previously	O
hypothesized	O
that	O
DFNB31	B-GENE
mutations	O
may	O
also	O
be	O
causative	O
for	O
nonsyndromic	O
retinal	B-DISEASE
degenerations	I-DISEASE
.	O

Eight	O
out	O
of	O
the	O
eighteen	O
variants	O
showed	O
the	O
highest	O
score	O
(	O
4	O
)	O
,	O
five	O
of	O
them	O
showed	O
a	O
score	O
of	O
3	O
,	O
two	O
of	O
the	O
variants	O
were	O
observed	O
to	O
show	O
a	O
score	O
of	O
2	O
and	O
the	O
three	O
remaining	O
changes	O
showed	O
a	O
score	O
of	O
1	O
.	O

Asp438Ala	I-VARIANT
,	O
predicted	O
by	O
SIFT	O
(	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
/	O
)	O
to	O
be	O
damaging	O
(	O
SIFT	O
score	O
0	O
.	O
01	O
)	O
and	O
by	O
Polyphen2	O
(	O
http	O
:	O
/	O
/	O
genetics	O
.	O
bwh	O
.	O
harvard	O
.	O
edu	O
/	O
pph2	O
/	O
)	O
to	O
be	O
probably	O
damaging	O
(	O
Polyphen2	O
score	O
1	O
.	O
0	O
)	O
.	O

,	O
2008	O
)	O
.	O

With	O
further	O
accumulation	O
of	O
more	O
diverse	O
types	O
of	O
samples	O
,	O
the	O
analysis	O
in	O
CNVs	O
may	O
significantly	O
expand	O
our	O
understanding	O
about	O
how	O
combined	O
DNA	O
sequence	O
and	O
structural	O
mutations	O
cause	O
deafness	B-DISEASE
in	O
humans	O
,	O
and	O
ultimately	O
could	O
help	O
to	O
better	O
explain	O
the	O
genetic	O
causes	O
of	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
in	O
patients	O
.	O

Standardization	O
was	O
performed	O
with	O
known	O
quantities	O
of	O
ATP	O
measured	O
under	O
the	O
same	O
conditions	O
.	O

Two	O
board	O
-	O
certified	O
child	O
psychiatrists	O
evaluated	O
the	O
autistic	O
symptoms	O
.	O

Red	O
arrows	O
in	O
upper	O
panel	O
indicate	O
reduced	O
coverage	O
of	O
USH2A	B-GENE
exons	O
in	O
patient	O
1598	O
.	O

Ca	O
V	O
1	O
.	O
3	O
is	O
expressed	O
in	O
adrenal	O
glomerulosa	O
.	O

Connexons	O
embedded	O
in	O
the	O
surfaces	O
of	O
adjacent	O
cells	O
associate	O
to	O
form	O
an	O
intercellular	O
channel	O
[	O
17	O
,	O
18	O
]	O
.	O

Ten	O
milliliters	O
of	O
venous	O
blood	O
was	O
collected	O
from	O
members	O
of	O
the	O
families	O
.	O

The	O
evolutionary	O
conservation	O
for	O
at	O
each	O
variant	O
position	O
was	O
measured	O
by	O
Genome	O
Evolutionary	O
Rare	O
Profiling	O
(	O
GERP	O
)	O
and	O
PhyloP	O
.	O

Lupski	O
and	O
Dr	O
.	O

,	O
2008	O
)	O
.	O

Previous	O
mutation	O
research	O
studies	O
performed	O
in	O
patients	O
referred	O
to	O
medical	O
genetic	O
clinics	O
showed	O
high	O
proportions	O
of	O
mutations	O
for	O
MYO7A	B-GENE
,	O
CDH23	B-GENE
and	O
PCDH15	B-GENE
in	O
USH1	B-DISEASE
patients	O
[	O
27	O
]	O
,	O
specifically	O
,	O
29	O
%	O
-	O
55	O
%	O
for	O
MYO7A	B-GENE
[	O
61	O
-	O
64	O
]	O
,	O
19	O
%	O
-	O
35	O
%	O
for	O
CDH23	B-GENE
[	O
58	O
]	O
,	O
11	O
%	O
-	O
15	O
%	O
for	O
PCDH15	B-GENE
[	O
65	O
]	O
,	O
and	O
for	O
USH2A	B-GENE
in	O
USH2	B-DISEASE
patients	O
[	O
28	O
,	O
60	O
,	O
66	O
]	O
,	O
whereas	O
the	O
implication	O
of	O
VLGR1	B-GENE
and	O
WHRN	B-GENE
in	O
the	O
latter	O
was	O
minor	O
[	O
11	O
,	O
12	O
]	O
.	O

The	O
patient	O
underwent	O
two	O
surgeries	O
on	O
the	O
skull	O
.	O

In	O
addition	O
,	O
in	O
one	O
case	O
(	O
family	O
28	O
,	O
557	O
)	O
,	O
a	O
de	O
novo	O
mutation	O
in	O
the	O
recessive	O
gene	O
USH2A	B-GENE
(	O
MIM	O
#	O
608	O
,	O
400	O
)	O
was	O
identified	O
,	O
with	O
the	O
second	O
mutation	O
being	O
inherited	O
from	O
the	O
mother	O
(	O
Fig	O
.	O

Following	O
mutagenesis	O
,	O
the	O
sequence	O
of	O
the	O
whole	O
plasmid	O
,	O
including	O
the	O
presence	O
of	O
the	O
mutation	O
(	O
G48S	B-VARIANT
,	O
R209H	B-VARIANT
,	O
or	O
E670A	B-VARIANT
)	O
,	O
was	O
verified	O
.	O

The	O
activity	O
of	O
complexes	O
I	O
,	O
II	O
,	O
III	O
,	O
and	O
V	O
in	O
patient	O
'	O
s	O
fibroblasts	O
did	O
not	O
differ	O
from	O
that	O
in	O
controls	O
.	O

arRP	B-DISEASE
,	O
adRP	B-DISEASE
and	O
LCA	B-DISEASE
genes	O
that	O
were	O
captured	O
and	O
subjected	O
to	O
NGS	O
in	O
this	O
study	O
.	O

Patient	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
using	O
standard	O
techniques	O
.	O

For	O
a	O
certificate	O
,	O
please	O
see	O
:	O
http	O
:	O
/	O
/	O
www	O
.	O
textcheck	O
.	O
com	O
/	O
certificate	O
/	O
K8ZiA4	O
.	O
Conceived	O
and	O
designed	O
the	O
experiments	O
:	O
CA	O
AS	O
LP	O
RL	O
GDA	O
.	O

Values	O
are	O
expressed	O
as	O
means	O
+	O
-	O
standard	O
errors	O
of	O
the	O
mean	O
.	O

Patients	O
'	O
survival	O
is	O
indicated	O
where	O
this	O
information	O
was	O
available	O
.	O

Out	O
of	O
the	O
three	O
profoundly	O
deaf	O
patients	O
,	O
two	O
(	O
IV	O
:	O
5	O
and	O
IV	O
:	O
6	O
)	O
had	O
received	O
a	O
cochlear	O
implant	O
.	O

The	O
clarification	O
of	O
the	O
individual	O
significance	O
of	O
either	O
mutation	O
in	O
a	O
family	O
with	O
a	O
compound	O
heterozygous	O
index	O
patient	O
requires	O
cascade	O
screening	O
to	O
be	O
performed	O
and	O
identification	O
of	O
carriers	O
of	O
the	O
single	O
mutations	O
.	O

Direct	O
sequencing	O
in	O
the	O
forward	O
and	O
reverse	O
directions	O
identified	O
a	O
homozygous	O
truncating	O
mutation	O
,	O
c	B-VARIANT
.	I-VARIANT
728C	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
S243X	I-VARIANT
)	O
,	O
in	O
all	O
three	O
USH1	B-DISEASE
affected	O
siblings	O
(	O
Figure	O
6	O
)	O
.	O

The	O
deletion	O
segregates	O
with	O
hearing	B-DISEASE
impairment	I-DISEASE
in	O
the	O
pedigree	O
and	O
was	O
not	O
observed	O
in	O
500	O
control	O
chromosomes	O
.	O

We	O
therefore	O
analysed	O
46	O
boys	O
seen	O
by	O
the	O
same	O
physician	O
during	O
the	O
childhood	O
or	O
adolescence	O
for	O
HH	B-DISEASE
.	O

This	O
should	O
urge	O
professional	O
and	O
family	O
caretakers	O
to	O
carefully	O
adjust	O
insulin	O
therapy	O
in	O
strict	O
avoidance	O
of	O
hypoglycemic	B-DISEASE
events	I-DISEASE
.	O

Mean	O
coverage	O
of	O
Capture	O
Next	O
Generation	O
Sequencing	O
.	O

Most	O
,	O
if	O
not	O
all	O
,	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
protein	O
-	O
containing	O
mutations	O
reported	O
to	O
date	O
in	O
DFNB42	B-DISEASE
patients	O
exhibit	O
failure	O
to	O
localize	O
at	O
TCs	O
and	O
defectiveness	O
in	O
tricellulin	B-GENE
recruitment	O
in	O
angulin	B-GENE
-	I-GENE
1	I-GENE
/	O
LSR	B-GENE
knockdown	O
EpH4	O
cells	O
[	O
8	O
]	O
.	O

PCR	O
products	O
were	O
digested	O
with	O
10	O
U	O
of	O
NcoI	O
restriction	O
endonuclease	O
(	O
New	O
England	O
Biolabs	O
,	O
Ipswich	O
,	O
MA	O
)	O
for	O
1	O
h	O
at	O
37	O
deg	O
C	O
.	O

The	O
clinical	O
phenotype	O
can	O
also	O
be	O
variable	O
,	O
ranging	O
from	O
normal	O
hearing	O
,	O
progressive	O
moderate	O
hearing	B-DISEASE
loss	I-DISEASE
starting	O
in	O
adult	O
life	O
,	O
to	O
profound	O
congenital	O
deafness	B-DISEASE
[	O
8	O
]	O
.	O

B	O
.	O

This	O
leads	O
to	O
the	O
exciting	O
possibility	O
that	O
novel	O
types	O
of	O
mechanisms	O
(	O
regulatory	O
mutations	O
,	O
cryptic	O
splice	O
site	O
formation	O
,	O
or	O
digenic	O
effects	O
)	O
are	O
contributing	O
to	O
the	O
genetic	O
cause	O
of	O
disease	O
in	O
our	O
patients	O
.	O

These	O
results	O
support	O
sequence	O
analysis	O
of	O
MYO15A	B-GENE
in	O
the	O
clinical	O
diagnostic	O
testing	O
of	O
individuals	O
with	O
ARNSHL	B-DISEASE
.	O

Bioinformatic	O
analysis	O
revealed	O
that	O
the	O
mutated	O
residues	O
were	O
conserved	O
across	O
species	O
(	O
Figure	O
2b	O
)	O
.	O

His	O
head	O
circumference	O
was	O
35	O
cm	O
.	O

Results	O
showed	O
that	O
probe	O
signals	O
from	O
exons	O
23	O
to	O
32	O
of	O
the	O
USH2A	B-GENE
gene	O
(	O
see	O
the	O
x	O
-	O
axis	O
)	O
were	O
significantly	O
decreased	O
(	O
ratio	O
on	O
the	O
y	O
-	O
axis	O
is	O
about	O
0	O
.	O
5	O
)	O
indicating	O
the	O
presence	O
of	O
a	O
deletion	O
across	O
those	O
exons	O
in	O
patient	O
CF	O
.	O

Table	O
2	O
shows	O
the	O
four	O
novel	O
homozygous	O
missense	O
,	O
nonsense	O
,	O
splice	O
site	O
and	O
frame	O
shift	O
variants	O
(	O
not	O
reported	O
in	O
dbSNP132	O
)	O
in	O
the	O
five	O
autozygous	O
regions	O
when	O
we	O
used	O
a	O
filter	O
of	O
minimum	O
8	O
x	O
read	O
depth	O
.	O

After	O
base	O
calling	O
,	O
sequence	O
results	O
were	O
aligned	O
with	O
a	O
bowtie	O
program	O
[	O
20	O
]	O
and	O
allele	O
frequencies	O
of	O
each	O
CDH23	B-GENE
mutation	O
in	O
patients	O
and	O
the	O
control	O
population	O
were	O
calculated	O
.	O

)	O
.	O

We	O
found	O
no	O
convincing	O
evidence	O
for	O
digenic	O
inheritance	O
in	O
this	O
study	O
;	O
no	O
subject	O
had	O
two	O
definitely	O
pathogenic	O
alleles	O
(	O
nonsense	O
,	O
frameshifts	O
or	O
splice	O
mutations	O
)	O
in	O
different	O
genes	O
,	O
which	O
given	O
the	O
overall	O
spectrum	O
of	O
mutations	O
in	O
Usher	B-DISEASE
syndrome	I-DISEASE
(	O
79	O
%	O
of	O
identified	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variants	O
were	O
truncating	O
mutations	O
and	O
21	O
%	O
were	O
missense	O
changes	O
)	O
one	O
might	O
expect	O
to	O
find	O
in	O
genuine	O
digenic	O
inheritance	O
.	O

Proband	O
is	O
indicated	O
by	O
an	O
arrow	O
.	O

The	O
mutations	O
in	O
the	O
nine	O
loci	O
of	O
prevalent	O
deafness	O
-	O
associated	O
genes	O
were	O
detected	O
in	O
13	O
.	O
06	O
%	O
of	O
Uyghur	O
NSD	B-DISEASE
patients	O
and	O
32	O
.	O
45	O
%	O
of	O
Han	O
Chinese	O
patients	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O

This	O
can	O
be	O
explained	O
by	O
the	O
involvement	O
of	O
CREB	O
-	O
dependent	O
gene	O
transcription	O
in	O
long	O
-	O
term	O
memory	O
formation	O
through	O
signaling	O
pathways	O
that	O
include	O
multiple	O
important	O
kinases	O
(	O
protein	O
kinase	O
A	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
,	O
and	O
calcium	O
/	O
calmodulin	O
-	O
dependent	O
kinase	O
IV	O
(	O
CaMKIV	O
)	O
)	O
in	O
the	O
nervous	O
systems	O
of	O
many	O
species	O
[	O
2	O
]	O
.	O

No	O
significant	O
differences	O
in	O
mutation	O
spectrum	O
or	O
prevalence	O
of	O
GJB2	B-GENE
and	O
SLC26A4	B-GENE
were	O
found	O
between	O
the	O
two	O
areas	O
.	O

Activation	O
and	O
inactivation	O
of	O
Ile770Met	B-VARIANT
channels	O
are	O
both	O
shifted	O
to	O
more	O
hyperpolarized	O
potentials	O
.	O

Array	O
data	O
were	O
analyzed	O
using	O
GenomeStudio	O
version	O
2011	O
.	O
1	O
(	O
Illumina	O
)	O
and	O
the	O
QuantiSNP	O
2	O
.	O
2	O
copy	O
-	O
number	O
detection	O
algorithm	O
.	O

The	O
IVS1	B-VARIANT
+	I-VARIANT
27G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
variation	O
was	O
not	O
previously	O
described	O
,	O
but	O
splice	O
site	O
prediction	O
programs	O
would	O
suggest	O
its	O
non	O
-	O
pathogenic	O
consequences	O
[	O
27	O
]	O
.	O

*	O
in	O
vitro	O
functional	O
characterization	O
performed	O
.	O

A	O
P	O
-	O
value	O
of	O
0	O
.	O
05	O
or	O
less	O
was	O
accepted	O
as	O
statistically	O
significant	O
.	O

EPS8	B-GENE
is	O
an	O
F	O
-	O
actin	O
capping	O
and	O
bundling	O
protein	O
.	O

PCR	O
amplification	O
,	O
and	O
Sanger	O
sequencing	O
of	O
the	O
coding	O
and	O
near	O
-	O
coding	O
regions	O
of	O
selected	O
genes	O
,	O
were	O
performed	O
according	O
to	O
standard	O
protocols	O
.	O

Affected	O
and	O
nonaffected	O
relatives	O
were	O
either	O
included	O
prior	O
to	O
this	O
study	O
or	O
requested	O
to	O
participate	O
after	O
the	O
identification	O
of	O
potentially	O
causative	O
variants	O
in	O
the	O
proband	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
novel	O
splice	O
site	O
mutation	O
in	O
the	O
COL4A5	B-GENE
gene	O
identified	O
in	O
a	O
Chinese	O
female	O
patient	O
who	O
presented	O
with	O
bilateral	O
giant	B-DISEASE
macular	I-DISEASE
holes	I-DISEASE
and	O
bilateral	B-DISEASE
anterior	I-DISEASE
and	I-DISEASE
posterior	I-DISEASE
lenticonus	I-DISEASE
.	O

Seven	O
families	O
(	O
10	O
patients	O
)	O
including	O
one	O
multiplex	O
family	O
showing	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
one	O
or	O
more	O
of	O
the	O
typical	O
features	O
of	O
BOR	B-DISEASE
syndrome	O
were	O
included	O
in	O
this	O
study	O
for	O
clinical	O
and	O
genetic	O
analyses	O
.	O

Last	O
nucleotide	O
of	O
the	O
exon	O
.	O

Those	O
with	O
the	O
GNRHR	B-GENE
mutation	O
R262Q	B-VARIANT
accompanied	O
by	O
another	O
GNRHR	B-GENE
mutation	O
may	O
be	O
prone	O
to	O
reversal	O
,	O
although	O
even	O
patients	O
with	O
a	O
truncating	O
mutation	O
in	O
CHD7	B-GENE
or	O
a	O
splice	O
-	O
site	O
mutation	O
in	O
FGFR1	B-GENE
can	O
recover	O
.	O

Table	O
S2	O
)	O
.	O

(	O
Internal	O
Medicine	O
)	O
Note	O
:	O
all	O
are	O
located	O
in	O
the	O
departments	O
noted	O
at	O
Washington	O
University	O
School	O
of	O
Medicine	O
,	O
St	O
.	O

Also	O
CDH23	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
His755Tyr	I-VARIANT
was	O
regarded	O
as	O
pathogenic	O
,	O
18	O
44	O
but	O
we	O
identified	O
it	O
in	O
a	O
consanguineous	O
USH2	B-DISEASE
family	O
(	O
203	O
)	O
segregating	O
a	O
homozygous	O
USH2A	B-GENE
nonsense	O
mutation	O
.	O

All	O
patients	O
had	O
received	O
hormonal	O
treatment	O
to	O
induce	O
or	O
complete	O
pubertal	O
development	O
.	O

Hearing	O
thresholds	O
were	O
recorded	O
by	O
pure	O
tone	O
audiometry	O
(	O
PTA	O
)	O
or	O
auditory	O
steady	O
state	O
responses	O
(	O
ASSR	O
)	O
,	O
depending	O
on	O
the	O
subject	O
'	O
s	O
age	O
and	O
cooperation	O
.	O

Targeted	O
exon	O
sequencing	O
of	O
selected	O
genes	O
using	O
the	O
Massively	O
Parallel	O
DNA	O
Sequencing	O
(	O
MPS	O
)	O
technology	O
will	O
potentially	O
enable	O
us	O
to	O
systematically	O
tackle	O
previously	O
intractable	O
monogenic	O
disorders	O
and	O
improve	O
molecular	O
diagnosis	O
.	O

In	O
contrast	O
,	O
our	O
findings	O
suggest	O
that	O
both	O
isoforms	O
have	O
significant	O
overlapping	O
but	O
non	O
-	O
redundant	O
functions	O
during	O
human	O
development	O
,	O
as	O
illustrated	O
by	O
the	O
indistinguishable	O
clinical	O
presentation	O
of	O
Baraitser	B-DISEASE
-	I-DISEASE
Winter	I-DISEASE
syndrome	I-DISEASE
patients	O
carrying	O
mutations	O
in	O
ACTB	B-GENE
and	O
ACTG1	B-GENE
(	O
Table	O
3	O
and	O
Supplementary	O
Table	O
6	O
)	O
.	O

S2	O
)	O
.	O

To	O
generate	O
DNA	O
samples	O
with	O
no	O
mosaicism	O
,	O
we	O
constructed	O
a	O
set	O
of	O
subcloned	O
plasmids	O
containing	O
each	O
exon	O
and	O
its	O
flanking	O
intronic	O
regions	O
in	O
the	O
NLRP3	B-GENE
gene	O
from	O
healthy	O
donor	O
genomic	O
DNA	O
using	O
a	O
Topo	O
TA	O
cloning	O
kit	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

To	O
assess	O
genotype	O
-	O
phenotype	O
correlations	O
for	O
WFS1	B-GENE
,	O
patients	O
were	O
divided	O
into	O
three	O
groups	O
according	O
to	O
the	O
predicted	O
functional	O
consequences	O
of	O
each	O
mutation	O
for	O
WFS1	B-GENE
protein	O
function	O
(	O
Table	O
4	O
,	O
Figure	O
1	O
)	O
.	O

(	O
h	O
)	O
hybrid	O
,	O
(	O
u	O
)	O
unspliced	O
(	O
b	O
)	O
RT	O
-	O
PCR	O
is	O
quantified	O
via	O
densitometric	O
analysis	O
of	O
the	O
bands	O
after	O
PstI	O
digestion	O
as	O
follows	O
:	O
ratio	O
of	O
the	O
spliced	O
band	O
and	O
the	O
sum	O
of	O
the	O
two	O
PstI	O
digest	O
bands	O
(	O
s	O
/	O
(	O
u1	O
+	O
u2	O
)	O
,	O
with	O
PstI	O
digestion	O
.	O

Retinal	O
imaging	O
of	O
BE	O
of	O
IV	O
:	O
2	O
at	O
age	O
37	O
.	O

A	O
Sequence	O
of	O
the	O
transcript	O
derived	O
from	O
the	O
c	B-VARIANT
.	I-VARIANT
35delG	I-VARIANT
allele	O
,	O
generated	O
by	O
use	O
of	O
the	O
known	O
acceptor	O
site	O
.	O

COS7	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
,	O
washed	O
with	O
PBS	O
,	O
permeabilized	O
with	O
0	O
.	O
2	O
%	O
Triton	O
/	O
PBS	O
,	O
blocked	O
with	O
10	O
%	O
goat	O
serum	O
in	O
PBS	O
for	O
1	O
h	O
,	O
incubated	O
with	O
rabbit	O
anti	O
-	O
flag	O
and	O
phalloidin	O
Alexa	O
fluor	O
-	O
647	O
for	O
1	O
h	O
,	O
stained	O
with	O
Alexa	O
Fluor	O
488	O
,	O
568	O
for	O
30	O
min	O
and	O
then	O
washed	O
with	O
PBS	O
.	O

Electropherograms	O
show	O
the	O
confirmation	O
of	O
the	O
three	O
point	O
mutations	O
by	O
Sanger	O
sequencing	O
(	O
arrows	O
:	O
position	O
of	O
the	O
mutations	O
)	O
.	O

Moreover	O
,	O
an	O
additional	O
132	O
patients	O
'	O
chromosomes	O
from	O
Qatar	O
,	O
6	O
from	O
Oman	O
and	O
52	O
from	O
Italy	O
were	O
negative	O
for	O
the	O
presence	O
of	O
this	O
variant	O
(	O
our	O
internal	O
database	O
)	O
.	O

5a	O
-	O
b	O
)	O
.	O

Interpretation	O
is	O
especially	O
challenging	O
for	O
STRC	B-GENE
analysis	O
since	O
we	O
cannot	O
rely	O
on	O
customary	O
mutation	O
and	O
allele	O
frequency	O
data	O
.	O

Nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
NSHL	B-DISEASE
)	O
contribute	O
70	O
%	O
of	O
inherited	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
most	O
of	O
NSHL	B-DISEASE
were	O
autosomal	O
recessive	O
up	O
to	O
80	O
%	O
,	O
in	O
comparison	O
to	O
20	O
%	O
autosomal	O
dominant	O
and	O
less	O
than	O
1	O
%	O
X	O
-	O
linked	O
or	O
mitochondrial	O
disorders	O
[	O
4	O
]	O
.	O

Sequencing	O
of	O
both	O
strands	O
was	O
performed	O
using	O
BigDye	O
(	O
r	O
)	O
Terminator	O
v1	O
.	O
1	O
(	O
Applied	O
Biosystems	O
,	O
UK	O
)	O
and	O
M13	O
primers	O
(	O
sense	O
5	O
'	O
-	O
CAGTTCTCACAGGAGCCACA	O
-	O
3	O
'	O
)	O
and	O
(	O
antisense	O
5	O
'	O
-	O
AGGTGAACTGGAACCACAGG	O
-	O
3	O
'	O
)	O
(	O
Taq	O
Copenhagen	O
,	O
Denmark	O
)	O
.	O

CDH23	B-GENE
mutations	O
detected	O
in	O
this	O
study	O
1	O
Prediction	O
of	O
a	O
change	O
being	O
damaging	O
(	O
<	O
0	O
.	O
05	O
)	O
or	O
tolerated	O
.	O

The	O
compound	O
heterozygous	O
variants	O
in	O
the	O
TMPRSS3	B-GENE
gene	O
in	O
the	O
present	O
families	O
included	O
one	O
novel	O
variant	O
,	O
p	B-VARIANT
.	I-VARIANT
Val199Met	I-VARIANT
,	O
and	O
four	O
previously	O
described	O
pathogenic	O
variants	O
,	O
p	B-VARIANT
.	I-VARIANT
Ala306Thr	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Thr70fs	I-VARIANT
,	O
p	B-VARIANT
.	I-VARIANT
Ala138Glu	I-VARIANT
,	O
and	O
p	B-VARIANT
.	I-VARIANT
Cys107Xfs	I-VARIANT
.	O

Thus	O
,	O
the	O
~	O
37	O
kDa	O
band	O
may	O
represent	O
either	O
an	O
alternate	O
isoform	O
or	O
partially	O
cleaved	O
product	O
of	O
the	O
~	O
40	O
kDa	O
protein	O
.	O

Immunofluorescence	O
analysis	O
of	O
neutrophil	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
showed	O
abnormal	O
diffuse	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
localization	O
,	O
with	O
several	O
circular	O
to	O
oval	O
cytoplasmic	B-DISEASE
inclusions	I-DISEASE
(	O
Fig	O
.	O

Evaluation	O
of	O
non	O
-	O
coding	O
regulatory	O
regions	O
may	O
identify	O
the	O
"	O
missing	O
hit	O
"	O
in	O
heterozygous	O
carriers	O
of	O
recessive	O
mutations	O
.	O

SNPs	O
were	O
called	O
using	O
GATK	O
8	O
,	O
9	O
for	O
all	O
trios	O
jointly	O
.	O

An	O
echocardiogram	O
showed	O
an	O
enlarged	O
left	O
ventricle	O
and	O
a	O
mildly	O
depressed	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
45	O
%	O
(	O
Table	O
)	O
.	O

Although	O
the	O
underlying	O
molecular	O
mechanisms	O
remain	O
to	O
be	O
investigated	O
,	O
this	O
may	O
suggest	O
a	O
protective	O
effect	O
of	O
wolframin	B-GENE
deficiency	O
on	O
the	O
development	O
of	O
classical	O
diabetes	B-DISEASE
complications	O
.	O

(	O
E	O
)	O
Error	O
rates	O
along	O
the	O
amplicon	O
sequence	O
of	O
exon	O
1	O
in	O
each	O
strand	O
for	O
insertions	O
and	O
deletions	O
in	O
the	O
upper	O
panel	O
and	O
mismatches	O
and	O
ambiguous	O
base	O
calls	O
in	O
the	O
lower	O
panel	O
.	O

Analysis	O
by	O
bioinformatics	O
shows	O
CEACAM16	B-GENE
molecules	O
consists	O
of	O
an	O
Ig	O
variable	O
(	O
IgV	O
)	O
-	O
like	O
N	O
domain	O
at	O
its	O
NH	O
2	O
-	O
terminus	O
(	O
N1	O
)	O
,	O
followed	O
by	O
Ig	O
constant	O
(	O
IgC	O
)	O
-	O
like	O
domains	O
of	O
subtypes	O
A	O
(	O
A	O
)	O
and	O
B	O
(	O
B	O
)	O
and	O
another	O
IgV	O
-	O
like	O
N	O
domain	O
at	O
its	O
COOH	O
-	O
terminal	O
(	O
N2	O
)	O
(	O
Figure	O
2	O
-	O
c	O
)	O
.	O

Novel	O
missense	O
variants	O
,	O
classified	O
as	O
UV2	O
-	O
UV4	O
and	O
pathogenic	O
,	O
were	O
also	O
assessed	O
using	O
Usher	B-DISEASE
Syndrome	I-DISEASE
Missense	O
Analysis	O
.	O

Applying	O
the	O
above	O
strategy	O
,	O
we	O
reduced	O
the	O
number	O
of	O
candidate	O
genes	O
by	O
more	O
than	O
90	O
.	O
33	O
%	O
.	O

She	O
had	O
shown	O
the	O
typical	O
behavioral	O
characteristics	O
of	O
Autism	B-DISEASE
from	O
early	O
infancy	O
,	O
including	O
abnormalities	O
in	O
communication	O
and	O
social	O
interaction	O
,	O
along	O
with	O
repetitive	O
behavior	O
and	O
restricted	O
interests	O
.	O

1A	O
)	O
.	O

The	O
mixture	O
was	O
then	O
added	O
to	O
cells	O
in	O
DMEM	O
medium	O
that	O
contained	O
2	O
%	O
FBS	O
and	O
grown	O
for	O
two	O
days	O
.	O

Complex	O
V	O
activity	O
was	O
immediately	O
assayed	O
on	O
this	O
cell	O
lysate	O
(	O
0	O
.	O
5	O
x	O
10	O
6	O
cells	O
)	O
in	O
a	O
Tris	O
/	O
KCl	O
buffer	O
,	O
composed	O
of	O
50	O
mM	O
Tris	O
and	O
10	O
mM	O
KCl	O
,	O
and	O
containing	O
2	O
mM	O
Phosphoenolpyruvate	O
(	O
PEP	O
)	O
,	O
0	O
.	O
5	O
mM	O
ATP	O
,	O
5	O
mM	O
MgCl	O
2	O
,	O
1	O
.	O
5	O
u	O
M	O
FCCP	O
,	O
2	O
.	O
5	O
u	O
g	O
/	O
u	O
l	O
antimycin	O
A	O
,	O
0	O
.	O
1	O
U	O
lactate	O
dehydrogenase	O
,	O
and	O
0	O
.	O
1	O
U	O
pyruvate	O
kinase	O
(	O
Roche	O
Diagnostics	O
,	O
Meylan	O
,	O
France	O
)	O
,	O
5	O
mg	O
/	O
ml	O
BSA	O
,	O
pH	O
8	O
.	O

Red	O
silhouettes	O
represent	O
carriers	O
of	O
de	O
novo	O
hot	O
zone	O
mutations	O
.	O

The	O
presence	O
or	O
absence	O
of	O
NMMHC	B-GENE
-	I-GENE
IIA	I-GENE
aggregates	O
was	O
studied	O
using	O
an	O
immunofluorescence	O
(	O
IF	O
)	O
technique	O
adapted	O
from	O
Kunishima	O
et	O
al	O
.	O

This	O
population	O
has	O
its	O
unique	O
genetic	O
background	O
,	O
and	O
that	O
is	O
why	O
Han	O
Chinese	O
in	O
Beijing	O
(	O
CHB	O
)	O
was	O
chosen	O
by	O
the	O
international	O
HapMap	O
project	O
as	O
one	O
of	O
the	O
four	O
populations	O
for	O
DNA	O
analysis	O
,	O
the	O
result	O
of	O
which	O
http	O
:	O
/	O
/	O
www	O
.	O
hapmap	O
.	O
org	O
/	O
also	O
showed	O
the	O
great	O
variation	O
between	O
CHB	O
and	O
the	O
other	O
three	O
populations	O
.	O

This	O
classification	O
remains	O
in	O
clinical	O
use	O
,	O
although	O
recent	O
progress	O
on	O
the	O
molecular	O
genetics	O
and	O
clinical	O
research	O
of	O
USH	B-DISEASE
has	O
revealed	O
broad	O
genetic	O
and	O
clinical	O
heterogeneity	O
[	O
3	O
,	O
6	O
]	O
.	O

One	O
family	O
was	O
later	O
found	O
to	O
be	O
associated	O
with	O
ear	O
pits	O
(	O
diagnosed	O
as	O
BOR	B-DISEASE
syndrome	I-DISEASE
)	O
(	O
family	O
#	O
4361	O
in	O
Fig	O
.	O

In	O
those	O
cases	O
where	O
mutations	O
were	O
detected	O
,	O
we	O
performed	O
segregation	O
analysis	O
.	O

Many	O
of	O
the	O
conditions	O
present	O
in	O
childhood	O
,	O
but	O
milder	O
phenotypes	O
presenting	O
in	O
adulthood	O
are	O
increasingly	O
recognized	O
[	O
25	O
]	O
.	O

Additionally	O
,	O
there	O
is	O
an	O
ATP	O
-	O
binding	O
site	O
near	O
Ile502	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
(	O
IRB	O
)	O
of	O
the	O
Seoul	O
National	O
University	O
Bundang	O
Hospital	O
(	O
Seongnam	O
,	O
Gyeonggi	O
,	O
Korea	O
)	O
.	O

2005	O
;	O
Pecci	O
et	O
al	O
.	O

Possible	O
new	O
splice	O
sites	O
are	O
in	O
bold	O
.	O

Rhodamine	O
-	O
phalloidin	O
(	O
red	O
)	O
staining	O
was	O
used	O
to	O
label	O
stereocilia	O
and	O
actin	O
cytoskeleton	O
of	O
cochlear	O
inner	O
hair	O
cells	O
and	O
three	O
rows	O
of	O
outer	O
hair	O
cells	O
.	O

No	O
other	O
family	O
members	O
had	O
all	O
three	O
mutations	O
suggesting	O
that	O
only	O
collectively	O
they	O
are	O
penetrant	O
.	O

1119	O
unrelated	O
patients	O
were	O
sequentially	O
accrued	O
during	O
the	O
study	O
period	O
.	O

Genotyped	O
variants	O
and	O
family	O
pedigrees	O
were	O
imported	O
into	O
Progeny	O
Lab	O
software	O
(	O
Progeny	O
,	O
LLC	O
)	O
where	O
haplotypes	O
were	O
constructed	O
from	O
a	O
combination	O
of	O
intragenic	O
variants	O
and	O
polymorphic	O
SNPs	O
in	O
individual	O
families	O
.	O

STGD	B-DISEASE
consists	O
of	O
childhood	B-DISEASE
visual	I-DISEASE
acuity	I-DISEASE
loss	I-DISEASE
,	O
central	B-DISEASE
scotomas	I-DISEASE
on	O
visual	O
field	O
testing	O
and	O
an	O
atrophic	B-DISEASE
maculopathy	I-DISEASE
.	O

Azam	O
CZS	O
TMS	O
AM	O
KM	O
STAS	O
AH	O
M	O
.	O

Although	O
early	O
diagnosis	O
is	O
now	O
possible	O
through	O
DNA	O
testing	O
,	O
performing	O
large	O
-	O
scale	O
mutation	O
screening	O
for	O
USH	B-DISEASE
genes	O
in	O
all	O
non	O
-	O
syndromic	O
HL	B-DISEASE
children	O
has	O
been	O
both	O
time	O
-	O
consuming	O
and	O
expensive	O
.	O

Ventricular	B-DISEASE
tachycardia	I-DISEASE
(	O
VT	B-DISEASE
)	O
is	O
a	O
common	O
manifestation	O
of	O
advanced	O
cardiomyopathies	B-DISEASE
.	O

First	O
-	O
visit	O
pure	O
-	O
tone	O
audiograms	O
for	O
eight	O
individuals	O
and	O
the	O
auditory	O
steady	O
state	O
response	O
(	O
ASSR	O
)	O
results	O
for	O
a	O
9	O
-	O
month	O
-	O
old	O
child	O
(	O
SB18	O
III	O
-	O
3	O
)	O
are	O
shown	O
in	O
Fig	O
.	O

Using	O
the	O
latest	O
census	O
data	O
for	O
the	O
North	O
of	O
England	O
(	O
Office	O
for	O
National	O
Statistics	O
,	O
2008	O
)	O
,	O
we	O
estimate	O
the	O
minimum	O
prevalence	O
of	O
DOA	O
+	O
at	O
0	O
.	O
36	O
per	O
100	O
000	O
(	O
95	O
%	O
CI	O
=	O
0	O
.	O
25	O
-	O
0	O
.	O
50	O
per	O
100	O
000	O
)	O
;	O
about	O
1	O
in	O
250	O
000	O
of	O
the	O
general	O
population	O
.	O

We	O
had	O
inadequate	O
clinical	O
data	O
for	O
10	O
/	O
87	O
patients	O
that	O
we	O
found	O
mutations	O
(	O
Table	O
6	O
)	O
.	O

These	O
observations	O
are	O
reminiscent	O
of	O
the	O
well	O
-	O
established	O
association	O
between	O
primary	O
mtDNA	O
Leber	B-DISEASE
hereditary	I-DISEASE
optic	I-DISEASE
neuropathy	I-DISEASE
mutations	O
and	O
a	O
multiple	B-DISEASE
sclerosis	I-DISEASE
-	I-DISEASE
like	I-DISEASE
illness	I-DISEASE
(	O
Harding	O
'	O
s	O
disease	O
)	O
(	O
Harding	O
et	O
al	O
.	O

In	O
the	O
case	O
of	O
pSTRC	O
,	O
inactivity	O
is	O
due	O
to	O
a	O
nonsense	O
mutation	O
in	O
exon	O
20	O
(	O
4	O
)	O
.	O

In	O
summary	O
,	O
PCR	O
and	O
RACE	O
experiments	O
,	O
PEX1	B-GENE
cDNA	O
database	O
entries	O
and	O
a	O
promoter	O
analysis	O
indicate	O
that	O
the	O
PEX1	B-GENE
polymorphism	O
at	O
c	O
.	O
-	O
137	O
is	O
not	O
necessarily	O
a	O
polymorphic	O
site	O
in	O
the	O
5	O
'	O
UTR	O
but	O
could	O
also	O
be	O
a	O
polymorphism	O
within	O
the	O
promoter	O
.	O

Mutations	O
in	O
these	O
histone	O
methyltransferases	O
have	O
been	O
previously	O
reported	O
in	O
leukemias	O
42	O
,	O
breast	B-DISEASE
cancer	I-DISEASE
24	O
,	O
and	O
renal	O
carcinomas	O
43	O
,	O
but	O
have	O
not	O
been	O
widely	O
reported	O
in	O
ovarian	B-DISEASE
carcinoma	I-DISEASE
.	O

ND	O
:	O
Not	O
determined	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
G572S	I-VARIANT
mutation	O
has	O
been	O
reported	O
in	O
LQTS	B-DISEASE
cohorts	O
around	O
the	O
world	O
4	O
,	O
5	O
,	O
23	O
,	O
25	O
,	O
39	O
-	O
44	O
but	O
has	O
not	O
been	O
identified	O
in	O
an	O
exome	O
sequencing	O
project	O
to	O
date	O
.	O

Since	O
variable	O
clinical	O
manifestations	O
concerning	O
onset	O
,	O
degree	O
,	O
type	O
,	O
and	O
progressiveness	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
can	O
be	O
seen	O
in	O
BOR	B-DISEASE
syndrome	O
,	O
auditory	O
rehabilitation	O
in	O
these	O
patients	O
have	O
to	O
be	O
carefully	O
evaluated	O
and	O
managed	O
according	O
to	O
individual	O
conditions	O
.	O

And	O
about	O
89	O
.	O
10	O
%	O
of	O
target	O
region	O
achieved	O
at	O
least	O
10	O
x	O
.	O

Briefly	O
,	O
5	O
u	O
g	O
of	O
each	O
genomic	O
DNA	O
sample	O
was	O
fragmented	O
by	O
sonication	O
and	O
purified	O
to	O
yield	O
fragments	O
of	O
150	O
-	O
200	O
bp	O
in	O
length	O
.	O

Variants	O
were	O
called	O
and	O
annotated	O
using	O
the	O
GATK	O
[	O
30	O
]	O
(	O
release	O
1	O
.	O
4	O
,	O
Best	O
Practices	O
V3	O
filters	O
and	O
"	O
DP	O
<	O
6	O
"	O
)	O
and	O
ANNOVAR	O
[	O
24	O
]	O
(	O
release	O
2012	O
March	O
08	O
)	O
software	O
packages	O
.	O

A	O
mean	O
coverage	O
of	O
133X	O
was	O
obtained	O
for	O
all	O
consensus	O
coding	O
sequence	O
(	O
CCDS	O
)	O
exons	O
using	O
the	O
Genome	O
Analysis	O
Toolkit	O
(	O
GATK	O
)	O
[	O
34	O
]	O
.	O

6B	O
)	O
.	O

Most	O
patients	O
with	O
neonatal	B-DISEASE
diabetes	I-DISEASE
caused	O
by	O
mutations	O
in	O
the	O
KCNJ11	B-GENE
or	O
ABCC8	B-GENE
genes	O
encoding	O
the	O
K	O
-	O
ATP	O
channel	O
subunits	O
Kir6	B-GENE
.	I-GENE
2	I-GENE
or	O
SUR1	B-GENE
achieve	O
improved	O
glycaemic	O
control	O
with	O
high	O
-	O
dose	O
sulfonylureas	O
[	O
2	O
]	O
.	O

The	O
onset	O
of	O
visual	B-DISEASE
impairment	I-DISEASE
caused	O
by	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
accompanied	O
by	O
USH1D	B-DISEASE
generally	O
occurs	O
during	O
adolescence	O
[	O
9	O
]	O
.	O

For	O
MA17	O
,	O
family	O
history	O
suggested	O
recessive	O
inheritance	O
of	O
RCD	B-DISEASE
caused	O
by	O
an	O
autozygous	O
mutation	O
.	O

Expressivity	O
and	O
penetrance	O
of	O
these	O
features	O
are	O
highly	O
variable	O
and	O
,	O
consistent	O
with	O
this	O
,	O
chromosome	O
22q11	O
.	O
2	O
deletions	O
have	O
been	O
identified	O
in	O
DiGeorge	O
syndrome	O
(	O
DGS	O
)	O
and	O
velocardiofacial	O
syndrome	O
(	O
VCFS	O
)	O
with	O
overlapping	O
but	O
different	O
patterns	O
of	O
clinical	O
features	O
[	O
1	O
]	O
.	O

The	O
same	O
systematic	O
prioritization	O
process	O
was	O
subsequently	O
applied	O
to	O
all	O
variants	O
in	O
the	O
molecularly	O
undiagnosed	O
RP	B-DISEASE
cohort	O
of	O
100	O
patients	O
.	O

We	O
captured	O
90	O
%	O
of	O
our	O
nuclear	O
target	O
regions	O
at	O
>	O
=	O
100X	O
coverage	O
and	O
achieved	O
3	O
,	O
359X	O
median	O
coverage	O
per	O
pool	O
,	O
corresponding	O
to	O
an	O
average	O
of	O
168X	O
per	O
individual	O
(	O
Supplementary	O
Fig	O
.	O

(	O
B	O
)	O
Representative	O
morphology	O
of	O
otic	O
capsules	O
in	O
zebrafish	O
embryos	O
at	O
72	O
hpf	O
either	O
injected	O
with	O
a	O
control	O
MO	O
or	O
MO	O
e1i1	O
.	O

Figure	O
2	O
Characteristic	O
radiologic	O
and	O
audiologic	O
markers	O
.	O

This	O
work	O
was	O
supported	O
by	O
Beijing	O
Nature	O
Science	O
Foundation	O
(	O
7102148	O
)	O
and	O
Ministry	O
of	O
Human	O
Resources	O
and	O
Social	O
Security	O
of	O
the	O
People	O
'	O
s	O
Republic	O
of	O
China	O
and	O
the	O
Foundation	O
Fighting	O
Blindness	O
,	O
USA	O
(	O
Grant	O
No	O
.	O
:	O
CD	O
-	O
CL	O
-	O
0808	O
-	O
0470	O
-	O
PUMCH	O
)	O
.	O

Detailed	O
ophthalmologic	O
examinations	O
of	O
the	O
subjects	O
,	O
including	O
visual	O
acuity	O
,	O
slit	O
-	O
lamp	O
biomicroscopy	O
,	O
applanation	O
intraocular	O
pressure	O
,	O
visual	O
field	O
,	O
dilated	O
funduscopic	O
examination	O
,	O
and	O
fundus	O
photography	O
,	O
as	O
well	O
as	O
audiometric	O
tests	O
,	O
were	O
performed	O
at	O
the	O
Union	O
Hospital	O
,	O
Tongji	O
Medical	O
College	O
,	O
Huazhong	O
University	O
of	O
Science	O
and	O
Technology	O
.	O

The	O
most	O
prevalent	O
USH2A	B-GENE
mutation	O
in	O
non	B-DISEASE
-	I-DISEASE
syndromic	I-DISEASE
RP	I-DISEASE
,	O
p	B-VARIANT
.	I-VARIANT
C759F	I-VARIANT
[	O
32	O
]	O
,	O
[	O
41	O
]	O
,	O
was	O
also	O
present	O
in	O
three	O
families	O
of	O
our	O
cohort	O
.	O

Undetected	O
variants	O
are	O
explained	O
.	O

ECochG	O
recordings	O
obtained	O
at	O
100	O
dB	O
SPL	O
from	O
one	O
control	O
with	O
normal	O
hearing	O
and	O
two	O
OPA1	B-GENE
-	O
M	O
patients	O
in	O
response	O
to	O
the	O
stimulus	O
sequence	O
reported	O
at	O
the	O
bottom	O
are	O
illustrated	O
in	O
the	O
left	O
panel	O
.	O

Pfeiffer	B-DISEASE
syndrome	I-DISEASE
is	O
divided	O
into	O
three	O
subtypes	O
9	O
)	O
.	O

She	O
was	O
found	O
to	O
carry	O
two	O
normal	O
copies	O
of	O
MYO7A	B-GENE
exon	O
11	O
.	O

The	O
USH2A	B-GENE
:	O
p	B-VARIANT
.	I-VARIANT
Glu767SerfsX21	I-VARIANT
mutation	O
was	O
the	O
most	O
common	O
mutation	O
in	O
the	O
entire	O
USH	B-DISEASE
cohort	O
,	O
accounting	O
for	O
31	O
%	O
of	O
all	O
USH2	B-DISEASE
alleles	O
and	O
33	O
.	O
7	O
%	O
of	O
identified	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
USH2A	B-GENE
alleles	O
.	O

Duplicate	O
reads	O
were	O
marked	O
using	O
Picard	O
(	O
http	O
:	O
/	O
/	O
picard	O
.	O
sourceforge	O
.	O
net	O
)	O
and	O
were	O
excluded	O
.	O

19	O
,	O
25	O
The	O
clinical	O
features	O
of	O
that	O
family	O
were	O
fluctuating	O
,	O
progressive	O
,	O
sensorineural	O
HL	B-DISEASE
that	O
began	O
in	O
the	O
second	O
decade	O
and	O
led	O
to	O
severe	B-DISEASE
-	I-DISEASE
to	I-DISEASE
-	I-DISEASE
profound	I-DISEASE
HL	I-DISEASE
by	O
the	O
age	O
of	O
40	O
years	O
old	O
.	O

This	O
variant	O
is	O
predicted	O
to	O
truncate	O
the	O
protein	O
in	O
the	O
EC2	O
domain	O
.	O

All	O
pathogenic	O
variants	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Activation	O
curves	O
were	O
calculated	O
from	O
b	O
,	O
while	O
the	O
inactivation	O
curves	O
were	O
calculated	O
from	O
fits	O
of	O
the	O
inactivation	O
time	O
courses	O
.	O

Whenever	O
substitutions	O
were	O
identified	O
in	O
a	O
patient	O
,	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
or	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
was	O
performed	O
on	O
all	O
available	O
family	O
members	O
and	O
the	O
control	O
group	O
.	O

DFNB31	B-GENE
was	O
screened	O
in	O
149	O
USH2	B-DISEASE
,	O
29	O
USH1	B-DISEASE
,	O
six	O
atypical	O
USH	B-DISEASE
,	O
and	O
11	O
unclassified	O
USH	B-DISEASE
patients	O
from	O
diverse	O
ethnic	O
backgrounds	O
.	O

Twenty	O
-	O
seven	O
patients	O
(	O
67	O
.	O
5	O
%	O
)	O
from	O
18	O
families	O
had	O
mutations	O
in	O
both	O
alleles	O
,	O
of	O
whom	O
8	O
probands	O
and	O
8	O
secondary	O
patients	O
were	O
in	O
consanguineous	O
families	O
(	O
i	O
.	O
e	O
.	O
,	O
W1	O
,	O
W3	O
,	O
W4	O
,	O
W6	O
,	O
W7	O
,	O
W9	O
,	O
W17	O
and	O
W18	O
)	O
.	O

Immittance	O
testing	O
was	O
used	O
to	O
evaluate	O
the	O
middle	O
-	O
ear	O
pressure	O
,	O
ear	O
canal	O
volume	O
,	O
and	O
tympanic	O
membrane	O
mobility	O
.	O

gallus	O
,	O
NP_001026515	O
.	O
1	O
;	O
P	O
.	O

(	O
c	O
)	O
Electrophoregrams	O
of	O
WFS1	B-GENE
gene	O
sequences	O
flanking	O
position	O
2005	O
of	O
the	O
affected	O
and	O
unaffected	O
family	O
members	O
.	O

NA	O
:	O
Not	O
applicable	O
.	O

Current	O
clinical	O
practices	O
have	O
focused	O
on	O
the	O
systematic	O
evaluation	O
of	O
a	O
set	O
of	O
known	O
genes	O
for	O
each	O
phenotype	O
,	O
but	O
this	O
approach	O
may	O
fail	O
in	O
patients	O
with	O
inaccurate	O
diagnosis	O
or	O
infrequent	O
genetic	O
cause	O
.	O

Among	O
19	O
patients	O
carrying	O
a	O
single	O
mutation	O
,	O
10	O
were	O
heterozygous	O
for	O
an	O
USH2A	B-GENE
pathogenic	O
allele	O
.	O

We	O
also	O
included	O
baits	O
for	O
sequencing	O
815	O
miRNA	O
that	O
were	O
already	O
predesigned	O
by	O
Agilent	O
.	O

Usher	B-DISEASE
syndrome	I-DISEASE
(	O
USH	B-DISEASE
)	O
is	O
an	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
the	O
association	O
of	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
(	O
RP	B-DISEASE
)	O
and	O
sensorineural	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
(	O
SNHL	B-DISEASE
)	O
,	O
with	O
or	O
without	O
vestibular	B-DISEASE
dysfunction	I-DISEASE
.	O

Recent	O
advances	O
in	O
technology	O
have	O
provided	O
powerful	O
tools	O
for	O
the	O
detection	O
and	O
analysis	O
of	O
CNVs	O
at	O
either	O
the	O
whole	O
-	O
genome	O
level	O
or	O
for	O
targeted	O
loci	O
.	O

f	O
,	O
female	O
;	O
m	O
,	O
male	O
;	O
(	O
+	O
)	O
,	O
mild	O
;	O
+	O
,	O
moderate	O
;	O
+	O
+	O
,	O
severe	O
;	O
n	O
.	O
a	O
.	O
,	O
not	O
available	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
stable	O
NARS2	B-GENE
over	O
-	O
expression	O
cell	O
lines	O
were	O
generated	O
by	O
lentiviral	O
transduction	O
of	O
patient	O
II	O
.	O
1	O
fibroblasts	O
with	O
cDNA	O
constructs	O
encoding	O
human	O
wild	O
type	O
or	O
p	B-VARIANT
.	I-VARIANT
Val213Phe	I-VARIANT
mutant	O
NARS2	B-GENE
cloned	O
into	O
a	O
pLVX	O
-	O
IRES	O
-	O
tdTomato	O
lentiviral	O
plasmid	O
.	O

Finally	O
,	O
although	O
it	O
has	O
been	O
proposed	O
that	O
COL9	O
-	O
MED	B-DISEASE
mutations	O
are	O
more	O
prevalent	O
in	O
Japan	O
[	O
Itoh	O
et	O
al	O
.	O
,	O
2006	O
]	O
,	O
it	O
is	O
interesting	O
to	O
note	O
that	O
of	O
the	O
14	O
COL9A2	B-GENE
mutations	O
published	O
to	O
date	O
,	O
12	O
have	O
actually	O
been	O
identified	O
in	O
families	O
from	O
Northern	O
Europe	O
(	O
UK	O
[	O
3	O
]	O
,	O
Netherlands	O
[	O
4	O
]	O
,	O
Germany	O
[	O
2	O
]	O
,	O
Sweden	O
[	O
1	O
]	O
,	O
and	O
unspecified	O
[	O
1	O
]	O
)	O
.	O

Firstly	O
,	O
due	O
to	O
the	O
presence	O
of	O
repetitive	O
sequences	O
,	O
not	O
all	O
fragments	O
can	O
be	O
included	O
in	O
the	O
selection	O
set	O
.	O

Autosomal	B-DISEASE
dominant	I-DISEASE
NSHI	I-DISEASE
(	O
ADNSHI	B-DISEASE
)	O
shows	O
great	O
variation	O
in	O
age	O
of	O
onset	O
,	O
rate	O
of	O
progression	O
,	O
severity	O
and	O
frequencies	O
affected	O
in	O
contrast	O
to	O
autosomal	B-DISEASE
recessive	I-DISEASE
NSHI	I-DISEASE
(	O
ARNSHI	B-DISEASE
)	O
that	O
is	O
usually	O
congenital	O
/	O
prelingual	O
and	O
non	O
-	O
progressive	O
[	O
1	O
]	O
.	O

Patient	O
P0432	O
has	O
a	O
c	B-VARIANT
.	I-VARIANT
4030_4037delATGGCTGG	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
M1344fsX42	I-VARIANT
)	O
mutation	O
in	O
USH2A	B-GENE
and	O
a	O
missense	O
mutation	O
in	O
CDH23	B-GENE
(	O
p	B-VARIANT
.	I-VARIANT
R1189W	I-VARIANT
)	O
,	O
but	O
his	O
father	O
,	O
who	O
has	O
neither	O
deafness	B-DISEASE
nor	O
retinitis	B-DISEASE
pigmentosa	I-DISEASE
,	O
also	O
carries	O
these	O
two	O
mutations	O
,	O
and	O
his	O
clinically	O
affected	O
sister	O
does	O
not	O
carry	O
the	O
mutation	O
in	O
CDH23	B-GENE
.	O

The	O
experiment	O
was	O
performed	O
in	O
triplicate	O
.	O

Gain	O
-	O
of	O
-	O
function	O
mutations	O
of	O
the	O
I	B-GENE
Ks	I-GENE
channel	O
are	O
expected	O
to	O
increase	O
the	O
repolarising	O
potassium	O
currents	O
which	O
could	O
abbreviate	O
the	O
cardiac	O
action	O
potential	O
duration	O
as	O
well	O
as	O
the	O
effective	O
refractory	O
period	O
in	O
cardiomyocytes	O
.	O

On	O
sequencing	O
of	O
the	O
mutation	O
regions	O
in	O
105	O
samples	O
from	O
the	O
normal	O
Brazilian	O
population	O
,	O
and	O
in	O
the	O
65	O
genetically	O
independent	O
cases	O
,	O
none	O
of	O
the	O
mutations	O
were	O
detected	O
.	O

5a	O
,	O
b	O
)	O
and	O
at	O
P21	O
stereocilia	O
were	O
thinner	O
and	O
at	O
times	O
also	O
shorter	O
(	O
Fig	O
.	O

In	O
situ	O
hybridization	O
studies	O
of	O
the	O
Tcof1	B-GENE
orthologue	O
demonstrated	O
that	O
there	O
is	O
a	O
peak	O
of	O
expression	O
of	O
the	O
gene	O
in	O
E8	O
.	O
5	O
-	O
9	O
.	O
5	O
mice	O
embryos	O
,	O
especially	O
in	O
the	O
first	O
and	O
second	O
pharyngeal	O
arches	O
[	O
11	O
]	O
.	O

EVA	B-DISEASE
is	O
the	O
most	O
common	O
form	O
of	O
the	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
associated	O
with	O
prelingual	O
or	O
postlingual	O
sensorineural	O
hearing	B-DISEASE
loss	I-DISEASE
and	O
is	O
an	O
important	O
feature	O
of	O
PS	B-DISEASE
[	O
17	O
,	O
18	O
]	O
.	O

This	O
may	O
partially	O
be	O
attributed	O
to	O
the	O
small	O
sample	O
sizes	O
and	O
/	O
or	O
selection	O
bias	O
;	O
However	O
,	O
this	O
frequency	O
might	O
reflect	O
the	O
prevalence	O
of	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
in	O
this	O
cohort	O
and	O
c	B-VARIANT
.	I-VARIANT
109G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
might	O
be	O
ascribed	O
to	O
founder	O
effect	O
in	O
south	O
Chinese	O
.	O

B	O
:	O
Ex	O
vivo	O
splicing	O
assays	O
were	O
performed	O
.	O

The	O
p	B-VARIANT
.	I-VARIANT
Asn109_Pro111dup	I-VARIANT
mutation	O
,	O
reported	O
in	O
a	O
consanguineous	O
Saudi	O
family	O
,	O
was	O
associated	O
with	O
a	O
non	O
-	O
progressive	O
downsloping	O
audiogram	O
from	O
severe	O
to	O
profound	O
across	O
higher	O
frequencies	O
.	O

(	O
c	O
)	O
WFS1	B-GENE
c	B-VARIANT
.	I-VARIANT
1957C	I-VARIANT
>	I-VARIANT
T	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
R653C	I-VARIANT
)	O
missense	O
mutation	O
in	O
the	O
JSNY	O
-	O
033	O
family	O
.	O

The	O
expression	O
of	O
wolframin	B-GENE
has	O
been	O
localized	O
to	O
the	O
mouse	O
cochlea	O
at	O
different	O
developmental	O
stages	O
and	O
is	O
widely	O
distributed	O
in	O
different	O
cochlear	O
cell	O
types	O
,	O
including	O
inner	O
and	O
outer	O
hair	O
cells	O
,	O
a	O
variety	O
of	O
supporting	O
cells	O
,	O
and	O
cells	O
of	O
the	O
lateral	O
wall	O
,	O
spiral	O
ganglion	O
,	O
and	O
vestibule	O
[	O
33	O
]	O
.	O

In	O
family	O
4	O
(	O
Figure	O
1	O
D	O
)	O
,	O
subjects	O
I	O
:	O
2	O
and	O
II	O
:	O
1	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
did	O
not	O
have	O
candidate	O
mutations	O
in	O
the	O
first	O
61	O
genes	O
.	O

In	O
order	O
to	O
compare	O
the	O
activation	O
kinetics	O
we	O
determined	O
the	O
time	O
needed	O
to	O
reach	O
the	O
half	O
-	O
maximal	O
current	O
level	O
(	O
t	O
1	O
/	O
2	O
)	O
.	O

These	O
variants	O
were	O
not	O
observed	O
in	O
over	O
6	O
,	O
500	O
individuals	O
of	O
European	O
and	O
African	O
American	O
ancestry	O
in	O
the	O
NHLBI	O
Exome	O
Sequencing	O
Project	O
database	O
,	O
in	O
the	O
ExAc	O
data	O
set	O
nor	O
in	O
our	O
internal	O
variant	O
databases	O
.	O

There	O
is	O
no	O
reduction	O
or	O
absence	O
of	O
cytochrome	O
-	O
c	O
-	O
oxidase	O
histochemical	O
reactions	O
observed	O
(	O
G	O
)	O
.	O

The	O
clinical	O
features	O
of	O
these	O
patients	O
are	O
reported	O
in	O
Table	O
1	O
.	O

Of	O
the	O
Pendred	B-DISEASE
syndrome	I-DISEASE
patients	O
,	O
93	O
%	O
(	O
14	O
/	O
15	O
)	O
were	O
carriers	O
,	O
as	O
were	O
77	O
%	O
(	O
49	O
/	O
64	O
)	O
of	O
the	O
nonsyndromic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
patients	O
.	O

For	O
PhyloP	O
prediction	O
,	O
C	O
:	O
Conserved	O
,	O
NC	O
:	O
Not	O
conserved	O
.	O

To	O
prioritize	O
the	O
disease	O
-	O
causing	O
variants	O
,	O
we	O
excluded	O
the	O
variants	O
whose	O
allele	O
frequencies	O
are	O
greater	O
than	O
0	O
.	O
01	O
in	O
both	O
the	O
public	O
databases	O
and	O
the	O
in	O
-	O
house	O
exome	O
database	O
consisting	O
170	O
unrelated	O
samples	O
.	O

He	O
was	O
delivered	O
after	O
an	O
uncomplicated	O
pregnancy	O
by	O
Cesarean	O
section	O
due	O
to	O
fetal	B-DISEASE
distress	I-DISEASE
.	O

Primers	O
of	O
TECTA	B-GENE
and	O
SLC26A4	B-GENE
gene	O
We	O
ascertained	O
a	O
Mongolian	O
family	O
with	O
autosomal	B-DISEASE
dominant	I-DISEASE
nonsyndromic	I-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
.	O

PCR	O
assays	O
were	O
used	O
for	O
MYO15A	B-GENE
c	B-VARIANT
.	I-VARIANT
4240G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E1414K	I-VARIANT
)	O
and	O
WFS1	B-GENE
c	B-VARIANT
.	I-VARIANT
2765G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
E864K	I-VARIANT
)	O
(	O
Additional	O
file	O
4	O
)	O
.	O

Two	O
patients	O
carried	O
V659L	B-VARIANT
,	O
including	O
1	O
who	O
was	O
verified	O
to	O
have	O
EVA	B-DISEASE
by	O
CT	O
scan	O
.	O

(	O
A	O
)	O
BLAT	O
alignment	O
of	O
the	O
sequenced	O
cDNA	O
(	O
labeled	O
"	O
CD164	B-GENE
transcript	O
"	O
in	O
the	O
"	O
your	O
sequence	O
from	O
Blat	O
search	O
"	O
track	O
)	O
from	O
peripheral	O
blood	O
from	O
a	O
patient	O
.	O

All	O
authors	O
had	O
final	O
approval	O
of	O
the	O
submitted	O
and	O
published	O
versions	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
patient	O
with	O
confirmed	O
compound	O
heterozygosity	O
of	O
OPA1	B-GENE
mutations	O
in	O
our	O
study	O
is	O
the	O
fourth	O
case	O
reported	O
so	O
far	O
[	O
38	O
,	O
39	O
]	O
,	O
which	O
represents	O
a	O
rare	O
event	O
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
the	O
isolated	O
MD	B-DISEASE
and	O
IEM	B-DISEASE
groups	O
(	O
P	O
>	O
0	O
.	O
5	O
)	O
and	O
no	O
difference	O
in	O
mutation	O
distribution	O
between	O
the	O
EVA	B-DISEASE
with	O
MD	B-DISEASE
group	O
and	O
EVA	B-DISEASE
group	O
(	O
P	O
>	O
0	O
.	O
5	O
)	O
.	O

An	O
analysis	O
of	O
high	O
-	O
frequency	O
thresholds	O
versus	O
age	O
(	O
Fig	O
.	O

No	O
known	O
or	O
potential	O
pathogenic	O
mtDNA	O
variants	O
were	O
identified	O
.	O

Sixty	O
-	O
five	O
trios	O
were	O
recruited	O
at	O
the	O
Genome	O
Sequencing	O
Clinic	O
at	O
Duke	O
University	O
Medical	O
Center	O
,	O
and	O
48	O
were	O
recruited	O
at	O
the	O
pediatric	O
clinic	O
of	O
the	O
Sheba	O
Medical	O
Center	O
in	O
Tel	O
HaShomer	O
,	O
Israel	O
.	O

Cells	O
were	O
then	O
incubated	O
at	O
RT	O
for	O
12	O
min	O
in	O
a	O
solution	O
containing	O
140	O
mM	O
K	O
-	O
gluconate	O
,	O
20	O
mM	O
HEPES	O
and	O
5	O
mM	O
glucose	O
(	O
pH	O
7	O
.	O
3	O
and	O
305	O
Osm	O
/	O
L	O
)	O
.	O

12	O
)	O
reported	O
that	O
a	O
daughter	O
had	O
unilateral	O
renal	O
agenesis	O
and	O
her	O
mother	O
had	O
a	O
nonfictional	O
kidney	O
a	O
patient	O
although	O
they	O
were	O
diagnosed	O
same	O
GATA3	B-GENE
mutation	O
.	O

Samples	O
were	O
fragmented	O
using	O
a	O
Bioruptor	O
(	O
Diagenode	O
,	O
Li	O
e	O
ge	O
,	O
Belgium	O
)	O
,	O
indexed	O
for	O
multiplexing	O
and	O
hybridised	O
(	O
in	O
pools	O
of	O
12	O
samples	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

We	O
computed	O
single	O
-	O
point	O
LOD	O
scores	O
for	O
all	O
markers	O
.	O

The	O
positions	O
G25	O
and	O
G60	O
in	O
KCNE1	B-GENE
are	O
highly	O
conserved	O
across	O
species	O
suggesting	O
a	O
functional	O
importance	O
(	O
Additional	O
file	O
1	O
:	O
Figure	O
S1	O
)	O
.	O

Three	O
distinct	O
pathogenic	O
or	O
presumably	O
pathogenic	O
mutations	O
in	O
USH1C	B-GENE
were	O
detected	O
in	O
three	O
patients	O
,	O
specifically	O
,	O
a	O
nucleotide	O
duplication	O
(	O
c	B-VARIANT
.	I-VARIANT
238_239dupC	I-VARIANT
;	I-VARIANT
p	B-VARIANT
.	I-VARIANT
R80fsX69	I-VARIANT
)	O
already	O
reported	O
in	O
several	O
patients	O
[	O
3	O
,	O
4	O
,	O
27	O
,	O
53	O
]	O
,	O
a	O
known	O
missense	O
mutation	O
(	O
p	O
.	O
R103H	O
)	O
affecting	O
an	O
amino	O
acid	O
residue	O
located	O
in	O
the	O
PDZ1	O
domain	O
of	O
the	O
protein	O
[	O
27	O
]	O
,	O
and	O
a	O
novel	O
missense	O
mutation	O
(	O
p	B-VARIANT
.	I-VARIANT
R357W	I-VARIANT
)	O
,	O
predicted	O
to	O
affect	O
the	O
first	O
coiled	O
-	O
coil	O
domain	O
of	O
the	O
protein	O
.	O

Thus	O
,	O
variance	O
in	O
expression	O
levels	O
at	O
different	O
time	O
points	O
could	O
account	O
for	O
the	O
intra	O
-	O
familial	O
variability	O
,	O
including	O
that	O
of	O
individual	O
II	O
-	O
5	O
.	O

Gene	O
sequencing	O
were	O
performed	O
for	O
all	O
of	O
them	O
.	O

(	O
A	O
)	O
RT	O
-	O
PCR	O
demonstrating	O
knock	O
down	O
of	O
homer2	B-GENE
transcript	O
using	O
two	O
morpholinos	O
:	O
MO	O
e1i1	O
and	O
MO	O
i3e4	O
.	O

1987	O
)	O
.	O

Out	O
of	O
199	O
Uyghur	O
patients	O
,	O
22	O
(	O
11	O
.	O
1	O
%	O
)	O
patients	O
exhibited	O
mutations	O
in	O
one	O
allele	O
or	O
more	O
.	O

Of	O
the	O
711	O
patients	O
analyzed	O
on	O
v5	O
,	O
11	O
patients	O
carried	O
causative	O
variants	O
in	O
genes	O
not	O
included	O
in	O
v4	O
,	O
thus	O
increasing	O
the	O
diagnostic	O
rate	O
by	O
2	O
%	O
in	O
all	O
patients	O
screened	O
with	O
V5	O
and	O
accounting	O
for	O
4	O
%	O
of	O
all	O
positive	O
diagnoses	O
(	O
11	O
of	O
263	O
positive	O
diagnoses	O
)	O
.	O

We	O
also	O
filtered	O
out	O
additional	O
variants	O
that	O
were	O
observed	O
in	O
six	O
ethnically	O
matched	O
control	O
exomes	O
.	O

A	O
history	O
of	O
hip	O
disorder	O
and	O
typical	O
radiologic	O
findings	O
lend	O
support	O
to	O
the	O
idea	O
that	O
the	O
identified	O
mutation	O
in	O
the	O
COL2A1	B-GENE
gene	O
transition	O
might	O
be	O
the	O
cause	O
of	O
the	O
disease	O
in	O
this	O
family	O
.	O

Four	O
microsatellite	O
markers	O
,	O
D8S1795	O
,	O
D8S1060	O
,	O
D8S1807	O
and	O
D8S570	O
,	O
in	O
the	O
region	O
of	O
2	O
Mb	O
including	O
the	O
EYA1	B-GENE
gene	O
were	O
selected	O
from	O
the	O
NCBI	O
database	O
(	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
gov	O
)	O
considering	O
their	O
heterozygosity	O
.	O

reported	O
their	O
identification	O
of	O
a	O
heterozygous	O
missense	O
CEACAM16	B-GENE
mutation	O
in	O
the	O
family	O
1070	O
(	O
i	O
.	O
e	O
.	O

Except	O
the	O
V142fsX251	B-VARIANT
found	O
in	O
exon	O
4	O
,	O
all	O
the	O
detected	O
mutations	O
are	O
located	O
in	O
exon	O
8	O
,	O
corresponding	O
to	O
the	O
transmembrane	O
region	O
and	O
carboxytail	O
of	O
Wolframin	O
protein	O
.	O

The	O
first	O
one	O
being	O
that	O
cardiac	O
action	O
potential	O
shortening	O
functions	O
as	O
a	O
substrate	O
for	O
re	B-DISEASE
-	I-DISEASE
entry	I-DISEASE
wavelets	I-DISEASE
in	I-DISEASE
the	I-DISEASE
atria	I-DISEASE
[	O
10	O
,	O
11	O
]	O
the	O
second	O
one	O
proposing	O
that	O
a	O
prolonged	B-DISEASE
effective	I-DISEASE
refractory	I-DISEASE
period	I-DISEASE
enhances	O
the	O
propensity	O
for	O
early	B-DISEASE
after	I-DISEASE
depolarization	I-DISEASE
,	O
and	O
thereby	O
increasing	O
the	O
susceptibility	O
to	O
AF	B-DISEASE
[	O
12	O
]	O
.	O

From	O
family	O
histories	O
,	O
79	O
patients	O
were	O
classified	O
as	O
sporadic	O
cases	O
,	O
54	O
defined	O
as	O
familial	O
cases	O
,	O
including	O
33	O
with	O
autosomal	O
recessive	O
,	O
19	O
with	O
autosomal	O
dominant	O
,	O
one	O
with	O
X	O
-	O
linked	O
and	O
one	O
ambiguous	O
modes	O
of	O
inheritance	O
.	O

-	I-VARIANT
22	I-VARIANT
-	I-VARIANT
2A	I-VARIANT
>	I-VARIANT
C	I-VARIANT
)	O
which	O
belongs	O
to	O
the	O
small	O
group	O
of	O
DFNB1	B-GENE
-	O
causing	O
mutations	O
that	O
lie	O
outside	O
the	O
coding	O
region	O
of	O
the	O
GJB2	B-GENE
gene	O
.	O

To	O
overcome	O
this	O
,	O
Sanger	O
sequencing	O
of	O
the	O
poorly	O
targeted	O
genes	O
can	O
be	O
performed	O
.	O

Tenascin	O
-	O
C	O
managed	O
the	O
recovery	O
of	O
sensory	O
receptors	O
in	O
vestibular	O
organ	O
in	O
birds	O
after	O
ototoxic	O
injury	O
[	O
15	O
]	O
.	O

Reversely	O
,	O
patients	O
with	O
ATP6V1B1	B-GENE
mutations	O
may	O
not	O
present	O
hearing	B-DISEASE
loss	I-DISEASE
[	O
11	O
]	O
.	O

48	O
Calcium	O
levels	O
control	O
many	O
aspects	O
of	O
Drosophila	O
phototransduction	O
.	O

Speech	O
audiometry	O
was	O
performed	O
under	O
the	O
aforementioned	O
conditions	O
using	O
standard	O
Dutch	O
monosyllabic	O
consonant	O
-	O
vocal	O
-	O
consonant	O
word	O
lists	O
.	O

In	O
all	O
patients	O
,	O
the	O
fixation	O
was	O
centered	O
on	O
the	O
macula	O
.	O

Constipation	B-DISEASE
(	O
seven	O
subjects	O
,	O
39	O
%	O
)	O
and	O
a	O
loss	B-DISEASE
of	I-DISEASE
normal	I-DISEASE
taste	I-DISEASE
sensation	I-DISEASE
(	O
three	O
subjects	O
,	O
17	O
%	O
)	O
were	O
reported	O
in	O
several	O
.	O

Upper	O
left	O
represents	O
dystopia	B-DISEASE
canthorum	I-DISEASE
.	O

Whilst	O
a	O
mild	O
crouzonoid	O
phenotype	O
was	O
generally	O
evident	O
,	O
only	O
a	O
minority	O
of	O
individuals	O
developed	O
overt	O
craniosynostosis	B-DISEASE
requiring	O
calvarial	O
surgery	O
.	O

Performed	O
the	O
experiments	O
:	O
DF	O
DL	O
DJ	O
.	O

Thus	O
,	O
45	O
probands	O
were	O
available	O
for	O
the	O
final	O
analysis	O
of	O
targeted	O
resequencing	O
results	O
.	O

The	O
visual	O
field	O
loss	O
was	O
concentric	O
,	O
and	O
the	O
degree	O
of	O
visual	O
acuity	O
ranged	O
from	O
0	O
.	O
15	O
to	O
0	O
.	O
8	O
,	O
depending	O
on	O
the	O
age	O
at	O
ophthalmological	O
evaluation	O
and	O
the	O
degree	O
of	O
progression	O
of	O
the	O
disease	O
.	O

Supported	O
by	O
the	O
NIH	O
Centers	O
for	O
Mendelian	O
Genomics	O
(	O
5U54HG006504	O
)	O
,	O
the	O
Fondation	O
Leducq	O
Transatlantic	O
Network	O
in	O
Hypertension	O
,	O
the	O
Deutsche	O
Forschungsgemeinschaft	O
and	O
by	O
the	O
Swedish	O
Cancer	O
Society	O
,	O
the	O
Swedish	O
Research	O
Council	O
,	O
and	O
the	O
Lions	O
Cancer	O
Fund	O
,	O
Uppsala	O
.	O

The	O
whole	O
-	O
genome	O
scan	O
was	O
performed	O
by	O
the	O
Affymetrix	O
GeneChip	O
Human	O
Mapping	O
250	O
K	O
Nsp	O
I	O
Array	O
Set	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
,	O
using	O
standard	O
protocols	O
as	O
described	O
in	O
the	O
GeneChip	O
(	O
r	O
)	O
Mapping	O
500	O
K	O
Assay	O
Manual	O
.	O

A	O
.	O

The	O
proband	O
(	O
III	O
-	O
2	O
)	O
of	O
Family	O
DE2675	O
was	O
a	O
7	O
-	O
year	O
-	O
old	O
girl	O
with	O
mild	O
low	O
-	O
tone	O
hearing	B-DISEASE
loss	I-DISEASE
,	O
and	O
her	O
mother	O
'	O
s	O
(	O
II	O
-	O
2	O
)	O
hearing	B-DISEASE
loss	I-DISEASE
began	O
at	O
adolescence	O
and	O
gradually	O
deteriorated	O
to	O
mild	O
SNHI	B-DISEASE
until	O
her	O
current	O
age	O
(	O
Figure	O
3D	O
)	O
.	O

There	O
were	O
two	O
heterozygous	O
missense	O
variants	O
in	O
genes	O
contained	O
in	O
the	O
candidate	O
region	O
on	O
chromosome	O
20	O
:	O
The	O
variant	O
c	B-VARIANT
.	I-VARIANT
1202G	I-VARIANT
>	I-VARIANT
C	I-VARIANT
(	O
p	B-VARIANT
.	I-VARIANT
Arg401Pro	I-VARIANT
)	O
in	O
GTPBP5	B-GENE
affects	O
an	O
evolutionarily	O
non	O
-	O
conserved	O
residue	O
and	O
has	O
been	O
annotated	O
as	O
a	O
polymorphism	O
,	O
rs200118420	B-VARIANT
,	O
with	O
an	O
MAF	O
of	O
0	O
.	O
04	O
%	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Institutional	O
Review	O
Boards	O
of	O
the	O
Quaid	O
-	O
I	O
-	O
Azam	O
University	O
and	O
the	O
Baylor	O
College	O
of	O
Medicine	O
and	O
Affiliated	O
Hospitals	O
prior	O
to	O
initiation	O
.	O

The	O
pixel	O
intensity	O
analyses	O
were	O
performed	O
using	O
ImageJ	O
software	O
on	O
images	O
that	O
were	O
acquired	O
with	O
the	O
same	O
microscope	O
settings	O
.	O

Among	O
the	O
100	O
normal	O
hearing	O
controls	O
,	O
we	O
also	O
identified	O
6	O
carriers	O
with	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
,	O
revealing	O
an	O
allele	O
frequency	O
of	O
3	O
.	O
0	O
%	O
(	O
6	O
/	O
200	O
chromosomes	O
)	O
.	O

To	O
confirm	O
that	O
individuals	O
DNA11	O
-	O
01005	O
and	O
DNA11	O
-	O
00996	O
are	O
the	O
biological	O
parents	O
,	O
16	O
highly	O
polymorphic	O
markers	O
distributed	O
across	O
the	O
genome	O
were	O
analyzed	O
,	O
showing	O
a	O
perfect	O
Mendelian	O
inheritance	O
for	O
all	O
markers	O
,	O
thereby	O
confirming	O
the	O
de	O
novo	O
event	O
(	O
Supp	O
.	O

5	O
)	O
.	O

(	O
Fig	O
.	O

Figure	O
1	O
.	O

However	O
,	O
we	O
found	O
it	O
in	O
five	O
of	O
486	O
control	O
alleles	O
from	O
French	O
and	O
Maghreban	O
populations	O
.	O

no	O
.	O

Flannick	O
for	O
assistance	O
with	O
pooled	O
sequence	O
analysis	O
,	O
I	O
.	O

The	O
cases	O
were	O
15	O
unrelated	O
probands	O
from	O
Denmark	O
(	O
the	O
index	O
patient	O
from	O
12	O
families	O
and	O
3	O
sporadic	O
cases	O
)	O
selected	O
based	O
on	O
their	O
hearing	B-DISEASE
impairment	I-DISEASE
phenotype	O
with	O
basin	O
shaped	O
audiograms	O
,	O
25	O
index	O
patients	O
from	O
the	O
Netherlands	O
based	O
on	O
phenotype	O
with	O
postlingual	O
onset	O
(	O
1	O
st	O
or	O
2	O
nd	O
decade	O
)	O
,	O
progression	O
of	O
the	O
hearing	B-DISEASE
impairment	I-DISEASE
and	O
cookie	O
-	O
bite	O
or	O
flat	O
audiogram	O
configuration	O
,	O
and	O
6	O
probands	O
of	O
Pakistani	O
families	O
with	O
ARNSHI	B-DISEASE
that	O
displayed	O
linkage	O
to	O
chromosome	O
6	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
the	O
long	O
isoform	O
is	O
low	O
in	O
the	O
cochlea	O
[	O
7	O
]	O
,	O
which	O
could	O
possibly	O
help	O
to	O
explain	O
the	O
absence	O
of	O
hearing	O
and	O
vestibular	O
impairments	O
in	O
some	O
patients	O
with	O
USH2A	B-GENE
mutations	O
[	O
15	O
]	O
,	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
.	O

It	O
'	O
s	O
interesting	O
to	O
note	O
that	O
patient	O
18	O
with	O
inner	B-DISEASE
ear	I-DISEASE
malformation	I-DISEASE
carry	O
one	O
missense	O
mutation	O
only	O
,	O
whether	O
the	O
missense	O
mutation	O
causes	O
dominant	O
negative	O
effect	O
and	O
/	O
or	O
specifies	O
a	O
different	O
phenotype	O
is	O
not	O
clear	O
.	O

The	O
TECTA	B-GENE
gene	O
encodes	O
the	O
alpha	O
-	O
tectorin	O
protein	O
in	O
the	O
striated	O
sheet	O
matrix	O
,	O
whereas	O
the	O
TM	O
is	O
an	O
acellular	O
gelatinous	O
structure	O
that	O
contacts	O
the	O
hair	O
cells	O
in	O
the	O
organ	O
of	O
Corti	O
;	O
therefore	O
,	O
mutation	O
of	O
the	O
TECTA	B-GENE
gene	O
leads	O
to	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

The	O
mutation	O
may	O
have	O
a	O
common	O
ancestor	O
,	O
although	O
the	O
families	O
are	O
not	O
aware	O
that	O
they	O
are	O
related	O
.	O

This	O
is	O
mutation	O
is	O
detected	O
at	O
the	O
highest	O
rates	O
among	O
Asian	O
populations	O
,	O
with	O
incidences	O
of	O
approximately	O
41	O
%	O
and	O
57	O
%	O
in	O
two	O
Japanese	O
reports	O
,	O
67	O
%	O
in	O
one	O
Taiwanese	O
study	O
,	O
and	O
73	O
%	O
in	O
one	O
Korean	O
study	O
[	O
6	O
,	O
10	O
,	O
45	O
,	O
46	O
,	O
48	O
]	O
.	O

There	O
were	O
fewer	O
vaso	O
-	O
proliferative	O
lesions	O
than	O
in	O
proband	O
II	O
.	O
1	O
.	O

The	O
SALSA	O
MLPA	O
292	O
-	O
A1	O
kit	O
was	O
used	O
according	O
to	O
manufacturer	O
'	O
s	O
instructions	O
.	O

English	O
terms	O
for	O
disorders	O
were	O
included	O
since	O
most	O
Chinese	O
biomedical	O
articles	O
contain	O
an	O
English	O
abstract	O
.	O

Data	O
on	O
diabetes	B-DISEASE
onset	O
,	O
remission	O
phase	O
,	O
insulin	O
requirements	O
,	O
glycemic	O
control	O
,	O
and	O
complications	O
in	O
WSD	B-DISEASE
were	O
compared	O
with	O
the	O
corresponding	O
data	O
of	O
24	O
,	O
164	O
patients	O
with	O
type	B-DISEASE
1	I-DISEASE
diabetes	I-DISEASE
aged	O
<	O
21	O
years	O
from	O
the	O
DPV	O
database	O
.	O

Mingjie	O
Zhang	O
from	O
Hong	O
Kong	O
University	O
of	O
Science	O
and	O
Technology	O
for	O
myosin	B-GENE
VIIA	I-GENE
p	B-VARIANT
.	I-VARIANT
R668H	I-VARIANT
molecular	O
modeling	O
.	O
Pendred	B-DISEASE
syndrome	I-DISEASE
is	O
a	O
common	O
autosomal	O
recessive	O
disorder	O
causing	O
deafness	B-DISEASE
.	O

Electropherograms	O
from	O
Sanger	O
sequencing	O
of	O
the	O
no	O
-	O
stop	O
mutation	O
with	O
hemizygosity	O
in	O
patient	O
110	O
(	O
upper	O
panel	O
)	O
and	O
heterozygosity	O
in	O
her	O
mother	O
(	O
lower	O
panel	O
)	O
.	O

20	O
22	O
23	O
In	O
two	O
of	O
our	O
patients	O
with	O
Hartsfield	B-DISEASE
syndrome	I-DISEASE
,	O
we	O
identified	O
homozygous	O
mutations	O
affecting	O
amino	O
acid	O
residues	O
located	O
in	O
the	O
extracellular	O
ligand	O
binding	O
domain	O
D2	O
of	O
FGFR1	B-GENE
:	O
L165S	B-VARIANT
,	O
in	O
patient	O
1	O
,	O
with	O
a	O
severe	O
phenotype	O
,	O
and	O
L191S	B-VARIANT
,	O
in	O
patient	O
2	O
,	O
with	O
a	O
moderate	O
phenotype	O
(	O
table	O
1	O
,	O
figure	O
1	O
)	O
.	O

29	O
)	O
.	O

PCR	O
primers	O
surrounding	O
the	O
suspected	O
variants	O
of	O
7	O
genes	O
.	O

Molecular	O
genetic	O
diagnosis	O
for	O
USH	B-DISEASE
has	O
developed	O
from	O
the	O
scanning	O
of	O
restricted	O
portions	O
of	O
USH	B-DISEASE
genes	O
(	O
Adato	O
et	O
al	O
.	O

We	O
also	O
confirmed	O
that	O
the	O
mutation	O
was	O
not	O
observed	O
in	O
200	O
control	O
chromosomes	O
.	O

Patients	O
who	O
performed	O
temporal	O
MRI	O
;	O
TBCT	O
=	O
temporal	O
bone	O
computed	O
tomography	O
;	O
MRI	O
=	O
temporal	O
magnetic	O
resonance	O
imaging	O
;	O
CH	O
=	O
cochlear	B-DISEASE
hypoplasia	I-DISEASE
;	O
VA	O
=	O
vestibular	B-DISEASE
aqueduct	I-DISEASE
;	O
ME	O
=	O
middle	O
ear	O
;	O
FN	O
=	O
facial	O
nerve	O
;	O
IAC	O
=	O
internal	O
auditory	O
canal	O
;	O
ED	O
=	O
endolymphatic	O
duct	O
;	O
ES	O
=	O
endolymphatic	O
sac	O
;	O
LSCC	O
=	O
lateral	O
semicircular	O
canal	O
.	O

(	O
B	O
)	O
Reference	O
chromatogram	O
in	O
exon	O
34	O
.	O

OPA1	B-GENE
is	O
situated	O
on	O
chromosome	O
3q28	O
-	O
29	O
,	O
spans	O
approximately	O
100	O
kb	O
,	O
and	O
is	O
composed	O
of	O
30	O
coding	O
exons	O
.	O

We	O
expect	O
these	O
results	O
to	O
help	O
with	O
the	O
diagnosis	O
and	O
the	O
management	O
of	O
young	O
patients	O
with	O
HH	B-DISEASE
.	O

As	O
such	O
,	O
it	O
is	O
unlikely	O
that	O
GJB4	B-GENE
p	B-VARIANT
.	I-VARIANT
C169W	I-VARIANT
leads	O
to	O
ADNSHL	B-DISEASE
given	O
its	O
high	O
allele	O
frequency	O
in	O
the	O
population	O
.	O

ELMOD3	B-GENE
immunoreactivity	O
was	O
also	O
found	O
in	O
the	O
supporting	O
cells	O
,	O
including	O
pillar	O
and	O
Dieters	O
'	O
cells	O
(	O
Figure	O
3	O
)	O
.	O

A	O
clinical	O
description	O
of	O
patients	O
identified	O
through	O
a	O
Danish	O
nationwide	O
survey	O
comprising	O
59	O
families	O
(	O
all	O
contributing	O
to	O
the	O
current	O
survey	O
)	O
has	O
recently	O
been	O
published	O
[	O
12	O
]	O
.	O

Three	O
subjects	O
had	O
undergone	O
reversal	O
already	O
before	O
participating	O
in	O
this	O
study	O
.	O

Transcriptome	O
analysis	O
revealed	O
a	O
57	O
-	O
fold	O
enrichment	O
of	O
Cib2	B-GENE
mRNA	O
in	O
mouse	O
cochlear	O
hair	O
cells	O
at	O
postnatal	O
day	O
7	O
(	O
P7	O
)	O
as	O
compared	O
to	O
supporting	O
cells	O
(	O
SHIELD	O
,	O
see	O
URLs	O
)	O
.	O

We	O
thank	O
all	O
members	O
of	O
the	O
Northwest	O
Genomics	O
Center	O
and	O
Genomic	O
Disorders	O
Group	O
Nijmegen	O
,	O
as	O
well	O
as	O
personnel	O
from	O
the	O
Microarray	O
Facility	O
and	O
Sequencing	O
Facility	O
Nijmegen	O
for	O
excellent	O
technical	O
assistance	O
.	O

To	O
date	O
,	O
six	O
deafness	B-DISEASE
causing	O
recessive	O
mutations	O
in	O
this	O
gene	O
have	O
been	O
identified	O
in	O
15	O
families	O
worldwide	O
[	O
4	O
,	O
7	O
,	O
9	O
,	O
10	O
]	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
mutations	O
in	O
ACTG1	B-GENE
,	O
POU4F3	B-GENE
,	O
and	O
SLC26A5	B-GENE
in	O
Japanese	O
families	O
with	O
hearing	B-DISEASE
loss	I-DISEASE
.	O

D	O
,	O
Facial	O
appearance	O
of	O
III	O
-	O
1	O
from	O
Family	O
2	O
aged	O
8	O
.	O
75	O
years	O
(	O
left	O
)	O
and	O
43	O
years	O
(	O
right	O
)	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
USH2A	B-GENE
in	O
USH2	B-DISEASE
,	O
mutation	O
screening	O
was	O
undertaken	O
in	O
three	O
Chinese	O
families	O
with	O
USH2	B-DISEASE
.	O

Additionally	O
,	O
we	O
observe	O
germline	O
truncation	O
variants	O
in	O
genes	O
not	O
previously	O
associated	O
with	O
ovarian	B-DISEASE
cancer	I-DISEASE
susceptibility	O
(	O
NF1	B-GENE
,	O
MAP3K4	B-GENE
,	O
CDKN2B	B-GENE
,	O
and	O
MLL3	B-GENE
)	O
.	O

The	O
m	B-VARIANT
.	I-VARIANT
1555A	I-VARIANT
>	I-VARIANT
G	I-VARIANT
mutation	O
is	O
observed	O
in	O
approximately	O
0	O
.	O
6	O
-	O
2	O
.	O
5	O
%	O
of	O
Caucasian	O
patients	O
with	O
NSHI	B-DISEASE
[	O
23	O
]	O
,	O
but	O
more	O
frequently	O
in	O
the	O
Asian	O
population	O
,	O
including	O
China	O
2	O
.	O
9	O
%	O
,	O
Japan	O
3	O
%	O
[	O
24	O
]	O
,	O
and	O
Indonesia	O
5	O
.	O
3	O
%	O
[	O
25	O
]	O
.	O

Finally	O
,	O
we	O
identified	O
causative	O
mutations	O
currently	O
only	O
associated	O
with	O
other	O
macular	O
dystrophies	O
,	O
not	O
clinical	O
STGD	B-DISEASE
.	O

Additional	O
Capture	O
Next	O
Generation	O
Sequencing	O
information	O
is	O
in	O
Table	O
S1	O
,	O
S4	O
.	O

Patient	O
genotypes	O
Variants	O
understood	O
to	O
be	O
novel	O
at	O
the	O
time	O
this	O
manuscript	O
was	O
written	O
are	O
shown	O
in	O
bold	O
typeface	O
.	O

Expression	O
analysis	O
of	O
our	O
patient	O
(	O
A	O
)	O
,	O
her	O
father	O
(	O
B	O
)	O
and	O
her	O
grandmother	O
(	O
C	O
)	O
shows	O
a	O
G	O
-	O
A	O
transition	O
of	O
COL2A1	B-GENE
(	O
c	B-VARIANT
.	I-VARIANT
1744G	I-VARIANT
>	I-VARIANT
A	I-VARIANT
)	O
,	O
while	O
expression	O
analysis	O
of	O
her	O
mother	O
(	O
D	O
)	O
and	O
a	O
normal	O
control	O
(	O
E	O
)	O
shows	O
no	O
mutation	O
in	O
the	O
COL2A1	B-GENE
coding	O
region	O
.	O

Five	O
generations	O
were	O
included	O
and	O
three	O
generations	O
are	O
living	O
(	O
III	O
to	O
V	O
)	O
.	O

The	O
USH1G	B-GENE
gene	O
(	O
NM_173477	O
)	O
was	O
selected	O
as	O
the	O
first	O
choice	O
from	O
within	O
this	O
interval	O
as	O
the	O
most	O
likely	O
disease	O
-	O
causing	O
candidate	O
.	O

Analyzed	O
the	O
data	O
:	O
MSim	O
EMR	O
XW	O
MSis	O
MSh	O
VHH	O
WGN	O
RH	O
SNK	O
MXG	O
TBF	O
DKW	O
VP	O
ShR	O
DCW	O
ZMA	O
TH	O
SaR	O
.	O

The	O
genotypes	O
at	O
c	O
.	O
1030	O
,	O
c	O
.	O
778	O
,	O
c	O
.	O
1264	O
and	O
c	O
.	O
1265	O
for	O
the	O
available	O
members	O
in	O
the	O
corresponding	O
family	O
are	O
given	O
respectively	O
.	O

The	O
mutation	O
was	O
investigated	O
in	O
all	O
available	O
family	O
members	O
and	O
showed	O
full	O
co	O
-	O
segregation	O
with	O
the	O
deafness	B-DISEASE
.	O

RNA	O
extraction	O
from	O
nasal	O
epithelial	O
cells	O
and	O
RT	O
-	O
PCR	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
[	O
11	O
]	O
.	O

Specifically	O
,	O
coding	O
SNP	O
data	O
from	O
WES	O
can	O
be	O
used	O
to	O
establish	O
multiphasic	O
exome	O
analyses	O
based	O
on	O
linkages	O
and	O
SNVs	O
[	O
4	O
,	O
9	O
]	O
.	O

Six	O
of	O
the	O
other	O
TP53	B-GENE
variants	O
observed	O
in	O
our	O
cohort	O
lie	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
,	O
the	O
protein	O
domain	O
containing	O
the	O
majority	O
of	O
cancer	O
-	O
associated	O
missense	O
mutations	O
.	O

D	O
:	O
sense	O
strand	O
of	O
1042C	B-VARIANT
>	I-VARIANT
T	I-VARIANT
mutation	O
.	O

S2	O
)	O
.	O

a	O
Age	O
of	O
death	O
.	O

35	O
36	O
ANSD	B-DISEASE
is	O
known	O
to	O
be	O
an	O
extremely	O
complex	O
disease	O
that	O
has	O
congenital	O
and	O
acquired	O
forms	O
.	O

The	O
distribution	O
of	O
per	O
-	O
base	O
sequencing	O
depth	O
in	O
target	O
regions	O
for	O
each	O
sample	O
.	O

Identical	O
FGFR1	B-GENE
mutations	O
may	O
vary	O
in	O
phenotypic	O
severity	O
.	O

All	O
participants	O
signed	O
the	O
informed	O
consents	O
.	O

All	O
parameters	O
remained	O
within	O
the	O
normal	O
range	O
.	O

2	O
,	O
3	O
New	O
strategies	O
for	O
the	O
prevention	O
and	O
control	O
of	O
ovarian	B-DISEASE
cancer	I-DISEASE
will	O
rely	O
on	O
a	O
thorough	O
understanding	O
of	O
the	O
contributing	O
genetic	O
factors	O
both	O
at	O
the	O
germline	O
and	O
somatic	O
levels	O
.	O

[	O
11	O
]	O
provided	O
evidence	O
that	O
splicing	O
mutations	O
occurring	O
in	O
most	O
USH	B-DISEASE
genes	O
can	O
be	O
identified	O
through	O
ex	O
vivo	O
analysis	O
of	O
mRNA	O
from	O
nasal	O
epithelial	O
cells	O
.	O

All	O
the	O
variants	O
and	O
their	O
segregation	O
in	O
each	O
family	O
were	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Among	O
these	O
groups	O
,	O
intermediate	O
-	O
sized	O
platelets	O
were	O
the	O
most	O
abundant	O
(	O
median	O
:	O
44	O
%	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

All	O
affected	O
individuals	O
showed	O
a	O
homozygous	O
haplotype	O
.	O

3171310	O
)	O
.	O

2001	O
)	O
,	O
but	O
the	O
HARS	B-GENE
gene	O
was	O
recently	O
proposed	O
as	O
a	O
novel	O
USH3	B-DISEASE
gene	O
(	O
Puffenberger	O
et	O
al	O
.	O

The	O
pairwise	O
Wilcoxon	O
test	O
followed	O
by	O
a	O
Benjamini	O
-	O
Hochberg	O
multiple	O
testing	O
correction	O
was	O
used	O
to	O
determine	O
whether	O
there	O
was	O
a	O
significant	O
difference	O
in	O
the	O
number	O
of	O
variants	O
in	O
the	O
control	O
versus	O
case	O
groups	O
.	O

Forward	O
primer	O
5	O
'	O
-	O
cggaggtcaacaacgagtct	O
-	O
3	O
'	O
and	O
reverse	O
primer	O
5	O
'	O
-	O
aggtgtaggggatgggagac	O
-	O
3	O
'	O
were	O
used	O
to	O
amplify	O
and	O
sequence	O
the	O
amplified	O
cDNA	O
fragments	O
along	O
with	O
flanking	O
RHO	O
sequences	O
as	O
present	O
in	O
the	O
vector	O
.	O

Amino	O
-	O
acid	O
residue	O
443	O
is	O
pink	O
in	O
the	O
wild	O
type	O
(	O
A	O
)	O
and	O
yellow	O
in	O
the	O
mutant	O
(	O
B	O
)	O
.	O

Their	O
mean	O
age	O
was	O
39	O
.	O
5	O
years	O
(	O
SD	O
=	O
17	O
.	O
8	O
years	O
,	O
range	O
6	O
.	O
0	O
-	O
78	O
.	O
0	O
years	O
)	O
,	O
with	O
a	O
male	O
to	O
female	O
ratio	O
of	O
1	O
.	O
06	O
:	O
1	O
,	O
and	O
DOA	O
+	O
clinical	O
features	O
were	O
present	O
in	O
11	O
out	O
of	O
64	O
patients	O
(	O
17	O
.	O
2	O
%	O
)	O
from	O
6	O
out	O
of	O
14	O
(	O
42	O
.	O
9	O
%	O
)	O
families	O
.	O

Therefore	O
,	O
we	O
used	O
a	O
pooled	O
sequencing	O
approach	O
to	O
assess	O
candidate	O
gene	O
exons	O
across	O
many	O
individuals	O
.	O

Deletion	O
of	O
PCDH15	B-GENE
exons	O
9	O
-	O
18	O
was	O
confirmed	O
by	O
MLPA	O
.	O

For	O
normal	O
individuals	O
II1	O
,	O
II2	O
,	O
and	O
III3	O
,	O
restrictive	O
digested	O
by	O
ScrFI	O
resulted	O
in	O
just	O
one	O
mixed	O
band	O
with	O
fragments	O
41	O
bp	O
and	O
48	O
bp	O
,	O
while	O
for	O
individuals	O
II3	O
,	O
II4	O
,	O
III1	O
,	O
and	O
III2	O
,	O
digested	O
by	O
ScrFI	O
resulted	O
in	O
two	O
bands	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
mutation	O
in	O
the	O
PCR	O
product	O
.	O

This	O
analysis	O
yielded	O
a	O
single	O
peak	O
for	O
all	O
samples	O
analyzed	O
(	O
four	O
affected	O
,	O
four	O
control	O
individuals	O
)	O
,	O
excluding	O
that	O
the	O
sequencing	O
failure	O
across	O
this	O
region	O
was	O
caused	O
by	O
a	O
trinucleotide	O
expansion	O
.	O

The	O
protein	O
is	O
involved	O
in	O
several	O
mitochondrial	O
functions	O
,	O
such	O
as	O
the	O
maintenance	O
of	O
the	O
integrity	O
of	O
the	O
cristae	O
formed	O
by	O
the	O
mitochondrial	O
inner	O
membrane	O
[	O
12	O
]	O
,	O
the	O
regulation	O
of	O
cytochrome	O
c	O
release	O
during	O
apoptosis	O
[	O
13	O
]	O
,	O
and	O
the	O
maintenance	O
of	O
mitochondrial	O
DNA	O
[	O
14	O
,	O
15	O
]	O
.	O

Hearing	B-DISEASE
loss	I-DISEASE
is	O
the	O
most	O
common	O
sensory	O
deficit	O
in	O
humans	O
,	O
affecting	O
278	O
million	O
individuals	O
worldwide	O
and	O
1	O
in	O
500	O
newborns	O
(	O
1	O
,	O
2	O
)	O
.	O

Chen	O
et	O
al	O
.	O

The	O
Agilent	O
SureSelect	O
Target	O
Enrichment	O
system	O
was	O
chosen	O
to	O
capture	O
the	O
genomic	O
regions	O
harboring	O
these	O
genes	O
,	O
based	O
on	O
the	O
hybridization	O
of	O
complementary	O
custom	O
-	O
designed	O
biotinylated	O
cRNA	O
oligonucleotides	O
to	O
the	O
target	O
DNA	O
library	O
and	O
subsequent	O
purification	O
of	O
the	O
hybrids	O
by	O
streptavidin	O
-	O
bound	O
magnetic	O
bead	O
separation	O
[	O
8	O
]	O
.	O

Linkage	O
analysis	O
was	O
performed	O
assuming	O
autosomal	O
dominant	O
inheritance	O
,	O
full	O
penetrance	O
,	O
and	O
a	O
disease	O
gene	O
frequency	O
of	O
0	O
.	O
0001	O
.	O

These	O
PTCs	B-DISEASE
are	O
known	O
to	O
be	O
targets	O
for	O
elimination	O
by	O
a	O
regulatory	O
and	O
specialized	O
surveillance	O
mechanism	O
,	O
known	O
as	O
nonsense	B-DISEASE
-	I-DISEASE
mediated	I-DISEASE
mRNA	I-DISEASE
decay	I-DISEASE
(	O
NMD	B-DISEASE
)	O
[	O
27	O
]	O
.	O

The	O
PCR	O
products	O
were	O
purified	O
again	O
with	O
QIAquick	O
MinElute	O
column	O
and	O
eluted	O
into	O
50	O
mu	O
l	O
of	O
hybridization	O
buffer	O
(	O
HB	O
,	O
Roche	O
NimbleGen	O
,	O
Madison	O
,	O
WI	O
)	O
.	O

Genomic	O
DNA	O
sequencing	O
of	O
exon	O
45	O
in	O
the	O
COL4A5	B-GENE
gene	O
.	O

8	O
mu	O
m	O
cryostatic	O
cross	O
sections	O
were	O
processed	O
according	O
to	O
standard	O
histological	O
/	O
histochemical	O
techniques	O
.	O

A	O
list	O
of	O
variants	O
that	O
are	O
present	O
in	O
group	O
1	O
and	O
absent	O
from	O
group	O
2	O
.	O

Amplified	O
ELMOD3	B-GENE
short	O
transcripts	O
from	O
the	O
cDNA	O
libraries	O
generated	O
using	O
the	O
blood	O
samples	O
of	O
affected	O
and	O
normal	O
hearing	O
individuals	O
.	O

Pedigree	O
,	O
PRS	O
enzymatic	O
activity	O
,	O
conservation	O
,	O
and	O
predicted	O
protein	O
structural	O
effects	O
of	O
the	O
novel	O
Gln277Pro	B-VARIANT
PRPS1	B-GENE
variant	O
.	O

He	O
had	O
a	O
sudden	O
anxiety	O
with	O
psychotic	O
hints	O
.	O

Patient	O
18	O
had	O
enlarged	B-DISEASE
vestibular	I-DISEASE
aqueduct	I-DISEASE
with	O
Mondini	B-DISEASE
dysplasia	I-DISEASE
(	O
Figure	O
1	O
)	O
.	O

recently	O
found	O
mutations	O
in	O
91	O
%	O
of	O
the	O
patients	O
tested	O
,	O
improving	O
the	O
molecular	O
diagnosis	O
of	O
Usher	B-DISEASE
syndrome	I-DISEASE
greatly	O
[	O
11	O
]	O
.	O

Figure	O
S2	O
.	O

Relevant	O
audiological	O
data	O
were	O
only	O
available	O
for	O
Slovak	O
hearing	B-DISEASE
impaired	I-DISEASE
subjects	O
(	O
n	O
=	O
6	O
)	O
from	O
five	O
families	O
.	O

The	O
patient	O
had	O
bilateral	O
proptosis	B-DISEASE
,	O
exophthalmos	B-DISEASE
,	O
maxillary	B-DISEASE
hypoplasia	I-DISEASE
,	O
high	B-DISEASE
arched	I-DISEASE
palate	I-DISEASE
,	O
broad	B-DISEASE
thumbs	I-DISEASE
and	O
medially	B-DISEASE
deviated	I-DISEASE
great	I-DISEASE
toes	I-DISEASE
that	O
were	O
surgically	O
corrected	O
(	O
Fig	O
.	O

Upon	O
depolarizing	O
voltage	O
steps	O
,	O
Ca	O
V	O
1	O
.	O
3	O
WT	O
calcium	O
currents	O
showed	O
fast	O
activation	O
,	O
followed	O
by	O
a	O
slow	O
decay	O
caused	O
by	O
voltage	O
-	O
dependent	O
(	O
VDI	O
)	O
and	O
calcium	O
-	O
dependent	O
inactivation	O
(	O
CDI	O
)	O
10	O
(	O
Supplementary	O
Fig	O
.	O

Indeed	O
,	O
freeze	O
-	O
fracture	O
electron	O
microscopy	O
has	O
revealed	O
alteration	O
of	O
the	O
ultrastructure	O
of	O
inner	O
ear	O
tTJ	O
from	O
angulin	B-GENE
-	I-GENE
2	I-GENE
/	O
ILDR1	B-GENE
deficient	O
mice	O
[	O
31	O
]	O
.	O

Platelet	O
count	O
(	O
PC	O
x	O
10	O
9	O
/	O
L	O
)	O
and	O
platelet	O
size	O
(	O
G	O
=	O
percentage	O
of	O
giant	O
platelets	O
;	O
M	O
=	O
percentage	O
of	O
intermediate	O
-	O
sized	O
platelets	O
;	O
N	O
=	O
percentage	O
of	O
normal	O
-	O
sized	O
platelets	O
)	O
in	O
bleeders	O
(	O
red	O
symbols	O
)	O
and	O
nonbleeders	O
(	O
black	O
symbols	O
)	O
.	O

B	O
:	O
Reduced	O
mitochondrial	O
ATP	O
synthesis	O
,	O
measured	O
by	O
luminescence	O
from	O
aliquot	O
samples	O
in	O
a	O
polarographic	O
chamber	O
,	O
was	O
found	O
in	O
the	O
patient	O
'	O
s	O
fibroblasts	O
in	O
comparison	O
to	O
controls	O
.	O

Figure	O
2	O
ABRs	O
recorded	O
at	O
90	O
dB	O
nHL	O
from	O
one	O
control	O
with	O
normal	O
hearing	O
and	O
three	O
subjects	O
with	O
DOA	B-DISEASE
,	O
one	O
included	O
in	O
the	O
OPA1	B-GENE
-	O
H	O
and	O
two	O
in	O
the	O
OPA1	B-GENE
-	O
M	O
group	O
.	O

The	O
PCR	O
products	O
were	O
purified	O
(	O
ExoSAP	O
-	O
IT	O
;	O
USB	O
Corp	O
.	O
,	O
USA	O
)	O
,	O
and	O
both	O
strands	O
of	O
the	O
gene	O
were	O
sequenced	O
with	O
an	O
automated	O
sequencer	O
(	O
Bio	O
Matrix	O
Research	O
;	O
Chiba	O
,	O
Japan	O
)	O
.	O

This	O
gene	O
is	O
a	O
member	O
of	O
the	O
mammalian	O
PAX	O
gene	O
family	O
that	O
encodes	O
for	O
DNA	O
-	O
binding	O
transcription	O
factors	O
and	O
plays	O
a	O
role	O
in	O
maintaining	O
stem	O
cell	O
pluripotency	O
,	O
cell	O
-	O
lineage	O
specification	O
,	O
proliferation	O
,	O
migration	O
,	O
apoptosis	O
,	O
and	O
inhibition	O
of	O
terminal	O
differentiation	O
[	O
28	O
,	O
29	O
]	O
.	O

The	O
table	O
shows	O
the	O
forward	O
and	O
reverse	O
primers	O
used	O
for	O
PCR	O
amplification	O
of	O
the	O
coding	O
exons	O
of	O
the	O
WFS1	B-GENE
gene	O
.	O

After	O
transfection	O
for	O
48	O
h	O
,	O
apoptotic	O
cell	O
ratios	O
were	O
determined	O
with	O
annexin	O
-	O
V	O
-	O
PE	O
-	O
staining	O
.	O

These	O
patients	O
had	O
12	O
different	O
mutations	O
,	O
of	O
which	O
11	O
are	O
novel	O
and	O
lead	O
to	O
protein	O
truncations	O
.	O

USH	B-DISEASE
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
.	O

The	O
cells	O
were	O
incubated	O
overnight	O
at	O
4	O
deg	O
C	O
with	O
a	O
primary	O
antibody	O
(	O
ZO1	O
,	O
Life	O
Technologies	O
;	O
anti	O
-	O
ELMOD3	B-GENE
)	O
in	O
3	O
%	O
NGS	O
/	O
PBS	O
/	O
0	O
.	O
1	O
%	O
Triton	O
-	O
X100	O
.	O

In	O
two	O
out	O
of	O
these	O
four	O
families	O
(	O
119	O
and	O
313	O
)	O
haplotype	O
analysis	O
indicated	O
the	O
presence	O
of	O
large	O
genomic	O
deletions	O
which	O
were	O
confirmed	O
by	O
MLPA	O
(	O
table	O
1	O
and	O
supplemental	O
figure	O
2	O
)	O
.	O

In	O
certain	O
scenarios	O
this	O
information	O
may	O
influence	O
analysis	O
or	O
experimental	O
design	O
to	O
reduce	O
some	O
of	O
the	O
limitations	O
in	O
surveying	O
exome	O
sequences	O
for	O
Mendelian	B-DISEASE
disease	I-DISEASE
gene	O
discovery	O
.	O

The	O
mutation	O
site	O
,	O
Met305	O
,	O
was	O
visualized	O
using	O
the	O
3D	O
structure	O
of	O
bovine	O
beta	O
-	O
actin	O
bound	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
with	O
profilin	O
(	O
Figure	O
4	O
C	O
)	O
.	O

A	O
total	O
of	O
66	O
cases	O
had	O
truncations	O
in	O
one	O
of	O
these	O
genes	O
(	O
Supplementary	O
Data	O
4	O
and	O
5	O
)	O
.	O

For	O
a	O
high	O
pathogenicity	O
profile	O
,	O
scores	O
recorded	O
in	O
the	O
Alamut	O
-	O
HT	O
report	O
included	O
BLOSUM62	O
(	O
Blo	O
cks	O
Su	O
bstitution	O
M	O
atrix	O
;	O
http	O
:	O
/	O
/	O
www	O
.	O
uky	O
.	O
edu	O
/	O
Classes	O
/	O
BIO	O
/	O
520	O
/	O
BIO520WWW	O
/	O
blosum62	O
.	O
htm	O
)	O
<	O
0	O
,	O
AGVGD	O
(	O
A	O
lign	O
G	O
rantham	O
V	O
ariation	O
and	O
G	O
rantham	O
D	O
eviation	O
;	O
http	O
:	O
/	O
/	O
agvgd	O
.	O
iarc	O
.	O
fr	O
/	O
agvgd_input	O
.	O
php	O
)	O
between	O
C15	O
and	O
C65	O
,	O
SIFT	O
(	O
S	O
orts	O
I	O
ntolerant	O
F	O
rom	O
T	O
olerant	O
substitutions	O
,	O
http	O
:	O
/	O
/	O
sift	O
.	O
jcvi	O
.	O
org	O
)	O
<	O
0	O
.	O
05	O
or	O
deleterious	O
and	O
MAPP	O
(	O
M	O
ultivariate	O
A	O
nalysis	O
of	O
P	O
rotein	O
P	O
olymorphism	O
;	O
http	O
:	O
/	O
/	O
mendel	O
.	O
stanford	O
.	O
edu	O
/	O
SidowLab	O
/	O
downloads	O
/	O
MAPP	O
)	O
=	O
bad	O
.	O

Exome	O
sequencing	O
provides	O
a	O
particularly	O
powerful	O
method	O
with	O
which	O
to	O
identify	O
disease	O
-	O
causing	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
in	O
Mendelian	O
disorders	O
[	O
1	O
-	O
4	O
]	O
.	O

Our	O
study	O
also	O
exemplifies	O
the	O
application	O
of	O
deep	O
sequencing	O
in	O
identifying	O
disease	O
causative	O
mutations	O
from	O
a	O
pedigree	O
.	O

We	O
found	O
the	O
common	O
constellation	O
(	O
c	O
.	O
-	O
137	O
TT	O
and	O
c	O
.	O
-	O
53	O
CC	O
)	O
in	O
13	O
(	O
43	O
%	O
)	O
of	O
the	O
patients	O
and	O
,	O
likewise	O
11	O
(	O
37	O
%	O
)	O
heterozygous	O
carriers	O
(	O
c	O
.	O
-	O
137	O
TC	O
and	O
c	O
.	O
-	O
53	O
GC	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
this	O
risk	O
is	O
similar	O
to	O
that	O
reported	O
in	O
other	O
countries	O
(	O
Table	O
5	O
)	O
.	O

Both	O
wild	O
type	O
and	O
g	B-VARIANT
.	I-VARIANT
8662T	I-VARIANT
>	I-VARIANT
C	I-VARIANT
substituted	O
whole	O
DSPP	B-GENE
gene	O
sequences	O
were	O
inputted	O
and	O
the	O
prediction	O
was	O
performed	O
using	O
default	O
settings	O
.	O

A	O
typical	O
WES	O
screen	O
will	O
identify	O
between	O
20	O
,	O
000	O
and	O
50	O
,	O
000	O
exonic	O
variants	O
[	O
5	O
]	O
.	O

Moreover	O
,	O
the	O
mutation	O
pR109W	B-VARIANT
in	O
the	O
LDLRA	O
domain	O
of	O
TMPRSS3	B-GENE
has	O
been	O
detected	O
in	O
multiple	O
Asian	O
familiar	O
deafness	B-DISEASE
cases	O
[	O
10	O
]	O
,	O
[	O
22	O
]	O
.	O

Therefore	O
,	O
the	O
most	O
common	O
USH1C	B-GENE
variant	O
is	O
USH1C_v2	O
(	O
also	O
known	O
as	O
variant	O
a	O
and	O
PDZ	O
-	O
73	O
;	O
see	O
Table	O
S7	O
for	O
more	O
information	O
)	O
.	O

(	O
PDF	O
)	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

(	O
c	O
)	O
DPOAE	O
levels	O
(	O
dBSPL	O
)	O
at	O
the	O
2f1	O
-	O
f2	O
frequency	O
are	O
plotted	O
against	O
the	O
f2	O
frequency	O
(	O
kHz	O
)	O
for	O
55	O
dBSPL	O
(	O
left	O
)	O
,	O
65	O
dBSPL	O
(	O
middle	O
)	O
and	O
75	O
dBSPL	O
(	O
right	O
)	O
L2	O
levels	O
.	O

Hong	O
-	O
Joon	O
Park	O
)	O
.	O

The	O
etiologies	O
of	O
ANSD	B-DISEASE
are	O
various	O
;	O
patients	O
range	O
from	O
infants	O
to	O
adults	O
,	O
42	O
%	O
of	O
which	O
are	O
associated	O
with	O
hereditary	O
neurological	O
disorders	O
,	O
10	O
%	O
with	O
toxic	O
,	O
metabolic	O
,	O
immunological	O
and	O
infectious	O
causes	O
,	O
and	O
48	O
%	O
with	O
unknown	O
causes	O
[	O
6	O
]	O
.	O

Targeted	O
NGS	O
was	O
carried	O
out	O
and	O
analyzed	O
by	O
TE	O
,	O
CB	O
and	O
HJB	O
.	O

Amongst	O
studies	O
of	O
genetic	B-DISEASE
hearing	I-DISEASE
loss	I-DISEASE
,	O
this	O
report	O
is	O
unique	O
as	O
no	O
restrictive	O
criteria	O
were	O
imposed	O
on	O
patient	O
selection	O
.	O

3B	O
2	O
)	O
.	O

Mutations	O
in	O
USH2A	B-GENE
were	O
the	O
molecular	O
cause	O
of	O
USH2	B-DISEASE
in	O
96	O
out	O
of	O
121	O
(	O
79	O
.	O
3	O
%	O
)	O
of	O
USH2	B-DISEASE
families	O
;	O
two	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variants	O
were	O
found	O
in	O
73	O
/	O
121	O
(	O
60	O
.	O
3	O
%	O
)	O
of	O
all	O
USH2	B-DISEASE
families	O
and	O
only	O
one	O
pathogenic	O
/	O
UV4	O
/	O
UV3	O
variant	O
was	O
identified	O
in	O
23	O
/	O
121	O
(	O
19	O
%	O
)	O
of	O
USH2	B-DISEASE
families	O
,	O
in	O
spite	O
of	O
full	O
sequence	O
analysis	O
.	O

This	O
explains	O
the	O
autosomal	O
-	O
recessive	O
and	O
X	O
-	O
linked	O
modes	O
of	O
inheritance	O
that	O
are	O
seen	O
in	O
clinical	O
practice	O
.	O

However	O
,	O
a	O
strategy	O
for	O
screening	O
other	O
hearing	B-DISEASE
loss	I-DISEASE
genes	O
is	O
difficult	O
,	O
and	O
Sanger	O
sequencing	O
of	O
candidate	O
genes	O
with	O
multiple	O
exons	O
,	O
such	O
as	O
MYO15A	B-GENE
,	O
is	O
time	O
-	O
consuming	O
.	O

We	O
included	O
both	O
polymorphisms	O
in	O
a	O
genotype	O
-	O
phenotype	O
analysis	O
of	O
30	O
PBD	B-DISEASE
patients	O
with	O
PEX1	B-GENE
mutations	O
representing	O
the	O
whole	O
spectrum	O
of	O
clinical	O
phenotypes	O
.	O

Two	O
distinct	O
RT	O
-	O
PCR	O
products	O
were	O
obtained	O
from	O
the	O
patient	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
enrichment	O
is	O
only	O
partially	O
explained	O
by	O
mutations	O
found	O
in	O
known	O
disease	O
-	O
causing	O
genes	O
.	O

XCI	O
was	O
extremely	O
skewed	O
(	O
defined	O
as	O
ratio	O
>	O
90	O
%	O
:	O
10	O
%	O
[	O
16	O
]	O
)	O
in	O
II	O
-	O
1	O
(	O
94	O
%	O
:	O
6	O
%	O
)	O
,	O
but	O
only	O
moderately	O
skewed	O
in	O
I	O
-	O
1	O
(	O
80	O
%	O
:	O
20	O
%	O
)	O
.	O

The	O
most	O
significant	O
mechanistic	O
insights	O
into	O
the	O
pathogenesis	O
of	O
hearing	B-DISEASE
loss	I-DISEASE
associated	O
with	O
EVA	B-DISEASE
are	O
based	O
upon	O
the	O
SLC26A4	B-GENE
knockout	O
(	O
SLC26A4	B-GENE
-	O
/	O
-	O
)	O
mouse	O
that	O
segregates	O
a	O
targeted	O
deletion	O
of	O
exon	O
8	O
of	O
SLC26A4	B-GENE
[	O
37	O
]	O
and	O
the	O
loop	O
mouse	O
line	O
segregating	O
a	O
chemically	O
induced	O
mutation	O
of	O
SLC26A4	B-GENE
[	O
38	O
]	O
.	O

The	O
kit	O
was	O
designed	O
to	O
target	O
a	O
total	O
of	O
252	O
human	O
protein	O
-	O
coding	O
genes	O
related	O
to	O
HL	B-DISEASE
.	O

Additionally	O
,	O
Ile770	O
is	O
conserved	O
in	O
all	O
paralogs	O
(	O
Fig	O
.	O

This	O
mutation	O
is	O
located	O
in	O
the	O
highly	O
conserved	O
GTPase	O
domain	O
and	O
has	O
been	O
previously	O
reported	O
once	O
in	O
two	O
related	O
patients	O
[	O
20	O
]	O
.	O

The	O
patient	O
underwent	O
surgery	O
for	O
correction	O
of	O
syndactyly	B-DISEASE
in	O
the	O
left	O
hand	O
.	O

The	O
overlapping	O
audiograms	O
of	O
these	O
subjects	O
revealed	O
no	O
significant	O
differences	O
between	O
the	O
subjects	O
with	O
truncating	O
mutations	O
associated	O
with	O
missense	O
mutations	O
and	O
those	O
with	O
biallelic	O
missense	O
mutations	O
(	O
Figure	O
4	O
)	O
.	O

Note	O
that	O
the	O
stretch	O
of	O
guanine	O
nucleotides	O
contains	O
only	O
five	O
guanines	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
leukocytes	O
by	O
standard	O
phenol	O
-	O
chloroform	O
extraction	O
method	O
[	O
11	O
]	O
.	O

Additional	O
phenotypic	O
information	O
on	O
select	O
syndromes	O
is	O
presented	O
in	O
Table	O
S6	O
.	O

We	O
attempted	O
to	O
sequence	O
all	O
samples	O
,	O
but	O
exome	O
sequencing	O
failed	O
due	O
to	O
insufficient	O
DNA	O
in	O
trios	O
4	O
,	O
24	O
and	O
30	O
,	O
leaving	O
a	O
total	O
cohort	O
of	O
26	O
trios	O
and	O
two	O
quads	O
(	O
couple	O
with	O
two	O
affected	O
fetuses	O
)	O
(	O
91	O
%	O
,	O
86	O
samples	O
)	O
.	O

The	O
WS	B-DISEASE
gene	O
,	O
WFS1	B-GENE
,	O
encodes	O
a	O
transmembrane	O
protein	O
called	O
Wolframin	O
,	O
which	O
recent	O
evidence	O
suggests	O
may	O
serve	O
as	O
a	O
novel	O
endoplasmic	O
reticulum	O
calcium	O
channel	O
in	O
pancreatic	O
beta	O
-	O
cells	O
and	O
neurons	O
.	O

Sanger	O
sequencing	O
was	O
performed	O
using	O
specific	O
primers	O
for	O
each	O
exon	O
as	O
described	O
(	O
Table	O
S1	O
)	O
.	O

The	O
inheritance	O
composition	O
of	O
the	O
subjects	O
was	O
as	O
follows	O
:	O
298	O
subjects	O
from	O
autosomal	O
dominant	O
or	O
maternally	O
inherited	O
families	O
(	O
two	O
or	O
more	O
generations	O
affected	O
)	O
;	O
919	O
subjects	O
from	O
autosomal	O
recessive	O
families	O
(	O
parents	O
with	O
normal	O
hearing	O
and	O
two	O
or	O
more	O
affected	O
siblings	O
)	O
or	O
subjects	O
with	O
sporadic	O
deafness	B-DISEASE
(	O
compatible	O
with	O
recessive	O
inheritance	O
or	O
non	O
-	O
genetic	O
hearing	B-DISEASE
loss	I-DISEASE
)	O
;	O
the	O
rest	O
had	O
unknown	O
inheritance	O
mode	O
.	O

The	O
colors	O
of	O
fundus	O
photos	O
were	O
different	O
between	O
two	O
eyes	O
in	O
both	O
patients	O
,	O
where	O
mild	O
retinal	B-DISEASE
hypopigmentation	I-DISEASE
was	O
demonstrated	O
in	O
the	O
left	O
eyes	O
of	O
both	O
patients	O
.	O

The	O
transfected	O
cells	O
were	O
analyzed	O
by	O
confocal	O
fluorescence	O
microscopy	O
.	O

Barcoded	O
libraries	O
of	O
captured	O
samples	O
were	O
pooled	O
and	O
paired	O
-	O
end	O
Illumina	O
sequencing	O
was	O
performed	O
using	O
the	O
Illumina	O
HiSeq	O
system	O
(	O
Illumina	O
;	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

We	O
used	O
targeted	O
exome	O
sequencing	O
and	O
designed	O
a	O
1	O
.	O
4Mb	O
panel	O
for	O
simultaneous	O
testing	O
of	O
more	O
than	O
4	O
,	O
800	O
exons	O
in	O
309	O
genes	O
involved	O
in	O
skeletal	B-DISEASE
disorders	I-DISEASE
.	O

In	O
our	O
cohort	O
of	O
patients	O
,	O
the	O
variant	O
was	O
detected	O
in	O
a	O
compound	O
heterozygous	O
patient	O
,	O
RP	B-DISEASE
-	O
1034	O
,	O
with	O
the	O
reported	O
deletion	O
comprising	O
exon	O
3	O
of	O
the	O
PCDH15	B-GENE
gene	O
[	O
22	O
]	O
.	O

The	O
lack	O
of	O
vestibular	O
symptoms	O
in	O
these	O
patients	O
might	O
reflect	O
the	O
slow	O
rate	O
of	O
the	O
degenerative	O
process	O
(	O
Fujikawa	O
and	O
Starr	O
,	O
2000	O
)	O
.	O

Numbers	O
designate	O
patients	O
,	O
colors	O
indicate	O
different	O
USH1	B-DISEASE
genes	O
.	O

Predicted	O
amplicon	O
sizes	O
were	O
confirmed	O
by	O
agarose	O
gel	O
electrophoresis	O
.	O

